Annual Congress of the European Association of Nuclear Medicine

October 21–25, 2017
Vienna, Austria

www.eanm.org
EANM FOCUS 1

THE INTERNATIONAL CONFERENCE ON "MOLECULAR IMAGING AND THERANOSTICS IN PROSTATE CANCER"

FEBRUARY 1 - 3, 2018
VALENCIA, SPAIN
# Table of Contents

Welcome Message 6  
EANM Committees 8  
EANM’17 Reviewers 10  
EANM National Societies: Delegates & Deputies 14  
UEMS/EBNM Committees 16  
UEMS/EBNM National Delegates & Deputies 18  
General Information 19  
Business Meetings 24  
Floorplans – ACV Vienna 28  
Public Transportation Map 32

## SCIENTIFIC PROGRAMME

### PROGRAMME OVERVIEWS
  - Saturday, October 21, 2017 36  
  - Sunday, October 22, 2017 38  
  - Monday, October 23, 2017 40  
  - Tuesday, October 24, 2017 42  
  - Wednesday, October 25, 2017 44

- Invited Speaker Sessions 46  
- Do.Mo.Re Track 50  
- M2M Track 50  
- EANM Young Daily Forum 51  
- Pre-Congress Symposia 52  

### ORAL SESSIONS
  - Saturday, October 21, 2017 58  
  - Sunday, October 22, 2017 63  
  - Monday, October 23, 2017 84  
  - Tuesday, October 24, 2017 106  
  - Wednesday, October 25, 2017 128

### e-POSTERS
  - e-Poster Walks 138  
  - e-Posters 152  
  - Technologist e-Poster Walks 252

### INDUSTRY PROGRAMME
  - Industry Sponsored Symposia 262  
  - List of Exhibitors 268  
  - Exhibition Halls Floorplans 278  
  - Company Profiles 284  
  - Corporate Members 360  

- Imprint 362
WELCOME TO THE
Dear colleagues, dear friends,

It is with great pleasure that the European Association of Nuclear Medicine welcomes you to its 30th Annual Congress in Vienna, Austria.

Over the 30 years since our first Congress, nuclear medicine has made significant strides. Overall usage of nuclear medicine procedures is expanding rapidly, and this trend is especially evident with respect to new imaging technologies. We can affirm that the revolution of tomographic hybrid imaging within the nuclear medicine landscape is now a matter of fact, spurred by evidence-based medicine. Our discipline’s next step is the integration of genome-specific targeted theranostics, utilising in vivo whole-body assessment of tissue morphology, physiology and biochemistry. The ultimate goal is to design personalised, super-selective therapies and to identify more precise means of monitoring response to treatment in routine clinical practice.
Welcome Letter

The annual EANM Congress has become the world-leading meeting in nuclear medicine. In order to maintain the high level of excellence of our Congress, the 2017 meeting will build on the traditions that are highly appreciated by all attendees, with expansion of the newer features introduced by the former Congress Chair. A specific educational track, implemented in collaboration with the European School of Multimodality Imaging and Therapy, will include up-to-date Teaching Sessions, enriched by Pitfalls & Artefacts and Continuous Medical Education (CME) sessions. In all these “active learning” sessions, attendees will have the possibility to enhance their knowledge of multimodality imaging. With similar pedagogic intent, numerous multidisciplinary joint symposia organised by EANM Committees and our sister societies will offer an integrative approach to various topics relevant to the state of the art in our discipline. On the occasion of its 30th anniversary, our Congress will feature two new events (as well as a very big surprise). First, a panel display of the best regional posters will illustrate its global scope. Second, a specific Presidential Session will be dedicated to the best-ranked papers from the under-30s. Our young colleagues represent the future of our discipline and should begin to shape their knowledge in ways that will contribute to a brighter tomorrow for the whole nuclear medicine community!

All these learning sessions will not impact adversely on the predominant role of the entire Congress, which is to enable the presentation of oral papers and posters about the latest achievements in clinical nuclear medicine, science and technology. On the contrary, the Rapid Fire sessions, for example, will be enriched. The spirit of such sessions is to draw attention to the most highly rated abstracts in specific areas: a panel of top-level presentations is followed by extensive discussions, providing attendees with an integrated and coherent view on a wide variety of topics. Furthermore, featured oral sessions with one invited speaker in combination with “regular” presentations will broaden the perspectives on all topics. The now well-established tracks M2M – Molecule to Man (basic and translational science) and Do.MoRe (radionuclide therapy and dosimetry) will promote high-quality research through interaction between basic and translational clinical scientists and allow presentation of the latest achievements and developments in the fields of clinical molecular imaging and nuclear medicine therapy. During the plenary lectures, distinguished speakers will address state of the art science together with new developments in clinical and allied sciences, covering a broad range of topics with the goal of promoting the best possible care for our patients. At the end of the meeting, two eminent lecturers, Prof. Stefano Fanti from Bologna, Italy and Prof. Clemens Decristoforo from Innsbruck, Austria will present the traditional Highlights Lecture.

The Congress will take place in Vienna, Austria, where the EANM Executive Office is also based. The city – located in the heart of Europe, on the banks of the river Danube – is world famous for its imperial heritage, its cultural attractions and its culinary highlights. To quote the slogan of the city: Vienna awaits you!

For all these reasons, I cordially invite you to the EANM’17 Congress and to actively participate in our 30th anniversary. Meet and interact with friends and colleagues from all over the world, break away from the daily routine and enjoy Vienna’s hospitality.

Francesco Giammarile
EANM Congress Chair 2017-2019
EANM Board & Committees

**Board**

President 2017 – 2018  
K. Muylle (Belgium)

President Elect 2017 – 2018  
W.J.G. Oyen (United Kingdom)

Committee Coordinator 2017 – 2018  
R. Delgado-Bolton (Spain)

Congress Chair 2017 – 2019  
F. Giammarile (Austria)

Education Chair 2017 – 2019  
J. Pruim (Netherlands)

Secretary/Treasurer 2017 – 2018  
J. Kunikowska (Poland)

**Advisory Council**

The EANM Advisory Council is composed of the members of the Board and of the Committee Chairs:

Bone & Joint Committee  
F. Paycha (France)

Cardiovascular Committee  
H. Verberne (Netherlands)

Dosimetry Committee  
M.W. Konijnenberg (Netherlands)

Drug Development Committee  
A. Gee (United Kingdom)

Ethics Committee  
W. Knapp (Germany)

Inflammation & Infection Committee  
A. Signore (Italy)

Neuroimaging Committee  
I. Law (Denmark)

Oncology Committee  
S. Fanti (Italy)

Paediatrics Committee  
Z. Bar-Sever (Israel)

Physics Committee  
C. Hindorf (Sweden)

Radionuclide Therapy Committee  
tba

Radiation Protection Committee  
M. Lassmann (Germany)

Radiopharmacy Committee  
M. Behe (Switzerland)

Technologist Committee  
P. Fragoso Costa (Germany)

Thyroid Committee  
M. Luster (Germany)

Translational Molecular Imaging & Therapy Committee  
M. de Jong (Netherlands)
### Scientific Programme Committee

- **Chair**: F. Giammarile (Austria)
- **Members**:  
  - M. de Jong (Netherlands)  
  - S. Fanti (Italy)  
  - F. Forrer (Switzerland)  
  - P. Fragoso Costa (Germany)  
  - V. Garibotto (Switzerland)  
  - A. Gee (United Kingdom)  
  - A. Glaudemans (Netherlands)  
  - M.W. Konijnenberg (Netherlands)  
  - T. Kuwert (Germany)  
  - M. Lassmann (Germany)  
  - T. Mindt (Switzerland)  
  - B. Sattler (Germany)  
  - H.J. Verberne (Netherlands)  
  - F. Verburg (Germany)  
  - P. Zucchetta (Italy)

### Technologist Committee

- **Chair**: P. Fragoso Costa (Germany)
- **Members**:  
  - M. Attard (Netherlands)  
  - L. Camoni (Italy)  
  - N. Gulliver (United Kingdom)  
  - S. Rac (Croatia)  
  - S. Rep (Slovenia)  
  - A. Santos (Portugal)  
  - C. Terwinghe (Belgium)
- **Senior Advisor**: G. Testanera (Italy)

### Congress Strategy Committee

- **Congress Chair 2017 – 2019**: F. Giammarile (Austria)
- **Committee Coordinator 2017 – 2018**: R. Delgado-Bolton (Spain)
- **Education Chair 2017 – 2019**: J. Pruim (Netherlands)
- **Members**:  
  - P. Elsinga (Netherlands)  
  - F. Hyañil (France)  
  - A. Lammertsma (Netherlands)  
  - M. Ljungberg (Sweden)  
  - T. van den Wyngaert (Belgium)
EANM’17 Reviewers

A
E. Aarntzen (Netherlands)
D. Aarsland (Norway)
B. Abbott (USA)
R. Abgral (France)
W. Acampa (Italy)
J. Adam (Netherlands)
D. Agostini (France)
N. Aide (France)
R. Aigner (Austria)
I. Ak (Turkey)
C. Aktolun (Turkey)
A. Al-Nahhas (United Kingdom)
L. Aloj (United Kingdom)
C. Altini (Italy)
V. Ambrosini (Italy)
S. Ametamey (Switzerland)
C. Anagnostopoulos (Greece)
L. Antunovic (Italy)
J. Arbizu (Spain)
C. Artigas (Belgium)
V. Artiko (Serbia)
S. Aisenbaum-Nan (Austria)
L. Atay Kapucu (Turkey)
M. Attard (Netherlands)

B
K. Bacher (Belgium)
S. Baldari (Italy)
L. Balkay (Hungary)
J. Ballinger (United Kingdom)
M. Baptista (Portugal)
Z. Bar-Sever (Israel)
J. Barbet (France)
M. Bardiès (France)
S. Barrington (United Kingdom)
P. Bartenstein (Germany)
H. Behe (Germany)
R. Baum (Germany)
J. Bax (Netherlands)
A. Beer (Germany)
M. Behe (Switzerland)
M. Beheshti (Austria)
N. Belcari (Italy)
O. Belohlavek (Czech Republic)
P. Bengel (Germany)
A. Benitez Segura (Spain)
G. Berding (Germany)
H. Bergmann (Austria)
K. Bergström (Finland)
M. Bernsen (Netherlands)
T. Beyef (Switzerland)
B. Bilgin (Turkey)
I. Binse (Germany)
A. Bischof Delaloye (Switzerland)
G. Bisi (Italy)
K. Blokland (Netherlands)
C. Blümel (Germany)
L. Bodei (USA)
R. Boellaard (Netherlands)
O. Boerman (Netherlands)
W. Bolch (USA)
J. Bomanji (United Kingdom)
J. Booij (Netherlands)
K. Borbely (Hungary)
L. Borgwardt (Denmark)
G. Bormans (Belgium)
M. Botelho (Portugal)
C. Bourdeau (France)
M. Bourguignon (France)
P. Bouziotis (Greece)
M. Bozkurt (Turkey)
W. Brenner (Germany)
M. Brom (Netherlands)
A. Brouwers (Netherlands)
J. Bucerus (Netherlands)
R. Buchert (Germany)
T. Buckle (Netherlands)
Z. Burak (Turkey)
L. Burroni (Italy)
J. Buscombe (United Kingdom)
I. Buvat (France)
A. Carcione (Italy)
G. Cardezo (Portugal)
I. Carri (Spain)
J. Castelli Conesa (Spain)
M. Castellani (Italy)
P. Castellucci (Italy)
C. Cawthorne (United Kingdom)
F. Ceci (Italy)
J. Ceri (Brazil)
R. Chakravarthy (United Kingdom)
G. Chetelat (France)
M. Chianelli (Italy)
A. Chiaravalloti (Italy)
C. Chiesa (Italy)
M. Chinol (Italy)
A. Chiti (Italy)
N. Chourin (France)
F. Cicone (Italy)
M. Coffey (Ireland)
E. Comans (Netherlands)
G. Cook (United Kingdom)
B. Cornelissen (United Kingdom)
G. Costa (Portugal)
F. Courbon (France)
P. Covens (Belgium)
U. Cremerius (Germany)
F. Crippa (Italy)
C. Crivellaro (Italy)
A. Cuocolo (Italy)
D
G. D’Angelo (Italy)
G. Dabasi (Hungary)
S. Dalma (Netherlands)
D. Daou (France)
M. de Jong (Netherlands)
J. de Klerk (Netherlands)
C. De Labriolle-Vaylet (France)
D. De Palma (Italy)
J. De Sutter (Belgium)
J. de Swart (Netherlands)
E. de Vries (Netherlands)
C. Decristoforo (Austria)
B. Dejmirci Polack (Turkey)
A. Del Guerra (Italy)
S. Del Vecchio (Italy)
<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>R. Delgado-Bolton</td>
<td>Spain</td>
</tr>
<tr>
<td>T. Derlin</td>
<td>Germany</td>
</tr>
<tr>
<td>C. Deroose</td>
<td>Denmark</td>
</tr>
<tr>
<td>W. Deuther-Conrad</td>
<td>Germany</td>
</tr>
<tr>
<td>A. Dias</td>
<td>Denmark</td>
</tr>
<tr>
<td>C. Dolci</td>
<td>Italy</td>
</tr>
<tr>
<td>M. Dottorini</td>
<td>Italy</td>
</tr>
<tr>
<td>A. Drzezga</td>
<td>Germany</td>
</tr>
<tr>
<td>H. Durak</td>
<td>Turkey</td>
</tr>
<tr>
<td>EANM'17 Reviewers</td>
<td></td>
</tr>
<tr>
<td>R. Delgado-Bolton</td>
<td>Spain</td>
</tr>
<tr>
<td>T. Derlin</td>
<td>Germany</td>
</tr>
<tr>
<td>C. Deroose</td>
<td>Belgium</td>
</tr>
<tr>
<td>W. Deuther-Conrad</td>
<td>Germany</td>
</tr>
<tr>
<td>A. Dias</td>
<td>Denmark</td>
</tr>
<tr>
<td>C. Dolci</td>
<td>Italy</td>
</tr>
<tr>
<td>M. Dottorini</td>
<td>Italy</td>
</tr>
<tr>
<td>A. Drzezga</td>
<td>Germany</td>
</tr>
<tr>
<td>H. Durak</td>
<td>Turkey</td>
</tr>
<tr>
<td>EANM'17 Reviewers</td>
<td></td>
</tr>
<tr>
<td>R. Delgado-Bolton</td>
<td>Spain</td>
</tr>
<tr>
<td>T. Derlin</td>
<td>Germany</td>
</tr>
<tr>
<td>C. Deroose</td>
<td>Belgium</td>
</tr>
<tr>
<td>W. Deuther-Conrad</td>
<td>Germany</td>
</tr>
<tr>
<td>A. Dias</td>
<td>Denmark</td>
</tr>
<tr>
<td>C. Dolci</td>
<td>Italy</td>
</tr>
<tr>
<td>M. Dottorini</td>
<td>Italy</td>
</tr>
<tr>
<td>A. Drzezga</td>
<td>Germany</td>
</tr>
<tr>
<td>H. Durak</td>
<td>Turkey</td>
</tr>
<tr>
<td>EANM'17 Reviewers</td>
<td></td>
</tr>
<tr>
<td>R. Delgado-Bolton</td>
<td>Spain</td>
</tr>
<tr>
<td>T. Derlin</td>
<td>Germany</td>
</tr>
<tr>
<td>C. Deroose</td>
<td>Belgium</td>
</tr>
<tr>
<td>W. Deuther-Conrad</td>
<td>Germany</td>
</tr>
<tr>
<td>A. Dias</td>
<td>Denmark</td>
</tr>
<tr>
<td>C. Dolci</td>
<td>Italy</td>
</tr>
<tr>
<td>M. Dottorini</td>
<td>Italy</td>
</tr>
<tr>
<td>A. Drzezga</td>
<td>Germany</td>
</tr>
<tr>
<td>H. Durak</td>
<td>Turkey</td>
</tr>
<tr>
<td>EANM'17 Reviewers</td>
<td></td>
</tr>
<tr>
<td>R. Delgado-Bolton</td>
<td>Spain</td>
</tr>
<tr>
<td>T. Derlin</td>
<td>Germany</td>
</tr>
<tr>
<td>C. Deroose</td>
<td>Belgium</td>
</tr>
<tr>
<td>W. Deuther-Conrad</td>
<td>Germany</td>
</tr>
<tr>
<td>A. Dias</td>
<td>Denmark</td>
</tr>
<tr>
<td>C. Dolci</td>
<td>Italy</td>
</tr>
<tr>
<td>M. Dottorini</td>
<td>Italy</td>
</tr>
<tr>
<td>A. Drzezga</td>
<td>Germany</td>
</tr>
<tr>
<td>H. Durak</td>
<td>Turkey</td>
</tr>
<tr>
<td>EANM'17 Reviewers</td>
<td></td>
</tr>
<tr>
<td>R. Delgado-Bolton</td>
<td>Spain</td>
</tr>
<tr>
<td>T. Derlin</td>
<td>Germany</td>
</tr>
<tr>
<td>C. Deroose</td>
<td>Belgium</td>
</tr>
<tr>
<td>W. Deuther-Conrad</td>
<td>Germany</td>
</tr>
<tr>
<td>A. Dias</td>
<td>Denmark</td>
</tr>
<tr>
<td>C. Dolci</td>
<td>Italy</td>
</tr>
<tr>
<td>M. Dottorini</td>
<td>Italy</td>
</tr>
<tr>
<td>A. Drzezga</td>
<td>Germany</td>
</tr>
<tr>
<td>H. Durak</td>
<td>Turkey</td>
</tr>
<tr>
<td>EANM'17 Reviewers</td>
<td></td>
</tr>
<tr>
<td>R. Delgado-Bolton</td>
<td>Spain</td>
</tr>
<tr>
<td>T. Derlin</td>
<td>Germany</td>
</tr>
<tr>
<td>C. Deroose</td>
<td>Belgium</td>
</tr>
<tr>
<td>W. Deuther-Conrad</td>
<td>Germany</td>
</tr>
<tr>
<td>A. Dias</td>
<td>Denmark</td>
</tr>
<tr>
<td>C. Dolci</td>
<td>Italy</td>
</tr>
<tr>
<td>M. Dottorini</td>
<td>Italy</td>
</tr>
<tr>
<td>A. Drzezga</td>
<td>Germany</td>
</tr>
<tr>
<td>H. Durak</td>
<td>Turkey</td>
</tr>
<tr>
<td>EANM'17 Reviewers</td>
<td></td>
</tr>
<tr>
<td>R. Delgado-Bolton</td>
<td>Spain</td>
</tr>
<tr>
<td>T. Derlin</td>
<td>Germany</td>
</tr>
<tr>
<td>C. Deroose</td>
<td>Belgium</td>
</tr>
<tr>
<td>W. Deuther-Conrad</td>
<td>Germany</td>
</tr>
<tr>
<td>A. Dias</td>
<td>Denmark</td>
</tr>
<tr>
<td>C. Dolci</td>
<td>Italy</td>
</tr>
<tr>
<td>M. Dottorini</td>
<td>Italy</td>
</tr>
<tr>
<td>A. Drzezga</td>
<td>Germany</td>
</tr>
<tr>
<td>H. Durak</td>
<td>Turkey</td>
</tr>
<tr>
<td>EANM'17 Reviewers</td>
<td></td>
</tr>
<tr>
<td>R. Delgado-Bolton</td>
<td>Spain</td>
</tr>
<tr>
<td>T. Derlin</td>
<td>Germany</td>
</tr>
<tr>
<td>C. Deroose</td>
<td>Belgium</td>
</tr>
<tr>
<td>W. Deuther-Conrad</td>
<td>Germany</td>
</tr>
<tr>
<td>A. Dias</td>
<td>Denmark</td>
</tr>
<tr>
<td>C. Dolci</td>
<td>Italy</td>
</tr>
<tr>
<td>M. Dottorini</td>
<td>Italy</td>
</tr>
<tr>
<td>A. Drzezga</td>
<td>Germany</td>
</tr>
<tr>
<td>H. Durak</td>
<td>Turkey</td>
</tr>
<tr>
<td>EANM'17 Reviewers</td>
<td></td>
</tr>
<tr>
<td>R. Delgado-Bolton</td>
<td>Spain</td>
</tr>
<tr>
<td>T. Derlin</td>
<td>Germany</td>
</tr>
<tr>
<td>C. Deroose</td>
<td>Belgium</td>
</tr>
<tr>
<td>W. Deuther-Conrad</td>
<td>Germany</td>
</tr>
<tr>
<td>A. Dias</td>
<td>Denmark</td>
</tr>
<tr>
<td>C. Dolci</td>
<td>Italy</td>
</tr>
<tr>
<td>M. Dottorini</td>
<td>Italy</td>
</tr>
<tr>
<td>A. Drzezga</td>
<td>Germany</td>
</tr>
<tr>
<td>H. Durak</td>
<td>Turkey</td>
</tr>
<tr>
<td>EANM'17 Reviewers</td>
<td></td>
</tr>
<tr>
<td>R. Delgado-Bolton</td>
<td>Spain</td>
</tr>
<tr>
<td>T. Derlin</td>
<td>Germany</td>
</tr>
<tr>
<td>C. Deroose</td>
<td>Belgium</td>
</tr>
<tr>
<td>W. Deuther-Conrad</td>
<td>Germany</td>
</tr>
<tr>
<td>A. Dias</td>
<td>Denmark</td>
</tr>
<tr>
<td>C. Dolci</td>
<td>Italy</td>
</tr>
<tr>
<td>M. Dottorini</td>
<td>Italy</td>
</tr>
<tr>
<td>A. Drzezga</td>
<td>Germany</td>
</tr>
<tr>
<td>H. Durak</td>
<td>Turkey</td>
</tr>
<tr>
<td>EANM'17 Reviewers</td>
<td></td>
</tr>
<tr>
<td>R. Delgado-Bolton</td>
<td>Spain</td>
</tr>
<tr>
<td>T. Derlin</td>
<td>Germany</td>
</tr>
<tr>
<td>C. Deroose</td>
<td>Belgium</td>
</tr>
<tr>
<td>W. Deuther-Conrad</td>
<td>Germany</td>
</tr>
<tr>
<td>A. Dias</td>
<td>Denmark</td>
</tr>
<tr>
<td>C. Dolci</td>
<td>Italy</td>
</tr>
<tr>
<td>M. Dottorini</td>
<td>Italy</td>
</tr>
<tr>
<td>A. Drzezga</td>
<td>Germany</td>
</tr>
<tr>
<td>H. Durak</td>
<td>Turkey</td>
</tr>
<tr>
<td>EANM'17 Reviewers</td>
<td></td>
</tr>
<tr>
<td>R. Delgado-Bolton</td>
<td>Spain</td>
</tr>
<tr>
<td>T. Derlin</td>
<td>Germany</td>
</tr>
<tr>
<td>C. Deroose</td>
<td>Belgium</td>
</tr>
<tr>
<td>W. Deuther-Conrad</td>
<td>Germany</td>
</tr>
<tr>
<td>A. Dias</td>
<td>Denmark</td>
</tr>
<tr>
<td>C. Dolci</td>
<td>Italy</td>
</tr>
<tr>
<td>M. Dottorini</td>
<td>Italy</td>
</tr>
<tr>
<td>A. Drzezga</td>
<td>Germany</td>
</tr>
<tr>
<td>H. Durak</td>
<td>Turkey</td>
</tr>
<tr>
<td>EANM'17 Reviewers</td>
<td></td>
</tr>
<tr>
<td>R. Delgado-Bolton</td>
<td>Spain</td>
</tr>
<tr>
<td>T. Derlin</td>
<td>Germany</td>
</tr>
<tr>
<td>C. Deroose</td>
<td>Belgium</td>
</tr>
<tr>
<td>W. Deuther-Conrad</td>
<td>Germany</td>
</tr>
<tr>
<td>A. Dias</td>
<td>Denmark</td>
</tr>
<tr>
<td>C. Dolci</td>
<td>Italy</td>
</tr>
<tr>
<td>M. Dottorini</td>
<td>Italy</td>
</tr>
<tr>
<td>A. Drzezga</td>
<td>Germany</td>
</tr>
<tr>
<td>H. Durak</td>
<td>Turkey</td>
</tr>
<tr>
<td>EANM'17 Reviewers</td>
<td></td>
</tr>
<tr>
<td>R. Delgado-Bolton</td>
<td>Spain</td>
</tr>
<tr>
<td>T. Derlin</td>
<td>Germany</td>
</tr>
<tr>
<td>C. Deroose</td>
<td>Belgium</td>
</tr>
<tr>
<td>W. Deuther-Conrad</td>
<td>Germany</td>
</tr>
<tr>
<td>A. Dias</td>
<td>Denmark</td>
</tr>
<tr>
<td>C. Dolci</td>
<td>Italy</td>
</tr>
<tr>
<td>M. Dottorini</td>
<td>Italy</td>
</tr>
<tr>
<td>A. Drzezga</td>
<td>Germany</td>
</tr>
<tr>
<td>H. Durak</td>
<td>Turkey</td>
</tr>
<tr>
<td>EANM'17 Reviewers</td>
<td></td>
</tr>
<tr>
<td>R. Delgado-Bolton</td>
<td>Spain</td>
</tr>
<tr>
<td>T. Derlin</td>
<td>Germany</td>
</tr>
<tr>
<td>C. Deroose</td>
<td>Belgium</td>
</tr>
<tr>
<td>W. Deuther-Conrad</td>
<td>Germany</td>
</tr>
<tr>
<td>A. Dias</td>
<td>Denmark</td>
</tr>
<tr>
<td>C. Dolci</td>
<td>Italy</td>
</tr>
<tr>
<td>M. Dottorini</td>
<td>Italy</td>
</tr>
<tr>
<td>A. Drzezga</td>
<td>Germany</td>
</tr>
<tr>
<td>H. Durak</td>
<td>Turkey</td>
</tr>
<tr>
<td>EANM'17 Reviewers</td>
<td></td>
</tr>
<tr>
<td>R. Delgado-Bolton</td>
<td>Spain</td>
</tr>
<tr>
<td>T. Derlin</td>
<td>Germany</td>
</tr>
<tr>
<td>C. Deroose</td>
<td>Belgium</td>
</tr>
<tr>
<td>W. Deuther-Conrad</td>
<td>Germany</td>
</tr>
<tr>
<td>A. Dias</td>
<td>Denmark</td>
</tr>
<tr>
<td>C. Dolci</td>
<td>Italy</td>
</tr>
<tr>
<td>M. Dottorini</td>
<td>Italy</td>
</tr>
<tr>
<td>A. Drzezga</td>
<td>Germany</td>
</tr>
<tr>
<td>H. Durak</td>
<td>Turkey</td>
</tr>
<tr>
<td>EANM'17 Reviewers</td>
<td></td>
</tr>
<tr>
<td>R. Delgado-Bolton</td>
<td>Spain</td>
</tr>
<tr>
<td>T. Derlin</td>
<td>Germany</td>
</tr>
<tr>
<td>C. Deroose</td>
<td>Belgium</td>
</tr>
<tr>
<td>W. Deuther-Conrad</td>
<td>Germany</td>
</tr>
<tr>
<td>A. Dias</td>
<td>Denmark</td>
</tr>
<tr>
<td>C. Dolci</td>
<td>Italy</td>
</tr>
<tr>
<td>M. Dottorini</td>
<td>Italy</td>
</tr>
<tr>
<td>A. Drzezga</td>
<td>Germany</td>
</tr>
<tr>
<td>H. Durak</td>
<td>Turkey</td>
</tr>
<tr>
<td>EANM'17 Reviewers</td>
<td></td>
</tr>
<tr>
<td>R. Delgado-Bolton</td>
<td>Spain</td>
</tr>
<tr>
<td>T. Derlin</td>
<td>Germany</td>
</tr>
<tr>
<td>C. Deroose</td>
<td>Belgium</td>
</tr>
<tr>
<td>W. Deuther-Conrad</td>
<td>Germany</td>
</tr>
<tr>
<td>A. Dias</td>
<td>Denmark</td>
</tr>
<tr>
<td>C. Dolci</td>
<td>Italy</td>
</tr>
<tr>
<td>M. Dottorini</td>
<td>Italy</td>
</tr>
<tr>
<td>A. Drzezga</td>
<td>Germany</td>
</tr>
<tr>
<td>H. Durak</td>
<td>Turkey</td>
</tr>
<tr>
<td>EANM'17 Reviewers</td>
<td></td>
</tr>
<tr>
<td>R. Delgado-Bolton</td>
<td>Spain</td>
</tr>
<tr>
<td>T. Derlin</td>
<td>Germany</td>
</tr>
<tr>
<td>C. Deroose</td>
<td>Belgium</td>
</tr>
<tr>
<td>W. Deuther-Conrad</td>
<td>Germany</td>
</tr>
<tr>
<td>A. Dias</td>
<td>Denmark</td>
</tr>
<tr>
<td>C. Dolci</td>
<td>Italy</td>
</tr>
<tr>
<td>M. Dottorini</td>
<td>Italy</td>
</tr>
<tr>
<td>A. Drzezga</td>
<td>Germany</td>
</tr>
<tr>
<td>H. Durak</td>
<td>Turkey</td>
</tr>
<tr>
<td>EANM'17 Reviewers</td>
<td></td>
</tr>
<tr>
<td>R. Delgado-Bolton</td>
<td>Spain</td>
</tr>
<tr>
<td>T. Derlin</td>
<td>Germany</td>
</tr>
<tr>
<td>C. Deroose</td>
<td>Belgium</td>
</tr>
<tr>
<td>W. Deuther-Conrad</td>
<td>Germany</td>
</tr>
<tr>
<td>A. Dias</td>
<td>Denmark</td>
</tr>
<tr>
<td>C. Dolci</td>
<td>Italy</td>
</tr>
<tr>
<td>M. Dottorini</td>
<td>Italy</td>
</tr>
<tr>
<td>A. Drzezga</td>
<td>Germany</td>
</tr>
<tr>
<td>H. Durak</td>
<td>Turkey</td>
</tr>
</tbody>
</table>
EANM'17 Reviewers

W. Knapp (Germany)
P. Knoll (Austria)
G. Knudsen (Denmark)
J. Knuutti (Finland)
C. Kobe (Germany)
P. Kolenc Peitl (Slovenia)
M. Konijnlenberg (Netherlands)
J. Környei (Hungary)
I. Kostadinova (Bulgaria)
M. Kostkiewicz (Poland)
J. Kotzerke (Germany)
J. Koziorowski (Sweden)
F. Kraeber-Bodéré (France)
S. Kramer (Switzerland)
G. Kramer-Marek (United Kingdom)
B. Krause (Germany)
A. Krizsan (Hong Kong)
J. Kunikowska (Poland)
J. Kurth (Germany)
T. Kuwert (Germany)

L
T. Lahoutte (Belgium)
A. Lammertsma (Netherlands)
W. Langsteger (Austria)
C. Lapa (Germany)
P. Lass (Poland)
M. Lassmann (Germany)
C. Lauri (Italy)
P. Laverman (Netherlands)
I. Law (Denmark)
E. Lazzeri (Italy)
D. Le Guludec (France)
E. Lemos Pereira (Portugal)
V. Lewington (United Kingdom)
O. Lindner (Germany)
B. Lipsky (United Kingdom)
M. Ljungberg (Sweden)
A. Loft Jakobsen (Denmark)
M. Lonsdale (Denmark)
E. Lopci (Italy)
M. Luster (Germany)

M
M. Maccario (Italy)
G. Madeddu (Italy)
H. Maecke (Germany)
A. Maes (Belgium)
L. Maffioli (Italy)
T. Maina-Nock (Greece)
A. Maldonado (Spain)
N. Manevskà (FYROM-Former Yugoslav Republic of Macedonia)
M. Mann (South Africa)
L. Mansi (Italy)
P. Maipelli (Italy)
F. Marafi (Kuwait)
C. Marcassa (Italy)
M. Marengó (Italy)
G. Mariáns (Italy)
J. Martin (United Kingdom)
J. Martin-Comín (Spain)
D. Mateo Navarro (Spain)
J. Mayol (Spain)
H. Medvedec (Croatia)
M. Meignan (France)
C. Menzel (Germany)
G. Meyer (Germany)
P. Meyer (Germany)
J. Mihailovic (Serbia)
R. Mikolajczak (Poland)
T. Mindt (Austria)
H. Minn (Finland)
M. Mitjavila Casanovas (Spain)
E. Mittra (USA)
T. Mognetti (France)
H. Mohan (United Kingdom)
M. Monsieurs (Belgium)
L. Mortelmans (Belgium)
E. Mossa (Italy)
F. Mottaghy (Germany)
L. Mu (Switzerland)
A. Mudun (Turkey)
C. Müller (Switzerland)
A. Muxi Pradas (Spain)
K. Muylle (Belgium)
M. Myslivecek (Czech Republic)

O
A. Orlova (Sweden)
M. Orrù (Italy)
W. Oyen (United Kingdom)
Z. Ozcan (Turkey)
O. Ozdogan (Turkey)
P. Ozgen Kiratli (Turkey)
M. Ozguven (Turkey)

P
G. Paganelli (Italy)
M. Pagani (Italy)
A. Palmieri (Italy)
S. Pappata (Italy)
C. Pascali (Italy)
M. Patt (Germany)
F. Paycha (France)
P. Payoux (France)
K. Pedersen (Denmark)
I. Perflerás (Spain)
G. Pepe (Italy)
L. Pereira-Arias Bouda (Netherlands)
C. Pestean (Romania)
Z. Petrovic (Slovenia)
A. Pfeffer (Germany)
T. Pfugler (Germany)
B. Pichler (Germany)
R. Pieters (Netherlands)
P. Pilkington (Spain)
E. Pipenko (Ukraine)
C. Pirich (Austria)
A. Plachcinska (Poland)
T. Poeppel (Germany)
V. Prassopoulou (Greece)
E. Prats-Rivera (Spain)
J. Pruim (Netherlands)
A. Pupi (Italy)

R
S. Rac (Croatia)
K. Rahbar (Germany)
M. Rajic (Serbia)
I. Rausch (Austria)
L. Ribah-Vidal (France)
F. Redondo (Chile)
S. Rep (Slovenia)
A. Resende Geao (Portugal)
S. Reske (Germany)
M. Rijpekema (Netherlands)
C. Rischpler (Germany)
M. Rodari (Italy)

M. Rodrigues Radischat (Austria)
### EANM'17 Reviewers

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Rodríguez-Gasén</td>
<td>Spain</td>
</tr>
<tr>
<td>V. Roelants</td>
<td>Belgium</td>
</tr>
<tr>
<td>F. Rogowski</td>
<td>Poland</td>
</tr>
<tr>
<td>A. Roivainen</td>
<td>Finland</td>
</tr>
<tr>
<td>J. Roland</td>
<td>Belgium</td>
</tr>
<tr>
<td>A. Rominger</td>
<td>Germany</td>
</tr>
<tr>
<td>F. Rösch</td>
<td>Germany</td>
</tr>
<tr>
<td>C. Rossetti</td>
<td>Italy</td>
</tr>
<tr>
<td>F. Rouzet</td>
<td>France</td>
</tr>
<tr>
<td>D. Rubello</td>
<td>Ireland</td>
</tr>
<tr>
<td>J. Ruhlmann</td>
<td>Germany</td>
</tr>
<tr>
<td>D. Ryder</td>
<td>Ireland</td>
</tr>
<tr>
<td>EANM'17 Reviewers</td>
<td></td>
</tr>
<tr>
<td>S. Sabri</td>
<td>Germany</td>
</tr>
<tr>
<td>L. Salgado</td>
<td>Portugal</td>
</tr>
<tr>
<td>P. Salvadori</td>
<td>Italy</td>
</tr>
<tr>
<td>M. Salvadori</td>
<td>Italy</td>
</tr>
<tr>
<td>M. Sámal</td>
<td>Czech Republic</td>
</tr>
<tr>
<td>A. Santos</td>
<td>Portugal</td>
</tr>
<tr>
<td>A. Santos</td>
<td>Portugal</td>
</tr>
<tr>
<td>B. Sattler</td>
<td>Germany</td>
</tr>
<tr>
<td>S. Savolainen</td>
<td>Finland</td>
</tr>
<tr>
<td>N. Schafer</td>
<td>Switzerland</td>
</tr>
<tr>
<td>M. Schafer</td>
<td>Germany</td>
</tr>
<tr>
<td>C. Scheiber</td>
<td>France</td>
</tr>
<tr>
<td>R. Schibli</td>
<td>USA</td>
</tr>
<tr>
<td>T. Schindler</td>
<td>USA</td>
</tr>
<tr>
<td>O. Schober</td>
<td>Germany</td>
</tr>
<tr>
<td>H. Schoder</td>
<td>USA</td>
</tr>
<tr>
<td>P. Schubiger</td>
<td>Switzerland</td>
</tr>
<tr>
<td>M. Schwaiger</td>
<td>Germany</td>
</tr>
<tr>
<td>S. Schwarz</td>
<td>Switzerland</td>
</tr>
<tr>
<td>S. Schwarzenböck</td>
<td>Germany</td>
</tr>
<tr>
<td>R. Sciapra</td>
<td>Italy</td>
</tr>
<tr>
<td>J. Sciuik</td>
<td>Germany</td>
</tr>
<tr>
<td>J. Sciut</td>
<td>Italy</td>
</tr>
<tr>
<td>M. Seppanen</td>
<td>Finland</td>
</tr>
<tr>
<td>T. Sevár</td>
<td>Hungary</td>
</tr>
<tr>
<td>E. Seregni</td>
<td>Italy</td>
</tr>
<tr>
<td>A. Serena Puig</td>
<td>Spain</td>
</tr>
<tr>
<td>G. Sgouris</td>
<td>USA</td>
</tr>
<tr>
<td>G. Siclari</td>
<td>Italy</td>
</tr>
<tr>
<td>A. Signore</td>
<td>Italy</td>
</tr>
<tr>
<td>K. Sjögren-Gleisner</td>
<td>Sweden</td>
</tr>
<tr>
<td>A. Skanjeti</td>
<td>Italy</td>
</tr>
<tr>
<td>R. Slart</td>
<td>Netherlands</td>
</tr>
<tr>
<td>G. Smith</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>G. Sobal</td>
<td>Austria</td>
</tr>
<tr>
<td>D. Sobic Saranovic</td>
<td>Serbia</td>
</tr>
<tr>
<td>C. Solbach</td>
<td>Germany</td>
</tr>
<tr>
<td>O. Solin</td>
<td>Finland</td>
</tr>
<tr>
<td>M. Sollini</td>
<td>Italy</td>
</tr>
<tr>
<td>A. Soricelli</td>
<td>Italy</td>
</tr>
<tr>
<td>J. Sowinski</td>
<td>Poland</td>
</tr>
<tr>
<td>K. Spaepen</td>
<td>Belgium</td>
</tr>
<tr>
<td>M. Stabin</td>
<td>USA</td>
</tr>
<tr>
<td>M. Steinbach</td>
<td>Germany</td>
</tr>
<tr>
<td>H. Steiner</td>
<td>Switzerland</td>
</tr>
<tr>
<td>H. Stevens</td>
<td>Netherlands</td>
</tr>
<tr>
<td>M. Stokkel</td>
<td>Netherlands</td>
</tr>
<tr>
<td>S. Strand</td>
<td>Sweden</td>
</tr>
<tr>
<td>K. Strobel</td>
<td>Switzerland</td>
</tr>
<tr>
<td>J. Sunderland</td>
<td>USA</td>
</tr>
<tr>
<td>A. Sundin</td>
<td>Sweden</td>
</tr>
<tr>
<td>A. Varrone</td>
<td>Sweden</td>
</tr>
<tr>
<td>P. Veit-Haibach</td>
<td>Canada</td>
</tr>
<tr>
<td>H. Verberne</td>
<td>Netherlands</td>
</tr>
<tr>
<td>A. Verbruggen</td>
<td>Belgium</td>
</tr>
<tr>
<td>F. Verburg</td>
<td>Germany</td>
</tr>
<tr>
<td>J. Vercueilie</td>
<td>France</td>
</tr>
<tr>
<td>A. Versari</td>
<td>Italy</td>
</tr>
<tr>
<td>J. Verzijlbergen</td>
<td>Netherlands</td>
</tr>
<tr>
<td>B. Vidovic</td>
<td>Germany</td>
</tr>
<tr>
<td>I. Virgolini</td>
<td>Austria</td>
</tr>
<tr>
<td>E. Visscher</td>
<td>Netherlands</td>
</tr>
<tr>
<td>D. Visvikis</td>
<td>France</td>
</tr>
<tr>
<td>M. Vlajkovic</td>
<td>Serbia</td>
</tr>
<tr>
<td>W. Vogel</td>
<td>Netherlands</td>
</tr>
<tr>
<td>D. Vriens</td>
<td>Netherlands</td>
</tr>
<tr>
<td>D. Vugts</td>
<td>Netherlands</td>
</tr>
<tr>
<td>W. Waddington</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>W. Wadsak</td>
<td>Austria</td>
</tr>
<tr>
<td>Z. Walker</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>S. Walrand</td>
<td>Belgium</td>
</tr>
<tr>
<td>J. Walz</td>
<td>France</td>
</tr>
<tr>
<td>W. Weber</td>
<td>USA</td>
</tr>
<tr>
<td>A. Welch</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>H. Wester</td>
<td>Germany</td>
</tr>
<tr>
<td>A. Windhorst</td>
<td>Netherlands</td>
</tr>
<tr>
<td>X. C. Xavier</td>
<td>Belgium</td>
</tr>
<tr>
<td>Z. K. Zambo</td>
<td>Hungary</td>
</tr>
<tr>
<td>L. Zanoni</td>
<td>Italy</td>
</tr>
<tr>
<td>M. Zellweger</td>
<td>Switzerland</td>
</tr>
<tr>
<td>S. Zerdouch</td>
<td>France</td>
</tr>
<tr>
<td>I. Zerizer</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>S. Ziegler</td>
<td>Germany</td>
</tr>
<tr>
<td>L. Zimmer</td>
<td>France</td>
</tr>
<tr>
<td>P. Zucchetta</td>
<td>Italy</td>
</tr>
</tbody>
</table>
## EANM National Societies: Delegates & Deputies

<table>
<thead>
<tr>
<th>Society</th>
<th>Delegate</th>
<th>Deputy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Armenian Society of Nuclear Medicine</td>
<td>V. Barsegian</td>
<td>G. Kevorkian</td>
</tr>
<tr>
<td>Austrian Society of Nuclear Medicine</td>
<td>A. Becherer</td>
<td>W. Langsteger</td>
</tr>
<tr>
<td>Azerbaijan Society of Nuclear Medicine</td>
<td>F. Novruzov</td>
<td>A. Aliyev</td>
</tr>
<tr>
<td>Belgian Society of Nuclear Medicine</td>
<td>F. Jamar</td>
<td>P. De Bondt</td>
</tr>
<tr>
<td>Bosnian Society of Nuclear Medicine</td>
<td>Z. Rajkovaca</td>
<td>D. Rozic</td>
</tr>
<tr>
<td>British Nuclear Medicine Society</td>
<td>S. Vinjamuri</td>
<td>R. Graham</td>
</tr>
<tr>
<td>Bulgarian Society of Nuclear Medicine</td>
<td>P. Bochev</td>
<td>V. Hadzhiyska</td>
</tr>
<tr>
<td>Croatian Society of Nuclear Medicine</td>
<td>M. Franceschi</td>
<td>D. Šnajder</td>
</tr>
<tr>
<td>Cyprus Society of Nuclear Medicine</td>
<td>S. Frangos</td>
<td>R.K. Demetriadou</td>
</tr>
<tr>
<td>Czech Society of Nuclear Medicine</td>
<td>O. Lang</td>
<td>M. Kaminek</td>
</tr>
<tr>
<td>Danish Society of Clinical Physiology and Nuclear Medicine</td>
<td>L. Jensen</td>
<td>P.S. Oturai</td>
</tr>
<tr>
<td>Dutch Society of Nuclear Medicine</td>
<td>R. Bennink</td>
<td>C. Ticheler</td>
</tr>
<tr>
<td>Estonian Nuclear Medicine Society</td>
<td>K. Ulst</td>
<td>S. Nazarenko</td>
</tr>
<tr>
<td>Finnish Society of Nuclear Medicine</td>
<td>M.P. Seppänen</td>
<td>H. Mussalo</td>
</tr>
<tr>
<td>FYR of Macedonian Society of Nuclear Medicine</td>
<td>A. Ugrinska</td>
<td>E. Janevik-Ivanovska</td>
</tr>
<tr>
<td>French Society of Nuclear Medicine</td>
<td>O.J. Mundler</td>
<td>J.-P. Vuillez</td>
</tr>
<tr>
<td>German Society of Nuclear Medicine</td>
<td>J. Kotzerke</td>
<td>F. M. Mottaghy</td>
</tr>
<tr>
<td>Greek Society of Nuclear Medicine &amp; Biology</td>
<td>D. Apostolopoulos</td>
<td>V.C. Prassopoulos</td>
</tr>
<tr>
<td>George de Hevesy Hungarian Society of NM</td>
<td>L. Pavics</td>
<td>J. Varga</td>
</tr>
<tr>
<td>Icelandic Society of Nuclear Medicine</td>
<td>E. Bjorgvinsson</td>
<td>J. Gudjonsdottir</td>
</tr>
<tr>
<td>Society</td>
<td>Delegate</td>
<td>Deputy</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>----------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>Irish Nuclear Medicine Association</td>
<td>M. O’Connell</td>
<td>J. Feeney</td>
</tr>
<tr>
<td>Israeli Society of Nuclear Medicine</td>
<td>Z. Bar-Sever</td>
<td>Z. Keidar</td>
</tr>
<tr>
<td>Italian Society of Nuclear Medicine</td>
<td>M. Picchio</td>
<td>E. Milan</td>
</tr>
<tr>
<td>Latvian Society of Nuclear Medicine</td>
<td>D. Berzina</td>
<td>J. Kedrova</td>
</tr>
<tr>
<td>Lithuanian Society of Nuclear Medicine</td>
<td>D. Vajauskas</td>
<td>I. Kulakiene</td>
</tr>
<tr>
<td>Luxembourg Society of Nuclear Medicine</td>
<td>C. Als</td>
<td>C.J. Picard</td>
</tr>
<tr>
<td>Malta</td>
<td>M.A. Aquilina</td>
<td>A. Samuel</td>
</tr>
<tr>
<td>Norwegian Society of Nuclear Medicine</td>
<td>T.C. Adamsen</td>
<td>R. Sundset</td>
</tr>
<tr>
<td>Polish Society of Nuclear Medicine</td>
<td>R. Czepczynski</td>
<td>A. Sowa-Staszczak</td>
</tr>
<tr>
<td>Portuguese Society of Nuclear Medicine</td>
<td>G. Costa</td>
<td>A.P. Moreira</td>
</tr>
<tr>
<td>Romanian Society of Nuclear Medicine</td>
<td>R. Mititelu</td>
<td>V.C. Mazilu</td>
</tr>
<tr>
<td>Russian Society of Nuclear Medicine</td>
<td>P. Rumyantsev</td>
<td>V. Soukhov</td>
</tr>
<tr>
<td>Serbian Nuclear Medicine Society</td>
<td>D. Sobic-Saranovic</td>
<td>J. Mihailovic</td>
</tr>
<tr>
<td>Slovak Society of Nuclear Medicine</td>
<td>P. Povinec</td>
<td>L. Kaliska</td>
</tr>
<tr>
<td>Slovenian Society of Nuclear Medicine</td>
<td>I. Zagar</td>
<td>K. Zaletel</td>
</tr>
<tr>
<td>Spanish Society of Nuclear Medicine</td>
<td>J.C. Alonso Farto</td>
<td>J.A. Vallejo Casas</td>
</tr>
<tr>
<td>Swedish Society of Nuclear Medicine</td>
<td>A. Sundin</td>
<td>A. Larsson Strömwall</td>
</tr>
<tr>
<td>Swiss Society of Nuclear Medicine</td>
<td>T. Krause</td>
<td>M. Wissmeyer</td>
</tr>
<tr>
<td>Turkish Society of Nuclear Medicine</td>
<td>B.H. Erbas</td>
<td>L.O. Atay</td>
</tr>
<tr>
<td>Ukrainian Society of Nuclear Medicine</td>
<td>to be announced</td>
<td>to be announced</td>
</tr>
</tbody>
</table>
# UEMS/EBNM National Delegates & Deputies

nominated from full UEMS Member Countries

<table>
<thead>
<tr>
<th>Country</th>
<th>Delegate</th>
<th>Deputy</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUSTRIA</td>
<td>I. Virgolini</td>
<td>R. Lipp</td>
</tr>
<tr>
<td>BELGIUM</td>
<td>K. Spaepen</td>
<td>G. Moulin-Romsee</td>
</tr>
<tr>
<td>BULGARIA</td>
<td>E. Piperkova</td>
<td>A.D. Tzonevska</td>
</tr>
<tr>
<td>CROATIA</td>
<td>D. Huic</td>
<td>S. Kusacicic Kuna</td>
</tr>
<tr>
<td>CYPRUS</td>
<td>R.K. Demetriadou</td>
<td></td>
</tr>
<tr>
<td>CZECH REPUBLIC</td>
<td>M. Kaminek</td>
<td>O. Lang</td>
</tr>
<tr>
<td>DENMARK</td>
<td>P.S. Oturai</td>
<td>L. T. Jensen</td>
</tr>
<tr>
<td>ESTONIA</td>
<td>E. Kelk</td>
<td>A. Poksi</td>
</tr>
<tr>
<td>FINLAND</td>
<td>K. Timonen</td>
<td>J. Kemppainen</td>
</tr>
<tr>
<td>FRANCE</td>
<td>E. Gremillet</td>
<td>J.-L. Pelletier</td>
</tr>
<tr>
<td>GERMANY</td>
<td>W. Brenner</td>
<td>M. Gotthardt</td>
</tr>
<tr>
<td>GREECE</td>
<td>I. Iakovou</td>
<td>S. Tsouris</td>
</tr>
<tr>
<td>HUNGARY</td>
<td>L. Pavics</td>
<td>I. Szilvasi</td>
</tr>
<tr>
<td>IRELAND</td>
<td>S. Skehan</td>
<td>R. McDermott</td>
</tr>
<tr>
<td>ITALY</td>
<td>B. Palumbo</td>
<td>A. Ciarmiello</td>
</tr>
<tr>
<td>LATVIA</td>
<td>I. Vevere</td>
<td>A. Berzina</td>
</tr>
<tr>
<td>LITHUANIA</td>
<td>D. Vajauskas</td>
<td>N. Jurkiene</td>
</tr>
<tr>
<td>LUXEMBOURG</td>
<td>P. Paulus</td>
<td>M. Doat</td>
</tr>
<tr>
<td>MALTA</td>
<td>A. Samuel</td>
<td>M. A. Aquilina</td>
</tr>
<tr>
<td>NETHERLANDS</td>
<td>R. J. Bennink</td>
<td>M. Stokkel</td>
</tr>
<tr>
<td>Country</td>
<td>Delegate</td>
<td>Deputy</td>
</tr>
<tr>
<td>------------------</td>
<td>------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>NORWAY</td>
<td>R. Midha</td>
<td>M. Revheim</td>
</tr>
<tr>
<td>POLAND</td>
<td>M. Dziuk</td>
<td>B. Birkenfeld</td>
</tr>
<tr>
<td>PORTUGAL</td>
<td>L. Salgado</td>
<td>M. T. Ferreira</td>
</tr>
<tr>
<td>ROMANIA</td>
<td>G. Andries</td>
<td>R. Mititelu</td>
</tr>
<tr>
<td>SLOVAKIA</td>
<td>A. Vondrak</td>
<td></td>
</tr>
<tr>
<td>SLOVENIA</td>
<td>M. Grmek</td>
<td>D. Hrastnik</td>
</tr>
<tr>
<td>SPAIN</td>
<td>J. C. Alonso Farto</td>
<td>F. Pons</td>
</tr>
<tr>
<td>SWEDEN</td>
<td>E. Trägårdh</td>
<td>P. Grybäck</td>
</tr>
<tr>
<td>SWITZERLAND</td>
<td>A. Boubaker</td>
<td>J. Müller-Brand</td>
</tr>
<tr>
<td>UNITED KINGDOM</td>
<td>S. Dizdarevic</td>
<td></td>
</tr>
</tbody>
</table>

nominated from UEMS Associate Member Countries

<table>
<thead>
<tr>
<th>Country</th>
<th>Delegate</th>
<th>Deputy</th>
</tr>
</thead>
<tbody>
<tr>
<td>TURKEY</td>
<td>Y. Yurekli</td>
<td>Z. Ozcan</td>
</tr>
</tbody>
</table>

nominated from UEMS Observer Countries

<table>
<thead>
<tr>
<th>Country</th>
<th>Delegate</th>
<th>Deputy</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISRAEL</td>
<td>A. Steinmetz</td>
<td>M. Quastel</td>
</tr>
</tbody>
</table>
UEMS/EBNM Committees

Executive Committee

President
L. Maffioli (Italy)

Secretary & Treasurer
S. Frangos (Cyprus)

Member
S. Mirzaei (Austria)

Fellowship Examination

Chair
A. Boubaker (Suisse)

Members
I. Kulakiene (Lithuania)
Z. Ozcan (Turkey)
J. R. Garcia Garzón (Spain)
S. Frangos (Cyprus)

Education & Syllabus

Chair
R. Hustinx (Belgium)

Members
F. Brunotte (France)
H. B. Sayman (Turkey)
D. Huic (Croatia)
T.V. Bogsrud (Norway)

Ex officio:
L. Maffioli (Italy)

CME Accreditation

Chair
T. Varetto (Italy)

Members
E. Lopci (Italy)
A. Haug (Austria)
S. Sillanmäki (Finland)

Accreditation of Nuclear Medicine Departments & Training Centres

Chair
J. Prior (Switzerland)

Members
S. Mirzaei (Austria)
A. García-Burillo (Spain)
N. Mutlukoca (Norway)
P.A.L. Van Boxem (Belgium)
M.L. Hall (United Kingdom)

Corresponding Members
F. Giesel (Germany)
A. Jiménez Hefferman (Spain)
I. Sippo-Tujunen (Finland)
N.G. Hartman (United Kingdom)
S.E. Bouyoucef (Algeria)
A. Ciarmiello (Italy)
General Information

Congress Venue
Austria Center Vienna (ACV)
Bruno-Kreisky-Platz 1
1220 Vienna, Austria
URL: www.acv.at
The ACV is within 2 minutes walking distance from the metro station Kaisermühlen VIC, right behind the Vienna International Center and United Nation’s headquarters. The metro U1 (red line) is the only one connecting the city centre with the ACV.

Audio & Video Recordings
Audio and/or video recordings during the congress are strictly prohibited and may not be made without prior written permission of the EANM Executive Office.

Badges
Badges must be worn at all times throughout the entire congress and during social events. Colour codes are as follows:
Purple – Attendees
Blue – Exhibitors
Green – Day Badges
Red – Accompanying Persons

Banks & ATMs
Banks are usually open from 08:00 to 12:30 and 13:30 to 15:00 (weekdays) and 08:00 to 12:30 and 13:30 to 17:30 (Thursday) and are closed during the weekends.
There are ATMs (Automatic Teller Machine) in the ACV and all over the city of Vienna. Currency exchange offices can be found at the airport, at the main train station and along the main streets of Vienna.

Certificate of Attendance
To obtain your certificate of attendance please visit www.eanm.org, log in to the vEANM Area with your personal account information and refer to the section vConfirmation > Congress related. The certificate will be available within 24 hours after you have scanned your congress badge.

Churches, Synagogues, Mosques
Although Vienna (like the rest of Austria) is mostly Catholic, different religions are practiced by many citizens. Catholic and Protestant churches as well as Synagogues and Mosques services are available. Please contact your hotel concierge for current times of services or nearby houses of prayer.

Climate
The daytime temperatures in mid-end October range between 7°-14° Celsius and it may also be rainy and windy during the entire month.

CME Credits & Certificates
To acquire CME credits, attendees are required to scan their congress badge upon first arrival at the congress venue as well as upon entrance into each CME session. For CME sessions, an evaluation form must also be completed for each session attended.
To obtain your CME certificate(s) please visit www.eanm.org, log in to the vEANM Area with your personal account information and refer to the section vConfirmation > Congress related. The certificate(s) will be available within 24 hours after you have scanned your congress badge.

Congress App
Get your smartphone prepared for EANM’17 and download our congress app for iOS or Android devices! The app provides you with the Scientific Programme, General Information and much more.
General Information

Congress Language
The congress language is English. No simultaneous translation will be provided.

Congress Office
Saturday, October 21, 2017: 07:30 – 18:00
Sunday, October 22, 2017: 07:30 – 18:00
Monday, October 23, 2017: 07:30 – 18:00
Tuesday, October 24, 2017: 07:30 – 18:00
Wednesday, October 25, 2017: 07:30 – 12:00

Congress Social Programme
All registered delegates and accompanying persons are cordially invited to:

Opening Ceremony & Welcome Reception
Saturday, October 21, 2017, 19:30 – 23:00
Hall A/B/C, ACV – Austria Center Vienna

Closing Ceremony & Farewell Cocktail
Wednesday, October 25, 2017, 13:15 – 14:30
Hall A, ACV – Austria Center Vienna
Please note that only delegates and accompanying persons wearing a valid congress name badge will be granted access.

Currency
The official currency in Austria is Euro (€). You can exchange your currency without any limits for total amount at all banks as well as many exchange offices in Vienna. When you are exchanging your currency, you need your passport or official ID card. If you do not have it with you, the bank may refuse to exchange your currency.

Disclaimer
Please note that in the event that the congress is cancelled by the organisers in case of force majeure, the registration fee, hotel deposit and any other service ordered through the registration will be partially refunded or forfeited, subject to the commitments of the congress organisers at that time. You may wish to insure yourself directly against such a risk.

EANM Executive Office
Schmalzhofgasse 26
1060 Vienna, Austria
Phone: +43-(0)1-890 44 27
Fax: +43-(0)1-890 44 27-9
Email: office@eanm.org
URL: www.eanm.org

EANM Members Assembly
The Members’ Assembly will be held on Saturday, October 21, 2017 from 16:00/17:00 – 18:30 (16:00 first call, 17:00 second call).

Please note: Only members in good standing* of the European Association of Nuclear Medicine are eligible to attend the Members’ Assembly.

(*Members in good standing are members who have paid their membership fees for the year 2017)

Electricity
The power supply in Austria is 220/240 V. Most electric outlets adhere to the continental standard (Schuko). Appliances from North America require a transformer and British ones an adaptor for the two-pin sockets which are used in Austria.

Industry Exhibition
Sunday, October 22 – Tuesday, October 24, 2017
09:00 – 17:00 (Level 0 and Level -2)

Insurance & Liability
Neither the organisers nor the Conference Bureau will assume any responsibility whatsoever for damage or injury to persons or property during the congress. It is recommended that participants arrange for their personal travel and health insurance.

Interactive Programme Planner
As in previous years, the EANM again offers the Interactive Programme Planner (IPP). The IPP gives you the opportunity to create your personal schedule and to download your individual abstract book. Visit http://onsite.eanm.org to create your personalized programme.
International Meetings and Announcement Board

Visit Exhibition Hall X2 to get information on upcoming events in Nuclear Medicine and more.

Internet Corner

Internet access will be provided at stations within the industry exhibition in Hall X2 (SUN-TUE) and in Room 2.17 (Level 2) on WED. Please limit the viewing time to max. 5 minutes per person.

Lost & Found

A lost and found service will be provided in the EANM Congress Office for the duration of the congress.

Medical Facilities

Medical assistance and an ambulance service will be available throughout the congress.

Museums

There are many different museums in Vienna. For prices and opening hours please refer to the hotel reception or any tourist information. Some museums and exhibitions are closed on Mondays.

Public Transportation

Public transportation is by far the easiest way to get around the city. The Vienna buses, trams and subways are quick, cheap and all-around excellent. Friday to Sunday the metro services are 24h. If the weather is good, we recommend to take a bike from the public network.

Please make sure to carry a valid ticket! Conductor do not hesitate to fine anyone €103 without a valid ticket (being a tourist is not a valid excuse).

Ticket machines can be found in each metro station.

For further public transportation information of the city of Vienna, please check: http://www.wienerlinien.at/

Public Bicycle Sharing System (CityBike Wien)

The city offers the environment-friendly bike system to both, locals and visitors. Bikes can be hired at over 120 bike stations across Vienna. They can be returned at any empty bikebox at any station. You need a one-time registration (either online or directly at the bike station) and a valid credit card. The first hour is free of charge, the second is for € 1,00 and it progressively increases until € 4,00/hour.

For more information or registration please visit: https://www.citybikewien.at/en/

Public Transportation Ticket (PTT)

All congress participants who book a hotel through the online registration page of EANM which is more than a 15-minute walk away from the congress venue will receive a complimentary public transportation ticket.

For an overview of hotels and their respective distance to the congress venue, please refer to the hotel list on the official EANM homepage.

Public Transportation Tickets (PPTs) are available for purchase at the Public Transportation Ticket Desk, which is located next to the Vienna Information Desk at the entrance foyer of the ACV (Austria Center Vienna).

**Opening hours:**
- Saturday, October 21, 2017: 10:00 – 19:00
- Sunday, October 22, 2017: 09:00 – 18:00
- Monday, October 23, 2017: 09:00 – 18:00
- Tuesday, October 24, 2017: 09:00 – 18:00
- Wednesday, October 25, 2017: 09:00 – 12:00

**Ticket types and prices:**
- 24 hours – 7,60€
- 48 hours – 13,30€
- 72 hours – 16,50€
- 4 days – 18,23€
- 7 days – 25,20€

Please note that the only accepted payment method onsite for PPTs is in cash.

Tickets do not have to be validated prior the first ride – they are valid per date printed on them.
General Information

Restaurants & Nightlife
There is a large choice of restaurants in Vienna, offering various kinds of local or international dishes. Downtown restaurants normally open for lunch from 11:00 to 15:00 and for dinner from 19:30 to 23:00. Cafés and breakfast bars may already open at 08:00, some even earlier. Fast food, kebab, and take-away pizza stalls usually serve food all day long, and some of them stay open until midnight. Bars, night clubs and discotheques usually open from 22:00 to 04:00. Wineries in Grinzing usually open from 16:00 onwards.

Safety Tips / Pick-pockets
In general Vienna is a very safe city. Vienna’s reputation reflects the country at large: according to the 2015 Global Peace Index, Austria was ranked the third most peaceful country in the world.
Nevertheless – as in each tourist hotspot – simply carry your wallets in closed/zipped bags and keep an eye on your bag when standing/walking in crowded areas, packed metro stations or buses, etc. The main emergency numbers are: Police: 133, Ambulance: 144. European Emergency call: 112.

Shopping
Vienna is an ideal destination to shop for a wide variety of items catering to everybody’s tastes and wishes. Shops and department stores are generally open Monday through Friday 9:00 hours to 18:00 hours, some until 19:00 hours, Saturdays 9:00 hours – 17:00 hours. In shopping malls and shopping streets, shops are open on Thursdays until 21:00 hours and on Saturdays until 18:00 hours. Only most souvenir shops are open on Sunday. Flea markets, f.e. Naschmarkt, are open every Saturday morning.
The closest shopping mall towards the congress centre is “Donauzentrum”. It is two stops with the metro line U1 away from the congress centre. The station is “Kagran”.

Social Media
The EANM is represented on several social media platforms to keep members, fans, followers and subscribers up to date on offers and activities of the EANM!
Follow us on and share your experiences by using the Hashtag #EANM ! With the tag #EANMLive you can address questions to the lecturers of CME & Plenary Sessions, which you are attending at that very moment.
With EANM on you can be sure never to miss anything and to always be right on time.
Subscribe to to become one of over 2.000 viewers and enjoy exclusive interviews, videos about social events, making of, insider-information and much more.
Follow us on, where the EANM shares photos of the annual congress and further meetings & events with you.

Taxis
Taxis are not the most affordable alternative to the public transportation. A 15 minutes journey will cost about € 15.00 depending on the traffic. It is not recommended to use taxis in the inner city as a lot of the streets are pedestrian areas and the traffic is quite high. The rates will be shown on the meter next to the driver. The minimum rate for a taxi is approx. € 4. Night rides start at € 4.50
Possible taxi numbers are: 0043/1 40100 or 0043/1 31300.
DO NOT PICK A JOB WITH GREAT VACATION TIME. PICK A CAREER THAT DOES NOT NEED ESCAPING FROM.

(UNKNOWN)

WORKSHOP 1
SUN. OCT. 22, 2017, 13:00-14:30
PRESENTATION SKILLS WORKSHOP

WORKSHOP 2
MON. OCT. 23, 2017, 13:00-14:30
NETWORKING - HOW TO BUILD PROFESSIONAL RELATIONSHIPS

WORKSHOP 3
TUE. OCT. 24, 2017, 13:00-14:30
BE STRONGER - MENTALLY, EMOTIONALLY, PHYSICALLY & SPIRITUALLY
Business Meetings during EANM’17
(chronological)

**EANM Assemblies**

<table>
<thead>
<tr>
<th>EANM Assemblies</th>
<th>Date</th>
<th>Time</th>
<th>Room</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>EANM Delegates Assembly</td>
<td>Sat. Oct. 21</td>
<td>13:45-15:45</td>
<td>Hall E1</td>
<td>0</td>
</tr>
<tr>
<td>EANM Members Assembly</td>
<td>Sat. Oct. 21</td>
<td>17:00-18:30</td>
<td>Hall E2</td>
<td>0</td>
</tr>
</tbody>
</table>

**EANM Committee Meetings**

<table>
<thead>
<tr>
<th>EANM Committee Meetings</th>
<th>Date</th>
<th>Time</th>
<th>Room</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular Committee Meeting</td>
<td>Sat. Oct. 21</td>
<td>09:00-11:00</td>
<td>-2.61-2 (Meeting Room 7)</td>
<td>-2</td>
</tr>
<tr>
<td>Oncology Committee Meeting</td>
<td>Sat. Oct. 21</td>
<td>13:00-15:00</td>
<td>-2.32-3 (Meeting Room 5)</td>
<td>-2</td>
</tr>
<tr>
<td>Bone &amp; Joint Committee Meeting</td>
<td>Sat. Oct. 21</td>
<td>13:00-15:00</td>
<td>-2.61-2 (Meeting Room 7)</td>
<td>-2</td>
</tr>
<tr>
<td>Radiation Protection Committee Meeting</td>
<td>Sat. Oct. 21</td>
<td>15:00-17:00</td>
<td>-2.47-8 (Meeting Room 6)</td>
<td>-2</td>
</tr>
<tr>
<td>Inflammation &amp; Infection Committee Meeting</td>
<td>Sat. Oct. 21</td>
<td>16:00-18:00</td>
<td>-2.61-2 (Meeting Room 7)</td>
<td>-2</td>
</tr>
<tr>
<td>Drug Development Committee Meeting</td>
<td>Sun. Oct. 22</td>
<td>09:00-11:00</td>
<td>-2.61-2 (Meeting Room 7)</td>
<td>-2</td>
</tr>
<tr>
<td>Neuroimaging Committee Meeting</td>
<td>Sun. Oct. 22</td>
<td>11:30-12:30</td>
<td>-2.31 (Meeting Room 4)</td>
<td>-2</td>
</tr>
<tr>
<td>Extraordinary Committee Meeting</td>
<td>Sun. Oct. 22</td>
<td>13:15-14:15</td>
<td>0.31-2 (Meeting Room 2)</td>
<td>0</td>
</tr>
<tr>
<td>Physics Committee Meeting</td>
<td>Mon. Oct. 23</td>
<td>08:00-10:00</td>
<td>-2.61-2 (Meeting Room 7)</td>
<td>-2</td>
</tr>
<tr>
<td>Thyroid Committee Meeting</td>
<td>Mon. Oct. 23</td>
<td>10:00-11:15</td>
<td>-2.47-8 (Meeting Room 6)</td>
<td>-2</td>
</tr>
<tr>
<td>Dosimetry Committee Meeting</td>
<td>Mon. Oct. 23</td>
<td>10:00-11:15</td>
<td>-2.61-2 (Meeting Room 7)</td>
<td>-2</td>
</tr>
<tr>
<td>Technologist Committee Meeting</td>
<td>Mon. Oct. 23</td>
<td>13:00-14:30</td>
<td>-2.61-2 (Meeting Room 7)</td>
<td>-2</td>
</tr>
<tr>
<td>Radiopharmacy Committee Meeting</td>
<td>Mon. Oct. 23</td>
<td>13:00-15:00</td>
<td>-2.32-3 (Meeting Room 5)</td>
<td>-2</td>
</tr>
<tr>
<td>Congress Strategy Committee Meeting</td>
<td>Mon. Oct. 23</td>
<td>13:15-13:45</td>
<td>-2.16 (Meeting Room 9)</td>
<td>-2</td>
</tr>
<tr>
<td>Paediatric Committee Meeting</td>
<td>Mon. Oct. 23</td>
<td>14:30-16:00</td>
<td>-2.61-2 (Meeting Room 7)</td>
<td>-2</td>
</tr>
<tr>
<td>EANM’18 Scientific Programme Committee Meeting</td>
<td>Mon. Oct. 23</td>
<td>16:30-18:00</td>
<td>-2.31 (Meeting Room 4)</td>
<td>-2</td>
</tr>
<tr>
<td>Translational Molecular Imaging Committee Meeting</td>
<td>Tue. Oct. 24</td>
<td>14:30-16:00</td>
<td>0.49-50 (Meeting Room 3)</td>
<td>0</td>
</tr>
</tbody>
</table>
### EANM Committee Interest Group Meetings

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Room Level</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sun. Oct. 22</td>
<td>14:00-15:00</td>
<td>-2.16</td>
<td>Meeting Room 9</td>
</tr>
<tr>
<td>Mon. Oct. 23</td>
<td>10:00-11:00</td>
<td>-2.31</td>
<td>Meeting Room 4</td>
</tr>
<tr>
<td>Mon. Oct. 23</td>
<td>10:00-11:30</td>
<td>-2.32-3</td>
<td>Meeting Room 5</td>
</tr>
<tr>
<td>Mon. Oct. 23</td>
<td>11:30-13:00</td>
<td>-2.31</td>
<td>Meeting Room 4</td>
</tr>
<tr>
<td>Mon. Oct. 23</td>
<td>13:00-14:00</td>
<td>-2.47-8</td>
<td>Meeting Room 6</td>
</tr>
<tr>
<td>Mon. Oct. 23</td>
<td>14:30-16:00</td>
<td>-2.31</td>
<td>Meeting Room 4</td>
</tr>
<tr>
<td>Mon. Oct. 23</td>
<td>15:00-16:00</td>
<td>-2.32-3</td>
<td>Meeting Room 5</td>
</tr>
<tr>
<td>Tue. Oct. 24</td>
<td>08:30-09:30</td>
<td>-2.31</td>
<td>Meeting Room 4</td>
</tr>
<tr>
<td>Tue. Oct. 24</td>
<td>11:30-13:00</td>
<td>-2.32-3</td>
<td>Meeting Room 5</td>
</tr>
<tr>
<td>Tue. Oct. 24</td>
<td>13:00-14:30</td>
<td>Hall C</td>
<td>2</td>
</tr>
<tr>
<td>Wed. Oct. 25</td>
<td>10:00-11:30</td>
<td>0.49-50</td>
<td>Meeting Room 3</td>
</tr>
</tbody>
</table>

### EANM Exhibitors Meeting

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Room Level</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mon. Oct. 23</td>
<td>10:00-11:15</td>
<td>0</td>
<td>Meeting Room 1</td>
</tr>
</tbody>
</table>

### EANM Exhibitors Meeting

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Room Level</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mon. Oct. 23</td>
<td>10:00-11:15</td>
<td>0</td>
<td>Meeting Room 1</td>
</tr>
</tbody>
</table>
### UEMS/EBNM Meetings

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Room</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sun. Oct. 22</td>
<td>14:00-16:00</td>
<td>Room -2.85-6 (Meeting Room 8)</td>
<td>-2</td>
</tr>
<tr>
<td>Mon. Oct. 23</td>
<td>10:00-14:30</td>
<td>Room -2.85-6 (Meeting Room 8)</td>
<td>-2</td>
</tr>
<tr>
<td>Mon. Oct. 23</td>
<td>15:00-17:00</td>
<td>Room 0.14 (Meeting Room 1)</td>
<td>0</td>
</tr>
</tbody>
</table>

### FEBNM Exam Dates*

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Room</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fri. Oct. 20</td>
<td>14:30-17:30</td>
<td>EANM Office*</td>
<td>4</td>
</tr>
<tr>
<td>Sat. Oct. 21</td>
<td>07:30-15:00</td>
<td>EANM Office*</td>
<td>4</td>
</tr>
<tr>
<td>Sat. Oct. 21</td>
<td>16:00-17:00</td>
<td>EANM Office*</td>
<td>4</td>
</tr>
</tbody>
</table>

*Attention: exam takes place in the EANM Executive Office, Schmalzhofgasse 26, 1060 Vienna

### WFNMB Meetings

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Room</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sun. Oct. 22</td>
<td>14:00-16:00</td>
<td>Room -2.61-2 (Meeting Room 7)</td>
<td>-2</td>
</tr>
<tr>
<td>Mon. Oct. 23</td>
<td>11:15-13:00</td>
<td>Room 0.31-2 (Meeting Room 2)</td>
<td>0</td>
</tr>
</tbody>
</table>
• Organ der Deutschen Gesellschaft für Nuklearmedizin (DGN)
• Organ der Österreichischen Gesellschaft für Nuklearmedizin und Molekulare Bildgebung (ÖGN)
• Organ der Schweizerischen Gesellschaft für Nuklearmedizin (SGNM, SSNM)


Berichte aus den Fachgesellschaften und den DGN-Arbeitskreisen, Nachrichten aus Forschung und Industrie sowie Beschreibungen innovativer technischer Geräte, Einrichtungen und Systeme runden das Konzept ab.

Die Abstracts der Jahrestagungen dreier europäischer Fachgesellschaften sind Bestandteil der Kongressausgaben.
Level 0
Austria Center Vienna
Level 2
Austria Center Vienna
Level -2
Austria Center Vienna
Disguising and Revealing

Ultimately it is about the game of transforming art into art

Werner Schuster draws on the possibilities that are open to him technically and thereby makes these his muse. He is the connecting link of this exhibition. Schuster illuminates and exposes. In the “Revealed” project, he emerges not merely as a researcher, but as a creator who, with the help of the technical tools at his disposal, can achieve things that we cannot. Here you can see computed tomography images, either left in the CT cross-section or reconstructed in the desired plane in 2D mode. What is concealed in art can even reveal something new. Rosa Roedellus conceals the sculptural core created by Andreas Buisman, providing it with novel form and meaning. Schuster’s X-ray photography brings him inevitably to this point, and leads him to new interpretative possibilities.

Visit the Exhibition near Foyer D.
Annual Congress of the European Association of Nuclear Medicine

Letter of Invitation

EANM'17

World Leading Meeting

October 21–25, 2017 | Vienna, Austria
30th
ANNUAL SCIENTIFIC MEETING
<table>
<thead>
<tr>
<th>Time</th>
<th>Hall A,B,C</th>
<th>Meeting Room</th>
<th>Hall E1</th>
<th>Hall E2</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:30 - 09:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00 - 09:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30 - 10:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 - 10:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 - 11:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 - 11:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30 - 12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00 - 12:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30 - 13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00 - 13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30 - 14:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00 - 14:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30 - 15:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00 - 15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30 - 16:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00 - 16:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30 - 17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00 - 17:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30 - 18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00 - 18:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30 - 20:30</td>
<td><strong>EANM Opening Ceremony</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Programme Overviews

#### Pre-Symposium 1
**Physics/Dosimetry**
Monte Carlo Simulation / Image Reconstruction – Part I

#### Pre-Symposium 2
**Oncology/Radionuclide Therapy/EWALT**
Integrated Approach for the Diagnosis and Treatment of Primary Liver Tumors (HCC & CCC)

#### Pre-Symposium 3
**Dosimetry/Radiation Protection**
Clinical Introduction of New Radiotherapeutics: Challenges and Opportunities

#### Pre-Symposium 4
**Neuroimaging/Drug Development/Radiopharmacy**
Tau Imaging in Humans

#### Pre-Symposium 5
**Radiopharmacy Validation & Risk Assessment**

#### Pre-Symposium 6
**Physics/Dosimetry**
Monte Carlo Simulation / Image Reconstruction – Part II

#### Pre-Symposium 7
**Oncology/Radionuclide Therapy**
PET Imaging for Response Assessment of Immune Modulation and Therapy

#### Pre-Symposium 8
**Drug Development/Neuroimaging**
The Contribution of Imaging in the Exploration of Autism

#### Pre-Symposium 9
**Translational Molecular Imaging & Therapy/Radiopharmacy/Drug Development**
Bioorthogonal and Click Chemistry for Molecular Imaging

#### Pre-Symposium 10
**Cardiovascular/Inflammation & Infection**
Role of Nuclear Medicine in the Detection of Infection of Cardiac Prosthesis or Devices
<table>
<thead>
<tr>
<th>Time</th>
<th>Hall A</th>
<th>Hall B</th>
<th>Hall C</th>
<th>Hall E1</th>
<th>Hall E2</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-08:30</td>
<td><strong>CME 1</strong></td>
<td></td>
<td></td>
<td><strong>Do. MoRe</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Physics Challenges and Solutions</td>
<td></td>
<td>Technologists’ Opening</td>
<td>Radionuclide Therapy - Miscellaneous (RIT &amp; Bone Palliation)</td>
<td></td>
</tr>
<tr>
<td>08:30-09:00</td>
<td></td>
<td></td>
<td></td>
<td>CTE 1 Technologists/ SNMNI Quality Control and Protocol Standardisation - Tech Guide Launch</td>
<td></td>
</tr>
<tr>
<td>09:00-09:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30-10:00</td>
<td><strong>Plenary 1</strong> incl. Marie Curie Lecture Theranostic Developments for Prostate Cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00-10:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30-11:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00-11:30</td>
<td></td>
<td></td>
<td></td>
<td><strong>CME 1</strong></td>
<td></td>
</tr>
<tr>
<td>11:30-12:00</td>
<td><strong>CME 2</strong></td>
<td></td>
<td></td>
<td>Plenary 1 incl. Marie Curie Lecture Theranostic Developments for Prostate Cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inflammation &amp; Infection/ESVS Vascular Graft Infection</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00-12:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30-13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00-13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30-15:00</td>
<td><strong>CME 3</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cardiovascular How to Perform Myocardial Perfusion Imaging According to EANM Recommendations</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00-15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30-16:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00-16:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30-17:00</td>
<td><strong>CME 4</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oncology PET in Multiple Myeloma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00-17:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30-18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Programme Overview: Sunday, October 22, 2017
<table>
<thead>
<tr>
<th>Hall F1</th>
<th>Hall F2</th>
<th>Hall K</th>
<th>Hall G1</th>
<th>Hall G2</th>
<th>e-Posters</th>
</tr>
</thead>
<tbody>
<tr>
<td>106 Pitfalls &amp; Artefacts 1 - ICC* Neuroimaging/Physics/EFOMP Pitfalls and Artefacts in Visual vs. Quantitative Reading</td>
<td>107 Clinical Oncology We Want a New Drug</td>
<td>108 Committee Symposium 1 Inflammation &amp; Infection/Drug Development ( ^{99m} )Ga-Tracers for Infection Imaging</td>
<td>110 Joint Symposium 16 Neuroimaging/JSNM Educating Referring Physicians and Recognising Their Needs</td>
<td>e-Poster Walks E-PW01, E-PW02, E-PW03</td>
<td></td>
</tr>
</tbody>
</table>

EANM Young Daily Forum


<table>
<thead>
<tr>
<th>Industry Sponsored Symposium</th>
<th>Industry Sponsored Symposium</th>
<th>Industry Sponsored Symposium</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neuroimaging/JSNM</td>
<td>Imaging Amyloid and Amyloidogenesis</td>
<td>Pulmonology &amp; Nephrourology</td>
</tr>
</tbody>
</table>

Conventional & Specialised Nuclear Medicine

<table>
<thead>
<tr>
<th>Creative Teaching</th>
<th>Industry Sponsored Symposium</th>
<th>Industry Sponsored Symposium</th>
</tr>
</thead>
<tbody>
<tr>
<td>NET, a Classic!</td>
<td>Imaging Amyloid and Amyloidogenesis</td>
<td>Pulmonology &amp; Nephrourology</td>
</tr>
</tbody>
</table>

Industry Sponsored Symposium

<table>
<thead>
<tr>
<th>Teaching Session 2 - ICC* Applied Cross Sectional Anatomy and Correlative Imaging – Foot and Ankle</th>
<th>Clinical Oncology NET, a Classic!</th>
<th>Cardiovascular System Myocardial Function, Metabolism &amp; Perfusion – From Preclinical to Clinical Practice</th>
<th>Neurosciences Imaging Neurotransmission Systems in Parkinson</th>
<th>Conventional &amp; Specialised Nuclear Medicine Paediatrics</th>
</tr>
</thead>
<tbody>
<tr>
<td>108</td>
<td>107</td>
<td>108</td>
<td>110</td>
<td>110</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Symposium 16</th>
<th>Symposium 15</th>
<th>Symposium 14</th>
<th>Symposium 13</th>
<th>Symposium 12</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neuroimaging/JSNM</td>
<td>Imaging Amyloid and Amyloidogenesis</td>
<td>Pulmonology &amp; Nephrourology</td>
<td>Neuroradiology</td>
<td>Interventional Cardiology</td>
</tr>
</tbody>
</table>

Programme Overviews
### Programme Overviews

**Monday, October 23, 2017**

<table>
<thead>
<tr>
<th>Hall A</th>
<th>Hall B</th>
<th>Hall C</th>
<th>Hall E1</th>
<th>Hall E2</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>0800 - 0830</strong>&lt;br&gt;061 CME 5&lt;br&gt; Radiopharmacy/Diagnosis&lt;br&gt; Drug Development/Radionuclide Therapy/&lt;br&gt; SNMMI&lt;br&gt; Theranostics and Companion Drugs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>0830 - 0900</strong>&lt;br&gt;062 Joint&lt;br&gt; Symposium 5&lt;br&gt; Cardiovascular/ESMI&lt;br&gt; Imaging Cardiac Remodelling</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>0900 - 0930</strong>&lt;br&gt;063 Technologists&lt;br&gt; Oral Presentations 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>0930 - 1000</strong>&lt;br&gt;064 Do.MoRe&lt;br&gt; PSMA Therapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1000 - 1030</strong>&lt;br&gt;065 M2M&lt;br&gt; Optical/Multimodality Imaging</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1030 - 1100</strong>&lt;br&gt;091 Plenary 2&lt;br&gt; Hot Topics in Nuclear Cardiology!</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1100 - 1130</strong>&lt;br&gt;092 Plenary 2&lt;br&gt; Hot Topics in Nuclear Cardiology!</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1130 - 1200</strong>&lt;br&gt;061 CME 6 - Interactive&lt;br&gt; Bone &amp; Joint&lt;br&gt; Skeletal Scintigraphy Today - Accurate&lt;br&gt; Diagnosis of Bone Disease with&lt;br&gt; Therapeutic Impact</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1200 - 1230</strong>&lt;br&gt;062 Joint&lt;br&gt; Symposium 6&lt;br&gt; Cardiovascular/ESCI&lt;br&gt; Fast-Track Cardiac Imaging: Is There an Ideal One-Stop Shop?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1230 - 1300</strong>&lt;br&gt;063 Technologists&lt;br&gt; Oral Presentations 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1300 - 1330</strong>&lt;br&gt;064 Do.MoRe - Featured&lt;br&gt; Harmonization of Hybrid Molecular Imaging</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1330 - 1400</strong>&lt;br&gt;065 M2M&lt;br&gt; Peptides</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1400 - 1500</strong>&lt;br&gt;061 CME 7&lt;br&gt; Radionuclide Therapy/Thyroid&lt;br&gt; Safety Aspects in Radionuclide Therapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1500 - 1530</strong>&lt;br&gt;062 Symposium 7&lt;br&gt; Bone &amp; Joint&lt;br&gt; Painful Hip Arthroplasty</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1530 - 1600</strong>&lt;br&gt;063 Technologists&lt;br&gt; Oral Presentations&lt;br&gt; 3&lt;br&gt; CTE 3 Technologists&lt;br&gt; Prostate Imaging&lt;br&gt; and Therapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1600 - 1630</strong>&lt;br&gt;064 Committee Symposium 4&lt;br&gt; Do.MoRe&lt;br&gt; Validation of Quantitative Imaging, Dosimetry &amp; Estimates of Uncertainty</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1630 - 1700</strong>&lt;br&gt;065 M2M&lt;br&gt; SPECT/CT &amp; SPECT/MRI</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1700 - 1730</strong>&lt;br&gt;061 CME 8&lt;br&gt; Radionuclide Therapy/Radiopharmacy/Dosimetry&lt;br&gt; Clinical Trial Design for Radionuclide Therapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1730 - 1800</strong>&lt;br&gt;062 Joint&lt;br&gt; Symposium 8&lt;br&gt; Neuroimaging/EANO&lt;br&gt; High Grade Glioma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1800 - 1830</strong>&lt;br&gt;063 CTE 4&lt;br&gt; Technologists/CAMRT&lt;br&gt; Radionuclide Production</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1830 - 1900</strong>&lt;br&gt;064 Do.MoRe&lt;br&gt; Dosimetry in Thyroid Disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1900 - 1930</strong>&lt;br&gt;065 M2M&lt;br&gt; PET/CT</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Programme Overviews

<table>
<thead>
<tr>
<th>Hall F1</th>
<th>Hall F2</th>
<th>Hall K</th>
<th>Hall G1</th>
<th>Hall G2</th>
<th>e-Posters</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pitfalls &amp; Artefacts 3 - ICC*</td>
<td>Clinical Oncology</td>
<td>Committee Symposium 2</td>
<td>Conventional &amp; Specialised Nuclear Medicine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oncology/Inflammation &amp; Infection/Bone &amp; Joint</td>
<td>Rapid Fire Session</td>
<td>Neuroimaging</td>
<td>Musculoskeletal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pitfalls and Artefacts in Abdomen and Pelvis</td>
<td>What’s New? Texture Analysis and More!</td>
<td>PET/MR - Making it Clinical</td>
<td>(Benign)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### EANM Young Daily Forum

<table>
<thead>
<tr>
<th>EANM Young Daily Forum</th>
<th>Industry Sponsored Symposium</th>
<th>Industry Sponsored Symposium</th>
<th>Industry Sponsored Symposium</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pitfalls &amp; Artefacts 4 - ICC*</td>
<td>Clinical Oncology</td>
<td>Committee Symposium 3</td>
<td>Tomorrow's Experts Session</td>
</tr>
<tr>
<td>Paediatrics</td>
<td>Women's Only</td>
<td>Inflammation &amp; Neuroimaging</td>
<td>Best-Ranked Papers from the Under-30s</td>
</tr>
<tr>
<td>Pitfalls and Artefacts - FDG-PET Imaging in Children</td>
<td></td>
<td>Neurological Autoimmune Disorders</td>
<td></td>
</tr>
</tbody>
</table>

### Industry Sponsored Symposium

<table>
<thead>
<tr>
<th>Industry Sponsored Symposium</th>
<th>Industry Sponsored Symposium</th>
<th>Industry Sponsored Symposium</th>
</tr>
</thead>
<tbody>
<tr>
<td>Teaching Session 3 - ICC*</td>
<td>Clinical Oncology</td>
<td>Committee Symposium 5</td>
</tr>
<tr>
<td>Applied Cross Sectional Anatomy and Correlative Imaging – Spine</td>
<td>It’s in the Blood</td>
<td>Cardiovascular System</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cardiac Sarcoidosis &amp; Amyloidosis</td>
</tr>
</tbody>
</table>

### Industry Sponsored Symposium

<table>
<thead>
<tr>
<th>Industry Sponsored Symposium</th>
<th>Industry Sponsored Symposium</th>
<th>Industry Sponsored Symposium</th>
</tr>
</thead>
<tbody>
<tr>
<td>Teaching Session 4 - ICC*</td>
<td>Joint Symposium 18</td>
<td>Cardiovascular System</td>
</tr>
<tr>
<td>Applied Cross Sectional Anatomy and Correlative Imaging – Abdomen &amp; Pelvis</td>
<td>Oncology/ESMO</td>
<td>Cardiac Sympathetic Innervation - 123I-mIBG &amp; Arrhythmias</td>
</tr>
<tr>
<td></td>
<td>Treatment Landscape in Metastatic CRPC</td>
<td></td>
</tr>
</tbody>
</table>

### Industry Sponsored Symposium

<table>
<thead>
<tr>
<th>Industry Sponsored Symposium</th>
<th>Industry Sponsored Symposium</th>
<th>Industry Sponsored Symposium</th>
</tr>
</thead>
<tbody>
<tr>
<td>Committee Symposium 6</td>
<td>Neurosciences</td>
<td>Conventional &amp; Specialised Nuclear Medicine</td>
</tr>
<tr>
<td>Thyroid</td>
<td>Imaging Neurodegeneration in Alzheimer's Disease by TAU and FDG Imaging</td>
<td>Infection &amp; Inflammation</td>
</tr>
</tbody>
</table>

E-PW04, E-PW05, E-PW06, E-PW07, E-PW08
## Programme Overview

### Tuesday, October 24, 2017

<table>
<thead>
<tr>
<th>Hall A</th>
<th>Hall B</th>
<th>Hall C</th>
<th>Hall E1</th>
<th>Hall E2</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>0800 - 08:30</strong></td>
<td><strong>10:30 - 10:00</strong></td>
<td><strong>11:00 - 11:30</strong></td>
<td><strong>1501</strong></td>
<td><strong>1102</strong></td>
</tr>
<tr>
<td><strong>0830 - 09:00</strong></td>
<td><strong>10:30 - 10:00</strong></td>
<td><strong>11:00 - 11:30</strong></td>
<td><strong>1103</strong></td>
<td><strong>1104</strong></td>
</tr>
<tr>
<td><strong>0900 - 09:30</strong></td>
<td></td>
<td><strong>11:00 - 11:30</strong></td>
<td><strong>1105</strong></td>
<td><strong>1106</strong></td>
</tr>
<tr>
<td><strong>0930 - 10:00</strong></td>
<td></td>
<td><strong>11:00 - 11:30</strong></td>
<td></td>
<td><strong>1107</strong></td>
</tr>
<tr>
<td><strong>1000 - 10:30</strong></td>
<td></td>
<td><strong>11:00 - 11:30</strong></td>
<td></td>
<td><strong>1108</strong></td>
</tr>
<tr>
<td><strong>1030 - 11:00</strong></td>
<td></td>
<td><strong>11:00 - 11:30</strong></td>
<td></td>
<td><strong>1109</strong></td>
</tr>
<tr>
<td><strong>1100 - 11:30</strong></td>
<td></td>
<td><strong>11:00 - 11:30</strong></td>
<td></td>
<td><strong>1110</strong></td>
</tr>
<tr>
<td><strong>1130 - 12:00</strong></td>
<td><strong>1107</strong></td>
<td><strong>1108</strong></td>
<td><strong>1111</strong></td>
<td><strong>1112</strong></td>
</tr>
<tr>
<td><strong>1200 - 12:30</strong></td>
<td><strong>10:40 - 10:30</strong></td>
<td><strong>1108</strong></td>
<td><strong>1112</strong></td>
<td><strong>1113</strong></td>
</tr>
<tr>
<td><strong>1230 - 13:00</strong></td>
<td><strong>10:40 - 10:30</strong></td>
<td><strong>1108</strong></td>
<td><strong>1112</strong></td>
<td><strong>1113</strong></td>
</tr>
<tr>
<td><strong>1300 - 13:30</strong></td>
<td><strong>10:40 - 10:30</strong></td>
<td><strong>1108</strong></td>
<td><strong>1112</strong></td>
<td><strong>1113</strong></td>
</tr>
<tr>
<td><strong>1330 - 14:00</strong></td>
<td><strong>10:40 - 10:30</strong></td>
<td><strong>1108</strong></td>
<td><strong>1112</strong></td>
<td><strong>1113</strong></td>
</tr>
<tr>
<td><strong>1400 - 14:30</strong></td>
<td><strong>10:40 - 10:30</strong></td>
<td><strong>1108</strong></td>
<td><strong>1112</strong></td>
<td><strong>1113</strong></td>
</tr>
<tr>
<td><strong>1430 - 15:00</strong></td>
<td><strong>10:40 - 10:30</strong></td>
<td><strong>1108</strong></td>
<td><strong>1112</strong></td>
<td><strong>1113</strong></td>
</tr>
<tr>
<td><strong>1500 - 15:30</strong></td>
<td><strong>10:40 - 10:30</strong></td>
<td><strong>1108</strong></td>
<td><strong>1112</strong></td>
<td><strong>1113</strong></td>
</tr>
<tr>
<td><strong>1530 - 16:00</strong></td>
<td><strong>10:40 - 10:30</strong></td>
<td><strong>1108</strong></td>
<td><strong>1112</strong></td>
<td><strong>1113</strong></td>
</tr>
<tr>
<td><strong>1600 - 16:30</strong></td>
<td><strong>10:40 - 10:30</strong></td>
<td><strong>1108</strong></td>
<td><strong>1112</strong></td>
<td><strong>1113</strong></td>
</tr>
<tr>
<td><strong>1630 - 17:00</strong></td>
<td><strong>10:40 - 10:30</strong></td>
<td><strong>1108</strong></td>
<td><strong>1112</strong></td>
<td><strong>1113</strong></td>
</tr>
<tr>
<td><strong>1700 - 17:30</strong></td>
<td><strong>10:40 - 10:30</strong></td>
<td><strong>1108</strong></td>
<td><strong>1112</strong></td>
<td><strong>1113</strong></td>
</tr>
<tr>
<td><strong>1730 - 18:00</strong></td>
<td><strong>10:40 - 10:30</strong></td>
<td><strong>1108</strong></td>
<td><strong>1112</strong></td>
<td><strong>1113</strong></td>
</tr>
</tbody>
</table>

**Programme Overview**

- **Hall A**
  - **1007** CME 9 Paediatrics/Inflammation & Infection: FDG PET in Paediatric Infections
  - **1007** Joint Symposium 9 Physics/EFOMP: New Developments in CT Technology

- **Hall B**
  - **1007** CME 10 Neuroimaging: Brain PET and SPECT in Dementia - Beyond Alzheimer’s Disease
  - **1007** Joint Symposium 10 Thyroid/ESES/IFCC: Diagnosis and Treatment of Hyperthyroidism

- **Hall C**
  - **1007** CME 11 Paediatrics/Oncology/SIOPEN: SSR Imaging and Therapy in Children
  - **1007** Joint Symposium 11 Cardiovascular/EACVI: Quantification of Myocardial Blood Flow

- **Hall E1**
  - **1007** Joint Symposium 12 Oncology/EORTC: PET Criteria for Response Assessment: Quo vadis PERCIST?
  - **1007** CTE 6 Technologists/Dosimetry: Imaging, Reconstruction and ROI Analysis Techniques for Dosimetry

- **Hall E2**
  - **1007** Joint Symposium 14 Do.MoRe: Rapid Fire Session Radionuclide Therapy, Miscellaneous
  - **1007** Joint Symposium 15 M2M: Best of European Molecular Imaging Meeting - EMIM 2017

**EANM’17**

October 21 – 25, 2017 | Vienna, Austria
### Programme Overviews

<table>
<thead>
<tr>
<th>Hall F1</th>
<th>Hall F2</th>
<th>Hall K</th>
<th>Hall G1</th>
<th>Hall G2</th>
<th>e-Posters</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1106</strong> Pitfalls &amp; Artefacts 5 - ICC* Oncology</td>
<td><strong>1107</strong> Clinical Oncology</td>
<td><strong>1108</strong> Cardiovascular System</td>
<td><strong>1109</strong> Do.MoRe</td>
<td>Clinical Dosimetry for 90Y Radioembolization</td>
<td><strong>1110</strong> Do.MoRe - e-Poster Sessions</td>
</tr>
<tr>
<td>Pitfalls and Artefacts of PET in Neuroendocrine Tumours</td>
<td>Cured or Not Cured?</td>
<td>Myocardial Perfusion PET - 13N-Ammonia and 15O-Water</td>
<td></td>
<td></td>
<td>(08:00-09:30) E-TPW1, E-TPW2, E-TPW3, E-TPW4</td>
</tr>
<tr>
<td><strong>1106</strong> Pitfalls &amp; Artefacts 6 - ICC* Dosimetry</td>
<td><strong>1107</strong> Clinical Oncology</td>
<td><strong>1108</strong> Cardiovascular System</td>
<td><strong>1109</strong> Do.MoRe</td>
<td>Detector Technology</td>
<td><strong>1110</strong> Do.MoRe - e-Poster Walks</td>
</tr>
<tr>
<td>Pitfalls and Artefacts in Pre- and Post-Therapeutic Imaging</td>
<td>Bad Brain</td>
<td>Myocardial Perfusion PET - 13N-Ammonia and 15O-Water</td>
<td></td>
<td></td>
<td>(08:30-09:30) E-PW09, E-PW10, E-PW11, E-PW12</td>
</tr>
</tbody>
</table>

### EANM Young Daily Forum

<table>
<thead>
<tr>
<th>Hall F1</th>
<th>Hall F2</th>
<th>Hall K</th>
<th>Hall G1</th>
<th>Hall G2</th>
<th>e-Posters</th>
</tr>
</thead>
<tbody>
<tr>
<td>EANM Young Daily Forum</td>
<td>Industry Sponsored Symposium</td>
<td>Industry Sponsored Symposium</td>
<td>Industry Sponsored Symposium</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1406</strong> Teaching Session 5 - ICC*</td>
<td><strong>1407</strong> Clinical Oncology</td>
<td><strong>1408</strong> Neurosciences</td>
<td><strong>1409</strong> Do.MoRe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Applied Cross Sectional Anatomy and Correlative Imaging – Cross Sectional CT and PETCT for the TNM Staging of Lung Cancer</td>
<td>Rapid Fire Session</td>
<td>Rapid Fire Session</td>
<td>Thyroid Cancer - Clinical</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mix it Up, please!</td>
<td>Imaging Brain Physiology in Preclinical &amp; Clinical Models</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Teaching Session 6 - ICC*

<table>
<thead>
<tr>
<th>Hall F1</th>
<th>Hall F2</th>
<th>Hall K</th>
<th>Hall G1</th>
<th>Hall G2</th>
<th>e-Posters</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1406</strong> Teaching Session 6 - ICC*</td>
<td><strong>1407</strong> Clinical Oncology</td>
<td><strong>1408</strong> Cardiovascular System</td>
<td><strong>1409</strong> Do.MoRe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Correlative Imaging for Nuclear Medicine Specialists: Interactive Live Radiology and Nuclear Medicine Quiz Using the Experior Medical System</td>
<td>In the Air &amp; Beyond</td>
<td>Myocardial Perfusion SPECT, Quantification &amp; Artificial Intelligence</td>
<td>- Featured - PET/MRI</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Programme Overview

Wednesday, October 25, 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Hall A</th>
<th>Hall B</th>
<th>Hall C</th>
<th>Hall E1</th>
<th>Hall E2</th>
</tr>
</thead>
</table>
| 08:00  | CME 13  
Dosimetry/Radionuclide Therapy/Radiation Protection  
Treatment Planning for Radionuclide Therapy: How Simple Can it Be?  
CME | Joint Symposium 13  
Paediatrics/SNMMI  
Standardisation of Diuresis Renography in Children | Do.MoRe  
Image Reconstruction | M2M  
Radiolabelling Methods |
| 08:30  | 10:00  | 11:00  | 11:30  |
| 09:00  | 12:00 | 13:00 |
| 10:00  | CME 14  
Dosimetry/Radiation Protection/Translational Molecular Imaging & Therapy  
Alpha Particle Dosimetry, Does High LET Lead to High RBE? | Joint Symposium 14  
Oncology/ESSO  
Head & Neck Cancer | CTE 7  
Interactive Technologists/Paediatrics  
Practical and Technical Aspects of Paediatric Nuclear Medicine | Do.MoRe  
Molecular Imaging Artefacts & Corrections | M2M  
CNS/Neurotransmission/Brain Targets |
| 11:00  | 13:00 | 13:30 |
| 11:30  | Awards Ceremony  
(11:45 - 12:15)  
Plenary 4  
Highlights Lecture  
(12:15 - 13:15)  
Closing Ceremony  
(13:15 - 13:20) | 10:30  | 12:30  | 13:00  | 13:30  |
| 12:00  | 12:30 | 13:00 | 13:30 |
| 12:30  | 13:00 | 13:30 | 13:30 |

Programme Overviews
### Programme Overview

<table>
<thead>
<tr>
<th>Hall F1</th>
<th>Hall F2</th>
<th>Hall K</th>
<th>Hall G1</th>
<th>Hall G2</th>
<th>e-Posters</th>
</tr>
</thead>
<tbody>
<tr>
<td>1606.</td>
<td>1607.</td>
<td>1608.</td>
<td>1610.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pitfalls &amp; Artefacts 7 - Oncology</td>
<td>Clinical Oncology</td>
<td>Cardiovascular System</td>
<td>Do.MoRe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pitfalls and Artefacts in PSMA PET Reading</td>
<td>Anything Goes</td>
<td>Myocardial Perfusion PET - 82-Rubidium</td>
<td>Dosimetry in Diagnostic Nuclear Medicine</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Hall F1</th>
<th>Hall F2</th>
<th>Hall K</th>
<th>Hall G1</th>
<th>Hall G2</th>
<th>e-Posters</th>
</tr>
</thead>
<tbody>
<tr>
<td>1701.</td>
<td>1702.</td>
<td>1703.</td>
<td>1704.</td>
<td>1705.</td>
<td>1707.</td>
</tr>
<tr>
<td>CME 14 - Dosimetry/Radiation Protection/Translational Molecular Imaging &amp; Therapy</td>
<td>Joint Symposium 14 - Oncology/ESSO</td>
<td>Interactive Technologists/ Paediatrics</td>
<td>Do.MoRe - Molecular Imaging Artefacts &amp; Corrections</td>
<td>M2M - CNS/Neurotransmission/Brain Targets</td>
<td>Clinical Oncology - PSMA - Saving Nuclear Medicine</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Hall F1</th>
<th>Hall F2</th>
<th>Hall K</th>
<th>Hall G1</th>
<th>Hall G2</th>
<th>e-Posters</th>
</tr>
</thead>
<tbody>
<tr>
<td>1801.</td>
<td>1802.</td>
<td>1803.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Session Overview

- **1606. Pitfalls & Artefacts 7 - Oncology**: Pitfalls and Artefacts in PSMA PET Reading
- **1607. Clinical Oncology**: Anything Goes
- **1608. Cardiovascular System**: Myocardial Perfusion PET - 82-Rubidium
- **1610. Do.MoRe**: Dosimetry in Diagnostic Nuclear Medicine
- **1701. CME 14 - Dosimetry/Radiation Protection/Translational Molecular Imaging & Therapy**: Alpha Particle Dosimetry, Does High LET Lead to High RBE?
- **1702. Joint Symposium 14 - Oncology/ESSO**: Head & Neck Cancer
- **1703. Interactive Technologists/ Paediatrics**: Practical and Technical Aspects of Paediatric Nuclear Medicine
- **1704. Do.MoRe - Molecular Imaging Artefacts & Corrections**: Atherosclerotic Plaque Imaging
- **1705. M2M - CNS/Neurotransmission/Brain Targets**: Any questions?
- **1707. Clinical Oncology**: PSMA - Saving Nuclear Medicine
- **1708. Cardiovascular System**: Atherosclerotic Plaque Imaging
- **1801. Awards Ceremony**: (11:45 - 12:15)
- **1802. Plenary 4 - Highlights Lecture**: (12:15 - 13:15)
Invited Speaker Sessions

Plenary Sessions

Plenary 1: Theranostic Developments for Prostate Cancer (incl. Marie Curie Lecture)
Plenary 2: Hot Topics in Nuclear Cardiology!
Plenary 3: Radiobiology of Molecular Radiotherapy
Plenary 4: Highlights Lecture

Continuing Medical Education (CME) Sessions

CME 1: Physics: Challenges and Solutions for MR-Based Attenuation Correction of PET
CME 2: Inflammation & Infection/ESVS: Vascular Graft Infection
CME 3: Cardiovascular: How to Perform Myocardial Perfusion Imaging According to EANM Recommendations
CME 4: Oncology: PET in Multiple Myeloma
CME 5: Radiopharmacy/Drug Development/Radionuclide Therapy/SNMMI: Theranostics and Companion Drugs
CME 6: Interactive: Bone & Joint: Skeletal Scintigraphy Today - Accurate Diagnosis of Bone Disease with Therapeutic Impact
CME 7: Radionuclide Therapy/Thyroid: Safety Aspects in Radionuclide Therapy
CME 8: Radionuclide Therapy/Radiopharmacy/Dosimetry: Clinical Trial Design for Radionuclide Therapy
CME 9: Paediatrics/Inflammation & Infection: FDG PET in Paediatric Infections
CME 10: Neuroimaging: Brain PET and SPECT in Dementia – Beyond Alzheimer’s Disease
CME 11: Paediatrics/Oncology/SIOPEN: SSR Imaging and Therapy in Children
CME 12: Translational Molecular Imaging & Therapy: Oncology/Neuroimaging: 18F-DOPA and Radiolabelled Choline PET in Recurrent Glioblastoma
CME 13: Dosimetry/Radionuclide Therapy/Radiation Protection: Treatment Planning for Radionuclide Therapy, How Simple Can it Be?
CME 14: Dosimetry/Radiation Protection/Translational Molecular Imaging & Therapy: Alpha Particle Dosimetry, Does High LET Lead to High RBE?
### Continuing Technologist Education (CTE) Sessions

<table>
<thead>
<tr>
<th>CTE 1</th>
<th>Joint Session with SNMMI: Quality Control and Protocol Standardisation – Tech Guide Launch</th>
</tr>
</thead>
<tbody>
<tr>
<td>CTE 2</td>
<td>Interactive: Joint Session with EARL: Interactive EARL for Technologists</td>
</tr>
<tr>
<td>CTE 3</td>
<td>Prostate Imaging and Therapy</td>
</tr>
<tr>
<td>CTE 4</td>
<td>Joint Session with CAMRT: Radionuclide Production</td>
</tr>
<tr>
<td>CTE 5</td>
<td>Gastrointestinal Imaging</td>
</tr>
<tr>
<td>CTE 6</td>
<td>Joint Session with Dosimetry Committee: Imaging, Reconstruction and ROI Analysis Techniques for Dosimetry</td>
</tr>
<tr>
<td>CTE 7</td>
<td>Interactive: Joint Session with Paediatrics Committee: Practical and Technical Aspects of Paediatric Nuclear Medicine</td>
</tr>
</tbody>
</table>

### Mini Course 1:
Cardiology: Pitfalls & Artefacts

### Mini Course 2:
Joint Session with Inflammation & Infection Committee: Inflammation: Pitfalls & Artefacts

### Mini Course 3:
Bone and Joint: Pitfalls & Artefacts

### Committee Symposia

<table>
<thead>
<tr>
<th>Committee Symposium 1</th>
<th>Inflammation &amp; Infection/Drug Development: $^{99m}$Tc Tracers for Infection Imaging</th>
</tr>
</thead>
<tbody>
<tr>
<td>Committee Symposium 2</td>
<td>Neuroimaging/Physics: PET/MR – Making it Clinical</td>
</tr>
<tr>
<td>Committee Symposium 3</td>
<td>Inflammation &amp; Infection/Neuroimaging: Neurological Autoimmune Disorders</td>
</tr>
<tr>
<td>Committee Symposium 4</td>
<td>Dosimetry (DoMoRe Track): Validation of Quantitative Imaging, Dosimetry &amp; Estimates of Uncertainty</td>
</tr>
<tr>
<td>Committee Symposium 5</td>
<td>Radiation Protection: CT-Optimisation of Hybrid Imaging</td>
</tr>
<tr>
<td>Committee Symposium 6</td>
<td>Thyroid: Update on Ablative Therapies in Thyroid Nodules</td>
</tr>
<tr>
<td>Symposium 7</td>
<td>Bone &amp; Joint: Painful Hip Arthroplasty</td>
</tr>
</tbody>
</table>
Invited Speaker Sessions

Joint Symposia

Joint Symposium 1: EANM/ESTRO: Molecular PET Imaging in Adaptive Radiotherapy: Focus on Current Trends, Challenges and Solutions
Joint Symposium 2: EANM/ENETS: Establishing a Position for PRRT in the Multidisciplinary Treatment of NETs
Joint Symposium 3: EANM/ETA-CRN: Update Thyroid Cancer Beyond I-131
Joint Symposium 4: EANM/ICRP/ICRU: Radiological Protection for Patients Receiving Radiopharmaceutical Therapy
Joint Symposium 5: EANM/ESMI: Imaging Cardiac Remodelling
Joint Symposium 6: EANM/EACVI: Fast-Track Cardiac Imaging: Is There an Ideal One-Stop Shop?
Joint Symposium 8: EANM/EANO: High Grade Glioma
Joint Symposium 9: EANM/EFOMP: New Developments in CT Technology
Joint Symposium 10: EANM/ESSES/IFCC: Diagnosis and Treatment of Hyperthyroidism
Joint Symposium 13: EANM/SNMMI: Standardisation of Diuresis Renography in Children
Joint Symposium 14: EANM/ESSO: Head & Neck Cancer
Joint Symposium 15: EANM/ESMI: Best of European Molecular Imaging Meeting – EMIM 2017
Joint Symposium 16: EANM/JSNM: Educating Referring Physicians and Recognising Their Needs
Joint Symposium 18: EANM/ESMO: Treatment Landscape in Metastatic CRPC

Special Session

UEMS/EBNM: Clinical Audit Session
Teaching Sessions

Teaching Session 1: Interactive: Applied Cross Sectional Anatomy and Correlative Imaging – Head and Neck
Teaching Session 2: Interactive: Applied Cross Sectional Anatomy and Correlative Imaging – Foot and Ankle
Teaching Session 3: Interactive: Applied Cross Sectional Anatomy and Correlative Imaging – Spine
Teaching Session 4: Interactive: Applied Cross Sectional Anatomy and Correlative Imaging – Abdomen & Pelvis
Teaching Session 5: Interactive: Applied Cross Sectional Anatomy and Correlative Imaging – Cross Sectional CT and PETCT for the TNM Staging of Cancer
Teaching Session 6: Interactive: Correlative Imaging for Nuclear Medicine Specialists: Interactive Live Radiology and Nuclear Medicine Quiz Using the Experior Medical System

Pitfalls & Artefacts Track

Pitfalls & Artefacts 1: Interactive: Neuroimaging/Physics/EFOMP: Pitfalls and Artefacts in Visual vs. Quantitative Reading
Pitfalls & Artefacts 2: Interactive: Cardiovascular: Pitfalls and Artefacts with CZT Cameras
Pitfalls & Artefacts 3: Interactive: Oncology/Inflammation & Infection/Bone & Joint: Pitfalls and Artefacts in Abdomen and Pelvis
Pitfalls & Artefacts 4: Interactive: Paediatrics: Pitfalls and Artefacts – FDG-PET Imaging in Children
Pitfalls & Artefacts 5: Interactive: Oncology: Pitfalls and Artefacts of PET in Neuroendocrine Tumours
Pitfalls & Artefacts 6: Interactive: Dosimetry: Pitfalls and Artefacts in Pre- and Post-Therapeutic Imaging
Pitfalls & Artefacts 7: Interactive: Oncology: Pitfalls and Artefacts in PSMA PET Reading
Do.MoRe

8th International Symposium on DOsimetry and MOlecular Radiotherapy

The format of the dosimetry and therapy meeting has evolved from a series of interesting and important Radiopharmaceutical and dosimetry symposia held approximately every 5 years since 1970. This series was continued at the EANM congresses 2004 (Helsinki) and at the SNM congress 2009 (Toronto). These symposia were formerly known by ISTARD: "International Symposium on Targeted Radiotherapy and Radiopharmaceutical Dosimetry". From 2015 these symposia are organised annually parallel to the EANM congress and the name has changed to Do.MoRe, emphasizing both the importance of dosimetry and the more regular organisation.

As a separate track within the EANM congress, this symposium will aim to bring together all disciplines concerned with Radiopharmaceutical Dosimetry, Physics, Radiobiology and Molecular Radiotherapy stimulating interdisciplinary scientific discussion.

As a prelude to Do.MoRe, a pre-symposium will be held on Monte Carlo based quantitative imaging reconstruction methods, focusing on PET and SPECT quantification for clinical use in dosimetry and impact of image reconstruction techniques. Another pre-symposium will highlight the added value of dosimetry guided radionuclide therapy, although at present it is seen as a great challenge to perform. Within the Do.MoRe a symposium is organised to outline the currently achievable accuracy in absorbed dose assessments and its reliability for predicting radionuclide therapy outcome.

The EANM Dosimetry, Therapy, Physics and Thyroid Committees will coordinate the scientific programme for the meeting jointly.

M2M

4th Molecule to Man Track on Basic and Translational Research in Molecular Imaging and Therapy

As a separate track within the EANM congress, we bring together all disciplines related to basic and translational research in molecular imaging and therapy, stimulating the interdisciplinary scientific discussion and educating the clinic for future developments in the field.

The format of the track consists of a series of plenary lectures, CME sessions, symposia and scientific sessions with a special focus on Basic and Translational Research.

The EANM Translational Molecular Imaging and Therapy, Drug Development, and Radiopharmacy Committees will coordinate the scientific programme for the meeting jointly.
EANM Young Daily Forum
Sun - Tue, 13:00 – 14:30

The EANM Young Daily Forum is the ideal platform for all young talents attending the EANM congress. It consists of a series of lunch-time sessions open to all participants, focusing particularly on those who are at the beginning of their career.

Each 1.5 hours’ time focuses on a different hot topic, moderated in an interactive way by the professional facilitator Roy Sheppard. Participants will not only benefit from Roy’s vast experience as moderator and speaker, but will also get to know new people in a relaxed atmosphere.

The first two sessions of the EANM Young Daily Forum, that made the lecture room almost burst last year, are back by popular demand. This year’s programme is rounded up by a very special session that will equip participants with tools to handle their daily stress level more easily.

**Sunday, October 21, 2017 | 13:00 – 14:30 | Hall F1**
*Presentation Skills Workshop*

The key to successful presentations is more than applying solid research methods, working hard and achieving outstanding results. Preparing the right things will be as important as handling heated discussions after your presentation. Back by popular demand, the Presentation Skills Workshop will give you an insight into the secrets of delivering powerful and effective presentations.

**Monday, October 22, 2017 | 13:00 – 14:30 | Hall F1**
*Networking - How to Build Professional Relationships*

In times of global connectivity, the value of your personal network cannot be overrated. You are attending events to meet new people and to expand your professional network, but you still feel uncomfortable talking to strangers and cannot remember people’s names? Or do you not consider yourself as talented ‘networker’ at all? In any case, this workshop will be the right one for you to attend.

**Tuesday, October 23, 2017 | 13:00 – 14:30 | Hall F1**
*Be stronger - Mentally, emotionally, physically & spiritually*

Are you constantly pushing yourself harder and harder to ‘keep up’ with your daily business? Do you regularly feel overwhelmed and stressed? Then you need new strategies, practical ideas and simple-to-adopt techniques which will make you more resilient and help you to cope more effectively with your current levels of stress and workload. Learn how to fully recharge your batteries and develop your personal root-system, that will keep you strong and flexible.
Pre-Congress Symposia
Saturday, October 21, 2017

Pre-Congress Symposium 1 (Physics/Dosimetry) 09:00 – 12:00, Hall F2
Monte Carlo Simulation / Image Reconstruction – Part I

Chairs: D. Visvikis (Brest), M. Ljungberg (Lund)

09:00 – 09:30  SPECT/(CT) Quantitative Reconstruction Techniques  
               R. van Holen (Ghent)
09:30 – 10:00  Motion Detection and Correction in PET/CT and PET/MRI  
               K. Thielemans (London)
10:00 – 10:15  Discussion
10:15 – 10:45  Coffee Break
10:45 – 11:10  Basics and Principles of 4D PET Image Reconstruction  
               A. Reader (London)
11:10 – 11:35  TOF Reconstruction Methods and Benefits for Clinical Imaging  
               J. Karp (Philadelphia)
11:35 – 12:00  A Focus on MLAAPET Reconstruction  
               R. Boellaard (Groningen)

Pre-Congress Symposium 2 (EANM/EWALT) 09:00 – 12:00, Hall K1
Integrated Approach for the Diagnosis and Treatment of Primary Liver Tumours (HCC & CCC)

Chairs: E. Lopci (Milan), I. Zerizer (London)

09:00 - 09:20  Pathological Diagnosis and Molecular Predictors in Primary Liver Tumours  
               L. Rubbia-Brandt (Genève)
09:20 - 09:40  Hepatologist Perspective on Primary Liver Tumours from Diagnosis to Prevention  
               Y. Kallis (London)
09:40 - 10:00  Molecular Imaging with FDG and Non-FDG PET Tracers  
               J.-N. Talbot (Paris)
10:00 - 10:20  Cross Sectional Imaging in HCC and CCC Including Novel MRI Techniques for Early Detection  
               M. Ronot (Paris)
10:20 - 10:40  Coffee Break
10:40 - 11:00  Locoregional Treatment in Primary Liver Tumours  
               L. Solbiati (Milan)
11:00 - 11:20  Innovative Surgical Approaches in HCC and CCC  
               G. Torzilli (EWALT, Milan)
11:20 - 11:40  Update on Oncological Management of Cholangiocarcinoma and HCC Including Novel Agent  
               N. Starling (London)
11:40 - 12:00  Role of Transarterial Radioembolisation in Primary Liver Tumours  
               S. Ezzedin (Homburg)
Pre-Congress Symposium 3 (Dosimetry/Radiation Protection) 09:00 – 12:00, Hall K2

Clinical Introduction of New Radiotherapeutics: Challenges and Opportunities

**Chairs:** G. Flux (London), M. Konijnenberg (Rotterdam)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00</td>
<td><strong>Introduction</strong> G. Flux (London) &amp; Mark Konijnenberg (Rotterdam)</td>
</tr>
<tr>
<td>09:15</td>
<td><strong>Phosphorous-32 Microparticles</strong> A. Soman (Sydney)</td>
</tr>
<tr>
<td>09:30</td>
<td><strong>Holmium-166 Microspheres</strong> F. Nijsen (Deventer)</td>
</tr>
<tr>
<td>09:45</td>
<td><strong>Y-90 Glass Microspheres</strong> T. Mauxion (Nantes)</td>
</tr>
<tr>
<td>10:00</td>
<td><strong>Alpha Therapy with Radium-223 and Thorium-227</strong> J. Gay (Berlin)</td>
</tr>
<tr>
<td>10:15</td>
<td><strong>Coffee Break</strong></td>
</tr>
<tr>
<td>10:45</td>
<td><strong>Treatment of NHL with Lutetium-177 Labelled Anti-CD37 Antibodies</strong> J. Dahle (Oslo)</td>
</tr>
<tr>
<td>11:00</td>
<td><strong>Lutetium-177 Peptides and Antibodies</strong> M. Mariani (Saint-Genis-Pouilly)</td>
</tr>
<tr>
<td>11:30</td>
<td><strong>Copper Isotopes for Imaging and Therapy</strong> M. Harris (Sydney)</td>
</tr>
<tr>
<td>11:30</td>
<td><strong>Panel Discussion: Opportunities for Collaborations</strong></td>
</tr>
</tbody>
</table>

Pre-Congress Symposium 4 (Neuroimaging/Drug Development/Radiopharmacy) 09:00 – 12:00, Hall G1

Tau Imaging in Humans

**Chairs:** V. Garibotto (Geneva), A. Lammertsma (Amsterdam)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00</td>
<td><strong>Tau Pathology in Tauopathies</strong> G. Kovacs (Vienna)</td>
</tr>
<tr>
<td>09:20</td>
<td><strong>Preclinical Pharmacokinetic Modelling: A Strategy to Select and Compare Tracers?</strong> S. Kramer (Zurich)</td>
</tr>
<tr>
<td>09:40</td>
<td><strong>Imaging Tau with 18F-THKS317</strong> A. Nordberg (Stockholm)</td>
</tr>
<tr>
<td>10:00</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>10:15</td>
<td><strong>Coffee Break</strong></td>
</tr>
<tr>
<td>10:45</td>
<td><strong>Imaging Tau with 18F-T807</strong> B. van Berckel (Amsterdam)</td>
</tr>
<tr>
<td>11:05</td>
<td><strong>Imaging Tau with 11C-PBB3 and its 18F Derivatives</strong> M. Higuchi (Chiba)</td>
</tr>
<tr>
<td>11:25</td>
<td><strong>Tau as a Therapeutic Target</strong> C. Wischik (Aberdeen)</td>
</tr>
<tr>
<td>11:45</td>
<td><strong>Discussion</strong></td>
</tr>
</tbody>
</table>
## Pre-Congress Symposium 5 (Radiopharmacy)  
**09:00 – 12:00, Hall G2**  
**Validation & Risk Assessment**

**Chairs:** S. Todde (Monza), P. Kolenc Peitl (Ljubljana)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 - 09:20</td>
<td>Economic Impact of Qualification/Validation from Full GMP Perspective</td>
</tr>
<tr>
<td></td>
<td>R. Suchi (Braunschweig)</td>
</tr>
<tr>
<td>09:20 - 09:40</td>
<td>Validation of Analytical Methods</td>
</tr>
<tr>
<td></td>
<td>N. Mathew Gillings (Copenhagen)</td>
</tr>
<tr>
<td>09:40 - 10:00</td>
<td>Risk Assessment - How Much Validation is Needed?</td>
</tr>
<tr>
<td></td>
<td>V. Ferrari (Buckinghamshire)</td>
</tr>
<tr>
<td>10:00 - 10:15</td>
<td>Discussion</td>
</tr>
<tr>
<td>10:15 - 10:45</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>10:45 - 11:15</td>
<td>Design, Qualification and Validation of a Cyclotron Facility: It’s Fun!</td>
</tr>
<tr>
<td></td>
<td>– Practical Example</td>
</tr>
<tr>
<td></td>
<td>L. Perk (Nijmegen)</td>
</tr>
<tr>
<td>11:15 - 11:45</td>
<td>Risk Assessment – Practical Example</td>
</tr>
<tr>
<td></td>
<td>P. Colombo (Monza)</td>
</tr>
<tr>
<td>11:45 - 12:00</td>
<td>Discussion</td>
</tr>
</tbody>
</table>

## Pre-Congress Symposium 6 (Dosimetry/Physics)  
**13:00 – 16:00, Hall F2**  
**Monte Carlo Simulation / Image Reconstruction – Part II**

**Chairs:** C. Hindorf (Lund), M. Ljungberg (Lund)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 – 13:15</td>
<td>Short Introduction to the Principles of Monte Carlo Methods</td>
</tr>
<tr>
<td></td>
<td>D. Visvikis (Brest)</td>
</tr>
<tr>
<td>13:15 – 13:45</td>
<td>Monte Carlo Simulation of PET Systems</td>
</tr>
<tr>
<td></td>
<td>S. Vandenberghe (Ghent)</td>
</tr>
<tr>
<td>13:45 – 14:15</td>
<td>Monte Carlo Simulation of SPECT Systems</td>
</tr>
<tr>
<td></td>
<td>D. Sarrut (Lyon)</td>
</tr>
<tr>
<td>14:15 – 14:45</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>14:45 – 15:15</td>
<td>Quality Assurance of Nuclear Medicine Procedures Using Monte Carlo Simulated Images of Virtual Patients</td>
</tr>
<tr>
<td></td>
<td>M. Ljungberg (Lund)</td>
</tr>
<tr>
<td>15:15 – 15:40</td>
<td>Full Monte Carlo Based Image Reconstruction – Are we there? Part 1</td>
</tr>
<tr>
<td></td>
<td>H. de Jong (Utrecht)</td>
</tr>
<tr>
<td>15:40 – 15:50</td>
<td>Full Monte Carlo Based Image Reconstruction – Are we there? Part 2</td>
</tr>
<tr>
<td></td>
<td>M. Ljungberg (Lund)</td>
</tr>
<tr>
<td>15:50 – 16:00</td>
<td>Concluding Remarks and Panel Discussion</td>
</tr>
</tbody>
</table>
Pre-Congress Symposium 7 (Oncology/Radionuclide Therapy) 13:00 – 16:00, Hall K1

PET Imaging for Response Assessment of Immune Modulation and Therapy

Chairs: N. Aide (Caen), E. de Vries (Groningen)

13:00 - 13:20  Introduction to Immune Modulation Therapy Focusing on PD1- anti PDL1 Checkpoint Inhibitors, CART-Cell Therapy and Vaccine Therapy
S. Lheureux (Toronto)

C. Le Tourneau (Paris)

13:40 - 14:00  Radiologic (CT) Aspects of Immune-Related Tumour Response Criteria and Patterns of Immune-Related Adverse Events in Patients Undergoing Immunotherapy
L. Umutlu (Essen)

14:00 - 14:15  Discussion

14:15 - 14:45  Coffee Break

14:45 - 15:05  FDG PET Imaging for Response to Immune Modulating Therapies
E. Lopci (Milan)

15:05 - 15:25  Case Series: How to Identify Pseudo Progression and Immune Toxicities on FDG PET
R. Hicks (Melbourne)

15:25 - 15:45  New Emerging PET Probes for Monitoring Immune Modulation Therapy
E. de Vries (Groningen)

15:45 - 16:00  Panel Discussion

Pre-Congress Symposium 8 (Drug Development/Neuroimaging) 13:00 – 16:00, Hall K2

The Contribution of Imaging in the Exploration of Autism

Chairs: L. Zimmer (Lyon), A. Gee (London)

13:00 - 13:20  Needs in Biomarkers for Autism Spectrum Disorder
F. Bonnet-Brihault (Tours)

M. Zilbovicius (Paris)

13:40 - 14:00  What Can Bring MRI to Autism Exploration?
A. Retico (Pisa)

14:00 - 14:15  Discussion

14:15 - 14:45  Coffee Break

14:45 - 15:05  Neurotransmission Imaging in Autism
J. Borg (Stockholm)

15:05 - 15:25  New Targets and Future PET Radiotracers for Autism
A. Gee (London)

15:25 - 15:45  Discussion
### Pre-Congress Symposium 9 (Translational Molecular Imaging & Therapy / Radiopharmacy / Drug Development) 13:00 - 16:00, Hall G1

**Bioorthogonal and Click Chemistry for Molecular Imaging**

**Chairs:** B. Cornelissen (Oxford), M. Robillard (Nijmegen)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chair/Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 - 13:35</td>
<td>The Basics of Click Chemistry</td>
<td>V. Bouvet (St John's)</td>
</tr>
<tr>
<td>13:35 - 14:05</td>
<td>Click Chemistry for Imaging of Glycoconjugates</td>
<td>V. Wittmann (Konstanz)</td>
</tr>
<tr>
<td>14:05 - 14:15</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>14:15 - 14:45</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>14:45 - 15:15</td>
<td>Imaging and Therapy Agents Using Click Chemistry</td>
<td>M. Robillard (Nijmegen)</td>
</tr>
<tr>
<td>15:15 - 15:45</td>
<td>Pre-Targeted Imaging Using Click Chemistry</td>
<td>J. Knight (Oxford)</td>
</tr>
<tr>
<td>15:45 - 16:00</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

### Pre-Congress Symposium 10 (Cardiovascular/Inflammation and Infection) 13:00 – 16:00, Hall G2

**Role of Nuclear Medicine in the Detection of Infection of Cardiac Prosthesis or Devices**

**Chairs:** O. Gheysens (Leuven), F. Hyafil (Paris)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chair/Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 - 13:25</td>
<td>Clinical Challenges in Establishing the Diagnosis Endocarditis</td>
<td>J. Ambrosioni (Barcelona)</td>
</tr>
<tr>
<td>13:25 - 13:50</td>
<td>Role of Echocardiography in the Diagnosis of Endocarditis</td>
<td>R. Dulgheru (Liège)</td>
</tr>
<tr>
<td>13:50 - 14:15</td>
<td>Role of White Blood Cell Scintigraphy in the Diagnosis of Endocarditis</td>
<td>P. Erba (Pisa)</td>
</tr>
<tr>
<td>14:15 - 14:45</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>14:45 - 15:10</td>
<td>Role of FDG-PET Imaging in the Diagnosis of Endocarditis</td>
<td>F. Rouzet (Paris)</td>
</tr>
<tr>
<td>15:10 - 15:35</td>
<td>Role of CTA and MRI in the Diagnosis of Endocarditis</td>
<td>G. Feuchtner (Innsbruck)</td>
</tr>
<tr>
<td>15:35 - 16:00</td>
<td>Is There an Optimal Imaging Strategy for Patients Suspected for Endocarditis?</td>
<td>F. Hyafil (Paris)</td>
</tr>
</tbody>
</table>
The ESMIT initiative represents EANM’s response to huge changes in the educational needs of the nuclear medicine community and the rising demand for greater multimodality content. The EANM is convinced that the community needs not only to be educated on all modalities that are used in imaging, but also to be well prepared in the therapeutic applications of our discipline.

More information at eanm.org/esmit or contact us at esmit@eanm.org
Scientific Programme

PS1  Saturday, October 21, 2017, 09:00 - 12:00, Hall F2
Pre-Congress Symposium 1 - Monte Carlo Simulation / Image Reconstruction – Part I

**Chairs:** D. Visvikis (Brest, FRANCE)  
M. Ljungberg (Lund, SWEDEN)

**PS01**  
SPECT/(ICT) Quantitative Reconstruction Techniques  
R. van Holen; Ghent University, Department of Electronics and Information Systems, Ghent, BELGIUM

**PS02**  
Motion Detection and Correction in PET/CT and PET/MRI  
K. Thielemans; University College London, UCL Hospital, Institute of Nuclear Medicine, London, UNITED KINGDOM

**PS05**  
Basics and Principles of 4D PET Image Reconstruction  
A. Reader; King’s College London, Biomedical Engineering Department, London, UNITED KINGDOM

**PS06**  
TOF Reconstruction Methods and Benefits for Clinical Imaging  
J. Karp; University of Pennsylvania school of Arts and Sciences, Department of Radiology, Philadelphia, UNITED STATES OF AMERICA

**PS07**  
A Focus on MLAAPET Reconstruction  
R. Boellaard; University of Groningen, Center for Medical Imaging, Groningen, NETHERLANDS

PS2  Saturday, October 21, 2017, 09:00 - 12:00, Hall K1
Pre-Congress Symposium 2 - EANM/EWALT: Integrated Approach for the Diagnosis and Treatment of Primary Liver Tumours (HCC & CCC)

**Chairs:** E. Lopci (Milan, ITALY)  
I. Zenzer (London, UNITED KINGDOM)

**PS08**  
Pathological Diagnosis and Molecular Predictors in Primary Liver Tumours  
L. Rubbia-Brandt; Hôpitaux Universitaires de Genève, Service de Pathologie Clinique, Geneva, SWITZERLAND

**PS09**  
Hepatologist Perspective on Primary Liver Tumours from Diagnosis to Prevention  
Y. Kallis; Barts and the London School of Medicine and Dentistry, Queen Mary University London, London, UNITED KINGDOM

**PS10**  
Cross Sectional Imaging in HCC and CCC Including Novel MRI Techniques for Early Detection  
M. Ronot; Department of Radiology, Beaujon Hospital, AP-HP, Paris, FRANCE

**PS11**  
Molecular Imaging with FDG and Non-FDG PET Tracers  
J.-N. Talbot; Hospital Tenon, AP-HP & Université P&M Curie, Paris, FRANCE

**PS13**  
Locoregional Treatment in Primary Liver Tumours  
L. A. Solbiati; Department of Biomedical Sciences - Humanitas University, Milan, ITALY

**PS14**  
Innovative Surgical Approaches in HCC and CCC  
G. Torzilli; Humanitas University, School of Medicine, Humanitas Research Hospital, IRCCS, Milan, ITALY

**PS15**  
Update on Oncological Management of Cholangiocarcinoma and HCC Including Novel Agent  
N. Starling; The Royal Marsden, London, UNITED KINGDOM

**PS16**  
Role of Transarterial Radioembolisation in Primary Liver Tumours  
S. Ezzedin; Universitätsklinikum des Saarlandes, Klinik für Nuklearmedizin, Homburg, GERMANY
PS3  Saturday, October 21, 2017, 09:00 - 12:00, Hall K2
Pre-Congress Symposium 3 - Clinical Introduction of New Radiotherapeutics: Challenges and Opportunities

Chairs: G. Flux (London, UNITED KINGDOM)
M. Konijnemberg (Rotterdam, NETHERLANDS)

PS17
Introduction
G. Flux; Royal Marsden NHS Trust & Institute of Cancer Research, London, UNITED KINGDOM.

PS18
Phosphorous-32 Microparticles
A. Soman; Oncosil medical Ltd, Sydney, AUSTRALIA.

PS19
Holmium-166 Microspheres
F. Nijsen; Quirem Medical, Groningen, NETHERLANDS.

PS20
Y-90 Glass Microspheres
T. Mauxion; BTG, Nantes, FRANCE.

PS21
Alpha Therapy with Radium-223 and Thorium-227
J. Gay; Bayer Healthcare, Berlin, GERMANY.

PS23
Treatment of NHL with Lutetium-177 Labelled Anti-CD37 Antibodies
J. Dahle; Nordic Nanovector, Oslo, NORWAY.

PS24
Lutetium-177 Peptides and Antibodies
M. Mariani; Advanced Accelerator Applications, Saint-Genis-Pouilly, FRANCE.

PS25
Copper Isotopes for Imaging and Therapy
M. Harris; Clarity Pharmaceuticals, Sydney, AUSTRALIA.

PS4  Saturday, October 21, 2017, 09:00 - 12:00, Hall G1
Pre-Congress Symposium 4 - Tau Imaging in Humans

Chairs: V. Garibotto (Geneva, SWITZERLAND)
A. Lammertsma (Amsterdam, NETHERLANDS)

PS27
Tau Pathology in Tauopathies
G. Kovacs; Institute of Neurology, Medical University Vienna, Vienna, AUSTRIA.

PS28
Preclinical Pharmacokinetic Modelling: A Strategy to Select and Compare Tracers?
S. Krämer; ETH Zurich, Institute of Pharmaceutical Sciences, Zurich, SWITZERLAND.

PS29
Imaging Tau with 18F-THK5317
A. Nordberg; Center for Alzheimer Research, Karolinska Institutet, Stockholm, SWEDEN.

PS32
Imaging Tau with 18F-T807
T. Timmers; VUMC, Amsterdam, NETHERLANDS.

PS33
Imaging Tau with 11C-PBB3 and its 18F Derivatives
M. Higuchi; National Institutes for Quantum and Radiological Science and Technology National Institute of Radiological Sciences, Chiba, JAPAN.

PS34
Tau as a Therapeutic Target
C. Wischik; School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UNITED KINGDOM.
Pre-Congress Symposium 5 - Validation & Risk Assessment

**Chairs:** S. Todde (Monza, ITALY)  
P. Kolenc Peitl (Ljubljana, SLOVENIA)

**PS36** Economic Impact of Qualification/Validation from Full GMP Perspective  
R. Suchi; GE Healthcare Buchler GmbH & Co. KG, Braunschweig, GERMANY.

**PS37** Validation of Analytical Methods  
N. M. Gillings; Copenhagen University Hospital, Rigshospitalet, PET & Cyclotron Unit, Copenhagen, DENMARK.

**PS38** Risk Assessment - How Much Validation is Needed?  
V. Ferrari; The Grove Centre, QA department, Amersham, Buckinghamshire, UNITED KINGDOM.

**PS41** Design, Qualification and Validation of a Cyclotron Facility: It’s Fun! – Practical Example  
L. Perk; Radboud University Medical Center, Radboud Translational Medicine, Nijmegen, NETHERLANDS.

**PS42** Risk Assessment – Practical Example  
P. Colombo; IBA Molecular Italy, San Gerardo dei Tintori Hospital, Monza, ITALY.

Pre-Congress Symposium 6 - Monte Carlo Simulation / Image Reconstruction – Part II

**Chairs:** C. Hindorf (Lund, SWEDEN)  
M. Ljungberg (Lund, SWEDEN)

**PS44** Short Introduction to the Principles of Monte Carlo Methods  
D. Visvikis; CHU MORVAN, Bat 2 bis, U650 INSERM, LATIM - I35, Brest, FRANCE.

**PS45** Monte Carlo Simulation of PET Systems  
S. Vandenberghe; Ghent University, Department of Electronics and information systems, Ghent, BELGIUM.

**PS46** Monte Carlo Simulation of SPECT Systems  
D. Sarrut; Léon Bérard cancer center, CREATIS, Lyon, FRANCE.

**PS48** Quality Assurance of Nuclear Medicine Procedures Using Monte Carlo Simulated Images of Virtual Patients  
M. Ljungberg; Lund University, Medical Radiation Physics, Lund, SWEDEN.

**PS49** Full Monte Carlo Based Image Reconstruction – Are we there? Part 1  
H. de Jong; University Medical Center Utrecht, Image Sciences Institute, Utrecht, NETHERLANDS.

**PS50** Full Monte Carlo Based Image Reconstruction – Are we there? Part 2  
M. Ljungberg; Lund University, Medical Radiation Physics, Lund, SWEDEN.
Pre-Congress Symposium 7 - PET Imaging for Response Assessment of Immune Modulation and Therapy

**Chairs:** N. Aide (Caen, FRANCE)  
E. de Vries (Groningen, NETHERLANDS)

**PS52**  
Introduction to Immune Modulation Therapy Focusing on PD1- anti PDL1 Checkpoint Inhibitors, CAR T-Cell Therapy and Vaccine Therapy  
S. Lheureux; Princess Margaret Hospital, Toronto, CANADA.

**PS53**  
Unmet Challenges and Clinical Needs for Assessing Response to Immunotherapy  
C. Le Tourneau; Oncology Department Cure Institute, Paris, FRANCE.

**PS54**  
Radiologic (CT) Aspects of Immune-Related Tumour Response Criteria and Patterns of Immune-Related Adverse Events in Patients Undergoing Immunotherapy  
L. Umutlu; Radiology Department, University Hospital, Essen, GERMANY.

**PS57**  
FDG PET Imaging for Response to Immune Modulating Therapies  
E. Lopci; Istituto Clinico Humanitas IRCCS, Nuclear Medicine Department, Milano, ITALY.

**PS58**  
Case Series: How to Identify Pseudo Progression and Immune Toxicities on FDG PET  
R. Hicks; Cancer Imaging, Peter Mac Callum Cancer Institute, Melbourne, AUSTRALIA.

**PS59**  
New Emerging PET Probes for Monitoring Immune Modulation Therapy  
E. de Vries; University Medical Centre, Medical Oncology Department, Groningen, NETHERLANDS.

Pre-Congress Symposium 8 - The Contribution of Imaging in the Exploration of Autism

**Chairs:** L. Zimmer (Lyon, FRANCE)  
A. Gee (London, UNITED KINGDOM)

**PS61**  
Needs in Biomarkers for Autism Spectrum Disorder  
F. Bonnet-Brihaul; University Hospital of Tours, INSERM, Department of Child Psychiatry, Tours, FRANCE.

**PS62**  
Social Brain and Autism  
M. Zilbovicius; University René Descartes, INSERM, Hôpital Necker, Department of Pediatric Radiology, Paris, FRANCE.

**PS63**  
What Can Bring MRI to Autism Exploration?  
A. Retico; Istituto Nazionale di Fisica Nucleare, University of Pisa, Pisa, ITALY.

**PS66**  
Neurotransmission Imaging in Autism  
J. Borg; Karolinska Institutet, Centre for Psychiatric Research, Stockholm, SWEDEN.

**PS67**  
New Targets and Future PET Radiotracers for Autism  
A. Gee; King’s College London, Division of Imaging Sciences, London, UNITED KINGDOM.
PS9  Saturday, October 21, 2017, 13:00 - 16:00, Hall G1

Pre-Congress Symposium 9 - Bioorthogonal and Click Chemistry for Molecular Imaging

*Chairs*: B. Cornelissen (Oxford, UNITED KINGDOM)  
M. Robillard (Nijmegen, NETHERLANDS)

**PS69**
The Basics of Click Chemistry
*V. Bouvet; Memorial University of Newfoundland, Department of Radiology, St. John's, St. John's, CANADA.*

**PS70**
Click Chemistry for Imaging of Glycoconjugates
*V. Wittmann; Universitaet Konstanz, Konstanz, GERMANY.*

**PS73**
Imaging and Therapy Agents Using Click Chemistry
*M. Robillard; Tagworks Pharmaceuticals, Nijmegen, NETHERLANDS.*

**PS74**
Pre-Targeted Imaging Using Click Chemistry
*J. Knight; University of Oxford, Department of Oncology, Oxford, UNITED KINGDOM.*

PS10  Saturday, October 21, 2017, 13:00 - 16:00, Hall G2

Pre-Congress Symposium 10 - Role of Nuclear Medicine in the Detection of Infection of Cardiac Prosthesis or Devices

*Chairs*: O. Gheysens (Leuven, BELGIUM)  
F. Hyafil (Paris, FRANCE)

**PS76**
Clinical Challenges in Establishing the Diagnosis Endocarditis
*J. Ambrosioni; Hospital Clinic - IDIBAPS, University of Barcelona, Barcelona, SPAIN.*

**PS77**
Role of Echocardiography in the Diagnosis of Endocarditis
*R. Dulgheru; Department of Cardiology, University of Liege Hospital, GIGA-Cardiovascular Sciences, Liege, BELGIUM.*

**PS78**
Role of White Blood Cell Scintigraphy in the Diagnosis of Endocarditis
*P. Erba; Nuclear Medicine, Department of Translational Research and New Technology in Medicine, University of Pisa, Pisa, ITALY.*

**PS80**
Role of FDG-PET Imaging in the Diagnosis of Endocarditis
*F. Rouzet; Nuclear Medicine Department and Département Hospital Universitaire Fibrose Inflammation et Remodelage en Pathologies Cardiovasculaires, Bichat Claude Bernard Hospital, AP-HP, University of Paris VII, Paris, FRANCE.*

**PS81**
Role of CTA and MRI in the Diagnosis of Endocarditis
*G. Feuchtner; Department of Radiology, Innsbruck Medical University, Innsbruck, AUSTRIA.*

**PS82**
Is There an Optimal Imaging Strategy for Patients Suspected for Endocarditis?
*F. Hyafil; CHU Bichat, AP-HP, Nuclear Medicine, PARIS, FRANCE.*
### CME 1 - Physics: Challenges and Solutions for MR-Based Attenuation Correction of PET

**Chairs:**

- S. Vandenberghe (Ghent, BELGIUM)
- S. Nekolla (Munich, GERMANY)

#### OP-001

*Introduction to MR-Based AC*

- **L. Eikenes,** Department of Circulation and Medical Imaging, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, NORWAY.

#### OP-002

*MR Based Attenuation Correction for Brain*

- **N. Burgos,** University College London, Translational Imaging Group, London, UNITED KINGDOM.

#### OP-003

*MR Based Attenuation Correction for the Body*

- **G. Schramm,** University of Leuven, Nuclear Medicine & Molecular Imaging, Leuven, BELGIUM.

### Joint Symposium 1 - EANM/ESTRO: Molecular PET Imaging in Adaptive Radiotherapy: Focus on Current Trends, Challenges and Solutions

**Chairs:**

- A. Loft (Copenhagen, DENMARK)
- E. Troost (Dresden, GERMANY)

#### OP-004

*Prostate Cancer: The Radiation Oncologist’s Point of View*

- **W. Vogel,** The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Departments of Nuclear Medicine and Radiation Oncology, Amsterdam, NETHERLANDS.

#### OP-005

*Prostate Cancer: The Nuclear Medicine Physician’s Point of View*

- **M. Picchio,** IRCCS San Raffaele Scientific Institute, Nuclear Medicine Department, Milan, ITALY.

#### OP-006

*Cervical Cancer: The Radiation Oncologist’s Point of View*

- **E. Troost,** Universitatsklinikum Carl Gustav Carus, Department of Radiotherapy and Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology-OncoRay, Dresden, GERMANY.

#### OP-007

*Cervical Cancer: The Nuclear Medicine Physician’s Point of View*

- **J. A. Adam,** Academic Medical Center Amsterdam, Department of Radiology and Nuclear Medicine, Amsterdam, NETHERLANDS.

#### OP-008

*Welcome and Opening of the Technologist’s Track*

- **S. Rep,** Ljubljana, SLOVENIA
- **D. Gilmore,** Boston, UNITED STATES OF AMERICA

### Joint Session with SNMMI:

#### Quality Control and Protocol Standardisation - Tech Guide Launch

**Chairs:**

- S. Rep (Ljubljana, SLOVENIA)
- D. Gilmore (Boston, UNITED STATES OF AMERICA)

#### OP-009

*Quality Control for PET Systems*

- **C. Pestean,** Dept. of Nuclear Medicine, “Ion Chiricuță” Oncology Institute, Cluj-Napoca, ROMANIA

#### OP-010

*Optimisation of PET-CT – Acquisition & Reconstruction*

- **D. M. York,** Chattanooga State Community College, Chattanooga, UNITED STATES OF AMERICA

#### OP-011

*Radionuclide Dose Calibrator*

- **A. Socan,** Department of Nuclear Medicine; University Medical Center, Ljubljana, SLOVENIA

### Do.MoRe: Radionuclide Therapy - Miscellaneous (RIT & Bone Palliation)

**Chairs:**

- M. Lassmann (Wurzburg, GERMANY)
- F. Kraeber-Bodéré (Nantes, FRANCE)

#### OP-012

*Pre-dosing with Lilotomab Prior to Antibody-Radionuclide Conjugate Therapy with $^{177}$Lu-Lilotomab Satetraextan Significantly Increases the Ratio of Tumour to Red Marrow Absorbed Dose in non-Hodgkin Lymphoma Patients*

- **J. Blakkisrud,** 1, A. Løndalen2, J. Dahle3, A. C. Martinsen4,1, H. Holte5, A. Kolstad5, C. Stokke1,6; 1Department of Diagnostic Physics, Oslo University Hospital, Oslo, NORWAY, 2Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, NORWAY, 3Nordic Nanovector ASA, Oslo, NORWAY, 4The Department of Physics, University of Oslo, Oslo, NORWAY, 5Department of Oncology, Radiumhospitalet, Oslo University Hospital, Oslo, NORWAY, 6Oslo and Akershus University College of Applied Science, Oslo, NORWAY

---

*EANM'17*

30th Annual Congress of the European Association of Nuclear Medicine
OP-013
Bi-213-anti-EGFR-MAb therapy of recurrent bladder cancer - a pilot study
K. Scheidhauer1, C. Seidl1, F. Bruchertseifer1, C. Apostolidis1, M. Autenrieth1, F. Kurz1, T. Horn1, M. Schwager1, J. Gschwend1, C. D’Alessandria1, C. Pfob1, R. Senekowitsch-Schmidtke1, A. Morgenstern2, 1Technische Universität München, München, GERMANY, 2EC, JRC, Directorate for Nuclear Safety and Security, Karlsruhe, GERMANY.

OP-014
Synfrizz : A first in Man study investigating the biodistribution, the safety and optimal recommended dose of a new radiolabeled monoclonal antibody targeting Frizzled homolog 10 (FZD10) in patients with relapsed or refractory non resectable synovial sarcomas
A. Giraudet1, P. Cassier1, G. Garin1, J. Badel1, S. Bacconnier1, D. Sarrut1, D. Kryza1, C. Iwao-Fukukawa1, Y. Nakamura1, A. Halty1, D. Perol1, J. Blay1, 1Centre Léon Bérard, Lyon, FRANCE, 2Centre Léon Bérard, Lyon, FRANCE, 3Céretis, Lyon, FRANCE, 4UCBL1, Lyon, FRANCE, 5OncoTherapy Science, Kawasaki City, JAPAN, 6University of Tokyo, Tokyo, JAPAN, 7Céretis, Lyon, FRANCE.

OP-015
Radioimmunotherapy with Panitumumab Modified with Metal Chelating Polymers (MCP) Labeled with 111In and 177Lu - A Novel Theranostic for Pancreatic Cancer
S. Aghevlian1, D. Hedley2, M. Winnik3, R. Reilly4, 1Department of Pharmaceutical Sciences, University of Toronto, Toronto, ON, CANADA, 2Princess Margaret Cancer Centre, University Health Network, Toronto, ON, CANADA, 3Department of Chemistry, University of Toronto, Toronto, ON, CANADA, 4Toronto General Research Institute and Joint Department of Medical Imaging, University Health Network, Toronto, ON, CANADA, 5Department of Medical Imaging, University of Toronto, Toronto, ON, CANADA.

OP-016
Radium-223-Dichloride in Castration-Resistant Metastatic Prostate Cancer: Therapy Assessment with 11C-choline PET/CT and Bone Scan
P. Ghedini1, T. Graziani1, E. Lodi Rizzini1, G. Lima1, I. Bossert1, F. Ceci1, G. Montini1, C. Pettinato1, F. Monari1, V. Dionisi1, A. Morganti1, P. Castellucci1, S. Fant1, 1Nuclear Medicine S. Orsola-Malpighi Hospital - University of Bologna, Bologna, ITALY, 2Nuclear Medicine & Physics Unit, Fondazione Salvatore Maugeri, Pavia, ITALY, 3Fisica Sanitaria - S. Orsola-Malpighi Hospital - University of Bologna, Bologna, ITALY, 4U.O. Radioterapia - S. Orsola-Malpighi Hospital - University of Bologna, Bologna, ITALY, 5U.O. Radioterapia - S. Orsola-Malpighi Hospital - University of Bologna, Bologna, ITALY.

OP-017
Quantification of skeletal tumor burden on bone scintigraphy for prediction of overall survival in Radium-223 therapy
M. Ø. Fosbøl1, P. M. Petersen, A. Kjaer, J. Mortensen; Rigshospitalet, Copenhagen, DENMARK.

OP-018
Radium-223 in Combination with Paclitaxel in Cancer Patients with Bone Metastases: Safety Results from an Open-Label, Multicenter Phase 1b Study
J. S. Lopez1, R. Perets2, S. Danson1, H. Joensuu1, A. Peer1, S. J. Harris1, F. Souza1, B. Ploeger1, K. M. C. Pereira1, R. Geva1, 1The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, UNITED KINGDOM, 2Rambam Health Care Campus, Haifa, ISRAEL, 3Sheffield Experimental Cancer Medicine Centre, Weston Park Hospital, Sheffield, UNITED KINGDOM, 4Helsinki University Hospital, Helsinki, FINLAND, 5Bayer HealthCare Pharmaceuticals, Whippany, NJ, UNITED STATES OF AMERICA, 6Bayer Pharma AG, Berlin, GERMANY, 7Bayer Pharma AG, São Paulo, BRAZIL, 8Tel Aviv Sourasky Medical Center, Tel Aviv, ISRAEL.

OP-019
Analysis of Clinical parameters for the outcome prediction of mCRPC patients treated with 223Ra-dichloride
V. Frantellizzi1, G. A. Follacchio, S. Sollaku, J. Lazzi, A. Farcomeni, M. Pacilio, M. Liberatoro, F. Monteleone, G. De Vincentis; Sapienza University of Rome, Rome, ITALY.

OP-020
Preclinical evaluation of astatinated nanobodies for targeted alpha therapy
Y. D. Dekempeneer1, 2, 3, M. D’Huyvetter1, A. Eneheim2, C. Xavier1, T. Lahoutte1, 4, F. Bäck5, H. Jensen2, V. Caveliers1, 2, S. Lindegren3, 1Vrije Universiteit Brussel, Jette/Brussel, BELGIUM, 2Belgian Nuclear Research Center (SCK-CEN), Mol, BELGIUM, 3Targeted Alpha Therapy group, University of Gothenburg, Gothenburg, SWEDEN, 4Cyclotron and PET Unit, UZ Brussels, Jette/Brussel, BELGIUM, 5Synkera Biosciences, Umeå, SWEDEN.
OP-021
Locoregional alpha-RIT, a novel therapeutic option, against peritoneal metastasis of gastric cancer
H. K. Li,1,2, Y. Morokoshi,1, S. Hasegawa1; 1Graduate School of Medical and Pharmaceutical Sciences, Chiba University, Chiba, JAPAN, 2Research Fellow of Japan Society for the Promotion of Science, Tokyo, JAPAN, 3National Institute of Radiological Sciences, QST, Japan, Chiba, JAPAN.

OP-022
Re-localization of 212Pb from 224Ra sources due to thoron (220Rn) diffusion
E. Napoli1,2, S. Westrøm1,2,3, T. B. Bønsdorff1, Ø. S. Bruland1,2, R. H. Larsen1; 1University of Oslo, Oslo, NORWAY, 2The Norwegian Radium Hospital, Oslo, NORWAY, 3Oncoinvent AS, Oslo, NORWAY.

OP-024
Novel Intracavitary α-Therapeutic Based on Calcium Carbonate Microparticles As Carriers for 224Ra: Biodistribution and Toxicity in Mice
S. Westrøm1,2,3, T. B. Bønsdorff1, M. M. Malenge1, Ø. S. Bruland1,2, R. H. Larsen1; 1University of Oslo, Oslo, NORWAY, 2The Norwegian Radium Hospital, Oslo, University Hospital, Oslo, NORWAY, 3Oncoinvent AS, Oslo, NORWAY.

OP-025
A Novel Multi-Component Reaction for 211At-Astatination: Providing new Tools for (pre) Targeted Alpha Therapy
C. Denk1, E. H. K. Aneheim1, S. Lindegren1, M. Herth1, M. Wilkovitsch1, H. Mikula1; 1Vienna University of Technology, Vienna, AUSTRIA, 2The Sahlgrenska Academy, University of Gothenburg, Gothenburg, SWEDEN, 3Ringhospitalet, Copenhagen, DENMARK, 4University of Copenhagen, Copenhagen, DENMARK.

OP-026
Bismuth-213 labeled nanobodies as a new treatment approach in Targeted Alpha Therapy
Y. Dekempeneer, Jr.,1,2, D. Maertens2, M. Gysemans1, T. Lahoute2,3, M. D'Huyvetter1, T. Cardinaels1,2, V. Cavaliere1,2; 1Vrije Universiteit Brussel, Jette/ Brussel, BELGIUM, 2Belgian Nuclear Research Center (SCK•CEN), Mol, BELGIUM, 3Department of Nuclear Medicine (UZBrussel), Jette/ Brussel, BELGIUM, 4Department of Chemistry (KU Leuven), Leuven, BELGIUM.
### Joint Symposium 16 - EANM/JSNM: Educating Referring Physicians and Recognising Their Needs

**Chairs:** M. Hosono (Osaka-Sayama, JAPAN)  
S. Hesse (Leipzig, GERMANY)

<table>
<thead>
<tr>
<th>OP-036</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Increasing the Reliance of Referring Physicians on Nuclear Cardiology: A Cardiologist’s Perspective</strong></td>
</tr>
<tr>
<td><strong>T. Chikamori</strong>; Department of Cardiology, Tokyo Medical University, Tokyo, JAPAN.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>OP-037</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>The Role of PET for Selecting Surgical Candidates and Deciding a Mode of Surgery for Lung Cancer</strong></td>
</tr>
<tr>
<td><strong>K. Suzuki</strong>; Department of General Thoracic Surgery, Juntendo University School of Medicine, Tokyo, JAPAN.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>OP-038</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>The Integration of Dementia Molecular Imaging into Clinical Management</strong></td>
</tr>
<tr>
<td><strong>V. Garibotto</strong>; Geneva University and Geneva University Hospitals, Geneva, SWITZERLAND.</td>
</tr>
</tbody>
</table>

### Plenary 1: Theranostic Developments for Prostate Cancer (incl. Marie Curie Lecture)

**Chairs:** K. Muylle (Brugge, BELGIUM)  
F. Giammarile (Lyon, FRANCE)

<table>
<thead>
<tr>
<th>OP-040</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical Aspects</strong></td>
</tr>
<tr>
<td><strong>J. Walz</strong>; Institute Paoli-Calmettes, Dept. of Urology, Marseille, FRANCE.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>OP-041</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PSMA Imaging – Which Knife is the Sharpest?</strong></td>
</tr>
<tr>
<td><strong>K. Herrmann</strong>; Universitätsklinikum Würzburg, Nuclear Medicine, Würzburg, GERMANY.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>OP-042</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PSMA Labelled with Alfa-Emitters</strong></td>
</tr>
<tr>
<td><strong>U. Haberkorn</strong>; University Hospital Heidelberg, Department of Nuclear Medicine, Heidelberg, GERMANY.</td>
</tr>
</tbody>
</table>

## Joint Symposium 2 - EANM/ENETS: Establishing a Position for PRRT in the Multidisciplinary Treatment of NETs

**Chairs:** L. Bodei (New York, UNITED STATES OF AMERICA)  
D. O’Toole (Dublin, IRELAND)

<table>
<thead>
<tr>
<th>OP-046</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Current Status of PRRT in the Post-NETTER1 Phase</strong></td>
</tr>
<tr>
<td><strong>L. Bodei</strong>; Memorial Sloan Kettering Cancer Center, New York, UNITED STATES OF AMERICA.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>OP-047</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Lessons from the Various Clinical Trials in NETs: Evidence-Based Results and Post-Hoc Analysis</strong></td>
</tr>
<tr>
<td><strong>M. Pavel</strong>; Campus Virchow-Klinikum Charité, Centrum 13, Berlin, GERMANY.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>OP-048</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Where does PRRT fit in?</strong></td>
</tr>
<tr>
<td><strong>D. O’Toole</strong>; Trinity College Dublin, the University of Dublin, St James’s Hospital &amp; National Centre for Neuroendocrine Tumours</td>
</tr>
</tbody>
</table>
303  Sunday, October 22, 2017, 11:30 - 13:00, Hall C

CTE 2 - Joint Session with EARL: Technologist Role in Research and EARL Accreditation

**Chairs:** R. Boellaard (Groningen, NETHERLANDS)  
G. Testanera (London, UNITED KINGDOM)

**OP-049**  
Research Opportunities as a Nuclear Medicine Technologist  
K. Pathmaraj; Austin Health Melbourne, Department of Molecular Imaging and Therapy, Melbourne, AUSTRALIA.

**OP-050**  
EARL Accreditation Projects and Possible Evolution  
R. Boellaard; University of Groningen, Center for Medical Imaging, Groningen, NETHERLANDS.

**OP-051**  
Technologist Involvement in Accreditation and Future Directions  
G. Testanera; Department of Nuclear Medicine, Barts Health NHS Trust, London, UNITED KINGDOM.

304  Sunday, October 22, 2017, 11:30 - 13:00, Hall E1

Do.Mo.Re: Modeling & Radiobiology

**Chairs:** M. Bardies (Toulouse, FRANCE)  
U. Eberlein (Wurzburg, GERMANY)

**OP-053**  
DNA damage in blood leukocytes after internal in-vitro irradiation of blood with the α-emitter 223Ra  
S. Schumann1, U. Eberlein1, R. Muhtadi2, M. Lassmann1, H. Scherthan2; 1University of Würzburg, Würzburg, GERMANY, 2Bundeswehr Institute of Radiobiology affiliated to the University of Ulm, München, GERMANY.

**OP-055**  
Internal exposure of 131I - potential biomarkers and functional analysis for long-term effects in thyroid  
M. Larsson1, N. Rudqvist1, J. Spetz1, B. Langen1, T. Parris1, K. Hêlou2, E. Forsell-Aronsson1; 1Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Cancer Center, Sahlgrenska Academy, Gothenburg, SWEDEN, 2Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Cancer Center, Sahlgrenska Academy, Gothenburg, SWEDEN.

**OP-056**  
Contribution of macro and micro-dosimetry in alphatherapy  
N. Benabdallah1, M. Bernardini1, D. Franck1, C. de Labriolle-Vaylet1,2, W. Bolch3, A. Desbrée1; 1IRSN - Institute for Radiological Protection and Nuclear Safety, Fontenay aux Roses, FRANCE, 2Georges Pompidou European Hospital, Paris, FRANCE, 3UPMC, University of Paris 06 Biophysics, Paris, FRANCE, 4Trousseau Hospital, Paris, FRANCE, 5Department of Biomedical Engineering, University of Florida, Gainesville, FL, UNITED STATES OF AMERICA.

**OP-057**  
Monte-Carlo modelling of energy deposition within a realistic 3D model of follicular lymphoma  
J. Bordes1,2, S. Incerti3,4, C. Rossi1,2,3, J. Bordenave1,2, C. Bezombes1,2, M. Bardies1,2, M. Bordage1,2, Centre de Recherches en Cancérologie de Toulouse, Toulouse, FRANCE, 3Centre d’Études Nucléaires de Bordeaux-Gradignan, Gradignan, FRANCE, 4CNRS/IN2P3/Université de Bordeaux, Gradignan, FRANCE, 5Service d’hématologie clinique, CHU le Bocage, Dijon, FRANCE.

**OP-058**  
Voxel-based multi-model fitting method for modelling time activity curves in SPECT images  
D. Sarrut, Sr.1, A. Halty1, J. Bade1, L. Ferrer1, M. Bardies4; 1CREATIS / CLB, Lyon, FRANCE, 2CLB, Lyon, FRANCE, 3ICO / CRCINA, Nantes, FRANCE, 4CRCT, Toulouse, FRANCE.

**OP-059**  
A Monte Carlo method to evaluate confidence intervals of time-integrated activity curve in molecular radiotherapy  
B. Cassano1, A. Napolitano1, M. Longo1, E. Genovese1, S. Donariello1, T. Insero1, E. Richetta2, M. Pasquino2, M. Stas2, M. Pacilio1, V. Cannata3; 1Medical Physics Unit, Bambino Gesù Children’s Hospital, Rome, ITALY, 2Medical Physics Department, AO Ordine Mauriziano di Torino, Turin, ITALY, 3Medical Physics Department, Azienda Ospedaliero Universitaria Policlinico Umberto I, Rome, ITALY.

**OP-059**  
A Monte Carlo method to evaluate confidence intervals of time-integrated activity curve in molecular radiotherapy  
B. Cassano1, A. Napolitano1, M. Longo1, E. Genovese1, S. Donariello1, T. Insero1, E. Richetta2, M. Pasquino2, M. Stas2, M. Pacilio1, V. Cannata3; 1Medical Physics Unit, Bambino Gesù Children’s Hospital, Rome, ITALY, 2Medical Physics Department, AO Ordine Mauriziano di Torino, Turin, ITALY, 3Medical Physics Department, Azienda Ospedaliero Universitaria Policlinico Umberto I, Rome, ITALY.
OP-060
Validation of a voxel-dosimetry and radiobiology tool for patient specific peptide receptor radionuclide therapy
D. Finocchiaro1, S. Berenato2, E. Grassi3, F. Fioroni2, G. Castellani2, N. Lanconelli2, A. Versari2, E. Spezi2, M. Iori1; 1Medical Physics Unit, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, ITALY, 2Dept. of Physics, University of Bologna, Bologna, ITALY, 3School of Engineering, Cardiff University, Cardiff, UNITED KINGDOM, 4Nuclear Medicine Unit, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, ITALY.

OP-061
Immunotargeting of Galectin-3 in thyroid orthotopic tumor models opens new challenges for thyroid cancer imaging and biological characterization in vivo
C. D’Alessandria1, F. De Rose1, M. T. Kuhlmann2, M. Brauer1, S. Reder1, S. Braesh-Andersen3, A. Bartolazzi4, M. Schweiger1; 1Klinikum rechts der Isar - Technical University of Munich, Munich, GERMANY, 2European Institute for Molecular Imaging (EIMI), University of Munster, Munster, GERMANY, 3Mabtech AB Research Laboratory, Stockholm, SWEDEN, 4Pathology Research Laboratory, Sant’Andrea Hospital, University Sapienza, Rome, ITALY.

OP-062
Pretargeted radionuclide therapy of HER2-expressing SKOV-3 human xenografts using an Affibody molecule-based PNA-mediated pretargeting
M. Altar1, K. Westerlund2, M. Konijnenberg2, B. Mitran3, M. Oroujeni4, M. de Jong1, A. Eriksson-Karlström3, A. Orlava1, V. Tolmachev1; 1Institute of Immunology, Genetics and Pathology, Uppsala, SWEDEN, 2Division of Protein Technology, Royal Institute of Technology, Stockholm, SWEDEN, 3Department of Nuclear Medicine and Radiology, Erasmus MC, Rotterdam, NETHERLANDS, 4Division of Molecular Imaging, Uppsala, SWEDEN.

OP-063
Immuo-PET imaging for PD-L1 expression in non-small cell lung cancer xenograft
D. Li, S. Cheng, S. Zou, D. Zhu, X. Zhu; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

OP-064
SPECT imaging of carbonic anhydrase IX with 111In-girentuximab-F(ab')2 as radiotracer in head and neck xenografts
F. J. Huizing, B. A. W. Hoeven, S. Heskamp, J. Bussink, O. C. Boerman; Radboudumc, Nijmegen, NETHERLANDS.

OP-065
Ab-1881, An Anti-PDL1 Immune Checkpoint Inhibitor Serves as A Theranostic Agent for Cancer Immunotherapy
M. Xu, Y. Han, Z. Liu; Peking University, Beijing, CHINA.

OP-066
Monitoring tumor PD-L1 expression with microSPECT/CT during radiotherapy
S. Heskamp, J. D. M. Molkenboer-Kuenen, G. W. Sandker, P. J. Wierstra, J. Bussink, O. C. Boerman; Radboud University Nijmegen Medical Centre, Nijmegen, NETHERLANDS.

OP-067
PET Imaging of Programmed Cell Death Protein 1 (PD-1) in a Humanized Mouse Model of Lung Cancer

OP-068a
Radiocobalt-labeled anti-HER1 affibody molecule DOTA-ZGEP2317 for imaging of low HER1 expression in prostate cancer pre-clinical model
B. Mitran1, J. Garousi1, M. Rosestedt1, E. Lindström1, K. G. Andersson2, S. Ståhl1, J. Löblom1, V. Tolmachev1, A. Orlova1; 1Uppsala University, Uppsala, SWEDEN, 2KTH-Royal Institute of Technology, Stockholm, SWEDEN.

OP-068b
Preclinical evaluation of a single-chain variable anti TEM-1 fragment labeled with 111In and 152Tb
F. Cicone1, T. Denoël2, D. Viertl3, G. Jakka1, S. Dunn4, T. Stora5, I. O. Prior1; 1Nuclear Medicine, CHUV, Lausanne, SWITZERLAND, 2Marie Skłodowska-Curie Innovative Training Network MEDICIS-PROMED, CERN, Geneva, SWITZERLAND, 3Ludwig Center for Cancer Research, Lausanne, SWITZERLAND, 4ISOLDE/CERN, Geneva, SWITZERLAND, 5Paul Scherrer Institut, Villigen-PSI, SWITZERLAND, 6Institut Laue-Langevin, Grenoble, FRANCE.

OP-069
Preclinical evaluation of a single-chain variable anti TEM-1 fragment labeled with 111In and 152Tb
F. Cicone1, T. Denoël2, D. Viertl3, G. Jakka1, S. Dunn4, T. Stora5, I. O. Prior1; 1Nuclear Medicine, CHUV, Lausanne, SWITZERLAND, 2Marie Skłodowska-Curie Innovative Training Network MEDICIS-PROMED, CERN, Geneva, SWITZERLAND, 3Ludwig Center for Cancer Research, Lausanne, SWITZERLAND, 4ISOLDE/CERN, Geneva, SWITZERLAND, 5Paul Scherrer Institut, Villigen-PSI, SWITZERLAND, 6Institut Laue-Langevin, Grenoble, FRANCE.
Scientific Programme

306 Sunday, October 22, 2017, 11:30 - 13:00, Hall F1
Pitfalls & Artefacts 2 (Interactive) - Cardiovascular: Pitfalls and Artefacts with CZT Cameras

Chairs: D. Agostini (Caen, FRANCE)  A. Gimelli (Pisa, ITALY)

OP-069 Acquisition (Detector pbs, Gating, Patient Movement, Quality Control)
O. Lairez: Rangueil University Hospital, Toulouse, FRANCE

OP-070 Image Analysis (Attenuation, Image Quality)
J. van Dijk: Isala Klinieken, afd. Nucleaire Geneeskunde, Enschede, NETHERLANDS.

OP-071 Signal Quantification (LVEF, Bulls Eye, Extent of Myocardial Perfusion Abnormality)
A. Gimelli: Fondazione Toscana Gabriele Monasterio, CNR, Pisa, ITALY

OP-072 Blood Pool Gated Acquisitions / Dual Isotope Acquisitions
A. Manrique: Centre Hospitalier Universitaire de Caen, Caen, France

307 Sunday, October 22, 2017, 11:30 - 12:45, Hall F2
Clinical Oncology: We want a New Drug

Chairs: C. Decristoforo (Innsbruck, AUSTRIA)  M. Picchio (Milan, ITALY)

OP-073 Comparison study between 18F-Choline (FCH) and 68Ga-NODAGA-MJ9 (MJ9, Bombesin) PET-CT in prostate cancer initial staging
L. Haefliger1, P. Mitsakis1, T. Zilli1, C. Pozzessere1, J. Delage1, H. Maecke1, R. Mans1, R. Miralbell1, N. Schaefer1, J. Prior1; 1Department of Nuclear Medicine, Lausanne University Hospital, Lausanne, SWITZERLAND, 2Department of Radiation, Oncology, Geneva University Hospital, Geneva, SWITZERLAND, 3Department of Pharmacy, Lausanne University Hospital, Lausanne, SWITZERLAND, 4Department of Nuclear Medicine, University Hospital of Freiburg, Freiburg, GERMANY, 5Institut Oncològic Teknon, Barcelona, SPAIN.

OP-074 Clinical translation of bombesin antagonist based GRP receptor PET radiotracer 68Ga-NOTA-RM26
J. Zhang1, 2, G. Niu1, X. Fan1, L. Lang1, H. Wu1, J. Zang1, G. Hou1, F. Li1, Z. Zhu1, X. Chen1; 1Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHINA, 2Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, MD, UNITED STATES OF AMERICA, 3Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHINA, 4Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHINA.

OP-075 Correlation of Clinical GRP Receptor PET Imaging of Prostate Cancer to Receptor Expression Status
I. L. Bakker1, G. J. L. H. van Leenders1, M. Segbers1, A. C. Fröberg1, S. U. Dalm1, J. Veenland1, M. Konijnenberg1, M. B. Busstra1, J. F. Verzijlbergen1, I. Schouts1, E. de Blois1, W. M. van Weerden1, T. Maina2, B. Nock1, M. de Jong1; 1Erasmus MC, Rotterdam, NETHERLANDS, 2NCSR „Demokritos", Athens, GREECE.

OP-076 Imaging GRPr expression in metastatic castration resistant prostate cancer with 68Ga-RM2 - A head-to-head comparison with 68Ga-PSMA-11
V. Kramer1, 2, R. Fernandez1, J. Ribbeck1, R. Puzzo1, E. Hernandez-Behm1, A. Haeger1, B. Morales1, H. Lavado1, H. Amara1; 1Positronpharma SA, Santiago de Chile, CHILE, 2Nuclear Medicine & PET/CT Fundación Arturo López Pérez, Santiago de Chile, CHILE.
OP-077 Imaging tumor biology with ⁸⁹Zr-cetuximab, ¹⁸O-H₂O and ¹⁸F-FDG PET/CT in patients with advanced colorectal cancer treated with cetuximab monotherapy

E. J. van Helden; O. S. Hoekstra, M. C. Huismann, E. Boon, S. C. van Es, G. A. M. S. van Dongen, D. J. Vugts, D. J. de Groot, R. Boellaard, C. M. L. van Herpen, E. G. E. de Vries, H. M. W. Verheul, C. W. Menke - van der Houven van Oordt; ¹Department of Medical Oncology, VU University Medical Center, Amsterdam, Amsterdam, NETHERLANDS, ²Department of Radiology and Nuclear Medicine, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, NETHERLANDS, ³Department of Medical Oncology, Radboud University Medical Center, Nijmegen, NETHERLANDS, ⁴Department of Medical Oncology, University Medical Center Groningen, Groningen, NETHERLANDS, ⁵Department of Radiology and Nuclear Medicine, University Medical Center Groningen, Groningen, NETHERLANDS.

OP-078 A PET imaging study to investigate the biodistribution and clearance of an albumin binding domain antibody (AlbudAb™) in healthy subjects

K. Thorneloe; M. Bergstrom, L. Galinanes-Garcia, P. Galette, W. Al-Azzam, V. Vincent, D. Vugts, G. van Dongen, P. Elsinga, J. Wiegens, A. Glauemarns, J. Renaux, M. Cleveland, S. Zhang; GSK, King of Prussia, PA, UNITED STATES OF AMERICA, ²GSK, Stevenage, UNITED KINGDOM, ³VU University Medical Centre, Amsterdam, NETHERLANDS, ⁴University Medical Center Groningen, Groningen, NETHERLANDS.

OP-079 A proof-of-concept study of ⁶⁸Ga-TATE-RGD PET/CT for dual-target imaging of somatostatin receptor and integrin αβ₃ to detect lung cancer and neuroendocrine tumor in a single scan

Y. Zheng; H. Wang, X. Cui, L. Zhang, H. Tan, S. Yao, Z. Zhu; Peking Union Medical College Hospital, Beijing, CHINA, ²China-Japan Friendship Hospital, Beijing, CHINA.

OP-079b Core-Satellite Nanomaterials for Multimodal Image-Guided Combination Cancer Therapy

W. Cai; S. Goel, T. E. Barnhart; University of Wisconsin-Madison, Madison, WI, UNITED STATES.

OP-079c Targeted Photodynamic Therapy in CEA Expressing Colorectal Tumor Xenografts


OP-079d Photodynamic therapy in rheumatoid arthritis; targeting the activated fibroblasts

D. N. Dorst; M. Buitinga, D. Brom, A. Freimoser, C. Klein, G. Walgreen, M. I. Koenders, M. Gotthardt; ¹Radboud University Medical Center, Nijmegen, NETHERLANDS, ²Utrecht University, Utrecht, NETHERLANDS.

OP-079e Photodynamic treatment of rheumatoid arthritis by liposomal targeting of macrophages

M. Boss; M. Buitinga, D. N. Dorst, G. Storm, M. I. Koenders, M. Gotthardt; ¹Radboud University Medical Center, Nijmegen, NETHERLANDS, ²University Medical Center Groningen, Groningen, NETHERLANDS.

OP-080 ¹⁸F-Choline PET-CT in assessment of primary hyperparathyroidism comparing with ⁹⁹mTc-Se-stamibi or ⁹⁹mTc-Tetrafosmin SPECT-CT: How differentiate parathyroid hyperplasia from adenoma?

C. Pirich; L. Hehenwarter, L. Imamovic, G. Rendl, O. Tsybrovskyy, D. Hackl, F. Fitz, W. Langsteiger, M. Beheshtir; ¹Nuclear Medicine & Endocrinology, Medical University of Salzburg, Salzburg, AUSTRIA, ²PET-CT Center Linz, St. Vincent’s Hospital, Linz, AUSTRIA.

Conventional & Specialised Nuclear Medicine: Benign Thyroid & Parathyroid Diseases

Chairs: L. Giovanella (Bellinzona, SWITZERLAND) C. Pirich (Salzburg, AUSTRIA)

OP-079a From Radionuclide Imaging to Photodynamic Therapy – Novel Prospects for Nuclear Medicine

M. Gotthardt; Radboud UMC, Nijmegen, NETHERLANDS.
OP-081
Quantitative Washout Rate of $^{99m}$Tc-Sestamibi in Parathyroid and Thyroid Tissues Assessed Using Quantitative SPECT-CT
J. Gardner, B. Ziebarth, S. Bazarjani, S. Razavi, R. Klein, L. S. Zuckier, W. Zeng; The Ottawa Hospital, Ottawa, ON, CANADA.

OP-082
A Type of Uptake in Dual-phase $^{99m}$Tc-Sestamibi SPECT/CT Parathyroid Scintigraphy & a Level of Parathormone Might Indicate a Histopathology Diagnosis in Patients with Primary Hyperparathyroidism-Experience of One Centre
M. H. Listewnik, H. Piwowarska-Bilska, K. Safranow, M. Ostromiski, J. Iwanowski, M. Chosia, A. Borowiecki, M. Laszczynska, M. Kurnatowicz, B. Birkenfeld; Pomeranian Medical University in Szczecin, Szczecin, POLAND.

OP-083
Comparison of F-18 Choline PET/CT with Tc-99m MIBI and USG for Detection of Parathyroid Adenomas in Patients with Elevated Parathyroid Hormone Levels: Preliminary Results
L. Uslu-Be/uni, K. Sönmezoğlu, E. Kaymak Akgün, S. Teksar, E. Karayel, H. Pehtiranoglu, M. Ocaq, F. Oztürk, S. Sağer, L. Kabasakal, Y. Büyük; 1Istanbul University Cerrahpaşa Medical Faculty Department of Nuclear Medicine, Istanbul, TURKEY; 2Istanbul University Cerrahpaşa Medical Faculty Department of General Surgery, Istanbul, TURKEY; 3Istanbul University Pharmacy Faculty Department of Pharmaceutical Technology, Istanbul, TURKEY; 4Istanbul University Cerrahpaşa Medical Faculty Department of Pathology, Istanbul, TURKEY.

OP-084
Impact of F18-Fluorocholine PET/CT in the pre-surgical work up of primary hyperparathyroidism
S. Grimaldi, J. Young, P. Kamenicky, D. Hartl, M. Terroir, S. Lebouleux, E. Baudin, M. Schlumberger, D. Deandreas, 1, 2, 3; Institut Gustave Roussy, Villejuif, FRANCE, 4Hôpital de Bicêtre, Le Kremlin-Bicêtre, FRANCE, 5Università degli Studi, Torino, ITALY.

OP-085
Factors Associated with the Occurrence of Graves’ Orbitopathy after Radioiodine Therapy in Patients with Graves’ disease
S. Gaberscek, D. Šfiligoj, K. Zaletel, E. Pirnat, P. Jaki Mejkavič, 1, 2; 1Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, SLOVENIA, 2Faculty of Medicine, University of Ljubljana, Ljubljana, SLOVENIA.

OP-086
Factors Associated with the Duration of Graves’ Orbitopathy Activity in Patients with Graves’ disease
S. Gaberscek, D. Šfiligoj, K. Zaletel, E. Pirnat, P. Jaki Mejkavič, 1, 2; 1Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, SLOVENIA, 2Faculty of Medicine, University of Ljubljana, Ljubljana, SLOVENIA.

OP-087
Stress Test
O. Lindner; Institut für Radiologie, Nuklearmedizin und Molekularmedizin, Herz- und Diabeteszentrum NRW, Bad Oeynhausen, GERMANY.

OP-088
Injected Doses and Tracers
J. Bucerius; Department of Nuclear Medicine, Maastricht University Medical Center (MUMC+), Maastricht, NETHERLANDS.

OP-089
Image Analysis
A. Scholten; Department of Nuclear Medicine, Meander Medical Center, Amersfoort, NETHERLANDS.

OP-090
Reporting
E. Trägårdh; Department of Clinical Sciences, Clinical Physiology and Nuclear Medicine Unit, Lund University, Skåne University Hospital, Malmö, SWEDEN.
**Scientific Programme**

**402** Sunday, October 22, 2017, 14:30 - 16:00, Hall B

Joint Symposium 3 - EANM/ETA-CRN: Update Thyroid Cancer Beyond I-131

*Chairs: F. Verburg (Marburg, GERMANY)  
L. Fugazzola (Milan, ITALY)*

**OP-091**

I-131 Refractory Differentiated Thyroid Cancer

*M. Kreissl; Klinik für Radiologie und Nuklearmedizin, Universitätshospital Magdeburg A.ö.R., Otto-von-Guericke Universität, Magdeburg, GERMANY.*

**OP-092**

Medullary Thyroid Cancer

*L. Giovanella; Oncology Institute of Southern Switzerland, Nuclear Medicine and PET Centre, Bellinzona, SWITZERLAND.*

**OP-093**

Anaplastic Thyroid Cancer

*L. Fugazzola; University of Milan, Department of Endocrinology, Milan, ITALY.*

**403a** Sunday, October 22, 2017, 14:30 - 15:30, Hall C

Mini Course 1: Cardiology - Pitfalls & Artefacts

*Chairs: F. Bertagna (Brescia, ITALY)  
L. Camoni (Brescia, ITALY)*

**OP-094**

Common Artefacts in Nuclear Cardiology Imaging

*A. Ghilardi; Nuclear Medicine DPT and Medical Physics DPT, ASST Papa Giovanni XXIII, Bergamo, ITALY.*

**OP-095**

Artefacts and Image Interpretation

*A. Flotats; Universitat Autònoma de Barcelona, Consultant, Nuclear Medicine Department, Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN.*

**403b** Sunday, October 22, 2017, 15:45 - 16:45, Hall C

Mini Course 2: Inflammation and Infection - Pitfalls & Artefacts

*Chairs: A. Glaudemans (Groningen, NETHERLANDS)  
C. Terwinghe (Leuven, BELGIUM)*

**OP-096**

Pitfalls and Artefacts in Infection and Inflammation Imaging: Labelled Leukocytes

*E. Lazzeri; Regional Center of Nuclear Medicine AOUPI, Pisa, ITALY.*

**OP-097**

Pitfalls in FDG-PET Imaging of Infection and Inflammation

*A. Glaudemans; University of Groningen, Groningen, NETHERLANDS.*

**OP-098**

Bone and Joint – Pitfalls and Artefacts

*W. Groothans; Leiden University Medical Centre, Radiology and Nuclear Medicine Department, Leiden, NETHERLANDS.*

**OP-099**

177 Lu-Dota-octreotate therapy in advanced Gastrointestinal Neuroendocrine tumors: outcomes after 5 years follow up

1Nuclear Medicine and Radiometabolic Unit, IRST-Istituto Scientifico Romagna per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC), ITALY, 2Nuclear Medicine Unit, Faenza Hospital, Romagna Local Health Service, Faenza (RA), ITALY, 3Radiology Unit, IRST-Istituto Scientifico Romagna per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC), ITALY, 4Oncology Pharmacy, IRST-Istituto Scientifico Romagna per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC), ITALY, 5‘Unit of Biostatistics and Clinical Trials, IRST-Istituto Scientifico Romagna per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC), ITALY, 6Osteoncology and Rare Tumors Center, IRST-Istituto Scientifico Romagna per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC), ITALY, 7Nuclear Medicine, Azienda Ospedaliero-Universitaria di Bologna, Bologna (Bo), ITALY, 8Division of Nuclear Medicine, European Institute of Oncology Milan (IEO), Milan (MI), ITALY.*

**OP-100**

Do.MoRe: Radiopeptides for Therapy

*Chairs: S. Ezzidin (Homburg, GERMANY)  
M. Paphiti (Athens, GREECE)*

**OP-101**

177 Lu-Dota-octreotate therapy in advanced Gastrointestinal Neuroendocrine tumors: outcomes after 5 years follow up
OP-100
Update: Edmonton Lu-177 Protocol (Induction and Maintenance Regimen) Improves Progression Free Survival (PFS) in Patients with Advanced Neuroendocrine Tumours (NETs)
A. J. B. McEwan, M. Wieler, D. Murray, M. B. Sawyer, D. Morrish, B. A. Schaitel, L. D. Schrader, T. McMullen; 1University of Alberta, Edmonton, AB, CANADA, 2Cross Cancer Institute, Alberta Health Services, Edmonton, AB, CANADA.

OP-101
Improvement of PFS and OS after salvage therapy with 177-Lu[Dota\text{\textregistered},Tyr\text{\textregistered}3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumours - the Rotterdam cohort
W. A. van der Zwan, T. Brabander, B. L. K. Kam, J. J. M. Teunissen, E. P. Krenning, D. J. K. Kwekkeboom, W. W. de Herder; 1Erasmus MC, Rotterdam, NETHERLANDS, 2Cyclotron BV, Rotterdam, NETHERLANDS.

OP-102
Investigation of Receptor Radionuclide Therapy with 177Lu dotatate in GEP-NEN patients with High Grade Ki67
S. Nicolini, S. Severi, M. Sansovini, A. Ianniello, P. Carolii, A. Bongiovanni, A. Rossi, F. Di Mauro, E. Mezzenga, E. Scarpi, G. Paganeli; 1Nuclear Medicine and Radiometabolic Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC), ITALY, 2Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC), ITALY, 3Radiology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC), ITALY, 4Nuclear Medicine Unit, University of Messina, Messina, Italy, Messina, ITALY, 5Medical Physics Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC), ITALY, 6Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC), ITALY.

OP-103
177Lu-Dotatate Peptide Receptor Radionuclide Therapy Dose Response in Small Intestinal Neuroendocrine Tumors
U. M. M. Jahn, E. Ilan, M. Sandström, M. Bamemy, U. Garske-Roman, M. Lubberink, A. Sundin; 1Radiology, Uppsala, SWEDEN, 2Nuclear Medicine, Uppsala, SWEDEN, 3Nuclear Medicine, Gothenburg, SWEDEN.

OP-104
Gender-related differences in absorbed dose to risk organs in patients receiving 177Lu-Octreotate therapy
M. Sandstrom, Sr., E. Ilan, K. Fröss-Baron, U. Garske-Roman, D. Granberg, B. Erikssson, A. Sundin, M. Lubberink; 1Nuclear medicine and PET, Uppsala University, Uppsala, SWEDEN, 2Medical physics, Uppsala University Hospital, Uppsala, SWEDEN, 3Endocrine Oncology, Uppsala University, Uppsala, SWEDEN.

OP-105
177Lu-DOTATATE therapy in radio iodine refractory differentiated thyroid cancer: a single center experience
W. Roll, B. Riemann, M. Schäfers, L. Stegger, A. Vrachimis; University Hospital Münster, Münster, GERMANY.

OP-106
Best Therapy Response vs Variability of Tumor Size, Absorbed Dose And Ki-67 Index After n.c.a. Lu-177 Dotatate Intra-arterial Infusions
M. Paphiti, I. Karfis, E. Z. Dimitriadis, S. Chondroyiannis, G. Nikou, V. Michalaki, G. Fragulidis, D. Varos, V. R. McCready, D. Rubello, G. S. Limours; 1Medical Faculty, National and Kapodistrian University of Athens, Athens, GREECE, 2Institute Clausud Regaud, University of Paul Sabatier, Toulouse, FRANCE, 3Nuclear Medicine Department, Santa Maria della Misericordia Hospital, Rovigo, ITALY, 4Il Surgical Dept, of ‘Aretaieon’ Hospital, Medical Faculty, National and Kapodistrian University of Athens, Athens, GREECE, 5Institute Cancer Research, Sutton Surrey & Royal Sussex County Hospital, Brighton, UNITED KINGDOM.

OP-107
Radiochemistry and Preclinical Evaluation of Two Novel Peptide Analogues Targeting Glucagon Receptor for Anti-Diabetic Drug Development
I. Velikyan, M. Bossart, T. Haack, I. Laitinen, P. Larsen, O. Plettenburg, L. Johansson, S. Pierrou, M. Wagner, O. Eriksisson; 1PET Centre, Centre for Medical Imaging, Uppsala University Hospital, Uppsala, SWEDEN, 2Section of Nuclear Medicine and PET, Department of Surgical Sciences, Uppsala University, Uppsala, SWEDEN, 3Sanofi-Aventis, Frankfurt, GERMANY, 4Helmholtz Zentrum, München, GERMANY, 5Antaros Medical AB, Molndal, SWEDEN, 6Uppsala University, Uppsala, SWEDEN.
Development of a new 68Ga radiolabelled PET imaging agent to evaluate in vivo expression of angiomotin in malignant brain tumors
A. Moyon, P. Garrigue, P. Brige, M. Nollet, L. Balasse, S. Fernandez, M. Blot-Chabaud, F. Dignat-George, B. Guillot, UMR_S1076 VRCM, Marseille, FRANCE, CERIMED, Marseille, FRANCE, APHM, Marseille, FRANCE.

([11C]Erlotinib as a PET radiotracer to measure OATP2B1 transport activity in the human liver

First in vivo imaging and in vitro studies of [18F]DABTA in rat model with E46K alpha synuclein mutation

Targeting αvβ6-integrin with radiometallated peptides for therapy of pancreatic carcinoma
S. Förber, K. Steiger, F. Reichardt, M. Schweiger, H. Kessler, H. Wester, J. Notni, Technische Universität München, Garching, GERMANY, Technische Universität München, München, GERMANY.

Imaging beta cells in patients after Roux-en-Y gastric bypass (RYGB) surgery by 68Ga-NODAGA-exendin-4 PET/CT
M. Boss, L. N. Deden, E. O. Aarts, H. de Boer, M. C. Jansen, M. Brom, F. J. Berends, M. Gotthardt, Radboud University Medical Center, Nijmegen, NETHERLANDS, Rijnstate hospital, Arnhem, NETHERLANDS, Rijnstate Hospital, Arnhem, NETHERLANDS.

68Ga-Pentixafor PET/CT Imaging Targeting CXCR4 chemokine receptors: The First Clinical Experience in Lung carcinoma subtypes

Evaluation of Lu-177 LABELLED 6A10 Fab as Carbonic Anhydrase 12 Targeting Agent
L. Fiedler, M. Kellner, A. Gosewisch, G. Böning, S. Lindner, P. Bartenstein, F. Gildehaus, Department of Nuclear Medicine, LMU, Munich, GERMANY, Research Group Prevention and Immunomodulation; Helmholtz-Zentrum, Munich, GERMANY, Department of Otorhinolaryngology, LMU, Munich, GERMANY.

Targeting αvβ6-integrin with radiometallated peptides for therapy of pancreatic carcinoma
S. Förber, K. Steiger, F. Reichardt, M. Schweiger, H. Kessler, H. Wester, J. Notni, Technische Universität München, Garching, GERMANY, Technische Universität München, München, GERMANY.

PSMA-targeting alpha-Radiation therapy with 225Actinium-PSMA-617: Dosimetry, toxicity and duration of tumor-control
OP-117
68Ga-PSMA PET/CT to restage prostate cancer after radical therapy. Results of a prospective single-center trial
F. Ceci, P. Castellucci, T. Graziani, A. Farolfi, R. Renzi, R. Schiavina, M. Borghesi, F. Lodri, S. Boschi, S. Fanit
1Department of Surgical Sciences, University of Bologna, Bologna, ITALY, 2Nuclear Medicine, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, ITALY, 3Department of Urology, S.O. Malpighi Hospital, University of Bologna, Bologna, ITALY.

OP-118
Integrated 68Ga-PSMA-11 PET/MRI enhances discriminatory power of multi-parametric prostate MRI
1University Hospital Essen, Essen, GERMANY, 2University Hospital Duesseldorf, Duesseldorf, GERMANY.

OP-119
Te-99-MIP-1404 Imaging for the Detection of PSMA-Positive Lesions. A Pilot Study in 380 Patients with Histologically Confirmed Prostate Cancer
Universitätsklinikum Erlangen, Erlangen, GERMANY.

OP-120
Correlation Between Uptake of 18F-1-amino-3-fluorocyclobutane-1-carboxylic acid ("18F-fluciclovine") and Expression of Amino Acid Transporters ASCT2 and LAT1 in prostate cancer
1Gunma University, Maebashi, JAPAN, 2Turku PET Centre, University of Turku, Turku, FINLAND, 3Japan Society the promotion of science, Tokyo, JAPAN, 4Department of Pathology, University of Turku and Turku University Hospital, Turku, FINLAND, 5Turku University Hospital, Turku, FINLAND, 6Turku University Hospital, Departments of Oncology and Radiotherapy, Turku, FINLAND, 7Department of Radiology, Baystate Medical Center, University of Massachusetts, Springfield, MA, UNITED STATES OF AMERICA, 8Turku University Hospital, Departments of Nuclear Medicine, Turku, FINLAND, 9Turku University Hospital, Departments of Urology, Turku, FINLAND, 10Turku University Hospital, Departments of Pathology, Turku, FINLAND.

OP-121
Impact of Ga-68 PSMA PET/CT on radiation treatment planning of prostate cancer
S. M. Schwarzenboeck, L. Schubert, H. Renauer, J. Kurrth, B. J. Krause, G. Hildebrandt
1Department of Nuclear Medicine, Rostock University Medical Centre, Rostock, GERMANY, 2Department of Radiotherapy, Rostock University Medical Centre, Rostock, GERMANY.

OP-122
[68Ga]Ga-PSMA-PET/CT imaging of localized prostate cancer patients for intensity modulated prostate cancer treatment planning with integrated boost
1Department of Nuclear Medicine, Universitaetsklinikum Bonn; Department of Radiation Medicine, Oregon Health and Science University, Portland, OR, UNITED STATES OF AMERICA, 2LMU Munich, Department of Radiation Oncology, Munich, GERMANY, 3Department of Radiation Medicine, Oregon Health and Science University, Portland, OR, UNITED STATES OF AMERICA, 4Department of Nuclear Medicine, Universitaetsklinikum Bonn, Bonn, GERMANY, 5Department of Radiology, Universitaetsklinikum Bonn, Bonn, GERMANY.

OP-123
Intra-individual comparison of 18F-labelled PSMA-1007-PET/CT, mpMRI and radical prostatectomy specimen in patients with primary prostate cancer
1Department of Urology, University Hospital Heidelberg, Heidelberg, GERMANY, 2Division of Radiology, German Cancer Research Center (DKFZ), Heidelberg, GERMANY, 3Section of Molecular Urooncology, Department of Urology, University Hospital Heidelberg, Heidelberg, GERMANY, 4Institute of Pathology, University Hospital Heidelberg, Heidelberg, GERMANY, 5Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, GERMANY.
OP-124
68Ga-PSMA PET/CT for restaging prostate cancer patients with early biochemical recurrence and PSA values lower than 0,5 ng/mL
A. Farolfi1, F. Ceci1, T. Graziani1, P. Castelucci1, L. Esposito1, A. Lombertini1, E. Lodi Rizzini1, R. Schiavina1, F. Lodi1, S. Fanti1; 1Nuclear Medicine Unit, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, ITALY, 2Department of Urology, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, ITALY.

OP-125
Oligometastatic Prostate Cancer radiotherapy treatment based on 68Ga-PSMA PET/CT: preliminary results
C. Artigas1, C. Florian1, D. Van Gestel1, D. Van Gestel2, P. Flamen1, F. Otte1; 1Jules Bordet Institut, Brussels, BELGIUM, 2Jules Bordet Institut Brussels, Brussels, BELGIUM.

OP-126
Impact of 68Ga-PSMA-11 PET/CT on salvage radiotherapy planning in post-prostatectomy patients with early biochemical recurrence
J. Calais1, J. Czernin1, W. P. Fendler1, K. Hermann1, I. Rauscher1, N. Hegemann1, T. Poeppel1, M. Cao1, M. Eiber1, N. Nickols1; 1UCLA, LOS ANGELES, CA, UNITED STATES OF AMERICA, 2Ludwig-Maximilians-University, Munich, GERMANY, 3Universitätsklinikum Essen, Essen, GERMANY, 4Klinikum rechts der Isar, Technical University of Munich, Munich, GERMANY.

OP-127
First Clinical Experience with Ultra-High Resolution Multi-Focal Collimators for Tc-99m-PSMA Imaging
C. Schmidkonz1, C. Hollweg1, J. Sanders1, M. Beck1, D. Schmidt1, H. Vija1, T. Kuwert1, P. Ritt1; 1Universitätsklinikum Erlangen, Erlangen, GERMANY, 2Siemens Medical Solutions, Hoffman Estates, IL, UNITED STATES OF AMERICA.
OP-130
Reshaping the amyloid buildup curve in Alzheimer’s disease? - Partial volume effect correction of longitudinal amyloid PET data
M. Rullmann, O. Sabri, H. Barthel; University of Leipzig, Department of Nuclear Medicine, Leipzig, GERMANY.

OP-131
Improved Risk Stratification for Conversion from Mild Cognitive Impairment to Alzheimer’s Disease with a multi-analytical Evaluation of [18F]-AV45 Amyloid PET
L. Wagner1, M. Brendel1, F. Scheuwein1, A. Delker1, J. Sauerbeck1, P. Bartenstein1, K. Ishii2, C. Hosakawa2, A. Rominger1; 1Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Muenchen, GERMANY, 2Department of Radiology, Kinki University Osaka, Osaka, JAPAN.

OP-132
Higher amyloid deposition in the striatum in familial Alzheimer’s disease: a preliminary PET/CT and PET/MRI study
L. Fu, J. Zhang, B. Xu, J. Tian; Department of Nuclear Medicine, the Chinese PLA General Hospital, Beijing, CHINA.

OP-133
[18F]Florbetapir PET/CT to assess the cerebral β-amyloid binding in Parkinson’s Disease Dementia - does the striatum still a key player?
M. Gennaro1, G. Aghakhanyan1, S. Mazzari1, G. Puccini1, G. Palermo1, D. Frosin1, G. Manca1, L. Antonacci1, S. Muccioli1, L. Fantechi1, J. Pagliani1, R. Ceravolo1, U. Bonuccelli1, D. Volterrani1; 1Regional Center of Nuclear Medicine, University Hospital of Pisa, Pisa, ITALY, 2Unit of Neurology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, ITALY.

OP-134
A Pilot Study on Hybrid 18F-Florbetaben PET/ MRI in Patients with White Matter Diseases
M. Rullmann1, S. Haars2, P. Werner1, R. Schmidt2, J. Orthgieß1, S. Tiepolt1, M. Patt1, D. Lobsien1, K. Hoffmann1, O. Sabri1, H. Barthel1, O. Then Bergh1; 1University of Leipzig, Department of Nuclear Medicine, Leipzig, GERMANY, 2University of Leipzig, Department of Neurology, Leipzig, GERMANY, 3University of Leipzig, Department of Neuroradiology, Leipzig, GERMANY.

OP-135
Human Whole-body Biodistribution and Radiation Dosimetry of [18F]PF-06684511, a Novel Radioligand for Brain Imaging of Beta-secretase
A. Varrone1, R. Arakawa1, A. Takano1, S. Nag1, V. Stepanov1, P. Stenkrona1, P. Grybäck1, M. Bolin2, L. Chen1, L. Zhang1, P. He1, A. Villalobos1, T. McCarthy3, C. Hallén1; 1Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, SWEDEN, 2Karolinska University Hospital, Medical Radiation Physics and Nuclear Medicine, Stockholm, SWEDEN, 3Worldwide Research & Development, Pfizer Inc., Cambridge, MA, UNITED STATES OF AMERICA, 4Worldwide Research & Development, Pfizer Inc., Groton, CT, UNITED STATES OF AMERICA.

OP-136
The impact of Lung Perfusion Scintigraphy in the emergency management of patients with suspected Pulmonary Embolism
C. Ferrari, A. Niccoli Asabella, A. Cimino, G. Bianco, M. Fanelli, E. P. Mossa, A. Di Palo, G. Rubini; Nuclear Medicine Unit, AOU Policlinic of Bari, University of Bari, bari, ITALY.

OP-137
The Prognostic Significance Of Abnormal Lung Perfusion In Patients With Idiopathic Pulmonary Arterial Hypertension
L. Wang, R. Ma, D. Wu, W. Fang; Chinese Academy of Medical Science & Fu Wai Hospital, Beijing, CHINA.

OP-138
Assessment Of Lung Glucose Uptake In Patients With Systemic Erythematous Pulmonary Arterial Hypertension: A Quantitative FDG PET Imaging Study
L. Wang1, Q. Wang2, L. Zhao1, X. Zeng1, W. Fang1; 1Chinese Academy of Medical Science & Fu Wai Hospital, Beijing, CHINA, 2Peking Union Medical College Hospital, Beijing, CHINA, 3Imperial College London, London, UNITED KINGDOM.
**OP-139**
Comparative analysis of regional lung perfusion measurements using radiolabeled microspheres and PET/CT and fluorescence-labeled microspheres in an experimental, anesthesiological study of acute lung injury in pigs

A. Braune, A. Gueldner, J. Kotzerke, M. Gama de Abreu; University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, GERMANY.

**OP-140**
A novel, simple equation improving the accuracy of glomerular filtration rate (GFR) measurement from two blood samples

G. Arsos¹, E. Moralidis¹, D. Katsampoukas¹, E. Manou², C. Sachpekidis²;¹ 3rd Department of Nuclear Medicine, Medical School, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Thessaloniki, GREECE,² Nephrology Department, Papageorgiou General Hospital, Thessaloniki, GREECE, Institute of Nuclear Medicine, Bern University Hospital, Bern, SWITZERLAND.

**OP-141**
Contribution Of Isotopic Renogram And SPECT-CT In The Diagnosis Of The Complications Of The Renal Transplantation

J. Gómez Hidalgo, A. Cobo Rodríguez, A. Sainz-Esteban, C. Gamazo Laherran, M. Alonso Rodríguez, M. Ruiz Gómez, M. González Selma, R. Ruano Pérez; Hospital Clínico Universitario de Valladolid, Valladolid, SPAIN.

**OP-142**
The usefulness of advanced numerical parameters of kidney output in the analysis of Tc-DTPA diuresis renography

S. Beatovic¹, M. Radulovic¹, M. Jankovic¹, D. Sobic Saranovic¹, B. Ajdinovic¹, V. Artiko¹;¹ University of Belgrade Faculty of Medicine, Center for Nuclear Medicine, Clinical Center of Serbia, Belgrade, SERBIA,² Institute for Nuclear Medicine Military Medical Academy, Belgrade, SERBIA,³ University of Belgrade Faculty of Electrical Engineering, Belgrade, SERBIA.

**OP-143**
Background Subtraction in Dynamic Renal Scintigraphy Revisited

M. Samal¹, V. Pracnik², H. Jiskrova², D. Skibova²;¹ Charles University, First Faculty of Medicine, Prague, CZECH REPUBLIC,² General University Hospital, Prague, CZECH REPUBLIC.

---

**501 Sunday, October 22, 2017, 16:30 - 18:00, Hall A**

**CME 4 - Oncology: PET in Multiple Myeloma**

Chairs: M. Meignan (Créteil, FRANCE) C. Nanni (Bologna, ITALY)

**OP-144**
What is Expected from Imaging in Multiple Myeloma (MM)

C. Touzeau; CHU Nantes, Haematology, Nantes, FRANCE.

**OP-145**
Standard MRI in MM and Perspectives

C. Messiou; The Royal Marsden Hospital, Department of Radiology, London, UNITED KINGDOM.

**OP-146**
Role of PET for Initial Evaluation and Response Assessment in Multiple Myeloma: Towards New Imaging Criteria

C. Nanni; Policlinico S.Orsola-Malpighi, Department of Nuclear Medicine, Bologna, ITALY.

---

**502 Sunday, October 22, 2017, 16:30 - 18:00, Hall B**

**Joint Symposium 4 - EANM/ICRP/ICRU: Radiological Protection for Patients Receiving Radiopharmaceutical Therapy Solutions**

Chairs: R. Howell (Newark, UNITED STATES OF AMERICA) Y. Yonekura (Chiba, JAPAN) K. Sjögreen Gleisner (Lund, SWEDEN)

**OP-147**
Tumour Response - What is Needed and What is Possible?

R. Howell; New Jersey Medical School, Division of Radiation Research, Newark, UNITED STATES OF AMERICA.

**OP-148**
Stochastic Effects in Patients Treated with Radiopharmaceuticals; Estimations, Observations and Possible Ways to Reduce Their Occurrence

S. Mattsson; Lund University, Medical Radiation Physics, Malmö, SWEDEN.

**OP-149**
Deterministic Tissue Reactions in Radionuclide Therapy, Observations and Ways to Reduce Their Occurrence

M. Konijnenberg; Erasmus MC, Radiology & Nuclear Medicine, Rotterdam, NETHERLANDS.
OP-150
Low-Dose Radiation Effects on Salivary Gland Stem Cells - Mechanisms and Clinical Relevance

R. Coppes; University Medical Center Groningen, Department of Cell Biology & Radiation Oncology, Groningen, NETHERLANDS.

OP-155
Quantitative gamma camera imaging of \(^{227}\)Th and \(^{223}\)Ra with application in \(^{227}\)Th targeted alpha therapy

E. Larsson; G. Braelin, A. Cleton, T. Ohlsson, C. Hindorf; Radiation Physics, Lund, SWEDEN, 2Bayer AG, Berlin, GERMANY.

OP-156
Comparison of lesion SUVs between \(^{99m}\)Tc-HDP SPECT/CT and \(^{18}F\)-NaF PET/CT

S. Arvola; 1, J. Jambor, A. Kuisma, M. Seppanen; 1, T. Noponen; 1, Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku, FINLAND, 2Department of Diagnostic Radiology, University of Turku, Turku, FINLAND, 3Department of Oncology and Radiotherapy, University of Turku, Turku, FINLAND, 4Turku PET Centre, Turku, FINLAND.

OP-157
Noise and Resolution Analysis of the xSPECT Quant Reconstruction Algorithm for \(^{177}\)Lu

J. Tran-Gia; M. Lassmann; Department of Nuclear Medicine, University of Würzburg, Würzburg, GERMANY.

OP-158
Quantitative SPECT Imaging of Thorium-227: A phantom experiment

M. Ghaly; Y. Du, G. Sgouros, D. Thorek, E. C. Frey; Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA.
Scientific Programme

OP-162
Improvement of peptide receptor radionuclide therapy effects via modulation of the DNA damage response
J. Nonnekens, M. de Jong, D. C. van Gent; Erasmus MC, Rotterdam, NETHERLANDS.

OP-163
In Vitro and In Vivo Growth Inhibitory and Radiosensitizing Effects of the Anti-HSP90 agent Onalespib
D. Spiegelberg, S. Lundsten, A. C. Mortensen, A. Abramenko, B. Stenerlöw, M. Nestor; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, SWEDEN.

OP-164
Boramino Acid: A New Theranostic Platform Serves Imaging Guided Boron Neutron Capture Therapy
J. Li, Y. Han, Z. Liu; Peking University, Beijing, CHINA.

OP-165
Second Generation Trifunctional PSMA Binding Ligands with Application to the Imaging of Prostate Cancer by Positron Emission Tomography and to its Treatment by Targeted Endoradiotherapy
J. M. Kelly1, A. Amor-Coarasa1, S. Ponnala1, A. Nikolopoulos2, C. Williams, Jr., D. Kim, J. W. Babich2,3; 1Division of Radiopharmaceutical Sciences and M13, Department of Radiology, Weill Cornell Medicine, New York, NY, UNITED STATES OF AMERICA, 2Citigroup Biomedical Imaging Center, Weill Cornell Medicine, New York, NY, UNITED STATES OF AMERICA, 3Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, UNITED STATES OF AMERICA.

506 Sunday, October 22, 2017, 16:30 - 18:00, Hall F1
Teaching Session 2 (Interactive): Applied Cross Sectional Anatomy and Correlative Imaging - Foot and Ankle
Chair: M. Bozkurt (Ankara, TURKEY)

OP-166
Applied Cross Sectional Anatomy and Correlative Imaging – Foot and Ankle
C. Fowler; Brighton and Sussex University Hospital, Brighton, UNITED KINGDOM.

507 Sunday, October 22, 2017, 16:30 - 18:00, Hall F2
Clinical Oncology: NET, a Classic!
Chairs: D. Wild (Basel, SWITZERLAND), R. Werner (Baltimore, UNITED STATES OF AMERICA)

OP-167
Peptide receptor radionuclide therapy in combination with lanreotide Autogel/Depot: a retrospective study in progressive digestive and bronchopulmonary neuroendocrine tumours (PRELUDE)
V. Prasad1, R. Srirajaskanthan2, C. Tourpanakis3, C. M. Grana4, T. Shah5, J. Valle6, F. Courbon7, X. Tuong Thanh8, A. Houchard9, L. Bode10; 1Chanté Universitätsmedizin Berlin, Berlin, GERMANY, 2King’s College Hospital NHS Foundation Trust, London, UNITED KINGDOM, 3Royal Free Hospital, London, UNITED KINGDOM, 4Instituto Europeo di Oncologia, Milan, ITALY, 5Queen Elizabeth Hospital, Birmingham, UNITED KINGDOM, 6The Christie NHS Foundation Trust, Manchester, UNITED KINGDOM, 7IUCT Oncopole, Toulouse, FRANCE, 8Ipsen, Boulogne-Billancourt, FRANCE, 9Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.

OP-168
Clinical, tumour, and treatment parameters to predict overall survival after PRRT - a multivariate analysis in 783 patients
E. A. Aalbersberg1, D. M. V. Huizing1, H. R. Kulkarni2, I. Walkaven1, B. J. de Wit – van der Veen1, A. Singh2, M. P. M. Stokkel3, R. P. Baum2; 1Department of Nuclear Medicine, ENETS Center of Excellence, Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam, NETHERLANDS, 2THERANOSTICS Center for Molecular Radiotherapy, ENETS Center of Excellence, Zentralklinik Bad Berka, Bad Berka, GERMANY, 3Department of Radiation Oncology, ENETS Center of Excellence, Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam, NETHERLANDS.

OP-169
A Prospective study of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE and Concurrent Capecitabine in Metastatic Paragangliomas
S. Ballal, M. P. Yadav, D. Yadav, C. Bal; All India Institute of Medical Sciences, New Delhi, INDIA.
First-in-human PET/CT Imaging of somatostatin receptor expressing tumors with the novel somatostatin receptor antagonist 

**OP-170**

68Ga-NODAGA-LM3 - a comparison with 68Ga-DOTATOC PET/CT

A. Singh1, H. R. Kulkarni1, T. Langbein1, D. Müller1, S. Senftleben1, M. Faní1, H. Maecke1, R. P. Baum1; 1Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Bad Berka, GERMANY, 2Division of Radiopharmaceutical Chemistry, University Hospital of Basel, Basel, SWITZERLAND, 3Department of Nuclear Medicine, University Hospital Freiburg, Freiburg, GERMANY.

Biodistribution and radiation dosimetry of 68Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors

**OP-171**

S. Krebs; J. O’Donoghue, D. Reidy, N. Pandit-Taskar, B. Beattie, L. Bodei, W. A. Weber; Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.

First experience using LMI1195 in patients with the suspicion of pheochromocytoma or paraganglioma

**OP-172**

C. Rischpler1, A. M. Schlitter1, M. Herz2, B. Youssefi1, A. von Werder1, R. Tauber1, T. Maurer1, K. Scheidhauer3, S. Robinson4, C. Orlandi1, S. G. Nekolla1, M. Schwaiger1; 1Technical University Munich, Munich, GERMANY, 2Lantheus Medical Imaging, N. Billerica, MA, UNITED STATES OF AMERICA.

68Ga-NODAGA-exendin-4 PET/CT for the localization of insulinomas: preliminary data from a prospective multicenter imaging study

**OP-173**

M. Boss, Sr.1, M. Buitinga1, M. Brom1, D. Wild2, V. Prasad1, P. Nuutila1, A. Brouwers1, F. Pattou2, M. Goethard1; 1Radboud University Medical Center, Nijmegen, NETHERLANDS, 2University of Basel Hospital, Basel, SWITZERLAND, 3Charite University Hospital of Berlin, Berlin, GERMANY, 4University of Turku, Turku PET Centre, Turku, FINLAND, 5University Medical Center Groningen, Groningen, NETHERLANDS, 6University Hospital, Lille, Lille, FRANCE.

AZEDRA® (iobenguane I 131I) in Patients with Malignant and/or Recurrent Pheochromocytoma/ Paraganglioma (PPGL): Overall Tumor Response Assessment

**OP-174**

D. A. Pryma1, B. B. Chin2, R. B. Noto3, J. S. Dillon4, L. Solnes5, J. Jensen6, T. White6, N. Stambler7, S. Apfel7, V. Wong7, C. Jimenez7; 1Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA, 2Duke University, Durham, NC, UNITED STATES OF AMERICA, 3University of Iowa Carver College of Medicine, Iowa City, IA, UNITED STATES OF AMERICA, 4Johns Hopkins Medicine, Providence, RI, UNITED STATES OF AMERICA, 5Progenics Pharmaceuticals, Inc., New York, NY, UNITED STATES OF AMERICA, 6University of Texas M. D. Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA.
OP-179
Segmental comparison of myocardial inflammation, area at risk, edema and irreversible tissue damage after acute myocardial infarction

OP-180
Prediction of Functional Recovery After Primary PCI Estimating Myocardial Salvage in Early Gated SPECT
R. Sciagrà, R. Calabretta, F. Linguanti, F. Tutino, A. Ciaccio; Nuclear Medicine, DECBS, University of Florence, FLORENCE, ITALY.

OP-181
Association of brain and cardiac glucose metabolism in patients with coronary artery disease and prior myocardial infarction
X. Lu1, T. Mou1, Z. Yang1, H. Mi1, Q. Wang1, X. Xie1, X. Li2, M. Hacker1, Y. Wei1, X. Zhang1; 1Beijing Anzhen Hospital, Capital Medical University, Beijing, CHINA, 2`Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA.

OP-182
Predictive and prognostic value of left ventricular mechanical dyssynchrony assessed by myocardial perfusion SPECT in asymptomatic patients under hemodialysis
F. Caobelli1, C. Popescu2, R. Laudicella2, A. Comis1, S. A. Pignata1, R. Sara2, C. Rossetti2; 1Young AIMN Working Group, 2`University Hospital Basel, Basel, SWITZERLAND.

509 Sunday, October 22, 2017, 16:30 - 18:00, Hall G1
Neurosciences: Imaging Neurotransmission Systems in Parkinson

OP-183
Comparisons of glucose metabolism and striatal DAT binding in PD patients with different subtypes
L. Li1, C. Jiang2, P. Wu1, J. Zhao1, C. Zuo2; 1PET Center, Huashan Hospital, Fudan University, Shanghai, CHINA, 2Department of Neurology, Huashan Hospital, Fudan University, Shanghai, CHINA.

OP-184
Role of an artificial neural network classifier, a classification tree (CIT), to diagnose Parkinson’s disease in early phase by using 123I-FP-CIT brain SPECT data
B. Palumbo1, A. Santonicola1, S. Cascianni2, S. Nuvoli1, M. L. Fravolini2, M. Minestrini2, M. Scialpi2, N. Tambasco2, A. Spanu1, G. Madeddu1; 1`Univ. of Perugia-Dept. of Surgical and Biomed. Sciences- Section of Nuclear Medicine, PERUGIA, ITALY, 2Univ. of Perugia-Dept. of Engineering, PERUGIA, ITALY, 3Univ. of Sassari-Dept. of Clinical and Experimental Medicine- Section of Nuclear Medicine, SASSARI, ITALY, 4`Univ. of Perugia-Dept. of Surgical and Biomed. Sciences- Section of Diagnostic Imaging, PERUGIA, ITALY, 5Unit of Neurology- Perugia University Hospital, PERUGIA, ITALY.

OP-185
Comparison of machine learning and semi-quantification approaches for DaTSCAN classification
J. Taylor; Sheffield Teaching Hospitals, Sheffield, UNITED KINGDOM.

OP-186
Abnormal striatal DAT distribution and PDRP expression in patients with rapid-eye-movement sleep behavior disorder
P. Wu1, C. Jiang1, L. Li1, J. Ge1, H. Yu2, J. Wu1, C. Zuo1; 1PET Center, Huashan Hospital, Fudan University, Shanghai, CHINA, 2Department of Neurology, Huashan Hospital, Fudan University, Shanghai, CHINA.

OP-187
Striatal and extra-striatal F-Dopa PET binding potential index related to age, gender, smoker status and Carbidopa premedication
S. Toch1, S. Poussier1, E. Micard1, P. Marie1, E. Guerdi2, A. Verger1; 1CHU Nancy, Nancy, FRANCE, 2Assistance Publique des Hôpitaux de Marseille, Marseille, FRANCE.

OP-188
Validation of a reliable and convenient PET protocol for striatal dopaminergic dysfunction imaging using 18F-LBT-999
N. Arlicot1,2, J. Verougille1,2, K. Mondon1,2, V. Gisso1,2, S. Mao3, L. Barantin1,2, Y. Peltier1,2, J. Cottier1,2, J. Houeto1,2, J. Deloye1, D. Guilloteau1,2, M. Ribeiro1,2, 1Centre Hospitalier Universitaire, Tours, FRANCE, 2Université François Rabelais, Tours, FRANCE, 3UMR U930 “Imaging and Brain”, Tours, FRANCE, 4Centre Hospitalier Universitaire, Poitiers, FRANCE, 5Laboratoires Cyclopharma, Clermont-Ferrand, FRANCE.
OP-189
Validation of (S,S)-(11C)-Methylreboxetine Positron Emission Tomography in Parkinson’s Disease
J. Brumberg, J. Tran-Gia, C. Keserheim, G. Brandt, C. Lapa, J. Volkmann, A. Buck, S. Sannick, J. U. Isaias; University Hospital Würzburg, Würzburg, GERMANY.

OP-190
PET imaging of mGluR5 with [18F]FPEB in Parkinson’s disease
Y. Kang, B. He, A. Verma, C. Henchcliffe, P. J. Kothari, D. Schlyer, K. Schmidt, P. C. Chiao, S. Vallabhajosula, P. D. Moyle; 1Weill Cornell Medicine, New York, NY, UNITED STATES OF AMERICA, 2Biogen Idec, Inc., Cambridge, MA, UNITED STATES OF AMERICA.

OP-191
Comparison of FDG PET/MRI and FDG PET/CT in Pediatric Oncology: Gazi University Pediatric PET/MRI Experience
L. Ö. Atay Kapucu, L. Uslu Beşli, Ü. Ö. Akdemir, U. Aydos, M. Özçelik, F. G. Fnarih, A. Okur, N. I. Karabacak, K. Karadeniz; 1Gazi University Medical Faculty, Department of Nuclear Medicine, Ankara, TURKEY, 2Istanbul University Cerrahpaşa Medical Faculty, Department of Nuclear Medicine, Istanbul, TURKEY, 3Gazi University Medical Faculty, Department of Pediatric Oncology, Ankara, TURKEY.

OP-192
Positive & negative predictive value of FDG PET/CT in pre-therapy assessment of Bone Marrow infiltration in pediatric lymphoma patients
M. A. Abdelwahab, S. A. Badri, M. H. Kotb, H. Mostafa; 1National Cancer Institute, Giza, EGYPT, 2NEMROCK, Cairo University, Giza, EGYPT.

OP-193
Grading and outcome prediction of pediatric diffuse astrocytic tumors with diffusion and arterial spin labeling perfusion MRI in comparison with 18F-DOPA PET Grading and outcome prediction of pediatric diffuse astrocytic tumors with diffusion and arterial spin labeling perfusion MRI in comparison with 18F-DOPA PET

OP-194
FDG PET in response evaluation of bulky masses in paediatric Hodgkin Lymphoma patients enrolled in the Italian AIEOP LH2004 trial
E. Lopci, M. Mascarin, A. Piccardo, C. Elia, L. Guerra, E. Borsatti, A. Sala, A. Todisco, A. Todisco, P. Zucchetta, F. P. Farruggia, A. Cistaro, S. Buffardi, P. Bertolini, M. Bianchi, M. Moletti, F. Bunkheila, P. Indolfi, A. Garaventa; 1Humanitas Clinical and Research Hospital, Milano, ITALY, 2Centro di Riferimento Oncologico, Aviano, Aviano, Pordenone, ITALY, 3Galliera Hospital, Genova, ITALY, 4Hospital San Gerardo, Monza, ITALY, 5University Hospital, Padova, Padova, ITALY, 6Ospedale dei Bambini, Palermo, Palermo, ITALY, 7IRMET, Torino, Torino, ITALY, 8Napoli – Pausilipon, Napoli, ITALY, 9Azienda Ospedaliera Parma, Parma, ITALY, 10Regina Margherita, Torino, ITALY, 11Università La Sapienza, Roma, ITALY, 12Hospital San Salvatore, Pesaro, ITALY, 13Napoli – 2 Università, Napoli, ITALY, 14G. Gaslini Hospital, Genova, ITALY, 15University Hospital S. Anna, Ferr, ITALY.

OP-195
Usefulness Of FDG-PET/CT In Assessing Bone And Bone Marrow Involvement In Pediatric Hodgkin Lymphoma
P. Guglielmo, C. Dolci, A. Sala, M. Spinelli, F. Elisei, E. Turilli, C. Crivellaro, C. Landoni, L. Guerra; 1University of Milan Bicocca, Milano, ITALY, 2Fondazione Tecnomed, ASST Monza - Ospedale San Gerardo, Milano, ITALY, 3Fondazione MBBM, Monza, ITALY, 4ASST - Monza, Ospedale San Gerardo, Monza, ITALY, 5Fondazione Tecnomed, ASST Monza - Ospedale San Gerardo, Monza, ITALY.
OP-196
The Role of FDG PET/CT Metabolic Parameters In Predicting Metastatic Disease In Pediatric Osteosarcoma Patients and The Prognostic Importance
A. K. Fidan, G. Ucmak, I. Kerimel, B. E. Akkas, B. B. Demirel; S.B.U. Ankara Oncology Research and Training Hospital, Nuclear Medicine Department, Ankara, TURKEY.

OP-197
Argentinean experience with the use of PET CT 18F DOPA in patient with suspected congenital hyperinsulinism
M. J. Bastianello1,2; 1Instituto Universitario CEMIC, CIUDAD DE BUENOS AIRES, ARGENTINA. 2Universidad Nacional de San Martin, Bs. As., ARGENTINA.

OP-198
Lymphoscintigraphic anomalies in children with Gorham's disease
M. Pizzoferro, M. F. Villani, A. Jenkner, I. Rana, O. Barbuti, M. C. Garganese; IRCCS Bambino Gesù Paediatric Hospital, Rome, ITALY.

OP-199
Theranostic Concepts, Exemplified on PSMA and CXCR4
H.-J. Wester; Technical University of Munich, Faculty of Chemistry and Faculty of Medicine, Munich, GERMANY.

OP-200
Development of Novel Theranostics
C. Cutler; Brookhaven National Laboratory, Upton, UNITED STATES OF AMERICA.

OP-201
Pretargeting in the Context of Theranostics and Companion Diagnostics
J. Barbet; Arronax GIF, Saint-Herblain, FRANCE.

602 Monday, October 23, 2017, 08:00 - 09:30, Hall B
Joint Symposium 5 - EANM/ESMI: Imaging Cardiac Remodelling Solutions
Chairs: F. Bengel (Hanover, GERMANY)  F. Hyafl (Paris, FRANCE)

OP-202
Imaging Cardiac Metabolism with PET
A. Saraste; Turku PET Centre, Turku University Hospital and University of Turku, Turku, FINLAND.

OP-203
Imaging Cardiac Metabolism with MRI
J. Prompers; Biomedical NMR, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, NETHERLANDS.

OP-204
Imaging Cardiac Remodelling Using PET-MRI
C. Rischpler; Department of Nuclear Medicine, Technical University Munich, Munich, GERMANY.

OP-205
Imaging Cell Trafficking in the Heart
J. Thackeray; Department of Nuclear Medicine, Hannover Medical School, Hanover, GERMANY.

603 Monday, October 23, 2017, 08:00 - 09:30, Hall C
Technologist Oral Presentations 1
Chairs: M. Vartzokas (London, UNITED KINGDOM)  C. Copland (London, UNITED KINGDOM)

OP-206
Using an asymmetric energy window improves image quality in planar bone scans
J. F. Machado1, S. K. Doshi1, R. Smith1, M. Evans1, S. Redman1, R. N. J. Graham1, D. Little2; 1Royal United Hospitals Bath, Bath, UNITED KINGDOM, 2Auckland District Health Board, Auckland City Hospital, Auckland, NEW ZEALAND.

OP-207
Semi-quantitative analysis in salivary glands scintigraphy: a contribution for technical validation
OP-208
Advanced method to reconstruct SPECT image from few number of projection data
Y. Yamaguchi, Y. Okura, M. Yamamoto; 1Hiroshima International University Graduate School, Higashihiroshima-shi, JAPAN, 2Hiroshima International University, Higashihiroshima-shi, JAPAN.

OP-209
Wireless Online Monitoring of Radiation Dose Rate of Radiodine (I-131) Ablation Patients: Saves Staff’s Doses and Resources
M. C. Lehtinen Gil Compte, P. H. Puhakka, K. Levänen, M. Honkanen, S. Myöhänen, J. Heikkinen; South Savo Social and Health Care Authority, Mikkel, FINLAND.

OP-210
The EU directive 2010/32, prevention from sharp injuries in the hospital and healthcare sector, in relation to ALARA: To recap or not?
A. F. Rekveld-van Moerkerken, K. Hart, F. Bomert, H. J. Verberne; Academic Medical Center (AMC), Amsterdam, NETHERLANDS.

OP-211
The effect of PET scan time on the off-line PET image quality in proton therapy
H. Gunchul, J. Joonyung, C. Eunson, L. Hyuk; Samsung medical center, seoul, KOREA, REPUBLIC OF.

OP-212
MOLY Project: a Mo-99 Production Program at ENEA TRIGA RC-1 Nuclear Research Reactor in Italy

OP-213
F-18-FDG PET-CT Studies Reproducible Quantitative Assessment for Clinical Use
D. B. Faria, J. Teixeira, A. Martins, J. Fernandes, J. Pinto, J. Vale, J. Patrino, A. Roçado, D. Sousa; HPP - Medicina Molecular SA, Porto, PORTUGAL, 2Lenitudes Medical Center & Research, Santa Maria da Feira, PORTUGAL, 3School Of Health Sciences - University of Aveiro, Aveiro, PORTUGAL.

OP-214
Digital PET/CT in clinical routine: Dose reduction and image quality
J. Trinckaft, M. Horbauer, M. Hülßner, I. Burger; University Hospital Zürich, ZURICH, SWITZERLAND.
**OP-220**

Lu-177 PSMA Radioligand Therapy might Prolong Survival in Metastatic Castration-Resistant Prostate Cancer: Results from a Single Center over 4 Years  
H. R. Kulkarni1, A. Singh1, C. Schuchardt1, T. Langbein1, K. J. Pienta1, R. P. Baum1; 1THERANOSTICS Center for Molecular Radiotherapy, Bad Berka, GERMANY, 2The Brady Urological Institute, Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA.

**OP-221**

Targeted Alpha Radioligand Therapy (TART) using Bismuth-213 PSMA in End-stage Progressive Treatment-refractory PSMA-expressing Metastatic Prostate Cancer: Results of a Pilot Study  
H. R. Kulkarni1, A. Singh1, T. Langbein1, C. Lehmann1, D. Mueller1, S. Marx1, K. J. Pienta1, R. P. Baum1; 1THERANOSTICS Center for Molecular Radiotherapy, Zentralklinik Bad Berka, Bad Berka, GERMANY, 2Division of Radiopharmacy, Zentralklinik Bad Berka, Bad Berka, GERMANY, 3ITG Isotope Technologies Garching GmbH, Munich, GERMANY, 4The Brady Urological Institute, Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA.

**OP-222**

Initial Theranostics Experience Using 68Ga-PSMA-11 PET/CT and 177Lu-PSMA-617 in a Chilean Oncology Center  
H. Amaral1,2, R. Fernández1, V. Kramer1, H. Lavados1, E. Hernández1, B. Morales1, R. Pruzzo1, A. Haeger1, J. Ribbeck1, J. Flores1; 1FALP / PositronMed, Santiago, CHILE, 2PositronPharma, Santiago, CHILE.

**OP-223**

Diagnostic Tumor Imaging Using Renally Excretable Nanoparticles: Focus on Active and Passive Targeting  
K. Pant1, K. Zarschler1, C. Neuber1, J. Pufe1, J. Steinbach1, R. Haag1, J. Pietzsch1, H. Stephan1; 1Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, GERMANY, 2Technische Universität Dresden, Department of Chemistry and Food Chemistry, Dresden, GERMANY, 3Freie Universität Berlin, Department of Chemistry and Biochemistry, Berlin, GERMANY.

**OP-224**

Multicolor fluorescence click-chemistry as a means to select membrane targets for pre-targeting by function of their internalization  
S. van der Wal1, C. M. de Korne1, G. L. S. Sand1, P. C. W. Hogendoorn, K. Szuha1, F. W. B. van Leeuwen1, T. Buckle1; LUMC, Leiden, NETHERLANDS.

**OP-225**

Multicolor fluorescence imaging as a means to reduce the toxicity during nodal dissections in prostate cancer  
P. Meershoek1, G. H. KleinJan2, M. N. van Oosterom1, E. M. Wit1, N. Grivas1, A. Mottrie1, F. W. B. van Leeuwen1, H. G. van der Poel1; 1Leiden University Medical Center, Leiden, NETHERLANDS, 2The Netherlands Cancer Institute (NKI-Avl.), Amsterdam, NETHERLANDS, 3OLV Vattikutti Robotic Surgery Institute, Melle, BELGIUM.

**OP-226**

Development of a tumor microenvironment(FAP alpha) targeted near infrared dye for fluorescence guided surgery of cancers  
J. Roy1, P. S. Low2; 1National Cancer Institute, Bethesda, MD, UNITED STATES OF AMERICA, 2Purdue University, West Lafayette, IN, UNITED STATES OF AMERICA.

**OP-227**

SPECT-based navigation of fluorescence cameras during soft-tissue surgery - is it possible to use a single navigation setup for various open and laparoscopic radioguided surgery applications?  
M. N. van Oosterom1, P. Meershoek1, G. H. KleinJan1, K. Hendrickx1, N. Navab1, C. J. H. van de Velde1, H. G. van der Poel1, F. W. B. van Leeuwen1; 1Leiden University Medical Center, Leiden, NETHERLANDS, 2The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS, 3Technical University Munich, Munich, GERMANY.

**OP-228**

Molecular imaging of malaria through fluorescent labelling of Plasmodium species within the mosquito host  
B. M. F. Winkel1, M. N. Oosterom1, A. Bunschoten, M. Welling1, M. C. Langenberg, F. Franke-Fayard, C. De Korne1, S. C. Chevalley, M. Yazdanbakhsh, F. W. B. van Leeuwen1, M. Roestenberg1; LUMC, Leiden, NETHERLANDS.
**OP-229**


M. Schottelius[^1], A. Wurzer[^1], K. Wisssmiller[^1], R. Beck[^1], J. Notni[^1], M. Koch[^2], D. Gorpas[^1], V. Ntziachristos[^1], M. Schwaiger[^1], T. Buckle[^1], F. van Leeuwen[^1], H. Wester[^1];


**OP-230**

s-Tetrazine: a “clickable” platform for the site-specific dual-labeling of proteins

C. Canovas[^1], M. Moreau[^1], C. Bernhard[^1], M. Cordonnier[^2], J. Gobbo[^3], A. Oudot[^3], F. Denat[^1], V. Goncalves[^1];


**606 Monday, October 23, 2017, 08:00 - 09:30, Hall F1**

**Pitfalls & Artefacts 3 (Interactive) - Oncology/Inflammation & Infection/Bone & Joint:**

**Pitfalls and Artefacts in Abdomen and Pelvis**

**Chairs:** L. Mansi (Naples, ITALY)

T. Kuwert (Erlangen, GERMANY)

**OP-231**

CT in Abdomen and Pelvis

T. Bäuerle[^1]; Institute of Radiology, University Hospital Erlangen, Erlangen, GERMANY

**OP-232**

Pitfalls in Planar Imaging

L. Mansi[^1]; Università della Campania “Luigi Vanvitelli”, Nuclear Medicine Department, Naples, ITALY.

**OP-233**

Pitfalls in SPECT/CT

T. Kuwert[^1]; Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, GERMANY

**OP-234**

Pitfalls in PET/CT

L. Evangelista[^1]; Istituto Oncologico Veneto I.R.C.C.S., Padova, ITALY

**607 Monday, October 23, 2017, 08:00 - 09:30, Hall F2**

**Clinical Oncology - Rapid Fire Session:**

**What’s New? Texture Analysis and More!**

**Chairs:** J. Adam (Amsterdam, NETHERLANDS)

P. Pilkington (Madrid, SPAIN)

**OP-236**

**Textural features assessed by dual time point 18 FDG PET/CT in locally advanced breast cancer: Relation with SUV-based variables and tumor biology**

A. García Vicente[^1], G. Jimenez Londoño[^1], D. Molina[^2], J. Perez-Beteta[^2], M. Arna-Salas[^2], A. Martinez Gonzalez[^2], M. Tello Galan[^1], V. Perez-Garcia[^2], A. Soriano Castrejon[^1];


**OP-237**

**First Interim Results of the Radium-223 REASSURE Observational Study: Analysis of Patient Characteristics and Safety by Prior Use of Chemotherapy**

S. Dizdarevic[^1], P. Meidahl Petersen[^2], M. Fessler[^2], A. Versari[^2], J. Bourre[^3], C. La Fougère[^4], R. Valdagni[^5], G. Paganelli[^6], S. Ezziddin[^6], J. Kalinovský[^10], Y. De Sanctis[^11], Y. Dü[^12];


**OP-238**

**Repeatability of tumour hypoxia imaging using [18F]EF5 PET/CT in head and neck cancer**

OP-239  Prostate-Specific Antigen Flare Induced by (223)Ra therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
A. Castello1, H. A. Macapinlac2, E. B. Santos2;
1Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences, Florence, ITALY; 2Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA.

OP-240  The Role of Texture Features Derived from FDG-PET/CT to Characterize Lung Lesions and Predict Survival in Non-Small Cell Lung Cancer Patients Undergoing Surgery
M. Kirienko1, M. Sollini1, L. Cozzi2, L. Antunovic2, E. Voulaz3, G. Veronesi1, N. Gennaro1, R. Muglia1, O. Santonocito1, A. Chiti1; 1Humanitas University, Milano, ITALY, 2Humanitas Clinical and Research Center, Milano, ITALY.

OP-241  Transitioning New Technology into the Reading Room - A Secondary Reconstruction Approach for Evaluation of Next-generation Digital PET/CT
K. Binzel1, J. Zhang1, C. L. Wright1, P. Maniawski2, M. V. Knopp1; 1The Ohio State University, Columbus, OH, UNITED STATES OF AMERICA, 2Philips Healthcare, Cleveland, OH, UNITED STATES OF AMERICA.

OP-242  Radiomics analysis predicts N- and M-stage of primary cervical cancer using multiple PET/ MR-derived quantitative features
J. Grueneisen, F. Nensa, K. Herrmann, A. Bariye, M. Forsting, L. Umutlu; University Hospital Essen, Essen, GERMANY.

OP-243  Simultaneous whole-body 18F-PSMA-1007-PET/MRI with integrated high-resolution multiparametrical imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer
M. T. Freitag1, C. Keschi, J. Cardinale1, P. Flechsig1, R. Floca1, M. Eiber1, D. Bonekamp1, J. P. Radtke2, C. Krahostiwi2, K. Kopka1, H. Schlenmer1, U. Habsch1, F. L. Giesel1; 1German Cancer Research Center, Heidelberg, GERMANY, 2University Hospital Heidelberg, Heidelberg, GERMANY, 3Technical University Hospital Munich, Munich, GERMANY.

OP-244  Combined use of Ga-68 PSMA-HBED and multiparametric MRI imaging of patients with carcinoma of the prostate in the primary staging setting and in cases of biochemical recurrence after radical prostatectomy
Z. E. Ballok1, M. Frydenberg2, K. Marshmann1, R. O’Sullivan1, D. Reilly1, 1BRI, Richmond, AUSTRALIA, 2MMC, Melbourne, AUSTRALIA, 1Australian Urology Association, Malvern, AUSTRALIA.

OP-245  Texture analysis is more predictive than SUV in 18F-Choline PET of the aggressiveness of prostate cancer
F. Hives1, A. Fagart2, K. Bouharrati-Moussa3, M. Fares3, L. Drelon1, P. Danjou1, O. Decave3, B. Makk3, S. Adib3; 1Service de médecine nucléaire, centre hospitalier de Béthune, Béthune, FRANCE, 2Service de médecine nucléaire, Université Lille 2, Lille, FRANCE, 3Service de radiothérapie, Centre Pierre Curie, Béthune, FRANCE, 4Service d’urologie, clinique des deux caps, Coquelles, FRANCE, 5Service de médecine nucléaire, centre hospitalier de Lens, Lens, FRANCE, 6Service d’urologie, clinique Anne d’Artois, Béthune, FRANCE.

OP-246  SPECT-CT visualization of sentinel and second echelon lymph nodes for lymph flow guided radiotherapy of tongue cancer
S. Novikov, P. Krzhivitskiy, Z. Radzhabova, O. Ponomareva, M. Girshovitch, S. Kanaev; N.N. Petrov Institute Oncology, St Petersburg, RUSSIAN FEDERATION.

OP-247  18F-FDG PET/CT radiomics in endometrial cancer
C. Crivellaro1,2, E. De Bernardi1, D. Vicini1, F. Elisei2, M. Cuzzocrea1, A. Buda1, F. De Poni3, F. P. Sina1, L. Guerra2, R. Fruscio1, C. Landoni1, 1University Milan-Bicocca, Monza, ITALY, 2Nuclear Medicine, ASST-Monza, San Gerardo Hospital, Monza, ITALY, 3Clinic of Obstetrics and Gynecology, ASST-Monza, San Gerardo Hospital, Monza, ITALY, 4Medical Physics, ASST-Monza, San Gerardo Hospital, Monza, ITALY.
609  Monday, October 23, 2017, 08:00 - 09:30, Hall G1
Committee Symposium 2 - Neuroimaging: PET/MR - Making it Clinical

**Chairs:** B. Sattler (Leipzig, GERMANY)
A. Lammertsma (Amsterdam, NETHERLANDS)

**OP-248**
Attenuation correction - is it solved?
C. Ladefoged; Copenhagen University Hospital Rigshospitalet, Nuclear Medicine & PET, Copenhagen, DENMARK.

**OP-249**
Brain Tumours
I. Law; Copenhagen University Hospital Rigshospitalet, Nuclear Medicine & PET, Copenhagen, DENMARK.

**OP-250**
Epilepsy - what does simultaneous PET-MR achieve that PET+MR does not?
A. Hammers; King’s College London, Imaging Sciences and Biomedical Engineering, London, UNITED KINGDOM.

**OP-251**
Dementia
A. Drzezga; University of Cologne, Nuclear Medicine, Cologne, GERMANY.

610  Monday, October 23, 2017, 08:00 - 09:30, Hall G2
Conventional & Specialised Nuclear Medicine: Musculoskeletal (Benign)

**Chairs:** F. Paycha (Paris, FRANCE)
S. Gratz (Stuttgart, GERMANY)

**OP-252**
Low Dose Radiation 18F-Fluoride PET/CT in the assessment of Unilateral Condylar Hyperplasia of the mandible: preliminary results of a 16 patients single centre experience

**OP-253**
Diagnostic ability of bone scan index for differentiating dental diseases
S. Watanabe, K. Nakojima, N. Noguchi, S. Kawashiri, A. Mizokami, M. Inokuchi, S. Kiryu; Kanazawa University Hospital, Kanazawa, JAPAN.

**OP-254**
Influence of 18F-FDG-PET/CT on therapeutic decision-making of patients with spondylodiscitis
A. Pöllmann, D. Maskopp, M. Plotkin; Vivantes Klinikum im Friedrichshain, Berlin, GERMANY.

**OP-255**
SPECT/CT imaging in Bertolotti’s Syndrome
K. Bayardo1,2, V. Depons3, J. Vilari2,3, D. Muñpz3, A. Bategazzore4, A. Silva5, R. Ferrando1,2; 1Clinics Hospital, University of the Republic, Montevideo, URUGUAY; 2Ferran Ferrando Páez Nuclear Medicine Clinic, Montevideo, URUGUAY.

**OP-256**
Scintigraphy of rhabdomyolysis - cornerstone in patient management?
D. Jocius1, D. Vajauskas1, A. E. Tamosiūnas1,2, A. Skrebunas1, M. Gutauskas1; 1Viñiunus University Hospital Santaros Klinikos, Vilnius, LITHUANIA; 2Viñiunus University, Vilnius, LITHUANIA.

**OP-257**
Clinical relevance of 99mTc-HDP SPECT/CT in the diagnosis of spondyloarthropathies
A. Bakos1, Z. Besenyő1, S. Urbán1, R. Hemelein2, L. Kovács1, L. Pávics1; 1Department of Nuclear Medicine University of Szeged, Szeged, HUNGARY; 2Department of Rheumatology University of Szeged, Szeged, HUNGARY.

**OP-258**
Increased Uptake in Synchondrosis of the Lower Limbs: Added Value of SPECT/CT.
K. Bayardo1,2, A. Zamora3, J. Vilari2,3, R. Ferrando1,2; 1Clinics Hospital, University of the Republic, Montevideo, URUGUAY; 2Consultorio de Medicina Nuclear Ferrari Ferrando Páez, Montevideo, URUGUAY.

**OP-259**
SPECT/CT is equivalent to diffusion-weighted MRI in characterizing equivocal osseous lesions detected by planar bone scintigraphy
M. Khalil1, Y. G. Abdelhafez1, H. Atta1, A. A. Kandeel2; 1South Egypt Cancer Institute, Assiut University, Assiut, EGYPT; 2Faculty of Medicine, Cairo University, Cairo, EGYPT.
Scientific Programme

SPS  Monday, October 23, 2017, 08:00 - 09:30, Room 0.31-2
UEMS/EBNM: Clinical Audit Session

Chairs: J. Prior (Lausanne, SWITZERLAND)
        S. Mirzaei (Vienna, AUSTRIA)

Welcome and Introduction
J. Prior, Lausanne, SWITZERLAND

NM Resources Manual- Guide for decision makers
D. Paez, IAEA

Clinical Audit in Algeria
S. Bouyoucef, ALGERIA

Clinical Audit in Spain
A. Garcia-Burillo, Barcelona, Spain

Clinical Audit in Switzerland
S. Gnesin, Lausanne, SWITZERLAND

UEMS/EBNM Accreditation from non-ISO-9001 certification
S. Mirzaei, Vienna, AUSTRIA

Presentation of accredited centers and training program since EANM 2016

801 Monday, October 23, 2017, 11:30 - 13:00, Hall A
CME 6 (Interactive) - Bone & Joint: Skeletal Scintigraphy Today - Accurate Diagnosis of Bone Disease with Therapeutic Impact

Chairs: F. Paycha (Paris, FRANCE)
        T. van den Wyngaert (Antwerp, BELGIUM)

OP-263
High Resolution SPECT/CT and Beyond
P. Ritt; University Hospital Erlangen, Clinic of Nuclear Medicine, Erlangen, GERMANY.

OP-264
SPECT/CT Quantification
T. Kuwert; Friedrich-Alexander-University Erlangen-Nurnberg, Clinic of Nuclear Medicine, Erlangen, GERMANY.

OP-265
The End of Planar: Whole-Body SPECT as New Paradigm
Z. Keidar; Rambam Health Care Campus, Department of Nuclear Medicine, Haifa, ISRAEL.

802 Monday, October 23, 2017, 11:30 - 13:00, Hall B
Joint Symposium 6 - EANM/EACVI: Fast-Track Cardiac Imaging: Is There an Ideal One-Stop Shop?

Chairs: O. Gämperli (Zurich, SWITZERLAND)
        R. Slart (Groningen, NETHERLANDS)

OP-266
Top Ten Diagnoses Made Possible by SPECT/CT
G. Gnanasegaran; Royal Free London NHS Foundation Trust, Department of Nuclear Medicine, London, UNITED KINGDOM.

OP-267
Healthcare Economic Perspectives on One-Stop Shop Cardiac Imaging
L. Hakkaart-van Roijen; Institute of Health Policy & Management (iBMG), Institute for Medical Technology Assessment (iMTA), Rotterdam, NETHERLANDS.

OP-268
Nuclear Medicine Physicians’ Perspective on One-Stop Shop Cardiac Imaging
M. Mouden; Isala Hospital, Department of Cardiology, Zwolle, NETHERLANDS.
Scientific Programme

OP-269
Radiologists’ Perspective on One-Stop Shop Cardiac Imaging

T. Leiner; Department of Radiology and Nuclear Medicine, Utrecht University Medical Center, Utrecht, NETHERLANDS.

OP-270
Cardiologists’ Perspective on One-Stop Shop Cardiac Imaging

D. Neglia; Fondazione G. Monasterio CNR-Regione Toscana and CNR Institute of Clinical Physiology, Pisa, ITALY.

OP-271
Ultra-low Dose CT for Attenuation Correction of 82Rb Cardiac PET

M. B. Sørensen, K. Bouchelouche, L. P. Tolbod; Dept. Nuclear Med. & PET-Centre, Aarhus University Hospital, Aarhus, DENMARK.

OP-272
Pediatric Anesthesia on Daily PET/CT workflow: Impact Quantification Based on Three Indicators

C. Barbosa1, S. Mendes1, I. Ferreira1, P. Gil1, P. Ribeira2, G. Costa1,2, J. Pedroso de Lima1,2,1 Centro Hospital e Universitário de Coimbra (CHUC), Coimbra, PORTUGAL, 2Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL.

OP-273
18F-FDG PET/CT in pediatric lymphoma patients: the role of technologist

M. Ciaccio1, C. Nava2, D. Bonacina2, M. Maurizio3, A. Perri4, A. Renaioli2, S. Morzenti1, L. Guerra1, C. Crivellaro1,2; 1ASST-Monza, San Gerardo Hospital, Nuclear Medicine, Monza, ITALY, 2University Milan-Bicocca, Nuclear Medicine, Monza, ITALY, 3ASST-Monza, San Gerardo Hospital, Medical Physics, Monza, ITALY.

OP-274
Practical Guide for 18F-Choline PET Imaging in hyperparathyroidism

M. Hofbauer, J. Trinckaft, M. Hüllner; UniversitätsSpital Zür, Zurich, SWITZERLAND.

OP-275
68Ga-PSMA PET/CT Protocol Review

E. Poel; Academic Medical Center, Amsterdam, NETHERLANDS.

OP-276
Reducing artefacts in PSMA PET/MR due to hip prosthesis with MAVRIC SL

T. Oblasser, M. Hofbauer, J. Trinckaft, T. Berthold, K. Friedrich, I. Burger; Department of Nuclear Medicine, PET/CT - MR Zentrum für Klinische Forschung, UniversitätsSpital Zür, Zurich, SWITZERLAND.

OP-277
Improving alignment between 18F-FDG PET and CT scans by controlling breathing movements during the CT-scan.

T. K. Lehnskov1, C. P. Jansson2, L. B. Katz3, D. A. Riisberg4; 1Bispebjerg/Fredeniksberg Hospital, København NV, DENMARK, 2Metropolitan University College, København N, DENMARK.

OP-278
Myocardium metabolic suppression protocol for 18F-FDG PET Sarcoïd Scan

E. M. Bagi, A. Garcia-Campos, K. Wechalekar; Royal Brompton & Harefield NHS Foundation Trust, 77 Wimpole Street, London, W1G 9RU, London, UNITED KINGDOM.

OP-279
PET imaging with 45Ti and the technical challenges involved

P. Costa1, N. Arantes2; 1Nuclear Medicine Department, ESSP|P. Porto, Porto, PORTUGAL, 2Independent Nuclear Medicine Technologist, Braga, PORTUGAL.

OP-280
Molecular Imaging Systems in Harmony – Necessity and Feasibility

I. Rausch; Medical University of Vienna, Vienna, AUSTRIA.

803 Monday, October 23, 2017, 11:30 - 13:00, Hall C
Technologist Oral Presentations 2

Chairs: S. Rep (Ljubljana, SLOVENIA) W. Kemps (Brussels, BELGIUM)

OP-277
Improving alignment between 18F-FDG PET and CT scans by controlling breathing movements during the CT-scan.

T. K. Lehnskov1, C. P. Jansson2, L. B. Katz3, D. A. Riisberg4; 1Bispebjerg/Fredeniksberg Hospital, København NV, DENMARK, 2Metropolitan University College, København N, DENMARK.

OP-278
Myocardium metabolic suppression protocol for 18F-FDG PET Sarcoïd Scan

E. M. Bagi, A. Garcia-Campos, K. Wechalekar; Royal Brompton & Harefield NHS Foundation Trust, 77 Wimpole Street, London, W1G 9RU, London, UNITED KINGDOM.

OP-279
PET imaging with 45Ti and the technical challenges involved

P. Costa1, N. Arantes2; 1Nuclear Medicine Department, ESSP|P. Porto, Porto, PORTUGAL, 2Independent Nuclear Medicine Technologist, Braga, PORTUGAL.

804 Monday, October 23, 2017, 11:30 - 13:00, Hall E1
Do.MoRe - Featured: Harmonization of Hybrid Molecular Imaging

Chairs: I. Rausch (Vienna, AUSTRIA) M. Lubberink (Uppsala, SWEDEN)

OP-280
Molecular Imaging Systems in Harmony – Necessity and Feasibility

I. Rausch; Medical University of Vienna, Vienna, AUSTRIA.
OP-281
Feasibility of state-of-the-art PET/CT system performance harmonisation
A. Kaalep1, T. Sera2, S. Rijsdorp3, M. Yaqub4, A. Talsma4, M. A. Lodge5, R. Boellaard6,7, 8, 1North Estonia Medical Centre, Tallinn, ESTONIA, 2University of Szeged, Szeged, HUNGARY, 3University of Szeged, Szeged, HUNGARY, 4EANM Research Limited, Vienna, AUSTRIA, 5Catharina Hospital, Eindhoven, NETHERLANDS, 6VU University Medical Center, Amsterdam, NETHERLANDS, 7Martini Hospital, Groningen, NETHERLANDS, 8Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA, 9University Medical Center Groningen, Groningen, NETHERLANDS.

OP-282
Feasibility of a brain PET harmonization program for state of art PET/CT systems
R. Boellaard1, S. Golla2, A. Kaalep3, M. Yaqub2, T. Sera4, S. Rijsdorp3, R. Kogan5, N. Leenders6, A. Lammertsma7; 1University Medical Center Groningen, GRONINGEN, NETHERLANDS, 2VU University Medical Center, Amsterdam, NETHERLANDS, 3North Estonia Medical Centre Foundation, Tallinn, ESTONIA, 4University of Szeged, Szeged, HUNGARY, 5Rostock University Medical Center, Rostock, GERMANY, 6Humanitas University, Rozzano, ITALY, 7The European Organisation for Research and Treatment of Cancer, Brussels, BELGIUM.

OP-283
EANM/EARL FDG-PET/CT accreditation - summary results from the first 150 accredited imaging sites
A. Kaalep1, T. Sera2, W. Oyen3, B. J. Krause4, A. Chiti5, Y. Liu5, R. Boellaard6,7, 8, 1North Estonia Medical Centre, Tallinn, ESTONIA, 2University of Szeged, Szeged, HUNGARY, 3University of Szeged, Szeged, HUNGARY, 4The Royal Marsden Hospital, London, UNITED KINGDOM, 5Rostock University Medical Center, Rostock, GERMANY, 6Humanitas University, Rozzano, ITALY, 7Humanitas Research Hospital, Rozzano, ITALY, 8The European Organisation for Research and Treatment of Cancer, Brussels, BELGIUM, 9University Medical Center Groningen, Groningen, NETHERLANDS, 10VU University Medical Center, Amsterdam, NETHERLANDS.

OP-284
Development of the IAEA-NMQC toolkit for automated analysis of quality control tests on SPECT systems
G. L. Poli1, A. Vergara Gil2, L. Torres Arache3; 1International Atomic Energy Agency, Vienna, AUSTRIA, 2Division of Clinical Research, Centre of Isotopes, Havana, CUBA, 3Department of Medical Physics, ASST Monza, Monza, ITALY.

OP-285
Implications of a FDG-PET EARL Protocol for Ga-68 PET Imaging
D. Koopman1,2, W. A. Noortman1,2, P. L. Jager1, C. H. Slump1, J. A. van Dalen1, 1Isala, Department of Nuclear Medicine, Zwolle, NETHERLANDS, 2MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, NETHERLANDS, 1Isala, Department of Medical Physics, Zwolle, NETHERLANDS.

OP-286
Robustness of EQ•PET SUV harmonization to tumor-to-background variations
B. S. Spottswoode1, M. V. Mattoli2, M. Milite3, M. L. Calcagni4, A. Giordano2, L. Indovina2; 1Siemens Medical Solutions USA, Inc., Knoxville, TN, UNITED STATES OF AMERICA, 2Università Cattolica del Sacro Cuore, Rome, ITALY, 3Siemens Healthcare Srl, Milan, ITALY, 4Fondazione Policlinico Universitario A. Gemelli, Rome, ITALY.

805 Monday, October 23, 2017, 11:30 - 13:00, Hall E2
M2M: Peptides

OP-287
A New ⁶⁴Cu-Labeled, Metabolic-Resistant Peptide with Nanomolar Affinity for NPY-Y1R for Breast Cancer Targeting
M. Paquette, V. Dumulon-Perreault, S. Ait-Mohand, B. Guérin; Université de Sherbrooke, Sherbrooke, QC, CANADA.

OP-288
New Radiolabeled Exendin Analogue Shows Increased Renal Clearance
L. Joosten, C. Frielink, M. Goethard, M. Brom; Radboud University Medical Center, Nijmegen, NETHERLANDS.

OP-289
Metabolic fate of [¹¹¹In]Sarabesin 3 in mice: Identifying radiometabolites in peripheral blood as well as neutral endopeptidase as the key degrading protease
B. A. Nock1, E. Lympers1, W. Sallegger2, A. Kaloudi3, E. P. Krening1, M. de Jong1, T. Maina4; 1Molecular Radiopharmacy, INRAS, NCSR, Athens, GREECE, 2PiChem, Graz, AUSTRIA, 3Department of Nuclear Medicine, Erasmus MC, Rotterdam, NETHERLANDS, 4Department of Radiology, Erasmus MC, Rotterdam, NETHERLANDS, 5Molecular Radiopharmacy, INRAS, NCSR ‘Demokritos’, Athens, GREECE.
OP-290
New radiolabelled minigastrin analogues with improved CCK2R targeting for diagnostic and therapeutic use
M. Klingler1, C. Rangger2, D. Summer1, J. Foster*, J. K. Sosabowski2, E. von Guggenberg1; 1Medical University of Innsbruck, Innsbruck, AUSTRIA, 2Barts and the London School of Medicine, London, UNITED KINGDOM.

OP-291
Application of SSTR radioligands in Breast Cancer

OP-292
Radionuclide tumor targeting using ADAPT scaffold proteins: aspects of label positioning and residualizing properties of the label
J. Garousi1, S. Lindbo2, B. Mitran1, M. Altai1, J. Buijs4, A. Orlova3, S. Hober2, V. Tolmachev1; 1Institute for Immunology, Genetics and Pathology, Uppsala University, Uppsala, SWEDEN, 2School of Biotechnology, Division of Protein Technology, KTH Royal Institute of Technology, Stockholm, SWEDEN, 3Division of Molecular Imaging, Department of Medicinal Chemistry, Uppsala University, Uppsala, SWEDEN, 4Uppsala University, Uppsala, SWEDEN.

OP-293
Effectivity of a combined treatment with the m-TOR inhibitor RAD001 and Peptide Receptor Radionuclide therapy with Lu-177 DOTA TATE evaluated with Ga-68 DOTA TATE PET in a tumor model of the mouse
J. Zellmer1, L. Vomacka1, G. Böning1, F. J. Gildehaus1, J. Carlser1, E. Mille1, M. Hacker1, P. Bartenstein1, A. R. Haug2, H. Ilhan1; 1Department of Nuclear Medicine, University Hospital of Munich, Munich, GERMANY, 2Division of Nuclear Medicine, Department of Biomedical Imaging and Image Guided Therapy, Medical University of Vienna, Vienna, AUSTRIA.

OP-294
The Receptor UT of Urotensin-II is a New Target for Imaging Solid Tumor with Radiolabeled DOTA-Peptide Ligands
B. Poret1,2, L. Desruel3, N. Perzo4, P. M. Coly5, J. E. Joubert2, M. A. Bonin1, R. Leduc2, R. Modzelewski1, F. Morin6, H. Castet1, P. Vera1, P. Bohn1, P. Gandolfo2; 1EA 4108, Laboratory of Computer Science, Information Processing and Systems (LITIS), team “QuantIT”, Centre Henri Becquerel, Rouen, FRANCE, 2Normandie Univ, UNIROUEN, INSERM 1239, OC2N, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Mont-Saint-Aignan, FRANCE, 3Department of Physiology & Pharmacology, Institute of Sherbrooke, Faculty of Medicine and Health Sciences, Sherbrooke University – Health Campus, Sherbrooke, QC, CANADA.

OP-295
Patient Preparation and Technical Artefacts
C. Franzius; MR-, Nuklearmedizin und PET/CT-Zentrum Bremen Mitte, Bremen, GERMANY

OP-296
Combined imaging in cervical cancer with hybrid FDG-PET/MRI for primary staging followed by Tc-99m-SPECT/CT for pre-surgical sentinel lymph node mapping
S. Sahrai1, F. Fiz2, F. Tarari2, S. Brucker2, D. Wallwiener2, A. Staebler1, H. Dittmann1, C. la Fougère1; 1Nuclear Medicine, Tubingen, GERMANY, 2Gynecology and Obstetrics, Tubingen, GERMANY, 3Pathology, Tubingen, GERMANY.
OP-299
Utility of multiparametric PET/MRI for response assessment of radiochemotherapy or neoadjuvant chemotherapy in cervical cancer patients
T. Sarabhai, Y. Erfanian, M. Forsting, K. Herrmann, L. Umutlu, J. Grueneisen; University Hospital Essen, Essen, GERMANY.

OP-300
Preoperative staging of endometrial cancer: prognostic role of PET-derived parameters
P. Mapelli1, E. Incerti1, A. Bergamini1, F. Fallanca1, P. M. V. Rancoita1, R. Cioffi1, M. Petrone1, E. Rabaiotti1, G. Mangili2, L. Gianoli2, M. Picchio1; 1Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, Milano, ITALY, 2Obstetrics and Gynecology, IRCCS San Raffaele Scientific Institute, Milano, ITALY, 3University Centre of Statistics in the Biomedical Sciences, Vita-Salute San Raffaele University, Milano, ITALY.

OP-301
Prognostic value of 18F-FDG PET/CT in restaging of locally advanced cervical cancer after concomitant chemo-radiation therapy
G. M. Lima, A. Matti, E. De Crescenzo, G. Polverari, A. M. Perrone, P. De Iaco, C. Nanni, S. Fant; S.Orsola-Malpighi University Hospital, Bologna, ITALY.

OP-302
Combined FDG and 4FMFES PET Imaging in ER+ Breast Cancer Patients for Improved Diagnostic and Prognostic Value
M. Paquette, É. Lavallée, S. Phoenix, H. Senta, B. Guérin, J. E. van Lier, R. Lecomte, É. E. Turcotte; Université de Sherbrooke, Sherbrooke, QC, CANADA.

OP-303
Qualitative and quantitative analyses of 18F-FES and 18F-FDHT uptake in patients with metastatic breast cancer: an interobserver variability study
L. H. Mammatas1, C. M. Venema2, C. P. Schroder3, M. van Kruchten1, G. Apollonio3, A. W. J. M. Glaudemans4, A. H. H. Bongaerts1, O. S. Hoekstra5, H. M. W. Verheul6, E. Boamer1, B. van der Vegt7, E. F. J. de Vries8, E. G. E. de Vries8, R. Boellaard9, G. A. P. Hospelers4, C. W. Menke-van der Houwen van Oordt1; 1Department of Medical Oncology, VUMc Cancer Center Amsterdam, VU University Medical Center, Amsterdam, NETHERLANDS, 2Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS, 3Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS, 4Department of Radiology and Nuclear Medicine VU University Medical Center, Amsterdam, NETHERLANDS, 5Department of Pathology & Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS.

OP-304
68Ga-NOTA-BBN-RGD PET/CT for GRPR and Integrin αvβ3 Imaging in Patients with Breast Cancer
J. Zhang1,2, F. Mao1, G. Niu2, L. Peng3, L. Lang4, F. Li5, H. Ying5, H. Wu5, B. Pan5, Z. Zhu5, X. Chen2; 1Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHINA, 2Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, MD, UNITED STATES OF AMERICA, 3Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHINA, 4Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHINA, 5Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHINA.

OP-305
PET Imaging of Chemokine Receptor CXCR4 in Patients with Primary and Recurrent Breast Cancer
T. Vag1, A. Rossmann1, S. Metz2, H. Wester3, M. Schwager4; 1Klinikum Rechts der Isar, Munich, GERMANY, 2Institute of Pharmaceutical Radiochemistry, Technical University Munich, Munich/ Garching, GERMANY.
OP-308
PET Imaging of Brain Involvement in Systemic Autoimmune Disorders
R. Dierckx; University Medical Center Groningen, Medical Imaging Center, Dep. of Nuclear Medicine and Molecular Imaging, Groningen, NETHERLANDS.

OP-309
Quantitative characterization of xSPECT algorithm: influence of reconstruction parameters (number of iterations and subsets) on image quality
L. Lorenzon1, A. Fraccetti1, M. Bonelli1, M. Tredici2, V. Zilio3, M. Farsad2, M. Haller1; 1Department of Medical Physics, Hospital of Bolzano, Bolzano, ITALY, 2Department of Nuclear Medicine, Hospital of Bolzano, Bolzano, ITALY.

OP-310
Dual-labeled PSMA-11 for PET/CT imaging and precise fluorescence guided intraoperative identification of prostate cancer
A. Baranski1, M. Schafer1, U. Bauder-Wüst1, M. Roscher1, J. Schmidt1, E. Stenu1, T. Simplendorfer1, L. Maier-Hein1, B. Hadaschik2, U. Haberkorn2, K. Kopka2, M. Eder1,2; 1German Cancer Research Center, Heidelberg, GERMANY, 2University Hospital, Heidelberg, GERMANY.

OP-311
SVM based detection of a disease specific metabolic brain pattern in a rat model for Parkinson’s disease using longitudinal 18F-FDG PET imaging
M. Devrome1, M. Crabbé1, V. Baekelandt1, K. Van Laere1, C. Casteels1, M. Koole1; 1Division of Nuclear Medicine, KU Leuven, Leuven, BELGIUM, 2Molecular Small Animal Imaging Centre, KU Leuven, Leuven, BELGIUM.

OP-312
Quantitative myocardial stress perfusion in patients with chest pain and normal coronary arteries to assess subsequent improvement of symptoms with transcutaneous electrical nerve stimulation
A. G. Monroy-Gonzalez1, M. J. L. De Jongste2, E. Andersonson-Rosas2, R. A. Tio3, R. H. J. A. Start4; 1University Medical Center Groningen, Groningen, NETHERLANDS, 2Department of Physiology, National Autonomous University of Mexico, MEXICO.

OP-313
TSPO-PET for high-grade glioma imaging using the novel ligand [18F]GE-180 - first in human results in the course of radiotherapy
M. Unterrainer1, D. Fleischmann1, S. Lindner1, A. Brunengraf1, F. Vettermann1, L. Vomacka1, M. Brendel1, R. Rupprecht1, C. Belk1, P. Bartenstein1, M. Niyazi2, N. Albert1; 1Ludwig-Maximilian-University Munich, München, GERMANY, 2University of Regensburg, München, GERMANY.

OP-314
Relationship between Intraprostatic Hybrid Tracer Deposition and Lymphatic Drainage Pattern in Prostate Cancer Patients
C. M. de Korne1, T. Buckle1, N. S. van den Berg1, J. de Jong2, R. A. Valdes-Olmos1, F. W. B. van Leeuwen1, H. G. van der Poe1; 1LUMC, Leiden, NETHERLANDS, 2NKI-AVL, Amsterdam, NETHERLANDS.

OP-315
Efficacy and Safety of 177Lu-PSMA-617 Treatment in Castration Resistant Prostate Cancer with Organ Metastasis
O. E. Sahin1, E. Akgün1, E. Demirci2, M. Oca1, A. Akgün1, B. Akovalı1, E. Karayel1, H. Pehlivangolu1, L. Kabasakal1; 1Department of Nuclear Medicine, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, TURKEY, 2Department of Nuclear Medicine Sisli Efaf Training and Research Hospital, Istanbul, TURKEY, 3Department of Pharmaceutical Technology, Pharmacy Faculty, Istanbul University, Istanbul, TURKEY.
810 Monday, October 23, 2017, 11:30 - 13:00, Hall G2
Committee Symposium 6 - Thyroid: Update on Ablative Therapies in Thyroid Nodules

**Chairs:** M. Kreissl (Magdeburg, GERMANY)
M. Luster (Marburg, GERMANY)

**OP-316**
Ablative Therapies in Thyroid Nodules - The Endocrinologist’s Perspective
*L. Hegedüs*, University of Odense, Department of Endocrinology and Metabolism, Odense, DENMARK.

**OP-317**
Ablative Therapies in Thyroid Nodules - The Surgeon’s Perspective
*C. Vorländer*, Bürgerhospital Frankfurt, Department of Endocrine Surgery, Frankfurt, GERMANY.

**OP-318**
Ablative Therapies in Thyroid Nodules - The Nuclmed Perspective
*M. Kreissl*, Klinik für Radiologie und Nuklearmedizin, Universitätssklinikum Magdeburg A.ö.R., Otto-von-Guericke Universität, Magdeburg, GERMANY.

YDF2 Monday, October 23, 2017, 13:00 - 14:30, Hall F1
EANM Young Daily Forum 2: Networking - How to Build Professional Relationships
*R. Sheppard*, Somerset, UNITED KINGDOM.

901 Monday, October 23, 2017, 14:30 - 16:00, Hall A
CME 7 - Radionuclide Therapy/Thyroid: Safety Aspects in Radionuclide Therapy

**Chairs:** I. Zerizer (London, UNITED KINGDOM)
M. Hoffmann (Vienna, AUSTRIA)

**OP-321**
Radiobiological Aspects in Radionuclide Therapy
*K. Pouget*, IRCM/INSERM U896, Montpellier, FRANCE.

**OP-322**
Early and Late Side Effects of Radionuclide Therapy
*L. Bodet*, Memorial Sloan Kettering Cancer Center, New York, UNITED STATES OF AMERICA.

902 Monday, October 23, 2017, 14:30 - 16:00, Hall B
Symposium 7 - Bone & Joint: Painful Hip Arthroplasty

**Chairs:** F. Paycha (Paris, FRANCE)
U. Kampen (Hanburg, GERMANY)

**OP-324**
Biomechanics of Normal Hip and Hip Arthroplasty
*D. Pioletti*, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lab. of Biomechanical Orthopedics, Lausanne, SWITZERLAND.

**OP-325**
What the Surgeon Wants to Know From Imaging
*R. Nizard*, Hospital Lariboisière - Assistance Publique – Hôpitaux de Paris, Service de Chirurgie Orthopédique et Traumatologique, Paris, FRANCE.

**OP-326**
Radiologic Imaging
*A. Feydy*, Hospital Cochin - Assistance Publique – Hôpitaux de Paris, Service de Radiologie, Paris, FRANCE.

**OP-327**
Hybrid Imaging: Role and Limits
*A. Santos* (Lisbon, PORTUGAL)
G. Testanera (London, UNITED KINGDOM)

903 Monday, October 23, 2017, 14:30 - 16:00, Hall C
CTE 3: Prostate Imaging and Therapy

**Chairs:** A. Santos (Lisbon, PORTUGAL)
G. Testanera (London, UNITED KINGDOM)

**OP-328**
PET-CT Imaging in Prostate Cancer
*P. Castellucci*, S. Orsola-Malpighi, Nuclear Medicine, Bologna, ITALY.

**OP-329**
Radionuclide Therapy in Prostate Cancer
*T. D. Poeppel*, University Hospital Essen, Essen, GERMANY.

**OP-330**
Radiation Therapy and PET-CT Aided Radiotherapy Planning in Prostate Cancer
*A. Skanjeti*, Nuclear Medicine Department, Hospices Civils de Lyon, Lyon, FRANCE.
904  Monday, October 23, 2017, 14:30 - 16:00, Hall E1
Do.Mo.Re - Committee Symposium 4
- Dosimetry: Validation of Quantitative Imaging, Dosimetry & Estimates of Uncertainty

**Chairs:** J. Gear (London, UNITED KINGDOM)
F. Verburg (Marburg, GERMANY)

**OP-331**
The Need for Dosimetry Validation - A Clinician’s View Point
F. A. Verburg; Philipps-University of Marburg, Marburg, GERMANY.

**OP-332**
The Use of Monte Carlo for Validation and Uncertainty Analysis
J. R. Gustafsson; Department of Medical Radiation Physics, Lund University, Lund, SWEDEN.

**OP-333**
Propagation of Uncertainty Analysis for Absorbed Dose Calculations
J. Gear; Royal Marsden NHSFT & Institute of Cancer Research, London, UNITED KINGDOM.

**OP-334**
Validation of Calibration Protocols and the MRTDosimetry Project
A. Robinson; National Physical Laboratory, Teddington, UNITED KINGDOM.

905  Monday, October 23, 2017, 14:30 - 16:00, Hall E2

**M2M: SPECT/CT & SPECT/MRI**

**Chairs:** F. Beekman (Delft, NETHERLANDS)
M. Bernsen (Rotterdam, NETHERLANDS)

**OP-336**
Characterization of $^{11}$In-labeled site-specifically conjugated anti-PSMA antibody-drug conjugates for treatment of PSMA-expressing tumors
S. Lütje$^1$, D. Gerrits$^2$, J. D. Molkenboer-Kuenen$^2$, K. Hermann$^3$, G. Fracasso$^4$, M. Colombatti$^4$, O. C. Boerner$^4$, S. Heskamp$^4$; Dept. Radiology and Nuclear Medicine, Radboud university medical center, Nijmegen, NETHERLANDS, $^2$Clinic for Nuclear Medicine, University Hospital Essen, Essen, GERMANY, $^3$Dept. of Medicine, University of Verona, Verona, ITALY.

**OP-337**
Novel high affinity affibody for radionuclide imaging of VEGFR2 in glioma vasculature: proof-of-principle in murine model
B. Mitan$^1$, R. Guler$^1$, F. Po Roche$^1$, E. Lindstrom$^1$, R. Selvaraj$^2$, F. Fleetwood$^2$, S. S. Rinne$^2$, L. Claesson-Welsh$^2$, V. Tolmachev$^2$, S. Stahl$^2$, A. Orkova$^2$, J. Löblom$^2$; Uppsala University, Uppsala, SWEDEN, $^3$KTH-Royal Institute of Technology, Stockholm, SWEDEN.

**OP-338**
Development and evaluation of gonadotropin releasing hormone SPECT radioligands
R. Fjellaksel$^{1,2,3}$, J. Hansen$^1$, A. Oteiza$^{4,5}$, M. Martin-Armas$^{1,6}$, A. Molde-Anaya$^{1,6}$, P. Riss$^{2,3,5}$, R. Sundset$^{1,5}$; $^1$Medical Imaging Group, Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, NORWAY, $^2$Drug Transport and Delivery Group, Department of Pharmacy, UiT The Arctic University of Norway, Tromsø, NORWAY, $^3$Organic Chemistry Group, Department of Chemistry, UiT The Arctic University of Norway, Tromsø, NORWAY, $^4$Preclinical PET/SPECT/CT, Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, NORWAY, $^5$Neurology Research Group, Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, NORWAY, $^6$Department of nephropathy and psychosomatic medicine, Oslo University Hospital, Oslo, NORWAY, $^7$Realomics SFI, Department of Chemistry, University of Oslo, Oslo, NORWAY, $^8$Norsk Medisinsk Syklotronsenter AS, Oslo, NORWAY.

**OP-339**
Somatostatin receptor type 2 as a marker for pro-inflammatory macrophages
S. T. van Tiel$^1$, L. Utomo$^1$, E. J. Meester, J. de Swart$^1$, N. Kops, R. H. de Blois, M. de Jong, Y. Bastiaansen-Jenniskens, M. Bernsen; ErasmusMC, Rotterdam, NETHERLANDS.

**OP-340**
Quantitative Analysis of 99mTc-DMSA Renal Scintigraphy of Animal AKI Models; Comparison with Histopathological and Biochemical Assays
K. Tanha$^1$, H. Fatemikia$^1$, M. Seyedabadi$^1$, K. Tanha$^1$, Z. Karim$^1$, M. Assadi$^1$; The Persian Gulf Nuclear Medicine Research Center, Bushehr University of Medical Sciences, Bushehr, IRAN, ISLAMIC REPUBLIC OF, $^2$Department of Physiology, Medical School, Bushehr University of Medical Sciences, Bushehr, IRAN, ISLAMIC REPUBLIC OF, $^3$Department of Biostatistics, School of Public Health, Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, $^4$Shiraz Nephron Urology Research Center, Shiraz University of Medical Sciences, Shiraz, IRAN, ISLAMIC REPUBLIC OF.
PET/CT And SPECT/CT Based Identification of Novel Rodent BAT and Beige Depots—An Image Guided Exploration of Human-like Thermogenic Tissues in Mice

O. K. Oz1, F. Zhang1, G. Hao1, G. Hassan1, M. Shao1, Y. An1, Q. Wang1, C. Kusminski1, K. Nham1, Q. Zhai1, P. Scherer1; 1UT Southwestern Medical Center, Dallas, TX, UNITED STATES OF AMERICA, 2Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, CHINA.

SPECT-MRI and histological analysis to map PRRT radiobiology for a better understanding of local treatment effects

J. Nonnukens, G. N. Doeswijk, J. C. Haecq, M. W. Konijnenberg, D. C. van Gent, M. de Jong; Erasmus MC, Rotterdam, NETHERLANDS.

Comparison study of TCO-functionalized vector systems for in vivo click chemistry using [111In]In-DOTA-Tetrazine

P. E. Edem1,2, J. T. Jørgensen1,2, K. Nørregaard1,2, E. J. L. Steen1, R. Rossin1, A. Birke2, C. Denk1, A. Yazdani3, J. F. Valliant4, H. Mikula5, M. Barz6, M. Robillard6, M. M. Herth1,2, A. Kjer1,2; Rigshospitalet, Copenhagen, DENMARK, 3Tagworks Pharmaceuticals, Eindhoven, NETHERLANDS, 4Johannes Gutenberg-University Mainz, Mainz, GERMANY, 5TUWien, Vienna, AUSTRIA, 6McMaster University, Hamilton, ON, CANADA, 7Johannes Gutenberg-University Mainz, Mainz, GERMANY.
OP-349
Staging Patients with Hodgkin Lymphoma - Is Bone Marrow Biopsy Still Necessary in the Era of 18F-FDG PET?
C. Voltin1, S. Stockter1, C. Baues2, M. Fuchs1, M. Dietlein1, J. Mettler1, A. Engert1-3, P. Borchmann1-4, A. Drzezga1, C. Kobe1; 1Department of Nuclear Medicine, University Hospital of Cologne, Cologne, GERMANY, 2Department of Radiation Oncology, University Hospital of Cologne, Cologne, GERMANY, 3German Hodgkin Study Group (GHSG), University Hospital of Cologne, Cologne, GERMANY, 4Department of Internal Medicine I, University Hospital of Cologne, Cologne, GERMANY.

OP-350
FDG-PET/CT at the end of immuno-chemotherapy in Follicular Lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET)
S. Annunziata1, A. Cuccaro2, M. C. Tisi2, S. Hohaus2, A. Giordano1, V. Rufini1; 1Institute of Nuclear Medicine, Università Cattolica del Sacro Cuore, Rome, ITALY, 2Institute of Hematology, Università Cattolica del Sacro Cuore, Rome, ITALY.

OP-351
Interim treatment response assessment in paediatric Hodgkin's lymphoma by using Deauville and delta SUVmax in FDG PET CT
K. Shahe, S. Shah, N. Purandare, A. Agrawal, A. Puranik, V. Rangarajan; TATA Memorial Hospital, Mumbai, INDIA.

OP-352
B-cell lymphoma radioimmunotherapy: effect of co-infusion of cold and radiolabelled antibody on absorbed dose to healthy tissues and tumours, a preclinical study in dogs
F. Morio1-2, C. Ibisch1-2, F. Nguyen1-3, M. Berthaud1, J. Abadie1-2, A. Vidal1, M. Bourgeois1-2, K. Remorande1, S. Becavin1, M. Rousse1, J. Ferrer1-3, C. Bodet-Milin1-3, N. Chouin1-2, F. Davodeau1; 1AMaROC, Oniris (Nantes Atlantic College of Veterinary Medicine, Food Science and Engineering), NANTES, FRANCE, 2Team 13 "Nuclear oncology research", CRCINA, INSERM UMR1232, Université d'Angers, Université de Nantes, Nantes, FRANCE, 3Team 8 "Stress Adaptation and Tumor Escape", CRCINA, INSERM UMR 1232, Université d'Angers, Université de Nantes, Nantes, FRANCE, 4Team 8 "Stress Adaptation and Tumor Escape", CRCINA, INSERM UMR 1232, Université d'Angers, Université de Nantes, Nantes, FRANCE, 5Team 8 "Stress Adaptation and Tumor Escape", CRCINA, INSERM UMR 1232, Université d'Angers, Université de Nantes, Nantes, FRANCE, 6Radiopharmacy Department, ARRONAX Cyclotron, Saint-Herblain, FRANCE, 7Department of Nuclear Medicine, University Hospital, Nantes, FRANCE, 8Recombinant Protein Core Facility of The University of Nantes, NANTES, FRANCE, 9Institut de Cancérologie de l'Ouest, Medical Physics Department, Saint-Herblain, FRANCE.
OP-359
Cardiac amyloid imaging with 18F Florbetapir PET - initial results from a UK study
J. Page1,2, T. Wagner1, M. Burniston1, J. Ross2, A. Skillern2, D. McCool1, T. Lane1, R. Manwani1, M. Fontanna1, P. Hawkins1, A. Wechalekar1; 1National Amyloidosis Centre, London, UNITED KINGDOM, 2Royal Free London NHS Foundation Trust, London, UNITED KINGDOM.

OP-360
Cardiac FDG-PET/CT in systemic sclerosis
Z. Besenyői1, G. Ágoston1, R. Hemelein1, A. Bakos1, L. Kovács1, A. Varga2, L. Pávics1; 1Department of Nuclear Medicine University of Szeged, Szeged, HUNGARY, 2Department of Family Medicine University of Szeged, Szeged, HUNGARY, 3Department of Rheumatology University of Szeged, Szeged, HUNGARY.

909 Monday, October 23, 2017, 14:30 - 16:00, Hall G1
Neurosciences: Imaging Neurodegeneration in Alzheimer’s Disease by TAU and FDG Imaging

Chairs: G. Chételat (Caen, FRANCE)
A. Drzezga (Cologne, GERMANY)

OP-361
Flortaucipir perfusion PET is a suitable replacement for FDG PET in patients with neurodegenerative diseases
J. Hammes1, I. Leuwer1, G. N. Bischof2, A. Drzezga1, T. van Eimeren1,2; 1Clinic of Nuclear Medicine, University Hospital Cologne, Cologne, GERMANY, 2INM-3, Research Center Jülich, Jülich, GERMANY.

OP-362
The impact of education on the association between tau deposits and cognition in Mild Cognitive Impairment
S. Trombella1, G. B. Frisoni1, V. G. Garibotto1; 1Geneva University, Geneva, SWITZERLAND, 2Geneva University and Geneva University Hospital, Geneva, SWITZERLAND.

OP-363
Parametric imaging of tau load in Alzheimer’s patients and controls using Flortaucipir
S. S. V. Golla1, E. Wolters1,2, T. Timmers1,2, R. Ossenkoppele1,2, C. Groot1, S. Verfaillie1, P. Scheltens2, W. M. van der Flier3, L. Schwarte4, M. A. Mintun5, M. Devous6, R. C. Schuit7, A. D. Windhorst1, A. A. Lammertsma1, R. Boellaard1,8, B. N. M. van Berckel1, M. Yaqub1; 1Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, NETHERLANDS, 2Alzheimer Center & Department of Neurology, VU University Medical Center, Amsterdam, NETHERLANDS, 3Department of Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, NETHERLANDS, 4Department of Anaesthesiology, VU University Medical Center, Amsterdam, NETHERLANDS, 5Avid Radiopharmaceuticals, Inc., Philadelphia, PA, UNITED STATES OF AMERICA, 6Department of Nuclear Medicine & Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS.

OP-364
Association between tau deposition, amyloid-ß, age and memory performance in cognitively normal subjects: influence of partial volume correction
I. Sonni1, A. Maaß2, S. N. Lockhart2, S. M. Landau2, S. L. Baker1, W. J. Jagust1,2; 1Lawrence Berkeley National Laboratory, Berkeley, CA, UNITED STATES OF AMERICA, 2Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, CA, UNITED STATES OF AMERICA.

OP-365
On- and Off-target binding of [18F]AV-1451 in Substantia Nigra post-mortem tissues of Alzheimer’s Disease (AD) patients and Normal Control (NC) subjects
L. Gomez1, Y. Lin2, Q. Liang1, M. Mintun2, G. Attardo2; 1Avid R.P., Philadelphia, PA, UNITED STATES OF AMERICA.

OP-366
Clinical evaluation of 18F-PI-2620, a next generation tau PET agent in subjects with Alzheimer’s disease, progressive supranuclear palsy, and non-demented controls
J. Seibyl1, O. Barret1, A. Stephens1, J. Madonia1, D. Alagille1, A. Mueller1, H. Schieferstein1, M. Berndt1, H. Kroth1, S. Bullich1, C. Papin1, V. Carroll1, C. Sandiego1, A. Pfeifer1, A. Muhs1, L. Dinkelborg2, G. Tamagnan1, K. Marek1; 1Molecular Neuroimaging, New Haven, CT, UNITED STATES OF AMERICA, 2Piramal Imaging, Berlin, GERMANY, 3AC Immune SA, Lausanne, SWITZERLAND.
OP-367
Metabolic patterns underlying disease heterogeneity and severity in patients with dementia with Lewy Body: a project of the European Consortium for Dementia with Lewy Body (E-DBL)
S. Morbelli1,2, M. Brendel1, A. Rominger1, V. Garibotto2, N. Nicastro1, A. Pilotto1, A. Padovani1, B. Paghera1,2, S. Garcia-Ptacek1, I. Savitcheva3, M. G. Kramberger1, M. Trost1, A. W. Lemstra4, J. J. van der Zande1,2, S. Pappata4,5, M. Calcagni4,2, A. Cistaro1,2, V. Berti1,2, D. Volterrani1,2, S. Sestini1,2, M. Bauckneht1,2, F. Sensi1,2; 1IRCCS San Martino - IST, Genoa, ITALY, 2Neurology Study Group of the Italian Association of Nuclear Medicine, AIMN, ITALY, 3Department of Nuclear Medicine, University of Munich, Munich, GERMANY, 4Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospitals, Geneva, SWITZERLAND, 5Division of Neurorehabilitation, Department of Clinical Neurosciences Geneva, Geneva University Hospitals, Geneva, SWITZERLAND, 6Neurology Unit, University of Brescia, Brescia, ITALY, 7Parkinson's disease rehabilitation Centre, FERB ONLUS S.Isidoro Hospital, Trescore Balneario, (BG), ITALY, 8Nuclear Medicine, Spedali Civili Brescia, Brescia, ITALY, 9Division of Clinical Geriatrics, Center for Alzheimer Research, Karolinska Institutet, Stockholm, SWEDEN, 10Department of Radiology, Karolinska Institutet, Stockholm, SWEDEN, 11Department of Neurology, University Medical Centre, Ljubljana, SLOVENIA, 12Alzheimer Center & Department of Neurology, UU University Medical Center and Neuroscience Campus, Amsterdam, THE NETHERLANDS, 13Institute of Biostucture and Bioimaging, CNR, Naples, ITALY, 14Institute of Nuclear Medicine, Fondazione Policlinico Universitario Agostino Gemelli, Università Cattolica del Sacro Cuore, Rome, ITALY, 15Positron Emission Tomography Centre IRMET S.p.A., Turin, ITALY, 16Nuclear Medicine Unit, University of Florence, Florence, ITALY, 17Nuclear Medicine Unit, University Hospital of Pisa, Pisa, ITALY, 18Nuclear Medicine Unit, U.S.L. Toscana Centro, Prato, ITALY, 19Istituto Nazionale di Fisica Nucleare, Sezione di Genova, Genoa, ITALY, 20Centre for Age-Related Medicine (SESAM), Stavanger University Hospital, Stavanger, NORWAY, 21Wolfson Centre for Age-Related Diseases, King's College London, London, UNITED KINGDOM, 22Clinical Neurology, Department of Neuroscience (DINO), University of Genoa, Genoa, ITALY.

OP-368
Diagnosis of Alzheimer’s Disease Through Identification of Abnormality Patterns in Molecular Brain Imaging
N. Burgos1, J. Samper-Gonzalez2, A. Bertrand2,3, M. Habert1, S. Ourselin1,4, S. Durrieu1,2, M. Cardoso4, O. Colliot2,1, I. Ilinia, Aramis project-team, Paris, FRANCE, 2Sorbonne Universités, UPMC Univ Paris 06, Inserm, CNRS, ICM, Paris, FRANCE, 3Pitié-Salpêtrière Hospital, Neuroradiology, Paris, FRANCE, 4Pitié-Salpêtrière Hospital, Nuclear Medicine, Paris, FRANCE, 5University College London, Translational Imaging Group, London, UNITED KINGDOM, 6University College London, Dementia Research Centre, London, UNITED KINGDOM.

910 Monday, October 23, 2017, 14:30 - 16:00, Hall G2
Conventional & Specialised Nuclear Medicine: Infection & Inflammation

OP-369
Role of 18Fluorine-Fluorodeoxyglucose positron emission tomography/computed tomography in the diagnosis of endocarditis: a bicentre study on 84 patients
P. Ferro1, D. Albano2, C. Popescu3, M. Bertoli4, I. Cersosimo5, F. Bertagni6, R. Sara7, G. Giubbini8, C. Rossetti9; 1Università Milano-Bicocca, Ospedale Niguarda Ca’ Granda, Milano, ITALY, 2Università Milano-Bicocca, Spedali Civili, Brescia, ITALY, 3Ospedale Niguarda Ca’ Granda, Milano, ITALY, 4Università Milano-Bicocca, Spedali Civili, Brescia, ITALY, 5Università Milano-Bicocca, Spedali Civili, Brescia, ITALY, 6Demographics Pro, Beijing, CHINA.

OP-370
Digestive incidentalomas in FDG-PET/CT images of patients with infectious endocarditis; relationship with the involved microorganisms

OP-371
Role of 18FDG PET/MR in the diagnosis and follow-up of retroperitoneal fibrosis
P. Zucchetta, F. Cribi1, C. Lacognata, R. Marcolongo, D. Cecchin, V. Bodanza, J. Doraku, D. Miotto, F. Bui; University Hospital - Padova, Padova, ITALY.
Scientific Programme

OP-372
Comparison of F18 FDG and Ga68 citrate PET/CT in the evaluation of patient with tuberculosis
A. O. Ankrah1, I. O. Lawal1, T. M. G. Boshomane1, M. Vorster1, H. C. Klein1, A. W. M. J. Glaudemans2, M. M. Sathekge1; 1University of Pretoria, Pretoria, SOUTH AFRICA, 2University Medical Center Groningen, Groningen, NETHERLANDS.

OP-373
The diagnostic value of 18F-FDG-PET /CT, MRI and 18F-FDG-PET/MRI in suspected vertebral osteomyelitis - a prospective study
I. Kouijzer1, H. Scheper1, J. de Rooy1, J. Bloem1, M. Janssen1, L. van den Hoven1, A. Hosman1, L. Visser1, W. Oyen1, C. Bleeker-Rovers1, L. de Geus-Oei1,2, 1Radboudumc, Nijmegen, NETHERLANDS, 2University of Twente, Enschede, NETHERLANDS, 1LUMC, Leiden, NETHERLANDS, 4The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UNITED KINGDOM.

OP-374
18F-FDG PET/CT as a diagnostic tool for infection assessment in post-traumatic non-unions
L. Antunovic, N. Trenti, L. Di Mento, E. Malagoli, G. Cusato, L. Balzarini, A. Kirienko, A. Chiti, M. Berlusconi; Humanitas Clinical and Research Hospital, Rozzano, ITALY.

OP-375
Relationship between WBC scintigraphy with Tc99m HMPAO-labeled leucocytes and clinical outcome in patients with suspected prostatic joint infections
T. Pellegrino1, M. Petretta2, V. Cantonii, V. Piscopo3, G. De Matteis1, S. Pellegrino1, A. Cuocolo2; 1Department of Biostucture and Bioimaging, National Council of Research, Naples, ITALY, 2Department of Translational Medical Sciences, University Federico II, Naples, ITALY, 3Department of Advanced Biomedical Sciences, University Federico II, Naples, ITALY.

OP-376
Typical uptake distribution patterns that help the diagnosis of polymyalgia rheumatica on FDG-PET/CT
K. Nakatani, S. Yuge, K. Yoshino, T. Koyama; Kurashiki Central Hospital, Kurashiki, JAPAN.
1003  Monday, October 23, 2017, 16:30 - 18:00, Hall C
CTE 4 - Joint Session with CAMRT: Radionuclide Production

Chairs: P. Fragoso Costa (Oldenburg, GERMANY)  
F. Couillard (Ottawa, CANADA)

OP-383 Reactor Produced Radioisotopes Used in Nuclear Medicine
F. Rösch; Johannes Gutenberg-University Mainz, Institute of Nuclear Chemistry, Mainz, GERMANY.

OP-384 Cyclotron Produced Radioisotopes Used in Nuclear Medicine
F. Alves; Coimbra University, Institute of Nuclear Sciences Applied to Health, Coimbra, SPAIN.

OP-385 Molybdenum-99 World Supply
F. Couillard; CAMRT, Ottawa, CANADA.

1004  Monday, October 23, 2017, 16:30 - 18:00, Hall E1
Do.Mo.Re: Dosimetry in Thyroid Disease

Chairs: M. Luster (Marburg, GERMANY)  
M. Hoffmann (Vienna, AUSTRIA)

OP-386 First biosafety, biodistribution and dosimetry study of the gastrin analogue $^{111}$In-CP04 in medullary thyroid cancer. Phase I clinical trial, GRANT-T-MTC
M. Koninchenberg1, P. A. Erba2, R. Mikolajczak3, C. Decistorto4, H. Macek5, T. Maina-Now6, K. Zalete1, P. Kolenc-Periti1, I. Virgolin1, E. Przybylik-Mazurek4, C. Rangger1, M. Trofimuk-Muldner6, K. Skorkiewicz3, L. Ležaj7, L. Scarpa2, G. Di Santo2, A. Sowa-Staszczak8, M. de Jong1, L. Froberg7, P. Garnuszek8, D. Pawlak8, G. Göbel1, B. Nock9, D. Bergant10, A. Hubalewska-Dydejczyk10, 1Erasmus MC, Rotterdam, NETHERLANDS, 2Nuclear Medicine, Azienda Ospedaliero Universitaria Policlinico Umberto I, Rome, ITALY, 3Department of Nuclear Medicine, University Hospital Freiburg, Freiburg, GERMANY, 4Institute of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA, 5Nuclear Medicine, Department of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA, 6Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, SLOVENIA, 7Institute of Oncology, University Medical Centre Ljubljana, Ljubljana, SLOVENIA, 8Chair and Department of Endocrinology, Jagiellonian University Medical College, Krakow, POLAND, 9Institute of Oncology, Ljubljana, SLOVENIA.

OP-387 Lesion dosimetry in metastatic thyroid cancer treated with $^{131}$I: method and preliminary results
E. Richetta, C. Cutai, M. Pasquino, L. Sacco, A. Codegone, R. Pellerito, M. Stasi; AO Ordine Mauriziano di Torino, Turin, ITALY.

OP-388 Analysis deviation of the absorbed dose of thyroid for Graves’ disease with hyperthyroidism treated by iodine-131 with simplified Quimby-Marinelli-Hine formula method
Y. Chen; Quanzhou 1st Hospital, Quanzhou, CHINA.

OP-389 Micro-scale Modeling for the Salivary Gland: Insights into Toxicity from $^{131}$I Therapy for Thyroid Cancer
R. F. Hobbs1, A. McGuffey1, W. Jentzen2, D. Plyku1, A. Bockisch2, G. Spouras1; 1Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA, 2Universitaetsklinikum Essen, Essen, GERMANY.

OP-390 Dose-response correlation in radioiodine therapy of hyperthyroidism from nodular thyroid disease
M. Pacilio1, G. Ventroniti2, V. Frantellizzi3, B. Cassano4, E. Verdolini3, T. Montesanti4, G. De Vincenti4, L. Mangol5; 1Department of Medical Physics, University Ospedaliero Universitaria Policlinico Umberto I, Rome, ITALY, 2Department of Nuclear Medicine, Azienda Ospedaliera San Camillo Forlanini, Rome, ITALY, 3Department of Medical Physics, University Ospedaliero Universitaria Policlinico Umberto I, Rome, ITALY, 4Postgraduate School of Medical Physics, “Sapienza” University of Rome, Rome, ITALY, 5Department of Biological, Geological and Environmental Sciences, “Sapienza” University of Rome, Rome, ITALY.

OP-391 First-in-human administration of the CCK-2 receptor agonist $^{177}$Lu-PP-F11N in patients with metastasized medullary thyroid carcinoma - preliminary results of the “Lumed” trial
C. Rottenburger1, G. Nicolas1, L. McDougall2, F. Kaul2, E. Christ2, R. Schibli2, S. Geistlich2, M. Béhé3, D. Wild3; 1University of Basel Hospital, Basel, SWITZERLAND, 2Paul Scherrer Institut, Villigen, SWITZERLAND.

OP-392 Red marrow dosimetry in metastatic thyroid cancer treated with $^{131}$I: a simplified method
E. Richetta, G. Lo Moro, C. Cutai, M. Pasquino, L. Sacco, G. Brusasco, R. Pellerito, M. Stasi; AO Ordine Mauriziano di Torino, Turin, ITALY.
OP-393
Differences in radioiodine biokinetics between papillary thyroid carcinoma low-risk patients treated with 1.11 GBq of 131I-Nal and high-risk patients treated with 3.7 GBq of 131I-Nal
P. Mínguez Gabiña1, M. Domínguez Ayala1, A. Expósito Rodríguez, J. Genollá Subirats1, E. Rodeño Ortiz de Zaraate1, Gurutzeta/Cruces University Hospital, Barakaldo, SPAIN, 2Basurto University Hospital, Barakaldo, SPAIN.

OP-394
Radiolabelling with carbon-11 of sulfasalazine for PET imaging of cystine transporter Xc- involved in the radioresistance of glioblastoma
M. Morloz, M. Ibazizene, C. Perrio, L. Barre, F. Gourand; Cyceron, UNICAEN, CEA, CNRS, ISTCT/LDM-TEP group, Caen, FRANCE.

OP-395
A Successive Triple PET Tracer Approach to Characterize ER and HER2 Status In Vivo in a Breast Cancer Mouse Xenograft Model
M. Paquette, S. Beaudoin, S.Phoenix, L. Fafard-Couture, E. E. Turcotte, B. Guérin, R. Lecomte, J. V. Leyton, Université de Sherbrooke, Sherbrooke, QC, CANADA.

OP-396
In vivo tracking of T cells by [18F]BF4 PET/CT in a mouse model of human breast cancer
E. Kurtys1, L. Lim1, F. Mani, A. Volpe1, J. Maher1, G. O. Fruhwirth1,2; 1Department of Imaging Chemistry and Biology, Division of Imaging Sciences and Biomedical Engineering, St. Thomas’ Hospital Campus, King’s College London, London, UNITED KINGDOM, 2Division of Cancer Studies, King’s College London, SE1 9RT, UK, London, UNITED KINGDOM, 3Comprehensive Cancer Imaging Centre King’s College London & UCL, London, UNITED KINGDOM.

OP-397
Differentiation of CNS lymphoma and glioblastoma with [18F]fludarabine-PET: comparison with [18F]FDG in human xenograft models
N. Hovhannisyan1, S. Guillouet1, M. Dhily1, M. Ibazizene1, F. Fillesoye1, S. Valable1, B. Plancoulaine1, L. Barré1, 2Normandie Univ, UNICAEN, CEA, CNRS, CHU Caen, ISTCT/LDM-TEP group, Caen, FRANCE, 2Normandie Univ, UNICAEN, CEA, CNRS, CHU Caen, ISTCT/CERV/TEP group, Caen, FRANCE, 3Normandie Univ, UNICAEN, INSERM, ANTICIP, Caen, FRANCE.

OP-398
Convenient synthesis and biological evaluation of [18F]-labeled MIBG analog with an improved detectability
A. Yamaguchi, H. Hanaoka, T. Higuchi, Y. Tsushima; Gunma University Graduate School of Medicine, Maebashi, JAPAN.

OP-399
Targeting glucose metabolism and EGFR signaling in oncogene-driven non-small cell lung cancer
V. De Rosa1, F. Iommelli1, M. Monti2, C. Terlizzi2, S. Del Vecchio1,2; 1Institute of Biostructures and Bioimaging, National Research Council, Naples, ITALY, 2Department of Advanced Biomedical Sciences, University of Naples “Federico II”, Naples, ITALY.

OP-400
A direct comparison of four different 68Ga-labeled RGD peptides for PET/CT imaging of angiogenesis
D. Lobeek1, S. Y. A. Terry1, G. M. Franssen1, M. T. Ma1, H. Wester1, C. Decristoforo2, W. J. G. Oyen1,2, O. C. Boerman1, M. Rijpkema1; 1Radboud University Medical Center Nijmegen, Nijmegen, NETHERLANDS, 2King’s College London, London, UNITED KINGDOM, 3King’s College London, London, UNITED KINGDOM, 4Technische Universität München, Garching, GERMANY, 5Medical University Innsbruck, Innsbruck, GERMANY, 6Institute of Cancer Research, Royal Marsden NHS Trust, London, UNITED KINGDOM.

OP-401
Synthesis and biological evaluation of novel five 18F labelled radioligands for detection of MAO-B activity
S. Nag1, A. Jackson2, A. Takano1, K. Jia1, R. Arakawa1, M. Jhan1, R. Ahmd1, S. Luthra1, R. Maior1, C. Halldin1; 1Karolinska Institutet, Stockholm, SWEDEN, 2GE Healthcare, London, UNITED KINGDOM.

1005 Monday, October 23, 2017, 16:30 - 18:00, Hall E2
M2M: PET/CT
Chairs: P. Laverman (Nijmegen, NETHERLANDS) B. Cornelisssen (Oxford, UNITED KINGDOM)

OP-402
Applied Cross Sectional Anatomy and Correlative Imaging – Abdomen & Pelvis
D. Yakar; University Medical Centre, Groningen, NETHERLANDS.
Joint Symposium 18 - EANM/ESMO: Treatment Landscape in Metastatic CRPC

Chairs: C. Kratochwil (Heidelberg, GERMANY) W. Gerritsen (Nijmegen, NETHERLANDS)

Current Treatment Algorithm of Metastatic CRPC
W. Gerritsen; Radboud University Medical Centre Nijmegen, Nijmegen, NETHERLANDS.

Imaging of Metastatic CRPC in the PSMA Era
P. Castellucci; S. Orsola-Malpighi, Nuclear Medicine, Bologna, ITALY.

SMA Targeted Radioligand Therapy – What Do We Know So Far?
C. Kratochwil; University Hospital Heidelberg, Department of Nuclear Medicine, Heidelberg, GERMANY.

New Treatment Strategies and Options for Metastatic CRPC – Is There Space for PSMA RLT?
R. Tauber; Klinik und Poliklinik für Urologie, Klinikum rechts der Isar, Technische Universität München, Munich, GERMANY.

Standardization of MIBG Heart-to-Mediastinum Ratio Using a Phantom-based Calibration Method
K. Nakajima1, K. Okuda2, K. Yakoyama3, T. Yoneyama1, S. Tsuj1, S. Tsuj1, H. Oda1, M. Yoshida1, K. Kubota1; 1Kanazawa University Hospital, Kanazawa, JAPAN, 2Kanazawa Medical University, Uchinada, JAPAN, 3Public Central Hospital of Matto Ishikawa, Hakusan, JAPAN, 4Hokuriku National Hospital, Nanto, JAPAN.

Inter-study reproducibility of SPECT 123I-mIBG left atrial innervation imaging for the identification of left atrial ganglionated plexi in patients with paroxysmal atrial fibrillation
J. Stirrup1, U. Voss2, S. Gregg3, R. Baavour4, N. Roth5, C. Breault1, S. Ernst2, S. Underwood2; 1Royal Berkshire NHS Foundation Trust, Reading, UNITED KINGDOM, 2Royal Brompton and Harefield NHS Foundation Trust, London, UNITED KINGDOM, 3Spectrum Dynamics Medical Ltd, Caesarea, ISRAEL.

Evaluation of the effectiveness of radiofrequency ablation of atrial fibrillation: a 123-Iodine-MIBG myocardial scintigraphy study
Y. Saushkina, V. Saushkin, K. Zavadovsky, I. Kisteneva, I. Kostina, Z. Vesnina, Y. Lishmanov, S. Popov, R. Karpov; Cardiology Research Institute, Tomsk NRMIC, Tomsk, RUSSIAN FEDERATION.

Value of Gated-perfusion SPECT, synchrony and I123-MIBG scintigraphy in predicting cardiac resynchronization therapy response
A. García-Burillo1, P. Hinojosa, S. Aguadé, J. Pérez-Rodón, M. N. Pizzi, G. Cases, M. Andrés, N. Rivas, A. Moya; Hospital General Universitari Vall d’Hebron, Barcelona, SPAIN.

Effect of resynchronization therapy on endothelial dysfunction and functional parameters in patients with chronic heart failure and left bundle branch block
T. Massardo1, J. Pereira2, C. G. Sáez2, J. Aramburu3, R. Morris4, S. Brugère1, A. Pino5, E. Swett6, E. Hiplan1, R. Aguayo3, R. Aguayo7, G. Paillahueque1, L. Alarcón1, J. Torres1, J. Spuler1, R. Fernández7, E. Sanhueza1, M. Palominos5, N. Olavero1, J. A. Valenzuela1, J. A. Asenjo2; 1Hospital Clínico Universidad de Chile, Santiago, CHILE, 2Pontificia Universidad Católica de Chile, Santiago, CHILE, 3Hospital San Juan de Dios, Santiago, CHILE.

MIBG scintigraphy to better identify patients who benefit from AICD in primary prevention
G. Bertuccio, G. Scrima; Ospedale S. Croce - ASLTOS, Moncalieri, ITALY.
OP-413
The potential role of myocardial viability assessment using 18F-FDG PET-CT in patients with non-ischemic cardiomyopathy eligible for catheter radiofrequency ablation of ventricular tachycardias: preliminary considerations
S. Capitanio1, R. Sara2, C. Popescu2, G. Colombo2, S. Pedretti2, P. Ferro2, M. Miele2, C. Rossetti2; 1ASUITS Hospital, Trieste, ITALY, 2Niguarda Hospital, Milano, ITALY.

1010 Monday, October 23, 2017, 16:30 - 18:00, Hall G2
Committee Symposium S - Radiation Protection: CT-Optimisation of Hybrid Imaging
Chairs: M. Lassmann (Wurzburg, GERMANY)
        K. Muylle (Brugge, BELGIUM)

OP-414
Technical Optimisation
K. Bacher; Ghent University, Department of Medical Physics, Ghent, BELGIUM.

OP-415
Optimisation in Oncology
P. Veit-Haibach; University of Toronto, Joint Department of Medical Imaging, Toronto, CANADA.

OP-416
Optimisation in Paediatric Nuclear Medicine
P. Dinis de Almeida; Institute of Biophysics and Biomedical Engineering, Faculty of Sciences, University of Lisbon, Lisbon, PORTUGAL.

OP-417
The View of HERCA on Optimisation
S. Ebdon-Jackson; CRCE, Public Health England, Oxfordshire, UNITED KINGDOM.

1101 Tuesday, October 24, 2017, 08:00 - 09:30, Hall A
CME 9 - (Paediatrics/Inflammation & Infection: FDG PET in Paediatric infections
Chairs: A. Piccardo (Genova, ITALY)
        A. Signore (Rome, ITALY)

OP-419
FDG PET in the Evaluation of Lymphadenopathy in Children
L. Borgwardt; Clinic for Clinical Physiology, Nuclear Medicine & PET, 4011, Diagnostic Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen, DENMARK.
OP-427
In-vivo biokinetics of $^{177}$Lu-OPS201 in mice and pigs as a model for predicting human dosimetry
S. Beykan1, M. Fani2, G. Nicolas2, D. Wild1, R. Bejo1, J. Kaufmann1, H. Bouterfa3, S. Jensen4, M. Lassmann1; 1Department of Nuclear Medicine, University of Würzburg, Würzburg, GERMANY, 2Division of Nuclear Medicine, University Hospital of Basel, Basel, SWITZERLAND, 3Octreopharm Science GmbH, Ipsen Group, Berlin, GERMANY, 4Department of Chemistry and Biosciences, Aalborg University, Department of Nuclear Medicine, Aalborg University Hospital, Aalborg, DENMARK.

OP-428
A comparison of 2D and 3D kidney absorbed dose measures in patients receiving Lutate therapy
K. Willowson1, R. Hu1, A. Singh2, P. Jackson3, E. Eslick2, D. Bailey3; 1University of Sydney, Sydney, AUSTRALIA, 2Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, AUSTRALIA, 3Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA.

OP-429
Patient-specific pharmacokinetics and dosimetry over multiple therapy cycles during $^{177}$Lu-based radionuclide therapy: a study for $^{177}$Lu-DOTATATE and $^{177}$Lu-PSMA
A. Gosewisch, L. Ermoschkin, H. Ilhan, A. Todica, L. Vomacka, P. Bartenstein, G. Böning; University Hospital Munich, Munich, GERMANY.

OP-430
The effect of the total tumour volume on the kidneys, salivary glands and tumour BEDs for $^{177}$Lu-labelled PSMA ligands
N. J. Begum1, A. Thiemer1, J. Allmann2, M. Eiber3, A. J. Beer1, G. Glatting1, P. Kletting1; 1Medical Radiation Physics, Department of Nuclear Medicine, Ulm University, Ulm, GERMANY, 2Department of Nuclear Medicine, Klinikum Rechts der Isar der Technischen Universität München, Munich, GERMANY, 3Department of Nuclear Medicine, Ulm University, Ulm, GERMANY.

OP-431
Concurrent use of $^{90}$Y, $^{177}$Lu and $^{225}$Ac-labelled PSMA-binding radiopharmaceuticals can lead to improved treatment efficacy
A. M. Denis-Bacelar, A. J. Fenwick, K. M. Ferreira, J. L. Wevrett, A. P. Robinson; National Physical Laboratory, Teddington, UNITED KINGDOM.

OP-432
Assessing the impact of registration methods on absorbed dose calculation in Peptide Receptor Radionuclide Therapy
S. Berenato1, E. Grassi2, F. Fioroni2, D. Finocchiaro2,1, M. Ioii1, E. Spezi2; 1School of Engineering, Cardiff University, Cardiff, UNITED KINGDOM, 2Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, ITALY.

OP-433
Evaluation of the Correlations Between the Absorbed Bone Marrow Dose and Bone Marrow Response During the First Cycle of $^{177}$Lu-DOTATATE Treatment
L. Hagmarker1, J. Svensson2, T. Rydén1, B. Wångberg3, A. Sundlöv4, K. Sjögreen Gleisner5, P. Bernhardt1; 1Institution of Clinical Sciences, Göteborg, SWEDEN, 2Department of Oncology, Göteborg, SWEDEN, 3Department of Surgery, Göteborg, SWEDEN, 4Department of Oncology, Skåne University Hospital, Lund, SWEDEN, 5Department of Radiation Physics, University of Lund, Lund, SWEDEN.

OP-434
Prospective Dosimetry and Optimization of RPT-XRT Combination Therapies

OP-435
A 3D-Printed Automated Dual Reactor Synthesizer for Challenging Multi-Step $^{18}$F-Fluorinations: Testing and Validation
A. Amor-Coarasa, J. M. Kelly, D. Kim, W. Qu, P. Kothari, J. W. Babich; Weill Cornell Medical College, New York City, NY, UNITED STATES OF AMERICA.

OP-436
Optimization of a Novel Automated Loop Method for Production and Development of Analytical Methods for $^{11}$C-Nicotine Injectable
K. Kumar, J. M. Kelly, D. Kim, W. Qu, P. Kothari, J. W. Babich; Weill Cornell Medical College, New York City, NY, UNITED STATES OF AMERICA.
OP-437  
**Synthesis Of 64Cu Radiopharmaceuticals For Cell Radiolabelling Using Anion Exchange Column And Labelling Of WBCs**  
A. Socan¹, P. Kolenc Peitl¹, M. Kroselj¹, M. Petrik², C. Decristoforo¹; ¹Nuclear Medicine Department, University Medical Centre, Ljubljana, SLOVENIA, ²Institute of Molecular and Translational Medicine, Olomouc, CZECH REPUBLIC, ¹University Clinic for Nuclear Medicine, University for Medicine, Innsbruck, AUSTRIA.

OP-438  
**Production and Purification of 99mTc Pertechnetate from 100Mo Targets Irradiated in a Nirta Solid Target Station on an IBA Cyclone® 18 Cyclotron**  
K. Buckley¹, P. Martinii¹, M. Dodd¹, S. McDiarmid¹, V. Hanemayer¹, B. Hook¹, J. Kumin¹, S. Zeisler¹, P. Schaffer¹, C. Marshall³, A. Dabkowski¹, M. Talboys¹, S. Wiltshire¹, F. Devillers¹, D. Blampain¹, B. Nactega³; ¹TRIUMF, Vancouver, BC, CANADA, ³Wales Research and Diagnostic PET Imaging Centre, Cardiff, UNITED KINGDOM, ³IBA RadioPharma Solutions, Louvain-la-Neuve, BELGIUM.

OP-439  
**Cyclotron production and automated new 2-column processing of [68Ga]GaCl₃**  
M. Nair¹, S. Happel², T. Eriksson¹, M. K. Pandey³, T. R. DeGrado³, K. Gagnon¹; ¹General Electric, Uppsala, SWEDEN, ²Triskem, Bruz, FRANCE, ³Mayo Clinic, Rochester, MN, UNITED STATES OF AMERICA.

OP-440  
**Fully automated GMP-compliant single-step synthesis of [18F]-PSMA-1007 using SPE-cartridge purification**  
O. C. Neels¹, R. Martini¹, J. Cardinale¹, R. Smits¹, M. Schäfer¹, A. Hoeppling¹, M. Müller¹, K. Kapka¹; ¹German Cancer Research Center, Heidelberg, GERMANY, ²ABX advanced biochemical compounds, Radeberg, GERMANY.

OP-441  
**Automated Synthesis of Pt-195m Cisplatin for GMP Production**  
K. Codée-van der Schiden¹, O. Zwaagsta¹, D. van der Born²; ¹NRG, Petten, NETHERLANDS, ²FutureChemistry Holding BV, Nijmegen, NETHERLANDS.

OP-442  
**Automatic synthesis of a PSMA ligand with Al¹⁸F**  
J. Giglio, M. Zeni, E. Savio, H. Engler; CUDIM, Montevideo, URUGUAY.

1106  
**Tuesday, October 24, 2017, 08:00 - 09:30, Hall F1**  
**Pitfalls & Artefacts 5 (Interactive) - Oncology: Pitfalls and Artefacts of PET in Neuroendocrine Tumours**  
**Chairs:** J. Talbot (Paris, FRANCE)  
M. Bozkurt (Ankara, TURKEY)

OP-443  
**18F-fluorodopa**  
S. Balogova; Comenius University, Faculty of Medicine & St. Elisabeth Cancer Institute, Nuclear Medicine, Bratislava, SLOVAKIA.

OP-444  
**Somatostatin Receptor PET/CT in Gastro-Entero-Pancreatic (GEP) NEN**  
V. Ambrosini; University of Bologna and S.Orsola-Malpighi Hospital, Nuclear Medicine, Bologna, ITALY.

OP-445  
**Somatostatin Receptor PET in Other NET**  
J.-N. Talbot; Hospital Tenon, AP-HP & Université P&M Curie, Paris, FRANCE.

1107  
**Tuesday, October 24, 2017, 08:00 - 09:30, Hall F2**  
**Clinical Oncology: Cured or Not Cured?**  
**Chairs:** N. Aide (Caen, FRANCE)  
R. Nuñez Miller (Vienna, AUSTRIA)

OP-446  
**Accuracy of F-18-FDG-PET/CT in monitoring tumour response after neoadjuvant chemoradiotherapy (nCRT) in patients with locoregional oesophageal cancer**  
M. J. Valkema¹, B. J. Noordman¹, B. P.L. Wijnhoven¹, V. M. C. W. Spaander¹, J. P. Ruurda¹, G. A. P. Nieuwenhuijzen¹, M. I. Van Berge Henegouwen¹, M. N. Sosef¹, J. J. B. Van Lanschot¹, R. Valkema¹; ¹Erasmus MC University Medical Centre, Rotterdam, NETHERLANDS, ²University Medical Centre, Utrecht, NETHERLANDS, ³Catharina Hospital, Eindhoven, NETHERLANDS, ⁴Academic Medical Centre, Amsterdam, NETHERLANDS, ⁵Atrium Medical Centre, Heerlen, NETHERLANDS.
OP-447
18F-FDG-PET/CT For Evaluating Bevacizumab-Based Chemotherapy Combined With Regional Deep Capacitive Hyperthermia In Metastatic Cancer Patients
C. Ferrari¹, G. Ranieri¹, A. Niccolì Asabella¹, A. Di Palo¹, I. Marech¹, M. Porcelli¹, M. Fanelli¹, G. Rubini¹, C. Gadaleta¹; ¹Nuclear Medicine Unit, AOPI Policlinic of Bari, University of Bari, bari, ITALY, ²Interventional Radiology Unit with Integrated section of Medicinal Oncology, National Cancer Research Centre IRCCS “Giovanni Paolo II” bari, ITALY, ³Interventional Radiology Unit with Integrated Section of Medicinal Oncology, National Cancer Research Centre, IRCCS “Giovanni Paolo II”, bari, ITALY.

OP-448
SUVmax from 18F-FDG PET/CT may outperform volumetric biomarkers in assessment of primary tumor response to neoadjuvant chemoradiotherapy in patients with esophageal cancer
E. R. Hassan¹, Y. G. Abdelhafez¹, M. A. Abougabal², C. Yeh³, Y. Chao³, C. Tseng³, Y. Chang³; ¹South Egypt Cancer Institute, Assiut University, Assiut, EGYPT, ²Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Department of Pathology, Taoyuan, TAIWAN, ³Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Division of Thoracic Surgery, Taoyuan, TAIWAN, ⁴Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Department of Radiation Oncology, Taoyuan, TAIWAN, ⁵Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Chang Gung Memorial Hospital, Nuclear Medicine Department, Taoyuan, TAIWAN.

OP-449
18F-FDG PET-CT versus MRI-based External Beam Radiotherapy Volumes in Inoperable Cervical Cancer
J. A. Adam¹, H. Arkies², K. Hinnen¹, J. Stalpers¹, J. H. van Waesberghede¹, J. Stoker¹, B. L. J. van Eck-Smit¹; ¹Academic Medical Center Amsterdam, Amsterdam, NETHERLANDS, ²Isala Hospital, Zwolle, NETHERLANDS, ³VU University Medical Center Amsterdam, Amsterdam, NETHERLANDS.

OP-450
Low tracer availability of ⁶⁸Ga-DOTATOC and ⁶⁸Ga-DOTATATE in blood for patients with high SSTR density leads to non-linear correlation between SUV and Kᵣ
E. Ilan¹, A. Sundin¹, I. Velikyan¹, M. Sandström¹, M. Lubberink¹, J. H. van Waesberghede¹, J. Stoker¹, B. L. J. van Eck-Smit¹; ¹Academic Medical Center Amsterdam, Amsterdam, NETHERLANDS, ²Isala Hospital, Zwolle, NETHERLANDS, ³VU University Medical Center Amsterdam, Amsterdam, NETHERLANDS.
OP-455
Effect of differences in CT- and SPECT-based tumor delineation on tumor dose and dose response following 90Y Selective Internal Radiation Therapy (SIRT)
A. Balagopal, A. Mahvash, S. C. Kappadath; UT MD Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA.

OP-456
Absorbed dose correlates with metabolic response to radioembolization of liver metastases with resin 90Y-microspheres

OP-457
Is there any relationship between 90Y-PET absorbed doses and damage to the target non tumoral liver (TNTL) after SIRT?
L. Sancho Rodriguez1, M. Rodríguez Fraile1, J. Bilbao1, M. Iñarrairaegui1, C. Bearlegui Arteta2, A. Benito1, V. Moran1, J. Martí-Clement1, E. Guillen1, B. Sangro2; 1Clínica Universidad de Navarra, Pamplona, SPAIN, 2Universidad de Navarra, Pamplona, SPAIN.

OP-458
Evaluation of 99TcMAA SPECT and 90Y PET similarity metrics on clinical cases with reference values from multiple realizations of phantom scans
J. Mikell, B. Majdalany, R. Srinivasa, K. Younge, Y. Dewaraja; University of Michigan Hospital and Health Systems, Ann Arbor, MI, UNITED STATES OF AMERICA.

OP-459
Retrospective Dosimetry for Hepatocellular Carcinoma Radioembolization with Yttrium-90 Resin Microspheres Planned using Body Surface Area Method
M. Kafrouni1,2, M. Fourcade1, S. Vauclin1, A. Ilonca1, D. Mariano-Goulart1; 1Montpellier University Hospital - Department of Nuclear Medicine, Montpellier, FRANCE, 2Dosisoft SA, Cachan, FRANCE.

OP-460
Assessment of dose-response correlation of selective internal radiation therapy (SIRT) for liver metastases from colorectal cancer (mCRC)
H. Levillain1, G. Marin1, T. Guiot2, Z. Wisnawa2, M. Vouche2, P. Delatte1, E. Woff1, A. Hendlisz3, B. Vanderlinden1, P. Flamme1; 1Nuclear Medicine Department, Jules Bordet Institute, Université Libre de Bruxelles (ULB), Brussels, BELGIUM, 2Radiology Department, Jules Bordet Institute, Université Libre de Bruxelles (ULB), Brussels, BELGIUM, 3Digestive Oncology Department, Jules Bordet Institute, Université Libre de Bruxelles (ULB), Brussels, BELGIUM.

OP-461
On the origin of spurious extrahepatic activities observed in 90Y nonTOF-PET imaging post radioembolization
S. Walrand, M. Hesse, F. Jamar, R. Lhomme; Université Catholique de Louvain, Brussels, BELGIUM.

OP-462
DNA Damage and Repair Processes at High and Low Dose Rates
D. van Gent; Erasmus MC, Department of Molecular Genetics, Rotterdam, NETHERLANDS.

OP-463
Feasibility of Non-DNA Targeted Radionuclide Therapy: Contribution of Bystander Effects
J.-P. Pouget; IRCM/INSERM U896, Montpellier, FRANCE.

OP-464
Selective Targeting of the Cell Membrane; Attacking the Tumour House of Cards
B. Bednarz; University of Wisconsin-Madison, Department of Medical Physics at Wisconsin Institutes for Medical Research, Madison, UNITED STATES OF AMERICA.
CME 10 - Neuroimaging: Brain PET and SPECT in Dementia - Beyond Alzheimer’s Disease

**Chairs:** S. Morbelli (Genova, ITALY)  
J. Arbizu (Pamplona, SPAIN)

**OP-465**  
Brain PET and SPECT in Patients with FrontoTemporal Dementia  
**K. Herholz:** Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UNITED KINGDOM.

**OP-466**  
Brain PET and SPECT Imaging in Lewy Body Diseases  
**N. Pavese:** Imperial College London, London, UNITED KINGDOM.

**OP-467**  
Brain SPECT and PET in Tau-Related Parkinsonism  
**J. Arbizu:** Department of Nuclear Medicine, University of Navarra, Pamplona, SPAIN.

Joint Symposium 10 - EANM/ESES/IFCC: Diagnosis and Treatment of Hyperthyroidism

**Chairs:** F. Verburg (Marburg, GERMANY)  
L. Giovanella (Bellinzona, SWITZERLAND)

**OP-468**  
Laboratory Testing in the Diagnosis of Hyperthyroidism  
**L. C. Giovanella:** Oncology Institute of Southern Switzerland, Bellinzona, SWITZERLAND

**OP-469**  
Nuclear Diagnostics and Therapy of Hyperthyroidism  
**F. A. Verburg:** Philippus-University of Marburg, Marburg, GERMANY

**OP-470**  
Surgical Treatment of Hyperthyroidism  
**M. Barczynski:** Jagiellonian University Medical College, Department of Endocrine Surgery, Third Chair of General Surgery, JUMC, Krakow, POLAND.
**Scientific Programme**

**OP-475**
A review of thyroid blockade strategies used in paediatric 123I MIBG scintigraphy, and an evaluation of their relative effectiveness
B. Thurlow1, T. Melhuish1, P. Leanne1, E. Morris1, S. Johns1, M. Guy1, S. King1, L. Biassoni1; 1Great Ormond Street Hospital for Children NHS Foundation Trust, London, UNITED KINGDOM, 2University Hospitals Southampton NHS Foundation Trust, Southampton, UNITED KINGDOM, 3University of the West of England, Bristol, UNITED KINGDOM.

**OP-476**
Evaluation of the influence of adipose tissue in attenuation and scattering correction in Myocardial Perfusion SPECT/CT
B. Guerreiro1, S. Valente1, P. Pereira1, R. Rosa1, L. Vieira1, E. Sousa2, F. Branco2, T. Freixo2, P. Almeida2, F. D. Jorge1, T. C. Ferreira1; 1Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa, Lisboa, PORTUGAL, 2Hospital dos Lusíadas, Departamento de Medicina Nuclear, Lisboa, PORTUGAL, 3GReS-Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa, Lisboa, PORTUGAL, 4Instituto de Biofísica e Engenharia Biomédica, Faculdade de Ciências, Universidade de Lisboa, Lisboa, PORTUGAL.

**OP-477**
Planar versus SPECT Acquisition in Pulmonary Embolism: comparison of some European Practices
T. C. S. Melo1, D. Vieira1, A. Nunes2, C. Sibley-Allen2, D. Dasgupta2, H. Ahmed2, S. M. Peikut3, S. Mirzaei1, C. Sonneck-Koene1, W. Zehetner1, J. A. Silva1, M. Oliveira1, J. Nery1, R. Castro1, L. F. Metello1, 1ESS-IPP, ATC &Curso Med. Nuclear, Porto, PORTUGAL, 2Department of Nuclear Medicine Guy’s and St.Thomas Hospital, London, UNITED KINGDOM, 3Wilhelminenspital, Department of Nuclear Medicine and PET center, Vienna, AUSTRIA, 4CHP-Hosp. Sta.António EPE, Dept. de Med.Nuclear, Porto, PORTUGAL, 5Slovak Medical University, Bratislava, SLOVAKIA, 6Faculty of Biomedical Engineering, CTU Prague, Kladno, CZECH REPUBLIC, 7Faculty of Safety Management of PACR, Prague, CZECH REPUBLIC, 8Slovak Legal Metrology, NGO, Bratislava, SLOVAKIA, 9BIONT Inc., Bratislava, SLOVAKIA.

**OP-478**
Preliminary results for: Optimised diagnostics of lung embolus with ventilation/perfusion SPECT/CT with use of CPAP prior to lung scintigraphy
J. P. Paludan, S. R. Andersen, J. Abrahamsen, M. S. Jensen, C. Høyer; Region Hospital Viborg, Viborg, DENMARK.

**OP-480**
Comparison of the methods for eye lens dose measurement by a Monte Carlo method
M. Fulop1, J. Hudzietszová2, P. Ragan1, J. Sabol1, D. Solvajiš2, P. Vlk3; 1Slovak Medical University, Bratislava, SLOVAKIA, 2Faculty of Biomedical Engineering, CTU Prague, Kladno, CZECH REPUBLIC, 3Slovak Legal Metrology, NGO, Bratislava, SLOVAKIA, 4BIONT Inc., Bratislava, SLOVAKIA.
OP-485
Validation of Siemens CARE kv for use with PET/CT: dose reduction and PET quantification
T. Jørgensen1, M. A. Micheelsen1, E. Dupont1, N. A. Bebbington2; 1Department of Clinical Physiology and Nuclear Medicine, Zealand University Hospital, Naestved, DENMARK, 2Department of Clinical Physiology and Nuclear Medicine, Zealand University Hospital, Køge, DENMARK.

OP-486
Measuring, Monitoring, and Reporting Effective Dose on an Hybrid Equipment: one year results and challenges to integrate with MDCT
G. Tosi1, A. Chiti2, K. Marzo1, F. Zanca1; 1Humanitas Research Hospital, ROZZANO, ITALY, 2Humanitas University, ROZZANO, ITALY.

OP-487
In vitro and in vivo characterization of a [18F] AlF-labeled PSMA ligand for imaging of PSMA-expressing xenografts
S. Lütje1,2, G. M. Franssen1, M. Gotthardt1, K. Herrmann2, O. C. Boerman1, S. Heskamp1; 1Dept. Radiology and Nuclear Medicine, Radboud university medical center, Nijmegen, NETHERLANDS, 2Clinic for Nuclear Medicine, University Hospital Essen, Essen, GERMANY.

OP-488
Synthesis and Radiolabelling of a DOTA-Bisphosphonate-Conjugated PSMA Inhibitor
N. Pfannkuchen1, F. Rösch1, R. Bergmann1; 1Institute of Nuclear Chemistry, Johannes Gutenberg University, Mainz, GERMANY.

OP-489
Synthesis and evaluation of 18F-labeled trifluoroborate derivatives of PSMA-617 for imaging prostate cancer with positron emission tomography
H. Kuo1, J. Pan1, H. Merkens1, J. Lau1, C. Zhang1, N. Colpo2, D. M. Perrin2, K. Lin1, F. Bénard1; 1BC Cancer Research Centre, Vancouver, BC, CANADA, 2University of British Columbia, Vancouver, BC, CANADA.
**Scientific Programme**

**EANM’17**

**World Leading Meeting**

**OP-492**

**89Zr-df-IAB2M for PET/CT imaging of prostate cancer**


**OP-493**

Comparative biodistribution of the parental murine monoclonal antibody 5A10 and its humanized version for PSA-targeting in prostate cancer

T. Tran; Dept of Radiopharmacy, Stockholm, SWEDEN.

**OP-494**

GRPR-Targeted Radiotherapy: Influence of Chelator on Labeling and Biodistribution of Four $^{177}$Lu-Labeled Analogues of the GRPR-Antagonist PEG2-RM26


**1306 Tuesday, October 24, 2017, 11:30 - 13:00, Hall F1**

**Pitfalls & Artefacts 6 (Interactive) - Dosimetry: Pitfalls and Artefacts in Pre- and Post-Therapeutic Imaging**

**Chairs:** F. Forrer (St. Gallen, SWITZERLAND)  
M. Konijnenberg (Rotterdam, NETHERLANDS)

**OP-495**

An Imaging Based Guide in Individualisation of Neuroendocrine Tumour Therapy

P. Manoharan; The Christie NHS Foundation Trust, Manchester, UNITED KINGDOM.

**OP-496**

Post-Therapy Imaging of the Treatment Effects After 177Lu-DOTA-Octreotate Therapy

U. Garske-Román; Sahlgrenska University Hospital, Gothenburg, SWEDEN.

**OP-497**

Prospective Dosimetry Based Treatment Planning Based on pre- (99mTc-SPECT-CT) and post- (90Y PET TOF) Radioembolisation Imaging

C. Chiesa; Foundation IRCCS Istituto Nazionale Tumori, Nuclear Medicine Division, Milan, ITALY.

**1307 Tuesday, October 24, 2017, 11:30 - 12:45, Hall F2**

**Clinical Oncology: Bad Brain**

**Chairs:** N. Albert (Munich, GERMANY)  
I. Law (Copenhagen, DENMARK)

**OP-498**

$^{18}$F-fluciclovine PET/MRI in the evaluation of brain glioma

A. Karlberg, E. M. Berntsen, H. Johansen, M. Myrthue, A. J. Skjulsvik, J. Reinertsen, M. Esmaeili, H. Y. Dai, Y. Xiao, H. Rivaz, P. Borghammer, O. Solheim, L. Ekenes; 1Department of Radiology and Nuclear Medicine, St. Olavs University Hospital, Trondheim, NORWAY, 2Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, NORWAY, 3Department of Pathology and Medical Genetics, St. Olavs University Hospital, Trondheim, NORWAY, 4Department of Laboratory Medicine, Children’s and Women’s Health, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, NORWAY, 5Norwegian National Advisory Unit for Ultrasound and Image Guided Therapy, St. Olavs University Hospital, Trondheim, NORWAY, 6Department of Medical Technology, SINTEF, Trondheim, NORWAY, 7PERFORM Centre, Concordia University, Montreal, QC, CANADA, 8Department of Electrical and Computer Engineering, Concordia University, Montreal, QC, CANADA, 9Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Aarhus, DENMARK, 10Department of Neurosurgery, St. Olavs University Hospital, Trondheim, NORWAY, 11Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, NORWAY.

**OP-499**

Immunohistochemically evaluated PSMA expression in 122 treatment naive glioma patients related to $[^{11}$C]-methionine PET and survival


**OP-500**

Improved detection of postoperative remaining meningioma tissue with 68Ga-DOTATATE PET/CT scans compared to surgeon’s estimated Simpson Grade

F. J. Vettermann, M. Ueberschaerr, M. Unterrainer, P. Bartenstein, J. Tonni, C. Schichor, N. L. Albert; 1Department of Nuclear Medicine, Ludwig-Maximilians-University, Munich, GERMANY, 2Department of Neurosurgery, Ludwig-Maximilians-University, Munich, GERMANY.
Impact of chemotherapy with Temozolomide on physiological brain 18F-DOPA uptake in patients with glioma

L. Carideo1, F. Cicone1, C. Scaringi1, I. Russo1, G. Minniti2, F. Scopinaro1; 1Nuclear Medicine Unit, Sant’Andrea Hospital, Sapienza University of Rome, Italy, Rome, ITALY; 2Radiotherapy Unit, Sant’Andrea Hospital, Sapienza University of Rome, Italy, Rome, ITALY.

IDH1-R132H mutation and semiquantitative [11C]-methionine PET: Independent prognostic factors for characterization of newly diagnosed and treatment naive gliomas


Differential Diagnosis of Recurrence and Radiation Necrosis in High Grade Gliomas Using Multiparametric Analysis of Combined Dynamic O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI

D. A. Hiob1, C. Preibisch1, J. Gempt1, J. Schlegel1, C. Straube2, C. Zimmer2, M. Schwaiger1, T. Pyka1; 1Department of Nuclear Medicine, Klinikum rechts der Isar der TU München, Muenchen, GERMANY, 2Department of Neurosurgery, Klinikum rechts der Isar der TU München, Muenchen, GERMANY.

Voxel-based analysis of dynamic 18F-FET-PET in gliomas : association with IDH1 mutational status and survival.

P. Blanc-Durand1, A. Van Der Gucht1, A. Kourilsky2, V. Dunet1, A. Verger1, K. Langen1, M. Reije1, M. Nicod-Lalonde1, N. Schaefer1, J. Prior1; 1CHUV, Lausanne, SWITZERLAND, 2Beaujon, Paris, FRANCE, 3CH, Nancy, FRANCE, 4Forshungszentrum, Jülich, GERMANY.

Assessment of the functional significance of coronary artery stenoses in patients with CAD using dynamic stress PET / CT with 13N-ammonium with the use of absolute values of myocardial blood flow and coronary flow reserve

I. V. Shurupova, I. P. Aslanidis, M. G. Shavman, E. P. Derevyanko, E. P. Derevyanko, I. V. Ekaeva; Bakoulev Scientific Center for Cardiovascular Surgery, Moscow, RUSSIA.

Prognostic value of quantitative absolute myocardial stress perfusion in patients with chest pain and normal coronary arteries: A Nitrogen-13 Ammonia PET study

A. G. Monroy-Gonzalez1, R. A. Tio1, E. Alexanderson-Rosas1, R. H. J. A. Slart1; 1University Medical Center Groningen, Groningen, NETHERLANDS, 2Department of Physiology, National Autonomous University of Mexico, MEXICO.

Feasibility of layer myocardial blood flow

R. Calabretta1, E. Milan1, R. Giubbini1, R. Durmso1, L. Gallo1, T. Kubik2, R. Sciagra1; 1Nuclear Medicine, DECBS, University of Florence, FLORENCE, ITALY, 2Chair of Nuclear Medicine, University of Brescia, Brescia, ITALY, 3Pmod Technologies LLC, Zurich, SWITZERLAND, 4Institute of Metrology and Biomedical Engineering, Warsaw University of Technology, Warsaw, POLAND.
OP-509
Effect of motion-induced PET-CT misalignment on cardiac function and myocardial blood flow measured using dynamic 18O-water PET
M. Lubberink1, M. Ebrahimi1, H. J. Harms2,3,4, L. Poulsen Tolbod4, J. Sörensen1,5; 1Uppsala University, Uppsala, SWEDEN, 2Århus University, Århus, DENMARK, 3Brigham and Women’s Hospital, Boston, MA, UNITED STATES OF AMERICA, 4VU University Medical Centre, Amsterdam, NETHERLANDS.

OP-510
Automatic extraction of left ventricular mass and volumes using parametric images from non-ECG-gated 15O-water PET/CT
J. Nordström1,2, H. J. Harms1, M. Lubberink1,4, L. Tolbod1, J. van den Berg1, T. Baron1, F. A. Flachskampf1, T. Kero1,6; 1Nuclear medicine & PET, Department of Surgical Sciences, Uppsala University, Uppsala, SWEDEN, 2Centre for Research and Development, Uppsala University / Gävleborg County, Gävle, SWEDEN, 3Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Aarhus, DENMARK, 4Medical Physics, Uppsala University Hospital, Uppsala, SWEDEN, 5Cardiology, Department of Medical Sciences, Uppsala University, Uppsala, SWEDEN, 6Medical Imaging Centre, Uppsala University Hospital, Uppsala, SWEDEN.

OP-511
A Promising PET Detector Design that Achieves 100 ps FWHM Coincidence Time Resolution
J. W. Cates1,2, C. S. Levin; 1Stanford University, Stanford, CA, UNITED STATES OF AMERICA, 2University of Tennessee Graduate School of Medicine, Knoxville, TN, UNITED STATES OF AMERICA.

OP-512
First human images from a next generation SiPM based PET/CT system with improved time and spatial resolution
M. Casey1, Z. Burbar1, H. Rathfuss1, V. Panin1, D. Bharkhada1, W. Howe1, Y. Bradley1; 1Siemens Medical Solutions, Knoxville, TN, UNITED STATES OF AMERICA, 2University of Tennessee Graduate School of Medicine, Knoxville, TN, UNITED STATES OF AMERICA.

OP-513
Ultra-high Definition Isotropic 1mm Voxel Reconstruction in Clinical Wholebody PET - Is Digital PET Making It a Reality?
M. V. Knopp1, J. Zhang2, K. Binzel3, M. J. Knopp4, R. Moore5, M. Friel6, F. Giesel7, C. L. Wright7; 1The Ohio State University, Columbus, OH, UNITED STATES OF AMERICA, 2University Hospitals Heidelberg, Heidelberg, GERMANY.

OP-514
Evaluation of Whole-Body and Small FOV CZT Gamma Cameras
J. W. Hugg1, B. W. Harris, H. Tomita; 1Kromek / eV Products, Saxnubon, PA, UNITED STATES OF AMERICA.

OP-515
First Experience with Fast Imaging Using Discovery MI PET/CT
I. Sonni, S. Park, L. Baratta, N. Hatami, G. Davidzon, S. Sinivas, S. Gambhir, A. H. Jagaru; 1Stanford University, Stanford, CA, UNITED STATES OF AMERICA.

OP-516
Phase Ia Trial Comparing Higher Definition Digital Photon Counting PET/CT with Current Photomultiplier PET/CT for Head and Neck Oncology
C. L. Wright1, A. D. Bhatt1, K. Binzel2, I. R. Washington2, P. Bhatia3, P. Subramanian4, J. Zhang5, P. Maniawski6, M. V. Knopp7; 1The Ohio State University, Columbus, OH, UNITED STATES OF AMERICA, 2Philips Healthcare, Cleveland, OH, UNITED STATES OF AMERICA.

OP-517
PET 20.0: a cost-efficient, 2mm spatial resolution Total Body PET with point sensitivity up to 22% and adaptive axial FOV of maximum 2.00m
S. Vandenberghe1, E. Mikhailov2, B. Brans1, M. Defrise1, T. Lahoutre1, K. Myrile1, R. Van Holen1, D. R. Schaart1, J. S. Karp1; 1MEDISIP-Ugent, Gent, BELGIUM, 2Department of Biomedical Engineering, University of California Davis, Davis, CA, UNITED STATES OF AMERICA, 3Department of Nuclear Medicine UZGent/UGent, Gent, BELGIUM, 4Department of Biomedical Engineering, University of California Davis, Davis, CA, UNITED STATES OF AMERICA, 5Medicine Science & Technology, Delft University of Technology, Delft, NETHERLANDS, 6PET instrumentation Group, University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA.

OP-518
A New Direction to Explore to Advance Coincidence Time Resolution for Time-of-Flight Positron Emission Tomography
L. Tao, C. S. Levin; 1Stanford University, Stanford, CA, UNITED STATES OF AMERICA.
YDF3  Tuesday, October 24, 2017, 13:00 - 14:30, Hall F1
EANM Young Daily Forum 3: Be Stronger - Mentally, Emotionally, Physically & Spiritually
R. Sheppard; Somerset, UNITED KINGDOM.

1401  Tuesday, October 24, 2017, 14:30 - 16:00, Hall A
CME 11 - Paediatrics/Oncology/SIOPEN: SSR Imaging and Therapy in Children
Chairs: M. Castellani (Milan, ITALY) L. Borgwardt (Copenhagen, DENMARK)

OP-519 The Importance of miBG in the International Neuroblastoma Community. Perspectives from SIOPEN Collaborations: Past, Present, Future
R. Ladenstein; St. Anna Kinderkrebsforschung, Vienna, AUSTRIA.

OP-520 Somatostatin Receptor Imaging in Paediatric Tumours
M. F. Bozkurt; Hacettepe University Faculty of Medicine, Department of Nuclear Medicine, Ankara, TURKEY.

OP-521 Theranostic Application of PRRT in Neuroblastoma
G. Kong; Peter MacCallum Cancer Centre, Centre for Molecular Imaging, Melbourne, AUSTRALIA.

1402  Tuesday, October 24, 2017, 14:30 - 16:00, Hall B
Joint Symposium 11 - EANM/EACVI: Quantification of Myocardial Blood Flow
Chairs: O. Gämperli (Zurich, SWITZERLAND) F. Hyafil (Paris, FRANCE)

OP-522 Pathophysiology of Myocardial Blood Flow and Fractional Flow Reserve
J. Piek; AMC Heart Center, Academic Medical Center, University of Amsterdam, Amsterdam, NETHERLANDS.

OP-523 Quantification of Stress Myocardial Blood Flow with PET and SPECT
R. Sciagra; Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences ‘Mario Sera’, University of Florence, Florence, ITALY.

OP-524 Quantification of Myocardial Blood Flow with CTA
G. Pontone; Centro Cardiologico Monzino, IRCCS, Milan, ITALY.

OP-525 Quantification of Myocardial Blood Flow with MRI
S. Nekolla; Clinic of Nuclear Medicine, Technical University, Munich, GERMANY.

1403 Tuesday, October 24, 2017, 14:30 - 16:00, Hall C
CTE 5: Gastrointestinal Imaging
Chairs: N. Gulliver (London, UNITED KINGDOM) I. Larg (Cluj-Napoca, ROMANIA)

OP-526 Pearls & Pitfalls in Gastrointestinal Imaging with Conventional Nuclear Medicine Scintigraphy
G. Vivian; King’s College Hospital, London, UNITED KINGDOM.

OP-527 The Clinical Use of PET-CT in Upper Gastrointestinal Oncology
M. Bertoli; University of Brescia, Brescia, ITALY.

OP-528 The Clinical Use of PET-CT in Lower Gastrointestinal Oncology
S. Hess; Odense University Hospital, Odense, DENMARK.

1404 Tuesday, October 24, 2017, 14:30 - 16:00, Hall E1
Do.MoRe - Dosimetry/Physics/AAPM: PET Auto-Segmentation: Review and Evaluation Strategies - Insights from AAPM Task Group No. 211
Chairs: A. Kirov (New York, UNITED STATES OF AMERICA) R. Buchert (Hamburg, GERMANY)

OP-529 Components of a Standard and a Procedure for Evaluation of PET-AS Methods
A. Kirov; Memorial Sloan-Kettering Cancer Center, New York, USA

OP-530 State-of-the-Art of Current PET-AS Algorithms and their Advantages and Limitations for Clinical Application
M. Hatt; Centre Hospitalier Régional Universitaire Morvan INSERM, Brest, FRANCE
**OP-531**  
**Design, Implementation and First Results of the Future Standard for Evaluation of PET-AS Methods**  
E. DeBernardi; Università degli Studi di Milano-Bicocca, Milan, ITALY.

**OP-532**  
**An intrinsically radioactive metal-organic framework (MOF) nanomaterial for Cerenkov luminescence-triggered cancer phototherapy: focused on deep-tissue tumor**  
H. Hong, D. Chen, D. Yang, W. Lu; University of Michigan, Ann Arbor, MI, UNITED STATES OF AMERICA.

**OP-533**  
**Formulation and in vivo biodistribution of 57Co-porphyrin-labelled hydrophobic liquid nanoparticles**  
P. Hervella⁴, J. Domno, H. Thysgaard, C. Baun, B. B. Olsen⁴, P. Hjilund-Carlsen⁴, D. Needham⁴; ¹Center for Single Particle Science and Engineering, Odense, DENMARK, ²Odense University Hospital, Odense, DENMARK.

**OP-534**  
**Pretargeted tumor imaging with a polymer: Reducing absorbed radiation dose and increasing imaging contrast**  
E. J. L. Steen⁴, K. Nørregaard⁴, A. Birke⁴, P. E. Edemy⁴, J. T. Jørgensen⁴, R. Rossin⁴, M. Robillard⁴; ¹University of Copenhagen, Copenhagen, DENMARK, ²Rigshospitalet, University Hospital, Copenhagen, DENMARK, ³Johannes-Gutenberg University, Mainz, GERMANY, ⁴Tagworks Pharmaceuticals BV, Eindhoven, NETHERLANDS.

**OP-535**  
**Nanoparticle-based radiopharmaceuticals: is there a future to ⁴⁵TiO₂ nanoparticles?**  
P. Costa⁴, L. F. Metello⁴, F. Alves⁴, M. D. Naia⁴; ¹Nuclear Medicine Department, ESS|Porto, Porto, PORTUGAL, ²IsoPor S.A, Porto, PORTUGAL, ³Institute for Nuclear Sciences Applied to Health, University of Coimbra, Coimbra, PORTUGAL, ⁴CEMUC® - Physics Department, ECT-UTAD, Vila Real, PORTUGAL.

**OP-536**  
**Radiollabeling and biodistribution studies in a rat model of lipid-based nanosystems designed for the treatment of wounds.**  
M. Collantes¹, G. Quiñoces², R. Ramos-Membrive³, M. Ecy², A. Aldave³, M. Pastor³, G. Gainza³, E. Gainza³, I. Peñuelas¹⁴, I. Nuclear Medicine, Clínica Universidad de Navarra, Pamplona, SPAIN, ²Radiopharmacy Unit, Clínica Universidad de Navarra, Pamplona, SPAIN, ³MicroPET Unit, Clínica Universidad de Navarra, Pamplona, SPAIN, ⁴Center for Applied Medical Research, Pamplona, SPAIN, ⁵Biopraxis Research AIE, Vitoria, SPAIN.

**OP-537**  
**Chelator-free Radiolabeling of Iron Oxide Nanoparticles with ⁶⁸Ga For Dual-Modality PET/ MR Imaging**  
M. Karageorgou¹, J. Gall¹, C. Tsoukalas¹, S. Xanthopoulos¹, M. Paravatou-Petsotas¹, D. Stamopoulos¹², M. Barbirore-López³, P. Bouziotis³; ¹INRAS, NCSR “DEMOKRITOS”, Athens, GREECE, ²Advanced (magnetic) Theranostic Nanostructures Lab, INL, Braga, PORTUGAL, ³Department of Solid State Physics, NKUA, Athens, GREECE, ⁴Institute of Nanosciences and Nanotechnology, NCSR “Demokritos”, Athens, GREECE.

**OP-538**  
**Multifunctional Nanoprobes for Integrated PET / MR Imaging**  
S. Roux¹, F. Bouraleh Hoch¹, V. Thakare¹, C. Bernhard¹, R. Bazzi¹, A. Oudot², B. Collin², F. Brunotte², F. Boschetti², F. Denat¹; ¹Université de Bourgogne Franche-Comté, Besançon, FRANCE, ²Université de Bourgogne Franche-Comté, Dijon, FRANCE, ³Centre Georges-François Leclerc, Dijon, FRANCE, ⁴ChemMatech S.A.S., Dijon, FRANCE.

**OP-539**  
**Biodistribution of ⁹⁹mTc-Phytate in a Sterile Inflammation Model in Mice**  
D. Priftakis¹, M. Papachristou¹, S. Xanthopoulos², I. Datseris¹, P. Bouziotis¹; ¹Evaggelismos Hospital, Athens, GREECE, ²NCSR “Demokritos”, Athens, GREECE.
Scientific Programme

Teaching Session 5 (Interactive): Applied Cross Sectional Anatomy and Correlative Imaging – Cross Sectional CT and PETCT for the TNM Staging of Lung Cancer

Chair: P. Elsinga (Groningen, NETHERLANDS)

OP-540
Applied Cross Sectional Anatomy and Correlative Imaging – Cross Sectional CT and PETCT for the TNM Staging of Lung Cancer

T. Lynch: Belfast, UNITED KINGDOM.

Clinical Oncology - Rapid Fire Session: Mix it Up, please!

Chairs: K. Herrmann (Essen, GERMANY) C. Nanni (Bologna, ITALY)

OP-541
Combination of baseline FDG-PET/CT total metabolic tumor volume and gene expression profile have a robust predictive value in patients with Diffuse Large B-Cell Lymphoma

M. N. Toledano1,2, P. Desbordes3, I. Gardin1,2, P. Vera1,2, F. Jardin4,5, P. Ruminy6, H. Tilly3,4, H. N. Toledano1, University of Rouen, Rouen, FRANCE, 2Nuclear Medicine Department, Henri Becquerel Centre and Rouen University Hospital, Rouen, France, 3Hematology department, Henri Becquerel Centre and Rouen University Hospital, Rouen, France, 4INSERM U918, Henri Becquerel Centre, Rouen, France.

OP-542
Improved Pulmonary Nodule Detection Using a Next Generation 18F-FDG PET Imaging System

S. Park, L. Baratto, N. Hatami, G. Davidzon, S. Srinivas, V. Nair, A. Iagaru; Stanford University Medical Center, Stanford, CA, UNITED STATES OF AMERICA.

OP-543
Treatment Reduction in Patients with Advanced-Stage Hodgkin Lymphoma and Negative Interim FDG-PET: Final Results of the International, Randomized, Phase 3 HD18 Trial by the German Hodgkin Study Group

C. Kobe1, H. Goergen1, M. Fuchs1, H. T. Eich1, C. Baues1, V. Diehl2, G. Kuhner1, A. Drzezga1, M. Dietel1, A. Engert1, P. Borchmann1,2,3, German Hodgkin Study Group (GHSG), University Hospital of Cologne, Cologne, GERMANY, 1German Department of Nuclear Medicine, University Hospital of Cologne, Cologne, GERMANY, 2German Department of Radiation Oncology, University Hospital of Muenster, Muenster, GERMANY, 3Department of Internal Medicine I, University Hospital of Cologne, Cologne, GERMANY.

OP-544
Experimental validation of absolute SPECT/CT quantification for response monitoring in breast cancer

A. Collarino1, L. M. Pereira Arias-Bouda1, R. A. Valdés Olmos1,2, J. P. van der To1, P. Dibbets-Schneider1, L. de Geus-Oei1,2, F. H. P. van Velden1,2, 1Section of Nuclear Medicine, Department of Radiology, Leids Universitair Medisch Centrum, Leiden, NETHERLANDS, 2Department of Nuclear Medicine, Alrijne Ziekenhuis, Leiderdorp, NETHERLANDS, 3Department of Internal Medicine, Leiden University Medical Center, Leiden, NETHERLANDS, 4Department of Nuclear Medicine, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS, 5Medical Physics, Department of Radiology, Leids Universitair Medisch Centrum, Leiden, NETHERLANDS, 6Biomedical Photonics Imaging Group, MIRA Institute, University of Twente, Enschede, NETHERLANDS, 7Department of Radiology and Nuclear Medicine, Radboudumc, Nijmegen, NETHERLANDS.

OP-545
Somatostatin antagonist theranostic pair 68Ga-OPS202 and 177Lu-OPS201 for well-differentiated neuroendocrine tumors (NETs)

D. Reidy, N. Pandit-Taskar, S. Krebs, J. O’Donoghue, N. Raj, E. Cruz, H. Pham, A. Lashley, L. Bodei, W. A. Weber; Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.

OP-546
Comparison of 18F-FDG PET/MRI and MRI for primary evaluation and treatment planning of cervical cancer patients

J. Grueneisen1, T. Sarabhai2, B. Schlaarschmidt3, M. Forsting1, K. Herrmann1, L. Umuhlu2, University Hospital Essen, Essen, GERMANY, University Hospital Düsseldorf, Düsseldorf, GERMANY.

OP-547
[123/131I]IMAZA as a new theranostic tool in patients with advanced adrenocortical carcinoma

A. Schirbel1, C. Blümel1, B. Heinze1, A. Plaß1, C. T. Fuß1, F. Megerle1, T. Deutschbein1, M. Fassnacht1, M. Kroiss2, H. Hänseheid2, A. K. Buck3, S. Hahner2; University of Wuerzburg, Department of Nuclear Medicine, Wuerzburg, GERMANY, University of Wuerzburg, Department of Medicine I, Division of Endocrinology and Diabetes, Wuerzburg, GERMANY.
OP-548
ImmunoPET imaging to assess target engagement: Experience from 89Zr-anti-HER3 mAb (GSK2849330) in patients with solid tumors
A. Mcgeoch1,2, C. Menke-van der Houven van Oordt1, M. Bergstrom1, I. McSherry1, D. Smith3, M. Cleveland4, O. Hoekstra3, D. Vugts3, A. Weber1, I. Freedman1, M. Huisman1, C. Matheny1, G. van Dongen3, S. Zhang1, GSK, Stevenage, UNITED KINGDOM, 1University of Cambridge, Cambridge, UNITED KINGDOM, 2VU University Medical Centre, Amsterdam, NETHERLANDS, 3PAREXEL International, Durham, NC, UNITED STATES OF AMERICA, 4GSK, King of Prussia, PA, UNITED STATES OF AMERICA.

OP-549
FDG-PET/CT in single pulmonary nodule (SPN): a preliminary experience from a multicenter Italian Assessment of Lung Indeterminate Accidental Nodule (ITALIAN) trial
L. Evangelista1, M. Spadafora2, L. Mansi3, L. Pace4, M. Arosio5, G. Saladini6, M. Santinibbio7, M. Salvatore8, G. Pepe8, G. Cusato9, M. Ferdeghini10, G. Cusato9, L. Chiaramonti11, M. Giuliano11, M. Farsad12, S. Pellegrino13, G. Cusato9, L. Evangelista1, M. Ferdeghini10, M. Farsad12, S. Pellegrino13; 1Nuclear Medicine and Molecular Imaging Unit, Veneto Institute of Oncology IOV - IRCCS, Padova, ITALY, 2Nuclear Medicine Unit, Department of Imaging, S.G. Moscati Hospital, Avellino, ITALY, 3Dipartimento Medico-Chirurgico di Internistica Clinica e Sperimentale, Second University of Naples, Napoli, ITALY, 4Department of Medicine and Surgery, University of Salerno, Baronissi (SA), ITALY, 5Nuclear Medicine Unit, San Gerardo Hospital, University of Milano Bicocca, Milano, ITALY, 6Service of Nuclear Medicine, Policlinico S. Orsola Malpighi, University of Bologna, Bologna, ITALY, 7Nuclear Medicine Unit, Department of Imaging, SDN Foundation, Napoli, ITALY, 8Nuclear Medicine Unit, Cancer Center, Humanitas Hospital, Rozzano, Milano, ITALY, 9Nuclear Medicine Unit, Department of Imaging, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, ITALY, 10Department of Biomedicine and Prevention, University of Rome Tor Vergata, Roma, ITALY, 11Nuclear Medicine Unit, Department of Imaging, Medicina Futura IOS, Accera, Napoli, ITALY, 12Department of Nuclear Medicine, Hospital of Bolzano, Bolzano, ITALY, 13Department of Advanced Biomedical Sciences, University of Naples Federico II, Napoli, ITALY, 14Institute of Nuclear Medicine, Università Cattolica del S. Cuore, Roma, ITALY.

OP-550
68GaNeoBOMB1 in oligometastatic GIST: first results from a Phase-I/IIa study
L. Gruber1, A. Buschiazzo2, L. Ermont1, S. Rave1, V. Cassu1, S. Brun1, A. Bellini1, L. Raffaghello3, F. Di Giulio3, G. Bianchi3, S. Morbelli1, C. Manni3, G. Sambucetti3,4; 1Nuclear Medicine Unit, IRCCS AO San Martino-IST, Genoa, ITALY, 2Department of Health Sciences, University of Genova, Genoa, ITALY, 3Animal facility, IRCCS AO San Martino-IST, Genoa, ITALY, 4Department of Pharmacy, Biochemistry Laboratory, University of Genova, Genoa, ITALY, 5Department of Experimental Medicine, University of Genova, Genoa, ITALY, 6Laboratory of Oncology, G. Gaslini Institute, Genoa, ITALY, 7NR Institute of Biomagers and Molecular Physiology, Milan, ITALY.

OP-551
18F-FDG PET/CT for treatment response assessment in classical Hodgkin Lymphoma (cHL), in the era of innovative immunomodulatory PD-1 blocked (nivolumab) therapy
I. Sandler1, A. Broccoli1, P. Castellucci1, C. Nanni1, C. Pellegrini1, F. Quirini1, C. Zinzani1, S. Fantl1; 1Nuclear Medicine Unit, University of Bologna, S.Orsola-Malpighi Hospital, Bologna, ITALY, 2Institute of Hematology and Medical Oncology “L.&A. Seràgnoli,” University of Bologna, S.Orsola-Malpighi Hospital, Bologna, ITALY.

OP-552
Gender differences in the cerebral uptake of 18F-FDG

OP-553
Brain Metabolic Response to Prolonged Starvation: a micro-PET study
A. Orengo1, A. Buschiazzo2, L. Ermont1, S. Rave1, V. Cassu1, S. Brun1, A. Bellini1, L. Raffaghello3, F. Di Giulio3, G. Bianchi3, S. Morbelli1, C. Manni3, G. Sambucetti3,4; 1Nuclear Medicine Unit, IRCCS AO San Martino-IST, Genoa, ITALY, 2Department of Health Sciences, University of Genova, Genoa, ITALY, 3Animal facility, IRCCS AO San Martino-IST, Genoa, ITALY, 4Department of Pharmacy, Biochemistry Laboratory, University of Genova, Genoa, ITALY, 5Department of Experimental Medicine, University of Genova, Genoa, ITALY, 6Laboratory of Oncology, G. Gaslini Institute, Genoa, ITALY, 7NR Institute of Biomagers and Molecular Physiology, Milan, ITALY.

OP-554
Altered Insulin-Dependent Brain Glucose Metabolism During Obesity Depends On Specific Brain Areas
C. Malbert1, S. Bahn1; 1INRA, Saint-Gilles, FRANCE, 2University of Tunis, Tunis, TUNISIA.
**OP-555**

Brain [11C]PK11195 and [18F]FDG PET imaging in a rat model of postoperative cognitive dysfunction


**OP-556**

Muscinol Reduces D2 Receptor Binding in the Mesolimbothalamic System of the Rat

S. Nikolaus*, 1, H. Wittsack1, M. Beu*, M. A. De Souza Silva1, C. Antke1, F. Wickrath1, A. Müller-Lutz1, G. Antoch1, J. P. Huston1, H. Müller1, H. Hautzel1; University Hospital Düsseldorf, Düsseldorf, GERMANY.

**OP-557**

Cross-Species Physiological Assessment of Brain Estrogen Receptor Expression Using 4FMFES PET Imaging

M. Paquette, S. Phoenix, J. A. Rousseau, O. Sarrihi, B. Guérin, E. E. Turcotte, L. M. Broersen; Université de Sherbrooke, Sherbrooke, QC, CANADA.

**OP-558**

Determining the Effects of Age and Gender on Normal Pediatric Brain Metabolism Using FDG-PET

S. Turpin*, 1, P. J. Martineau, 2, M. A. Levasseur, 3, R. Lambert; 1CHU Sainte-Justine, Montreal, QC, CANADA, 2University of Ottawa, Ottawa, ON, CANADA, 3CHU Sherbrooke, Sherbrooke, QC, CANADA.

**OP-559**

Impact of plasma glucose on the pattern of brain FDG uptake and on its performance for prediction of dementia in mild cognitive impairment


**OP-560**

Using EQ-PET to reduce reconstruction-dependent variation in FDG PET brain imaging

M. Vanhoucke†, 1, R. Lopes†, G. Pety†, C. Hossein-Foucher†, A. Aziz†, J. Jaillard†, H. Lahousse†, A. Semah†, R. Fahmi†; Siemens Healthineers / Univ. Lille, Inserm U1171, CHU Lille, F-59000 Lille, France, Lille, FRANCE, 2Univ. Lille, Inserm U1171, CHU Lille / CHU Lille, Department of Neuroradiology, Lille, FRANCE, 3CHU Lille, Department of Nuclear Medicine, Lille, FRANCE, 4Univ. Lille, Inserm U1171, CHU Lille / CHU Lille, Department of Nuclear Medicine, Lille, FRANCE, 5Nutricia Research, Utrecht, NETHERLANDS.

**OP-561**

Calculation of image-derived input function for absolute quantification of clinical [18]FDG PET/MRI studies of the brain

I. Shiyyam Sundar*, O. Muzik, L. Rischka*, A. Hahn*, I. Rausch*, R. Lanzenberger*, M. Hienert*, E. Maria Klebermass*, T. Traub-Weidinger, T. Beyr; 1Medical University Vienna, Vienna, AUSTRIA, 3Wayne State University School of Medicine, Detroit, MI, UNITED STATES OF AMERICA.

**OP-562**

18FDopa PET/CT is more sensitive than WB-MRI for the detection of structural disease in medullary thyroid cancer with increased calcitonin.

M. Terroir, I. Borget, C. Caramella, K. El Farsaoui, D. Deandaies, S. Grimaldi, A. Berdelou, E. Lebouleux; Gustave Roussy, Villejuif, FRANCE.

**OP-563**

Role of 68Ga-DOTA RGD PET/CT in patients with TENIS (Thyroglobulin elevation with negative iodine scintigraphy) syndrome and its comparison with 18 F FDG PET/CT.

A. S. Parihar, R. Basher, J. Shukla, R. Vatsa, A. Sood, A. Bhattacharyya, B. R. Mittal; Post Graduate Institute of Medical Education & Research, Chandigarh, INDIA.
**Scientific Programme**

**OP-564**
Comparison of F-18 DOPA and Ga-68 DOTA TATE in detection of recurrences or metastasis of medullary thyroid cancer

S. Asa1, K. Sönmezoglu1, E. Kaymak Akgun1, S. Razavi Khosroshah1, S. Toksoz2, H. Pehlivanoglu1, E. Karayel1, M. Ocak1, L. Kabasakal1, Y. Bükevi1; Istanbul University Cerrahpasa Medical Faculty Department of Nuclear Medicine, Istanbul, TURKEY; 2Istanbul University Cerrahpasa Medical Faculty Department of General Surgery, Istanbul, TURKEY; 3Istanbul University Pharmacy Faculty, Istanbul, TURKEY.

**OP-565**
Characteristics of malignant thyroid lesions on [18F]Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET)/Computed Tomography (CT)

H. Nasr1,2, H. Farghaly1,2, A. Alqarni3, S. Al-Salem1; 1Radiology Department, Prince Sultan Military Medical City, Riyadh, SAUDI ARABIA, 2Nuclear Medicine Unit, Kasr Al-Aini Cairo University Hospital, Cairo, EGYPT, 3Nuclear Medicine Unit, Assuit University Hospital, Assuit, EGYPT.

**OP-566**
FDG+/RAI+ patients with distant metastases from differentiated thyroid cancer can benefit from RAI treatment

I. Males1, S. Grimaldi2, M. Terroir3, J. Lumbroso1, D. Deandrea1, A. Berdelou1, E. Baudin1, M. Schlumberger1, S. Leboulleux1; 1Institut Gustave Roussy, Villejuif, FRANCE, 2Serena Grimaldi, villejuif, FRANCE, 3Marie Terroir Cassou de Mouna, Villejuif, FRANCE.

**OP-567**
Underestimation of the risk of metastatic disease in differentiated thyroid cancer adopting the 2015 ATA guidelines

D. Albano1, M. Gazzilli2, M. Bonacina, R. Durmo3, E. Cerudelli, M. Panarotta, F. Bertagna, R. Giubbini; Spedali Civili Brescia, Brescia, ITALY.

**OP-568**
30 mCi Radioiodine Treatment of Thyroid Carcinoma Patients in the post ESTIMABL Era

D. Rusu1, V. Fleury1, C. Palpacuer1, M. Le Thiec1, M. Colombi2, F. Kraeber-Bodéné2,3, C. Rousseau1; 1Nuclear Medicine, ICO Cancer Fighting Center, - SAINT HERBLAIN, FRANCE, 2Statistics Unit, ICO Cancer Fighting Center, - SAINT HERBLAIN, FRANCE, 3Nuclear Medicine, University Hospital, Nantes, FRANCE; 1CRCNA, Inserm U992, CNRS UMR 6299, Nantes, FRANCE.
World Leading Meeting

Scientific Programme

1504 Tuesday, October 24, 2017, 16:30 - 18:00, Hall E1
Do.Mo.Re - Rapid Fire Session: Radionuclide Therapy, Miscellaneous

Chairs: R. Baum (Bad Berka, GERMANY)
F. Forrer (St. Gallen, SWITZERLAND)

OP-581 Peptide receptor radionuclide therapy (PRRT) in ENETS Grade 3 (G3) Neuroendocrine Neoplasia (NEN) - a single-institution retrospective analysis
S. Thang1,2, M. Lung1, G. Kong1, M. Hofman1, J. Callahan1, M. Michael1, R. Hicks1; Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA. 2Singapore General Hospital, Singapore, SINGAPORE.

OP-582 The HSP90-inhibitor Onalespib Potentiates 177Lu-Dotatate Treatment of Neuroendocrine Tumors
S. Lundsten, A. Mortensen, A. Mäkinen, O. Spiegelberg, B. Stenerlöw, M. Nestor; Department of Immunology, Genetics and Pathology, Uppsala University, UPPSALA, SWEDEN.

OP-583 Heterogeneity derived by somatostatin receptor PET Predicts Overall Survival in G1/2 Pancreatic NET Patients Envisaged for Endoradiotherapy
R. A. Werner1, H. Illhan1, M. Moz2, S. Lehner1, L. Papp1, N. Sződté2, I. Schakta2, D. O. Muggel1, T. Higuchi1, A. K. Buck1, P. Bartenstein1, F. Bengel1, M. Essler1, C. Lapa1, R. A. Bundschuh1; 1Department of Nuclear Medicine, Universitätsklinikum Würzburg, Würzburg, GERMANY, 2Department of Nuclear Medicine, Ludwig-Maximilians-University Munich, Munich, GERMANY, 3Department of Nuclear Medicine, Charité - Universitätsmedizin Berlin, Berlin, GERMANY, 4Department of Nuclear Medicine, Hannover Medical School, Hannover, GERMANY, 5Department of Nuclear Medicine, University Medical Center Bonn, Bonn, GERMANY.

OP-575 PET Response Criteria for Patients Undergoing Target Radioligand Therapy
W. Fendler; Ahmanson Translational Imaging Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, UNITED STATES OF AMERICA.

OP-576 Assessing Response to Immunotherapy - Where are we?
R. Hicks; Cancer Imaging, Peter Mac Callum Cancer Institute, Melbourne, AUSTRALIA.

OP-577 Ongoing EORCT Reflexions on the Use of FDG PET and Other Imaging Biomarkers in Clinical Trials
C. Deroose; ZU Leuven, Nuclear Medicine Department, Leuven, BELGIUM.

OP-578 Image Reconstruction and Target Delineation on PET/CT for Radiotherapy Treatment Planning
M. Josipovic; Rigshospitalet, Department of Oncology, section for Radiotherapy, Copenhagen, DENMARK.

OP-579 Technical Challenges in 99mTc-MAA SPECT and 90Y PET Based Radioembolisation Dosimetry
C. Chiesa; Foundation IRCCS Istituto Nazionale Tumori, Nuclear Medicine Division, Milan, ITALY.

OP-580 Image Based Radionuclide Dosimetry Techniques
K. Bacher, Ghent University, Department of Medical Physics, Ghent, BELGIUM;
OP-584
Hyperkalemia in patients treated with radioligand or peptide receptor radionuclide therapy
C. H. Pfob¹, A. Ott², F. Maurer³, P. Luppa¹, K. Scheidhauer¹, U. Heemann⁵, M. Schwäger¹, C. Schmaderer⁶; ¹Department of Nuclear Medicine, Technische Universität München, Klinikum rechts der Isar, Munich, GERMANY; ²Biomedical Informatics, Institute of Medical Statistics and Epidemiology, Technische Universität München, Klinikum rechts der Isar, Munich, GERMANY; ³Hospital Pharmacy Department, Technische Universität München, Klinikum rechts der Isar, Munich, GERMANY; ⁴TU Munich Department of Pathobiotechnology, Technische Universität München, Klinikum rechts der Isar, Munich, GERMANY; ⁵Department of Nephrology, Technische Universität München, Klinikum rechts der Isar, Munich, GERMANY.

OP-585
Adjuvant post-operative radiosynovectomy in patients with rare cases of ankle pigmented villonodular synovitis (PVS)
I. Iakovou¹, J. Kotrotsios¹, K. Badiavas¹, M. Potoupnis², V. Mpalaris¹, G. Arsos¹; ¹Academic Nuclear Medicine dept, Papageorgiou hsp, THESSALONIKI, GREECE, ²Academic Orthopedic dept, Papageorgiou hsp, THESSALONIKI, GREECE.

OP-586
Impact of external cooling on PSMA uptake in salivary glands
L. W. M. van Kalmthout, M. G. E. H. Lam, B. de Keizer, A. J. A. T. Braat; University Medical Center Utrecht, Utrecht, NETHERLANDS.

OP-587
Functional imaging of the salivary glands for evaluation of radiation-induced sialadenitis before and after Lu-177 PSMA radioligand therapy
T. Langbein, H. R. Kulkarni, A. Singh, R. P. Baum; Zentralklinik Bad Berka, Bad Berka, GERMANY.

OP-588
Fluorocholine PET CT parameters predictive for hematological toxicity to 223Ra-Dichloride Therapy

OP-589
Baseline 18F-Fluoride PET-derived parameters predict modification of toxicity- and response-related blood biomarkers in prostate cancer patients treated with 223Ra-Dichloride: preliminary results
V. Ceriani¹, G. Fornarini¹, M. Bauckneht¹, S. Morbelli¹, E. Zanardi¹, E. Pompousi¹, A. Buschiazzi¹, I. Calamia¹, M. Ippoliti¹, F. Fiz¹, R. Piva¹, P. Mataraci Bettini¹, F. Boccardo¹, G. Sambuceti¹; ¹IRCCS AUO San Martino IST, Genova, ITALY, ²Nuclear Medicine Unit, A.O. SS. Antonio e Biagio e Cesare Arrigo, Alessandria, ITALY, ³Dep. of Nuclear Medicine and Clinical Molecular Imaging University Hospital, Tübingen, GERMANY.

OP-590
Mechanisms of Bone Marrow Failure in Prostate Cancer Patients treated with Radium-223 Therapy
F. Fiz¹, C. Campi¹, S. Sahba¹, J. Schwanck¹, M. Weissinger¹, M. Bauckneht¹, R. Piva¹, C. Marinis¹, H. Dittman¹, M. Piana¹, G. Sambuceti¹, C. La Fougère¹; ¹University of Tuebingen, Tuebingen, GERMANY, ²National Council of Research - SPIN, Genoa, ITALY, ³University of Genoa, Genoa, ITALY, ⁴CNR - IBFM, Genoa, ITALY.

OP-591
Prediction of hematological toxicity in Radium-223 therapy in patients with advanced metastatic castration-resistant prostate cancer
M. Ø. Fosbøl, P. M. Petersen, A. Kjaer, J. Mortensen; Rigshospitalet, Copenhagen, DENMARK.

OP-592
90Y PET-CT based method of dose calculation to evaluate the efficacy of internal selective radiotherapy (SIRT)
E. Kalogianni, N. Heraghty, D. Levart, B. Corcoran, N. Mulholland, M. Vadrucci, G. Vivian; King’s College Hospital, LONDON, UNITED KINGDOM.

OP-593
Correlation of SUVmax values & liver metastasis size/number with survival of colorectal Ca patients undergoing TARE treatment
B. Sönmez¹, A. Gülçü², R. Bekiş², B. Polack¹; ¹Dokuz Eylul University, Faculty of Medicine, Department of Nuclear Medicine, Izmir, TURKEY, ²Dokuz Eylul University, Faculty of Medicine, Department of Radiology, Izmir, TURKEY.
1505  Tuesday, October 24, 2017, 16:30 - 18:00, Hall E2
Joint Symposium 15 - EANM/ESMI: Best of European Molecular Imaging Meeting - EMIM 2017

Chairs: L. Evangelista (Padova, ITALY)
T. Lahoutte (Brussels, BELGIUM)

OP-594
Simultaneous Imaging of Tumor Metabolism and Vascularity During Tumor Growth with a Hybrid Positron Emission Tomography (PET) / Ultrafast Sonography (US) System
A. Garofalakis; Paris-Cardiovascular Research Center, Paris Descartes University; Georges Pompidou European Hospital, Paris, FRANCE.

OP-595
AI18F-Labelling of Heat-Sensitive Biomolecules for Positron Emission Tomography Imaging
F. Cleeren; Laboratory for radiopharmacy, University of Leuven / Department of Pharmacy and Pharmacology, Leuven, BELGIUM.

OP-596
Purinergic Receptor P2Y12: A Potential Target for PET Imaging of Neuroinflammation in Multiple Sclerosis and EAE
W. Beaino; VU University Medical Center, Department of Radiology, Amsterdam, NETHERLANDS.

1506  Tuesday, October 24, 2017, 16:30 - 18:00, Hall F1
Teaching Session 6 (Interactive): Correlative Imaging for Nuclear Medicine Specialists: Interactive Live Radiology and Nuclear Medicine Quiz Using the Experior Medical System

Chair: I. Burger (Zurich, SWITZERLAND)

OP-597
Correlative Imaging for Nuclear Medicine Specialists: Interactive Live Radiology and Nuclear Medicine Quiz Using the Experior Medical System
T. Lynch; Belfast, UNITED KINGDOM.

1507  Tuesday, October 24, 2017, 16:30 - 18:00, Hall F2
Clinical Oncology: In the Air & Beyond

Chairs: B. Fischer (Copenhagen, DENMARK)
tba.

OP-598
Prognostic impact of pre-treatment 18FDG-PET/CT restaging in patient with HNSCC
O. Delcroix1, J. Leclère2, P. Robin1, S. Querellou1, P. Le Roux1, P. Salaun1, C. Guezenne2, U. Schick1, G. Valette2, J. Rousset2, R. Abgral1; 1Department of Nuclear Medicine, Brest University Hospital, BREST, FRANCE, 2Department of Head and Neck Surgery, University Hospital of Brest, BREST, FRANCE, 3Department of Radiotherapy, Brest University Hospital, BREST, FRANCE, 4Department of Radiology, Military Hospital of Brest, BREST, FRANCE.

OP-599
Inter-observer and inter-contouring method variability for textural analysis in head and neck cancer in pre-therapeutic 18-FDG PET/CT

OP-600
PET/CT imaging of angiogenesis in head and neck squamous cell carcinoma patients
D. Lobeek1, S. Y. A. Terry2, M. A. W. Merkx1, R. P. Takes1, P. J. Slootweg1, W. J. G. Oyen1,3, O. C. Boerman1, M. Rijpkema1; 1Radboud University Medical Center Nijmegen, Nijmegen, NETHERLANDS, 2King’s College London, London, UNITED KINGDOM, 3Institute of Cancer Research, Royal Marsden NHS Trust, London, UNITED KINGDOM.

OP-601
Voxel based comparison and texture analysis of 18F-FDG and 18F-FMISO PET of 38 Patients with head-and-neck cancer
M. Kroenke3, K. Hirata4, S. Watanabe5, S. Okamoto6, K. Magata7, T. Shiga7, Y. Kuge7, N. Tamaki7; 1Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, München, GERMANY, 2Department of Nuclear Medicine, Graduate School of Medicine of Hokkaido University, Sapporo, JAPAN, 3Central Institute of Isotope Science, of Hokkaido University, Sapporo, JAPAN.
Role of FDG-PET in disclosing RECIST-based pseudoprogression in non-small cell lung cancer (NSCLC) patients treated with Nivolumab


Heterogeneity in tumours; Validating the use of textural analysis and shape analysis on 18F-FDG PET/CT scans of lung cancer patients as a prognostic tool. Preliminary analysis

**M. M. K. Krarup**, L. Nygård, I. Vogelius, M. M. Siddique, G. Cook, V. Goh, F. L. Andersen, B. M. Fischer; 1University Hospital of Copenhagen, Rigshospitalet, Copenhagen, DENMARK, 2St. Thomas’ Hospital, London, UNITED KINGDOM, 3St. Thomas’ Hospital/King’s College, London, UNITED KINGDOM.

Segmental FDG-PET/CT In Solitary Pulmonary Nodule: Preliminary Data Of The PET Italian Tailored Assessment of Lung Indeterminate Accidental Nodule (ITALIAN) Trial

**M. Spadafora**, L. Mansi, A. Cucolo, L. Evangelista, V. Rizzo, L. Guerra, S. Fanti, E. Nicolai, A. Chirò, M. Zuffante, O. Schillaci, G. Peluso, S. Annunziata, A. Fracchetti, D. Ripani, A. Gniadkowski, P. Miletto, L. Pace; 1Nuclear Medicine Unit, Department of Imaging, S.G. Moscati Hospital, Avellino, ITALY, 2Dipartimento Medico-Chirurgo di Internistica Clinica e Sperimentale, Second University of Naples, Napoli, ITALY, 3Department of Advanced Biomedical Sciences, University of Naples Federico II, Napoli, ITALY, 4Nuclear Medicine and Molecular Imaging Unit, Veneto Institute of Oncology IOV - IRCCS, Padova, ITALY, 5Nuclear Medicine Unit, San Gerardo Hospital, University of Milano Bicocca, Monza, ITALY, 6Service of Nuclear Medicine, Policlinico S. Orsola Malpighi, University of Bologna, Bologna, ITALY, 7Nuclear Medicine Unit, Department of Imaging, SON Foundation, Napoli, ITALY, 8Nuclear Medicine Unit, Cancer Center, Humanitas Hospital, Rizzano, Milano, ITALY, 9Nuclear Medicine Unit, Department of Imaging, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, ITALY, 10Department of Biomedicine and Prevention, University of Rome Tor Vergata, Roma, ITALY, 11Nuclear Medicine Unit, Department of Imaging, Medicina Futura IOS, Acerro, Napoli, ITALY, 12Institute of Nuclear Medicine, Università Cattolica del S. Cuore, Roma, ITALY, 13Department of Medical Physics, Hospital of Bolzano, Bolzano, ITALY, 14Division of Medical Oncology, S. G. Moscati Hospital, Avellino, ITALY, 15Department of Medicine and Surgery, University of Salerno, Baronissi (SA), ITALY.

Quantitative 99mTc-Galacto-RGD2 SPECT/CT to Evaluate Lung Cancer Physiology and Malignancy: A Comparative Multi-center Study with 18F-FDG PET/CT

**T. Wang**, Y. Liang, G. Zhang, M. Li, W. Fang, H. Dai, B. He, X. Wang; 1The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, CHINA, 2Navy General Hospital, Beijing, CHINA, 3First Hospital of Shanxi Medical University, Taiyuan, CHINA, 4Fuwai Hospital, Beijing, CHINA, 5Dianli Hospital, Beijing, CHINA, 6University of Missouri-Columbia, Columbia, MO, UNITED STATES OF AMERICA.

Evaluating stress and rest absolute quantification of uptake in myocardial perfusion SPECT using GE Q.Metrix

**I. Armstrong**, N. Fyle, P. Arumugam; Central Manchester University Hospitals, Manchester, UNITED KINGDOM.

Dynamic Single Photon Emission Computer Tomography in assessment of Coronary Flow Reserve in Patients with stable coronary artery diseases

**A. Mochula**, K. Zavadovsky, S. Andreev, Y. Lishmanov; 1Cardiology Research Institute, Tomsk NRMC, Tomsk, RUSSIAN FEDERATION, 2National Research Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION.

One-day protocol for myocardial perfusion stress-testing by combination of Rutland-Patlak analysis of 99mTc-MIBI uptake and adenosine challenge

**W. Y. Ussov**, V. M. Gulyaev, E. N. Karpov, O. Y. Borodin; 1Institute of Cardiology, Tomsk, RUSSIAN FEDERATION, 2Tomsk Regional Institute of Oncology, Tomsk, RUSSIAN FEDERATION.
OP-609
Modelling Factors Affecting Apparent Transmural Flow Gradient in Ungated Tomographic Myocardial Perfusion Imaging
A. Bellini,1 C. Marini,1 F. Ticconi,1 S. D. Morbelli,1 M. Bauckneht,1 F. Fiz2, I. Calamia,1 A. Nieri1, S. Maggio1, G. Sambuceti1,4 1Nuclear Medicine Unit, Department of Health Sciences, University of Genoa, Genoa, ITALY, 2CNR Institute of Bioimages and Molecular Physiology, Milan, ITALY, 3IRCCS AOI San Martino-IST, Genoa, ITALY, 4Nuclear Medicine Unit, Department of Radiology, Uni-Klinikum Timbingen, Tubingen, GERMANY.

OP-610
Simulation of Patient Motion with Myocardial Perfusion CZT SPECT: Data-Driven Motion Detection and Correction
D. Daou,1,2 R. Sabbah,1 Y. Alattar,1 C. Coaguila4, H. Boulahdour1,5 1Cochin Hospital, APHP, PARIS, FRANCE, 2EA 7334 REMES, Université Paris-Diderot, Sorbonne Paris-Cité, Paris, FRANCE, 3CHU Jean Minjoz, Besançon, FRANCE, 4Centre Hospitalier de Bigorre, Tarbes, FRANCE, 5EA 4662, Université de Franche-Comté, Besançon, FRANCE.

OP-611
Artificial Intelligence for Myocardial Perfusion Imaging Compared with Expert Interpretation
K. Nakajima,1, K. Kiso2, T. Kudo3, Y. Taniguchi4, S. Matsuo1, M. Nakagawa5, T. Nakata1, H. Hida, H. Tanaka6, M. Sarai9, K. Okuda1,2, L. Edenbrandt13 1Kanazawa University Hospital, Kanazawa, JAPAN, 2National Cerebral and Cardiovascular Center, Osaka, JAPAN, 3Nagasaki University, Nagasaki, JAPAN, 4Hyogo Brain and Heart Center, Himeji, JAPAN, 5Akita City Hospital, Akita, JAPAN, 6Hakodate Goryoukaku Hospital, Hakodate, JAPAN, 7Tokyo Medical University Hospital, Tokyo, JAPAN, 8Tokyo Medical University Ibaraki Medical Center, Ibaraki, JAPAN, 9Fujita Health University Hospital, Toyoake, JAPAN, 10Public Central Hospital of Matto Ishikawa, Hakusan, JAPAN, 11Tokyo Women's Medical University, Tokyo, JAPAN, 12Kanazawa Medical University, Uchinada, JAPAN, 13University of Gothenburg, Gothenburg, SWEDEN.

OP-612
Diagnostic Performance of Artificial Neural Network for the localization of coronary artery disease
H. Shimoyama, S. Nakayama, Y. Kotake, S. Shimamoto, R. Futai, Itami City Hospital, Itami, JAPAN.
OP-618  Joint Hardware and Patient Attenuation Correction for Hybrid PET/MR Imaging
T. Heußer1, Y. Berké1, M. T. Freitag1, M. Kachelrieß2; 1German Cancer Research Center (DKFZ), Heidelberg, GERMANY, 2RWTH Aachen University, Aachen, GERMANY.

OP-619  Comparison of quality control between PET/MRI and PET/CT systems using NEMA tests
M. Abuqbeitah1, M. Demir1, N. Yeyin1, T. Toklu1, S. Sezgin1, H. Çetin1, K. Sönmezoglu1; 1Istanbul University, Istanbul, TURKEY, 2Editepe University, Nuclear Medicine Department, Istanbul, TURKEY, 3Epsilon Laboratory, Istanbul, TURKEY.

OP-620  Joint Symposium 13 - EANM/SNMMI: Standardisation of Diuresis Renography in Children
Chairs: A. Santos (Lisbon, PORTUGAL)  Z. Bar-Sever (Petach-Tikva, ISRAEL)

OP-621  The SNMMI-EANM Joint Guidelines for Diuresis Renogram in Children: The F+0 Protocol
D. De Palma; Circolo Hospital and Macchi Foundation, Nuclear Medicine Unit, Varese, ITALY.

OP-622  The SNMMI-EANM Joint Guidelines for Diuresis Renogram in Children: The F+(20 to 30 minutes) Protocol
M. Majd; Children’s National Med Center, Dept. of Diagnostic Imaging & Radiology, Washington, UNITED STATES OF AMERICA.

OP-623  The Actual Role and Clinical Impact of Diuresis Renogram in Management of Prenatally Diagnosed Hydronephrosis
A. Springer; EAPU, Medical University of Vienna, Vienna, AUSTRIA.

OP-624  Examples of Workflow and Requirements for Patient-Specific Dosimetry-Guided Treatments
K. Jörgen-Giesler; Lund University, Medical Radiation Physics, Lund, SWEDEN.

OP-625  Optimisation of penalized likelihood estimation reconstruction on a digital time-of-flight PET-CT scanner for four different PET tracers
E. Lindström1, 2, A. Sundin1, 3, C. Trampal1, J. Sörensen1, 3, M. Lubberink1, 2; 1Department of Surgical Sciences/Nuclear Medicine & PET, Uppsala University, Uppsala, SWEDEN, 2Department of Medical Sciences, Uppsala University, Uppsala, SWEDEN, 3PET Centre, University Hospital, Uppsala, SWEDEN.
OP-632
Determining the Minimum Administered Activity for Tumour FDG PET/CT Imaging that satisfies EARL Specifications, and Investigation of Bayesian Penalised Likelihood Reconstruction
T. Sanderson, J. Dickson; University College London Hospital, London, UNITED KINGDOM.

OP-633
Investigation into Optimal PET-CT Image Reconstruction for the Detection and Quantification of Inflammation and Infection Associated with Implanted Cardiac Devices
Y. Boucharbe1,2, J. Thomas1, G. Delanerolle1, H. Jan1, N. Hartman1, A. Haroon1; 1Barts Health NHS Trust, London, UNITED KINGDOM, 2Queen Marys University, London, UNITED KINGDOM.

OP-634
SMART(SimulAtion and ReconsTruction) PET: An efficient PET simulation-reconstruction tool
E. Pfaehler, R. Boellaard, J. De Jong; UMCG Groningen, Groningen, NETHERLANDS.

OP-635
Comparison of a statistical analysis method and a visual assessment of Monte Carlo based SPECT reconstruction concerning liver metastases in 111In-octreotide diagnosis
E. Wikberg1, M. van Essen2, T. Rydén1, J. Svensson3, P. Gjertsson2, P. Bernhardt1; 1Department of Radiation Physics, Gothenburg, SWEDEN, 2Department of Nuclear Medicine, Gothenburg, SWEDEN, 3Department of Oncology, Gothenburg, SWEDEN.

OP-636
A post-acquisition normalization to co-analyze textural features from multi-center PET images
F. Orlhac1, S. Boughdad2, C. Noche1, J. Albenini1, M. Soussan1,2, I. Buvat1; IMIV, CEA, Inserm, CNRS, Univ. Paris-Sud, Université Paris-Saclay, CEA-SHIF, Orsay, FRANCE, 1Department of Nuclear Medicine, Institut Curie-René Huguenin, Saint-Cloud, FRANCE, 2Department of Nuclear Medicine, Assistance Publique - Hôpitaux de Paris, Avicenne Hospital, Bobigny, FRANCE.

OP-637
Comparison of Tumor Heterogeneity Assessed with Textural Parameters in 68Ga-PSMA PET/CT and 177Lu-PSMA SPECT/CT in Patients with Metastatic Prostate Cancer
L. Schwarte1, L. Thomas1, E. Eppard1, M. Meisenheimer1, C. Weiss-Wichert2, M. Essler1, R. A. Bundschuh1; 1Department of Nuclear Medicine, Universitätsklinikum Bonn, Bonn, Germany, Bonn, GERMANY, 2Mediso GmbH, Münster, GERMANY.
**Scientific Programme**

**OP-643**
Influence of composition of cysteine-containing peptide based chelators on biodistribution of $^{99m}$Tc-labelled anti-EGFR affibody molecules

M. Oroujeni, K. G. Andersson, J. Garousi, M. Altai, A. Vorobyeva, X. Steinhardt, B. Mitran, S. Ståhl, A. Orlov, J. Löfblom, V. Tolmachev; 1Uppsala University, Uppsala, SWEDEN, 2KTH-Royal Institute of Technology, Stockholm, SWEDEN.

**OP-648**
Restaging

P. Castellucci; S. Orsola-Malpighi, Nuclear Medicine, Bologna, ITALY.

**OP-649**
Response to Therapy

F. Giesel; Universitätsklinikum Heidelberg, Nuclear Medicine, Heidelberg, GERMANY.

**OP-644**
H4neunpa-trastuzumab: Evaluation of a Novel Bifunctional Chelator for 111In Radiopharmaceuticals and Immuno-SPECT Imaging


**OP-645**
2-[18F]Fluoro-5-iodopyridine ([18F]FIPy): a novel thiol reactive prosthetic group for the fast site specific labeling at ambient temperature

A. Omrane, B. Zlatopolskiy, B. Neumaier; 1Forschungszentrum Juelich GmbH: Institute of Neuroscience and Medicine, INM-5, Juelich, GERMANY, 2Institute of Radiochemistry and Experimental Molecular Imaging, University Clinic, Cologne, GERMANY, 3Max Planck Institute for Metabolism Research, Cologne, GERMANY.

**OP-646**
Introduction PSMA, EANM Procedure Guideline

W. Fendler; Ahmanson Translational Imaging Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, UNITED STATES OF AMERICA.

**OP-647**
Staging

M. Eiber; Technische Universität München, Nuclear Medicine, Munich, GERMANY.

**OP-648**
Restaging

P. Castellucci; S. Orsola-Malpighi, Nuclear Medicine, Bologna, ITALY.

**OP-649**
Response to Therapy

F. Giesel; Universitätsklinikum Heidelberg, Nuclear Medicine, Heidelberg, GERMANY.

**1607 Wednesday, October 25, 2017, 08:00 - 09:30, Hall F2**
Clinical Oncology: Anything Goes

**Chairs:** M. Bozkurt (Ankara, TURKEY)
B. Krause (Rostock, GERMANY)

**OP-650**
Regional hepatic glucose metabolism correlates with regional distribution of hepatic fat

A. Dunford, G. Keramidas, A. M. Peters; 1Royal Sussex County Hospital, Brighton, UK, Brighton, UNITED KINGDOM, 2Royal Brompton and Harefield Hospitals NHS FT, London, UNITED KINGDOM, 3Royal Sussex County Hospital, Brighton, UK & Clinical Imaging Sciences Centre, Brighton Sussex Medical School, Brighton, UK, UNITED KINGDOM.

**OP-651**
Assessment of Effect of Fatty Infiltration on Hepatic FDG Uptake

F. Özülker, T. Özülker; 1University of Health Sciences, Okmeydani Hospital, Department of Nuclear Medicine, Uskumruköy/Saray/Istanbul, TURKEY, 2University of Health Sciences, Okmeydani Hospital, Department of Nuclear Medicine, Uskumruköy/Saray/Istanbul, TURKEY.

**OP-652**
The correlation between pathological profile and metabolic parameters of $^{18}$F-FDG PET/CT in patients with gastroesophageal junction cancer

J. Song; Beijing Cancer Hospital, Beijing, CHINA.

**OP-653**
Early variation of FDG-PET parameters as predictors of response after treatment in locally advanced pancreatic carcinoma patients

E. Incerti, P. Mapelli, E. G. Vangori, U. Bini, C. Gumina, N. Slim, P. Passoni, G. M. Cattaneo, L. Gianoli, M. Picchio; 1Unit of Nuclear Medicine, IRCCS San Raffaele Scientific Institute, Milan, ITALY, 2Unit of Medical Physics, IRCCS San Raffaele Scientific Institute, Milan, ITALY, 3Unit of Radiotherapy, IRCCS San Raffaele Scientific Institute, Milan, ITALY.

1606 Wednesday, October 25, 2017, 08:00 - 09:30, Hall F1
Pitfalls & Artefacts 7 (Interactive) - Oncology: Pitfalls and Artefacts in PSMA PET Reading

**Chairs:** K. Herrmann (Essen, GERMANY)
P. Castellucci (Bologna, ITALY)

**OP-649**
Response to Therapy

F. Giesel; Universitätsklinikum Heidelberg, Nuclear Medicine, Heidelberg, GERMANY.

**OP-651**
Assessment of Effect of Fatty Infiltration on Hepatic FDG Uptake

F. Özülker, T. Özülker; 1University of Health Sciences, Okmeydani Hospital, Department of Nuclear Medicine, Uskumruköy/Saray/Istanbul, TURKEY, 2University of Health Sciences, Okmeydani Hospital, Department of Nuclear Medicine, Uskumruköy/Saray/Istanbul, TURKEY.

**OP-652**
The correlation between pathological profile and metabolic parameters of $^{18}$F-FDG PET/CT in patients with gastroesophageal junction cancer

J. Song; Beijing Cancer Hospital, Beijing, CHINA.

**OP-653**
Early variation of FDG-PET parameters as predictors of response after treatment in locally advanced pancreatic carcinoma patients

E. Incerti, P. Mapelli, E. G. Vangori, U. Bini, C. Gumina, N. Slim, P. Passoni, G. M. Cattaneo, L. Gianoli, M. Picchio; 1Unit of Nuclear Medicine, IRCCS San Raffaele Scientific Institute, Milan, ITALY, 2Unit of Medical Physics, IRCCS San Raffaele Scientific Institute, Milan, ITALY, 3Unit of Radiotherapy, IRCCS San Raffaele Scientific Institute, Milan, ITALY.

**withdrawn**
OP-654
Robotic arm assisted real time $^{18}$F-FDG PET/CT guided percutaneous metabolic sampling of abdominal lesions- Initial Experience
R. Kumar, B. R. Mittal, H. Singh, T. K. Jain, A. Sood, A. Bhattacharya; PGIMER, Chandigarh, INDIA.

OP-655
The Role of $^{18}$F-Sodium Fluoride (NaF) PET-CT in the evaluation of metastatic bone disease in morbidly obese patients
S. Usmani, F. Marafi, A. Esmail, F. Al Kandari; Kuwait Cancer Control Center, Kuwait, KUWAIT.

OP-656
Tc-99m-DPD bone scan quantification: Metastasis of prostate cancer vs. osteoarthritis
F. Tabotta, M. Jreige, N. Schaefer, J. O. Prior, M. Nicod Lalonde; CHUV, Lausanne, SWITZERLAND.

OP-657
Convolutional neural networks for segmentation of 49 selected bones in CT images show high reproducibility
M. Sadik, R. Kaboteh, O. Enqvist, J. Ullén, E. Trågårdh, M. H. Poulsen, J. A. Simonsen, P. F. Hørild-Carlsen, L. Edenbrandt; 1Department of Clinical Physiology, Göteborg, SWEDEN, 2Department of Signals and Systems, Göteborg, SWEDEN, 3Eigenvision AB, Malmö, SWEDEN, 4Department of Translational Medicine, Malmö, SWEDEN, 5Department of Urology, Odense, DENMARK, 6Department of Nuclear Medicine, Odense, DENMARK.

1608 Wednesday, October 25, 2017, 08:00 - 09:30, Hall K
Cardiovascular System: Myocardial Perfusion PET - $^{82}$Rubidium

OP-658
Prognostic Value of Quantitative Coronary Artery Calcium and Myocardial Blood Flow Assessed by Hybrid Rubidium-$^{82}$PET/CT Imaging in Patients With Suspected Coronary Artery Disease
E. Zampella, R. Assante, T. Mannarino, G. De Simini, A. Genova, M. Panico, V. Gaudieri, C. Nappi, C. Mainolfi, W. Acampa, M. Petretto, P. Arumugam, A. Cuocolo; 1Department of Advanced Biomedical Sciences, University Federico II, Naples, ITALY, 2Institute of Biostructure and Bioimaging, National Council of Research, Naples, ITALY, 3Department of Translational Medical Sciences, University Federico II, Naples, ITALY, 4Department of Nuclear Medicine, Central Manchester University Hospitals, Manchester, UNITED KINGDOM.

OP-659
Cardiac $^{82}$Rb PET/CT: The added value in diabetic Heart Transplant Patients
M. L. De Rimini, G. Borrelli, A. Russo, S. Carrino, C. Maiello, P. Muto; 1Nuclear Medicine Unit - AO Ospedali dei Colli - Monaldi, Naples, ITALY, 2Cardiovascular Unit; Vanvitelli University of Campania, Naples, ITALY, 3Pharmacy Unit - AO Ospedali dei Colli - Monaldi, Naples, ITALY, 4Cardiac Transplant Unit - AO Ospedali dei Colli - Monaldi, Naples, ITALY.

OP-660
Relationship between microvascular disease assessed using myocardial flow reserve with $^{82}$Rubidium positron emission tomography and the severity of diabetic nephropathy
L. Potier, R. Chequer, C. Amouyal, K. Mohammed, A. Hartemann, M. Marre, R. Roussel, D. Le Guludec, F. Hyafil; 1Department of Diabetology, Bichat Hospital, AP-HP, PARIS, FRANCE, 2Department of Nuclear Medicine, Bichat Hospital, AP-HP, PARIS, FRANCE, 3Department of Diabetology, Pitie-Salpetriere Hospital, AP-HP, PARIS, FRANCE, 4Department of Diabetology, Bichat Hospital, AP-HP, PARIS, FRANCE, 5Department of Diabetology, Pitie-Salpetriere Hospital, AP-HP, PARIS, FRANCE.

OP-661
Low-dose myocardial blood flow imaging using $^{82}$Rb-PET (RUBILOW 2.0)
C. M. Hoff, L. P. Tolbod, H. J. Harms, K. Bouchelouche, J. Frakker, J. Sørensen; Aarhus University Hospital, Aarhus, DENMARK.
**OP-662**

**Value of Rubidium-82 Flow Measurements in Patients with CABG**

B. J. H. G. van Gageldonk¹, A. T. L. Fiolet¹, J. E. M. Bank², A. Mosterd¹, H. J. Verberne¹, J. M. H. de Klerk¹, A. M. Scholten¹; ¹Meander Medical Center, Amersfoort, NETHERLANDS, ²University Medical Center, Utrecht, NETHERLANDS, ³Academic Medical Center, Amsterdam, NETHERLANDS.

**OP-663**

**Higher diagnostic performances of 82Rubidium-PET in comparison to SPECT myocardial perfusion scintigraphy for the detection of three-vessel coronary artery disease**

F. Hyafil¹, R. Chequer¹, E. Sorbets¹, T. Alfaiate¹, H. Regaieg², F. Rouzet¹, N. Mikail³, G. Ducrocq², R. Ben Azzouna¹, S. Leygnac¹, M. Milliner¹, C. Estellat¹, D. Le Guludec¹; ¹Department of Nuclear Medicine, Bichat Hospital, AP-HP, Paris, FRANCE, ²Department of Cardiology, Avicennes Hospital, AP-HP, Bobigny, FRANCE, ³Unite de Recherche Clinique Paris Nord, Bichat Hospital, AP-HP, Paris, FRANCE, ⁴Department of Cardiology, Bichat Hospital, AP-HP, Paris, FRANCE.

**OP-664**

**Need for Correction of Myocardium Movement during Dynamic Rubidium-82 Stress PET for Accurate Myocardial Blood Flow Quantification**

S. S. Koenders¹,², J. D. van Dijk¹, P. L. Jager¹, C. H. Slump¹, J. Ottervanger¹, J. A. van Dalen³; ¹Department of Nuclear Medicine, Isala, Zwolle, NETHERLANDS, ²MIRA: Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, NETHERLANDS, ³Department of Cardiology, Isala, Zwolle, NETHERLANDS, ⁴Department of Medical Physics, Isala, Zwolle, NETHERLANDS.

**OP-665**

**Estimation and reliability of myocardial blood flow after motion correction with dynamic PET using a Bayesian framework**

A. Saillant¹,², K. Saint¹, M. Memmotti¹, I. Armstrong¹, V. Shah¹, S. Zuehlsdorff¹, J. Declercq¹, M. Jenkinson², M. Chappell²; ¹Siemens Healthineers, Knoxville, TN, UNITED STATES OF AMERICA, ²University of Oxford, Oxford, UNITED KINGDOM, ³Central Manchester University Hospital, Manchester, UNITED KINGDOM, ⁴Siemens Healthineers, Oxford, UNITED KINGDOM.

**OP-666**

**Voxel based internal dosimetry of radiopharmaceuticals in diagnostic nuclear medicine**

N. Petoussi-Henss¹, J. Ocampo Ramos², M. Zankl¹, W. Li¹, W. Rühm¹; ¹Helmholtz Zentrum München, Neuherberg, GERMANY, ²Universidad Nacional de Colombia, Medellín Branch, COLOMBIA.

**OP-667**

**IDAC-Dose 2.1, an internal dosimetry program for diagnostic nuclear medicine using the official ICRP specific absorbed fractions for the adult ICRP/ICRU reference computational voxel phantoms**

M. Andersson¹, L. Johansson¹, K. Eckerman¹, S. Mattsson¹; ¹Medical Radiation Physics, Malmo, SWEDEN, ²Department of Radiation Sciences, Umeå, SWEDEN, ³Center for Radiation Protection Knowledge, Oak Ridge National Laboratory, Oak Ridge, TN, UNITED STATES OF AMERICA.

**OP-668**

**Image based preclinical absorbed dose estimation through GATE Monte Carlo simulation using ¹⁸F-FDG PET/CT images of mice**

A. Gupta¹, M. S. Lee¹, J. H. Kim¹, S. H. Park², H. S. Park³, S. E. Kim¹, D. S. Lee¹, J. S. Lee¹; ¹Seoul National University (SNU), Seoul, KOREA, REPUBLIC OF, ²Seoul National University (SNU), Seoul, KOREA, REPUBLIC OF, ³Graduate School of Convergence Science and Technology, Seoul, KOREA, REPUBLIC OF.

**OP-669**

**Radiation dosimetry of the tau PET Tracer ¹⁸F-PI-2620 in humans**

J. Seibyl¹, O. Barret¹, A. Stephens², J. Madonia², D. Alagille³, A. Mueller³, H. Schieferstein³, M. Berndt¹, H. Kroth¹, S. Bullich¹, C. Papin¹, V. Carroll², C. Sandiego¹, A. Pfeifer¹, A. Muhs¹, L. Dinkelborg², G. Tamagnan¹, K. Marek¹; ¹Molecular Neuroimaging, New Haven, CT, UNITED STATES OF AMERICA, ²Piramal Imaging, Berlin, GERMANY, ³AC Immune SA, Lausanne, SWITZERLAND.
OP-670
Preliminary Results of Biodistribution and Dosimetric Analysis with \[^{68}\text{Ga}]\text{Ga-DOTA}\text{\textsuperscript{Zn}}; A new bone seeking PET radionuclide
A. Khawar\textsuperscript{1}, E. Eppard\textsuperscript{1}, H. Ahmadzadehfar\textsuperscript{1}, S. Kürpik\textsuperscript{1}, M. Meisenheimer\textsuperscript{1}, F. C. Gaertner\textsuperscript{1}, F. Roesch\textsuperscript{2}, M. Essler\textsuperscript{1}, R. A. Bundschuh\textsuperscript{1}; \textsuperscript{1}Department of nuclear medicine, University Hospital, Bonn, GERMANY, \textsuperscript{1}Institute for nuclear chemistry, Johannes Gutenberg-University, Mainz, GERMANY.

OP-671
PET-based human dosimetry of \[^{68}\text{Ga}\text{-NODAGA-exendin-4}, a tracer for beta cell imaging
M. Boss\textsuperscript{1}, M. Buttinga\textsuperscript{1}, T. J. P. Janssen\textsuperscript{1}, M. Brom\textsuperscript{1}, E. P. Visser\textsuperscript{1}, M. Gotthardt; Radboud University Medical Center, Nijmegen, NETHERLANDS.

OP-672
PET-based biodistribution and radiation dosimetry of \[^{64}\text{Cu}\text{copper dichloride}, first-in-human healthy volunteer evaluation
M. A. Avila-Rodríguez\textsuperscript{1}, C. Rios\textsuperscript{1}, J. Carrasco-Hernández\textsuperscript{1}, P. Manrique-Arias\textsuperscript{1}, R. Martínez-Hernández\textsuperscript{1}, E. Martínez-Rodríguez\textsuperscript{2}, F. O. García-Pérez\textsuperscript{3}, M. Romero-Piña\textsuperscript{4}, A. Jalilian\textsuperscript{1}, A. Díaz-Ruiz\textsuperscript{1}; \textsuperscript{1}Universidad Nacional Autónoma de México, CDMX, MEXICO, \textsuperscript{2}Instituto Nacional de Neurología y Neurocirugía, CDMX, MEXICO, \textsuperscript{3}Instituto de Oncología, CDMX, MEXICO, \textsuperscript{4}International Atomic Energy Agency, Vienna, AUSTRIA.

OP-673
Validation of semi Monte Carlo, voxel-based radionuclide dosimetry software using 3D printed phantom experiments with TLD measurements and patient indium-111 Exendin scans using SPECT/CT
W. D. Wormgoor\textsuperscript{1}, A. P. W. Meeuws\textsuperscript{2}, I. Sechopoulos\textsuperscript{2}, E. Hippeläinen\textsuperscript{2}, A. Schilberg\textsuperscript{3}, E. P. Visser\textsuperscript{4}, ZGT, Hengelo, NETHERLANDS, \textsuperscript{2}Radboud University Medical Center, Nijmegen, NETHERLANDS, \textsuperscript{3}University of Helsinki and Helsinki University Hospital, Helsinki, FINLAND, \textsuperscript{4}Joint Authority for Päijät-Häme Social and Health Care, Lahti, FINLAND.
**Scientific Programme**

**OP-680**
Additional Non-SLN Metastases in Early Oral Cancer Patients with Positive SLN  
*R. de Bree;* UMC Utrecht Cancer Center, University Medical Center Utrecht, Department of Head and Neck Surgical Oncology, Utrecht, NETHERLANDS.

**OP-681a**
The Added Value of PET/MR in H&N Tumours  
*M. Hüllner;* University Hospital Zurich, Clinic of Nuclear Medicine, Zurich, SWITZERLAND.

**OP-681b**
Sensitivity of SLNB in H&N Melanoma Patients  
*A. J. M. Balm;* The Netherlands Cancer Institute, Department of Head and Neck Oncology and Surgery, Amsterdam, NETHERLANDS.

---

**1703 Wednesday, October 25, 2017, 10:00 - 11:30, Hall C**

**CTE 7 (Interactive) - Joint Session with Paediatrics: Practical and Technical Aspects of Paediatric Nuclear Medicine**

**Chairs:** S. Rac (Rijeka, CROATIA)  
P. Zucchetta (Padova, ITALY)

**OP-682**
How to Set Up a Paediatric Nuclear Medicine Department  
*Z. Bar-Sever;* Schneider Children’s Medical Center of Israel, Petach-Tikva, ISRAEL.

**OP-683**
Paediatric Nephrology – What Do We Do With Infants?  
*S. Grbac-Ivanković;* Clinical hospital centre Rijeka, Department of nuclear medicine, Rijeka, CROATIA.

**OP-684**
Paediatric Imaging Methods in Oncology - The Key is in Dosimetry, Do We Have a Solution?  
*A. Balenović;* Dom zdravlja Zagreb-Centar /Health Care Center Zagreb, Zagreb, CROATIA.

---

**OP-685**
Clinical Evaluation of Data-driven Motion Correction for PET Imaging  
*C. F. Uribe*1, F. Rousseau1, F. Lacroix-Poisson1, T. Aldén1, S. Wollenweber1, F. Benard1; ‘BC Cancer Agency, Vancouver, BC, CANADA, ‘GE Healthcare, Waukesha, WI, UNITED STATES OF AMERICA.

**OP-686**
ParaPET, A New Statistical Methodology to Derive 3D Maps of FDG-PET Kinetic Parameters  
*E. Colard*1, L. Padovani1, S. Delcourt1, S. Thureau1, B. Farman Araba1, P. Gouel2, J. Gardin2, P. Verd2, D. Taieb2, D. Barbolosia, S. Hapdey2; ‘UTIS QuantIF EA4108, Rouen, FRANCE, ‘Department of Radiotherapy, La Timone University Hospital, Marseille, FRANCE, ‘Department of Nuclear Medicine, La Timone University Hospital, Marseille, FRANCE, ‘Department of Nuclear Medicine, La Timone University Hospital and European Center for Research in Medical Imaging (CERIMED), Marseille, FRANCE, ‘SMARTc, INSERM, UMR 911 CR02, Marseille, FRANCE.

**OP-687**
Assessment of whole-body scatter correction for Ga-68 PSMA PETCT  
*H. Bai*1, J. Hong1, F. Buther2, M. Aykac1, K. Schaefers3, M. Conti1; ‘Siemens Healthineers, Knoxville, TN, UNITED STATES OF AMERICA, ‘University of Muenster, Muenster, GERMANY.

**OP-688**
Impact of motion compensation and partial volume correction on 18F-NaF PET/CT imaging of coronary plaque  
*J. Cal-Gonzalez*1, C. Tsoumpas1, M. Lassen1, S. Rasul1, M. Hacker1, K. Schaefers3, T. Beyer1; ‘QIMP group, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, AUSTRIA, ‘Division of Biomedical Imaging, University of Leeds, Worsley Building, LIGHT Labs, LS2 9NL, Leeds, United Kingdom, Leeds, UNITED KINGDOM, ‘Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA, ‘European Institute for Molecular Imaging, University of Muenster, Muenster, GERMANY.
OP-689
A phantom evaluation of a commercial algorithm for photopenic artefact reduction in high contrast PET/CT and implications for 124I PET/CT
P. Braad, P. F. Høilund-Carlsen; Department of Nuclear Medicine, Odense University Hospital, Odense C, DENMARK.

OP-690
Evaluation of respiratory motion correction in PET/CT using a 3D printed phantom
J. H. Vilsbøll1, S. W. Hasler1, L. D. L. Duchstein1, J. E. Wilhelmi1, M. N. Lonsdale2; 1Technical University of Denmark, Copenhagen, DENMARK; 2Bispebjerg and Frederiksberg Hospital, Copenhagen, DENMARK.

OP-691
Evaluation of the Impact of Using TOF Technique on Metal Artifact Reduction in PET/CT Images
R. Sharifpour1,2, P. Ghafarian3,4, M. R. Ay1,2; 1Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF; 2Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF; 3Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Tehran, IRAN, ISLAMIC REPUBLIC OF; 4PET/CT and Cyclotron Center, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

OP-692
Acquisition optimization for Lutetium-177 SPECT quantification
D. M. V. Huizing1, B. J. de Wit - van der Veen1, E. J. Rijkhorst2, M. P. M. Stokkel1; 1Department of Nuclear Medicine, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, NETHERLANDS; 2Department of Medical Physics and Technology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, NETHERLANDS.

OP-693
M. Toth1, S. Nag1, Z. Jia1, J. Hagkvist1, J. Mukherjee1, A. Varrone1, C. Halldin1; 1Karolinska Institutet, Stockholm, SWEDEN; 1University of California-Irvine, Irvine, CA, UNITED STATES OF AMERICA.

OP-694
Quantitative PET of GABA-A receptor binding in gerbils after intra-peritoneal F-18-Flumazenil injection does not resemble accurate results obtained in rats after intravenous administration
M. Mamach1,2, M. Kessler1,2, J. P. Bankstahl1, T. L. Ross1, F. M. Bengel1, L. Geworski1, G. M. Klump1,2, G. Berding1,2; 1Hannover Medical School, Hannover, GERMANY, 2Cluster of Excellence Hearing4all, Hannover/ Oldenburg, GERMANY, 3University of Oldenburg, Oldenburg, GERMANY.

OP-695
In Silico, Design, Synthesis, Pre-clinical studies of [11CH3]-BTZ-MPP: PET neuroimaging agent for 5-HT1A /5-HT1A /5-HT1A Dimeric Serotonin receptors
P. Jha1,2, S. Chaturvedi1, P. P. Hazari1, S. Pal1, N. Jain1, A. K. Mishra1; 1Institute of Nuclear Medicine and Allied Sciences, DRDO, Delhi, INDIA, 2Indian Institute of Technology, Delhi, Delhi, INDIA.

OP-696
Head to head comparison of (R)-[11C]verapamil and [18F]MC225 in non-human primates; tracers for measuring P-gp function at the blood-brain barrier
J. Toyohara1, L. Garcia-Varela2, T. Kakiuchi3, O. Htoryuki3, S. Nishiyama1, T. Tago1, D. Vallez-Garcia1, R. Boellaard2, P. H. Elsinga2, H. Tsukada1, G. Luurtsema2; 1Tokyo Metropolitan Institute of Gerontology, Tokyo, JAPAN, 2University of Groningen, Groningen, NETHERLANDS, 3Hamamatsu Photonics, Hamamatsu, JAPAN.
OP-697 Identification and development of a highly specific monoacylglycerol lipase (MAGL) PET tracer 11C-PF-06809247

OP-698 Development of a radiolabeled ligand targeting 5-HT1 receptors in the brain
A. Takano1, V. Stepanov1, M. Svedberg1, J. Häggkvist1, L. Tari1, M. Töth1, R. Krasikova1, N. Amini1, C. Sanchez2, C. Bundgaard2, M. Jessing2, B. Bang-Andersen2, C. Halldin1; 1Karolinska Institutet and Stockholm County Council, Stockholm, SWEDEN, 2H. Lundbeck A/S, Lundbeck Research, Copenhagen, DENMARK.

R. Arakawa1, L. Chen2, M. Svedberg1, J. Häggkvist1, L. Tari1, M. Töth1, R. Krasikova1, N. Amini1, C. Sanchez2, C. Bundgaard2, M. Jessing2, B. Bang-Andersen2, C. Halldin1; 1Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, SWEDEN, 2Worldwide Research & Development, Pfizer Inc., Cambridge, MA, UNITED STATES OF AMERICA.

OP-700 Predictor factors of 68Ga-PSMA PET/CT positivity in biochemical recurrent Prostate Cancer.

OP-701 Ga-68 PSMA-11 PET-CT in the Evaluation of Newly Diagnosed Prostate Adenocarcinoma
N. Ergül, T. F. Çernek; Istanbul Training and Research Hospital, Istanbul, TURKEY.
OP-708
Non-invasive visualization of healing phase 2 after myocardial infarction (MI) using $^{68}$Ga-NOTA-anti-CD206-Nb: targeting mannose receptor (MR, CD206) on M2 macrophages

Z. Varasteh, A. Bartels, S. Mohanta, A. Steinsiek, Y. Li, M. Braeuer, N. López Armbruster, S. Nekolla, A. Habenicht, G. Raes, S. Hernot, H. Sager, M. Schweiger; 1Klinikum rechts der Isar, München, GERMANY, 2University Hospital of Ludwig-Maximilians-University, München, GERMANY, 3Klinik für Herz und Kreislaufkrankungen, München, GERMANY, 4Vrije Universiteit Brussel, Brussels, BELGIUM.

OP-709
Non-invasive visualization of atherosclerotic plaques using $^{68}$Ga-NOTA-anti-CD206-nanobody: targeting mannose receptor (MR, CD206) on M2 macrophages

Z. Varasteh, S. Mohanta, Y. Li, N. López Armbruster, M. Braeuer, S. Nekolla, A. Habenicht, H. Sager, G. Raes, S. Hernot, M. Schweiger; 1Klinikum rechts der Isar, München, GERMANY, 2University Hospital of Ludwig-Maximilians-University, München, GERMANY, 3Klinik für Herz und Kreislaufkrankungen, München, GERMANY, 4Vrije Universiteit Brussel, Brussels, BELGIUM.

OP-710
[68Ga]Pentixafor-PET/MRI for atherosclerotic plaque imaging

X. Li, D. Heber, X. Lu, X. Zhang, M. Mitterhauser, W. Wadsak, A. Haug, M. Hacker; 1Vienna General Hospital Medical University of Vienna, Vienna, AUSTRIA, 2Vienna General Hospital, Vienna, AUSTRIA, 3Beijing Anzhen Hospital, Capital Medical University, Beijing, CHINA, 4Ludwig Boltzmann Institute Applied Diagnostics, Vienna, AUSTRIA.

OP-711
Imaging of LFA1 in Atherosclerotic Plaques Using a Novel SPECT Radiotracer

E. J. Meester, B. J. Krenning, M. R. Bernsen, G. Doeswijk, E. H. de Blois, J. F. Norelbergen, M. de Jong, K. van der Heiden; 1Erasmus MC, Rotterdam, NETHERLANDS, 2University of New Mexico, Albuquerque, NM, UNITED STATES OF AMERICA.

OP-712
A Bradykinin Derivative Differentiates Vulnerable and Stable Atherosclerosis Plaques in Monkey

Y. Xu, Z. Zhang, K. Lin, Z. Liu; 1Peking University, Beijing, CHINA, 2BC Cancer Agency, Vancouver, BC, CANADA.

OP-713
Is FDG-PET/ CT a valuable diagnostic tool for verifying accelerated atherosclerosis secondary to diabetes mellitus in the aortic segments and large arteries?

G. G. Bural, D. A. Torigian, M. Houseni, M. K. Sozmen, A. Alavi; 1Izmir Katip Celebi University, Izmir, TURKEY, 2Hospital of the University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA, 3Liver Institute, Cairo, EGYPT.

OP-714
Diagnosis of Deep Venous Thrombosis and Pulmonary Embolism Using $^{18}$F-GP1 Positron Emission Tomography: An Exploratory Open-label Study


OP-715
Highlights Lecture

S. Fant; University of Bologna, Radiological Sciences - Nuclear Medicine, Bologna, ITALY.

OP-716
Highlights Lecture

C. Decristoforo; Universitätskliniken - Landeskrankenhaus Innsbruck, Medizinische Universität Innsbruck, Universitätsklinik für Nuklearmedizin, Innsbruck, AUSTRIA.
e-Poster Walks

E-PW01 Sunday, October 22, 2017, 08:30 - 09:30, e-Poster Walk Area, Level 2, Foyer A, Screen 1

Cardiovascular System: Vascular Inflammation

**Chairs:**
- W. Acampa (Naples, ITALY)
- H. Verberne (Amsterdam, NETHERLANDS)

**E-PW001**
The FDG-PET metabolic pattern, involving a low baseline-level and a subsequent increase, remains a landmark of less favorable outcome for the abdominal aortic aneurysms treated by endovascular prosthesis

_P. Marie_1, D. Pisonnier1, S. Bravetti1, R. Coscas1, M. Rouer1, S. Haulon1, D. Mandy1, J. Alsac1, S. Malikov1, N. Settembre1, Y. Goueffic1, O. More1, V. Roch1, E. Micard1, Z. Lamiral1, J. Michel1, P. Rossignol1; 1CHRU-Nancy, Vandoeuvre, FRANCE, 2CHU-Rouen, Rouen, FRANCE, 3Hôpital Ambroise Paré, Paris, FRANCE, 4CHRU-Lille, Lille, FRANCE, 5Hôpital HEGP, Paris, FRANCE, 6CHU-Nantes, Nantes, FRANCE, 7CHU-Besançon, Besançon, FRANCE, 8INSERM Bichat, UMR 698, Paris, FRANCE.

**E-PW002**
Prospective study comparing scintigraphy to radiolabeled leukocytes and 18F-FDG PET in patients suspected of vascular prosthesis infection

_J. Pinaquy, Sr._, M. Puges, X. Berard, J. Ruiz, F. Debordeaux, A. Desclaux, L. Stecken, S. Pereyre, L. Bordenave, C. Cazanave; CHU BORDEAUX, Bordeaux, FRANCE.

**E-PW003**
Comparison of 3 18FDG-PET visual interpretation scales for the diagnosis of vascular prosthesis infection

_J. Pinaquy, Sr._, M. Puges, C. Cazanave, J. Ruiz, F. Debordeaux, A. Desclaux, L. Stecken, S. Pereyre, L. Bordenave, X. Berard, CHU BORDEAUX, Bordeaux, FRANCE.

**E-PW004**
18-FDG Pet-TC as tool to evaluate the efficacy of tocilizumab as a steroid-sparing agent for the treatment of Giant Cell Arteritis with Large-Vessel Involvement: a real-life single-centre case series

_C. Oliani_1, G. Vitiello1, C. Orsi Battaglini1, N. Orsi Battaglini1, R. Di Dato1, S. Nicolas1, D. Cammelli1; 1Nuclear Medicine Unit, Hospital-University Careggi, Florence, ITALY, 2Experimental and Clinical Medicine Department, University of Florence, Florence, ITALY, 3Nuclear Medicine Unit, University of Florence, Florence, ITALY, 4Nuclear Medicine Unit, Hospital of Palermo, Palermo, ITALY.

**E-PW005**
Tissue-to-background-ratio in major arterial vessels - comparison of 18F-FDG and 18F-Fluoromethylcholine PET-CT

_J. Jamsek_1, M. Grmek, S. Hawlina, L. Lezaic; Klinični center Ljubljana, Ljubljana, SLOVENIA.

**E-PW006**
Correlation Between Vascular 18F-NaF Avidity and the Presence of Vascular Illness: A PET/CT Study

_J. F. Alban_1, P. Lapa1,2, M. Marques1, A. Albuquerque1, G. Costa1,2, J. Pedroso de Lima1,2,3; 1Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL, 2Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL, 3Instituto das Ciências Nucleares Aplicadas às Saúde (ICNAS), Coimbra, PORTUGAL.

**E-PW007**
Differences in semiquantitative 18F-FDG PET/CT findings of non-infectious and infectious inflammation

_V. Mergen_1, J. Einspieler1, M. Mustafa1, H. Wendorff1, K. Thumel1, M. Schwaiger1; 1Department of Nuclear Medicine, Klinikum rechts der Isar TU Muenchen, Munich, GERMANY, 2Clinic for Cardiovascular Surgery, Klinikum rechts der Isar TU Muenchen, Munich, GERMANY, 3Department of Nephrology, Klinikum rechts der Isar TU Muenchen, Munich, GERMANY.
E-PW008
18F-FDG PET/CT imaging for detection of aortic wall inflammation in patients with repaired coarctation of aorta
A. Georgakopoulos1, N. Pianou1, E. Oikonomou1, A. S. Antonopoulo1, I. Koutagiar1, P. Kaloumis1, M. Metaxas1, D. Tousouli2, S. Brili1, C. Anagnostopoulo1; 1Center for Experimental Surgery, Clinical and Translational Research, Biomedical Research Foundation, Academy of Athens, Athens, GREECE, 21st Department of Cardiology, ‘Hippokration’ Hospital, University of Athens Medical School, Athens, GREECE, 3Center of Systems Biology, Biomedical Research Foundation of the Academy of Athens, Athens, GREECE, 4Department of Informatics and Telecommunications, University of Athens, Athens, GREECE.

E-PW009
Activity Assessment of Large Vessel Vasculitis with F18-FDG-PET/CT
N. Schramm1, J. Ingenhoff2, C. Dechant3, F. Proft3, H. Schulze-Koops4, U. Hoffmann1, A. Rominger1, M. Czihal2; 1Department of Nuclear Medicine, Ludwig-Maximilians University Hospital, Munich, GERMANY, 2Division of Angiology, Department of Medicine IV, Ludwig-Maximilians University Hospital, Munich, GERMANY, 3Rheumatology Unit, Department of Medicine IV, Ludwig-Maximilians University Hospital, Munich, GERMANY, 4Rheumatology Unit, Department of Medicine IV, Ludwig-Maximilians University Hospital, Munich, GERMANY.

E-PW010
Clinical translation of the caspase 3/7 specific PET radiotracer [18F]ICMT-11 for measuring chemotherapy induced apoptosis in breast and lung cancer
S. Dubash1, S. Merchant1, K. Heinzmann1, F. Mauri1, I. Lavdas2, M. Inglese2, K. Kozlowski2, N. Rama2, N. Massou1, J. Steel1, A. Thornton1, A. K. Lim1, C. Lewanski2, S. Cleator4, R. C. Coombes4, L. Kenny4; 1Department of Surgery and Cancer, Imperial College London, London, UNITED KINGDOM, 2Department of Radiology, Imperial College Healthcare NHS Trust, London, UNITED KINGDOM, 3Department of Computer, Control and Management engineering Antonio Ruberti, University of Rome, La Sapienza, ITALY, 4Department of Surgery and Cancer, Imperial College Healthcare NHS Trust, London, UNITED KINGDOM.

E-PW011
18F-RPS-544: An Imaging Agent Targeting CXCR4. Imaging and Biodistribution
A. Amor-Coarasa, J. M. Kelly, S. Ponnala, C. Williams, Jr., Y. Vedyays, D. Kim, J. W. Babich; Weill Cornell Medical College, New York City, NY, UNITED STATES OF AMERICA.

E-PW012
In vitro characterization of [18F]THK5351 binding to melanin-containing cells
T. Tago1, T. Toyohara1, R. Harada1, S. Furumoto2, N. Okamura3, Y. Kudo3, J. Takahashi-Fujigasaki3, S. Murayama1, K. Ishii4; 1Tokyo Metropolitan Institute of Gerontology, Tokyo, JAPAN, 2Tohoku University, Sendai, JAPAN, 3Tohoku Medical and Pharmaceutical University, Sendai, JAPAN.

E-PW013
Alcohol-enhanced Cu-mediated radiofluorination
J. Zischler1, N. Kalks2, D. Modemann1, B. D. Zlatopolskiy1, B. Neumaier1; 1Forschungszentrum Jülich GmbH, Institute of Neuroscience and Medicine, JINM-5: Nuclear Chemistry, Jülich, GERMANY, 2University Clinic Cologne, Institute of Radiochemistry and Experimental Molecular Imaging, Cologne, GERMANY.

E-PW014
Novel 18F-labeled triarylphosphonium derivatives for mitochondria imaging
S. Furumoto1, T. Tominaga1, R. Akita1, A. Kazama1, Y. Ishikawa1, R. Iwata1, K. Ishiwata1; 1Tokyo Metropolitan Institute of Gerontology, Tokyo, JAPAN, 2Tohoku University, Sendai, JAPAN, 3Southern TOHOKU Research Institute for Neuroscience, Koriyama, JAPAN.

E-PW015
Synthesis and initial biological evaluation of [18F]fluorotryptophans ([18F]FTrps)
B. D. Zlatopolskiy1,2,3, J. Zischler1, H. Endepols1, M. Gulyev1, D. Schäfer1, E. A. Urusova1,2, B. Neumaier1; 1University Clinic of Cologne, Cologne, GERMANY, 2Forschungszentrum Jülich GmbH, Jülich, GERMANY, 3Max Planck Institute of Metabolism Research, Cologne, GERMANY.

E-PW016
Positron emission tomography imaging of glioblastoma with a monocarbohydrate-based contrast agent
H. Hong1, D. Yang1, D. Chen1, W. Lu1, X. He1; 1University of Michigan, Ann Arbor, MI, UNITED STATES OF AMERICA, 2Hannjiang University, Wuhan, CHINA.
E-PW017  
**The Evolving Role of Succinate in Tumor Metabolism**  
P. Garrigue1, A. Bodin-Huttin2, L. Balasse1, S. Fernandez3, W. Essalhi2, F. Dignat-George1, K. Pacak4, D. Taieb5, B. Guillet1; 1Aix-Marseille Université, Marseille, FRANCE, 2AP-Hôpital Marseille, Marseille, FRANCE, 3NIH, Bethesda, MD, UNITED STATES OF AMERICA.

E-PW018  
**The Preparation of Radiolabeled Aromatic Amino Acids via Cu-Mediated Radiouclideination of Ni-Complexes**  
A. S. Craig1,2, N. Kolks1, E. A. Urusova1, B. D. Zlatopolskiy1, B. Neumaier1; 1Institute for Neuroscience and Medicine, INM-5: Nuclear Chemistry, Forschungszentrum Julich, Julich, GERMANY, 2University Clinic of Cologne, Institute for Radiochemistry and Experimental Molecular Imaging, Cologne, GERMANY.

E-PW019  
**Development of a tumor-associated fetal protein derived peptide as a potential tool for the targeting of estrogen receptor positive breast cancer**  
S. M. Okarvi, I. Aljammaz; King Faisal Specialist Hospital and Research Center, Riyadh, SAUDI ARABIA.

E-PW020  
**Diagnosis of the sentinel lymphatic nodes in laryngeal and laryngopharyngeal cancer**  

E-PW021  
**PET/CT with 18F-FDG and 11C-Methionine for Assessment of Remission Status after Autologous Stem Cell Transplantation in Multiple Myeloma Patients**  
O. Mukhortova1, I. Aslanidis1, T. Katunina1, A. Rumjantzev1, A. Silchenkov1, M. Solovev1, L. Mendeleeva1; 1Bakoulev Scientific Center for Cardiovascular Surgery, Moscow, RUSSIAN FEDERATION, 2National Research Center for Hematology, Moscow, RUSSIAN FEDERATION.

E-PW022  
**Cancer Lesions Detectability Limits in the SPECT Breast Imaging**  
E. Stiliaris1, D. Mantas1, D. Zarketa1; 1National & Kapodistrian University of Athens, Athens, GREECE, ‘Institute of Isotopic Studies, Iatrikon Hospital, Athens, GREECE.

E-PW023  
**Impact of Postoperative Diagnostic 131I Whole Body Scan with SPECT-CT on Staging, Risk Stratification and Radioiodine Therapy Planning in Low Risk Differentiated Thyroid Cancer**  
W. Teeyasoontranon, T. Kaewchur, S. Namwongprom, A. Klaipetch, M. Eknaehachai; Division of Nuclear Medicine, Department of Radiology, Faculty of Medicine, Chiang Mai University, Chiang mai, THAILAND.

E-PW024  
**May 18F-Fluorocholine PET/CT Have A Role To Localize Parathyroid Adenoma In Patients With Negative 99mTc-MIBI?**  
F. Di Gregorio1, M. Rensi1, F. Vescini2, D. Capobianco1, F. Giacomuzzi1, G. Ferretti1, M. Povolato1, O. Geatti1; 1Department of Nuclear Medicine University Hospital, Udine, ITALY, 2Department of Endocrinology University Hospital, Udine, ITALY.

E-PW025  
**Sentinel node biopsy for bladder cancer using ICG-99mTc-nanocolloid**  
P. Meershoek1,2, E. M. Wit1, B. W. G. van Rhijn1, G. H. KleinJan1,2, E. Vegi3, M. L. Donswijk1, R. A. Valdés-Olmos1, H. G. van der Poel1, F. W. B. van Leeuwen1; 1Leiden University Medical Center, Leiden, NETHERLANDS, 2Netherlands Cancer Institute (NKI-AvL), Amsterdam, NETHERLANDS.

E-PW026  
**Correlation of hypoxia inducible transcription factor-1α, glucose transporter-1, carbonic anhydrase IX and FDG uptake in invasive ductal breast cancer**  
Y. Jeong, B. Choi, Y. Cho, S. Park, H. Oh, S. Kang; Catholic University of Daegu School of Medicine, Daegu, KOREA, REPUBLIC OF.

E-PW027  
**Effect of stem cell transplantation on breast cancer-related lymphedema quantified by lymphoscintigraphy**  
J. A. Simonsen1, S. Hvidsten1, J. A. Sørensen1,2, P. F. Høilund-Carlsen1,2, H. M. Toyesker1,2; 1University Hospital, Odense C, DENMARK, 2University of Southern Denmark, Odense C, DENMARK.
E-PW028
Comparison of Magnetic Resonance Imaging (MRI) and 18F-NaF PET/CT for Detection of Spinal Bone Metastases in high-Risk Patients with Breast Carcinoma
E. Panagiotidis, A. Mistry, A. Famworth, N. Seshadri, S. Virjanur; Royal Liverpool University Hospital, Liverpool, UNITED KINGDOM.

E-PW029
Evaluation of the Total Distribution Volume of 18FBPA in Normal Tissues of Healthy Volunteers by Non-Compartmental Kinetic Modeling
V. Romanov, K. Isohashi, E. Shimosegawa, T. Watabe, R. Beshr, J. Hatazawa; Osaka University Graduate School of Medicine Department of Nuclear Medicine and Tracer Kinetics, Osaka, JAPAN.

E-PW030
Uncertainty in activity measurements using radionuclide calibrators due to source geometry effects
C. Saldarriaga Vargas1, A. Carbutti2, J. Dabin1, K. Baete1, L. Struelens1; 1Belgian Nuclear Research Centre (SCK-CEN), Mol, BELGIUM, 2Politecnico di Torino, Turin, ITALY, 3UZ Gasthuisberg, Leuven, BELGIUM.

E-PW031
Accuracy, Repeatability and Reproducibility of xSPECT Quant Sensitivity Calibrations using a NIST-traceable Point Source
P. C. Holdgaard1, H. C. Larsen1, N. A. Bebbington2; 1Lillebælt Hospital, Vejle, DENMARK, 2Siemens Healthineers, Aarhus, DENMARK.

E-PW032
Determining the calibration factor of a SPECT/CT camera
L. Beels1, F. Lavent1, I. Decostere1, L. Tack2, C. Van de Wiele1, A. Maes1; 1AZ Groeninge, Kortrijk, BELGIUM, 2KU Leuven, Leuven, BELGIUM.

E-PW033
Impact of the modelling of charge collection on the simulation of SPECT recordings from semiconductor CZT cameras
L. Imbert1,2, J. Jurzcak4, G. Karcher1,2, P. Marie1,2,5; 1CHU Nancy, Vandoeuvre-lès-Nancy, FRANCE, 2Plateforme d’Imagerie Expérimentale Nancydate, Nancy, FRANCE, 3ADI, U947, Vandoeuvre-lès-Nancy, FRANCE, 4Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, FRANCE, 5Université de Lorraine, Faculté de Médecine, Nancy, FRANCE.

E-PW034
Simultaneous High-Sensitivity High-Resolution Molecular SPECT Imaging with Spinning Slit-Hole Collimator: A Monte Carlo Simulation Study
M. Ay1,2, H. Mahani1, G. Raisati1, A. Kamali-Ash1; 1Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 2Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

E-PW035
Accuracy of gamma camera efficiency determination using different experimental configurations
W. Zhao1,2, P. L. Esquinas1,2, X. Hou1, C. F. Uribe1, M. Gonzalez1, J. Beauregard3, Y. Dewaraja1, A. Celler4; 1Department of Physics and Astronomy, University of British Columbia, Vancouver, BC, CANADA, 2Medical Imaging Research Group, Department of Radiology, University of British Columbia, Vancouver, BC, CANADA, 3BC Cancer Agency, Vancouver, BC, CANADA, 4Vancouver Coastal Health Authority, Vancouver, BC, CANADA, 5Department of Radiology and Nuclear Medicine, Université Laval, Quebec City, QC, CANADA, 6Department of Medical Imaging, CHU de Quebec – Université Laval, Quebec City, QC, CANADA, 7Department of Radiology, University of Michigan Medical School, Ann Arbor, MI, UNITED STATES OF AMERICA.

E-PW036
Atlas-based pulmonary lobes segmentation implemented with MIM® for quantitative lung perfusion SPECT/CT analysis
C. P. L. Fulcheri1, C. Tranfaglia2, V. Reggioli1, A. Chiappinello1, R. Tarducci1, M. E. Dottorini1; 1Medical Physics Department, Hospital Santa Maria della Misericordia, Perugia, ITALY, 2Nuclear Medicine Department, Hospital Santa Maria della Misericordia, Perugia, ITALY, 3Physics and Geology Department, University of Perugia, Perugia, ITALY.
E-PW037
Development of a new phantom for DaTSCAN imaging

J. Taylor1, R. Holmes2, J. Fenner3; 1Sheffield Teaching Hospitals, Sheffield, UNITED KINGDOM, 2University Hospitals Bristol, Bristol, UNITED KINGDOM, 3University of Sheffield, Sheffield, UNITED KINGDOM.

E-PW038
SPECT-CT quantification of 131-Iodine - Reducing uncertainty with PSF modelling based reconstruction

L. Jenkins1, A. Sohlberg2; 1Queen Elizabeth Hospital Birmingham, Birmingham, UNITED KINGDOM, 2Hermes Medical Solutions, Stockholm, SWEDEN.

E-PW039
Impact of brain ventricle size on semi-quantitative index derived from 123-I-FP-CIT images using a novel 3D-striatum digital brain (3D-SDB)

H. Onishi1, A. Furuta1, K. Nakamoto1, M. Takayama1, H. Amijima2; 1Program in Health and Welfare Sciences, Graduate School of Comprehensive Scientific Research, Prefectural University of Hiroshima, Mihara, Hiroshima, JAPAN, 2Graduate School of Nursing, Hyogo University of Health Sciences, Kobe, Hyogo, JAPAN.

E-PW040
The role of [18F]FDG PET/CT in monitoring therapy with Lenvatinib in radio-iodine refractory differentiated thyroid cancer patients


E-PW041
Comparison of [18F]-fluorodeoxyglucose PET/CT, [18F]-FDG PET/CT and [131I] radioactive iodine diagnostic scan in patients of differentiated thyroid carcinoma with skeletal metastases: evaluation of the role of [18F]-FDG PET/CT in bony metastatic disease from differentiated thyroid cancer

R. V. Parghane, S. Basu; Radiation Medicine Center (BARC), Mumbai, INDIA.

E-PW042
Incremental value of ultrasonography in incidental focal thyroid uptake at 18F-FDG PET-CT.

W. Yao; College of Medicine, National Cheng Kung University, TAINAN, TAIWAN.

E-PW043
131I-SPECT/CT in the diagnosis and characterization of metastatic lesions in patients with differentiated thyroid carcinoma (DTC) in chronic follow-up

A. Spanu1, I. Gelo, L. Mele, B. Piras, S. Nuvoli, G. Madeddu; University of Sassari, SASSARI, ITALY.

E-PW044
Diagnostic Utility of Molecular and Imaging Biomarkers in Cytologically Indeterminate Thyroid Nodules: a Systematic Review and Meta-Analysis


E-PW045
Thyroid hormone withdrawal versus recombinant human TSH administration in radio-iodine therapy of thyroid cancer: comparison of I-131 effective half-life

K. Perisinakis1, C. Donas, A. Dimitraki, S. Koukouraki; University of Crete, Medical School, Heraklion, GREECE.

E-PW046
Analysis of long-term clinical follow-up outcome, demographic and histopathological risk factors in a large DTC series

C. Soydal, E. Ozkan, D. Nak, N. O. Kucuk, M. K. Kir; Ankara University Medical Faculty, Nuclear Medicine Department, Ankara, TURKEY.

E-PW047
FDG-PET can predict response to vandetanib treatment in patients suffering from advanced medullary thyroid carcinoma

R. A. Werner1; 1Johns Hopkins School of Medicine, The Russell H Morgan Department of Radiology and Radiological Science, Baltimore, MD, UNITED STATES OF AMERICA, 2Department of Nuclear Medicine, Universitätsklinikum Würzburg, Würzburg, GERMANY, 3National Cardiovascular Center, Osaka, JAPAN, 4Institute for Pathology, Hospital Augsburg, Augsburg, GERMANY, 5Medical Department II, Hospital Augsburg, Augsburg, GERMANY, 6Department of Internal Medicine
Introduction: The prognosis of medullary thyroid carcinoma (MTC) is poor using common chemotherapeutic approaches. However during the last years encouraging results of recently introduced tyrosine kinase inhibitors (TKI) such as vandetanib have been published. In this study we aimed to correlate the results of 18F-fluorodeoxyglucose ([18F]FDG) positron emission tomography (PET) imaging with treatment outcome.

Subjects and Methods: Eighteen patients after thyroidectomy with advanced and progressive MTC scheduled for vandetanib treatment underwent baseline [18F]FDG PET/CT prior to and a follow-up examination 3 months after TKI initiation. During further follow-up, restaging was assessed every 3 months according to RECIST. The predictive ability for progression-free (PFS) and overall survival (OS) was examined by investigating [18F]FDG mean/maximum standardized uptake values (SUVmean/max) of the metabolically most active lesion as well as by analyzing clinical parameters (tumor marker doubling times {calcitonin, carcinoembryonic antigen (CEA)}, prior therapies, RET mutation status, disease type).

Results: Within a median 3.6 years of follow-up, 9 patients showed disease progression after a median interval of 8.5 months and 8 patients died from their disease (median, 2.9y) after TKI initiation. Pre-therapeutic increased glucose metabolism with an SUVmean >4.0 could predict a significantly shorter PFS (PFS: 2.0y vs. 5.3y; p=0.04). Longer pre-therapeutic CEA doubling times were significantly related to prolonged PFS and OS (r>0.7, p<0.007, respectively). None of the other clinical parameters reached significance in response prediction. Conclusion: [18F]FDG PET/CT can serve as a prognostic tool in patients with advanced MTC treated with vandetanib. An elevated glucose consumption assessed by baseline PET was related to shorter PFS; therefore those patients need to be monitored more closely as compared to those with low FDG uptake at baseline. This project has received funding from the European Union’s Framework Programme for Research and Innovation Horizon 2020 (2014-2020) under the Marie Sklodowska-Curie Grant Agreement.

E-PW048
Successful redifferentiation of radioiodine refractory BRAF-mutated papillary thyroid cancer using dabrafenib
M. C. Kreissl1, A. Todica1, R. Dorn1, A. Pfeiffer1, C. Spitzweg1, P. Bartenstein1, P. Bartenstein1; 1Otto-von-Guericke Universität Magdeburg, Magdeburg, GERMANY, 2Klinikum Augsburg, Augsburg, GERMANY, 3LMU München, München, GERMANY.

E-PW049
Lowest effective 131I activity for lymph node metastases therapy of differentiated thyroid cancer patients; Dosimetry-based model for estimation
V. Stebner, J. Phaosricharoen, K. Hermann, W. Jentzen; Department of Nuclear Medicine, Medical Faculty, University Duisburg-Essen, Essen, GERMANY.

E-PW050
DNA damage in blood leukocytes after internal irradiation with 68Ga - in-vivo and in-vitro studies
S. Schumann1, H. Scherthari2, C. Lapa3, C. Bluener1, J. Müller1, A. K. Buck1, M. Port1, M. Lassmann1, U. Eberlein1; 1University of Würzburg, Würzburg, GERMANY, 2Bundeswehr Institute of Radiobiology affiliated to the University of Ulm, Munich, GERMANY.

E-PW051
Monte Carlo-Based Bremsstrahlung SPECT Reconstruction for Whole-Liver Dosimetry in Treatments with 90Y-Microspheres - Comparison with 90Y PET
J. Gustafsson1, K. KneSaurek1; 1Medical Radiation Physics, Clinical Sciences Lund, Lund University, Lund, SWEDEN, 2Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, UNITED STATES OF AMERICA.

E-PW052
Safety, efficacy and outcome of Y-90-resin-microspheres radioembolization in 73 patients with unresectable intrahepatic cholangiocarcinoma: a single center experience
A. Todica, K. J. Paprottka, F. Schäppe, M. Ingrisch, P. Bartenstein, P. M. Paprottka, H. Ilhan; University of Munich, Munich, GERMANY.
E-PW053  
**Quantitative Y-90 PET/CT for Dosimetry in Radioembolization**  
H. Lim1, N. Clinthorne1, M. Conti2, J. A. Fessler1, Y.K. Dewaraja1; 1University of Michigan, Ann Arbor, MI, UNITED STATES OF AMERICA, 2Siemens Healthcare Molecular Imaging, Knoxville, TN, UNITED STATES OF AMERICA.

E-PW054  
**Initial Experiences with Post-Interventional Imaging of Residual Yttrium-90 Activity Within Microsphere Delivery Systems using Next-Generation Digital Photon Counting PET/CT Technology**  
C. L. Wright1, K. Binzel1, J. Zhang1, D. Konate1, P. Maniawski2, M. V. Knopp1; 1The Ohio State University, Columbus, OH, UNITED STATES OF AMERICA, 2Philips Healthcare, Cleveland, OH, UNITED STATES OF AMERICA.

E-PW055  
**223Ra-Chloride Therapy: The First Multidisciplinary and Multicenter Italian Study**  
G. Boni1, S. Mazzari1, C. Cianci1, L. Galli1, A. Fanesi1, E. Borsati1, R. Bertulius1, L. Fratino1, C. Giobitti1, E. Lamas1, P. Ghedin1, E. Rodi Rizzini1, V. Dionisi1, S. Fant1, D. Volterrani1, F. Monaco1; 1Nuclear Medicine Department, pisa, ITALY, 2Medical Oncology Division, pisa, ITALY, 3Nuclear Medicine Unit, aviano, ITALY, 4Radiotherapy Unit, aviano, ITALY, 5Medical Oncology, aviano, ITALY, 6Nuclear Medicine Department, bologna, ITALY, 7Radiotherapy Unit, bologna, ITALY.

E-PW056  
**Age-adjusted risk factors for patients undergoing molecular radiotherapy**  
J. Thurston, G. Flieder; Royal Marsden Hospital, London, UNITED KINGDOM.

E-PW057  
**Bone metastases affect bone marrow response during 177-Lu-DOTATATE treatments**  
J. Svensson1, L. Hagmarker1, T. Rydén1, R. Hermann1, B. Wängberg1, A. Sundlov1, K. Sjögreen-Gleisner1, P. Bernhardt1; 1Institution of Clinical Sciences, Dep of Oncology, Göteborg, SWEDEN, 2Institution of Clinical Sciences, Dep of Radiation Physics, Göteborg, SWEDEN, 3Institution of Clinical Sciences, Dep of Surgery, Göteborg, SWEDEN, 4Clinical Sciences, Dep of Oncology and Pathology, Lund, SWEDEN, 5Clinical Sciences, Dep of Radiation Physics, Lund, SWEDEN.

E-PW058  
**3-Dimensional Dose Mapping after PRRT with 177Lu-DOTATATE/-TOC by One-Single Measurement after Four Days**  
R. A. Werner1, C. Lapa1, A. K. Buck1, M. Lassmann1, H. Hänscheid1; 1Department of Nuclear Medicine, Universitätsklinikum Würzburg, Würzburg, GERMANY, 2Johns Hopkins School of Medicine, The Russell H Morgan Department of Radiology and Radiological Science, Baltimore, MD, UNITED STATES OF AMERICA.

E-PW059  
**Detecting Prostate Cancer Bone Metastasis With 18F DCFBC (a PSMA Targeted Agent) Compared to 18F Sodium Fluoride**  
L. Lindenberg1, E. Mena Gonzalez1, I. Turkbey1, J. Shih1, E. Bergvall1, A. Lindenberg1, W. Dahut1, M. Pomper1, P. Choyke1; 1National Cancer Institute, Bethesda, MD, UNITED STATES OF AMERICA, 2Fort Belvoir Community Hospital, Ft Belvoir, VA, UNITED STATES OF AMERICA, 3Johns Hopkins University School of Medicine, Baltimore, MD, UNITED STATES OF AMERICA.
E-PW062
The Value of Somatostatin Receptor Imaging (SRI) in Patients with NENGI/G2 Pancreatic Neuroendocrine Neoplasms (pNENs) Base on Pathological and Clinical Follow-up.
S. J. Konsek1, A. Kolaisinska-Cwikla1, A. Lewczuk1, L. Sawicki1, M. Kidd4, A. Cichocki1, A. Nasirowska-Gutmejer1, M. Tenderenda1, J. B. Cwikla1, I. M. Modlin6; 1Faculty of Medical Sciences, University of Warmia and Mazury, Olsztyn, POLAND, 2MSC Memorial Cancer Centre and Institute Maria Sklodowska-Curie, Warsaw, POLAND, 3Medical University of Gdansk, Gdansk, POLAND, 4Wren Laboratories, Branford, CT, UNITED STATES OF AMERICA, 5Hospital Ministry of Internal Affairs, Warsaw, POLAND, 6Yale University, New Haven, CT, UNITED STATES OF AMERICA.

E-PW063
68Ga-PSMA-11 PET/CT in the evaluation of bone metastases in prostate cancer
C. Sachpekidis1, P. Bäumer2, B. A. Hadaschik3, U. Haberkorn1; 1Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, GERMANY, 2Department of Radiology, German Cancer Research Center, DKFZ, Heidelberg, GERMANY, 3Department of Urology, University Hospital Heidelberg, Heidelberg, GERMANY.

E-PW064
PSMA-PET MRI/TRUS robot-guided targeted prostate biopsy for detection and localisation of Primary prostate cancer
M. Mix1, K. Schaal1, M. Krönig1, V. Drendel1, U. Wetterauer1, W. Schultz-Seeemann1, C. A. Jilg1, P. T. Meyer1; 1University of Freiburg, Medical Center, Freiburg, GERMANY.

E-PW065
Usefulness of 18F-choline PET/CT to evaluate patients eligible for Radium-223 Dichloride Therapy
E. Biggi1, C. Fuccio1, F. Ottelevi1, F. D’Emidio1, L. D’Angelo1, A. Berbellini1; 1Nuclear Medicine Unit, Ospedale “C. G. Mazzoni”, Ascoli Piceno, ITALY, 2Diagnostic Radiology Unit, Ospedale “C. G. Mazzoni”, Ascoli Piceno, ITALY, 3Medical Physics Unit, Ospedale “C. G. Mazzoni”, Ascoli Piceno, ITALY.

E-PW066
64CuCl2 PET/CT and Fused-64CuCl2 PET/MRI in prostate cancer relapse. Comparison with 18F-Choline PET/CT, Fused-18F-Choline PET/MRI and multiparametric MRI
G. Ferrarazzo1, G. Bottino1, F. Paparo1, M. Puntoni1, L. Bucigalupo1, S. Zanardi1, A. DeCensi1, S. Righi1, E. Lopci1, M. Cabria1, A. Piccardo1; 1Ospedale Galliera, Genova, ITALY, 2Humanitas Research Hospital, Milano, ITALY.

E-PW067
Additional value of early [68]Ga-PSMA-11 PET imaging in the assessment of local recurrence in prostate cancer patients with biochemical recurrence
C. Uprimny1, A. S. Kroiss2, J. Fritz2, C. Decristofaro2, E. von Guggenberg3, B. Nilica3, J. Bektic3, W. Horninger3, J. I. Virgolini4; 1Medical University Innsbruck, Innsbruck, AUSTRIA.

E-PW068
177Lutetium PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer; assessment of response, clinical evaluation.
H. R. Rathore1, G. Bhat1, P. Aland1, C. Kannor1, C. Kale1, A. Parab1, P. Chaudhuri1, V. Lele1; 1Jaslok Hospital and Research Centre, Mumbai, INDIA.

E-PW069
One-step kit-based radiolabeled 68Ga-THP-PSMA for PET imaging of PSMA expression: Biodistribution and first clinical experience
S. Schmuck1; 1E.O. Ospedali Galliera, Genova, ITALY.

E-PW070
18F-Organotrifluoroborate Probes Targeting PSMA for PET Imaging of Prostate Cancer: One-step Radiosynthesis, High Tumor Uptake and High T:NT Ratios
M. L. Lepage1, H. Kua1, H. Merkens1, N. Colpa2, F. Bénard3, K. Lin3, D. M. Perrin1; 1University of British Columbia, Vancouver, BC, CANADA, 2BC Cancer Research Centre, Vancouver, BC, CANADA.

E-PW088
Monday, October 23, 2017, 08:30 - 09:30, e-Poster Walk Area, Level 2, Foyer B, Screen 5
M2M: PET/CT

Chairs: G. Limouris (Athens, GREECE) J. Mihailovic (Sremska Kamenica, SERBIA)

E-PW071
Usefulness of 18F-choline PET/CT to evaluate patients eligible for Radium-223 Dichloride Therapy
E. Biggi1, C. Fuccio1, F. Ottelevi1, F. D’Emidio1, L. D’Angelo1, A. Berbellini1; 1Nuclear Medicine Unit, Ospedale “C. G. Mazzoni”, Ascoli Piceno, ITALY, 2Diagnostic Radiology Unit, Ospedale “C. G. Mazzoni”, Ascoli Piceno, ITALY, 3Medical Physics Unit, Ospedale “C. G. Mazzoni”, Ascoli Piceno, ITALY.

E-PW08
One-step kit-based radiolabeled 68Ga-THP-PSMA for PET imaging of PSMA expression: Biodistribution and first clinical experience
S. Schmuck1; 1E.O. Ospedali Galliera, Genova, ITALY.

E-PW067
Additional value of early [68]Ga-PSMA-11 PET imaging in the assessment of local recurrence in prostate cancer patients with biochemical recurrence
C. Uprimny1, A. S. Kroiss2, J. Fritz2, C. Decristofaro2, E. von Guggenberg3, B. Nilica3, J. Bektic3, W. Horninger3, J. I. Virgolini4; 1Medical University Innsbruck, Innsbruck, AUSTRIA.

E-PW068
177Lutetium PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer; assessment of response, clinical evaluation.
H. R. Rathore1, G. Bhat1, P. Aland1, C. Kannor1, C. Kale1, A. Parab1, P. Chaudhuri1, V. Lele1; 1Jaslok Hospital and Research Centre, Mumbai, INDIA.

E-PW069
One-step kit-based radiolabeled 68Ga-THP-PSMA for PET imaging of PSMA expression: Biodistribution and first clinical experience
S. Schmuck1; 1E.O. Ospedali Galliera, Genova, ITALY.

E-PW08
Monday, October 23, 2017, 08:30 - 09:30, e-Poster Walk Area, Level 2, Foyer B, Screen 5
M2M: PET/CT

Chairs: G. Limouris (Athens, GREECE) J. Mihailovic (Sremska Kamenica, SERBIA)
E-PW071
2-deoxy-glucose is a Respiratory Substrate for Endoplasmic Reticulum of Murine Breast Carcinoma Cells: New View on PET-Imaging
V. Cossu1, S. Ravera2, S. Bruno3, A. Oren1, A. Buschiazzo1, A. Bellini1, F. Grillo1, M. Bauckneht2, M. Piana2, C. Ghersi3, S. Marbetti3, C. Marini1, G. Sambuceti4,5,6; 1Nuclear Medicine Unit, IRCCS AOU San Martino-IST, Genoa, ITALY, 2Pharmacy Department, Biochemistry Laboratory, University of Genoa, Genoa, ITALY, 3Pathology Unit, IRCCS AOU San Martino-IST, Genoa, ITALY, 4Department of Experimental Medicine, University of Genoa, Genoa, ITALY, 5Department of Health Sciences, University of Genoa, Genoa, ITALY, 6Department of Mathematics, University of Genoa, Genoa, ITALY, 7CNR Institute of Bioimages and Molecular Physiology, Milan, ITALY.

E-PW072
Assessment of pharmacokinetic properties of copper-64 and gallium-68 labelled NODAGANOC analogues for neuroendocrine tumours detection.
M. Asti1, R. S. B. H. Schreuder2, M. Iori1, P. C. Capponi1, S. Rubagotti3, G. Cicoria3, R. Zijlma2, G. L. K. van der Woude1, C. B. Yim3, P. Laverman2, H. H. Boersma1, P. H. Elsinga2, G. Luurtsema2; 1Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, ITALY, 2University Medical Center Groningen, Groningen, NETHERLANDS, 3S. Orsola-Malpighi University Hospital, Bologna, ITALY.

E-PW073
18F-FLT PET/CT imaging and inhibition of multiple signaling pathways downstream EGFR and MET receptors in resistant NSCLC
F. Iommelli1, V. De Rosa1, M. Monti2, C. Terlizz2, M. Panico1, S. Del Vecchio1; 1Institute of Biostuctures and Biomaging, National Research Council, Naples, ITALY, 2Department of Advanced Biomedical Sciences, University “Federico II”, Naples, ITALY.

E-PW074
New Sensitive Method For HEPES Quantification in [68Ga]-Radiopharmaceuticals
I. F. Antunes1, G. M. Franssen1, R. Zijlma1, G. L. K. van der Woude1, C. B. Yim1, P. Laverman2, H. H. Boersma1, P. H. Elsinga1; 1University Medical Center of Groningen, Groningen, NETHERLANDS, 2Radboud University Medical Center, Nijmegen, NETHERLANDS, 3University of Turku, Turku, FINLAND.

E-PW075
Effect of Selective Endothelin B Receptor Agonist IRL-1620 on [18F]FDG Uptake in a Mouse Model of Breast Cancer
A. Yatsyna, O. Sarhini, M. Bentourkia, R. Lecomte, S. V. Selivanova; Sherbrooke Molecular Imaging Centre, CRCHUS, Université de Sherbrooke, Sherbrooke, QC, CANADA.

E-PW076
Prediction of the synergistic efficacy of capcitabine and TAS-102 in mice with colon cancer xenografts using [18F]fluorothymidine positron emission tomography
S. Kim1, J. JUNG1, H. Lee1, H. Soh1, S. Lee2, S. Oh2, S. Chae3, J. Lee4, S. Lee4, Y. Hong4, T. Kim4, D. Moon5; 1Asan Institute for Life Sciences, Asan Medical Center, Seoul, KOREA, REPUBLIC OF, 2Department of Nuclear Medicine, Asan Medical Center, Seoul, KOREA, REPUBLIC OF, 3Department of Pharmacology, Chungnam National University College of Pharmacy, Daejeon, KOREA, REPUBLIC OF, 4Department of Oncology, Asan Medical Center, Seoul, KOREA, REPUBLIC OF.

E-PW077
[18F]-5-fluoroaminosuberic acid ([18F]FASu) superior to [18F]FDG in small animal PET/CT imaging of human xenografts
M. Colovic1,2, H. Yang3, H. Merkens4, L. Southcott1, N. Colpo2, J. Rousseau2, F. Benard2,3, P. Schaffer1,3; 1TRIUMF, Vancouver, BC, CANADA, 2British Columbia Cancer Research Centre, Vancouver, BC, CANADA, 3Department of Radiology, University of British Columbia, Vancouver, BC, CANADA.

E-PW078
Imaging Cancer Metastases in a Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Rodent Model Using (4S)-4-(3-18F-fluoropropyl)-L-Glutamate (FSPG) by Small-Animal PET/CT: a Preclinical Study
M. CHENG1, Y. Huang1, L. Hsin2, C. Shue1, Y. Chang1, R. Yen1, Y. Tien1; 1National Taiwan University Hospital, Taipei, TAIWAN, 2School of Pharmacy, Molecular Imaging Center, and Center for Innovative Therapeutics Discovery, National Taiwan University, Taipei, TAIWAN, 3National Taiwan University Hospital and Molecular Imaging Center, Taipei, TAIWAN.
E-PW079
Potential of PET imaging to monitor upregulation of NET-1 transporter
S. M. Turnock1, D. R. Turton1, D. M. Ciobota1, O. Yoge2, L. Chesler1, T. Wilson1, V. Gouverneur1, G. Smith1, G. Kramer-Marek2; 1The Institute of Cancer Research, Sutton, UNITED KINGDOM; 2University of Oxford, Oxford, UNITED KINGDOM.

E-PW080
Early response evaluation by 18F-FDG-PET influences management in gastrointestinal stromal tumor patients treated with neo-adjuvant intent
S. Farag1, N. Steeghs1, W. T. van der Graaf1,2, F. van Coevorden1, D. J. Grunthagen1, A. K. L. Reynolds1, P. A. Boonstra1, H. J. Gelderblom1, L. de Geus-Oei1,2; 1Antoni van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS; 2The Radboud University Medical Center, Nijmegen, NETHERLANDS; 1Institute of Cancer Research, London, UNITED KINGDOM; 1Erasmus Medical Center - Cancer Institute, Rotterdam, NETHERLANDS; 2University of Groningen, Groningen, NETHERLANDS; 3Leiden University Medical Center, Leiden, NETHERLANDS; 4University of Twente, MIRA Institute, Twente, NETHERLANDS.

E-PW081
The prognostic significance of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) with F18 FDG PET/CT in non-small cell lung cancer (NSCLC)
S. Göksel1, Y. Yürekli1, A. Cengiz1; Adnan Menderes University Medical School Department of Nuclear Medicine, Aydın, TURKEY.

E-PW082
Prediction of small early lung adenocarcinoma with aggressive histopathologic subtypes using PET and CT radiomic features
C. Liu, W. Choi, S. Riyahi, W. Lu, J. Oh, J. Deasy, P. Adusumilli, W. Weber; Memorial Sloan-Kettering Cancer Center, New York City, NY, UNITED STATES OF AMERICA.

E-PW083
Total lesion glycolysis of the primary tumour as a biomarker derived from pre-operative FDG PET/CT outperforms established prognostic parameters in oral squamous cell carcinoma
D. Weidt1, G. Spanier2, T. Reichert1, J. Meier1, D. Hellwig2, J. Große1; 1Department of Nuclear Medicine, University of Regensburg Medical School, Regensburg, GERMANY; 2Department of Oral and Maxillofacial Surgery, University Hospital Regensburg, Regensburg, GERMANY.

E-PW084
Adaptive 18F-FDG-PET-guided reirradiation for recurrent and second primary head and neck cancer
J. Schatteman1, D. Van Gestel1, D. Benvouts1, W. De Gersem1, G. De Kerf1, W. De Neve1, B. De Ost1, A. Olteanu1, S. Rottey1, T. Vercauteren1, F. Duprez1, L. Goethals1; 1Ghent University Hospital, Ghent, BELGIUM; 2Jules Bordet Institute, Brussels, BELGIUM; 3Antwerp University Hospital, Antwerp, BELGIUM.

E-PW085
Recurrent germinal tumor carcinoma: clinical and prognostic value of FDG-PET/TC
P. Alongi1, M. Picchio2, F. Caobelli3, M. Spallino4, L. Gionolfi5, M. Midiri1, L. Evangelista6; 1San Raffaele G.Giulio Institute, Cefalú, ITALY; 1IRCCS San Raffaele Scientific Institute, Milano, ITALY; 2Basel University Hospital, Basel, SWITZERLAND; 3University of Milano-Bicocca, Milano, ITALY; 4Veneto Institute of Oncology IOV - IRCCS, Padova, ITALY.

E-PW086
Costeffectiveness of second line diagnostic investigation in patients included in DANTE trial
E. Lopci1, E. Morenghi1, D. Tanzi1, S. Cavuto2, F. Lutman1, G. Chiesa1, E. Vanni1, A. Chiti1, M. Infante4; 1Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Milan, ITALY; 2IRCCS San Raffaele Scientific Institute, Milano, ITALY; 3Humanitas Gavazzeni, Bergamo, ITALY; 4AIOU, Verona, ITALY.

E-PW087
User-guided 3D active contour segmentation of complex-shaped tumours: an efficient semi-automatic approach in FDG PET thoracic oncology
F. L. Besson1,2, T. Henry1, C. Meyer1, V. Chevance1, V. Roblot1, E. Blanchet1, V. Arnould1, G. Grimol1, M. Chekroun1, L. Mobil1, F. Parent1, A. Sefarian1, S. Builfon1, D. Montani1, M. Humbert1, P. Chaumet-Riffaud1, V. Lebon1, E. Durand2; 1AP-HP Université Paris Sud, Le Kremlin Bicêtre, FRANCE; 2IRAM-UMR 8081 Université Paris-Sud Université Paris-Saclay CNRS, Orsay, FRANCE; 3CEA SHS, Orsay, FRANCE; 4C3MI, Clamart, FRANCE.
E-PW088
In-vivo tumour characterization of breast cancer using [18F]FDG-PET/CT and supervised machine-learning
L. Papp, T. Nakuz, H. Magometschnigg, M. Grahovac, T. Helbich, G. Karanikas, A. Haug, K. Pinker, T. Beyer, M. Hacker; Medical University of Vienna, Vienna, AUSTRIA.

E-PW089
Evaluation of diagnostic accuracy and impact of FDG PET/CT in pre-operative management of early breast cancers
P. Chandra, S. Nath, S. Kumar; MIOT international hospital, Chennai, INDIA.

E-PW090
Myocardial Technetium-99M Methylene Diphosphonate Uptake And Left Ventricular Motion In Transthyretin Related Cardiac Amyloidosis
F. Ticconi1, A. Nieri1, J. Calamia1, V. Ceriani1, F. Fiz2, M. Canepa1, M. Pennone1, M. Sicignano1, G. Villa1, S. Marbelli1, P. Gancitano1, G. Sambuceti1,2, C. Marin1; 1Department of Health Sciences, University of Genoa, Genoa, ITALY, 2Nuclear Medicine Unit, Department of Radiology, Uni-Klinikum, Tübingen, GERMANY.

E-PW091
Prevalence of heart failure in elderly patients with myocardial uptake on bone scan

E-PW092
Bone99mTC-DPD Scintigraphy: More Data To Confirm Its Utility For The Diagnosis OF TTR Heart Amyloidosis In Patients With Restrictive Hypertrophic Myocardiopathy
A. Mari Hualde, E. Ardila Manjarres, R. Pérez Pascual, J. Orcajo Rincón, A. Rotger Regí, L. Regueira Berenguer, J. Alonso Farto; Gregorio Marañón Hospital, Madrid, SPAIN.

E-PW093
Tc99m-DPD scan in the diagnosis of Cardiac Transthyretin Amyloidosis

E-PW094
A comparison between Tc99m-DPD and Tc99m-HDP myocardial uptake in the diagnosis of cardiac amyloidosis

E-PW095
Myocardial uptake of bone scintigraphic agents associated with cardiac amyloidosis in daily practice
S. Fukuzawa, S. Okino, T. Uchiyama, N. Kuroiwa, Y. Iwata, M. Inagaki; Funabashi Municipal Medical Center, Chiba, JAPAN.

E-PW096
Is there a relationship between clinical parameters and cardiac uptake in 99mTc-DPD scintigraphy in patients with cardiac amyloidosis?
E. Abou Jokh Casas, V. Pubul Núñez, M. Garrido Pumar, B. Sopena, A. Varela Roman, M. Pombo Pasin, J. Cortéz, S. Argibay, Á. Ruibal; Complejo Hospitalario Universitario Santiago de Compostela, Santiago de Compostela, SPAIN.

E-PW097
Clinical Utility of 99mTc-PYP and 201TI-Cl SPECT Imaging in Patients with Suspected Cardiac Amyloidosis
S. Ito, N. Kodani, K. Tanabe; Shimane University, Izumo, Shimane, JAPAN.
E-PW098
Florbetaben Whole-Body PET/MRI for Evaluation of Systemic Amyloid Deposition
S. Park, L. Baratto, P. Gulaka, R. Herfkens, R. Witteles, A. Iagaru; Stanford University School of Medicine, Stanford, CA, UNITED STATES OF AMERICA.

E-PW099
18F-FDG-PET/CT as a diagnostic tool in native valve endocarditis
I. Kouijzer1,2, M. Berrevoets1, E. Aarnzen1, M. Janssen1, J. de Vries1, A. van Dijk1, W. Oyen1,2, L. de Geus-Oei4,2, C. Bleeker-Rovers1; 1Radboudumc, Nijmegen, NETHERLANDS, 2University of Twente, Enschede, NETHERLANDS, 4The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UNITED KINGDOM.

E-PW100
Effect of blood flow on 18F-Florbetaben PET quantitation: a simulation study
S. Bullich1, N. Koglin1, G. Becker1, S. De Sant1, A. Jovalek1c, H. Barthel1, O. Sabri2, Piramal Imaging GmbH, Berlin, GERMANY, 1Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, GERMANY.

E-PW101
Can relative flow derived from dynamic 11C-PIB scans replace FDG scans in Alzheimer disease PET studies?
T. van der Goot, F. E. Reesink, D. E. Peretti, D. Vállez García, A. T. M. Willemsen, P. P. De Deyn, R. Boellaard; UMCG, Groningen, NETHERLANDS.

E-PW102
Different Patterns of Dopamine and Serotonin Dysfunction in Manic, Depressive and Euthymic Phases of Bipolar Disorder
S. Nikolaus, H. Müller, H. Hautzel; University Hospital Düsseldorf, Düsseldorf, GERMANY.

E-PW103
First quantification results for the new TSPO radioligand 18F-GE-180 in patients with multiple sclerosis
L. Vomacka1, N. L. Albert1, S. Lindner1, M. Unterrainer1, C. Mahler1, M. Brendel1, L. Ermoschkin1, A. Gosewisch1, A. Brunegra1, C. Buckley1, W. Trigg1, T. Kümpfel1, R. Rupprecht1, M. Kerschensteiner1, P. Bartenstein1, G. Böning1; 1Department of Nuclear Medicine, LMU Munich, Munich, GERMANY, 2Institute of Clinical Neuroimmunology, LMU Munich, Munich, GERMANY, 3GE Healthcare, Grove Centre, Amersham, UNITED KINGDOM, 4LEONI, Munich, GERMANY.

E-PW104
A. Niñerola-Baizán1,2, B. Martí-Fuster1, A. Martín-Pero1, R. Tudela1, M. Mayoral2, X. Setoain1, D. Ro2, J. Pavia1; 1Grupo de Imagen Biomédica, Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Barcelona, SPAIN, 2Unitat de Biofísica i Bioenginyeria, Facultat de Medicina, Universitat de Barcelona, Barcelona, SPAIN, 3Servicio de Medicina Nuclear, Hospital Clinic, Barcelona, SPAIN.

E-PW105
123I-Ioflupane scintigraphy in asymptomatic LRRK2-G2019S mutation carriers
I. Martínez-Rodriguez1, M. Jiménez-Alonso1, J. López-Defíl1, J. Infante2, M. Sierra3, J. Jiménez-Bonilla1, N. Martinez-Amador1, M. De Arcos-Torres1, F. Gómez-de la Fuente1, D. Meza-Escobar1, I. Banzo1; 1Nuclear Medicine Service, Marqués de Valdecilla University Hospital, Molecular Imaging Group (IDIVAL), University of Cantabria, Santander, SPAIN, 2Neurology Service, Marqués de Valdecilla University Hospital, IDIVAL, Centro de Investigación Biomédica en Red de Enfermedades Degenerativas (CIBERNED), University of Cantabria, Santander, SPAIN.

E-PW106
Impact of Resolution Recovery Reconstruction on Quantitative Analysis of PETCT beta-Amyloid Plaque Brain Imaging
R. T. Meades1, L. M. Perry1, K. S. Nijran1, Z. Win2; 1Radiological Sciences Unit, Imperial College Healthcare NHS Trust, London, UNITED KINGDOM, 2Nuclear Medicine Department, Imperial College Healthcare NHS Trust, London, UNITED KINGDOM.
E-PW107  Asymmetric Parkinson’s disease and effects of unilateral subthalamic nucleus deep brain stimulation on neural networks: a pilot PET study

P. David1, X. Palard-Novello1, S. Draper1, M. Verin1, F. Le Jeune1; 1Hôpital Européen Georges Pompidou, Paris, FRANCE, 2Centre Eugene Marquis, Rennes, FRANCE, 3Centre Hospitalier Universitaire, Rennes, FRANCE.

E-PW108  Cortical metabolic patterns related to CSF total tau, Aβ42 and phosphorylated tau protein in Alzheimer disease

A. Chiavarotti1, 2, M. Ricci1, A. Martarana1, F. Calabria1, P. Sannino1, O. Schiacci1, 2; 1Department of Biomedicine and Prevention, University Tor Vergata, Rome, ITALY, 2IRCCS Neuromed, Pozzilli, ITALY, 3Nuclear Medicine Unit, University La Sapienza, Rome, ITALY, 4Department of Neurosciences, University Tor Vergata, Rome, ITALY, 5Neuroimaging PET/MRI Research Unit, Institute of Molecular Bioimaging and Physiology, National Research Council, Catanzaro, ITALY.

E-PW109  18F-FDG PET brain in presurgical management of patients with periventricular nodular heterotopias related epilepsy: diagnostic features and long term outcome

C. E. Popescu1, C. Rossetti1, R. Mai1, R. Sara1, M. Milella1, D. Redaelli1, A. Liumi1, F. Caobelli2; 1Niguarda Hospital, Milan, ITALY, 2University Hospital Basel, Basel, SWITZERLAND.

E-PW110  Ultra-fast or Ultra-low Count Density Wholebody PET Imaging - Pushing the Envelope with Next-generation Digital PET

M. I. Knopp, J. Zhang, K. Binzel, R. Moore, M. Friel, C. L. Wright, M. V. Knopp; The Ohio State University, Columbus, OH, UNITED STATES OF AMERICA.

E-PW111  A Noise Smoothing Origin Ensemble Algorithm Based on Regional Filtering

K. Chuang1, C. Chiang1, H. Lin1, Y. Ni1; 1National Tsing-Hua University, Hsin-Chu, TAIWAN, 2Chang Gung University, Chang Gung Memorial Hospital, Taoyuan, TAIWAN, 3Institute of Nuclear Energy Research, Long-Tan, TAIWAN.

E-PW112  A Simultaneous Method for MRI-based Partial Volume Correction and Image Registration in Brain PET

M. Ibaraki, K. Matsubara, T. Kinoshita; Akita Research Institute of Brain and Blood Vessels, Akita, JAPAN.

E-PW113  A lesion detection study to evaluate a weight-based dose protocol combined with Pixon Planar Processing for wholebody bone scans

N. Gunson1, V. Militano2, N. Ali1, A. Spencer1, M. J. Memmo1, K. J. Saint1, J. D. Thompson1, I. S. Armstrong2; 1Christie Hospital, Manchester, UNITED KINGDOM, 2Central Manchester University Hospitals, Manchester, UNITED KINGDOM, 3University of Salford, Manchester, UNITED KINGDOM.

E-PW114  Image Quantitation for LEHR-collimated Tc-99m-TRODAT-1 SPECT: An Experimental Study with Striatal Phantom

M. Wu1, K. Lin1, B. Hsu2; 1Dept of Nuclear Medicine, Mackay Memorial Hospital, Taipei, TAIWAN, 2Nuclear Science and Engineering Institute, University of Missouri-Columbia, Columbia, MO, UNITED STATES OF AMERICA.

E-PW115  Initial Experience with a New PET/CT System Using SiPM Detectors

S. Park, L. Baratto, N. Hatami, G. Davidson, S. Srinivas, S. Gambhir, A. Jagaraju; Stanford University Medical Center, Stanford, CA, UNITED STATES OF AMERICA.

E-PW116  Improvements of game-theoretical image segmentation algorithm using PVE correction for nuclear medicine imaging

D. Borys1, K. Szczyuka-Borys1, J. Gorczewska1, A. d’Amico1; 1Institute of Automatic Control, Silesian University of Technology, Gliwice, POLAND, 2Department of Nuclear Medicine and Endocrine Oncology, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, POLAND, 3Department of PET Diagnostics, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, POLAND.

E-PW117  Large bed overlap and short acquisition time or vice versa?

T. Andersen, P. Braad, P. Holund-Carlsen; Odense University Hospital, Odense, DENMARK.
E-PW118
Optimal quantitative SUV metrics over wide range of lesion sizes in advanced image reconstruction (TOF and PSF) for PET
I. Shiri1, P. Ghafarian3, S. Ashrafinia4, A. Bitarafan-Rajabi4,5, M. Ay6,7, A. Rahmim4,8; 1Department of Medical Physics, School of Medicine, Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 2Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 3PET/CT and Cyclotron Center, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 4Department of Electrical and Computer Engineering, Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA, 5Cardiovascular Intervention Research Center, Rajaee Cardiovascular Medical and Research Center, Iranian University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 6Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 7Department of Medical Physics, School of Medicine, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 8Department of Radiology, Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA.

E-PW119
A demonstration of the concept of numerical twins in esophageal cancer patients
F. Orlhac1, C. Nioche1, S. Boughdad1,2, M. Soussan1,3, I. Buvat1; 1IMIV, CEA, Inserm, CNRS, Univ. Paris-Sud, Université Paris-Saclay, CEA-SHFI, Orsay, FRANCE, 2Department of Nuclear Medicine, Institut Curie – René Huguenin, Saint-Cloud, FRANCE, 3Department of Nuclear Medicine, Assistance Publique - Hôpitaux de Paris, Avicenne Hospital, Bobigny, FRANCE.
EP-0001
Conventional and microfluidic PET tracer synthesis on a novel synthesizer platform
C. Rensch 1, C. Frank 1, R. Salvamoser 1, G. Winter 1, S. Lindner 1, P. Bartenstein 1, F. Renser 1, A. Hienzsch 1, R. Hesse 1, H. Lankau 1, M. Müller 1, A. Hoepfner 1, V. Samper 1.
1GE Global Research, Garching near Munich, GERMANY, 2Department of Nuclear Medicine, University Hospital Munich LMU, Munich, GERMANY, 3GE Healthcare, Upplands Väsby, SWEDEN, 4ABX advanced biochemical compounds GmbH, Radeberg, GERMANY.

EP-0002
The Influence of Crystal Material and Size on the Sensitivity of Recently Developed SiPM Based Animal PET Scanner: a Monte Carlo Study
P. Ghahramani 1,2, N. Zeraatkar 1, N. Vosoughi 1, M. R. Ay 1,2.
1Radiation Medicine Engineering Department, Sharif University of Technology, Tehran, IRAN, ISLAMIC REPUBLIC OF, 2Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0003
Monte Carlo Based Performance estimation of breast PET scanners due to reduction of the ring diameter
A. Emami 1,2,3, H. Ghadiri 1,2, P. Ghafarian 1,2, M. Ay 1,2.
1Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 2Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 3International Campus, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0004
Measurement of 225 ps CRT on 20 mm thick monolithic LYSO and CeBr3 crystals using Temporal imaging
C. Tata Zafari 1, A. Ilitis 1, G. Zeufack Tadonkeng 1, L. Rodrigues 1, H. Snoussi 1, Damavan imaging, TROYES, FRANCE, 2Université de Technologie de Troyes, TROYES, FRANCE.

EP-0005
Design and Development of a Small-Animal PET Scanner Based on Pixelated Crystals and Silicon Photomultipliers
M. Ay 1,2, N. Zeraatkar 1, S. Sajedi 1, M. Taheri 1, S. Kaviani 1, S. Sarkar 1,2.
1Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 2Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0006
SiPM PET/CT vs. Standard PET/CT: A Pilot Study Comparing Semi-Quantitative Measurements in Normal Tissues and Lesions
L. Baratto 1, S. Park 1, N. Hatami 1, G. Davidzon 1, S. Srinivas 1, S. S. Gambhir 1, A. Iagaru 1.
1Stanford University, Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford, CA, UNITED STATES OF AMERICA, 2Stanford University, Radiological Sciences Laboratory, Stanford, CA, UNITED STATES OF AMERICA, 3Stanford University School of Medicine, Departments of Radiology, Bioengineering, Materials Science and Engineering, Stanford, CA, UNITED STATES OF AMERICA.

EP-0007
Optimization of the crystal thickness for a monolithic LYSO animal PET detector with anger and CSE positioning method using Monte Carlo simulation
A. Sanaat 1,2, M. Shamsaie 1, B. Teymorian 1, R. Hashemi 1,2, M. Ay 1,2.
1Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 1Department of Energy and Physics, Amirkabir University of Technology (Tehran Polytechnic), Tehran, IRAN, ISLAMIC REPUBLIC OF, 2Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 3Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.
EP-0008  
Performance Evaluation of a New High Resolution Non-human Primate (NHP) PET/CT System (LFER 150 PET/CT)  
Z. Sarnyai1, K. Nagy2, G. Patay2, M. Molnár2, G. Rosenqvist1, M. Tóth1, A. Takano1, B. Gulyás1, C. Halldin1, P. Major1, A. Varrone1; 1Karolinska Institutet, Stockholm, SWEDEN, 2Mediso Ltd., Budapest, HUNGARY.

EP-0009  
Design optimization of partial cylindrical PET scanner based on trapezoid-shaped block detector and monolithic crystals using Monte Carlo simulation  
P. Sheikhzadeh1,2, H. Ghadiri1,2, P. Geramifar3, P. Ghaffarian1,2, M. Ay1,2; 1Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 2Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 3Research Center for Nuclear Medicine, Shaniati Hospital, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 4Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of medical science, Tehran, IRAN, ISLAMIC REPUBLIC OF, 5PET/CT and Cyclotron Center, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0010  
Feasibility of Whole Body Dynamic Acquisitions using Digital PET/CT - A Preclinical Phase I Study  
K. Binzel1, J. Zhang1, M. I. Menendez2, M. Friel1, M. J. Knopp1, R. Moore1, C. L. Wright1, P. Maniawska1, M. V. Knopp1; 1The Ohio State University, Columbus, OH, UNITED STATES OF AMERICA, 2Philips Healthcare, Cleveland, OH, UNITED STATES OF AMERICA.

EP-0011  
Accuracy and precision of activity concentration measurements for GE Q.Metrix absolute SPECT quantification  
I. Armstrong; Central Manchester University Hospitals, Manchester, UNITED KINGDOM.

EP-0012  
Impact of Point-Spread Function on the Image Quality in Small-Voxel Reconstructions of 18F-FDG-PET Images  
N. Assink1,2, J. A. van Dalen1, D. Koopman1,2, H. Stevens1, C. H. Slump1, P. L. Jager1; 1Department of Nuclear Medicine, Isala, Zwolle, NETHERLANDS, 2MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, NETHERLANDS, 3Department of Medical Physics, Isala, Zwolle, NETHERLANDS.

EP-0013  
A Comparison Study on Two Novel Statistical Reconstruction Algorithms Developed for Slit-Hole Collimation Data in Small Animal SPECT Imaging  
H. Mahani1,2, G. Raisali1, A. Kamali-Asl1, M. Ay2,4; 1Nuclear Science and Technology Research Institute (NSTRI), Tehran, IRAN, ISLAMIC REPUBLIC OF, Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 2Research Center for Nuclear Medicine, Shaniati Hospital, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 3PET/CT and Cyclotron Center, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0014  
Development of Monte Carlo Simulation Based Quantitative Image Reconstruction for SPECT/CT  
K. Sakaguchi1,2,3, S. Yoshida1, S. Watanabe1,2, K. Matano1, M. Okumura1, M. Hosono1,2, K. Ishii4, T. Murakami4,5; 1Department of Radiology, Kindai University Hospital, Osaka, JAPAN, 2Division of Positron Emission Tomography, Institute of Advanced Clinical Medicine, Faculty of Medicine, Kindai University, Osaka, JAPAN, 3Laboratory of Radiation Biology, Department of Biological Science, Graduate School of Science, Osaka Prefecture University, Osaka, JAPAN, 4Department of Radiology, Kindai University, Osaka, JAPAN, 5PET/CT and Cyclotron Center, Kindai University, Osaka, JAPAN.

EP-0015  
Evaluation of optimized iterative reconstruction parameters using channelized Hotelling observer in brain receptor PET imaging  
K. Matsumoto1, H. Ogawa1, Y. Matsumoto1, G. Akamatsu1, M. Senda1, K. Murase1, K. Endo1; 1Kyoto College Of Medical Science, Kyoto, JAPAN, 2Institute of Biomedical Research and Innovation, Kobe, JAPAN, 3Graduate School of Medicine, Osaka University, Osaka, JAPAN.
EP-0016
The Impact of a Penalized Likelihood Reconstruction Algorithm on the Quantitative Evaluation of Hepatic Metastases Shown on 18F-FDG-PET/CT Studies - Preliminary Results
S. Czibor, Z. Varga, A. Fekéházy, L. Jorgov, B. Kári, B. Magyar, J. Tórók, G. Dabasi, T. Györke; Semmelweis University, Nuclear Medicine Centre, Budapest, HUNGARY.

EP-0017
Evaluation of FDG PET/CT lesion detectability and quantification harmonization
J. Devriese1, L. Beels2, E. Deboever1, B. Decru1, A. Maes2, C. Van de Wiele2, H. Potel1; 1KU Leuven campus Kortrijk, Kortrijk, BELGIUM, 2AZ Groeninge, Kortrijk, BELGIUM.

EP-0018
Phantom and Patient Analysis of the Impact Of Q.Clear Regularization in Texture Indices
G. Reynés-Llompart1, J. Robles-Barba1, E. Linares-Tello1, P. C. Notta1, J. Gil-Viciano1, A. Sabaté-Llobera1, J. L. Vercher-Condejero1, N. Calvo1, C. Gámez-Cenzano1, J. M. Martí-Climent1; 1PET Unit, Nuclear Medicine Department. IDI. Hospital Universitari de Bellvitge. IDIBELL, L’Hospital de Llobregat, SPAIN, 2Nuclear Medicine Department, Clinica Universidad de Navarra, Pamplona, SPAIN.

EP-0019
Improving Quantitative Accuracy with use of High and Ultra-high Definition PET/CT Reconstruction
K. Binzel1, J. Zhang1, R. Moore1, M. Friel1, P. Maniawski2, M. V. Knopp1; 1The Ohio State University, Columbus, OH, UNITED STATES OF AMERICA, 2Philips Healthcare, Cleveland, OH, UNITED STATES OF AMERICA.

EP-0020
Assessment of different reconstruction parameters for quantification of FDG-PET brain imaging
T. C. G. Moalosi1,2,3, P. Dupont3,4, A. Ellmann3,4, J. Warwick1, A. Doruyter1, M. Du Toit1, M. Mix1,2; 1Tygerberg Hospital (Nuclear Medicine), Cape Town, SOUTH AFRICA, 2Tygerberg Hospital (Medical Physics), Cape Town, SOUTH AFRICA, 3Stellenbosch University, Cape Town, SOUTH AFRICA, 4KU Leuven, Leuven, BELGIUM, 5University of Freiburg, Freiburg, GERMANY.

EP-0021
Accelerated 3D Detector Modelling using a Lookup-table based on GATE Simulations of a single Detector Block
H. Xu, J. Scheins, M. Lenz, C. Lerche, N. Shah; Forschungzentrum Juelich, Juelich, GERMANY.

EP-0022
Sub-centimeter lesion detectability in Point-spread function (PSF) and Time of flight (TOF) reconstructed PET images
I. Shiri1, P. Ghafarian2,3, A. Bitorafan-Rajabi1, M. Ay4,5; 1Department of Medical Physics, School of Medicine, Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 2Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 3PET/CT and Cyclotron Center, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 4Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 5Department of Medical Physics, School of Medicine, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0023
Impact of matrix size on metabolic tumor volume (MTV) and total lesion glycolysis (TLG) in PSF-based PET image
I. Shiri1, A. Rahmim2,3, S. Ashrafinia1, P. Geramifar4, A. Bitorafan-Rajabi1,5; 1Department of Medical Physics, School of Medicine, Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 2Department of Radiology, Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA, 3Department of Electrical and Computer Engineering, Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA, 4Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 5Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0024
Quantiﬁcation of 177-Lu and 131-I: a phantom study
J. Kupferschlaeger, H. Dittmann, S. Poß, C. la Fougère; University Hospital Tuebingen/ Nuclear medicine, Tuebingen, GERMANY.
EP-0025
The quantitative SPECT/CT scoring of MIBG cardiac scintigraphy to identify patients with Lewy body diseases
S. Matsuo, H. Wakabayashi, K. Nakajima, K. Okuda, H. Yoneyama, S. Kinuya; Kanazawa University, Kanazawa, JAPAN.

EP-0026
Relationship between image and clinical indices in the differential diagnosis of dementia using 18F-FDG-PET images and machine learning
M. Sakata, X. Wang, K. Ishii, Y. Kinura, K. Wagatsuma, K. Ishibashi, J. Toyohara, N. Yata, Y. Manabe; Tokyo Metropolitan Institute of Gerontology, Tokyo, JAPAN.

EP-0027
Noninvasive quantitation of rat cerebral blood flow using 99mTc-HMPAO without arterial blood sampling
C. Suzuki, M. Kosugi, Y. Magata; Hamamatsu University School of Medicine, Hamamatsu, JAPAN.

EP-0028
Dosimetric survey on administered activity of 11C-CHOLINE in PET/CT examinations in Sardinia from 2012 to 2016: a retrospective analysis
A. Loi, S. Zucca, M. Carta, D. De Vittor, G. Melis, S. Loi; Alliance Medical, Cagliari, ITALY.

EP-0029
Regional-wide survey on administered activity of 18F-FDG in PET/CT examinations in Sardinia

EP-0030
Plasma to blood ratio derived parent fractions for robust plasma input based kinetic analysis of dynamic 18F-FLT PET studies in NSCLC cancer patients
A. Avendaño-Estrada, G. Kramer, V. Frings, D. Vallez García, E. Smit, A. Lammertsma, O. Hoekstra, R. Boellaard; QuicConcept Consortium.

EP-0031
Importance of algorithms in SUV calculation. Quantitative comparison of differences in SUV obtained from OSEM and Q.Clear® algorithms. Our experience
M. Agolti, B. Moglia, J. Biurrun Manresa, J. Bustos; Clinica Modelo, Parana, ARGENTINA.

EP-0032
A quantitative functional and structural multiple sclerosis analysis: A 99mTcECD brain SPECT study with statistical parametric mapping SPM evaluation and voxel based morphometry VBM analysis of brain MRI using CAT12 toolbox
N. Chabi, R. Nemati, M. Assadi; Division of Biomedical Engineering (BME), The Persian Gulf Nuclear Medicine Research Center, Bushehr University of Medical Sciences, Bushehr, IRAN.

EP-0033
Prediction of chemotherapy response in osteosarcoma using multi-parametric PET/MRI texture feature
Y. Park, W. Kim, B. Byun, J. Kang, C. Kong, W. Song, I. Lim, Y. Lee, B. Kim, S. Lim, S. Woo; Korea Institute of Radiological and Medical Sciences, Seoul, KOREA.
EP-0034
An efficient software tool for measuring the total metabolic tumor volume in whole body PET

C. Nioche1, A. Cotterau2, M. Meignan3, I. Buvat2,1; 1Service Hospitalier Frédéric Joliot, Imiv, Cea, Inserm, Cnrs, Univ. Paris-sud, Université Paris Saclay, CEA-SHFi, Orsay, Orsay, FRANCE, 2Médecine Nucléaire, Lysa Im, Hôpital Teton et Hôpitaux Universitaires Henri Mondor, Paris, Paris, France, 3Lysa Im, Hôpitaux Universitaires Henri Mondor, Créteil, Créteil, FRANCE.

EP-0035
Motion detection for static objects imaged with CZT cardiac camera

A. Budzynska, M. Dziuk; Military Institute of Medicine, Warsaw, POLAND.

EP-0036
Monte-Carlo simulated amyloid PET for testing the performance of Partial Volume Correction methods

G. Salvador1,2,3, A. Niñerola-Baizán4,5, M. Garcia4, J. Pavía6, D. Ros1,7, J. Lombera8, J. Gisbert2, R. Sala-Llonch2; 1Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, SPAIN, 2Department of Biomedicine, University of Barcelona, Barcelona, SPAIN, 3Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Zaragoza, SPAIN, 4Servei de Medicina Nuclear, Hospital Clinic., Barcelona, SPAIN, 5Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, SPAIN, 6Alzheimer’s Disease and Other Cognitive Disorders Unit, Hospital Clinic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, SPAIN.

EP-0037
Group-Sequential Analysis May Allow for Early Trial Termination: Illustration by an Intra-Observer Repeatability Study

O. Gerke2,1, M. H. Vistrup1, U. Halekoh, P. Hailund-Carlsen1; 1Odense University Hospital, Odense, DENMARK, 2University of Southern Denmark, Odense, DENMARK.

EP-0038
A [11C]-(R)-PK11195 PET human brain template for spatial normalization in statistical parametric mapping of neuroinflammation

P. N. Schuck1, A. M. Marques da Silva1,2, C. M. Dartora1, C. S. Matushita1, B. Hochhegger1; 1Brain Institute, Porto Alegre, BRAZIL, 2PUCRS, Porto Alegre, BRAZIL.

EP-0039
Significantly Low Effective Dose from 18FDG PET/CT Scan Using Dose Reducing Strategies: “Lesser is Better”

M. U. Zaman1, N. Fatima1, A. Zaman3, M. Sajid3, S. Zaman3; 1Aga Khan University Hospital, Karachi, PAKISTAN, 2Dow Medical College, Dow University of Health Sciences (DUHS), Karachi, PAKISTAN, 3Karachi Institute of Radiotherapy And Nuclear Medicine (KIRAN), Karachi, PAKISTAN.

EP-0040
Reducing Radiophobia in Nuclear Medicine Patients

A. Shabestani Monfared1, M. Amiri1, J. Cameron1, A. Gholami1; 1Babol University of Medical Sciences, Babol, IRAN, ISLAMIC REPUBLIC OF, 2University of Wisconsin, Madison, WI 53706 USA, Madison, WI, UNITED STATES.

EP-0041
Radiation doses result from radioactive iodine therapy versus living quality

H. M. Yassin, R. M. Abdel-Halim; Cairo Univeristy, Cairo, EGYPT.

EP-0042
Dosimetry and Radiation Risk in Infants after 99mTc-MAG3 Scans


EP-0043
Effective dose of for medical workers during Y 90 microspheres radioembolization

K. Dalianis1, F. Vlachou1, R. Efthymiadou2, T. Pipkos2, J. Andreou2, G. Kollias1, V. Prassopoulos2; 1Medical Physics Department, Hygeia SA, Maroussi, GREECE, 2Nuclear Medicine & PET/CT Department, Hygeia SA, Maroussi, GREECE, 3PET/CT Department, Hygeia SA, Maroussi, GREECE.

EP-0044
Radiation exposure to Allied Health personnel handling blood specimens from patients receiving radioactive iodine-131 and recombinant human TSH stimulation

K. Loke; Singapore General Hospital, Singapore, SINGAPORE.
EP-0045
Occupational exposure for eye, thyroid and gonads to medical workers operating in a PET/CT facility
K. Dalianis, F. Vlachou, R. Efthymiadou, T. Pipikos, J. Andreou, G. Kallias, V. Prassopoulos; 1Medical Physics Department, Hygeia SA, Marousi, GREECE, 2Nuclear Medicine & PET/CT Department, Hygeia SA, Marousi, GREECE, 3PET/CT Department, Hygeia SA, Marousi, GREECE.

EP-0046
Automatic CT Dose Collection Software (OpenREM) for CT Dose Audits in PET/CT and SPECT/CT
T. Sanderson, J. Dickson; University College London Hospital, London, UNITED KINGDOM.

EP-0047
Area Monitoring in Radionuclide Treatment Ward, Surrounding Areas, and Radiation Exposure to Family Caregiver in Paediatric Patient Receiving High Dose 131Iodine-MIBG
K. Chuamsaamarkkee, N. Knumwang, S. Monthonwattana, W. Changmuang, K. Thongkla, P. Chareenphum, A. Kosittwanarerk, Y. Anongporjossakul, W. Chamosoonrat, C. Sritara; 1Ramathibodi Hospital, Mahidol University, Bangkok, THAILAND, 2Thailand Institute of Nuclear Technology (Public Organisation), Nakhonnayok, THAILAND.

EP-0048
Efficiency evaluation of Lead Rubber aprons in Nuclear medicine applications: an approach with Monte Carlo method
F. Di Matteo, F. Zagni, S. Vichi, G. Cicoria, D. Pancaldi, D. Mostacci, M. Marengo; 1Montecuccolino Nuclear Engineering Laboratory, Department of Industrial Engineering, University of Bologna, Bologna, ITALY, 2Medical Physics Department, University Hospital “S.Orsola – Malpighi”, Bologna, ITALY.

EP-0049
Ionising radiation exposure of children during the course of neuroblastoma or other oncological diseases due to diagnostic procedures- a preliminary report
J. Iwanowski, H. Piwowarska-Bilska, D. Skupinski, J. Peregud-Pogorzelski, A. Walecka, B. Birkenfeld; Pomeranian Medical University in Szczecin, Szczecin, POLAND.

EP-0050
Dose rates from diagnostic nuclear medicine patients
V. de Sousa, G. Cardoso, A. I. Santos; 1Serviço de Medicina Nuclear – Hospital Garcia de Orta, Almada, PORTUGAL, 2Novo Medical School – Universidade Nova de Lisboa, Lisboa, PORTUGAL.

EP-0051
Personnel dose saving in dispensing of beta emitters-labelled radiopharmaceuticals using automatic device
F. Fioroni, E. Grassi, M. Asti, C. Benini, G. Guidi, A. Versari, M. Iori; 1Medical Physics Unit, Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, ITALY, 2Nuclear Medicine Unit, Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, ITALY, 3Comecer SpA, Castel Bolognese (RA), ITALY.

EP-0052
Belgian Diagnostic Reference Levels for Radiopharmaceuticals in Daily Practice

EP-0053
Exposure of eye lens as a possible limiting factor?
J. Hudzietzova, M. Fülep, J. Sabol, J. Doležal, P. Povinec, D. Baček, D. Solívaj, Z. Zelenka; 1Faculty of Biomedical Engineering CTU in Prague, Kladno, CZECH REPUBLIC, 2Slovak Medical University, Bratislava, SLOVAKIA, 3Faculty of Safety Management of PACR, Prague, CZECH REPUBLIC, 4Department of Nuclear Medicine, University Hospital, Hradec Králové, CZECH REPUBLIC, 5Nuclear Medicine Clinic, BIONT, Bratislava, SLOVAKIA, 6 Slovak Legal Metrology, Bratislava, SLOVAKIA, 7NUVIA Dosimetry, s.r.o., Prague, CZECH REPUBLIC.

EP-0054
Radiation Protection and Dosimetry for worker used 18F-FDG
H. M. Yassin, M. S. El-Nagdy, A. Wahdan; 1Cairo University, Cairo, EGYPT, 2Helwan University, Cairo, EGYPT.

EP-0055
Estimation of Organ and Effective Doses for CT Scan During Whole Body PET/CT examination
L. Chipiga, V. Golikov, C. Bernhardsson; 1Institute of Radiation Hygiene after Prof. P.V. Ramzaev, St. Petersburg, RUSSIAN FEDERATION, 2Federal Almazov North-West Medical Research Centre, St. Petersburg, RUSSIAN FEDERATION, 3Scane University Hospital, Malmö, SWEDEN.
EP-0056
Effects of Nanoparticle and Radiation Doses on Red Blood Cells
J. Lee¹, M. Hur², S. Yang², K.-H. Yu², J. Park²; ¹Korea Atomic Energy Research Institute, Jeongeup, KOREA, REPUBLIC OF; ²Department of Chemistry, Dongguk University-Seoul, Seoul, KOREA, REPUBLIC OF.

EP-0057
Patient release after Lu-177 DOTATATE and Lu-177 PSMA 617 therapies
C. Mair, B. Worwitz, S. Buxbaum, I. J. Virgolini; LKH Universitätskliniken Innsbruck, Univ.-Klinik für Nuklearmedizin, Innsbruck, AUSTRIA.

EP-0058
Radiation dose rates of post Y90 therapy patients - Is it safe to nurse or visit them?
M. Tong, H. Cheng, J. M. Lara; National University Hospital, Singapore, SINGAPORE.

EP-0059
Justification of New Radiofarmaceuticals and Methods in Nuclear Medicine
A. Andersen, Sr.; Norwegian Radiation Protection Authority, Østerås, NORWAY.

EP-0060
Optimizing Administered Ga-68-DOTATOC Activity for PET Imaging
D. Koopman³, W. A. Noortman¹, P. L. Jager¹, N. Schreuder¹, C. H. Slump³, J. A. van Dalen³; ¹Isala, Department of Nuclear Medicine, Zwolle, NETHERLANDS, ²MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, NETHERLANDS, ³GE Healthcare Radiofarmacy, Zwolle, NETHERLANDS, ⁴Isala, Department of Medical Physics, Zwolle, NETHERLANDS.

EP-0061
Optimisation of Scintigraphic Imaging of the Novel Therapeutic Agent Ra223 in the Treatment of Metastatic Castration Resistant Prostate Cancer
S. Maguire¹, P. Giligan¹, M. Carson; Mater Private Hospital, Dublin 7, IRELAND.
EP-0069
Investigation of the axial sampling rate of helical mode multi-pinhole SPECT dedicated for human brain imaging with a Multi-Disk phantom
A. Forgacs, Á. Krizsán, I. Garai, S. Szabó; Scanomed Ltd, Debrecen, HUNGARY.

EP-0070
Comparison of estimated and measured pixel variance in Whole Body PET affecting SUV uncertainty
Á. K. Krizsán1, G. Nagy2, M. Szolik1, I. Garai1, M. Dahlbom1, L. Balkay2; 1ScanoMed Nuclear Medicine Centers, Debrecen, HUNGARY, 2Department of Nuclear Medicine, University of Debrecen, Debrecen, HUNGARY.

EP-0071
Robustness and reproducibility PET image radiomic features: the impact of delineation and segmentation
I. Shiri1, A. Rahimia2, H. Abdollahia1, P. Geramifar3, A. Bitarafan-Rajabi1; 1Department of Medical Physics, School of Medicine, Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 2Department of Radiology, Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA, 3Department of Electrical and Computer Engineering, Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA.

EP-0072
Comparison of estimated and measured isotope specific spatially variant point spread functions on the HRRT PET scanner
J. M. Anton Rodriguez1,2, G. Kokos1, M. Asselin1, F. Kotasidis2, P. Julyan3, A. Archer1, O. Morris1, J. C. Matthews1; 1Wolfson Molecular Imaging Centre-University of Manchester, Manchester, UNITED KINGDOM, 2Geneva University Hospital Faculty of Medicine, Geneva, SWITZERLAND, 3Christie NHS Foundation, Manchester, UNITED KINGDOM.

EP-0073
Computational 3D Preoperative Simulation As Useful Tool For Sentinel Lymph Node Detection In Breast Carcinoma Surgery
M. Matovic1, D. Nikolic2, N. Filipovic1, M. Jeremic1, S. Jankovic1, S. Ninkovic1, A. Cvetkovic2, M. Vlajkovic2; 1Dpt. of Nuclear Medicine Clinical Center Kragujevac, Kragujevac, SERBIA, 2University of Kragujevac Faculty of Engineering, Kragujevac, SERBIA.

EP-0074
Monte Carlo simulation of PET EC decay requires the modelling of electron bremsstrahlung and of long energy resolution tail
S. Walrand1,2; 1Université Catholique de Louvain, Brussels, BELGIUM, 2Institut Universitaire du Cancer de Toulouse, Toulouse, FRANCE.

EP-0075
Modelization of trues over prompts events ratio to optimize individual posology on a high-sensitive BGO PET/CT system
D. Vallot1,2, M. Bauriaud1, S. Brillouet1, L. Dierickx1, S. Kanoun1, S. Zerdoud1, F. Courbon1, O. Caselles1; Institut Universitaire du Cancer de Toulouse, Toulouse, FRANCE.

EP-0076
Comparison of SUVmax obtained by Non-Time of flight PET system with Time of flight PET system: a phantom based study
A. K. Jha1, A. R. Mithun1, A. D. Purankar1, N. C. Purandare1, S. Shah1, A. Agrawal1, V. Rangarajan1; Tata Memorial Hospital, Mumbai, INDIA.

EP-0077
Yield estimation for 62,63Zn via proton induced reactions using GEANT4
M. Rostampour1,2, M. Aboudzadeh-Rovaisi1, S. Sadeghi1, S. Hamidi1, S. Hosseini1; 1Department of Physics, Arak University, Arak, IRAN, ISLAMIC REPUBLIC OF, 2Nuclear Science and Technology Research Institute, Tehran, IRAN, ISLAMIC REPUBLIC OF.
EP-0078
Validation of the GAMOS Monte-Carlo Toolkit for Nuclear Medicine Dosimetry
P. Ritt1, K. Reuss1, J. C. Sanders2, N. Lanconelli3, M. Pacilio1, T. Kuwert1; 1University Hospital Erlangen, Erlangen, GERMANY, 2Pattern Recognition Lab, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, GERMANY, 3Department of Physics and Astronomy, Alma Mater Studiorum, University of Bologna, Bologna, ITALY, 4Department of Medical Physics, Azienda Ospedaliera S. Camillo Forlanini, Rome, ITALY.

EP-0079
Partial volume correction changes intra-tumoral heterogeneity in 18F-FDG PET
I. Shiri1, A. Rahimi2, G. Hajianfar1, H. Abdollahi1, P. Geramifar4, P. Ghafrani3, A. Bitorafan-Rajabi1; 1Department of Medical Physics, School of Medicine, Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 2Department of Radiology, Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA, 3Department of Electrical and Computer Engineering, Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA, 4Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 4Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 5PET/CT and Cyclotron Center, Masih Daneshmand Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 6Cardiovascular Intervention Research Center, Rajae Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0080
Relationship between intra-tumoral heterogeneity indices and metabolic parameters in 18F-FDG PET
I. Shiri1, H. Abdollahi1, P. Geramifar4, A. Bitorafan-Rajabi1; 1Department of Medical Physics, School of Medicine, Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 2Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 3PET/CT and Cyclotron Center, Masih Daneshmand Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 4Cardiovascular Intervention Research Center, Rajae Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0081
The role of 18F-FDG PET-CT in patients with fever of unknown origin
I. Kostadinova1, A. Demirev1, M. Baimakova1; 1Clinic of nuclear medicine, City Clinic Oncology, Sofia, BULGARIA, 2Military Medical Academy, Sofia, BULGARIA.

EP-0082
Thoracic duct lesion: Detection by 124I-heptadecanoic acid PET/CT
H. Petersen1, S. Inglev2, S. Hvidsten3, P. Høilund-Carlsen4, J. A. Simonsen; 1Department of Nuclear Medicine, Odense University hospital, Odense, DENMARK.

EP-0083
The value of dual-time FDG PET/CT for differentiating primary lung cancer from inflammatory nodules with an initial standard uptake value greater than 2.5 in a tuberculosis-endemic area, A preliminary retrospective study
J. Wang1, J. J. Wang2, C. Y. Pu2, J. G. Yang3; 1Chinese Armed force police General Hospital, Beijing, CHINA, 2Beijing Friendship Hospital affiliated to Capital Medical University, Beijing, CHINA.

EP-0084
Uptake patterns and peculiarities of metabolic tumor pointers on initial staging FDG PET/CT in patients with untreated primary gastrointestinal extranodal lymphomas
E. Alagoz1, K. Okuyucu1, S. Ince1, S. Ozaydın1, N. Arslan1; 1Gülnane Training and Research Hospital, Department of Nuclear Medicine, Ankara, Turkey, Ankara, TURKEY, 2Gülnane Training and Research Hospital, Department of Medical Oncology, Ankara, Turkey, Ankara, TURKEY.

EP-0085
Correlation of lymph node size with PSMA expression & SUVmax values on Ga-68 PSMA PET/CT imaging
B. Sönmezer1, E. Acar1, E. Erköyün1, G. Çapa Kaya2; 1Dokuz Eylül University, Faculty of Medicine, Department of Nuclear Medicine, Izmir, TURKEY, 2Dokuz Eylül University, Faculty of Medicine, Department of Public Health, Izmir, TURKEY.

EP-0086
18FDG PET-CT for Characterization of Adrenal Lesions in Cancer Patients
A. Tzonevska1, M. Garcheva2, I. Kostadinova; Acibadem City Clinic, Sofia, BULGARIA.
EP-0087  
**Ratio of mediastinal lymph node to primary tumor FDG uptake improves prediction of nodal metastases in lung cancer**  
F. Al-Lhedan, R. Klein, J. Gardner, L. S. Zuckier, W. Zeng; The Ottawa Hospital, Ottawa, ON, CANADA.

EP-0093  
**Towards Diagnostic Reference Levels in PET-CT in Finland**  
J. Liukkonen, S. P. Kaajalauto, P. M. Toroi, R. Bly; STUK - Radiation and Nuclear Safety Authority in Finland, Helsinki, FINLAND.

EP-0088  
**Artifacts and physiologic soft tissue activities on NaF PET/CT bone images**  
I. Sarikaya, A. Elgazzar, M. Alfeeli, A. Sarikaya;  
1Kuwait University Faculty of Medicine, Kuwait, KUWAIT,  
2Mubarak Al Kabeer Hospital, Kuwait, KUWAIT;  
3Trakya University Faculty of Medicine, Edirne, TURKEY.

EP-0094  
**Motion correction during dynamic FDG-PET/CT studies performed in the staging of breast cancer**  
T. Tokes, K. Kajáry, M. Dank, Z. Lengyel;  
1Semmelweis University Center of Oncology, Budapest, HUNGARY,  
2Pozitron PET/CT Center, Budapest, HUNGARY.

EP-0089  
**Normal tissue 18-FDG activities are similar after either 60 or 90 minute uptake**  
1Cardiff and Vale University Health Board, Cardiff, UNITED KINGDOM,  
2Cardiff University, Cardiff, UNITED KINGDOM.

EP-0090  
**Irisin, an exercise-induced hormone, targets glioblastoma tumor in vivo PET/CT imaging may serve as a novel theranostic agent**  
1Chang Gung Memorial Hospital, Taoyuan, TAIWAN,  
2National Taiwan University, Taipei, TAIWAN.

EP-0091  
**Somatostatine receptor PET/CT imaging in patients with sarcoidosis - preliminary report**  
J. Kunikowska, D. Pawlak, L. Królicki;  
1Nuclear Medicine Department, Medical University of Warsaw, Warszawa, POLAND,  
2National Centre for Nuclear Research, Radioisotope Centre POLATOM, Otwock, POLAND.

EP-0092  
**Liver-spleen axis: hepatic and splenic metabolic activities are linked**  
G. Keramida, A. Dunford, C. D. Anagnostopoulos, A. M. Peters;  
1Royal Brompton and Harefield Hospitals, NHS, FT, London, UNITED KINGDOM,  
2Brighton and Sussex University Hospitals NHS Trust, Brighton, UNITED KINGDOM,  
3Biomedical Research Foundation Academy, Athens, GREECE,  
4Brighton and Sussex University Hospitals NHS Trust, Clinical Imaging Sciences centre, Brighton Sussex medical School, Brighton, UNITED KINGDOM.

EP-0093  
**Mismatch Between68Ga-PSMA-HBED-CC PET/CT And mpMRI In Prostate Cancer Lesion Detection: Relation With Gleason Score, PSA Kinetics And Previous Therapy**  
G. Ferreira, I. Lucena Sampaio, L. Sobral Violante, J. Teixeira, H. Duarte; Instituto Português de Oncologia Francisco Gentil, Porto, PORTUGAL.

EP-0096  
**Measurement of urinary radiation dose of PET patient by using Compton camera**  
D. Kano, R. Enomoto, S. Hosokawa, R. Wakamatsu, T. Watanabe, Y. Nakagami, M. Yamaguchi;  
1National Cancer Center Hospital East, Kashiwa, JAPAN,  
2ICRR, University of Tokyo, Kashiwa, JAPAN,  
3University of Hirosaki, Hirosaki, JAPAN,  
4College of Science, Ibaraki University, Ibaraki, JAPAN,  
5Tokyo Metropolitan University, Tokyo, JAPAN.

EP-0097  
**Efects of iMAR on CT and PET reconstructions in patients with metal hip implants**  
P. Holdgaard, L. Grønnemark;  
1Sygehus Lillebælt, Vejle, DENMARK,  
2Siemens Healthineers, Århus, DENMARK.

EP-0098  
**[18F] - NaF positron emission tomography assessed microcalcifications in symptomatic and asymptomatic human carotid plaques**  
1University Medical Center Groningen, Groningen, NETHERLANDS,  
2University of Twente, Enschede, NETHERLANDS.
EP-0099
FDG-PET/CT for evaluation of inflammation in the lumbar spine following surgery for lumbar disc herniation
C. C. Støttrup1, M. Zadeh1, C. Constantinescu1, S. O’Neill1, M. Ø. Andersen1, A. Alavi1, P. Hailund-Carlsen1, 2, 1Lillebaelt Hospital, Middelfart, DENMARK, 2University of Southern Denmark, Odense, DENMARK, 1University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA, 2Odense University Hospital, Odense, DENMARK.

EP-0100
Diagnostic performance of 18F-FDG PET/CT semiquantitative analysis in the management of sarcoidosis
C. Altini, A. Niccoli Asabella, C. Ferrari, A. Cimino, C. Magarelli, E. P. Mossa, M. Fanelli, G. Rubini; Nuclear Medicine Unit, DIM, University of Bari “Aldo Moro”, bari, ITALY.

EP-0101
Comparisons of cerebral glucose metabolism and striatal DAT binding in PD patients with and without RBD
Q. Xu, P. Wu, C. Jiang, H. Yu, J. Wu, C. Zuo; Huashan Hospital of Fudan University, Shanghai, CHINA.

EP-0102
Quantification and Reduction of respiratory induced errors in attenuation correction of PET data using respiration averaged CT: a simulation study
P. Ghaftarian1,2, F. Fatemi1, P. Geramifar3, M. Ay1,2, 1PET/CT and Cyclotron Center, Masih Daneshvar Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 2Palliative Care Research Center, National Institute for Research and Development in Tuberculosis and Lung Diseases, Tehran, IRAN, 3Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0103
Is the incremental diagnostic value of Mammi PET higher than MRI on detection and characterization of breast lesions with equivocal conventional imaging modalities?
L. Pan, M. Sun; Fudan University Shanghai Cancer Center, shanghai, CHINA.

EP-0104
The diagnostic performance of a dedicated breast PET (MAMMI) in patients with small and dense breasts in China
L. Pan, M. Sun; Fudan University Shanghai Cancer Center, shanghai, CHINA.

EP-0105
FDG uptake in a dedicated breast PET (MAMMI): correlation with histopathological prognostic factors
L. Pan, M. Sun; Fudan University Shanghai Cancer Center, shanghai, CHINA.

EP-0106
Contribution of 18F-FDG PET/CT to conventional imaging techniques in the suspicion of recurrence in patients with uterine cervical cancer: preliminary results
P. Garcia - Talavera1, F. Gómez-Caminero1, C. A. Achury1, L. G. Díaz2, M. J. Doyague3, P. Soria4, J. Corredera5, B. Pérez1, P. Tamayo1, 1Nuclear Medicine Department, Hospital Universitario de Salamanca, Salamanca, SPAIN, 2Gynecology and Obstetrics Department, Hospital Universitario de Salamanca, Salamanca, SPAIN, 3Radiotherapy Department, Hospital Universitario de Salamanca, Salamanca, SPAIN.

EP-0107
Combined model-based and patient-specific dosimetry for 18F-DCFPyL, a PSMA-targeted PET agent
R. F. Hobs, D. Plyku, E. Mena, S. P. Rowe, Z. Szabo, S. Y. Cho, M. G. Pomper, G. Sgouros; Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA.

EP-0108
Determinants of C-X-C motif chemokine receptor CXCR4 Expression after myocardial infarction with [68Ga]Pentixafor-PET/CT in correlation with cardiac MRI
M. Kircher, T. Reiter, A. Schirbel, S. Kropf, R. Werner, G. Ertl, A. Buck, H. Wester, W. Bauer, C. Lapa; Uniklinikum Würzburg, Würzburg, GERMANY.
**EP-0109**  
**Development of low dose CT protocols with acceptable CT image quality for CTAC of PET data: Phantom Study**  
**Z. Mojabi**,1,2, **P. Ghafarian**1,4, **H. Ghadiri**,1,2, **M. Bakhshayeshkaram**1,4, **M. Ay**,1,2; 1Department of Medical Physics & Biomedical Engineering, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 2Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 3Institute for Chronic and Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 4PET/CT and Cyclotron Center, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

**EP-0110**  
**The relationship between Ga-68 PSMA accumulation intensity and Gleason score, PSA levels in primary staging and evaluation of biochemical recurrence of prostate cancer: The preliminary results**  
**G. Ege Aktas**,1, **V. Çağloğu**,1, **N. Can**,1, **H. Akdere**,1, **F. Ustun**,1, **G. Durmus Altun**1; 1Trakya University Medical Faculty Department of Nuclear Medicine, Edirne, TURKEY.

**EP-0111**  
**Application of F-18-Sodium Fluoride (NaF) dynamic PET-CT (dPET-CT) for defect healing: comparison of biomaterials in an experimental osteoporotic rat model**  
**C. Cheng**,1, **V. Ali**,1, **L. Pan**,1, **U. Thormann**,2, **R. Schnettler**,2, **A. Dimitrakopoulou-Strauss**,1; 1DKFZ, Heidelberg, GERMANY, 2University Hospital Giessen-Marburg GmbH, Giessen, GERMANY.

**EP-0112**  
**Correlation between FDG uptake in the lung and pulmonary function in sarcoidosis patients treated with infliximab**  
**M. Schwillens-Dirkx**,1, **M. Vredenduin**,1, **D. Hartmans**,1, **R. Keijers**; Sint Antonius Hospital, Nieuwegein, NETHERLANDS.

**EP-0113**  
**The value of SUVmax is related to major chemotherapy-related tumor markers expression and serum tumor markers in gastric adenocarcinoma patients**  
**X. Duan**,1; the General Hospital of Xi’an Jiaotong University, Xi’an, CHINA.

**EP-0114**  
**Adrenal Glands Uptake Patterns in 18F-Fluoroethylcholine PET/CT**  
**E. J. Bialek**,1,2, **P. Kwasiborski**2, **M. Dziuk**2,4, **A. Mazurek**2,2, **E. Witkowska-Patena**,1, **A. Gżewska**2,2, **S. Piszczek**2,2, **S. Osiecki**2; 1Affidea Mazovian PET/CT Centre, Warsaw, POLAND, 2Department of Nuclear Medicine, Military Institute of Medicine, Warsaw, POLAND, 3Angiology and Hemodynamics Laboratory, Regional Specialistic Hospital in Miedzylesie, Warsaw, POLAND.

**EP-0115**  
**Fluorodeoxyglucose-positron emission tomography disease activity assessment in patients with biopsy-proven giant cell arteritis**  
**M. Simó**1, **I. NAVALES**2, **J. MESTRES**1, **F. MARTINEZ**1, **R. SOLANS**1, **M. SALCEDO**1, **M. BARIOS**2, **J. CASTELL**1; 1HOSPITAL UNIVERSITARI VALL DE HEBRON, BARCELONA, SPAIN, 2UNITAT IDI. HOSPITAL UNIVERSITARI VALL DE HEBRON, BARCELONA, SPAIN.

**EP-0116**  
**Automated evaluation of normal uptake in different skeletal parts in 18F-sodium fluoride (NaF) PET/CT using a new convolutional neural network method**  
**S. Lindgren Belal**1, **M. Sadik**2, **R. Kaboteh**2, **O. Enqvist**3, **J. Ulén**4, **H. Kjölhede**5, **O. Bratt**2, **E. Trägårdh**1; 1Department of Clinical Physiology, Sahlgrenska University Hospital, Göteborg, SWEDEN, 2Department of Signals and Systems, Chalmers University of Technology, Göteborg, SWEDEN, 3Eigenvision AB, Malmö, SWEDEN, 4Department of Translational Medicine, Division of Urological Cancers, Lund University, Malmö, SWEDEN.

**EP-0117**  
**18FDG-PET/CT clinical impact in patients with pure testicular seminoma and residual retroperitoneal mass post-chemotherapy treatment**  
EP-0118
Clinical implications of FDG PET/CT in left ventricular assist device (LVAD) infection
J. M. Sohns1,2, H. Kröhn1,2, J. D. Schmitto1, A. Schöde1, A. Haverich1, F. M. Bengel1; 1Hanover Medical School, Hanover, GERMANY, 2abstract contributed equally, Hanover, GERMANY.

EP-0119
Assessment of Effective Dose estimation in hybrid imaging (PET/CT)
G. Tosi1, K. Marzo1, A. Chiti2, F. Zanca3; 1Humanitas Research Hospital, ROZZANO, ITALY, 2Humanitas University, ROZZANO, ITALY, 3GE Healthcare, BUC, FRANCE.

EP-0120
Impact of Specific Activity of 68Ga-PSMA-11 on its accumulations in PSMA-expressing Tumors
A. Ahad, H. Zhang, A. Sadique, S. Larson, N. Pillarsetty, W. Weber; Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.

EP-0121
Usefulness Of PET-CT In Non-Oncology Pathology: A Review Of Cases Of Patients Diagnosed With Erdheim-Chester Disease

EP-0122
18 F FDG PET/CT uptake patterns in the diagnosis of vascular graft infection
J. R. Orozco Cortés1, H. Bowles2, J. Ambrosioni3, G. Mestres4, M. Hernandez-Meneses5, M. Almela5, J. Llopis5, D. Fuster5, A. Moreno5, V. Riambau5, F. Lomeña5, J. Miró5; Hospital Clinic Endocarditis Study Group, Hospital Clinic Valencia, Valencia, SPAIN, 1Hospital Clinic Barcelona, Barcelona, SPAIN.

EP-0123
Polyostotic Fibrous Dysplasia in McCune-Albright Syndrome Resembling Malignant Bone Dissemination: Pitfalls in PET/CT Interpretation
G. Horvatic Herceg1, I. Bracic1, M. Hrabak Paar1, R. Petrovic1; 1Department of Nuclear Medicine and Radiation Protection, University Hospital Center Zagreb, Zagreb, CROATIA, 2Department of Diagnostic and Interventional Radiology, University Hospital Center Zagreb, Zagreb, CROATIA.

EP-0124
Persistent Pneumothoraces Observed Following Percutaneous Transthoracic Needle Biopsy of Lung Nodules Mandates Vigilance when Interpreting PET-CT Images
L. S. Zuckier, J. Sommerfeldt, T. L. Miao, A. Gupta; The Ottawa Hospital, Ottawa, ON, CANADA.

EP-0125
FDG PET/CT in multiple myeloma: dual time point imaging results can predict response to treatment in patients receiving high dose chemotherapy
B. Oestergaard1, R. Taghvaei2, A. L. Nielsen1, M. Z. Zirakchian3, W. Y. Raynor2, T. A. Asmussen1, P. Holdgaard4, T. Plesner2, N. Abildgaard5, P. F. Holund-Carlsen5; 1Odense University Hospital, Odense, DENMARK, 2University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA, 3University of Virginia, Charlottesville, VA, UNITED STATES OF AMERICA, 4Odense University Hospital, Odense, DENMARK, 5University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA, 6Vejle Hospital, Vejle, DENMARK.

EP-0126
FDG PET/CT in multiple myeloma: changed FDG uptake in the brain of patients receiving high dose chemotherapy
B. Oestergaard1, S. P. Shams2, J. H. Hwang2, M. Z. Zirakchian3, W. Y. Raynor2, A. L. Nielsen1, P. Holdgaard4, T. Plesner2, N. Abildgaard5, P. F. Holund-Carlsen5; 1Odense University Hospital, Odense, DENMARK, 2University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA, 3University of Virginia, Charlottesville, VA, UNITED STATES OF AMERICA, 4Odense University Hospital, Odense, DENMARK, 5University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA, 6Vejle Hospital, Vejle, DENMARK.

EP-0127
NaF-PET/CT in multiple myeloma: assessing bone remodeling at baseline in newly diagnosed myeloma patients compared to a healthy control group
B. Oestergaard1, M. Z. Zirakchian3, W. Y. Raynor2, R. Taghvaei2, A. L. Nielsen1, P. Holdgaard4, T. Plesner2, N. Abildgaard5, P. F. Holund-Carlsen5; 1Odense University Hospital, Odense, DENMARK, 2University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA, 3University of Virginia, Charlottesville, VA, UNITED STATES OF AMERICA, 4Odense University Hospital, Odense, DENMARK, 5University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA, 6Vejle Hospital, Vejle, DENMARK.
EP-0129
Role of F18-FDG-PET/CT in malignant otitis externa. Preliminary study

EP-0130
Role of 18F-FDG PET/CT in radiotherapy planning for patients with non-small cell lung cancer
P. Garcia-Talavera, M. Matias-Perez, C. Cigarrale, F. Gómez-Camino, L. A. Pérez-Romasanta, M. E. Martín, E. Martín, P. Tamayo; 1Nuclear Medicine Department. Hospital Universitario de Salamanca, Salamanca, SPAIN, 2Radiotherapy Department. Hospital Universitario de Salamanca, Salamanca, SPAIN.

EP-0131
TSPO Brain PET using [18F]FEPPA in a lipopolysaccharide induced animal model
W. Huang, Y. Huang, Y. Kuo, C. Shiue, H. Yeh; 1Department of Nuclear Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Taipei, TAIWAN, 2PET Center, Department of Nuclear Medicine, National Taiwan University Hospital, Taipei, TAIWAN, 3Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan, Taipei, TAIWAN, 4PET Center, Department of Nuclear Medicine, National Taiwan University Hospital, Taipei, Taipei, TAIWAN, 5Molecular Imaging Center, National Taiwan University, Taipei, Taiwan, Taipei, TAIWAN, 6Brain Research Center, National Yang-Ming University, Taipei, Taiwan, Taipei, TAIWAN.

EP-0132
Semi-quantitative assessment with PETRA soft-platform of 18F-Florbetaben PET in patients with cognitive impairment
R. Sánchez-Vañó, S. Prado-Wohlwend, M. Gómez-Rior, F. Segovia-Román, P. Sopena Novales, J. M. Gómez-Sáez, E. Uruburu-Garcia, M. Martinez-Lozano; 1Nuclear Medicine Department Hospital Nisa 9 de Octubre, VALENCIA, SPAIN, 2Nuclear Medicine Department Hospital Virgen de las Nieves, Granada, SPAIN, 3Dept. Signal Theory, Networking and Communications, UGR, Granada, SPAIN, 4Memory and Dementia Unit. Hospital La Magdalena., Castellón, SPAIN.

EP-0133
Tumour Primary and possible Pitfalls in Paediatric PET/CT
A. A. Nawwar, M. Abou Gabal, A. Tawakol, W. Omar, H. Mostafa; 1Faculty of Medicine, Cairo University, Cairo, EGYPT, 2National Cancer Institute, Cairo University, Cairo, EGYPT.

EP-0134
Radio-metabolomics: association between CT radiomics features and metabolic indices in 18F-FDG PET
I. Shiri, H. Abdollahi, P. Geramifar, A. Bitarafan-Rajabi; 1Department of Medical Physics, School of Medicine, Iran University of Medical Sciences, Tehran, IRAN, 2Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, IRAN, 3Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IRAN, 4Memorial & Multimodality Imaging: SPECT & SPECT/CT

EP-08
The influence of gene polymorphism, cctpqa1b, ctpc1405v, abc1, in the influence of myocardium ischemia with spect imaging, in patients with familial hypercholesterolemia
A. Jakovidou, V. Kolovou, A. Theodorakos, D. Degiannis, M. Koutelou, G. Kolovou; 1Onassis Cardiosurgery Center, Athens, GREECE, 2Nuclear Medicine Department Cardiology Department, Onassis Cardiac Surgery Center, Athens, GREECE.
EP-0136
Gastric & Intestinal Scintigraphy in Adhesive Small Bowel Obstruction
N. Kudryashova, P. Yartsev, A. Lebedev, E. Migunova, O. Sinyakova, I. Selina, E. Trofimova; Skifosovsky Research Institute for Emergency Medicine, Moscow, RUSSIAN FEDERATION.

EP-0137
Diagnosis of Urinary Leakage with Scintigraphy
E. Migunova, A. Pinchuk, B. Khubutia, N. Kudryashova, O. Sinyakova; Skifosovsky Research Institute for Emergency Medicine, Moscow, RUSSIAN FEDERATION.

EP-0138
LM/SL with SPECT/CT in cervical cancer: A Systematic Review of the Literature Data
T. Z. Belhocine1, M. Prefontaine2; 1Biomedical Imaging Research Centre (BIRC), Western University - London, ON, CANADA, 2London Health Sciences Centre (LHSC), Western University - London, ON, CANADA.

EP-0139
Added value of SPECT/CT over planar bone scintigraphy in the diagnosis and management of patients with breast or prostate cancer
A. Gafita1, M. Mereuta1, G. Andreies2; 1Iuliu Hatieganu’ University of Medicine and Pharmacy, Cluj-Napoca, ROMANIA, 2Department of Nuclear Medicine, County Emergency Clinical Hospital, Cluj-Napoca, ROMANIA.

EP-0140
An incidentally detected breast cancer on 99mTc-MIBI SPECT/CT parathyroid imaging
T. Costa, A. Sanches, C. Cruz, A. Pepe, D. Solano; Hospital Português, Salvador-BA, BRAZIL.

EP-0141
Usefulness of SPECT/CT with 99mTc-Methylene Diphosphonate Bone Scintigraphy in Patients with Chest Wall Pain
S. Park1, J. Hwang1, J. Park2, J. Hwang2; 1Soochunhyang University Hospital, Seoul, KOREA, REPUBLIC OF, 2Soochunhyang University Bucheon Hospital, Bucheon, KOREA, REPUBLIC OF.

EP-0142
Optimisation of acquisition duration in extremities SPECT/CT
A. C. A. Gomes Moura, A. Nunes, A. Eccles, F. Hassan, D. Dasgupta; Guy’s and St Thomas’ NHS Foundation Trust, London, UNITED KINGDOM.

EP-0143
Complex radionuclide evaluation of response to cardiac resynchronization therapy
V. Saushkin, K. Zavadovsky, I. Kostina, D. Lebedev, S. Popov; Cardiology Research Institute, Tomsk, RUSSIAN FEDERATION.

EP-0144
Rare parangangioma localizations caught by MRI and CT hybrid 123I-MIBG SPECT imaging.
M. Pontico, G. Follacchio, V. Frantellizzi, L. Cosma, M. Ricci, M. Liberatori, F. Monteleone, G. DeVincentis; Università di Roma Sapienza, Roma, ITALY.

EP-0145
Sagliker Syndrome in a Patient with Secondary Hyperparathyroidism and Chronic Renal Insufficiency: A Case Report
S. Shakeri, S. Zareparvar Moghadam, N. Ayati; Mashhad university of medical science, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-0146
Comparison of reporting outcomes for Simultaneous and Sequential perfusion SPECT in VQ SPECT/CT
C. Sibley-Allen, H. Ahmed, S. Johnson, D. Dasgupta; Guy’s and St Thomas’ NHS Foundation Trust, London, UNITED KINGDOM.

EP-0147
Manual fused single photon emission tomography/computed tomography in 123I-MIBG scintigraphy: a 13 years’ experience
M. F. Villani, M. Pizzoferro, A. Castellano, M. Longo, A. Serra, E. Villanucci, M. C. Garganese; Bambino Gesù Children’s Hospital, Rome, ITALY.

EP-0148
The usefulness of SPECT/CT and neck pinhole SPECT (P-SPECT) as complementary tools to planar parathyroid scintigraphy in hyperparathyroidism (HPT)
A. Spanu, S. Sanna, S. Galassi, M. Stazza, B. Piras, F. Chessa, A. Falchi, S. Nuvoli, G. Madeddu; University of Sassari, Sassari, ITALY.

EP-0149
Diagnostik Value of Quantitative 99mTc-DPD-SPECT/CT for the detection of prosthetic loosening in patients with hip- and knee joint replacement
M. Braun1, M. Cachovan2, G. Pagenstert3, A. H. Vija3, D. Wild1, M. Kretschmar1; 1University Hospital Basel, Basel, SWITZERLAND, 2Siemens Healthcare GmbH, Molecular Imaging, Forchheim, GERMANY.
EP-0150
Value of hybrid imaging in the detection of bone abnormalities in brucellosis
O. Ben Hamida, F. Hamza, I. Jardak, W. Amouri, M. Maaloul, F. Kallel, S. Charfeddine, K. Chourou, F. Guermazi; Habib Bourguiba Hospital, Sfax, TUNISIA.

EP-0151
Concordance Among SPECT-CT, Peroperative Gamma probe Sentinel Localisation and Patent Blue Dye Technique for mapping hidden Sentinel nodes in Early Stage Breast Cancer patients
M. Siddique, A. Hassan, H. Bashir, M. K. Nawaz, A. I. Khan; Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, PAKISTAN.

EP-0152
Challenges of low count in vivo imaging

EP-0153
Usefulness of examining hepatic functional volumetry with Tc-99m galactosyl serum albumin (GSA) using SPECT/CT in patients with liver disease
K. Maruyama, K. Utsumoni, N. Kan, Y. Konos, Y. Ueno, N. Tanigawa; Kansai Medical University, Hirakata, JAPAN.

EP-0154
SPECT/CT mapping of sentinel lymph nodes in patients with breast cancer
P. Krzhivitsky, S. Kanaev, S. Novikov, P. Krivorotko, N. Popova; Petrov research oncology institute, Saint-Petersburg, RUSSIAN FEDERATION.

EP-0155
Dual tracer SPECT/CT utilising the localization and exclusion of discordant spots
J. L. Pou, Sr., A. Arredondo, A. Balbuena; DIAGNOSTICO MAIPU, Buenos Aires, ARGENTINA.

EP-0156
Interobserver decreased variability by optimizing the SPECT/CT imaging fusion technique
J. L. Pou, A. Arredondo, A. Balbuena; DIAGNOSTICO MAIPU, Buenos Aires, ARGENTINA.

EP-0157
No added diagnostic value of contrast-enhanced CT versus low-dose CT in dual phase MIBI parathyroid SPECT/CT
T. B. Andersen, R. Aleksyniene, S. K. Boldsen, M. Gade, H. C. Bertelsen, L. J. Petersen; Aalborg University Hospital, Aalborg, DENMARK.

EP-0158
Collagen-based scaffolds and Non-Invasive SPECT/CT Bone Defect Pre-Clinical Imaging
E. Fragogeorgi, III, M. Rouchota, J. Daich, M. Georgiou, P. Bouziotis, G. Loudas; National Center for Scientific Research, Aghia-Paraskevi, GREECE.

EP-0159
Additional Value of SPECT-CT Versus SPECT in Progressive Necrotizing External Otitis Management
L. Zaabar, D. Ben Sellem, B. Letael, M. Ben Slimen; Salah Azaiez Institute, Ezzahra, TUNISIA.

EP-0160
SPECT CT in patients with non-specific hand and wrist pain
O. Ben Hamida, W. Amouri, F. Hamza, Y. Hentati, I. Jardak, F. Kallel, S. Charfeddine, Z. Mnif, F. Guermazi; Habib Bourguiba Hospital, Sfax, TUNISIA.

EP-0161
The Value of Somatostatin Receptor Imaging (SRI) in Patients with Broncho-Pulmonary Carcinoids (BPCs) including Large Cell NEC Base on Pathological and Clinical Follow-up
S. J. Konsek, M. Franeca, M. Lowczak, A. Kalasinska-Cwikla, A. Lewczkuk, M. Kid, A. Nasierowska-Guttmejer, M. Tenderenda, J. B. Cwikla, I. M. Modlin; Faculty of Medical Sciences, University of Warmia and Mazury, Olsztyn, POLAND.

EP-0162
Withdrawn
EP-0163
Withdrawn
EP-0162
Hepatobiliary Scintigraphy Combined With SPECT/CT In Predicting Liver Failure Before Major Hepatectomy: Preliminary Results Of The HIBA-Index At A Single Center
m. serenari1, c. pettinato1, l. zanoni1, c. collaud2, m. levorato1, l. esposito1, c. bonatti1, s. brocchi1, a. cappelli1, a. cucchielli1, r. golfieri1, a. d. piñaa, s. fanti1; 1sant’orsola-malpighi hospital, Bologna, ITALY, 2hospital italiano de buenos aires, Buenos Aires, ARGENTINA.

EP-0163
Use of wall-less radionuclide doped phantoms to determine the influence of non-active phantom walls in 99mTc and 123I SPECT/CT activity quantification and outlining of tissue volume
I. Ceric1, S. Leide-Svegborn2, M. Sydoff2,1; 1Clinical Physiology and Nuclear Medicine, Helsingborg, SWEDEN, 2Medical radiation physics, Malmö, SWEDEN.

EP-0164
Whole body SPECT/CT significantly improved inter-reader agreement compared to planar skeletal scintigraphy in detection of osseous metastases
R. Maklad1, Y. G. Abdelhafiz2, M. Abd Elkareem2, M. Abougabal2; 1South Egypt Cancer Institute, Assiut University, Assiut, EGYPT, 2Faculty of Medicine, Cairo University, Cairo, EGYPT.

EP-0165
Does whole body SPECT/CT significantly improve accuracy over planar skeletal scintigraphy in all cancer types?
M. Abd Elkareem1, Y. G. Abdelhafiz2, R. Maklad3, M. Abougabal2; 1Faculty of Medicine, Cairo University, Cairo, EGYPT, 2South Egypt Cancer Institute, Assiut University, Assiut, EGYPT.

EP-0166
Impact of reduced injected activity on the quantification of [18F]FLT and [18F]FDG SUV in NF2 patients with vestibular schwannomas
J. M. Anton Rodriguez1, I. Djoukhadap, P. Julyan1, D. Russell1, G. Evans1, A. Jackson1, J. C. Matthews1; 1Wolfson Molecular Imaging Centre-University of Manchester, Manchester, UNITED KINGDOM, 2Christie NHS Foundation, Manchester, UNITED KINGDOM, 3East Cheshire NHS Trust, Manchester, UNITED KINGDOM, 4Genomic Medicine, Central Manchester University Hospital, NHS Foundation Trust, Manchester, UNITED KINGDOM.

EP-0167
Accuracy of tumor segmentation from multi-sequence MRI and 18F-choline PET/CT for focal prostate cancer therapy applications
M. R. Pier1, P. Shankar1, J. Siddiqui1, V. Rogers1, L. P. Kunju1, J. Montgomery1, J. Hearn1, M. S. Davenport1; 1Turku PET Centre, University of Turku, Turku, FINLAND, 2Department of Medical Physics, Turku University Hospital, Turku, FINLAND, 3Turku PET Centre, Turku University Hospital, Turku, FINLAND, 4Institute of Biomedicine, University of Turku, Turku, FINLAND.

EP-0168
Early assessment of radiation treatment response in liver cancer by dual-tracers PET/MRI in preclinical study
Y. C. Chung1, C. Huang2, F. Chen2, C. Yu1, J. Hong2, T. Yen1; 1Chang Gung Memorial Hospital, Taiwan, Tao-Yuan, TAIWAN.

EP-0169
First use of Bruker Albira and ICON multimodal bed for acquisition of PET/CT/MRI images
J. D. Steinberg1, N. de Wit2, E. Semenova2; 1Netherlands Cancer Institute, Amsterdam, NETHERLANDS, 2World Leading Meeting.

EP-0170
Comparison of ZTE and atlas attenuation correction for brain [15O]H2O-PET/MR imaging
T. Hjørnevik1,2,3, A. P. Fandi1, M. Khalighi1, H. Gandhi2, D. Holley1, P.K. Gulaka2, B. Shen1, J. H. Park1, E. T. Chin1, G. Zaharchuk1; 1Oslo University Hospital, Oslo, NORWAY, 2Stanford University, Stanford, CA, UNITED STATES OF AMERICA, 3The Norwegian Medical Cyclotron Centre, Oslo, NORWAY, 4GE Healthcare, Menlo Park, CA, UNITED STATES OF AMERICA.

EP-0171
Total Activity method: A fully automated approach to calculate the image-derived input function from [18F]FDG PET/MRI brain studies
I. Shiyam Sundar1, I. Rausch1, O. Muzik1, L. Rischk1, A. Hahn1, T. Lanzenberger1, M. Hienert1, E. Maria Klebemass1, T. Traub-Weidinger1, T. Beyer1; 1Medical University Vienna, Vienna, AUSTRIA, 2Wayne State University School of Medicine, Detroit, MI, UNITED STATES OF AMERICA.

EP-0172
Multi-radiotracer PET/MR Truncation Correction by Segmentation of TOF-NAC-PET Images with F18-FDG, Ga-68 PSMA and O-15-H2O
J. Teuho1, V. Saunavaara2,3, M. Lahesmaa1, M. Teräs2,4; 1Turku PET Centre, University of Turku, Turku, FINLAND, 2Department of Medical Physics, Turku University Hospital, Turku, FINLAND, 3Turku PET Centre, Turku University Hospital, Turku, FINLAND, 4Institute of Biomedicine, University of Turku, Turku, FINLAND.
EP-0173
Impact of MR-based attenuation correction on the evaluation of time-activity-curves and time-to-peak analysis in F-18 PET/MRI
I. Rausch1, A. Ziterl1, A. Haug1, R. Aghamohammadi-Sareshti1, M. Fenchel1, M. E. Mayerhofer1, T. Beyer1, T. Traub-Weidinger1; 1Medical University of Vienna, Vienna, AUSTRIA, 2Siemens Healthcare GmbH, Erlangen, GERMANY.

EP-0174
Assessing the impact of different attenuation correction methods on clinical image-derived input functions extracted from 18F-FDG PET/MRI brain data
I. Rausch1, L. Shiyam Sundar1, O. Muzik1, L. Rischka1, A. Hahn1, R. Lansenberger1, M. Hienert1, E. Klebermass1, M. Fenchel1, T. Traub-Weidinger1, T. Beyer1; 1Medical University of Vienna, Vienna, AUSTRIA, 2Wayne State University School of Medicine, Detroit, MI, UNITED STATES OF AMERICA, 3Siemens Healthcare GmbH, Erlangen, GERMANY.

EP-0175
P. Padmanabhan, Z. Wang, C. Yang, K. K. GHOSH, C. Halldin, B. Z. Gulyás; LKC Medicine, NTU, Singapore, SINGAPORE.

EP-0176
Image fusion analysis of 18F-Choline-PET-CT studies in patients with recurrent or persistent hyperparathyroidism (HPTH)
J. Kronbichler, J. Röper-Kelmayr, J. Pilz, S. Jäger, M. Hatzl, H. Huber, M. Gabriel; Kepler University Hospital, Linz, AUSTRIA.

EP-0177
Image fusion analysis of 68Ga-PSMA-PET-CT and MRI for initial evaluation in suspected prostate carcinoma patients
J. Kronbichler, J. Röper-Kelmayr, J. Pilz, S. Jäger, M. Hatzl, H. Huber, M. Gabriel; Kepler University Hospital, Linz, AUSTRIA.

EP-0178
Monte Carlo Simulation for Scatter Correction in Brain PET/MRI based on GPU Acceleration
B. Ma1,2, L. Caldeira1,2, L. Tellmann1, P. Lahmann1, J. Scheins1, E. Kops1, H. Xu1, C. Lerche1, N. J. Shah1, U. Pietrzyk1,2, 1Institute of Neuroscience and Medicine (INM-4), Forschungszentrum Jülich GmbH, Jülich, GERMANY, 2Institute of High Energy Physics, Chinese Academy of Sciences, Beijing, CHINA, 3School of Mathematics and Natural Sciences, University of Wuppertal, Wuppertal, GERMANY.

EP-0179
Gadobutrol and 18F-FDG Do Not Interact When Combined in a Single Syringe for Combined Contrast PET/MRI
B. Wilk1,2, J. Hicks1, F. S. Prato1,2, J. D. Thiessen1,2; 1University of Western Ontario, London, ON, CANADA, 2Lawson Health Research Institute, London, ON, CANADA.

EP-0180
Feasibility of Multi-Week PET Studies with a Single Injection of 89Zr-phosphate on a Clinical PET/MRI
J. D. Thiessen1,2, J. Sykes1, L. Keenliske1, H. Biemaski1, J. Butler1, N. Cockburn1, D. E. Goldhawk1,2, R. T. Thompson1,2, F. S. Prato1,2; 1Lawson Health Research Institute, London, ON, CANADA, 2Western University, London, ON, CANADA.

EP-0181
PET/MRI technique role in Alzheimer disease
D. Viera1, R. Vardas1,3, J. M. Tavares1; 11NEGL, Faculty of Engineering, University of Porto, Porto, PORTUGAL, 2LABIOMEP, UISPA-LAETA-INEGI, Faculty of Engineering, University of Porto, Porto, PORTUGAL, 3Medical Imaging Research Unit, University of South Wales, Pontypridd, UNITED KINGDOM.

EP-0182
Effect of attenuation and its correction in brain PET/MR imaging: a phantom study
M. Soret1, J. J. M. Soto1, M. Khalifé1, A. Kas1; 1HU Pitié Salpetrière, Paris, FRANCE, 2Institut du Cerveau et de la Moëlle épinière, Paris, FRANCE.

EP-0183
11C-Choline, multiparametric MR and T2 mapping for the study of prostate cancer with simultaneous PET/MRI
E. A. Marino1,2, G. Peña1, R. Isoardi1, V. Rada1; 1FUESMEN, Mendoza, ARGENTINA, 2CNEA(Comision Nacional de Energia Atómica), Mendoza, ARGENTINA.

EP-0184
GE Signa Integrated PET/MR: NEMA NU 2-2007 Performance Characteristics for 68Ga PET Imaging
P. Caribi1, M. Koole1, S. Vandenberghhe1, T. Deller1; 1Medical Imaging and Signal Processing – MEDISIP, UZ Ghent; IMEC, Ghent, BELGIUM, 2National Council for Scientific and Technological Development – CNPq, São Paulo, BRAZIL, 3Division of Nuclear Medicine – UZ/ KU, Leuven, BELGIUM, 4General Electric Healthcare, Waukesha, WI, UNITED STATES OF AMERICA.
EP-0185  
**Assessment of acute response to bone loading in humans with 18F-NaF PET/MRI: a pilot study**  
B. Haddock¹, A. P. Fan², C. Suetta¹, F. Kogan², G. E. Gold¹,²; ¹Dep. of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Glostrup, DENMARK, ²Department of Radiology, Stanford University, Stanford, CA, UNITED STATES OF AMERICA.

EP-0186  
**18F-FDG PET/MR imaging in optimizing monitoring and management of patients with sarcoidosis**  
D. Jurgilewicz¹,², P. Szumowski¹,², M. Mojsak¹,², B. Kubas¹,², B. Kukłinska¹,², M. Hladunski¹,², A. Ameljan¹,², J. Myśliwiec¹,², R. Mroż¹,²; ¹Medical University of Białystok, Białystok, POLAND, ²Laboratory of Molecular Imaging Medical University of Białystok, Białystok, POLAND.

EP-0187  
**Longitudinal PET studies on bone uptake of F-18-fluoride in healthy mice with respect to age, sex and circadian rhythm**  
N. Beindorff¹, V. Dorau¹, K. P. Huang¹, C. Rosner², O. Schulze¹, M. Lukas², C. Lange², , E. J. Kosiolek¹, B. Gregor-Mamoudou¹, I. G. Steffen², W. Brenner²; ¹BERIC, Charité - Universitaetsmedizin Berlin, Berlin, GERMANY, ²Department of Nuclear Medicine, Charité - Universitaetsmedizin Berlin, Berlin, GERMANY.

EP-0188  
**In Vitro and In Vivo Bioaffinity Determination of FDG-Conjugated Magnetic Nanoparticles**  
V. Yasakci, P. Unak, O. Guldu, V. Tekin; Ege University, İzmir, TURKEY.

EP-0189  
**The influence of structural alterations on asymmetric cyanine 5 dyes on the photophysical properties and protein conjugation characteristics**  
S. J. Spa, A. Hensbergen, S. van der Wal, J. Kuij, T. Buckle, F. W. B. van Leeuwen; Leiden University Medical Center, Leiden, NETHERLANDS.

EP-0190  
**Optimization of cytotoxic T-cell activation by tracking of dendritic cell migration using reporter gene imaging**  
H. Lee¹, H. Lee², Y. Jeon³, S. Jeong³, S. Lee³, J. Lee³, B. Ahn³; ¹Dongnam institute of radiological & medical sciences (DIRAMS), Busan, KOREA, REPUBLIC OF, ²Kyungpook National University School of Medicine and Hospital, Daegu, KOREA, REPUBLIC OF.

EP-0191  
**Evaluation of non-peptidic small molecule targeted imaging and therapeutic agents LHRH receptor expressing tumors**  
J. Roy¹,², P. S. LOW²; ¹National Cancer Institute, Bethesda, MD, UNITED STATES OF AMERICA, ²Purdue University, West Lafayette, IN, UNITED STATES OF AMERICA.

EP-0192  
**Lysine as a versatile platform for the design of multimodal (optical/SPECT or PET) imaging probes**  
C. Goze¹, C. Bernhard¹, N. Maindron¹, M. Ipuy¹, D. Lhenry¹, M. Moreau¹, V. Thakare¹, A. Dubois¹, F. Boschet¹, F. Denat¹; ¹ICMUB, Dijon, FRANCE, ²Chematex, Dijon, FRANCE.

EP-0193  
**Pretargeted imaging of peritoneal carcinomatosis using bioorthogonal chemistry**  
A. Rondon¹,², N. Ty¹, J. Bequignat¹, M. Quintana¹, A. Briat¹, T. Witkowski¹, R. Bouchon¹, C. Boucheix¹, E. Miot-Noirault¹, J. Pouget¹, J. Cheza¹, I. Navarro-Teulon², E. Moreau¹, F. Degoul¹; ¹INSERM U1240, Clermont-Ferrand, FRANCE, ²INSERM U1194 IRCM, Montpellier, FRANCE, ³INSERM U935, Villejuif, FRANCE.

EP-0194  
**3D tumor margin demarcation combined with sentinel node resection using the hybrid tracer ICG-99mTc-nanocolloid**  
P. Meershoek¹,², N. S. van der Berg¹, G. H. KleinJan¹,², C. A. H. Lange¹, B. van der Heil¹, R. A. Valdés-Olmos³, W. M. C. Kloot³, A. J. M. Balm³, F. W. B. van Leeuwen³; ¹Leiden University Medical Center, Leiden, NETHERLANDS, ²Netherlands Cancer Institute (NKI-Avl), Amsterdam, NETHERLANDS, ³Leiden University Medical Center, Leiden, NETHERLANDS.
EP-0195 Utility of combined CT coronary angiography and SPECT myocardial perfusion imaging for the detection of functionally relevant coronary stenoses
P. Mohan, A. Vaidya, U. Kaul, H. Mahajan; Mahajan Imaging, NEW DELHI, INDIA.

EP-0197 Engineered DOTA antibody reporter with infinite affinity for in vivo tracking of lymphocytes
S. Krebs1, A. Ahadi1, H. Zhang1, C. Bajer1, S. M. Larson1, S. Gottschalk2, P. Adusumilli1, S. Mamarev1, W. A. Weber1; 
1Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA, 2Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, UNITED STATES OF AMERICA.

EP-0198 Development of PET in Europe
A. Stevens; Medical Options, London, UNITED KINGDOM.

EP-0199 Tumor alignment in proton therapy using the onboard functional imaging
H. Lin1,2, H. Chang1, T. Chao1,2, Y. Ni1,4, C. Shih1, K. Chuang1; 1Medical Physics Research Center, Institute for Radiological Research, Chang Gung University/Chang Gung Memorial Hospital, Taoyuan, TAIWAN, 2Department of Radiation Oncology, Chang Gung Memorial Hospital, Taoyuan, TAIWAN, 3Environmental Protection and Chemistry Section, Kuosheng Nuclear Power Station, Taiwan Power Company, New Taipei, TAIWAN, 4Department of Medical Imaging and Radiological Sciences, College of Medicine, Chang Gung University, Taoyuan, TAIWAN, 5Health Physics Division, Institute of Nuclear Energy Research, Atomic Energy Council, Taoyuan, TAIWAN, 6Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu, TAIWAN, 73D Printing Medical Research Center, China Medical University Hospital, China Medical University, Taichung, TAIWAN.

EP-0200 Development Of Multimodal Mannosylated Dextran For Sentinel Lymph Node Localization With SPECT/ PET And Optical Imaging
A. Shegani1, A. Papasaavedra2, S. Al-Qattan3, C. Karachaliou4, L. Palamaris1, C. Krintz1, C. Skalas1, C. Triantis1, G. Loudos1, P. Kyriakos5, A. Bontzios1, M. Pelecanou2, M. Papadopoulou1, I. Perimettis1; 1INRSTES, NCSR DEMOKRITOS, ATHENS, GREECE, 2IB-A, NCSR DEMOKRITOS, ATHENS, GREECE.

EP-0201 A Total Synthesis of High Optically Pure 18F-FP-(+)-DTBZ and Its Validation as a PET Imaging Agent for VMAT2
P. Zou, C. Liu, X. Li, J. Tang, C. Zhao, Z. Chen; Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, CHINA.

EP-0202 [18F]Fluoride retention and elution in a SAX microcartridge included in a lab-on-chip for radiopharmaceuticals
L. Fernandez-Maza1, B. Salvador2, A. Cortad2, D. Orta-Castello1, J. Fernandez-Gomez1, A. Luque1, J. Quero-Reboul3; 1Centro Nacional de Aceleradores. Universidad de Sevilla. CSIC. Junta de Andalucia, Seville, SPAIN, 2Departamento de Ingenieria Electronica. Escuela Tecnica Superior de Ingenieria. Universidad de Sevilla, Seville, SPAIN.

EP-0203 High yield 18F-FET production on AllinOne (Trasis) at commercial scale
T. Vergote, M. Otobashi, C. Vriamont, C. Desfours, C. Warnier, J. Morelle, G. Philippart; Trasis SA, Ans, BELGIUM.

EP-0204 PET imaging of Pheochromocytoma with a novel 18FAl labeled exendin-4 analog
D. Pan1,2, Y. Xu1, Y. Wang1, Y. Yue1, L. Wang1, J. Yan1, X. Wang1, R. Yang1, M. Yang1; 1Jiangsu Institute of Nuclear Medicine, Wuxi, CHINA, 2Jiangnan University, Wuxi, CHINA.

EP-0205 Influence of Enzyme Inhibitors on FSHR PET Imaging
M. Yang1,2, Y. Xu1,2, D. Pan1, Y. Wang1, Y. Yue1, L. Wang1, J. Yan1, X. Wang1, R. Yang1; 1Jiangsu Institute of Nuclear Medicine, Wuxi, CHINA, 2Jiangsu Institute of Nuclear Medicine, Nanjing, CHINA.

EP-0206 Synthesis Of Novel Copper-64 Labeled Rhodamine: A Potential PET Myocardial Perfusion Imaging Agent
L. Aljammaz, B. Al-Otaibi, S. Al-Yanbawi, F. Al-Rumayan and S. Okarv; kfsrhc, Riyadh, SAUDI ARABIA.
EP-0207
A Modified Procedure for the Synthesis of a Potential Tau Imaging Agent [18F]T807 Employing a Neutral Mobile Phase Containing Acetonitrile and a Buffer for Semi-preparative HPLC Purification
M. CHEUNG, N. NG, K. LIU, C. HO; HONG KONG SANATORIUM & HOSPITAL, HONG KONG, HONG KONG.

EP-0208
M. CHEUNG, N. NG, K. LIU, C. HO; HONG KONG SANATORIUM & HOSPITAL, HONG KONG, HONG KONG.

EP-0209
Fully automated 18F-FAZA production on AllInOne (Trasis) at commercial scale
T. Vergote, M. Otabashi, C. Vriamont, C. Desfours, J. Morelle, G. Philippart; Trasis SA, Ans, BELGIUM.

EP-0210
Synthesis of Two Neurological PET Tracers, 18F-FEPPA and 18F-NAV4694 on a FlexLab Synthesizer
L. Morandeau1, A. Asad1, J. Ioppolo1, S. Poniger2,3, A. Wilson1, R. Price1,3; 1Medical Technology and Physics Dpt, Sir Charles Gairdner Hospital, Nedlands, AUSTRALIA, 2iPHASE technologies Pty Ltd, Melbourne, AUSTRALIA, 3The Austin Hospital, Melbourne, AUSTRALIA.

EP-0211
Triphenylphosphonium Modified 18F-Silica Nanoparticles as Tumor Targeting Agent for PET Imaging
Y. Kim1, J. Lee2, G. Kim1, J. Park1, H. J. Jo1, S. Kim1; 1Dongguk university, gyeongju, KOREA, REPUBLIC OF, 2Korea Atomic Energy Research Institute, Jeongeup, KOREA, REPUBLIC OF, 3Dongguk University-Gyeongju, Gyeongju, KOREA, REPUBLIC OF.

EP-0212
[68Ga]Nivolumab: a novel PET tracer to detect PD-1 expressing tumors
S. Migliari, A. Sammartano, B. Pellegrino, V. Regina, D. Cavazzini, S. Ottone, G. Missale, A. Musolino, L. Ruffin; AOU Pr, Parma, ITALY.

EP-0213
Preparation and preclinical evaluation of 64Cu-NOTA-anti MUC1 as a radioimmunoconjugate for diagnosis of MUC1 breast cancer by PET
B. Alirezapour1,2, M. Davarpanah1, J. Mohammadnejad3, A. Jali1, S. Rajabifar1, E. Maadi1, M. Hashemizadeh1, N. SoItani1, F. Bolournovin1, P. Ashtari1, G. Aslani1; 1Nuclear Science and Technology Research Institute, Tehran, IRAN, ISLAMIC REPUBLIC OF, 2Pars Isotope Company, Tehran, IRAN, ISLAMIC REPUBLIC OF, 3Pars Isotope Company, Tehran, IRAN, ISLAMIC REPUBLIC OF, 4Department of Life Science Engineering, Faculty of New Sciences & Technologies, University of Tehran, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0214
Combination of [18F]F ion into Aromatic Ring Using Pinacol Boran Derivative for the Synthesis of LAT 1 tracer [18F]FBPA
S. Naka1, K. Uehara2, Y. Ohta2,3, Y. Hattori2, H. Takenaka1, K. Uehara1, T. Sakai1, E. Shimosegawa1, M. Krihata1, J. Hatazawa1; 1Osaka University Graduate School of Medicine, Suita, Osaka, JAPAN, 2Osaka Prefecture University, Sakai, Osaka, JAPAN, 3STELLA PHARMA CORPORATION, Sakai, Osaka, JAPAN.

EP-0215
Feasibility of radioiodine labeled gold nanoparticle using AS1411 DNA aptamer for targeting of nucleolin-expressing glioma
M. Kim, K. Kim, S. Woo, T. Lee, K. Lee, J. Kang, Y. Lee; Korea Institute of Radiological and Medical Sciences, Seoul, KOREA, REPUBLIC OF.

EP-0216
[18F] FBPA synthesis from pinacol boran precursor and [18F] fluoride ion with copper reagent
Y. Kanai1, Y. Ohta2,3, Y. Hattori1, H. Takenaka1, K. Uehara1, S. Naka1, T. Sakai1, E. Shimosegawa1, M. Krihata1, J. Hatazawa1; 1Osaka University Graduate School of Medicine, Suita, JAPAN, 2Research Center of Neutron Capture Therapy, Osaka Prefecture University, Sakai, JAPAN, 3STELLA PHARMA CORPORATION, Sakai, JAPAN.

EP-0217
Synthesis and in vitro evaluation of 68Ga-labeled peptides for metalloproteinase (MT1-MMP/ MMP-14) targeting on HT1080 cells
C. Loliios, U. Bauder-Wüst, M. Schäfer, K. Kopka; Department of Radiopharmaceutical Chemistry, German Cancer Research Center (DKFZ), Heidelberg, GERMANY.
EP-0219
Radiosynthesis of [18F]NKO028 as a L-type amino acid transporter 1 (LAT 1) PET tracer for cancer diagnosis
S. Naka1, Y. Kanai1, T. Watabe1, S. Nagamori1, T. Sakai1, H. Kato1, K. Isoshishi1, M. Tatsumi1, E. Shimosegawa2, Y. Kanai1, J. Hatazawa1; 1Osaka University Graduate School of Medicine, Suita, Osaka, JAPAN, 2Hanwa Intelligent Medical Center, Sakai, Osaka, JAPAN.

EP-0220
Minimising residual activities in daily 18F-FDG administrations. Preliminary results

EP-0221
Ga-68 Labeled Neurotensin Peptide for PET Receptor-targeting Imaging and its first human study
L. Huo1, G. Hu1, L. Wang1, S. Yao1, Z. Li1, Z. Wu1, F. Li1; 1Peking Union Medical College Hospital, Beijing, CHINA, 2University of North Carolina at Chapel Hill, North Carolina at Chapel Hill, NC, UNITED STATES OF AMERICA.

EP-0222
Optimization of C-11 labeled methyl iodide production
E. V. Nemeth1, D. Szikra1, I. Jószi1, V. Forgács1, P. Mikecz2, P. Larsen3; 1University of Debrecen, Faculty of Medicine, Debrecen, HUNGARY, 2Scansys Laboratoriumetnik ApS, Copenhagen, DENMARK.

EP-0223
In-vitro and in vivo evaluation of 2 enantiomers of Nanocyclix(R) EGFR targeted PET radiotracer
C. Berthet1,2, O. Ragui1,2, C. Mothes3,2, P. Provent1,2, G. Serin1,2, X. Tizon1, A. Oudot3,2, P. Walker4, D. Hoflack1,2, G. Viot4,2; 1ONCODESIGN, Dijon, France, 2Pharmimage, Dijon, France, 3Cyclopharma, SAINT-BEAUZIRE, FRANCE, 4Centre Georges François Leclerc, Dijon, France, 5CHU François Mitterand, Dijon, France.

EP-0224
Four Runs of [18F]FDG on a Single Cassette
C. Warnier, C. Vriamont, T. Vergote, J. Masset, M. Otabashi, C. Desfours, J. Morelle, G. Philippart; Trasis, Ans, BELGIUM.

EP-0225
Development of novel lipophilic [18F] thiosemicarbazone gallium fluoride complexes
D. H. R. Stimson1, T. K. Venkatachalam1, G. K. Pierens1, P. V. Bernhardt1, K. Mardon1, D. C. Reutens1, R. Bhalla1; 1University of Queensland, Centre for Advanced Imaging, St Lucia, QLD, AUSTRALIA, 2University of Queensland, School of Chemistry and Molecular Biosciences, St Lucia, QLD, AUSTRALIA.

EP-0226
Optimization of 6-[18F]Fluoro-α-methyl-L-tryptophan - a prospective tracer for in vivo studies of tryptophan metabolism
A. Vazquez-Romero, E. Revunov1, R. Kraskova1,2, M. M. Moein1, S. Cervenka1, S. Erhardt1, C. Halldin1, M. Schou1,4; 1Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, SWEDEN, 2Institute of Human Brain of the Russian Academy of Science, St. Petersburg, RUSSIAN FEDERATION, 3Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, SWEDEN, 4AstraZeneca PET Science Centre, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, SWEDEN.

EP-0227
Uptake of the MCHR1 PET-tracers [18F]FE@SNAP and [11C]SNAP-7941 in BAT: an adrenergic beta-3 receptor mediated effect?
T. Balber1,2, K. Benčurová1, M. Mitterhauser1,3, W. Wadsak1,4, H. Viernstein2, M. Hacker1, C. Philippe1,2; 1Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA, 2Department of Pharmaceutical Technology and Biopharmaceutics, Faculty of Life Sciences, University of Vienna, Vienna, AUSTRIA, 3Ludwig Boltzmann Institute Applied Diagnostics, Vienna, AUSTRIA, 4CBmed GmbH, Center for Biomarker Research in Medicine, Graz, AUSTRIA.

EP-0228
Alcohol-supported Cu mediated 18F-fluorination of iodonium salts under “minimalist” conditions
V. V. Orlovskaya1, O. F. Kuznetsova1, D. Modemann2, O. S. Fedorova1, B. D. Zlatopolskiy2,3,4, E. A. Urusova1,2, B. Neumaier2,3,4, R. N. Krasikova1; 1N.P. Bechtereva Institute of the Human Brain RAS, Saint-Petersburg, RUSSIAN FEDERATION, 2Institute of Neuroscience and Medicine, INM-5: Nuclear Chemistry, Forschungszentrum, Julich, GERMANY, 3Institute of Radiochemistry and Experimental Molecular Imaging University Clinic, Cologne, GERMANY, 4Max Planck Institute for Metabolism Research, Cologne, GERMANY.

EP-0229
Optimization and characterization of [18F]FDG as a PET tracer for imaging tumor hypoxia
E. V. Nemeth1, D. Szikra1, I. Jószi1, V. Forgács1, P. Mikecz2, P. Larsen3; 1University of Debrecen, Faculty of Medicine, Debrecen, HUNGARY, 2Scansys Laboratoriumetnik ApS, Copenhagen, DENMARK.
EP-0229
Microdose Study for Amino Acid Imaging Using D-[18F]FMT PET in Human Brains
K. Lee1, B. Byun1, B. Kim2, J. Lim2, C. Choi3, S. Youn1, C. Rhee1, S. Chu4, C. Park4, H. Kil4, B. Lee4, D. Chi4,5, S. Lim6; 1KIRAMS, Division of RI-Convergence Research, Seoul, KOREA, REPUBLIC OF; 2KIRAMS, Department of Nuclear Medicine, Seoul, KOREA, REPUBLIC OF; 3KIRAMS, Department of Neurosurgery, Seoul, KOREA, REPUBLIC OF; 4FutureChem Co. Ltd., Seoul, KOREA, REPUBLIC OF; 5Sogang University, Department of Chemistry, Seoul, KOREA, REPUBLIC OF.

EP-0230
Implementing [18F]FB-IL2 synthesis in GMP

EP-0231
Preparation of [18F]fluoroalkenyliodonium salts and their application for radiolabeling by Sonogashira coupling reactions
S. Humphert1, B. Zlatopolsky1, M. Holschbach1, B. Neuhaus2,3,1 Forschungszentrum Jülich GmbH, Institute of Neuroscience and Medicine, INM-5: Nuclear Chemistry, Jülich, GERMANY; 2Institute of Radiochemistry and Experimental Molecular Imaging, University Clinic Cologne, Köln, GERMANY; 3Max Planck Institute for Metabolism Research, Cologne, Köln, GERMANY.

EP-0232
Highly Improved and GMP compliant synthesis of [11C]UCB-J: in situ generation of boronic acid precursor
M. Onega1, H. Chong1, A. Roble1, C. Pissos1, M. Huihao1, J. Mercier1, M. Vandergeten1, J. Passchier1; 1Imanova Limited, London, UNITED KINGDOM, 2UCB Biopharma, Braine l'Alleud, BELGIUM.

EP-0233
O-TRENSOX, a new chelating agent for 68Ga radiopharmaceutical
J. Leenhardt1,2, M. Desruet1,2, L. Djalebi1,2, A. Jullier1, C. Ghezzi1, P. Bedouch1, A. Du Moulinet D’Hardemare1; 1Radiochemistry/pharmacy department, Grenoble Alpes University Hospital (CHUGA), Grenoble 38000, FRANCE, 2INSERM Unit U1039, Radiopharmaceutiques Biocliniques, University of Grenoble Alpes- Faculté de Médecine, Grenoble 38000, FRANCE, 3Department of nuclear medicine, Grenoble Alpes University Hospital (CHUGA), Grenoble 38000, FRANCE, 4DCM-Department of Molecular Chemistry, UMR5250, University of Grenoble-Alpes, 301 Rue de la Chimie, BP 53 GRENOBLE cedex 9, FRANCE.

EP-0234
Biodistribution And Micro-TEP Imaging Of68GA-NODAGA-RGD, A New Radiotracer For Tumor Angiogenesis: Human Glioblastoma Xenograft Model In Mice
S. ISAL1, A. Clément2, J. Pierson2, C. Collet1, N. Veran1, S. Fresvier1, S. Poussier1, G. Karcher1, P. Marie1, F. Maskali2; 1Nuclear Medicine and Nancyclotep imaging platform CHRU Nancy, Nancy, FRANCE; 2Nancyclotep imaging platform, CHRU Nancy, Nancy, FRANCE.

EP-0235
Evaluation Of Nucleophilic Synthesis Of [18F]FDOPA HPLC Free On Fastlab Platform
E. Cazzola1, A. D’Angelo1, L. Mora1, A. Purgo1, C. Malizia1, D. Peruzzi1, S. Costa1, J. Amico1, F. Lodr1, G. Gorgoni1; 1Sacro Cuore Hospital, Negrar, ITALY, 2Sant’Orsola Hospital, Bologna, ITALY.

EP-0236
Synthesis and Biological evaluation of 68Ga labeled NOTA-Capsaicin for Targeting Colon Cancer CT-26
G. Kim1,2, S. Kim1, M. Hur1, S. Yang1, J. Park1; 1Korea atomic energy research institute, jeongeup, KOREA, REPUBLIC OF; 2Dongguk University, Gyeongju, KOREA, REPUBLIC OF.

EP-0237
One-pot Synthesis of Surface Modified Gallium Incorporated Zeolitic Imidazolete Framework (ZIF-8) as a PET probe
P. Choi1,2, J. Lee1, G. Kim1, S. Kim1, J. Park1; 1Korea Atomic Energy Research Institute, jeongeup, KOREA, REPUBLIC OF; 2Dongguk University Gyeongju, Gyeongju, KOREA, REPUBLIC OF.
EP-0240
Fully automated one step [18F]F-PSMA-1007 production on AllinOne (Trasis)
A. Fasel, M. Otabashi; 1ABX advanced biochemical compounds, Radeberg, GERMANY; 2Trasis SA, Liege, BELGIUM.

EP-0241
High activity automated production of Eu-177 radiopharmaceuticals using Modular Lab-Eazy system
M. J. Latter, S. Tapper; 1Royal Brisbane and Women's Hospital, Herston, AUSTRALIA; 2Eckert and Ziegler, GER.

EP-0242
Fully automated production of [18F] LBT999, a dopamine transporter (DAT) radiopharmaceutical, for preclinical and clinical PET studies
C. Vala1,2, C. Mothes1,3, P. Magadur, G. Viot1; 1ABX advanced biochemical compounds, Radeberg, GERMANY, 2CERRP, Tours, FRANCE, 3Pharm'image, Dijon, FRANCE.

EP-0243
Improvement of [11C](+)-PHNO synthesis by evaluation of reaction temperatures
S. Pfaff1,2, C. Philippe1, V. Pichler1, A. Weidenauer1, M. Willer1, M. Hacker1, M. Mitterhauser4, W. Wadsak1,2,5, L. Nics1,6; 1Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, AUSTRIA, 2Department of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Vienna, AUSTRIA, 3Department of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna, Vienna, AUSTRIA, 4Ludwig Boltzmann Institute Applied Diagnostics, Vienna, AUSTRIA, 5Centre for Biomarker Research in Medicine, CBmed GmbH, Graz, AUSTRIA, 6Department of Nutritional Sciences, University of Vienna, Vienna, AUSTRIA.

EP-0244
Evaluation of benzoazolone based TSPO selective PET radiotracer to access microglial activation in ischemic rat brain
N. Kani1,2, S. BHAGAT1, A. Tiwari1; 1INSTITUTE OF NUCLEAR MEDICINE & ALLIED SCIENCES, DRDO, DELHI, INDIA; 2University of Delhi, Delhi, INDIA.

EP-0245
Measurement of the Stability of [18F]FDOPA with High Activity Concentration
T. Bali, A. Richard, G. Tihanyi, T. Cservanyi, T. Áncsán, T. Csipak, B. Bojtor, I. Repa, G. Bajtek, P. Mikecz; University of Kaposvár, Kaposvár, HUNGARY.

EP-0246
[11C]Me@NEBIQUINIDE: A Real Third Generation TSPO PET Tracer?
N. Berroterán-Infante1,2, S. Schmitl1, T. Kalina1, H. Spreitzer1, M. Hacker1, M. Mitterhauser1, K. Pallitsch4, W. Wadsak1,2, 1Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA, 2Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Vienna, AUSTRIA, 3Department of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna, Vienna, AUSTRIA, 4LBI Applied Diagnostics, Vienna, AUSTRIA, 5Center for Biomarker Research, Graz, AUSTRIA.

EP-0247
46Ga(III) complex with morin for kidney cancer cells labeling
K. Kilian, A. Sentkowski, A. Cheda, K. Pyrzyńska; University of Warsaw, Warszawa, POLAND.

EP-0248
Evaluation of arylpiperazinyl analogues as PET radioligand for 5HT7
A. K. Tiwari; Institute of Nuclear Medicine & Allied Sciences, Delhi, INDIA.

EP-0249
Development of [123I] 6-iodo-deoxy glucose ([123I] 6-IDG) with composite polymer precursor for imaging of brain glucose metabolism with SPECT.
Y. Kanai, H. Tanaka, A. Nagaoka, S. Naka, T. Sakai, T. Kamiya, G. Horitsugi, E. Shimosegawa, T. Takahashi, J. Hatazawa; 1Osaka University Graduate School of Medicine, Suita, JAPAN, 2Tokyo Institute of Technology, Tokyo, JAPAN, 3Tokyo University of Technology, Tokyo, JAPAN, 4Iwaki Seiyaku Co., Ltd, Tokyo, JAPAN, 5Hanwa Intelligent Medical Center, Sakai, JAPAN, 6Yokohama University of Pharmacy, Yokohama, JAPAN.

EP-0246
[11C]Me@NEBIQUINIDE: A Real Third Generation TSPO PET Tracer?
N. Berroterán-Infante1,2, S. Schmitl1, T. Kalina1, H. Spreitzer1, M. Hacker1, M. Mitterhauser1, K. Pallitsch4, W. Wadsak1,2, 1Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA, 2Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Vienna, AUSTRIA, 3Department of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna, Vienna, AUSTRIA, 4LBI Applied Diagnostics, Vienna, AUSTRIA, 5Center for Biomarker Research, Graz, AUSTRIA.

EP-0247
46Ga(III) complex with morin for kidney cancer cells labeling
K. Kilian, A. Sentkowski, A. Cheda, K. Pyrzyńska; University of Warsaw, Warszawa, POLAND.

EP-0248
Evaluation of arylpiperazinyl analogues as PET radioligand for 5HT7
A. K. Tiwari; Institute of Nuclear Medicine & Allied Sciences, Delhi, INDIA.

EP-0249
Development of [123I] 6-iodo-deoxy glucose ([123I] 6-IDG) with composite polymer precursor for imaging of brain glucose metabolism with SPECT.
Y. Kanai, H. Tanaka, A. Nagaoka, S. Naka, T. Sakai, T. Kamiya, G. Horitsugi, E. Shimosegawa, T. Takahashi, J. Hatazawa; 1Osaka University Graduate School of Medicine, Suita, JAPAN, 2Tokyo Institute of Technology, Tokyo, JAPAN, 3Tokyo University of Technology, Tokyo, JAPAN, 4Iwaki Seiyaku Co., Ltd, Tokyo, JAPAN, 5Hanwa Intelligent Medical Center, Sakai, JAPAN, 6Yokohama University of Pharmacy, Yokohama, JAPAN.
EP-0250
In vitro assessment of the accumulation of highly specific radiochemical compounds based on 99mTc-labeled recombinant molecules
O. Bragina1,2, M. Larkina, E. Stasyuk, V. Chernov, R. Zelchan, A. Medvedeva, Sinilkin I., M. Yusubov, V. Skuridin; 1Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION, 2National Research Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION.

EP-0251
The First Experience of Using a Radiopharmaceutical Based on Derivative of Glucose Labeled with Technetium-99m in Breast Cancer Imaging
R. Zelchan1,2, A. Medvedeva, I. Sinilkin, O. Bragina, V. Chernov, E. Stasyuk, A. Rogov, E. Ilin, V. Skuridin; 1Tomsk National Research Medical Center, Russian Academy of Science, Tomsk, RUSSIAN FEDERATION, 2National Research Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION.

EP-0252
Preparation of 131I-iodohexadecanoic acid: a tracer to localize lymphatic leakage lesions
H. Kvaternik, S. Stanzel, R. M. Aigner; Medical University of Graz, Graz, AUSTRIA.

EP-0253
A new method for the preparation of astatine-211(211At) and iodine-123(123I) labelled amino acid analogues of phenylalanine, 211At-Phe and 123I-Phe, for radionuclide therapy and SPECT imaging applications
Y. Shirakami1,2, H. Ike1, J. Hatazawa1; 1Osaka University Graduate School of Medicine, Suita, JAPAN, 2Cyclotron and Radioisotope center, Tohoku University, Sendai, JAPAN, 3Research Center for Electron Photon Science, Tohoku University, Sendai, JAPAN.

EP-0254
Current status of stress myocardial perfusion imaging pharmaceuticals and radiation exposure in Japan: Comparison with European nuclear cardiology practice
R. Otsuka, Y. Miyake, T. Kubo, M. Kawahara, J. takaesu, K. Kawai; Osaka University Graduate School of Medicine, Suita, JAPAN.

EP-0255
Synthesis And Radiolabeling Of Temozolomide Loaded Solid Lipid Nanoparticles
K. Arı, S. Teksöz, C. Ichedef, E. Uçar, A. Yurt Kılçar, E. &. Medine; Ege University, Izmir, TURKEY.

EP-0256
Partition Coefficient,Plasma Protein Binding Percentage and Pharmacokinetic Studies of 99mTc-ZL and 99mTc-ZLM for New Bone-imaging Agents
H. Wang, P. Zou, M. Xie, Y. Liu, J. Wu, H. Wu; Jiangsu Institute of Nuclear Medicine, Wuxi, CHINA.

EP-0257
Design Of A Radiolabeled Polymeric Drug Carrier System 99mTc(CO)3-Oxaliplatin-PEG-PLA
K. Senocak, S. Teksoz, A. Yurt Kılçar, E. Uçar, B. Aydin; Ege University Institute of Nuclear Sciences, Izmir, TURKEY.

EP-0258
Evaluation of the SPECT Image Using Probe 123I-EISB for SPECT of the Systemic Amyloidosis
K. Kashiwa1, K. Fukuda1, Y. Ando2, K. Tomiyoshi3; 1Graduate School of Health Science, Department of Radiological Science Kumamoto University, Kumamoto, JAPAN, 2Radiation Oncology, Yokohama City University Hospital, Kanagawa, JAPAN, 3Graduate School of Medical Science, Department of Neurology,Kumamoto University, Kumamoto, JAPAN.

EP-0259
99mTc-Al2O3 - new radiopharmaceutical for sentinel lymph nodes visualization: first experience in oncogynecologic cancer patients
V. Chernov1,2, R. Zelchan1,2, Lyapunov A., Sinilkin I., Chernyshova A, Ochirov M., Kolomiets L., Medvedeva A.; 1Tomsk National Research Medical Center of the Russian Academy of Sciences Cancer Research Institute, Tomsk, RUSSIAN FEDERATION, 2National Research Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION.

EP-0260
Evaluation of the labeling parameters of 99mTc-Nanocoll-ICG® for multimodal imaging of the sentinel lymph node
J. Dinet1, P. Bonijol1, Q. Becheras1, C. Faure1, J. Daugeron4, F. Giammarile5, D. Kryza5; 1GCS Lumen, Lyon, FRANCE, 2Université Claude Bernard Lyon 1, Lyon, FRANCE, 3Centre Léon Bérard, Lyon, FRANCE, 4Université d’Auvergne, Montluçon, FRANCE, 5Hospices Civils de Lyon - Université Claude Bernard Lyon 1, Lyon, FRANCE.

EP-0261
Optimization of affbody molecule for imaging of HER3 expression: negatively charged metal-chelator complex increases imaging contrast
S. S. Rinne1, B. Mitran1, C. Dahlsson Leitao2, S. Ståhl1, J. Löfblom1, V. Tolmachev1, A. Orlova1; 1Uppsala University, Uppsala, SWEDEN, 2KTH Royal Institute of Technology, Stockholm, SWEDEN.
EP-0262
Preparation of 99mTc-labelled hydroxyapatite nanoparticles and their in vitro/in vivo characterisation
Z. Nový1, M. Petrik1, S. Gurska1, J. Kozempel1, M. Vlk1, V. Lobaz1, J. Kucka1, M. Hruby1, J. Drymlova1, M. Hajduch1; 1Palacky University Olomouc, Olomouc, CZECH REPUBLIC, 2Czech Technical University in Prague, Praha, CZECH REPUBLIC, 3Czech Academy of Science, Praha, CZECH REPUBLIC, 4University Hospital Olomouc, Olomouc, CZECH REPUBLIC.

EP-0263
Cytotoxicity, In vitro binding and imaging evaluation of radiolabeled-DOTA-SP90 in 4T1 breast cancer model
M. Chen, Y. Huang, S. Lee, S. Lo, L. Chen, C. Chang; Institute of Nuclear Energy Research, Taoyuan City, TAIWAN.

EP-0264
Radiolabeled AMO conjugated nanoparticle for in vivo tumor imaging of cervical cancer
L. Kang, Y. Hud, P. Li, L. Zhang, P. Yan; Peking University Hospital, Beijing, CHINA.

EP-0265
Proof of Concept for Nucleolipids as potential SPECT tracer: Synthesis and Evaluation of Uridine derived Nucleolipid as Targeted Imaging Agent
S. Mishra1, S. Chaturvedi2, S. Paul1, P. Barthélémy1, B. Singh2, S. Mishra1; 1Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and Allied Sciences, Delhi, INDIA; 2Univ Bordeaux et Université de Bordeaux, Bordeaux F-33076, FRANCE, 3Department of Chemistry, Banaras Hindu University, Varanasi, INDIA.

EP-0266
Exendin-4 labeled with 99mTc, 111In and 68Ga - a comparative pharmacokinetics evaluation
B. Janota, U. Karczmarszyk, E. Laszuk, P. Gamuszek, R. Mikolajczak; National Centre for Nuclear Research Radiosotope Centre POLATOM, Otwock, POLAND.

EP-0267
Radiolabeling and preclinical assessment of 188Re-HYNIC-trastuzumab for Radioimmunotherapy
B. Alirezapour1, 2, M. Davarpanah1, 2, M. Rajabifar1, H. Abbasi1, B. Aziz Keshavarzi1, H. Johari Daha1, M. Hashemizadeh1, S. Jalili1, N. Soltani1, H. Masoumi2, S. Morsali1; 1Nuclear Science and Technology Research Institute, Tehran, IRAN, 2Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 3Pars Isotope Company, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0268
Validation of alternative methods for quality control of [99mTc-EDDA-HYNIC-D-Phe1, Tyr3]-Octreotide
M. A. Hernandez Fructuoso1, S. Ruiz Llama2, B. Santos Montero1, C. Beltran Gracia1, E. miñana Olmo1, J. Castell Conesa1; 1Hospital Universitari Vall d’Hebron - Institut de Diagnòstic per la Imatge, Barcelona, SPAIN, 2Hospital Universitari Vall d’Hebron, Barcelona, SPAIN.

EP-0269
Theranostic probe Lu-177-DOTA-NIR790 for multimodal diagnosis and therapy of cancer
C. Peng, Y. Shih, P. Chiang, Y. Kuo, T. Lua; Isotope Application Division, Institute of Nuclear Energy Research, Taoyuan, TAIWAN.

EP-0270
Stability assessment after reconstitution and investigation of the biodistribution in a pre-clinical mouse model of 99mTechnetium-Sestamibi (Cardiovis™)
C. Mak1, S. A. Barker1, J. K. Sosabowski1, J. M. Foster2, N. G. Hartman1; 1UCL School of Pharmacy, London, UNITED KINGDOM, 2John Vane Science Centre, Queen Mary University, London, UNITED KINGDOM, 3Barts Health NHS Trust, London, UNITED KINGDOM.

EP-0271
Evaluation of the physicochemical properties of 99mTechnetium-Exametazime (Medi-Exametazime™) and its biodistribution in a pre-clinical mouse model
W. Ahmed1, S. A. Barker1, J. Sosabowski1, J. M. Foster5, R. Soanes5, N. Hartman1; 1UCL School of Pharmacy, London, UNITED KINGDOM, 2John Vane Science Centre, Queen Mary University, London, UNITED KINGDOM, 3Barts Health NHS Trust, London, UNITED KINGDOM.

EP-0272
Validation of a Cost Effective Alternative Radiochemical Purity Analysis Method
F. P. Ekoume1, 2, S. M. Rubow2, H. H. Boersma2; 1Yaounde General Hospital, Yaounde, CAMEROON, 2Stellenbosch University, Cape Town, SOUTH AFRICA, 3University Medical Center, Groningen, NETHERLANDS.
EP-0273
Analysis of the new rules of clinical trials with drugs in Spain
L. Sanz-Ceballos, Á. Ramírez-Navarro, J. García-Redondo, J. M. Llamas-Elvira; Hospital Universitario Virgen de las Nieves, Granada, SPAIN.

EP-0274
Overview of 2.5 years experience of manual synthesis of in-house 68Ga labelled radiopharmaceuticals using non metallic 68Ge/68Ga column generator: An institutional experience
B. S. Shetye, Sr., P. Monteiro, M. Pathan, V. Rangarajan; Tata Memorial Hospital, Mumbai, INDIA.

EP-0275
Computer platform for radiopharmaceuticals prescription
J. García-Redondo, E. Morillo-Martínez, Á. Ramírez-Navarro, J. M. Llamas-Elvira; Hospital Universitario Virgen de las Nieves, Granada, SPAIN.

EP-0276
Leukocyte scintigraphy: biologic criteria for the decision of realization of the scintigraphy using the benchmark method of in vitro 99mTc-HMPAO (Ceretec®) granulocytes labeling
K. Casagrande1, J. Woillard2, I. Quelven1; 1CHU Dupuytren, Nuclear Medicine Department, Limoges, FRANCE, 2CHU Dupuytren, Pharmacology and Toxicology Department, Limoges, FRANCE.

EP-0277
Optimization of Gallium-68 radiolabelling methods: feedback in Centre Jean Perrin cancer institute
H. Nicolas1, M. Tempier1, P. Auzeloux2, M. Galmier1, S. Tarit1, E. Cachin1, R. Chevrier1, S. Levesque1; 1CRLCC Jean Perrin, Clermont ferrand, FRANCE, 2Université Clermont d’Auvergne, INSERM U1240, Imagerie Moléculaire et Stratégies Théranostiques, Clermont ferrand, FRANCE.

EP-0278
Routine GMP production of 68Ga-radiopharmaceuticals using two 68Ge/68Ga generators in sequence
G. M. Franssen1, M. van Riel1, D. Gerrits1, R. Bongaerts1, C. M. van Rij1, S. Kroft1, H. J. Wester1, P. Laverman5; 1Radboud university medical center, Nijmegen, NETHERLANDS, 2Scintomics GmbH, Furstenfeldbruck, GERMANY.

EP-0279
Establishment of Glomerular Filtration Rate reference values measured by 51Cr-EDTA clearance in patients over 75 years

EP-0280
Peptides labelling with 64Cu and 68Ga on heterogeneous phase using a microfluidic system
D. Seifert, M. Kleinova, A. Cepa, J. Ralí, P. Hanc, O. Lebeda; Nuclear Physics Institute of the CAS, Rez, CZECH REPUBLIC.
EP-0284
Radiolabeling with 68Ga and 44Sc in a capillary reactor
D. Szikra1, G. Nagy2, G. Trencsényi1, N. Dénes1, V. Forgács1, E. Berényi1, J. Garai1; 1University of Debrecen, Debrecen, HUNGARY, 2Scanomed Ltd., Debrecen, HUNGARY.

EP-0285
High yield separation of 67Cu from irradiated zinc targets
P. Martini1,2, A. Boschi3,2, M. Pasquali1,2, G. Cicoria4, L. Mou1, C. Rossi Alvarez3, S. Carturan3, S. Cane11a, J. Esposito1, L. Uccelli2,3, A. Duatti2, F. Haddad2, T. Sounalet1, G. Pupillo2, 1University of Ferrara, Physics Department, Ferrara, ITALY, 2Legnaro National Laboratories, National Institute for Nuclear Physics (LNL-INFN), Legnaro (Pd), ITALY, 3University of Ferrara, Laboratory of Nuclear Medicine, Department of Morphology, Surgery and Experimental Medicine, Ferrara, ITALY, 4Department of Nuclear Medicine, St. Orsola Hospital, Bologna, ITALY, 5Department of Nuclear Medicine, St. Anna Hospital, Ferrara, ITALY, 6University of Ferrara, Department of Chemical and Pharmaceutical Sciences, Ferrara, ITALY, 7GIP ARRONAX, Saint-Herblain, FRANCE.

EP-0286
Production of Sc radionuclides by separation of scandium from calcium target using UTEVA resin
D. Pawlak, W. Wojdowska, J. L. Parus, M. Żółtowska, P. Garnuszek, R. Mikolajczak; National Centre for Nuclear Research Radioisotope Centre POLATOM, Otwock, POLAND.

EP-0287
Development of solid target and automated synthesis module for the production of scandium-44 and scandium-44 labeled peptides
I. Hajdu, V. Forgács, A. Fekete, E. Várhalminé Németh, D. Szikra; University of Debrecen, Debrecen, HUNGARY.

EP-0288
Preliminary experimental tests of 68Cu production in combination with 18F
L. Auditore1, E. Amato1, G. Cicoria1, M. Marengo1, S. Baldari1; 1Nuclear Medicine Unit, University Hospital “G. Martino”, Messina, ITALY, 2Radiological Sciences Section, BIOMORF Dept., Messina, ITALY, 3Medical Physics Department, University Hospital “S. Orsola-Malpighi”, Bologna, ITALY.

EP-0289
11C-choline pharmacokinetics in recurrent prostate cancer
M. Grkovski, K. Gharzeddine, P. Sawan, H. Schöder, W. A. Weber, J. L. Humm; Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.

EP-0290
Development of 18F-labeled α-methyl L-phenylalanine for tumor specific imaging
H. Hanaoka, A. Yamaguchi, Y. Ohshima, T. Higuchi, N. S. Ishioka, Y. Tsushima; 1Gunma University, Maebashi, JAPAN, 2National Institutes for Quantum and Radiological Science and Technology, Takasaki, JAPAN.

EP-0291
Synthesis and evaluation of 125I-labeled tetrazine prosthetic group for an efficient bioorthogonal radiolabeling of trans-cyclooctene containing biomolecules
S. Mushtaq1,2, M. Choi1, H. Shim1, S. Yun1, C. Lee1, S. Park1,2, D. Choi1, B. Jang1, J. Jeon1,2; 1Korea Atomic Energy Research Institute, Jeongeup, Jeonbuk, KOREA, REPUBLIC OF, 2Korea University of Science and Technology, Deajeon 34113, KOREA, REPUBLIC OF.

EP-0292
Generation and evaluation of single chain fragments for molecular imaging of CD44v6-expressing cancers
A. Haylock1, J. Nilvebrant1, A. C. Mortensen1, I. Velikyan1, R. Falk1, M. Nestor2; 1Department of Surgical Sciences, Department of Immunology, Genetics and Pathology, Uppsala University, UPPSALA, SWEDEN, 2Division of Protein Technology, School of Biotechnology, Royal Institute of Technology, STOCKHOLM, SWEDEN, 3Department of Immunology, Genetics and Pathology, Uppsala University, UPPSALA, SWEDEN, 4Department of Medicinal Chemistry, Uppsala University, UPPSALA, SWEDEN, 5Department of Neuroscience, Karolinska Institutet, STOCKHOLM, SWEDEN.

EP-0294
Does nanocarrier tumour uptake increase with increasing size?
EP-0295
Radiolabeling and biodistribution study of engineered antibody-like protein with 99mTc for tumor therapy
D. Lee1, S. Mushtaq1, S. Yoon2, J. Kang3, D. Choi4, H. Kim5; 1Korea Atomic Energy Research Institute, Jeongeup, KOREA, REPUBLIC OF, 2Korea University of Science and Technology, Deajeon 34113, KOREA, REPUBLIC OF, 3Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, KOREA, REPUBLIC OF.

EP-0296
Evaluation of 89Zr Complexes With Dicarboxylic Acids for PET-Diagnosis Inflammatory Processes and Metabolic Skeletal Disorders
A. Larenkov1, A. Maruk, M. Zhukova, A. Krasnopyorova; 1Burnasyan FMBC, Moscow, RUSSIAN FEDERATION.

EP-0297
Bioaffinity testing of 68Ga/177Lu-DOTA-Neurotensin and neurotensin fragments as teranostic agent in colon cancer
D. Niculae1, D. Draganescu2, E. A. Min1, A. Raicu1, L. Chilu2, G. Manda1, R. A. Leonte1, I. Manea5, M. Costache1, 1Horia Hulubei National Institute for Physics and Nuclear Engineering, Magurele Ilfov, ROMANIA, 2University of Medicine and Pharmacy “Carol Davila”, Bucharest, ROMANIA, 3University Politehnica, Bucharest, ROMANIA, 4Victor Babes National Institute for Pathology and Biomedical Sciences, Bucharest, ROMANIA, 5Colentina Clinic Hospital, Bucharest, ROMANIA.

EP-0298
n.c.a. Lu-177-Dotatate Kinetics Comparison With In-111-DTPA-Oc in Intra-arterially Infused Liver Metastasized GEP-NET Patients; From Bench to Bedside
G. S. Limouris1, M. Paphiti2, S. Chondroyiannis3, D. Rubello3, V. R. McCready1; 1Medical Faculty, National and Kapodistrian University of Athens, Athens, GREECE, 2Nuclear Medicine Department, Santa Maria della Misericordia Hospital, Rovigo, ITALY, 3Institute Cancer Research, Sutton Surrey & Royal Sussex County Hospital, Brighton, UNITED KINGDOM.

EP-0299
New 99mTc labeled peptide for EGFR tumor targeting
N. Rahmanian1, S. Hosseinimehr2, A. Khalaj1, Z. Noaparast3, S. Abedi2; 1Tehran University of Medical Sciences, Tehran, ISLAMIC REPUBLIC OF, 2Mazandaran University of Medical Sciences, sari, ISLAMIC REPUBLIC OF.

EP-0300
Biodistirbution study of 111In-anti-CDH17 minibody using CDH17-positive gastric cancer xenograft mice
K. Fujiwara1,2, K. Koyama2, H. Akiba3, H. Iwanari4, T. Higashi1, K. Tsumoto1, T. Hamakubo4, T. Momose5; 1Department of Molecular Imaging and Theranostics, National Institute of Radiological Sciences, National Institutes of Quantum and Radiological Science and Technology, Chiba, JAPAN, 2Department of Radiology, Graduate School of Medicine, The University of Tokyo, Tokyo, JAPAN, 3Laboratory of Pharmacokinetic Optimizaiton, Center for Drug Design Research National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, JAPAN, 4Department of Quantitative Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, JAPAN, 5Department of Radiology, Faculty of Medicine, International University of Health and Welfare, Chiba, JAPAN.

EP-0301
68Ga-labelled Neuropeptide Y short analogue: A potential PET/CT tracer for breast cancer imaging
M. E. Cardoso1, K. Zirbesegger2, E. Savio2, H. Engler2, M. Terán3, A. M. Rey1; 1Área Radioquímica, Facultad de Química, Udelar, Montevideo, URUGUAY, 2Uruguayan Centre of Molecular Imaging (CUDIM), Montevideo, URUGUAY.

EP-0302
A novel peptide targeting GPC3 for HCC PET/CT imaging
Y. Qin1, Y. Li2, S. Zou1, D. Zhu1, H. Wu2, L. Zhu3, X. Zhu4; 1Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA, 2The First Affiliated Hospital of Xiamen University, Xiamen, CHINA, 3Emory University School of Medicine, Atlanta, GA, UNITED STATES OF AMERICA.
EP-0303
99mTc-HYNIC-ramucirumab: in vitro studies on binding to VEGFR2 and internalization in VEGFR2-positive cells
J. Janousek, Jr., P. Barta, F. Trejtnar; Faculty of Pharmacy in Hradec Kralove, Hradec Kralove, CZECH REPUBLIC.

EP-0304
Development of 90Y-DOTA-nimotuzumab: a specific tool for testing a new probe potentially suitable for β radio-guided surgery
T. Scotognella1, D. Maccora1, G. Bancivenga1, N. Misceo1, C. Martelli1, V. Marzano1, F. Marini1, I. Fratoddi1, I. Venditti1, A. Cartoni1, E. Solfaroli-Camillocci1, S. Marganti1, C. Mancini-Terracciano1, F. Collamati1, D. Rotili1, M. Chino1, M. Castagnola1, R. Faccini1, A. Giordano2; 1Nuclear Medicine Unit, Policlinico “A. Gemelli”, Rome, ITALY, 2Institute of Nuclear Medicine, Università Cattolica del S. Cuore “A. Gemelli”, Rome, ITALY.

EP-0305
Site-specific Bimodal Labeling of Proteins on Cysteine Residues with Chlorotetrazines
C. Canovas1, M. Moreau1, C. Bernhard1, A. Oudot1, M. Guillemin1, F. Denat1, V. Goncalves1; 1ICMUB, UMR 6302, CNRS, Université de Bourgogne Franche-Comté, Dijon, FRANCE, 2Centre Georges François Leclerc, Dijon, FRANCE.

EP-0306
Feasibility of Z Domain-Mediated Conjugation of PNA to Antibodies for Radionuclide Pretargeting
A. Vorobyeva1, M. Altai1, K. Westerlund1, A. Al-Ramadan1, V. Tolmachev1, A. Eriksson Karlström2; 1Uppsala University, Uppsala, SWEDEN, 2KTH Royal Institute of Technology, Stockholm, SWEDEN.
EP-19 during congress opening hours, e-Poster Area
Radiopharmaceuticals & Radiochemistry: New Targets

EP-0312
The Novel, Stapled HDM2/HDMX-p53 Antagonist PM2 Has Potent Antitumorigenic Activities and Enhances the Effects of External Radiotherapy
A. C. Mortensen, D. Spiegelberg, C. Brown, D. P. Lane, M. Nestor; 1Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, SWEDEN, 2p53 Lab, A*STAR, 8A, Biomedical Grove, #06-04/05 Neuro/Immunos, Singapore 138648, Singapore, SINGAPORE.

EP-0313
Preliminary Results Of The Production Of Gallium-68 With Cyclotron
G. Cicoria, F. Zagni, S. Vichi, L. Mora, M. Marengo, S. Riga; Policlinico S.Orsola-Malpighi, Bologna, ITALY.

EP-20 during congress opening hours, e-Poster Area
Radiopharmaceuticals & Radiochemistry: Miscellaneous

EP-0314
Structural Requirement of the 11b-Position Chirality of Tetrabenazine Analogs as VMAT2 Imaging Ligands: Synthesis and in vivo Evaluation
Z. Chen, D. Xue, C. Liu, X. Li, J. Tang, L. Cao, Y. Liu; Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, CHINA, 2Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, School of Pharmacy, Xuzhou Medical University, Xuzhou, CHINA.

EP-0315
Central Conducting Lymphatic Anomaly in Neonatal Chylothorax Visualized after Oral Administration of [131I]IHDA
S. Stanzel, H. Kwatemik, K. Pfurtscheller, R. Ulreich, R. M. Aigner; 1Medical University of Graz, Department of Radiology, Division of Nuclear Medicine, Graz, AUSTRIA, 2Medical University of Graz, University Children’s Hospital, Pediatric Intensive Care Unit, Graz, AUSTRIA.

EP-0316
Influence of the use of cryoprotectant on the radiolabeling of poly(lactic-co-glycolic acid) (PLGA) nanoparticles with 99mTc
R. Iglesias-Jerez, M. D. Cayero-Otero, L. Martin-Banderas, J. Borrego-Dorado; 1HU VIRGEN DEL ROCÍO. Avda Manuel Siurot s/n, 41013, Sevilla, SPAIN, 2Dpt. Farmacia y Tecnología Farmacéutica. Facultad de Farmacia. Universidad de Sevilla. c/Prof. Gracia Gonzalez nº2, 41012, Sevilla, SPAIN.

EP-0317
Gamma Ray Spectroscopy for Determination of Absolute Activities of Cyclotron-Produced Technetium Product Impurities and Waste

EP-0318
Radiolabeling optimization of radioaptamers as new heterotrimeric theranostic systems for antimetastatic therapy
R. Ramos-Membrive, G. Gan, M. Collantes, F. Pastor, M. Martínez-Soldevilla, I. de Miguel, M. Villalba, J. Oyarzabal, A. Calvo, J. Peñuelas; 1Radiopharmacy Unit, Clínica Universidad de Navarra, Pamplona, SPAIN, 2University College, London, UNITED KINGDOM, 3Nuclear Medicine, Clínica Universidad de Navarra, Pamplona, SPAIN, 4Aptamers and Small Molecules Unit, Center for Applied Medical Research (CIMA), Pamplona, SPAIN, 5Molecular Therapies, Center for Applied Medical Research (CIMA), Pamplona, SPAIN, 6Program in Solid Tumors and Biomarkers, Center for Applied Medical Research (CIMA), Pamplona, SPAIN.

EP-0319
Forecasting the production of medical radioisotopes at Extreme Light Infrastructure - Nuclear Physics gamma-beam system
D. Niculae, F. D. Puicea, S. Ilie, W. Luo, P. V. Cuong, G. Cata Daniel, C. A. Ur, D. Balabanski; 1Horia Hulubei National Institute for Physics and Nuclear Engineering, Magurele Ilfov, ROMANIA, 2Extreme Light Infrastructure - Nuclear Physics, Horia Hulubei National Institute for Physics and Nuclear Engineering, Magurele Ilfov, ROMANIA, 3Politehnica University, Bucharest, ROMANIA, 4School of Nuclear Science and Technology, University of South China, Hengyang, CHINA, 5Centre of Nuclear Physics, Institute of Physics, Vietnam Academy of Science and Technology, Hanoi, VIET NAM.

EP-0320 during congress opening hours, e-Poster Area
Cardiovascular System: Basic Science

EP-0321
Quantification of Myocardial Perfusion Defect in Rats with Ultra-high Resolution SPECT System using QPS Software: Comparison with High-resolution Autoradiography
H. Wakabayashi, J. Taki, A. Inaki, T. Hiromasa, K. Shibai, S. Kinuya; 1Dept. of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, JAPAN, 2Advanced Science Research Center, Kanazawa University, Kanazawa, JAPAN.
EP-0321  
Evaluation of diagnostic ability of an artificial neural network for detecting ischemia in myocardial perfusion imaging  
T. Yoneyama¹, K. Nakajima², T. Tsuji¹, K. Yokoyama¹, T. Michigishi¹; ¹Public Central Hospital of Mattou Ishikawa, Hakusan, JAPAN, ²Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, JAPAN.

EP-0322  
Lower Annual Cardiac Events in Diabetics with A Normal Exercise GMPI And A Functional Capacity ≥7 METS on Treadmill  
N. Fatima¹,², D. J. M. baloch¹, A. U. Hussain¹, S. Z. Rasheed¹; ¹Aga Khan University Hospital, Karachi, PAKISTAN, ²Dept of Nuclear Cardiology, Karachi Institute of Heart Diseases (KIHD), Karachi, PAKISTAN.

EP-0323  
The application of ATP stress SPECT cerebral blood flow perfusion imaging in ischemic cerebrovascular disease  
R. Wang¹, L. Yin¹, M. Zhong¹, R. Xu¹, C. Jin¹; ¹Peking University Friendship Hospital, Beijing, CHINA, ²China-Japan Friendship Hospital, Beijing, CHINA.

EP-0324  
Investigation of the Impact of Early Imaging on Systolic and Diastolic Dysfunction Parameters on Gated Myocardial Perfusion Scintigraphy  
A. O. Karacalioğlu, T. Hacıosmanoğlu, Ö. Emre, S. Ince, E. Alagöz, K. Okuyucu, N. Arslan; Gulhane Training and Research Hospital, Department of Nuclear Medicine, Ankara, TURKEY.

EP-0325  
Measurement of Cardiac Function Before and After TAVI (Transcatheter Aortic Valve Implantation) Using Myocardial Scintigram  
K. Yamaguchi; St. Marianna University School of Medicine, Kawasaki, JAPAN.

EP-0326  
Myocardial perfusion and neurotropic SPECT features in patients with primary pulmonary hypertension  
A. A. Ansheles¹, E. G. Valeeva¹, T. V. Martyenyuk¹, R. S. Karpo², V. B. Sergienko²; ¹Russian Cardiology Research Center, Moscow, RUSSIAN FEDERATION, ²Cardiology Research Institute, Tomsk, RUSSIAN FEDERATION.

EP-0327  
Rest/Stress vs. Stress only Myocardial Perfusion Imaging. How many exams could be avoided? Our experience  
S. Sollaku, V. Frantellizzi, G. A. Follacchio, J. Lazri, M. Ricci, M. Liberatore, F. Monteleone, G. De Vincentis; Sapienza University of Rome, Rome, ITALY.

EP-0328  
The relationship between myocardium sympathetic innervation dysfunction with the occurrence of ventricular tachycardia in patients with coronary artery diseases and implantable cardioverter defibrillator  
S. I. Sazonova¹,², T. A. Atabekov¹, R. E. Batalov¹, J. N. Ilushenkova¹, N. V. Varlamova¹, E. A. Nesterov¹, A. S. Semenov¹, S. V. Popov¹, Y. B. Lishmanov¹; ¹Cardiology Research Institute, Tomsk NRM, Tomsk, RUSSIAN FEDERATION, ²Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION.

EP-0329  
Myocardial Glucose Metabolism Evaluated by Fasting 18F-Fluorodeoxyglucose-Positron Emission Tomography in Pulmonary Hypertension  
T. Nakamura, N. Tahara, M. Bekki, Y. Sugiyama, A. Tahara, A. Honda, E. Kumaigai, S. Igata, Y. Fukumoto; Department of Internal Medicine, Division of Cardiovascular Medicine, Kurume University School of Medicine, Kurume, JAPAN.

EP-0330  
Left ventricular diastolic dysfunction in patients with typical angina pectoris and angiographically normal or near normal coronary arteries  
E. Khachirova, L. Samoylenko, O. Shevchenko; Moscow, Moscow, RUSSIAN FEDERATION.

EP-0331  
Higher event rate in patients with high risk Duke Treadmill Score despite of normal exercise gated MPI  
N. Fatima¹, M. U. Zaman¹, A. Zaman¹, R. Tahseen¹, S. Zaman¹, U. Zaman¹; ¹Aga Khan University Hospital, Karachi, PAKISTAN, ²Dow Medical College, Dow University of Health Sciences (DUHS), Karachi, PAKISTAN, ³Civil Hospital, Karachi, PAKISTAN.
EP-0332
Arterial Age Estimation in Patients with Suspected Coronary Artery Disease: a Suitable Tool to Predict Myocardial Ischemia
C. Nappi, V. Gaudieri, A. Genova, G. De Simini, P. Buongiorno, V. Cantoni, R. Green, E. Zampella, R. Assante, S. Daniele, W. Acampa, M. Petretta, A. Cuocolo; 1Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy, Naples, ITALY, 2Institute of Biostructure and Bioimaging, National Council of Research, Naples, Italy, Naples, ITALY, 3Department of Translational Medical Sciences, University Federico II, Naples, Italy, Naples, ITALY.

EP-0333
Pathological Asynchrony and Progressive Local Reduction of Myocardial Perfusion at the Apex as Important Sign of the Coming Loss of Heart Transplant
E. N. Ostroumov, E. D. Kotina, E. V. Migunova, N. E. Kudryashova, A. V. Ploskikh, A. V. Babin, S. Y. Shemakin, V. V. Golubitsky, M. V. Vovchenko; 1N.V. Sklifosovsky Research Institute for Emergency Medicine, Moscow, RUSSIAN FEDERATION, 2Saint Petersburg State University, Saint-Petersburg, RUSSIAN FEDERATION.

EP-0334
Possibility of software program provided Artificial Neural Network (ANN) analysis supporting interpretation of medical staffs in myocardial perfusion SPECT
K. Koyama, H. Yamada, T. Ogura, M. Kanou, K. Maehara, T. Ino, H. Hoshizaki, S. Oshima, T. Toyama; 1Gunma Cardiovascular Center, Maebashi, JAPAN, 2Toyama internal medicine and cardiovascular clinic, Maebashi, JAPAN.

EP-0335
Myocardial Perfusion Imaging With CZT SPECT: Impact of Prone Versus Supine Imaging Positions on Cardiac Respiratory-Motion Magnitude
D. Dao, R. Sabbah, Y. Alattar, C. Coquilla, H. Bouladour, C. Cochon Hospital, APHP, PARIS, FRANCE, 2EA 7334 REMES, Université Paris-Oderat, Sorbonne Paris-Cité, Paris, FRANCE, 3CHU Jean Minjoz, Besançon, FRANCE, 4Centre Hospitalier de Bigorre, Tarbes, FRANCE, 5EA 4662, Université de Franche-Comté, Besançon, FRANCE.

EP-0336
One week extension of a ketogenic diet provides a further decrease in myocardial FDG uptake and a high detectability of myocarditis by FDG PET in rats
A. Clement, S. Poussier, H. Boutley, J. Pierson, M. Lhuillier, A. Kolodziej, J. Olivier, G. Karcher, P. Marie, F. Maskali; 1Nancyclope, Experimental Imaging Platform, Vandoeuvre-Les-Nancy, FRANCE, 2Department of Biochemistry and Molecular Biology, CHRU-Nancy, Nancy, FRANCE, 3Department of Nuclear Medicine, CHRU, Vandoeuvre Les Nancy, FRANCE.

EP-0337
Comparison of the tolerability of Regadenoson and Adenosine in patients undergoing myocardial perfusion scintigraphy
A. Tsaroucha, C. Bourogliani, M. Stathaki, E. Papadaki, M. Alefantis, M. Galanopoulos, H. Mavrakis, M. Markou, S. Koukouraki; 1Department of Nuclear Medicine, University Hospital of Crete, Heraklion, GREECE, 2Department of Cardiology, University Hospital of Crete, Heraklion, GREECE.

EP-0338
SPECT myocardial perfusion assessment in asymptomatic patients with hypercholesterolemia using new quantitative parameters
A. A. Ansheles, L. A. Martirosyan, I. V. Sergienko, V. B. Sergienko; Russian Cardiology Research Center, Moscow, RUSSIAN FEDERATION.

EP-0339
Cardiac contraction motion compensation in gated Myocardial Perfusion SPECT
N. Salehi, M. Farahani, E. Fatemizadeh, S. Farzaneh, M. Ay, 2Tehran university of medical sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 2Research Center for Molecular and Cellular Imaging, Tehran, IRAN, ISLAMIC REPUBLIC OF, 2Electrical Engineering Department, Sharif University of Technology, Tehran, IRAN, ISLAMIC REPUBLIC OF, 2Department of Nuclear Medicine, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.
EP-0340
Prognostic Value of Left Ventricular Shape Index Assessed by Gated SPECT Myocardial Perfusion Imaging
V. Gaudieri1, C. Nappi2, W. Acampa2, E. Zampella2, R. Assante2, T. Mannarino2, A. Genova1, S. Daniele1, G. Melluso2, G. De Simini2, M. Petretta2, A. Cuocolo2; 1Institute of Biostructure and Bioimaging, National Council of Research, Naples, ITALY, 2Department of Advanced Biomedical Sciences, University Federico II, Naples, ITALY, 3Department of Translational Medical Sciences, University Federico II, Naples, ITALY.

EP-0341
Clinical Value of Late post stress Imaging of Gated SPECT Myocardial Perfusion Scintigraphy after Stress-only injection
M. Garcheva-Tsacheva, A. Zonevska, S. Shalamanov, S. Avramova; Acibadem City Clinic Sofia, Sofia, BULGARIA.

EP-0342
Quantitative myocardial-perfusion SPECT. Comparison of three cardiac software programs
S. Alexiou1,2, P. Georgoulas3, G. Angelidis1, V. Valotassiou1, I. Tsougos1, D. Pismadas1, D. Tsivaka1, V. Lakiotis1, A. Kasprian, D. Alexopoulos1, D. Apostolopoulos1, P. Vassilakos1; 1Department of Nuclear Medicine, University Hospital of Larissa, LARISSA, GREECE, 2Department of Nuclear Medicine, University Hospital of Patras, Patras, GREECE, 3Department of Medical Physics, Medical School, University of Thessaly, LARISSA, GREECE, 4Department of Cardiology, University Hospital of Patras, Patras, GREECE.

EP-0343
Higher non-fatal cardiac events in diabetics with HBA1C > 7.3 and normal stress myocardial perfusion scan
N. Fatima1,2, M. U. Zaman2, D. J. M. Baloch3, A. U. Hussaini3, S. Z. Rasheed1; 1Ag Khan University Hospital, Karachi, PAKISTAN, 2Depart of Nuclear Cardiology, Karachi Institute of Heart Diseases (KIHD), Karachi, PAKISTAN.

EP-0344
Hemodynamic and left ventricular mechanical dyssynchrony parameters in patients with ischemic dilated cardiomyopathy: a study with Tc-99m sestamibi stress-rest MPI using adenosine
G. Kumar, A. Sood, A. Ashwathanarayana, M. Parmar, B. Mittal; Post Graduate Institute of Medical Education and Research, Chandigarh, INDIA.

EP-0345
Gated Myocardial Perfusion Scintigraphy and Coronary Arteriography Correlation-A Retrospective Evaluation of Our Clinical Experience
B. T. Okudan1, O. Uçar Elalımı2, B. Özyazgan1, N. Coşkun1, P. Arcan1; 1Health Science University Ankara Numune Research and Training Hospital, Nuclear Medicine Clinic, Ankara, TURKEY, 2Health Science University Ankara Numune Research and Training Hospital, Cardiology Clinic, Ankara, TURKEY.

EP-0346
Left Ventricular Dyssynchrony: Influence of Attenuation Correction in Myocardial Perfusion Scintigraphy in an Overweight/Obese Population
A. Sá Pinto1, T. Vieira2, V. Alves1, S. Chaves1, A. Oliveira1, T. Faria1, J. Pereira1; 1Centro Hospitalar de São João, Porto, PORTUGAL, 2HPP - Medicina Molecular, SA; Lenitudes Medical Center & Research, Santa Maria da Feira, PORTUGAL.

EP-0347
Influence of Stress Test Activity in Left Ventricular Dyssynchrony Evaluation in an Overweight/Obese Population
A. Sá Pinto1, T. Vieira2, V. Alves1, S. Chaves1, A. Oliveira1, T. Faria1, J. Pereira1; 1Centro Hospitalar de São João, Porto, PORTUGAL, 2HPP - Medicina Molecular, SA; Lenitudes Medical Center & Research, Santa Maria da Feira, PORTUGAL.

EP-0348
Cardiac sympathetic neuronal damage precedes myocardial fibrosis in patients with Anderson-Fabry Disease
T. Pellegrino1, M. Imbracio2, V. Piscopo2, M. Petretta2, A. Ponsiglione2, C. Nappi1, M. Puglia2, S. Dell‘Avversana2, E. Riccio1, L. Spinelli1, A. Pisan1, A. Cuocolo1; 1Institute of Biostructure and Bioimaging, National Council of Research, Naples, ITALY, 2Department of Advanced Biomedical Sciences, University Federico II, Naples, ITALY, 3Department of Translational Medical Sciences, University Federico II, Naples, ITALY.

EP-0349
Relationship between focal reduction in cardiac I-123 metaiodobenzylguanidine uptake and left ventricular longitudinal function in patients with Anderson-Fabry Disease
T. Pellegrino1, L. Spinelli3, V. Piscopo1, C. Giudice2, S. Pellegrino1, G. De Matteis1, M. Imbracio2, B. Trimarco1, A. Cuocolo2; 1Institute of Biostructure and Bioimaging, National Council of Research, Naples, ITALY, 2Department of Advanced Biomedical Sciences, University Federico II, Naples, ITALY.
**EP-0350**
A novel clinical risk prediction model for myocardial infarction, coronary revascularization and cardiac death according to clinical, exercise and gated SPECT variables (VHRs)

**EP-0351**
Assessment of normal values of quantitative parameters of tissue muscle perfusion scintigraphy in population without peripheral artery disease - first experience
*N. Manevska1, S. Stojanoski1, D. Pop Gjorceva1, L. Todorovska1, D. Miladinov1, V. Majstorov1; 1Institute of Pathophysiology and Nuclear medicine, Skopje, MACEDONIA, THE FORMER YUGOSLAV REPUBLIC OF; 2Institute of Medical Physiology and Anthropology, Skopje, MACEDONIA, THE FORMER YUGOSLAV REPUBLIC OF.*

**EP-0352**
Clinical Follow-Up Post Coronary Artery Bypass Grafting in Patients with Viable Myocardium on 18F-FDG PET
*A. S. Kokkadan, M. Shankar, S. H. Venkat Rao, G. K. Chaitanya; Narayanan HRudayalaya, Bangalore, Karnataka, INDIA.*

**EP-0353**
Evaluation of multipoint pacing-cardiac resynchronization therapy (CRT) by Gated SPECT myocardial perfusion phase analysis and cardiac 123I-MIBG
*I. Casáns-Tormo1, R. Ruiz-Granell1, L. Bondanza-Saavedra2, R. Díaz-Exposito1, V. López-Prieto1; 1Nuclear Medicine, University Clinic Hospital, Valencia, SPAIN, 2Cardiology, University Clinic Hospital, Valencia, SPAIN.*

**EP-0354**
Hemodynamic Effects of Regadenoson Administration With Respect to MPI Findings: 6 Month Institutional Experience in Greece
*J. Koutsikos, G. Angelidis, E. Iliia, M. Vogiatzis, J. Mamarelis, V. Stefanidis, A. Zafirakis, K. Lazaridis, N. Dimakopoulou; Army Share Fund Hospital (417 NIMTS), ATHENS, GREECE.*

**EP-23**
Cardiovascular System: Clinical Science: Plaque and Vascular Imaging

**EP-0355**
A novel concept of F-18 NaF PET/CT: Molecular Calcium Scoring measured by F-18 NaF PET/CT in detection and global quantification of cardiovascular molecular calcification
*H. Onner, I. Ak Sivrikoz, E. Entok; Eskisehir Osmangazi University School of Medicine, Department of Nuclear Medicine, Eskisehir, TURKEY.*

**EP-0356**
Comparison of different semiquantitative approaches for the diagnosis of graft infection after thoracic and abdominal aortic repair using F18-FDG-PET/CT
*V. Mergen1, J. Einspieler1, M. Mustafa1, H. Wendorff2, K. Thumel1, M. Schwaiger1; 1Department of Nuclear Medicine, Klinikum rechts der Isar TU Muenchen, Munich, GERMANY, 2Clinic for Cardiovascular Surgery, Klinikum rechts der Isar TU Muenchen, Munich, GERMANY.*

**EP-0357**
Metabolic Findings Of 18F-FDG PET/CT In Patients With Suspected Inflammatory Vascular Disease
*I. Plaza de las Heras, B. Rodriguez Alfonso, R. de Teresa Herrera, C. Field Galán, C. Cañales Rodríguez, S. Seijas Marcos, J. Mucientes Rasilla, M. Mitjavila Casanovas; University Hospital Puerta de Hierro, Majadahonda, SPAIN.*

**EP-0358**
Role Of Positron Emission Tomography In The Early Diagnosis Of Infective Endocarditis
*E. Abou Jokh Casas, V. Pabul Núñez, M. Gamido Pumar, A. Martinez, M. Pombo Pasin, A. Anxo Martinez, C. Abou Jokh Casas, F. Pireo, I. Domínguez, S. Argibay, A. Ruibal; Complejo Hospitalario Universitario Santiago de Compostela, Santiago de Compostela, SPAIN.*

**EP-24**
Cardiovascular System: Imaging Systems

**EP-0359**
Myocardial ischemia in female patients with rheumatoid arthritis
*C. Sioka, K. Papadimitropoulos, A. Papadopoulos, J. Al-Boucharali, L. Lakkas, T. Kotsotsios, K. Pappas, A. Fotopoulos; University Hospital of Ioannina, Ioannina, GREECE.*
EP-0360
Improving nuclear cardiology efficiency: Novel CZT technology in combination with 99mTc-tetrofosmin and regadenoson
S. Kranz, Sr.; Nuklearmedizin Wandsbek Markt, Hamburg, GERMANY.

EP-0361
Advantages of simultaneous dual-isotope SPECT imaging using a cardiac semiconductor camera
T. Niimi1, M. Nanasato1, M. Sugimoto1, H. Maeda2; 1Nagoya Daini Red Cross Hospital, Nagoya, JAPAN, 2Nagoya University School of Health Sciences, Nagoya, JAPAN.

EP-0362
Assessment of the impact of small cardiac motions according to motion direction for SPECT images provided by different Anger- and CZT-cameras
L. Imbert1,2, J. Salvadori3, Y. Petegnief5, S. Rémi1, H. Boualahdou1, G. Karcher1,2, P. Y. Marie1,2,3; 1CHU Nancy, Vandoeuvre-lès-Nancy, FRANCE, 2Plateforme d’Imagerie Expérimentale Nancyclotep, Vandoeuvre-lès-Nancy, FRANCE, 3Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, FRANCE, 4CHRU de Besançon, Hôpital Jean Minjoz, Besançon, FRANCE, 5Université de Lorraine, Faculté de Médecine, Nancy, FRANCE.

EP-0363
Radionuclide renoscintigraphy and biochemical markers in the detection of renal dysfunction in patients undergoing myocardial revascularization
Z. Vesnina, Y. Arsenjeva; Cardiology Research Institute, Tomsk, RUSSIAN FEDERATION.

EP-0365
Quantitative evaluation of DNA damage in peripheral blood lymphocyte in patients after cardiac 201Tl/123I-BMIPP study

EP-0366
Cardiac twist quantified by gated myocardial perfusion SPECT: a new insight into nuclear cardiology
H. Javadi1, A. Keshavarz2, N. Shayestehnia1, M. Mansouri2, M. Assadi1; 1Golestan Research Center of Gastroenterology and Hepatology (GRCGH), Golestan University of Medical Sciences (GUOMS), Gorgan, IRAN, ISLAMIC REPUBLIC OF; 2Department of Electrical Engineering, Persian Gulf University, BUSHEHR, IRAN, ISLAMIC REPUBLIC OF. 1The Persian Gulf Nuclear Medicine Research Center, Bushehr University of Medical Sciences (BUMS), BUSHEHR, IRAN, ISLAMIC REPUBLIC OF.

EP-0367
Cardiac SPECT as a predictor of cardiotoxicity in patients with prostate cancer treated with abiraterone acetate after docetaxel therapy
S. S. Medina-Ornelas, F. O. García-Pérez; Instituto Nacional de Cancerología, Mexico City, MEXICO.

EP-0368
Left and Right Ventricular Performance and Cardiovascular Risk in Patients on Maintenance Hemodialysis - an Assessment with Radionuclide Ventriculography at Rest and During Exercise
N. Topuzović1, S. Topuzović2, I. Mihaljević1, 2; 1Osijek University Hospital, Osijek, CROATIA, 2Faculty of Medicine, University of Osijek, Osijek, CROATIA.

EP-0369
Exercise MPI coupled with impedance cardiography for better cardiac workload assessment - preliminary results
S. Osiecki, S. Piszczek, E. Witkowska-Potena, M. Dziuk; Military Institute of Medicine, Warszawa, POLAND.
EP-0370 Amantadine Influences Motor/Exploratory Behavior, but not D2 Receptor Binding in the Rat
S. Nikolaus1, M. Beu1, M. A. De Souza Silva1, F. Wickrath1, A. Müller-Lutz1, C. Antke1, H. Hautzel1, J. P. Huston1, H. Müller1, G. Antoch1, H. Wittsack1; 1University Hospital Düsseldorf, Düsseldorf, GERMANY, 2Heinrich-Heine University, Düsseldorf, GERMANY.

EP-0371 Bicuculline Elevates D2 Receptor Binding in the Rat Thalamus
S. Nikolaus1, H. Wittsack1, M. Beu1, M. A. De Souza Silva1, C. Antke1, F. Wickrath1, A. Müller-Lutz1, G. Antoch1, J. P. Huston1, H. Müller1, H. Hautzel1; 1University Hospital Düsseldorf, Düsseldorf, GERMANY, 2Heinrich-Heine University, Düsseldorf, GERMANY.

EP-0372 Bilateral stimulation of the abdominal vagus modifies dopamine connectivity in acquired obesity
C. Malbert1, C. Picq2, J. Divoux2, C. Henry3; 1INRA, Saint-Gilles, FRANCE, 2Axonic, Valloiris, FRANCE, 3Livanova, Clamart, FRANCE.

EP-0373 Metformin Effect on Brain Metabolism: the Role of Endoplasmic Reticulum
A. Buschiazzo1, A. M. Orengo1, S. Ravera1, L. Emionite1, V. Cossu1, A. Bellini1, S. Morbelli1, M. Bauckneht1, R. Raffaghello1, D. Gandolfo1, G. Bianchi1, S. Bruno1, G. Sambuceti1, C. Marin1, 2, 5; 1Nuclear Medicine Unit, Department of Health Sciences, University of Genoa, Genoa, ITALY, 2IRCCS AOU San Martino-IST, Genoa, ITALY, 5Laboratory of Oncology, G. Gaslini Institute, Genoa, ITALY, 3Department of Experimental Medicine, University of Genoa and IRCCS-AOU San Martino-IST, Genoa, ITALY, 4CNR Institute of Bioimages and Molecular Physiology, Milan, ITALY.

EP-0374 Activations in the gerbil auditory system can be demonstrated in 18F-FDG PET scans during anesthesia with fentanyl but not if ketamine/xylazine is used
M. Kessler1,2, M. Mamachi1,2, R. Beutelmann1, J. Banksta1, T. Ross1, F. Bengel1, G. Klump1,2, G. Berding1,2; 1Department of Nuclear Medicine, Hannover Medical School, Hannover, GERMANY, 2Cluster of Excellence Hearing4all, Hannover and Oldenburg, GERMANY, 3Department of Medical Physics and Radiation Protection, Hannover Medical School, Hannover, GERMANY, 4Animal Physiology and Behaviour Group, Department for Neuroscience, School of Medicine and Health Sciences, University of Oldenburg, Oldenburg, GERMANY.

EP-0375 18F-FET, 18F-FCH and 18F-DOPA uptake on human glioblastoma T98G cells: in vitro study
M. Hodolic1, M. Persico2, L. Lodola1, C. Aprielle1, R. Nano1, F. Pasi1; 1Nuclear Medicine Research Department, Iason, Graz, AUSTRIA, 2Department of Oncohaematology, Nuclear Medicine Unit, Fondazione IRCCS Policlinico San Matteo; Scuola Universitaria Superiore IUSS, Pavia, ITALY, 3Department of Oncohaematology, Nuclear Medicine Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, ITALY, 4Department of Oncohaematology, Nuclear Medicine Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, ITALY, 5Department of Oncohaematology, Radiotherapy Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, ITALY.

EP-0376 Preclinical evaluation of non-invasive imaging molecules of growth differentiation factor-11 for aging-related diseases’ uses
M. C. Weng1, M. H. Wang, C. H. Yang, W. M. Li, W. J. Lin; 1Institute of Nuclear Energy Research, Taoyuan, TAIWAN.

EP-0377 Imaging of basal metabolic activity in primary visual cortex in mice. A FDG-microPET study
A. Buschiazzo1, J. F. Mayo-Vetencourt1, F. Ticconi1, L. Emionite1, C. Eletheriou1, C. Marin1,2, S. Icardi1, A. Bellini1, C. Ghersi1, A. M. Orengo1, F. Benfenati1, G. Sambuceti1,2; 1Department of Health Sciences, University of Genoa, Genoa, ITALY, 2Center for Synaptic Neuroscience and Technology, Istituto Italiano di Tecnologia, Genoa, ITALY, 3Animal Facility, IRCCS San Martino-IST, Genoa, ITALY, 4Laboratory of Oncology, G. Gaslini Institute, Genoa, ITALY, 5Department of Experimental Medicine, University of Genova, Genoa, ITALY.
EP-0378
Brain network alterations in Alzheimer’s disease identified by early-phase PIB-PET
L. Fu1, J. Zhang1, B. Xu2, Y. Fan1, J. Tian1; 1Department of Nuclear Medicine, the Chinese PLA General Hospital, Beijing, CHINA, 2Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, UNITED STATES.

EP-0379
Accuracy of brain FDG PET for detection of Alzheimer’s disease in geriatric inpatients with newly manifested cognitive impairment
C. Lange1, I. Apostolova1,2, A. Maurer1, P. Suppa1,2, H. Amthauer3, W. Brenner1, R. Buchert1,2; 1Department of Nuclear Medicine, Charité - Universitätsmedizin Berlin, Berlin, GERMANY, 2Department of Radiology and Nuclear Medicine, University Hospital Magdeburg, Magdeburg, GERMANY, 3Department of Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, GERMANY.

EP-0380
Clinical value of 18F Florbetaben Amyloid-β PET in a memory clinic.
B. de Kwaasteniet, Jr., D. Raaymakers, senior, J. de Klerk, senior; Meander Medical Center, Amersfoort, NETHERLANDS.

EP-0381
Diagnostic accuracy of FDG-PET/MR for dementia—Estimation of the impact of commercial atlas-based MR attenuation correction
T. Sekine1, A. Buck2, G. Delso3, E. ter Voert4, M. W. Hueliner5, P. Veit-Haibach5, G. Warnock6; 1Nippon Medical School, Tokyo, JAPAN, 2University Hospital Zurich, Zurich, SWITZERLAND, 3GE Healthcare, Waukesha, WI, UNITED STATES OF AMERICA, 4University of Toronto, Toronto, ON, CANADA.

EP-0382
18F-FDG PET/CT Usefulness In Primary Progressive Aphasia (PPA) Variants And In Fronto-Temporal Dementia (FTD) Or Alzheimer’s Disease (AD) Development
S. Nuvoli1, M. R. Piras1, S. Contu2, B. L. J. Pung3, L. Calderoni1, B. Piras1, A. Nieddu1, A. Spanu1, G. Madeddu1; 1Unit of Nuclear Medicine, Clinical and Experimental Medicine DPT, University of Sassari, Sassari, ITALY, 2Unit of Neurology, Clinical and Experimental Medicine DPT, University of Sassari, Sassari, ITALY, 2Geriatrics DPT, Policlinico Sassarese, Sassari, ITALY.

EP-0383
Midbrain Serotonin transporter (SERT) evaluation by 123I-FP-CIT: a one-year retrospective study
M. Ricci1, S. Sollaku, V. Fratelli1, J. Lazri, F. Monteleone, M. Liberatore, G. De Vincentis; Università di Roma “Sapienza”, roma, ITALY.

EP-0384
Topographical overlap of β-amyloid deposition in patients with Alzheimer’s disease and mild cognitive impairment - a voxel-wise [18F] Flurbetapir PET/CT study
G. Agakhanyan1, M. Gennaro1, A. Vergalla1, V. Nicoletti2, G. Manca1, E. Garau1, G. De Laurentis1, E. Spinelli1, S. Bola1, M. Grosso1, C. Radicchi1, G. Tognoni2, U. Bonuccelli2, D. Volterrani2; 1Regional Center of Nuclear Medicine, University Hospital of Pisa, Pisa, ITALY, 2University of Pisa, Pisa, ITALY.

EP-0385
The impact of FDG and amyloid PET-CT in a clinical setting consisting of patients with suspected dementia: the Ferrara experience
A. Farolfi1, I. Rambaldi2, D. Gragnaniello1, P. Milani3, S. Panareo1, I. Santi1, S. Taralli2, M. Bartolomei, V. Tognoli1, C. Cittanti2; 1Nuclear Medicine Unit - S. Orsola-Malpighi Hospital - University of Bologna, Bologna, ITALY, 2University of Bologna, Bologna, ITALY, 3University of Ferrara, Ferrara, ITALY.

EP-0386
Change of glucose metabolism in white matter of AD patients using F-18 FDG PET
Y. Jeong1, H. Yoon, J. Jeong, D. Kong; Dong-A University Hospital, Busan, KOREA, REPUBLIC OF.

EP-0387
How Useful is Amyloid PET in Clinical Diagnosis? A Systematic Review and Meta-analysis
E. R. Fantoni1, A. Chalkidou2,3, G. Farrar1, A. Hammers4; 1GE Healthcare, Amersham, UNITED KINGDOM, 2King’s College London, St Thomas’ Hospital, London, UNITED KINGDOM, 3King’s Imaging Technology Evaluation Centre, St Thomas’ Hospital, London, UNITED KINGDOM, 4King’s College London, London, UNITED KINGDOM.
EP-0388
Coupled imaging with 18F FBB and 18F FDG in AD subjects show a selective association between amyloid burden and cortical dysfunction in brain
A. Chiaramarotti1, A. Castellano1, P. Sannino2, M. Zinari3, E. Di Giorgio3, F. Scalone3, R. Giancioli3, O. Schillaci4,5; 1Department of Biomedicine and Prevention, University Tor Vergata, Rome, ITALY, 2IRCCS Neuromed, Pozzilli, ITALY.

EP-0389
Evaluation of Magnetic Resonance and PET/CT methods with FDG-18F in the diagnosis of Alzheimer’s disease
B. L. Ferrari, G. C. Campos Neto, A. C. Felicia, E. Amaro, S. L. Silva, L. F. Gamara; Hospital Israelita Albert Einstein, São Paulo, BRAZIL.

EP-0390
Semiquantitative analysis of amyloid PET/CT and the performance of its own CT images for ROIs delimitation
F. Segovia Roman1, N. Testard Darde1, R. Sanchez Varo1, P. Sapena-Navales1, A. Gonzalez-Jimenez2, R. Sanchez Sanchez2, E. Triviño-Ibañez2, J. Ramírez Pérez de Inestrosa1, M. Gomez-Rio1, 1Universidad de Granada, Granada, SPAIN, 2Hospital Virgen de las Nieves, IBS, Granada, SPAIN, 3Hospital 9 de octubre, Valencia, SPAIN.

EP-0391
FDG PET as a golden standard in the evaluation of diagnostic significance of metabolic ratios measured with multivoxel H-MRS
J. Khomenko, G. Kataeva, E. Gromova, E. Chernysheva, D. Susin, A. Bogdan; N. P. Bechtereva Institute of the Human Brain, RAS, St. Petersburg, RUSSIAN FEDERATION.

EP-0392
Diagnostic implications of total hemispheric glucose metabolism ratio in Mild cognitive impairment and Alzheimer’s disease
E. A. Segtman1, A. Majdi1, C. Constantin1, C. S. Grue1, H. Dal1, O. Stam1, J. Holm1, M. Fisker1, M. Alavi1, S. Sadigh-Eteghad2, L. Weingarden3, M. Gjedde3, P. Hallund-Carlson2; 1Odense University Hospital, odense, DENMARK, 2National Center Research Center (NSRC), Tabriz, IRAN, 3Delft University of Technology, the Netherlands, ES; 4Division of Nuclear Medicine, Department of Radiology, Perelman School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA.

EP-0393
Clinical Utility of the Brain SPECT with Ioflupane 123I-FP-Scan in the Imagiological Diagnosis of Possible Dementia with Lewy Bodies
J. F. Alban1, M. J. Cunha1, M. Marques1, A. Albuquerque1, G. Costa1,2, J. Pedrosa de Lima1,2,3; 1Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL, 2Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL, 3Instituto das Ciências Nucleares Aplicadas à Saúde (ICNAS), Coimbra, PORTUGAL.

EP-0394
The Metabolic Basis of Cognitive Insight in Psychosis: a Positron Emission Tomography Study
G. Marotta, E. Caletti, G. Delvecchio, R. A. Paoli, M. Cigliobianco, C. Prunas, P. Brambilla, C. A. Altmann; Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, ITALY.

EP-0395
Cerebral metabolism changes and neurocognition in patients with somatic symptoms and related disorders and dissociative disorders: a qualitative PET study
G. Capriotti1, M. Conte1,2, A. Cassale1, G. Lauretti, L. Canedo1,2, D. Prosperi1, F. Scopinaro1; 1Sapienza University, Rome, ITALY, 2Sant’Andrea Hospital, Rome, ITALY.

EP-0396
Protective and restorative effects of the traditional Chinese medicine Jitai tablets against methamphetamine-induced dopaminergic neurotoxicity
S. Xu1, S. Tu1, J. Gao1, J. Liu1, Z. Guo1, J. Zhang1, X. Liu1, J. Liang1, Y. Huang1, M. Han1; 1Beijing Normal University, Beijing, CHINA, 2Chinese PLA General Hospital, Beijing, CHINA, 3Huashan Hospital, Fudan University, Shanghai, CHINA, 4Peking University School of Pharmaceutical Sciences, Beijing, CHINA, 5Yale University School of Medicine, New Haven, CT, UNITED STATES OF AMERICA.

EP-0397
Brain hypothyroidism induces the elevation of serotonin 1A receptor bindings in the limbic system
J. Lee1, Y. Ryu1, J. Park2, K. Lee3, K. Kim3, J. Cho3; 1Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KOREA, REPUBLIC OF, 2Korea Institute of Radiological & Medical Sciences, Seoul, KOREA, REPUBLIC OF.
EP-0398  
Striatal Dopaminergic Dysfunction in Patients with Gambling Disorder  
D. Di Giuda1, F. Caccioli2, M. Pettorruso1, I. Bruno3, V. Valenza3, G. Camardese1, G. Conte1, L. Janiri3, A. Giordano1 1Institute of Nuclear Medicine, Università Cattolica del Sacro Cuore, Rome, ITALY; 2Nuclear Medicine Unit, Ente Ecclesiastico Ospedale Generale “F. Muli”, Acquaviva delle Fonti, Bari, ITALY; 3Institute of Psychiatry, Università Cattolica del Sacro Cuore, Rome, ITALY.

EP-0399  
Anatomo-Functional Correlations of Personality Traits to Aggression and Aggressive Behavior in Cocaine Addicts  
R. Ferrando, C. Pasccovich, M. Langhain, A. Negrin, A. Silveira; Clinics Hospital, University of the Republic, Montevideo, URUGUAY.

EP-29 during congress opening hours, e-Poster Area  
Neurosciences: Neurodegeneration  
EP-0400  
11C-Pittsburgh Compound B PET in Primary Intracerebral Hemorrhage  
R. Yen, H. Tsai, L. Tsai, Y. Chen, J. Jeng; National Taiwan University Hospital, Taipei, TAIWAN.

EP-0401  
Divergent Metabolism in Brain and Spinal Cord in Patients with Amyotrophic Lateral Sclerosis: A FDG-PET/CT Study  
A. Buschiazzo1, C. Marinii, M. Piana1, C. Campi1, A. Bellini1, A. Cistaro1, A. Chiò1, C. De Vecchi1, I. Calamia1, A. M. Massone1, F. M. Nobili1, C. Caponnetto, S. D. Morbelli1, F. Fiz1, M. Bauckneht1, G. Sambuceti1,4; 1Nuclear Medicine Unit, Department of Health Sciences, University of Genoa, Genoa, ITALY; 2CNR Institute of Bioimages and Molecular Physiology, Milan, ITALY; 3Department of Mathematics, University of Genoa, Genoa, ITALY; 4Clinical Department of Neuroradiology, IRCCS Ospedale Sacro Cuore Don Gnocchi, Monza, ITALY; 5Department of Neurology, IRCCS Ospedale Sacro Cuore, Genova, ITALY; 6Department of Neurology, IRCCS Ospedale Sacro Cuore, Genova, ITALY; 7Department of Nuclear Medicine, IRCCS San Martino IST, Genoa, ITALY; 8IRCCS San Martino IST, Genoa, ITALY; 9IRCCS San Martino IST, Genoa, ITALY.

EP-0402  
Hypothalamic dysfunction is related to sleep impairment and CSF biomarkers in Alzheimer Disease  
A. Chiaravalloti1,2, C. Liguori3, M. Nuccetelli4, F. Izzi5, G. Sancesario1, A. Cimini1, S. Bernardini6, O. Schillaci7, N. Mercuri1, F. Placidi1; 1Department of Biomedicine and Prevention, University Tor Vergata, Rome, ITALY; 2IRCCS Neuromed, Pozzilli, ITALY; 3Sleep Medicine Centre, Neurophysiopathology Unit, Department of Systems Medicine, University Tor Vergata, Rome, ITALY; 4Clinical Biochemistry and Molecular Biology, University Tor Vergata, Rome, ITALY; 5Neurology Unit, Department of Systems Medicine, University Tor Vergata, Rome, ITALY.

EP-0403  
Cognitive Reserve (CR) interacts with brain metabolism in regions independent of the PD-related network: an 18F-FDG PET study in Parkinson disease (PD) de novo patients  
H. Efeıı̇rtürk1, M. Bauckneht1, D. Arnold2, A. Buschiazzo1, R. Piva1, F. Ticconi1, M. Pardini3, F. Massa1, A. Bugnolo2, N. Girtler1, J. Accardo2, G. Sambuceti1, F. Nobili1, S. Morbelli1; 1IRCCS San Martino – IST, University of Genoa, Genoa, ITALY; 2Clinical Neurology, IRCCS Ospedale Sacro Cuore, Genova, ITALY.

EP-0404  
Evaluation of age-related metabolic changes in healthy subjects: an italian brain 18F-FDG PET study  
V. Berti1, M. Allocco1, F. Linguanti1, M. L. Calcagni2, A. Cristaro1, U. P. Guerra2, F. Nobili2, S. Pappatà3, S. Sestini4, D. Volterrani5, F. Tusino6, A. Ciacchi7, R. Scaglia7; 1Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences “Mario Seno”, University of Florence, Florence, ITALY; 2Department of Nuclear Medicine, Fondazione Policlinico Universitario Agostino Gemelli, Università Cattolica del Sacro Cuore, Rome, ITALY; 3Clinical Neurology, IRCCS Ospedale Sacro Cuore, Genova, ITALY; 4Clinical Biochemistry and Molecular Biology, University of Genoa, Genoa, ITALY; 5Department of Neuroscience (DINOGMI), University of Genoa, Genoa, ITALY; 6Institute of Biostructure and Bioimaging, CNR, Naples, ITALY; 7Nuclear Medicine Unit, U.S.L. Toscana Centro, Prato, ITALY; 8Nuclear Medicine Unit, University-Hospital of Pisa, Pisa, ITALY.

EP-0405  
Voxel and surface-based structural and functional imaging study in patients with idiopathic REM sleep behavior disorder  
X. Han1, X. Li, W. Tang, H. Yu, P. Wu, C. Zuo; 1PET Center, Huashan Hospital, Fudan University, Shanghai, CHINA; 2Department of Radiology, Huashan Hospital, Fudan University, Shanghai, CHINA; 3Department of Neurology, Huashan Hospital, Fudan University, Shanghai, CHINA.
EP-0406  
[18F]FDG PET imaging study in early phase of unilateral 6-OHDA Parkinson disease rats model submitted to treadmill exercise protocol  
C. C. Real, K. H. Binda, P. C. Garcia, C. G. Carneiro, C. A. Buchpiguel, D. P. Faria, L. R. G. Britto; University of São Paulo, São Paulo, BRAZIL.

EP-0407  
Therapeutic effects of dietary intervention on neuroinflammation and brain metabolism in a rat model of photothrombotic stroke  
E. Kurtys1,2, C. Casteels1, C. C. Real1, U. L. M. Eisel1, J. M. Verkuyld, L. M. BROersen1, H. C. Klein1, R. A. J. O. Dierckx2, J. Doorduin2, E. F. J. De Vries1; 1King’s College London, London, UNITED KINGDOM, 2University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS, 3Catholic University Leuven, Leuven, BELGIUM, 4University of São Paulo, São Paulo, BRAZIL, 5University of Groningen, Groningen, NETHERLANDS, 6Nutricia Research, Utrecht, NETHERLANDS.

EP-0408  
Comparison of [18F]FE-PE2I and [18F]/fluorodopa/PET images in the LPS-induced Parkinsonian rat model  
K. Ma1, H. Ko1, S. Weng1, T. Chou1, C. Tsai1, Y. Huang1, R. Yen1, C. Shiue1; 1Department of Biology and Anatomy, National Defense Medical Center, Taipei, TAIWAN, 2Department of Nuclear Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, TAIWAN, 3Department of Nuclear Medicine, National Taiwan University Hospital, Taipei, TAIWAN, 4Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska University Hospital, Karolinska Institutet, Stockholm, SWEDEN.

EP-0409  
Evaluating the status of serotonin transporters in the LPS-induced rat model using 4-[	extsuperscript{18F}]ADAM/PET  
C. Cheng1, K. Ma1, T. Ho1, S. Weng1, T. Chou1, C. Shiue1; 1Department of Nuclear Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, TAIWAN, 2Department of Biology and Anatomy, National Defense Medical Center, Taipei, TAIWAN.

EP-0410  
Disease-related Metabolic Brain Patterns Associated with Parkinsonian and Cerebellar Subtypes of Multiple System Atrophy  
P. Wu1, J. Wang1, J. Wu1, C. Jiang1, J. Ge1, Y. Ma1, Y. Ma2, C. Zuo3; 1PET Center, Huashan Hospital, Fudan University, Shanghai, CHINA, 2Department of Neurology, Huashan Hospital, Fudan University, Shanghai, CHINA, 3Center for Neurosciences, Feinstein Institute for Medical Research, Manhasset, NY, UNITED STATES OF AMERICA.

EP-0411  
Chronic Exposure to Resveratrol Improves Cerebral Blood Flow and Cognitive Function in Aged Rats  
P. Garrigue1, Y. K. K. Siu2, P. Sere2, M. Alessi, F. Dignat-George1, B. C. B. De Koninck3, P. Demas3; 1Marseille Université, Marseille, FRANCE, 2CNRS, UMR 7241, INSERM U1108, INSERM U1115, France, 3McGill University, Montreal, CANADA.

EP-0412  
Effects of Pioglitazone on Amyloidogenesis, Neuroinflammation and Cognition in a Transgenic Amyloid Mouse Model  
M. Brendel1, M. Deussing1, B. Dehoux1, Y. Shi1, G. Kleinberger1, C. Fuchte, F. Kramer2, F. Gillehaus1, P. Bartenstein1, K. BAHL1, N. Haass1, H. Adelsberger2, A. Rominger3; 1University of Munich, Munich, GERMANY, 2Technische Universität München, Munich, GERMANY, 3DZNE, Munich, GERMANY, 4F. Hoffmann-La Roche, Basel, SWITZERLAND.

EP-0413  
Dopaminergic, Serotoninergic And Glucose Metabolism Disorders At Early Stage Of Disease In Accelerated Mouse Model Of Synucleinopathy  
E. Levigoureux1,2, C. Bouillot3, T. Baron4, L. Zimmer1,2, S. Lancelot1,2; 1Université Claude Bernard Lyon 1, INSERM, CNRS, Lyon Neuroscience Research Center, Lyon, France, Lyon, FRANCE, 2Hospices Civils de Lyon, Lyon, FRANCE, 3CERMEP, Imagierie du vivant, Lyon, FRANCE, 4ANSES, Lyon, FRANCE.

EP-0414  
123I-MIBG Cardiac Scintigraphy And 123I-OIFLUAPANE SPECT Combined Use In Uncertain Parkinsonian Syndromes  
S. Nuvoli1, M. R. Piras2, A. Mulas1, S. L. Pung1, B. Piras1, A. Santonicola1, B. Palumbo3, A. Spanu1, G. Mameddu1; 1Unit of Nuclear Medicine, Clinical and Experimental Medicine DPT, University of Sassari, Sassari, ITALY, 2Unit of Neurology, Clinical and Experimental Medicine DPT, University of Sassari, Sassari, ITALY, 3Section of Nuclear Medicine, Surgical and Biomedical Sciences DPT, University of Perugia, Perugia, ITALY.

EP-30  
Neurosciences: Neurotransmission

EP-31  
Neurosciences: Movement Disorders
EP-0415
Effects of different reconstruction methods on 123I-FP-CIT (DaTSCAN) SPECT quantification
A. Smith1, J. Niedbala1, Y. Dewaraja2, J. C. Dickson1; 1University College London Hospital, London, UNITED KINGDOM, 2University of Michigan, Ann Arbor, MI, UNITED STATES OF AMERICA.

EP-0416
Right versus left onset Parkinson’s disease metabolic patterns: a FDG PET study.
X. Palard-Novello1, P. David2, J. Houvenaghel1, A. Riou1, G. Robert2, S. Drapier1, M. Vérin1, F. Le Jeune1; 1Centre Eugène Marquis, Rennes, FRANCE, 2CHU Rennes, Rennes, FRANCE.

EP-0417
Evaluation of an automated classification method for DaTscanTM SPECT using a volumetric approach to the Southampton Method
D. Miranda, A. Kruzer, A. S. Nelson; MIM Software, Cleveland, OH, UNITED STATES OF AMERICA.

EP-0418
Hypometabolism of the putamen and the pallidum in 18F FDG PET is predictive of clinical disability in multiple system atrophy
F. Hives1, A. Payy-Le Traon2, J. Dupoux3, F. Ory-Magne1, C. Brefel-Courbon1,6,7, O. Rasco8,9, A. Hitzel1, P. Payoux10; 1Department of Nuclear Medicine, University Hospital of Toulouse, Toulouse, FRANCE, 2Institute of Cardiovascular and Metabolic Diseases, National Institute of Health and Medical Research (INSERM), UMR-1048, Toulouse, FRANCE, 3Pharmacoepidemiology Research Unit, INSERM 1027, University of Toulouse, Toulouse, FRANCE, 4Academic Department of Family Medicine, Faculty of Medicine Toulouse, University of Toulouse, Toulouse, FRANCE, 5INSERM UMR1214, Imagerie cérébrale et handicaps neurologiques, Toulouse, FRANCE, 6Department of Neurology, University Hospital of Toulouse, Toulouse, FRANCE, 7Department of Clinical Pharmacology, University Hospital of Toulouse, Toulouse, FRANCE, 8Department of Clinical Pharmacology and Neurosciences, University Hospital and University of Toulouse 3, Toulouse, FRANCE, 9INSERM CIC1436 and UMR825, Toulouse, FRANCE, 10INSERM UMR825, Imagerie cérébrale et handicaps neurologiques, Toulouse, FRANCE.

EP-0419
What is the diagnostic accuracy of FDG-PET in the Atypical Parkinsonian Syndromes
A. Buschiaggio1, A. Chincarini1, D. Volterrani2, G. Puccini3, B. Paghera4, U. P. Guerra5, M. Gregiani5, V. Fiore6, S. Sestini6, C. Mazzeo6, A. Cistaro7, F. Ticconi7, D. Amaldi7, G. Sambuceti7,8, S. Morbelli9,10, F. Nobili11; 1Department of Health Sciences, University of Genoa, Genoa, ITALY, 2National Institute of Nuclear Physics (INFN), Genoa section, Genoa, ITALY, 3University of Genoa, Genoa, ITALY, 4Department of Translational Research and Novel Technologies, University of Pisa, Pisa, ITALY, 5Nuclear Medicine Spedali Civili and University of Brescia, Brescia, ITALY, 6Nuclear Medicine Unit, San Giacomo Hospital, Castelfranco Veneta, ITALY, 7Department of Diagnostic Imaging, Nuclear Medicine Unit N.O.P.-S. Stefano, U.S.L. Toscana Centro, Prato, ITALY, 8Positron Emission Tomography Centre IRMET S.p.A. Euromedic inc., Turin, ITALY, 9Clinical Neurology, Department of Neuroscience (DINOBMI), University of Genoa and IRCCS AOU San Martino-IST, Genoa, ITALY, 10Nuclear Medicine Unit, IRCCS AOU San Martino-IST, Genoa, ITALY.

EP-0420
Negative correlation between dopamine transporter activity at caudate nucleus and the symptom duration at FP-CIT PET/CT in Parkinson disease
J. Park1, J. Park1, A. Lee1, J. Hwang1, S. Park2; 1Soonchunhyang University Bucheon Hospital, Bucheon, KOREA, REPUBLIC OF, 2Soonchunhyang University Seoul Hospital, Seoul, KOREA, REPUBLIC OF.

EP-32 during congress opening hours, e-Poster Area
Neurosciences: Data Analysis & Quantification

EP-0421
Cerebral 18F-FDG PET in macrophagic myofasciitis: an individual SVM based approach for computer aided diagnosis
P. Blanc-Durand1, A. van Der Gucht1, E. Guedj1, M. Abusli2, M. Sebit1, A. Verger1, L. Lerman1, F. Authier1, E. Itti1; 1Henri-Mondor, Créteil, FRANCE, 2La Timone, Marseille, FRANCE, 3CH Strasbourg, Strasbourg, FRANCE.

EP-0422
An investigation for intra-observer reproducibility of FP-CIT SPECT in patients with DLB
A. Okizaki, M. Nakayama, K. Takahashi; Asahikawa Medical University, Asahikawa, JAPAN.
EP-0423  
Impact of Computer Aided Diagnosis (CAD) on DaTSCAN reporting: a pilot study
J. Taylor1, M. Kinsella1, Y. Yang1, J. Azam1, R. Balachandar1, V. Balian1, M. King1, C. Lo1, O. Bandmann2, J. Fenner2; 1Sheffield Teaching Hospitals, Sheffield, UNITED KINGDOM, 2University of Sheffield, Sheffield, UNITED KINGDOM.

EP-0424  
Low-dose PET/MRI of patients with non-lesional epilepsy
J. Cal-Gonzalez1, G. Schramm1, K. Vunckx2, I. Rausch1, L. Shiyam Sundar1, J. Nuyts3, T. Traub-Weidinger4, T. Beyer1; 1QIMP group, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, AUSTRIA, 2KU/ILU Leuven, Department of Imaging and Pathology, Division of Nuclear Medicine, Leuven, BELGIUM, 3Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA.

EP-0425  
The effect of image reconstruction algorithms on topography of characteristic metabolic brain network for Parkinson disease
L. Jensterle1, P. Tomše1, M. Grmek1, Z. Pirtošek2, V. Dhawan1, D. Eidelberg3, Y. Ma1, M. Trošt1; 1University Medical Centre Ljubljana, Department of Nuclear Medicine, Ljubljana, SLOVENIA, 2The Feinstein Institute for Medical Research, Center for Neurosciences, New York, NY, UNITED STATES OF AMERICA.

EP-0426  
Application of Attenuation Correction for Quantitative Brain Perfusion SPECT in Patients with Dementia
A. K. Kondakov1, D. Y. Mosin2, D. S. Kharina2, A. V. Grechko1, I. A. Znamenskiy1; 1Pirogov RNRMU, Moscow, RUSSIAN FEDERATION, 2Central Clinical Hospital of the RAS, Moscow, RUSSIAN FEDERATION, 3Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow, RUSSIAN FEDERATION.

EP-0427  
Comparison of an image-based to an atlas-based set of volumes of interest for DaTScan quantification
R. Fahmi1, S. Zuehlsdorff1; 1GE Healthcare, Amersham, UNITED KINGDOM.

EP-0428  
Comparison of tissue time activity curve based image derived input function estimation methods in simulation for non-invasive CBF imaging
N. Kudomi2, H. Watabe1; 1Faculty Of Medicine, Kagawa University, KAGAWA, JAPAN, 2Cyclotron and Radioisotope Center, Tohoku University, Sendai, JAPAN.

EP-0429  
Validation of non-invasive tracer kinetic analysis of 18F-Florbetaben PET using a patient-friendly dual time-window acquisition protocol
S. Bullich1, A. Jovalekic2, N. Koglin1, G. Becker2, S. De Santii1, O. Sabri1, H. Barthel1; 1Piramal Imaging GmbH, Berlin, GERMANY, 2Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, GERMANY.

EP-0430  
Validation of a dose reduction simulation for neurodegenerative brain indications in 18F-FDG PET/MR
M. Soret1, J. Maisonneuve1, M. Khalifé2, A. Kos3; 1APHP, Hôpital Pitié-Salpêtrière, Paris, FRANCE, 2Institut du Cerveau et de la Moelle épinière, Paris, FRANCE.

EP-0431  
PET Kinetic Modeling with Arterial Sampling of 18F-Choline Uptake in Patients with a Suspected Initial Diagnosis of High Grade Glioma
S. Rubí1,2, P. Bibiloni3, M. Galimés4, M. Toscano1, M. Oporto1, M. Villar1, M. Ortiz1, J. Valera1, G. Matheu1, J. Molina1, M. Brell1,2, M. González1, A. Mir1, C. Peña1,2; 1Hospital Universitari Son Espases, Palma de Mallorca, SPAIN, 2Institut d’Investigació Sanitària Illes Balears (IdISBa), Palma de Mallorca, SPAIN, 3Hospital Quirónsalud Palmoplanas, Palma de Mallorca, SPAIN.

EP-0432  
Assessment of the Impact of Repeat Scanning on Centiloid Scaling Values using PMOD Image Quantification Software
M. Battle1, C. Buckley; GE Healthcare, Amersham, UNITED KINGDOM.

EP-0433  
xSPECT derived absolute SUV: An emerging accurate tool for I-123-ioflupane analysis
M. Jreige1, F. Tabotta1, M. Nicod Lalonde1, R. Fahmi1, N. Schaefer1, G. Allenbach1, J. O. Prior1; 1Centre Hospitalier Universitaire Vaudois (CHUV), LAUSANNE, SWITZERLAND, 2Siemens Medical Solutions USA, Inc., Knoxville, TN, UNITED STATES OF AMERICA.
EP-0434
Decline with Age in Normal Cerebral and Cerebellar Glucose Metabolism in Women and Men Determined by FDG PET/CT
F. Seifar1, N. Parnianfard1, C. Constantinescu2, K. Shakouri1, F. Høilund-Carlsen1; 1Tabriz University of Medical Sciences, Tabriz, IRAN, ISLAMIC REPUBLIC OF, 2Department of Nuclear Medicine, Odense University Hospital, Odense, DENMARK.

EP-0435
Assessment of False-Positive Results in SPM SPECT Group Comparisons
R. Ferrando, C. Pascoich, S. Parra, M. Langhain; Clinics Hospital, University of the Republic, Montevideo, URUGUAY.

EP-0436
The Effect of Obesity on the Availability of Dopamine and Serotonin Transporter
K. Pak1, Y. Lim1, S. Kim2; 1Pusan National University Hospital, Busan, KOREA, REPUBLIC OF, 2Pusan National University Yangsan Hospital, Yangsan, KOREA, REPUBLIC OF.

EP-0437
Interpretation and analysis of hyperperfusion in children with epilepsy
R. Wang, Z. Togao, M. Guo, X. Liu, J. Zhang; Peking University Fudan Hospital, Beijing, CHINA.

EP-0438
Brain death scintigraphy
P. Sirucek1,2, D. Novakova1, M. Havel1, O. Kraft1,2; 1University hospital, Ostrava, CZECH REPUBLIC, 2University of Ostrava, Department of Imaging Methods, Ostrava, CZECH REPUBLIC.

EP-0439
Ictal SPECT injector commercially available: EpilJET
X. Setoain, F. Campos, J. Pavia, O. Vernet, P. Paredes, M. Mayoral, M. Carreña, F. Lomeña; Hospital Clínico de Barcelona, Barcelona, SPAIN.

EP-0440
Neuromodulatory effects of galvanic white noise vestibular stimulation after bilateral labyrinthectomy in the rat
M. Lindner1, E. Elles1, L. Gunther1, A. Gosewisch1, L. Vomacka1, G. Xiong1, R. Oos1, P. Bartenstein1, R. Beck1, A. Zwerger1; 1Deutsches Schwindel- und Gleichgewichtszentrum (DSGZ), Klinikum der Universität München, Klinik und Poliklinik für Nuklearmedizin, Klinikum der Universität München, München, GERMANY, 2Klinik und Poliklinik für Nuklearmedizin, Klinikum der Universität München, München, GERMANY, 3Deutsches Schwindel- und Gleichgewichtszentrum (DSGZ), Klinikum der Universität München, Institut für klinische NeurowissenschaftenNeurologische Klinik, Klinikum der Universität München, München, GERMANY.

EP-0441
Cardiac selectivity of autonomic sympathetic alteration in Parkinson Disease
A. Nieri1, R. Piva1, G. Borgonovo1, V. Cerani1, M. Pennone1, G. Siclari1, F. Ticconi1, M. Sicignano2, G. Villa2, G. Sambuceti1,2, C. Marini2; 1Nuclear Medicine, Department of Health Sciences, University of Genoa and IRCCS AOU San Martino-IST, Genova, ITALY, 2Nuclear Medicine Unit, IRCCS San Martino-IST, Genova, ITALY, 3CNR Institute of Bioimages and Molecular Physiology, Milan, ITALY.

EP-0442
Brain 18F FDG abnormalities in Neurobechet Disease
A. Chiaravalloti1,2, F. Ursini1, S. D’Angelo1, A. Padula1, M. Gilio1, P. Lecce1, S. Pannino1, E. Di Giorgio1, F. Calabria1, O. Schillaci1,2, J. Olivieri1; 1Department of Biomedicine and Prevention, University Tor Vergata, Rome, ITALY, 2IRCCS Neuromed, Pozzilli, ITALY, 3Department of Health Sciences, University Magna Graecia, Catanzaro, ITALY, 4Azienda Ospedaliera Regionale San Carlo, Potenza, ITALY, 5Neuroimaging PET/MRI Research Unit, Institute of Molecular Bioimaging and Physiology, National Research Council, Catanzaro, ITALY.

EP-0443
Post traumatic olfactory dysfunction assessment by 99mTcHMPAO brain imaging
I. Konstantinidis1, I. Iakovou1, E. Tsakiropoulou1, V. Mpalaris1, V. Athanasiou2, D. Katsampoukas1, D. Lo Presti1, S. Georga1, G. Arso1, I. Livanis1; 1Academic ORL dpt, Papageorgiou hsp., THESSALONIKI, GREECE, 2Academic Nuclear Medicine dpt, Papageorgiou hsp., THESSALONIKI, GREECE.

EP-0444
e-Poster not submitted
EP-0444
99mTc HM-PAO Brain Spect Qualitative And Quantitative Analyses (QLA/QNA) In Fibromyalgia Syndrome (FMS) Treated With Hyperbaric Oxigen Therapy (HOT)
S. Nuvoli1, A. Bolognini2, G. Motroni3, L. Calderoni1; 1Unit of Nuclear Medicine, Clinical and Experimental Medicine DPT, University of Sassari, Sassari, ITALY, 2Hyperbaric Center, Sassari, ITALY, 3Unit of Functional Recovery and Rehabilitation AOU Sassari, Sassari, ITALY.

EP-0445
18F-FDG PET/MRI allows improved detection of epileptogenic focus in patients with normal MRI
C. E. Popescu1, F. Caobelli2, R. Mai1, R. Sara1, M. Milella1, A. Liuni1, C. Rossetti1; 1Niguarda Hospital, Milano, ITALY, 2University Hospital Basel, Basel, SWITZERLAND.

EP-0446
Radionuclide cisternography in the detection of cerebrospinal fluid leakage
D. Ben Sellem, L. Zaabar, B. Dhaoadi, I. El Bez, B. Letaief, M. F. Ben Slimene; University of Tunis El Manar, Tunis, TUNISIA.

EP-0447
Brain death scintigraphy - a 12 year experience
A. Fernandes1, T. Faria1, A. Oliveira1, J. Pereira1, P. Coelho1; 1Hospital de São João, Porto, PORTUGAL.

EP-0448
First results of combined brain perfusion SPECT and EEG measurements during speech processing in cochlear-implant users
M. Kessler1,2, I. Schierholz2,3, M. Mamach2,4, F. Wilke4, A. Hahne5, L. Gezvorki5, A. Büchler2,3, F. Bengel1, P. Sandmann1,3, G. Berding1,2; 1Department of Nuclear Medicine, Hannover Medical School, Hannover, GERMANY, 2Cluster of Excellence Hearing4all, Hannover and Oldenburg, GERMANY, 3Department of Otolaryngology, Hannover Medical School, Hannover, GERMANY, 4Department of Medical Physics and Radiation Protection, Hannover Medical School, Hannover, GERMANY, 5Saxon Cochlear Implant Center, University Hospital, Dresden, GERMANY, 6Department of Otorhinolaryngology, University of Cologne, Cologne, GERMANY.

EP-0449
Value of MIBG myocardial scintigraphy in the differential diagnosis of neurodegenerative disorders

EP-0450
Advanced FDG PET Imaging of the Orbits using an Ultra-High Definition Digital PET/CT Approach
C. L. Wright1, K. Binzel1, M. Mohamed1, J. Zhang1, P. Maniawski2, M. V. Knopp1; 1The Ohio State University, Columbus, OH, UNITED STATES OF AMERICA, 2Philips Healthcare, Cleveland, OH, UNITED STATES OF AMERICA.

EP-0451
Brain SPECT Findings In Patients With Malformations Of The Corpus Callosum: Clues For Neuroimaging Reports
L. Wichert-Ana1,2, A. C. Trevisan1, C. E. P. Baltazar1, L. Alexandre-Santos1, F. A. Pitella1, E. N. Itikawa1, M. Kato1, M. V. Simões1, M. V. Santos1, H. R. Machado1, A. C. Sakamoto1, A. C. Santos1; 1Ribeirão Preto Medical School, University of São Paulo - USP, Ribeirão Preto - SP, BRAZIL, 2Bioengineering Interunits Postgraduation Program, São Carlos Engineering School, University of São Paulo - USP, São Carlos - SP, BRAZIL.

EP-0452
Importance Of Using Portable Mini-Gamma Camera In Scintigraphic Brain Death Diagnosis
M. Godoy Bravo, P. Reyes Marles, A. Abella Tarazona, I. Sime Loayza, M. Castellon Sanchez, L. Mohamed Salem, L. Frutos Esteban, J. Navarro Fernendez, M. Nicolas Ruiz, M. Claver Valderas; Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, SPAIN.

EP-0453
Location Of Cerebrospinal Fluid (CSF) Leaks And Treatment With Epidural Blood Patch (EBP) In Spontaneous Intracranie Hypotension Syndrome (SHI) And Assessment Of Neuroimaging, MRI And Radionuclide Cisternography
P. Plaza1, N. Mayolas2, N. Morollon2, E. Rivera2, B. Domenech1, P. Pifarre1, J. Oglio2, A. Banguero2, R. Belvis2; 1Hospital Quironsalud Barcelona, Barcelona, SPAIN, 2Hospital Universitario Dexeus, Barcelona, SPAIN.
EP-0454
Prognostic Contribution Of SISCOM In The Presurgical Evaluation Of Patients With Refractory Epilepsy And Negative 3T MRI
L. Wichert-Ana1,2, E. N. Itikawa1,2, L. Alexandre-Santos1,2, F. A. Pitella1, H. H. Silvah1, A. C. Trevisan3, M. Kato1, V. Alexandre-Junior4, A. P. Martins5, F. N. Nakano3, T. R. Velasco1, A. P. Martins1, M. V. Simões1, A. C. Sakamoto1, A. C. Santos1; 1Ribeirão Preto Medical School, University of São Paulo - USP, Ribeirão Preto - SP, BRAZIL, 2Bioengineering Interunites Postgraduation Program, São Carlos Engineering School, University of São Paulo - USP, São Carlos - SP, BRAZIL.

EP-0455
Contribution of 18F-FDG PET/CT to the clinical diagnosis of Autoimmune Encephalitis: VISUAL vs VOXEL-BASED ANALYSIS
B. Garcia-Garcia, D. Moreno-Ajona, E. Prieto, E. Guillen, A. Minguiz, M. Morales, M. Riverol, J. Callejo, J. Arbizu; Clinica Universidad de Navarra, Pamplona, SPAIN.

EP-0456
Varying Standards for Brain Death Scintigraphy Across National and Professional Societies
L. S. Zuckier1, T. L. McFarland2; 1The Ottawa Hospital, Ottawa, ON, CANADA, 2University of British Columbia, Kelowna, BC, CANADA.

EP-0457
Brain Perfusion Scintigraphy As Confirmation Test Of Absent Cerebral Blood Flow
T. Samardzic, R. Petek, A. Solubic, J. Ljevak, V. Stamboljicic; University Hospital Centre Zagreb, Zagreb, CROATIA.

EP-0458
Betahistine improves vestibular compensation after unilateral labyrinthectomy: a [18F]FDG-µPET study in the rat
M. Lindner1, E. Elles1, L. Günther1, A. Gosewisch1, L. Vomacka1, G. Xiong1, R. Oos2, P. Bartenstein2, R. Beck1, A. Zweragi1; 1Deutsches Schwindel- und Gleichgewichtszentrum (DSGZ), Klinik und Poliklinik für Nuklearmedizin, Klinikum der Universität München, München, GERMANY, 2Klinik und Poliklinik für Nuklearmedizin, Klinikum der Universität München, München, GERMANY.

EP-0459
Role of 18F FDG PET/CT in documenting the disease burden in Pott’s spine
S. Gambhir, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, INDIA.

EP-0460
Reproducibility Of DAT SPECT Quantification
L. Wichert-Ana1,2, L. W. Alexandre-Santos1, A. C. Trevisan1, E. N. Itikawa1, F. A. Pitella1, M. Kato1, M. V. Simões1, J. Tumas1; 1Ribeirão Preto Medical School, University of São Paulo - USP, Ribeirão Preto - SP, BRAZIL, 2Bioengineering Interunites Postgraduation Program, São Carlos Engineering School, University of São Paulo - USP, São Carlos - SP, BRAZIL.

EP-0461
Pilot Study of 64Cu(I) for PET Imaging of Melanoma
L. Jiang1, Z. Cheng2; 1Zhongshan Hospital, Shanghai, CHINA, 2Molecular Imaging Program at Stanford, Stanford University, Stanford, CA, UNITED STATES OF AMERICA.

EP-0462
Preparation of 99mTc-labeled HER2:V2-Pemetrexed for HER2-Positive lung tumor imaging
X. Zhao, T. Ma, Z. Zheng, J. Jing, T. Yu; The Fourth Hospital of Hebei Medica; University, Shijiazhuang, CHINA.

EP-0463
Investigation of MSH receptor expression using 68Ga- and 44Sc-labeled molecules
G. Nagy, A. Kis, N. Dénes, I. Hajdu, I. Kertész, J. Hunyadi, E. Berényi, J. Garai, D. Szikra, G. Tencsényi1; 1Scanomed Ltd., Debrecen, HUNGARY, 2University of Debrecen, Debrecen, HUNGARY.

EP-0464
Positron loss in small objects in preclinical PET
J. de Swart, M. W. Konijnenberg, M. de Jong, M. R. Bernsen, S. F. Petts; Erasmus MC, Rotterdam, NETHERLANDS.
EP-0466
Molecular imaging of APN/CD13 receptors using 68Ga-labelled NGR peptides
A. Kiss1, N. Denes1, J. Peline Szabo1, T. Nagyi1-2, I. Kertesz1, I. Hajdu1, G. Mezo1, G. Farkasinszky1, G. Nagy1, I. Garai2, E. Berenyi1, G. Trenscenyi1,2; 1University of Debrecen, Faculty of Medicine, Division of Nuclear Medicine, Debrecen, HUNGARY, 2Scanomed Ltd., Debrecen, HUNGARY, 1MTA-ELTE, Research Group of Peptide Chemistry, Budapest, HUNGARY.

EP-0467
Application of 68Ga-NODAGA and 68Ga-HBED-CC conjugated procainamide derivatives for preclinical melanoma modeling
N. Denes1, G. Trenscenyi1,2, G. Nagy2, A. Kiss1, A. Vida1, J. P. Szabó1, F. Farkas1, T. Kovács1,2, P. Bay1,2,3, E. Berényi1, I. Garai1, J. Hunyadi1, I. Kertész1; 1University of Debrecen, Faculty of Medicine, Division of Nuclear Medicine, Debrecen, HUNGARY, 2Scanomed Ltd., Debrecen, HUNGARY, 3University of Debrecen, Department of Medical Chemistry, Debrecen, HUNGARY, 1MTA-DE Lendület Laboratory of Cellular Metabolism, Debrecen, HUNGARY, 2Research Center for Molecular Medicine, Debrecen, HUNGARY, 3University of Debrecen, Department of Dermatology, Debrecen, HUNGARY.

EP-0468
In Vivo Imaging Of Ischemia-Reperfusion Using (68)Ga-Labeled Peptides
G. Farkasinszky1, N. Denes1, J. S. Peline1, T. Nagyi1, G. Trenscenyi1,2, I. Kertész1, A. Kis1, G. Mezo1, J. Hunyadi1; 1Division of Nuclear Medicine, Faculty of Medicine, University of Debrecen, Debrecen, HUNGARY, 2Scanomed Ltd., Debrecen, HUNGARY, 3Research Group of Peptide Chemistry, MTA-ELTE, BUDAPEST, HUNGARY, 4Department of Dermatology, University of Debrecen, DEBRECEN, HUNGARY.

EP-0469
M. Kim1,2, T. Ishizu1,2-3, S. Forsback1, O. Eskola1, E. Arponen1, J. Tuomela1, H. Mihn1-3, T. J. Gronroos1,2,4; 1Turku PET Centre, University of Turku, Turku, FINLAND, 2MediCity Research Laboratory, University of Turku, Turku, FINLAND, 3Graduate School of Medicine, Gunma University and apan Society the promotion of science, Gunma and Tokyo, JAPAN, 4Department of Cell Biology and Anatomy, University of Turku, Turku, FINLAND, 1Department of Oncology and Radiotherapy, Turku University Hospital, Turku, FINLAND, 2Department of Oncology and Radiotherapy, Turku University Hospital, Turku, FINLAND.

EP-0470
Multimodal imaging of tumor invasion by targeting integrin αβ3 in a preclinical model of lung metastasis
F. Iommelli1, V. De Rosa1, M. Monti1, C. Terlizzi1, M. Gramanzini1, S. Gargiulo1, S. Del Vecchio1; 1Institute of Biostructures and Bioimaging, National Research Council, Naples, ITALY, 1Department of Advanced Biomedical Sciences, University “Federico II”, Naples, ITALY.

EP-0471
Optimization of High Throughput 18FDG Murine Imaging Using a Clinical Digital PET/CT System
K. Briley1, K. Binzel1, M. Friel1, R. Moore1, J. Ellis1, J. Zhang1, P. Maniawski1, M. V. Knopp1; 1The Ohio State University, Columbus, OH, UNITED STATES OF AMERICA, 1Philips Healthcare, Cleveland, OH, UNITED STATES OF AMERICA.

EP-0472
Endoscopic non-ablative fractional laser irradiation suppresses early tumor growth in orthotopic colon tumor model
S. Yoo1,2, G. Oh1, A. Safi1, S. Hwang1, Y. Seo1, K. Lee2, H. Song1, H. Bomi1, J. Min1, Y. Kim1, C. Chung1; 1Department of Nuclear Medicine, Chonnam National University Hwasun Hospital, Jeollanam-do, KOREA, REPUBLIC OF, 2Department of Biomedical Science and Engineering, Institute of Integrated Technology (IIT), Gwangju Institute of Science and Technology (GIST), Gwangju, KOREA, REPUBLIC OF, 1School of Mechanical Engineering, Gwangju Institute of Science and Technology (GIST), Gwangju, KOREA, REPUBLIC OF, 1Department of Pathology, Chonnam National University Hwasun Hospital and Medical School, Jeollanam-do, KOREA, REPUBLIC OF, 1Department of Nuclear Medicine, Chonnam National University Hospital, Gwangju, KOREA, REPUBLIC OF, 1Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN, UNITED STATES OF AMERICA.

EP-0473
Fluciclovine is a potential imaging biomarker of glutamine utilisation in breast cancer
EP-0474
Diagnostic Importance of 18F-FDG PET/CT Parameters And Total Lesion Glycolysis (TLG) in Differentiating Between Benign And Malignant Adrenal Lesions
E. Ciftci, B. Turgut, A. Cakmakicilar, S. Erturk; Cumhuriyet University, School of Medicine, Department of Nuclear Medicine, Sivas, TURKEY.

EP-0475
Does F18FDGPET/CT is Able to Differentiate Between Histological Subtypes of Lung Adenocarcinoma (LADC) and Their Mutation Status (ALK, EGFR) - Tertiary Referral Centre Experience
L. Calovi Motschenbacher, A. Parsai, M. Sheaff, S. Ellis, T. O’Shaughnessy, H. Jan, E. Nowosinska; Barts Health, London, UNITED KINGDOM.

EP-0476
Neutrophil Extracellular Traps as a New Target for Imaging of Integrin-Dependent Dissemination of Cancer Cells
M. Monti1, F. Lombriller2, V. De Rosa3, M. V. Carriero1, G. Di Minno1, S. Del Vecchio1; 1Department of Clinical Medicine and Surgery, University “Federico II”, Naples, ITALY; 2Institute of Biostructures and Bioimages, National Research Council, Naples, ITALY; 3Department of Experimental Oncology, National Cancer Institute, Naples, ITALY.

EP-0477
Volumetric metabolic parameters on FDG-PET independently predicts PD-L1 expression in patients with non-small cell lung cancer (NSCLC)
M. Jreige, I. Letovanec, J. O. Prior, N. Schaefer; Centre Hospitalier Universitaire Vaudois (CHUV), LAUSANNE, SWITZERLAND.

EP-0479
18F-FDG-PET imaging of genetically engineered mouse models elucidates oncogenic function of Nlp and FAM135B
W. Xiao1, D. Dong1, J. Li1, D. Li1, S. Han1, H. Yan1, L. Wang1, Q. Xie1, Q. Zhan1; 1National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, CHINA; 2Department of Biomedical Engineering, Huazhong University of Science and Technology, Wuhan, CHINA; 3Wuhan Raydata Technology Co., Ltd, Wuhan, CHINA.

EP-37 during congress opening hours, e-Poster Area
Basic Oncology: Animal Models
EP-0480
FDG-PET/CT in the incidental diagnosis of tumour thrombosis

EP-0481
Ex-vivo experience with beta- Radiation and Radioguided Surgery Technique in meningioma and neuroendocrine patients
C. M. Grana1, R. Faccini1, M. Schiatti2, M. Colandrea1, E. Solfaroli Camillocci1, S. L. V. Fracassi1, L. Gilardi1, S. M. Baj1, P. A. Rocca1, L. L. Travaini1, S. Papi1, S. Marganti1, M. Cremonesi1, M. E. Ferrari1, V. Bocci1, C. Mancini Terracciano2, A. Russomando2, F. Collamati2, E. Bertani1, E. Pisa1, L. Funicelli1, N. Fazio1, L. Bodei1, R. Ghisini1, M. Chinol1; 1Istituto Europeo di Oncologia, Milano, ITALY; 2Dipartimento di Fisica, Sapienza Università di Roma; INFN Sezione di Roma, Roma, ITALY; 3Istituto Neurologico Besta, Milano, ITALY; 4INFN Sezione di Roma, Roma, ITALY; 5Center for Life Nano Science@ Sapienza, Istituto Italiano di Tecnologia, Roma; Centro Cientifico Tecnologico de Valparaíso-CCTVal, Universidad Tecnic Federico Santa Maria, Chile, Roma, ITALY; 6INFN Sezione di Roma; Dip. Scienze di Base e Applicate per l’Ingegneria, Sapienza Univ. di Roma, Roma, ITALY; 7Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.

EP-0482
Influence of androgens (AND) and androgen metabolites on the Expression of the prostate specific Antigen (PSMA) and the cell cycle in in Vitro models of castration resistant prostate carcinoma
EP-0484
Evidence of therapeutic effect of Atorvastatin enhances initial penetration of trastuzumab to solid tumors in a HER2-positive gastric cancer model
J. Kim, Y. Lim, S. Lim; Korea Institute of Radiological & Medical Sciences, Seoul, KOREA, REPUBLIC OF.

EP-0485
Inhibition Of Autophagy During Epithelial To Mesenchymal Transition In Renal Cell Carcinoma Cells: Potential Therapeutic Role With mTOR Inhibitor
S. Bhattacharyya, M. Singla; Postgraduate Institute of Medical Education and Research, Chandigarh, INDIA.

EP-39 during congress opening hours, e-Poster Area Clinical Oncology: Brain

EP-0486
L. Papp, N. Potsch, M. Grahovac, V. Schmidbauer, M. Mitterhauser, W. Wadsak, T. Beyer, M. Hacker, T. Traub-Weidinger; Medical University of Vienna, Vienna, AUSTRIA.

EP-0487
Diagnostic Value of PET with [11C] Methionine in Recognizing Early Progression of Cerebral Glioma from Pseudoprogression

EP-0488
18F-Fluorocholine PET/CT in patients with newly diagnosed glioma: association with tumor biology. Preliminary analysis (FuMeGA study)

EP-0489
[18F-FDOPA PET And IDH Mutation As Prognostic Factors Of Velocity Of Diameter Expansion In Newly Diagnosed Diffuse Grade II-III Gliomas
S. Isal, G. Gauchotte, F. Rech, M. Blonski, S. Plane1; M. Chawki, G. Karcher, P. Marie, L. Tailandier, A. Verger;1 Nuclear Medicine, CHU Nancy, Nancy, FRANCE, 2Anatomopathology, CHU Nancy, Nancy, FRANCE, 3Neuro-surgery, CHU Nancy, Nancy, FRANCE, 4Neuro-oncology, CHU Nancy, Nancy, FRANCE, 5Neuro-radiology, CHU Nancy, Nancy, FRANCE.

EP-0490
Relationship between MRI contrast enhancement and 18F-Fluorocholine PET/CT to improve radiotherapy planning in resected high grade glioma patients

EP-0491
FBPA PET/CT of brain tumors after radiotherapy: a differential diagnosis between tumor recurrence and radiation necrosis
R. Beshr, K. Isohashi, T. Watabe, V. Romanov, E. Shimosegawa, J. Hatazawa; Osaka University, Graduate School of Medicine, Yamada Oka 2-2, Suita City, Osaka, JAPAN.

EP-0492
Utility of delayed-phase C-11 methionine PET in the evaluation of focal brain lesions with high methionine uptake: A preliminary study
K. Takenami, Y. Toyama, M. Saito, K. Takase; Tohoku University Hospital, Sendai, JAPAN.

EP-0493
Dynamic 18F-FET-PET predicts a highly malignant epigenetic signature of IDH wildtype and IDH mutant glioma.
EP-0494 Value of early and delayed imaging for 18F-FDOPA PET high grade gliomas evaluation
M. Paquet1, J. Doyen1, L. Mondot1, E. Saada Bouzid1, P. Bondiau1, F. Almairac2, D. Fontaine2, S. Chanalet3, M. Ouvrier2, C. Zwarthoed2, A. Schiazzai2, D. Benisy1, O. Humbert1, V. Bourgi1, J. Darcourt1; 1CAL, nice, FRANCE, 2CHU, nice, FRANCE.

EP-0495 FET PET in Brain Tumors: Higher Background Activity under Dexamethasone Therapy and in Female Patients
C. Stegnay, G. Stoffels, E. Rota-Kops, C. Fillé, L. Phillip, B. Neumaier, K. Langen; Forschungszentrum Juelich, Juelich, GERMANY.

EP-0496 F18-FET tumour to background ratio is a predictor of rate of disease progression in post surgery patients with Glioblastoma
J. R. Cain1,2, M. Bynevelt2, A. Nowak3, N. Loh1, L. Morandeau3, R. Francis3; 1Lancashire Teaching Hospitals, Preston, UNITED KINGDOM, 2Neurological Intervention & Imaging Service of WA, Perth, AUSTRALIA, 3Sir Charles Gairdner Hospital, Perth, AUSTRALIA.

EP-0497 Stereotactic histologic correlation of dynamic FET-PET/MRI in untreated high-grade glioma patients
T. Pyka1, J. Gempt1, M. Lukas1,2, J. Schlegel1, F. Ringel1,2, S. Forster1,4, C. Zimmer1, C. Preibisch1, M. Schwager1; 1TU Munich, Munich, GERMANY, 2Charité Universitätsmedizin Berlin, Berlin, GERMANY, 3Universitätzmedizin Mainz, Mainz, GERMANY, 4Klinikum Bamberg, Bamberg, GERMANY.

EP-0498 Prognostic significance of restaging 18F-FDG PET/CT for head and neck cancer patients
K. Musaiyeva1, B. M. M老yuk1, O. Solodiankova1, V. M. Kryukov1, E. K. Khvatov1, V. A. Khvatova1; 1Tomsk National Research Medical Center of the Russian Academy of Sciences Cancer Research Institute, Tomsk, RUSSIAN FEDERATION, 2National Cancer Institute, Kyiv, UKRAINE.

EP-0499 Predictive value of 11C-Metionine PET/CT (MET-PET) in the restaging of adenoid cystic carcinoma (ACC) of head and neck
F. Scalorbi1, E. Lodi Rizzini1, D. Calabrò2, G. Lauretti2, P. Castellucci1, F. Dionisi1, A. Tarisitani1, S. Battaglia1, D. Borsetto1, G. M. Lima1, S. Fanti1; 1Department of Nuclear Medicine, S Orsola-Malpighi University Hospital, Bologna, ITALY, 2Department of Nuclear Medicine, Andrea University Hospital, Rome, ITALY, 3Department of Oncology, Maxillofacial Surgery, Orsola-Malpighi University Hospital, Bologna, ITALY, 4Department of Otorhinolaryngology, University of Padova, Padova, ITALY.

EP-0500 Parotid incidentalomas on positron emission tomography: what is their clinical significance?
R. Barbara, D. Pawaroo, C. Beadsmoore, N. Hujairi, D. Newman; Norwich Radiology, Norwich Radiology Academy, Norwich, UNITED KINGDOM.

EP-0501 Diagnostic efficacy of FDG-PET/CT in head/neck carcinoma of unknown primary with cervical lymph node metastases
F. E. Noltenius, A. Pfeistroff, D. Librizzi, M. Luster; Philipps-Universität Marburg, Marburg, GERMANY.

EP-0502 99mTc sestamibi spect in evaluation of neoadjuvant chemotherapy effectiveness in larynx/laryngopharynx cancer patients
A. Medvedeva1, V. Chernov, R. Zelchan, Yu. Belevich, S. Chizhhevskaya, E. Choyzonov, I. Sinilkin; 1Tomsk National Research Medical Center of the Russian Academy of Sciences Cancer Research Institute, Tomsk, RUSSIAN FEDERATION, 2National Research Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION.

EP-0503 Textural and shape features of pretreatment lymph nodes images of FDG PET/CT: correlation to extranodal extension and impacts on survival of patients with nasopharyngeal squamous cell carcinoma
N. Cheng1, Y. D. Fang1, T. Yen1; 1Chang Gung Memorial Hospital, Keelung, TAINAN, 2Department of Biomedical Engineering, National Cheng Kung University, Tainan City, TAINAN, 3Chang Gung Memorial Hospital, Linkou, Taoyuan City, TAINAN.
EP-0504
Sentinel lymph node in early oral cavity squamous cell carcinoma

EP-0505
Morphologic and Metabolic differences between HPV-positive and HPV-negative Oropharyngeal cancer patients as detected with FDG F18 PET/CT
A. M. El-Sabbagh, Z. Asiri, A. Rayan, S. Frye, F. Ahmed, R. Walker, R. Muzaffar, M. M. Osman; Saint Louis University, Saint Louis, MO, UNITED STATES OF AMERICA.

EP-0506
18F-FDG-PET/CT In Locoregional Staging in Oropharynx, Oral Cavity and Lip Tumors and Correlation with Sentinel Lymph Node Biopsy
F. Gomez-Caminero Lopez, P. Garcia-Talavera San Miguel, B. Perez Lopez, P. Blanco Perez, J. Serradilla Lopez, C. Achury Murcia, D. Rampin, D. Rubello; Complejo Asistencial Universitario de Salamanca, Salamanca, SPAIN.

EP-0507
Head-and-neck dedicated acquisition after whole-body 18F-FDG PET/CT in head-and-neck tumours: can it provide a real added value?
M. C. Marzola, S. Chondrogiannis, G. Grassetto, E. Milan, M. L. Manerchia, L. Tamiso, L. Rampin, D. Rubello; Nuclear Medicine - PET/CT centre, Santa Maria della Misericordia Hospital of Rovigo, Rovigo, ITALY.

EP-0508
FDG PET/CT And MRI For The Assessment Of Therapeutic Response In Nasopharyngeal Cancer
F. Aydin, T. Bukulmez, K. Karaalı, S. Bozkurt, M. Genc; Akdeniz University Medical School, Antalya, TURKEY.

EP-0509
The impact of PET/CT in therapeutic management of patients with lymph node metastasis and cancer of unknown primary
P. Nikolova, V. Haidzhiyska, T. Petrov; University Hospital Alexandrovskia, Sofia, BULGARIA.

EP-0510
Effect of postoperative thyrotropin suppression on bone mineral density in postmenopausal women with differentiated thyroid carcinoma
D. Wang, Y. Huo, C. Ma; Affiliated Xinhua Hospital of Shanghai Jiaotong University School of Medicine, Shanghai, CHINA.

EP-0511
Stratification of recurrent differentiated thyroid cancer with elevated thyroglobulin and negative I-131 whole body scan by restaging 18F FDG PET/CT
K. Okuyucu, S. Ince, E. Alagoz, O. Erner, H. San, E. Balkan, A. Ayan, B. Gunalp, A. O. Karacalaglu, N. Arslan; Gulhane Training and Research Hospital, Department of Nuclear Medicine, Ankara, TURKEY.

EP-0512
SPECT/CT somatostatin-receptor scintigraphy in Medullary Thyroid Cancer
S. Sergieva, M. Atanasova, A. Fakirova, B. Robev, A. Saint-Georges; Sofia Cancer Center, Sofia, BULGARIA, Central Hospital Plovdiv, BULGARIA, Military Medical Academy, Sofia, BULGARIA, UH“St. Ivan Rilsky, Sofia, BULGARIA.

EP-0513
Diagnostic Accuracy of [99mTc]Tc-Sestamibi in the Assessment of Thyroid Nodules
A. Yordanova, S. Mahjoob, P. Lingohr, A. Türler, H. Palmedo, H. Biersack, G. Kristiansen, M. Essler, H. Ahmadzadehfar; Nuclear Medical Department of the University Hospital of Bonn, Bonn, GERMANY, Institute of Radiology and Nuclear Medicine, BG Kliniken Bergmannsheil, Bochum, GERMANY, Department of Surgery of University Hospital Bonn, Bonn, GERMANY, Department of General and Abdominal Surgery, Johanniter-Krankenhaus, Bonn, GERMANY, Institute of Radiology and Nuclear Medicine and PET-CT Center, Bonn, GERMANY, Institute of Pathology of University Hospital Bonn, Bonn, GERMANY.

EP-0514
68Ga-DOTA-NOC and 18F-FDG PET/CT for the Diagnosis of Iodine-refractory Differentiated Thyroid Cancer: pilot studies
S. Li, F. Wang, X. Yao, R. Liu, L. Zhang; Nanjing First Hospital, Nanjing, CHINA.
EP-0515
The role of air pollution in the incidence and mortality of thyroid cancer (TC) in 27 countries of the European Union for the years 1992, 2002, 2012
E. Giannoula1, I. Katsikavelas2, G. Giannoula1, I. Iakovou1, 1Academic Nuclear Medicine dpt, Papageorgiou hsp., Thessaloniki, GREECE, 2Aristotle University, Thessaloniki, GREECE, 3Faculty of General Medicine, Comenius University, Bratislava, SLOVAKIA.

EP-0516
Role of radioguided occult lesion localization (ROLL) in the management of cervical recurrences from differentiated thyroid cancer
V. Garbaccio1, M. Menga2, G. Mensa3, D. Deandreis1, R. E. Pellentoi1, 1Nuclear Medicine AOU S. Giovanni Battista, Città della Salute e della Scienza, Torino, ITALY, 2Nuclear Medicine Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, ITALY, 3General and Oncologic Surgery, Thyroid Unit AO Ordine Mauriziano Umberto I, Torino, ITALY, 4Nuclear Medicine AO Ordine Mauriziano Umberto I, Torino, ITALY.

EP-0517
The relevance of the BRAFV600E mutation in the treatment of the Papillary Thyroid Carcinoma
O. Ajuria, T. Navarro Martinez, B. Lorente Castro, J. Castro Beiras; Hospital Ramon y Cajal, Madrid, SPAIN.

EP-0518
An audit of Differentiated Thyroid Cancer (DTC) patients, post-surgery and Radiiodine therapy in a tertiary care centre and the effect of the ATA 2015 on them in terms of risk stratification and use of RAI
V. Rangarajan, A. Agrawal, S. Choudhury, G. Pantavaidy, P. Pat, S. Shah, A. D. Puranik, N. Purandare, A. K. D'Cruz; Tata Memorial Centre, Mumbai, INDIA.

EP-0519
Serum Calcitonin Increase-guided evaluation of MTC in Patients with Multinodal Goiter and correlation with Tc99m-DMSA (V) scintigraphy
V. Sukhov1, P. Kirchenko1, A. Marin1, W. Wiedermann1, K. Zaplatnikov1, 1Military Medical Academy, St. PETERSBURG, RUSSIAN FEDERATION, 1MAZ Nuclear Medicine, Nurnberg, GERMANY.

EP-0520
Correlation between stimulated thyroglobulin levels and positive 18F-FDG PET/CT findings in DTC patients with radiiodine refractory disease
D. Srbovan, S. Lučić, A. Peter, E. Matovina, V. Cimbalević; Institute of Oncology Vojvodina, Sremska Kamenica, SERBIA.

EP-0521
Retropharyngeal lymph nodes metastases in differentiated thyroid carcinoma might be under estimated
D. Benisvy, J. Birtwise Peyrottes, J. Santini, C. Zwarthoed, A. Schiazza, O. Humbert, J. Darcourt; Centre Antoine Lacassagne, Nice, FRANCE.

EP-0522
Evaluation of calcium stimulation test for the diagnosis and follow-up of medullary thyroid cancer: comparison with pentagastrin test
E. Rainer, A. Gesser, M. Krebs, B. Niederle, C. Scheuba, A. Haug, M. Hacker, S. Li; Medical University of Vienna, VIENNA, AUSTRIA.

EP-0523
Usefulness Of SPECT/CT Imaging In Patients With Differentiated Thyroid Carcinoma
S. Ucak Semirgin1, T. Basagulu1, Z. Sahin1, M. Sahin1, O. Yapici1; 1Ondokuz Mayis University Nuclear Medicine Department, Samsun, TURKEY, 2Yildiz Medstar Hospital, Antalya, TURKEY.

EP-42 during congress opening hours, e-Poster Area
Clinical Oncology: Breast
EP-0524
The Role of 18F-FDG PET/CT In the Evaluation of Tumor Marker Increase In Breast Cancer
I. Goktas, H. Cayvari; Ordu State Hospital, Clinic of Nuclear Medicine, Ordu, TURKEY.

EP-0525
Diagnostic accuracy of mammography and scintimammography with 99m Tc-MIBI in detection of early breast cancer
S. Novikov1, S. Kanaev, A. Chemaya, P. Krzhivitskiy, P. Krivorotka, L. Jukova, A. Artemyeva; N.N. Petrov Institute Oncology, St Petersburg, RUSSIAN FEDERATION.

EP-0526
Comparison of the efficiency for Tc-99m Tin-colloid and Tc-99m Phytate in sentinel node detection in breast cancer patients
J. Seok; Chung-Ang University Hospital, Seoul, KOREA, REPUBLIC OF.

EP-0527
Comparison of subareolar Injection lymphoscintigraphy with the 1 day and the 2 day protocol for the detection of sentinel lymph nodes in patients with breast cancer
J. Seok; Chung-Ang University Hospital, Seoul, KOREA, REPUBLIC OF.
EP-0528
Volumetric Retention Indexes by Early Delayed Dual-time-point FDG PET/CT Do Not Correlate with Prognostic Factors in Invasive Breast Cancer
H. Song; Jeju National University School of Medicine, Jeju-si, KOREA, REPUBLIC OF.

EP-0529
Evaluation of Metabolic Character of Breast Cancer with F-18 FDG PET/CT
H. Öner; E. Entek, M. Dinçer, S. M. Ercasap, Eskisehir Osmangazi Universitesi, Eskisehir, TURKEY.

EP-0530
CEA, CA15.3 and 18-FDG PET in the follow-up of early breast cancer patients: a prospective, multicentric, randomized trial—KRONOS patient-oriented new surveillance study Italy
E. Barbieri1, C. Zamagni1, M. Giori1, L. Maninati1, P. Steiber2, D. Rubino1, R. Wirtz2, A. Bernardi3, N. Cacciari3, S. Quercia3, M. Lenzi3, M. Cubelli3, C. Pizzirani3, M. Carapelle1, M. Pagliaro3, S. Tomasi1, S. Toracchio1, R. Baun2, S. Fanti1; Policlinico S. Orsola Malpighi, Bologna, ITALY, Centro Regionale Indicatori Biochimici di Tumore, Mestre, ITALY, Istituto Nazionale Tumori, Milano, ITALY, Institute of Clinical Chemistry, Munich, GERMANY, STRATIFYER Molecular Pathology GmbH, Cologne, GERMANY, Zentralklinik Bad Berka, Bad Berka, GERMANY.

EP-0531
Evaluation of metastatic breast cancer patients on FDG PET scan with PERCIST 1.0: Experience from University Hospital Oman
A. Jain, A. K. Mittal, S. Raniga, K. Al Baimani, S. Kumar, H. Al Dhuhi; Sultan Qaboos University Hospital, Muscat, OMAN.

EP-0532
Axillary staging for breast cancer during pregnancy. Feasibility and safety of sentinel lymph node biopsy
S. N. Han1, F. Amant1, E. H. Cardonick2, S. Loibl3, F. A. Peccatori1, O. Gheyens2, C. A. Sangalli4, V. Nekludova4, K. Dahl Steffensen5, M. Mhallem Gziri8, C. A. Sangalli3, V. Nekludova8, K. Dahl Steffensen5, M. Mhallem Gziri8; 1University Hospitals Leuven, Belgium, 2Cooper Medical School at Rowan University, Camden, NJ, UNITED STATES OF AMERICA, 3German Breast Group, Neu-Isenburg, GERMANY, 4Istituto Europeo di Oncologia, Milano, ITALY, 5Vejle Hospital, Veje, DENMARK, 6University Hospital Gasthuisberg, Leuven, BELGIUM, 7Universitätsmedizin Mainz, Mainz, GERMANY, 8Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, NETHERLANDS, 9Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, NETHERLANDS, 10Ospedale San Raffaele, Milano, ITALY.

EP-0533
68Ga-PSMA PET-CT in the evaluation of Metastatic Breast Cancer
S. S. Medina Ornelas, F. O. García-Pérez; Instituto Nacional de Cancerología, Mexico City, MEXICO.

EP-0534
Clinical Experience of a dedicated Breast PET and Whole Body PET / CT for Breast Imaging with F-18 FDG
K. Uno1, H. Sasamori1, J. Wu2, M. Irie3, T. Nakajima3, Y. Akiba3, Y. Tsuchiya4, N. Baba2; 1gaienhigashi clinic, Tokyo, JAPAN, 2Tokyo Kyousai Hospital, Tokyo, JAPAN.

EP-0535
Clinical value of prone position 18F-FDG PET/CT and MRI for predicting nipple-areolar complex involvement in breast cancer
J. Yoo, B. Kim, J. Chung, H. Yoon; Ewha Womans University School of Medicine, Seoul, South Korea, Seoul, KOREA, REPUBLIC OF.

EP-0536
Comparison of 18 F PET CT and tumor marker findings in advanced breast cancer patients with progression
E. E. Bayar1, E. O. Gur2, G. G. Bural1; 1Katip Çelebi University Ataturk Training and Research Hospital, Department of Nuclear Medicine, Izmir, TURKEY, 2Katip Çelebi University Ataturk Training and Research Hospital, Department of General Surgery, Izmir, TURKEY.

EP-0537
Prediction of breast tumor response to neoadjuvant chemotherapy through quantitative 99mTc sestamibi Molecular Breast Imaging (MBI)
S. C. Kappadath, B. Lopez, B. Adrada, K. Hess, G. Rauch; UT MD Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA.

EP-0538
Contribution of Morphologic Assessment of Axillary Lymph Nodes to the Staging of Invasive Lobular Breast Cancer in FDG PET-CT Imaging
S. Yildiz1, A. Yildiz2, M. Ozoğan1, B. Ozcan3, A. Ozlük4, S. Yılmaz5; 1Department of Radiology, SBU Antalya Education and Research Hospital, Antalya, TURKEY, 2Department of Nuclear Medicine, Medstar Hospital, Antalya, TURKEY, 3Department of Medicine, SBU Antalya Education and Research Hospital, Antalya, TURKEY, 4Department of Medical Oncology, Medstar Hospital, Antalya, TURKEY, 5Department of Surgery, Medstar Hospital, Antalya, TURKEY.
EP-0539
Value Of 18F-FDG PET/CT In Locally Advanced Breast Cancer Patients Treated With Neoadjuvant Chemotherapy
I. Acevedo Báñez, R. Fernandez Lopez, A. Bonilla Damia, L. Caballero Gullón, F. Frutos Arenas, L. Alfaro Galan, A. Montaño Periañez, B. Viteos Perez-Quintela, I. Borrego Dorado; Hospital Universitario Virgen Del Rocio, Sevilla, SPAIN.

EP-0540
Diagnosing recurrent breast cancer: Accuracy and inter-rater agreement of FDG-PET/CT and bone scintigraphy
Z. A. Farahani1, J. Holm1, C. Baun1, K. Falch1, O. Gerke1, P. Hovland-Carlsen1, A. Alavi2, M. G. Hildebrandt1; 1Odense University Hospital, Odense, DENMARK, 2Department of Radiology, Perelman School of Medicine, Pennsylvania, PA, UNITED STATES OF AMERICA.

EP-0541
Prognostic Value Of Initial 18F-FDG PET/CT IN ER+/HER2- Locally Advanced Breast Cancer Patients

EP-0542
Successful Diagnosis of a CT-Negative, Bone Scintigraphy-Negative and FDG-PET-Negative Metastatic Recurrence Case Using ER-Targeting 4FMFES-PET
M. Paquette, É. Lavallée, S. Phoenix, H. Senta, J. E. van Lier, R. Lecomte, B. Guérin, É. E. Turcotte; Université de Sherbrooke, Sherbrooke, QC, CANADA.

EP-0543
Contribution Of 18FDG PET-CT For Staging And Prognosis Of Primary Breast Neuroendocrine Carcinoma
E. Arslan1, T. Cermik1, F. Can Trabulus1, E. Kelten Talu1; 1İstanbul Health Science University Education and Research Hospital Clinic of Nuclear Medicine, Istanbul, TURKEY, 2İstanbul Health Science University Education and Research Hospital Clinic of General Surgery, Istanbul, TURKEY, 3İstanbul Health Science University Education and Research Hospital Clinic of Nuclear Medicine, Istanbul, TURKEY, 4İstanbul Health Science University Education and Research Hospital Department of Pathology, Istanbul, TURKEY.

EP-0544
18F FDG PET-CT To Stage And Determine Rarely Seen Apocrine Type And Basal Like-Triple Negative Breast Adenocarcinoma
E. Arslan1, T. Cermik1, F. Can Trabulus1, E. Kelten Talu1; 1İstanbul Health Science University Education and Research Hospital, Istanbul, TURKEY, 2İstanbul Health Science University Education and Research Hospital Clinic of Nuclear Medicine, Istanbul, TURKEY, 3İstanbul Health Science University Education and Research Hospital Clinic of General Surgery, Istanbul, TURKEY, 4İstanbul Health Science University Education and Research Hospital Department of Pathology, Istanbul, TURKEY.

EP-0545
Clinical Significance of Partial-volume Corrected SUVmax of Axillary Lymph Nodes suggesting Intraoperative Examination of Sentinel Lymph Nodes in Early Breast Cancer
S. Kang1, S. Ha2, H. An1, J. Lee1, G. Cheon1, J. Park1, W. Han1, D. Lee1, J. Chung1, K. Kang1; 1Department of Nuclear Medicine, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF, 2Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, KOREA, REPUBLIC OF, 3Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF, 4Department of Surgery, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF.

EP-0546
Assessment of biological, clinical aggressiveness of invasive ductal breast cancer using baseline fluorine-18 fluorodeoxyglucose positron-emission tomography/computed tomography-derived volumetric parameters
G. Ege Aktas1, E. Tastekin2, A. Sankaya3; 1Trakya University Medical Faculty Department of Nuclear Medicine, Edirne, TURKEY, 2Trakya University Medical Faculty Department of Pathology, Edirne, TURKEY.

EP-0547
99mTc-Sestamibi Molecular Breast Imaging (MBI) compared with digital mammography plus ultrasound in preoperative breast cancer detection: preliminary experience
S. Chiaccio1, G. Angelini1, G. Cottotto1, S. Muccioli1, S. Caputo1, D. Fontana1, G. Sennero1, M. Roncella1, C. Marin1, D. Vannini2; 1Regional Center of Nuclear Medicine, Università Ospedale Santa Chiara, Pisa, ITALY, 2Università Ospedale Pisa-Ospedale Santa Chiara, Pisa, ITALY, 3Senology Unit-Ospedale Santa Chiara, Pisa, ITALY.
EP-0548
Lymph node staging in primary breast cancer patients: supine FDG PET/CT compared to prone PET/CT, MRI and prone PET fused with MRI

EP-0549
The Localization of Nonpalpable Suspicious Breast Lesions and Sentinel Lymph Node with Single Injection: Our SNOLL Experience
P. Arıcan¹, B. T. Okudan¹, G. Dağlar²; ¹Ankara Numune Hospital, Nuclear Medicine Clinic, Ankara, TURKEY, ²Ankara Numune Hospital, General Surgery Clinic, Ankara, TURKEY.

EP-0550
Role of (18)F-3′-deoxy-3′-fluorothymidine (18F-FLT) PET/CT in early prediction of response in patients with breast cancer (BC) treated with neoadjuvant chemotherapy (NCT): preliminary results
L. Fantini¹, A. Fedeli¹, P. Caroli¹, M. Celli¹, A. Rocca¹, A. Moretti¹, R. Galassi¹, M. Dall'Agata¹, P. Serra¹, G. Paganelli¹, F. Matteucci¹; ¹IRST IRCCS, Meldola (FC), ITALY, ²Morgagni-Pierantoni Hospital, Forli’ (FC), ITALY.

EP-0551
Myocardial perfusion defects after radiation therapy for left-sided breast cancer: stress study necessary?
M. Amoui¹, D. Askari², M. Bakhshandeh³, H. R. Miziaee³, S. Saifollahi⁴, M. Malekzadeh⁴, E. Prayesh⁴, M. Pishgahi⁴, A. Rakhsa⁴, S. Azghandi⁴, P. Hajian⁴, A. Yousefi Kashi⁴, M. Hoshiani⁴, M. Mosavizadeh¹; ¹Department of Nuclear Medicine, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ²Department of Radiation Therapy, Faculty of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ³Department of Radiation Therapy, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ⁴Department of Cardiology, Faculty of Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ⁵Department of Diagnostic Pathology, Kurume University Hospital, Kurume, JAPAN.

EP-0552
Restaging Infiltrating Lobular Breast Cancer Patients With Nuclear Medicine
EP-0557
PET in radiotherapy planning for lung cancer
O. Solodyannikova; Institute of cancer, Kiev, UKRAINE.

EP-0558
Role of metabolic parameters evaluated from baseline F18-FDG PET/CT as prognostic markers in non-small cell lung cancer (NSCLC) patients undergoing platinum-based chemotherapy
A. Sharma, A. Mohan, A. S. Bhailla, S. Vishnubhatla, M. C. Sharma, C. J. Das, A. K. Pandey, C. D. Patel, C. S. Bal, R. Kumar; All India Institute of Medical Sciences, Delhi, INDIA.

EP-0559
Effect of Respiratory Gating System on PET Image of Lung Cancer: Relationship with Location and Size
T. Kamibayashi, N. Shuke, C. Miyazaki, T. Onishi, S. Aoyagi, K. Saita; Kushiro Kojinkai Memorial Hospital, Kushiro, JAPAN.

EP-0560
Diagnostic abilities of Dynamic and dual-time-point F-18 FDG PET/CT for lymph node metastasis in patients with lung carcinomas
M. Yamanaka1, T. Shinya2, Y. Otomi2, K. Terazawa1, K. Takechi2, M. Kubo1, H. Otsuka1, M. Harada1; 1Tokushima Univ. Hospital, Tokushima, JAPAN, 2Okayama Univ. Hospital, Okayama, JAPAN.

EP-0561
Quantitative Analysis of Respiratory-Gated PET/CT Images for the Evaluation of Hilar Lymph Nodes in Non-Small Cell Lung Cancer
L. Hehenwarter1, L. Renettenberger1, F. Zehentmayer1, C. Pirich1; 1Department of Nuclear Medicine and Endocrinology, University Hospital Salzburg, Salzburg, AUSTRIA, 2Department of Radiotherapy and Radiation-Oncology, University Hospital Salzburg, Salzburg, AUSTRIA.

EP-0562
18F-FAZA PET/CT to assess hypoxia in non-small cell lung cancer: comparison with glucose metabolism and immunohistochemistry
P. Mapelli1, E. Incerti1, V. Bettinardi1, F. Fallanca1, G. Negri1, G. Rossetti1, A. Coliva1, C. Doglioni1, L. Gianolli1, M. Picchio1; 1Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY.

EP-0563
FDG PET-derived parameters as prognostic tool in post-treatment progressive malignant pleural mesothelioma patients
E. Incerti1, P. Mapelli1, S. Broggi1, A. Fodor4, M. Cuzzocrea1, A. M. Samanes Gajate1, C. Fiorino2, I. Dell’Oca1, L. Gianolli1, N. Di Muzio1, M. Picchio1; 1Unit of Nuclear Medicine, IRCCS San Raffaele Scientific Institute, Milan, ITALY, 2Unit of Medical Physics, IRCCS San Raffaele Scientific Institute, Milan, ITALY, 3Unit of Radiotherapy, IRCCS San Raffaele Scientific Institute, Milan, ITALY, 4University of Milano-Bicocca, Milan, ITALY.

EP-0564
Tumor heterogeneity, hypoxia and immune markers in patients with non-small cell lung cancer candidate to surgery
E. Lopci1, L. Toschi1, F. Marchesi1, D. Rahal1, G. Castino1, N. Cortese1, S. Marchetti1, G. Fincocchiaro1, S. Rossi1, P. Allavena2, F. Grizzi1; 1Humanitas Clinical and Research Hospital, Milano, ITALY, 2Fondazione Humanitas per la Ricerca, Milano, ITALY.

EP-0565
FDG-PET/CT features of cavity-related primary lung cancers
N. Kawano, H. Otsuka, Y. Otomi, M. Otomo; Tokushima University Hospital, Tokushima, JAPAN.

EP-0566
FDG-PET in the assessment of metabolic response in patients with NSCLC treated with nivolumab: Preliminary results

EP-0567
FDG-PET findings provide insights into thyroid-related side-effects in patients with Advanced Non-Small Cell Lung Cancer (NSCLC) treated with the immune checkpoint inhibitor Nivolumab

EP-0568
Comparison between PERCIST and EORTC criteria in the evaluation of response to immune check-point inhibitors in Non-Small Cell Lung Cancer (NSCLC) patients
EP-0569
Prognostic features in non-small cell lung cancer: difference in metastatic behavior between adenocarcinoma and squamous cell carcinoma
E. A. Usmanij, A. Posthuma, N. Hugen, R. P. J. van den Ende, I. D. Nagtegaal, J. Bussink, L. F. de Geus-Oei; 1Radboudumc, Nijmegen, NETHERLANDS, 2Leiden University Medical Center, Leiden, NETHERLANDS.

EP-0570
Volume-dependent comparative analysis of positron emission tomography and diffusion-weighted magnetic resonance imaging parameters in lung adenocarcinoma tumourous tissue
S. Lucic, I. Dajan, S. Pena-Karan, A. Peter, N. Andjelic, O. Sveljø, K. Koprivsek, M. Lucic; 1Oncology Institute of Vojvodina/Medical Faculty University of Novi Sad, Sremska Kamenica/Novi Sad, SERBIA, 2Oncology Institute of Vojvodina, Sremska Kamenica/Novi Sad, SERBIA, 3Institute of Pulmonary Diseases of Vojvodina, Sremska Kamenica/Novi Sad, SERBIA, 4Medical Faculty University of Novi Sad, Novi Sad, SERBIA, 5Oncology Institute of Vojvodina/Faculty of Technical Sciences University of Novi Sad, Sremska Kamenica/Novi Sad, SERBIA.

EP-0571
Diagnostic value of SUVmax cut-off in assessment of lymph node metastases among patients with NSCLC imaged by 18F-FDG PET/CT
J. Teodorczyk, B. Brockhuis, G. Romanowicz, W. Cytawa, I. Wenzel-Duszyńska, J. Kozłowska-Gradził, P. Lass; 1Medical University of Gdańsk, Nuclear Medicine Department, Gdańsk, POLAND, 2Division of Molecular Spectroscopy, Institute of Experimental Physics, University of Gdańsk, Gdańsk, POLAND.

EP-0572
Detection and monitoring of thoracic sarcoidosis using F-18 FLT PET/CT: Comparison with F-18 FDG PET/CT
Y. Yamamoto, T. Norikane, H. Dobashi, Y. Nishiyama; Kagawa University, Kagawa, JAPAN.

EP-0573
Role Of PET CT In Management Of Resectable Non Small Cell Carcinoma Lung
P. Gupta, R. Mishra, M. Gupta, P. Choudhury; Rajiv Gandhi Cancer Institute, West DELHI, INDIA.

EP-0574
Prognostic value of metabolic tumor volume measured by 18F-FDG PET/CT in patients with non-small cell lung cancer ≤ 3 cm in size
S. Pellegrino, R. Fonti, E. Matano, M. Ottaviano, V. Damiano, L. Paccì, S. De Placido, S. Del Vecchio; 1Department of Advanced Biomedical Sciences, University “Federico II”, Naples, ITALY, 2Department of Clinical Medicine and Surgery, University “Federico II”, Naples, ITALY, 3Department of Medicine and Surgery, University of Salerno, Salerno, ITALY.

EP-0575
Metabolic features measured on 18F-FDG PET and aerogenous spread are prognostic factors for disease-free survival in early stage non-small cell lung cancer patients treated by curative surgical resection without adjuvant therapy
Y. Kang, Y. Song, W. Lee, S. Kim; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, KOREA, REPUBLIC OF.

EP-0576
Association of 18Fluorodeoxyglucose (FDG), complete pathological response and overall survival in patients with Pancoast tumours treated with trimodality therapy

EP-0577
Prognostic value of 18F-FDG PET/CT parameters in patients with operable non-small cell lung cancer: comparison with known high-risk clinicopathologic factors
S. Boo, H. Park, H. Cho, Y. Kim; Seoul St Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, KOREA, REPUBLIC OF.

EP-44 during congress opening hours, e-Poster Area
Clinical Oncology: Liver, Upper GI & Pancreatic Cancer
EP-0578
Clinical significance of FDG uptake of bone marrow on PET/CT in patients with gastric cancer
J. Lee, M. Lee, S. Lee; 1Catholic Kwandong University College of Medicine, Incheon, KOREA, REPUBLIC OF, 2Soonchunhyang University Hospital, Cheonan, KOREA, REPUBLIC OF, 3Soonchunhyang University Hospital, Cheonan, KOREA, REPUBLIC OF.
EP-0579  
Diagnostic value of TOF-18F-FDG PET/CT in patients with suspected pancreatic cancer  
S. Stanzel1, F. Quehenberger1, B. Pernthaler1, R. Weinke1, R. M. Aigner1; 1Medical University of Graz, Department of Radiology, Division of Nuclear Medicine, Graz, AUSTRIA.

EP-0580  
Effectiveness of dual-time-point F-18 FDG PET/CT imaging between fatty liver patients and FDG accumulation in the liver  
M. Nakayama, A. Okizaki, K. Takahashi; Asahikawa Medical University, Asahikawa, Hokkaido, JAPAN.

EP-0581  
Significance of 11C-acetate PET/CT in the evaluation of post-treatment recurrence for Gastrointestinal Stromal Tumor  
S. Chen, S. Cheung, K. Cheng, Y. Leung, K. Wong, Y. Wong, C. Ho; Hong Kong Sanatorium & Hospital, Hong Kong, HONG KONG.

EP-0582  
Incremental role of C11-acetate PET/CT in Hepatocellular carcinoma  
S. Z. Ali1,2, A. Sinha2, H. Loi3, L. Khor1; 1Khoo Teck Puat Hospital, Singapore, SINGAPORE, 2National University Hospital, Singapore, SINGAPORE.

EP-0583  
Prognostic value of F-18 FDG PET/CT in the Pre-transplant Evaluation of Patients with Hepatitis C Virus-related liver carcinoma  
B. Cho, S. Kang, Y. Yang; Catholic University of Daegu School of Medicine, Daegu, KOREA, REPUBLIC OF.

EP-0584  
Does TLG (total lesion glycolysis) superior value over SUVmax for pancreatic cancer assessment in operable cases and inoperable cases?  
R. Ideguchi1, A. Myssayev1, T. Kudo1; 1Department of Radioscintigraphy Medicine, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, JAPAN.

EP-0585  
18F-FMISO PET/CT as a preoperative prognostic factor in patients with pancreas cancer  
T. Yamane1, M. Aikawa1, M. Yasuda1, A. Seta1, I. Kuji1; 1Department of Nuclear Medicine, Saitama Medical University International Medical Center, Hidaka, JAPAN, 2Department of Gastroenterological Surgery, Saitama Medical University International Medical Center, Hidaka, JAPAN, 3Department of Diagnostic Pathology, Saitama Medical University International Medical Center, Hidaka, JAPAN.

EP-0586  
New exponential functions based on CT density to estimate the percentage of liver that is fat  
G. Keramida1, A. M. Peters1; 1Royal Brompton and Harefield Hospitals NHS FT, London, UNITED KINGDOM, 2Royal Sussex County Hospital & Clinical Imaging Sciences Centre, Brighton, UNITED KINGDOM.

EP-0587  
Study on diagnosis of primary liver cancer by PET/CT multimodal imaging  
X. Wu, X. Meng, K. Zhou, W. Shi, X. Wang; The Affiliated Hospital of Inner Mongolia Medical, Hohhot, CHINA.

EP-0588  
Improvement Of Survival In Patients With Hepatocellular Carcinoma After 90Y RESIN Microsphere Radioembolization: Our Experience  
F. Di Gregorio1, M. Rensi1, A. Vit2, G. Ferretti1, F. Giacomuzzi1, D. Capobianco1, M. Povolato1, L. Peressini1, M. Sponzo1, F. Ronutti1; 1Department of Nuclear Medicine University Hospital, Udine, ITALY, 2Department of Radiology University Hospital, Udine, ITALY, 3University Hospital, Udine, ITALY, 4Department of Medical Physics University Hospital, Udine, ITALY.

EP-0589  
Prognostic value of a computer based, machine learning-driven survival model for pancreatic cancer in treatment naive patients  
T. S. Nakuz1, Y. Bican1, L. Papp1, W. Wadsak1, A. Al-Mukhtar1, A. Haug1, M. Hacker1, G. Karamkas1; 1Medical University of Vienna, Department of Biomedical Imaging and Image-guided Therapy Division of Nuclear Medicine, Vienna, AUSTRIA, 2Medical University of Vienna, Department of Biomedical Imaging and Image-guided Therapy Division of Radiology, Vienna, AUSTRIA.
EP-0590
18F FDG PET CT, Circulating Tumor Cells and Alpha Fetoprotein in Patients With Hepatocellular Carcinoma on the Waiting List for Liver Transplantation

EP-0591
Role of PET-CT with 18F-FDG in the Detection of Pancreatic Neoplasm Recurrence: Preliminary Study
A. Sabaté Llobera1, J. J. Robles Barba1, P. Notta1, E. Linares Tello1, L. Rodríguez Bel1, J. Mestres Martí1, G. Reyes Llompart1, J. Fabregat Pous1, N. Calvo Malvar1, C. Gámiz Cenzano1; 1Unitat PET-Servicio de Medicina Nuclear. IDI. Hospital U. de Bellvitge-IDIBELL, L’Hospitalet de Llobregat, SPAIN, 2Servicio de Cirugía General. Hospital U. de Bellvitge-IDIBELL, L’Hospitalet de Llobregat, SPAIN.

EP-0592
The benefits of 18FDG-PET/CT in the evaluation of pancreatic IPMN
E. Tabacchi1, C. Nanni1, E. Lodi Rizzini1, P. Ghedini1, D. Santin1, A. De Leo1, F. Minni1, N. Pagan1, C. Ricci1, L. Calcutti1, R. Casadei1, S. Fant1; 1Department of Nuclear Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Italy, Bologna, ITALY, 2Anatomy, Pathological Histology Unit, S.Orsola-Malpighi University Hospital, Bologna, Italy, Bologna, ITALY, 3General Surgery Unit, S.Orsola-Malpighi University Hospital, Bologna, Italy, Bologna, ITALY, 4Gastroenterology Unit, S.Orsola-Malpighi University Hospital, Bologna, Italy, Bologna, ITALY, 5Radiology Unit, S.Orsola-Malpighi University Hospital, Bologna, Italy, Bologna, ITALY.

EP-0593
Simultaneous FDG-PET/CT and contrast-enhanced CT in cholangiocarcinoma: just pretty images?
A. Farolfi1, A. Lambertini1, L. Zanoni1, C. Mosconi2, S. Broccoli2, I. Pettinari2, V. Rossetti2, F. Mangiacotti2, D. Mascherini2, R. Golferi2, S. Fant1, C. Nanni1; 1Service of Nuclear Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, ITALY, 2Radiology Unit, Department of Diagnostic and Preventive Medicine, S. Orsola-Malpighi University Hospital, Bologna, ITALY, 3Nuclear Medicine Department, ASUITS, Trieste, ITALY.

EP-0594
The Contribution of Metabolical and Morphological Evaluation in FDG PET/CT in the Staging of Signet Ring Cell Carcinoma of the Stomach
A. Yıldız1, B. Özcân1, M. Ozdoğan1, H. Dikici1, C. Erçuğrular1, A. Gürkan1, Z. Şahin1; 1Nuclear Medicine, Medstar Hospital, Antalya, TURKEY, 2General Surgery, Medstar Hospital, Antalya, TURKEY, 3Medical Oncology, Medstar Hospital, Antalya, TURKEY, 4Gastroenterology, Medstar Hospital, Antalya, TURKEY.

EP-0595
The effect of long acting somatostatin analogue administration on 68Ga-DOTATATE uptake in primary and metastatic NET lesions
N. Ayati1, S. Lee1, R. Zakavi1, K. Pathmaraj1, L. Qatawneh1, A. Poont2, A. Scott2,4,5; 1Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF, 2Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, AUSTRALIA, 3Nuclear Medicine and Cyclotron Unit, King Hussein Medical Center, Jordanian Royal Medical Services, JORDAN, 4Olivia Newton-John Cancer Research Institute; 5School of Cancer Medicine, La Trobe University, Heidelberg, AUSTRALIA, 2Department of Medicine, University of Melbourne, Austin Health, Heidelberg, AUSTRALIA.

EP-0596
68Ga-DOTA-TOC PET/CT predicts exact tumor staging in head and neck paragangliomas, compared to 18F-DOPA PET/CT and 123I-MIBG SPECT/CT
A. S. Kroiss1, C. Uprimny1, L. Gruber1, B. L. Shulkin2, I. J. Virgolini1; 1Medical University Innsbruck, Innsbruck, AUSTRIA, 2St Jude Research Hospital, Memphis, TN, UNITED STATES OF AMERICA.

EP-0597
Indication of MDP bone scan after MIBG scintigraphy in patients with neuroblastoma
K. Chaurasiya, E. Kireeva, I. Krupina, Y. Likar; Dmitry Rogachev National Research and Practical Center of Pediatric Hematology, Oncology and Immunology, Moscow, RUSSIAN FEDERATION.
EP-0598
The role of 18F Fluorocholine PET/CT in the imaging of recurrence of parathyroid cancer after surgery
A. Florczak, I. Gorczewska, A. d’Amico; Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Poland, Gliwice, POLAND.

EP-0599
Orbital Metastasis Detected by Ga-68 Somatostatin Receptor PET/CT in Patients with Neuroendocrine Tumors
Z. Awange1, R. Baum2; 1Ministry of Health Malaysia, Melaka, MALAYSIA, 2Zentralklinik Bad Berka, Zentralklinik, GERMANY.

EP-0600
Performance of somatostatin receptor scintigraphy (SRS) and fluorodeoxyglucose (FDG) PET/CT in initial staging of gastro-enteropancreatic neuroendocrine tumors (GEP-NET)
S. P. Dhake, A. Agrawal, M. Ramadwar, N. Purandare, S. Shah, A. Puranik, V. Rangarajan; Tata Memorial Hospital, Mumbai, INDIA.

EP-0601
Cell dedifferentiation & somatostatin receptors expression can coexist in neuroendocrine carcinomas?
V. Ippolito, G. Annunziata, C. Mocerino, D. Scala, F. Scavuzzo, I. Valenti, M. Catalano; AORN Cardarelli, Naples, ITALY.

EP-0602
Advanced Digestive Neuroendocrine Neoplasms: prognostic role of 18F-FDG-PET
D. Prosperi1, M. Cucinotta1, M. Rinzivillo1, F. Ponzuto1, G. Capurso1, G. Capriotti1, E. Iannicelli1, M. Pacilio1, L. Carideo1, E. Pilazzi1, E. Merola1, S. Schillaci2, G. Delle Fave1, F. Scapinario1; 1Sant’Andrea University Hospital of Rome, Rome, ITALY, 2University of Rome Tor Vergata, Rome, ITALY.

EP-0603
Differences in uptake between 68Ga-Dotatate and 68Ga-HA-DOTATATE in normal organs and tumour lesions: a retrospective study in 342 patients
E. A. Aalbersberg, B. J. de Wit - van der Veen, M. M. Geluk - Jonker, L. Bonsen, M. P. M. Stokkel; Department of Nuclear Medicine, Netherlands Cancer Institute Antoni van Leeuwenhoek, Amsterdam, NETHERLANDS.

EP-0604
Fifty months of somatostatin receptor SPECT/CT with 99mTc-EDDA Hynic Toc: What have we learned?
N. Girotto, E. Kukić, M. Maršić, S. Rac, S. Grbac; Clinical Hospital Centre Rijeka, Rijeka, CROATIA.

EP-0605
Biodistribution of [68Ga]Ga-DATATOC in comparison with [68Ga]Ga-DOTANOC in normal tissues and neuroendocrine tumour lesions
B. Schmidt-Kreppel1, T. Plum1, F. C. Gaertner1, E. Eppard1, J. Sinnes1, H. Strunk1, R. A. Bundschuh1, F. Rösch1, M. Essler1; 1University Medical Center Bonn, Bonn, GERMANY, 2Johannes Gutenberg-University Mainz, Mainz, GERMANY.

EP-0606
Comparison of 68Ga-DATATOC & 68Ga-DOTANOC PET/CT Imaging in Patients with Neuroendocrine Tumours
D. Yadav, M. Tripathi, N. A. Damle, C. Bat; All India Institute of Medical Sciences, New Delhi, INDIA.

EP-0607
Association Between Somatostatin Receptor Scintigraphy And Chromogranine Levels In Patients With Neuroendocrine Tumors

EP-0608
Quality Of Life in Patients with Neuroendocrine Gastroenteropancreatic Tumors Treated with Peptide Receptor Radionuclide Therapy
A. Georgakopoulos1, T. Liotsou2, S. N. Chatziioannou1,2; 1Biomedical Research Foundation of the Academy of Athens, Clinical and Translational Research, Nuclear Medicine Division, PET/CT section, Athens, GREECE, 21st Radiology Department, “Attikon” University Hospital, Athens Medical School, National and Kapodistrian University of Athens, Nuclear Medicine Division, Athens, GREECE.
EP-0609
Quantification of 6-[18F]fluoro-L-3,4-dihydroxyphenyl alanine Uptake in Neuroendocrine Tumour Lesions: The Effect of Specific Activity
R. S. B. H. Schreuder¹, A. H. Brouwers¹, P. H. Elsinga¹, R. H. J. A. Start¹, A. M. E. Walenkamp², A. W. J. M. Glaudemans¹, G. Luurtsema¹; ¹Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, NETHERLANDS, ²Department of Medical Oncology, University Medical Center Groningen, Groningen, NETHERLANDS.

EP-0610
The role of Ga 68-DOTANOC PET-CT in treatment management of recurrent medullary thyroid cancer
A. Aliyev¹, A. Aliyeva¹, I. Aliyeva², E. Mehdí¹, F. Novruzov³; ¹Azerbaijan National Centre Of Oncology, Department Of Head and Neck Surgery, Baku, AZERBAIJAN, ²Azerbaijan Medical University, Department of Internal Medicine, Baku, AZERBAIJAN, ³Azerbaijan National Centre Of Oncology, Department Of Nuclear Medicine, Baku, AZERBAIJAN.

EP-0611
F-18-DOPA PET/CT in medullary thyroid carcinoma patients
A. T. Golubić¹, E. Pasini¹, M. Zuvic¹, S. Kucacic Kuna¹, T. Samardzic¹, M. Despot¹, D. Huic¹; ¹Department of Nuclear Medicine and Radiation Protection, University Hospital Centre Zagreb, Zagreb, CROATIA, ²School of Medicine, University of Zagreb, Zagreb, CROATIA.

EP-0612
Frequency of physiological 111In-DTPA-octreotide SPECT/CT uptake in pancreatic uncinate process: retrospective study on a large 198 patients review and comparison with 68Ga-DOTATOC PET/CT
P. Schwartz, CHU de Bordeaux, Pessac, FRANCE.

EP-0613
Complementary role of 18F-FDG PET-CT in patients with cystic pancreatic lesions
M. Cucca, L. Locatelli, M. Mongiato, M. Zuffante, M. Ferdeghini; Nuclear Medicine Unit, University Hospital of Verona, Verona, ITALY.

EP-0614
Role of 68Ga DOTANOC PET/CT in patients of paraganglioma and comparison with 131I-MIBG SPECT/CT scintigraphy
S. Arora, M. Tripathi, R. kumar, C. Bal, R. kumar; All India Institute of Medical Sciences, AIIMS, New Delhi, New Delhi, INDIA.

EP-0615
Advantages of Simultaneous PET/MRI in the Evaluation of Neuroendocrine Tumors with Ga-68 DOTATATE
D. Franceschi, R. Matthews, R. Chimpin, N. Relan; SUNY at Stony Brook, Stony Brook, NY, UNITED STATES OF AMERICA.

EP-0616
Indium 111 pentetreotide in Neuroendocrine Tumors: SPECT CT is truly needed

EP-0617
Preliminary results in the evaluation of PET/CT colonography in preoperative obstructive colorectal cancer diagnosed by incomplete optical colonoscopy
D. Fuster, M. Pagès, A. Ginés, E. Buxó, D. Mombllan, F. Campos, F. Pons, N. Sánchez, A. Tapias, F. Lomeña; Hospital Clinic, BARCELONA, SPAIN.

EP-0618
Clinical role of 18F FDG PET CT in recurrence of colorectal cancer with suspected conventional image findings irrespective of tumour markers
E. Kaya¹, H. Temiz¹, A. L. Güner¹, T. Aksoy¹, E. Vardareli¹, M. Emri¹, A. Karaman¹; ¹Acıbadem University Medical Faculty, Department of Nuclear Medicine, Istanbul, TURKEY, ²Acıbadem Silüesiyer Hospital, Department of Radiology, Istanbul, TURKEY, ³Acibadem University Medical Faculty, Department of Gastroenterology, Istanbul, TURKEY.

EP-0619
Correlation between metabolic tumor volume and prognostic hematological parameters in patients with colorectal cancer
A. Cengiz, Y. Yuıekli; Adnan Menderes University Medical School Department of Nuclear Medicine, Aydın, TURKEY.
EP-0620
Relationship between metabolic parameters and ras mutation status
E. Karci1, C. Soydal1, G. Utkan1, Y. Urun1, H. Akbulut1; 1Ankara University Medical Faculty, Medical Oncology, Ankara, TURKEY, 2Ankara University Medical Faculty, Nuclear Medicine, Ankara, TURKEY.

EP-0621
The FOXFIRE/SIRFLOX/FOXFIRE-Global randomised studies of first-line selective internal radiation therapy for metastatic colorectal cancer
N. K. Sharma1, P. Gibbs2, G. Van Hazel2, V. Heinemann3, J. Ricke3, M. P. Findlay4, V. Gebski5, J. Moschandreas6, P. Virdee6, P. Dutton6, J. Taieb6, M. Peeters7, P. Tait8, P. Boardman9, V. Lewington10, A. Al-Nahhas11, H. Wasan11, R. A. Sharma12; 1Penn State Hershey Cancer Institute, Hershey, PA, UNITED STATES OF AMERICA, 2The Royal Melbourne and Western Hospitals, Melbourne, AUSTRALIA, 3University of Western Australia, West Perth, AUSTRALIA, 4University of Munich, Munich, GERMANY, 5University of Magdeburg, Magdeburg, GERMANY, 6University of Auckland, Auckland, NEW ZEALAND, 7University of Sydney, Sydney, AUSTRALIA, 8University of Oxford, Oxford, UNITED KINGDOM, 9Imperial College Healthcare NHS Trust, London, UNITED KINGDOM, 10Oxford University Hospitals NHS Trust, Oxford, UNITED KINGDOM, 11Hammersmith Hospital, London, UNITED KINGDOM, 12University College London, London, UNITED KINGDOM.

EP-0622
Diagnostic value of 18F-FDG PET/CT in follow up of patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation before surgery
C. Altini, A. Niccoli Asabella, A. Di Pala, V. Lavelli, A. Cassano, E. P. Massa, G. Rubini; Nuclear Medicine Unit, AOU Policlinic of Bari, University of Bari, bari, ITALY.

EP-0623
Prognostic value of 18F-FDG PET/CT visual assessment and semiquantitative analysis in locally advanced rectal cancer treated with neoadjuvant chemoradiation
C. Altini, A. Niccoli Asabella, C. Ferrari, V. Lavelli, S. Sisto, M. Fanelli, G. Rubini; Nuclear Medicine Unit, AOU Policlinic of Bari, University of Bari, bari, ITALY.

EP-0624
18F FDG PET CT vs CT Scan in patients with pulmonary metastases previously operated on for colorectal liver metastases

EP-0625
Diagnostic value of 18F-FDG-PET/CT in the assessment of colorectal liver metastasis with neoadjuvant therapy pre-metastasectomy
A. M. Santos Bueno1, M. V. Guiote Moreno1, L. M. Mena Barés1, E. Carmona Asenjo1, F. R. Maza Muriet1, E. Ortega Moreno1, E. Rodríguez Cáceres2, J. A. Vallejo Casas2; 1HU Reina Sofia, Córdoba, SPAIN, 2IMIBIC, Córdoba, SPAIN.

EP-0626
The Role of 18F-FDG PET/CT in Restaging and Management of Patients with Colorectal Carcinoma
G. Mateva, I. Kostadinova; Acibadem City Clinic Cancer Center, Sofia, BULGARIA.

EP-0627
Role of 11C-Choline PET/CT in prostate cancer patients with biochemical recurrence after brachytherapy

EP-0628
Assessing the value of mediastinal lymph node uptake on 18F-choline PET/CT scans
V. Sousa, C. Loewenthal, M. Vieira; Hospital da Luz, Lisbon, PORTUGAL.

EP-0629
F-18 Fluorocholine PET/CT In Restaging Prostate Cancer Patients With Biochemical Recurrence After Radical Prostatectomy
S. K. Vadi, B. Singh, S. K. Singh, A. Watts, R. K. Basher, A. Sood, N. Kakkar, A. Lal; Post graduate institute of medical education and research, chandigarh, INDIA.
EP-0630
11C-Choline PET/CT in the Diagnostics of Bone Metastases in Prostate Cancer Patients with Biochemical Relapse
D. M. Pursanova1, I. P. Aslanidi1, O. V. Mukhortova1, T. A. Katunina1, V. I. Shirokorad1, D. A. Roshchin1; 1A.N.Bakoulev Scientific Center for Cardiovascular Surgery of the Ministry of Health of the Russian Federation, Moscow, RUSSIAN FEDERATION, 2Moscow City Oncology Hospital N62, Moscow, RUSSIAN FEDERATION, 3Lopatin Research Institute of urology and Interventional Radiology - Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, RUSSIAN FEDERATION.

EP-0632
68Ga PSMA PET/CT in prostate cancer - A single centre experience from India
A. Sasikumar1, A. Joy1, M. Pillai1, R. Nanabala1, S. Bindu1, J. Madhavan1, B. Thomas2, S. R. R. S. Thomas2; 1KIMS-DDNMRC, Trivandrum, INDIA, 2KIMS Hospital, Trivandrum, INDIA.

EP-0633
Therapeutical changes in the management of patients with biochemical relapse of prostate cancer and positive 11C-Choline PET/CT
F. J. Gómez-de la Fuente1, I. Martínez-Rodríguez2, R. Quirce3, M. De Arcos-Torres4, J. L. López-Delfín1, M. Jiménez-Alonso1, B. Lucas-Velázquez1, D. F. Tovar-Echeverri1, G. Molina-Mendoza1, J. Banzo1; Nuclear Medicine Service. Marqués de Valdecilla University Hospital. Molecular Imaging Group (IDIVAL). University of Cantabria, Santander, SPAIN.

EP-0634
Oligometastatic disease (OMD) in prostate cancer (PCa) detects by 18F-Choline (FCH) PET/CT in patients with PSA levels < 5 ng/mL
L. Cuppari1, A. Guttila2, M. Gardi3, A. Agostini4, A. Cervino5, P. Reccia6, M. Burei7, G. Saladini7, M. Hodolíc8, L. Evangelista1; 1Veneto Institute of Oncology IOV - IRCCS, Padova, ITALY, 2Camposampiero Hospital, Camposampiero (PD), ITALY, 3Hospital of Sant’Antonio, Padova, ITALY, 4Nuclear Medicine Research Department, Iason, Graz, AUSTRIA.

EP-0635
The effects of 18F-FDG-PET/CT on the management and prognosis of patients with bladder (Bca) and upper urinary tract urothelial carcinoma (UTUC)
L. Evangelista1, F. Zattoni2, E. Incerti3, V. Low4, I. Rambaldi5, S. Panareo6, R. Schiavina2, J. R. Kames4, M. Maschini1, V. Ficarra2, M. Colichia7, S. Fanti8, A. Briganti9, M. Picchio1; 1Nuclear Medicine and Molecular Imaging Unit., Veneto Institute of Oncology IOV - IRCCS, Padova, ITALY, 2Department of Urology, Hospital of Udine, Udine, ITALY, 3Nuclear Medicine Department, IRCCS Ospedale San Raffaele, Milano, ITALY, 4Division of Nuclear Medicine, Mayo Clinic, Rochester, MN, UNITED STATES OF AMERICA, 5Nuclear Medicine Unit, Diagnostic Imaging e Laboratory Medicine Department, University Hospital of Ferrara, Ferrara, ITALY, 6Nuclear Medicine Unit, Diagnostic Imaging e Laboratory Medicine Department, University Hospital of Ferrara, Padova, ITALY, 7Department of Urology, Sant’Orsola-Malpighi Hospital, Bologna, ITALY, 8Department of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milano, ITALY, 9Service of Nuclear Medicine, Policlinico S. Orsola Malpighi Hospital, University of Bologna, Bologna, ITALY, 11Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University., Milano, ITALY.
**EP-0640**
223Radium: analysis of effect of treatment in bone oligo-metastatic CRPC patients
V. Frantellizzi, G. A. Follacchio, M. Pontico, L. Cosma, A. Farcomeni, F. Monteleone, M. Liberatori, G. De Vincentis; Sapienza University of Rome, Rome, ITALY.

**EP-0641**
Analytical validation of an automated method for segmentation of the prostate gland in CT images
E. Polymeri1, M. Sadik1, R. Kaboteh1, O. Enqvist1, J. Ulén2, E. Trägårdh2, M. H. Poulsen2, J. A. Simonsen2, P. F. Hëllund-Carlsten2, L. Edenbrandt2, Å. Johnsson1; 1Department of Radiology, Göteborg, SWEDEN, 2Department of Clinical Physiology, Göteborg, SWEDEN, 3Department of Signals and Systems, Göteborg, SWEDEN, 4Eigenvision AB, Malmö, SWEDEN, 5Department of Translational Medicine, Malmo, SWEDEN, 6Department of Urology, Odense, DENMARK, 7Department of Nuclear Medicine, Odense, DENMARK.

**EP-0642**
Convolutional neural network based quantification of choline uptake in PET/CT studies is associated with overall survival in patients with prostate cancer
R. Kaboteh1, E. Polymeri1, M. Sadik1, O. Enqvist1, J. Ulén2, M. Ohlsson2, E. Trägårdh2, M. H. Poulsen2, J. A. Simonsen2, P. F. Hëllund-Carlsten2, L. Edenbrandt2, Å. Johnsson1; 1Department of Radiology, Göteborg, SWEDEN, 2Department of Clinical Physiology, Göteborg, SWEDEN, 3Department of Signals and Systems, Göteborg, SWEDEN, 4Eigenvision AB, Malmö, SWEDEN, 5Department of Translational Medicine, Malmo, SWEDEN, 6Department of Urology, Odense, DENMARK, 7Department of Nuclear Medicine, Odense, DENMARK.

**EP-0643**
Correlation between molecular active tumor volume evaluate with 68Ga-PSMA PET-CT and levels of antigen prostatic specific
F. O. García-Pérez, S. S. Medina-Ornelas, B. L. Abundiz-Lopez, A. Arellano-Zarate; Instituto Nacional De Cancerologia, Mexico City, MEXICO.

**EP-0644**
18F-choline PET/CT as a prediction diagnostic tool of the disease progression in patients with castration resistant prostate cancer
M. Grmek, S. Hawlina, L. Lezaic; University medical centre Ljubljana, LJUBLJANA, SLOVENIA.

**EP-0645**
Bone Scintigraphy Versus PSMA PET-CT in Primary Staging of Prostate Cancer
P. Kaldeway, H. van Melick, J. Lavalaye; St Antonius Hospital Nieuwegein, Nieuwegein, NETHERLANDS.

**EP-0646**
Comparison between 18F-Choline (FCH) PET/CT and Conventional Imaging (CI) in intermediate-high risk prostate cancer (PCa) patients: design and preliminary data of a phase III Italian Multicenter Randomized Trial
L. Evangelista1, B. Eugenio1, M. Farsad2, G. Trifiro2, S. Agostini3, E. Bombardieri3, T. Baresic4, A. Golemi5, E. Brugola5, F. Chierichetti5, M. Hodolic6, G. Saladini7; 1Nuclear Medicine and Molecular Imaging Unit, Veneto Institute of Oncology IOV - IRCCS, Padova, ITALY, 2Department of Nuclear Medicine, Centro Regionale Oncologico (CRO), Aviano (PD), ITALY, 3Department of Nuclear Medicine, Hospital of Bolzano, Bolzano, ITALY, 4Department of Nuclear Medicine, Fondazione Salvatore Maugeri IRCCS, Pavia, ITALY, 5Department of Nuclear Medicine, Hospital of Trento, Trento, ITALY, 6Department of Nuclear Medicine, Istituto Humanitas Gavazzi IRCCS, Bergamo, ITALY, 7Nuclear Medicine Research Department, Jason, Austria Palacky University, Olomouc, CZECH REPUBLIC.

**EP-0647**
68Ga-PSMA PET/CT; current impact on management in prostate cancer
F. Intema, A. Kooistra, A. P. Lont, L. P. J. Hendriks, J. P. Esser, R. Lange, J. M. H. de Klerk; Meander Medical Center, Amersfoort, NETHERLANDS.

**EP-0648**
Relationship between metabolic parameters of 18F-FDG PET of prostate cancer bone metastases
r. g. yang1, z. j. ren2, w. z. huo1, h. x. wang1, y. liu1, q. kong1; 1Shandong Cancer Hospital affi liated to Shandong University, Shandong province, CHINA, 2Shandong Jining No.1 People's Hospital, Shandong province, CHINA.

**EP-0649**
68Ga-PSMA-PET/MRI, 11C-acetate-PET/CT and stand-alone multi-parametric MRI with histopathology as reference in intermediate- and high-risk prostate cancer - preliminary data
S. Strandberg1, K. Sandgren1, J. Jonsson1, A. Axelsson1, M. Ögren1, T. Nyholm1, C. Thelenberg Karlsson1, L. Blomqvist1, M. Skorpil1, K. Riklund1, B. Friedrich1, A. Bergh1, A. Widmark1; 1Radiation Sciences, Umea, SWEDEN, 2Surgical and Perioperative Sciences, Umea, SWEDEN, 1Medical Biosciences, Umea, SWEDEN.
EP-0650
Hormonal therapy impact on 18F-Fluorcholine PET-CT detection rates in recurrent prostate cancer

E. Triviño-Ibáñez, I. Puche-Sanz, A. Rodríguez-Fernández, A. González-Jiménez, E. Moratalla-Aranda, B. El Fahimi, F. Vázquez-Alonso, M. Gómez-Rí0, J. Llamas-Evila, Virgen de las Nieves University Hospital, Granada, SPAIN.

EP-0651
Alkaline phosphatase (ALP) is a good predictor of skeletal metastasis in prostate cancer patients

K. M. G. Mokoala, M. W. H. Vangu; Charlotte Maxeke Johannesburg Academic Hospital, Parktown, Johannesburg, SOUTH AFRICA.

EP-0652
Dual-phase 18F-FDG PET/CT Combined Diuretic for Restaging of Bladder Cancer

Q. Zhao, Y. Jia, J. Li, L. He, F. Zhao, X. Zhuang, F. Zhang; General Hospital of Ningxia Medical University, Yinchuan, CHINA.

EP-0653
68Ga-PSMA-11 PET/MRI in Primary Intermediate/High-Risk Prostate Cancer

S. Park, Z. Zacharias, C. Harrison, L. Baratto, N. Hatami, A. Iagaru; Stanford University Medical Center, Stanford, CA, UNITED STATES OF AMERICA.

EP-0654
68Ga-PSMA for radioimaging of prostate cancer: an in-vitro study using LNCaP cells and PC3 cells

P. Cuber, M. Heuschkel, J. Rabenstein, A. Hohn, W. Rutz, O. W. Hackenberg, D. Fischer, B. J. Krause; 1Department of Nuclear Medicin Rostock, Rostock, GERMANY, 2Department of Urology Rostock, Rostock, GERMANY, 3Department of Paediatrics, Rostock, GERMANY.

EP-0655
Comparison of Ga-68 PSMA-11 PET, Tc-99m DPD bone SPECT and computed tomography for the detection of bone metastases in patients with metastatic prostate cancer

H. Ilhan, S. Reinhardt, W. P. Fendler, A. Todica, F. J. Gildehaus, C. Cyran, C. Gratze, A. Herleman, V. Wenter, P. Bartenstein, A. Rominger; 1Department of Nuclear Medicine, University Hospital of Munich, Munich, GERMANY, 2Institute for Clinical Radiology, University Hospital of Munich, Munich, GERMANY, 3Department of Urology, University Hospital of Munich, Munich, GERMANY.

EP-0656
18F-Choline (FCH) PET/CT for initial staging of patients with intermediate and high risk prostate cancer (PCa) in routine use: results and perspective

C. Rousseau, M. Barbaud, L. Ferrer, V. Fleury, M. Le Thiec, D. Rusu, L. Campion, F. Kraeber-Bodéré; 1ICO Cancer Center, Nuclear Medicine Unit, Saint Herblain, FRANCE, 2CRCINA, Inserm U1232, CNRS UMR 6299, Nantes, FRANCE, 3ICO Cancer Center, Medical Physics Unit, Saint Herblain, FRANCE.

EP-0657
What factors should be considered before proposing 18-F-Choline (FCH) PET/CT in rising PSA prostate cancer patients who are being considered for targeted therapy?

M. Barbaud, L. Ferrer, V. Fleury, M. Le Thiec, D. Rusu, T. Rousseau, G. Bochereau, H. Monsaingt, F. Kraeber-Bodéré; 1Nuclear Medicine Unit, ICO Cancer Center, Saint Herblain, FRANCE, 2Medical Physics Unit, ICO Cancer Center, Saint Herblain, FRANCE, 3Urologic Clinic Nantes-Atlantis, Saint Herblain, FRANCE, 4Urologic Unit, Saint Augustin Clinic, Nantes, FRANCE, 5Urologic Unit, Urologic Medipole Group, Vannes, FRANCE, 6Biometrics Unit, ICO Cancer Center, Saint Herblain, FRANCE.

EP-0658
Ga68 PSMA-11 PET/MRI: Influence of Scan Time on Image Quality

S. Park, L. Baratto, H. Gandhi, P. Gulaka, A. Iagaru; Stanford University School of Medicine, STANFORD, CA, UNITED STATES OF AMERICA.

EP-0659
68Ga PSMA PETCT improves initial management plan of patients with intermediate and high risk prostate cancer

A. Al-Ibraheem, A. Alsharif, A. Al-Daghamen, S. Salah, J. Khader, M. Alkhaldi, M. Abu Nasser, J. KHzouz; King Hussein Cancer Center, Amman, JORDAN.

EP-0660
Seminal vesicles infiltration

L. Holody, M. Tarnowska-Szulakowska, M. Obbarzanowski, J. Jaskulski, J. Kopacz, M. Medzierecki; Swietokrzyskie Centrum Onkologii, Kielce, POLAND.

EP-0661
Impact of Whole Body 99m-Tc-HDP SPECT-CT On Treatment Decisions In Patients With High Risk Prostate Cancer

K. E. Esa Kauppila; Seinäjoki Central Hospital, Seinäjoki, FINLAND.
EP-0662
Correlation of Prostate specific antigen and Gleason score with Standardized uptake values of 68Ga PSMA PET/CT in initial staging of prostate cancer
A. Agrawal1, K. Shaha, G. Prakash, G. Baski, S. Menon, N. Purandare, S. Shah, A. Puranik, V. Rangarajan; Tata Memorial Hospital, Mumbai, INDIA.

EP-0663
Somatostatin receptor expression in renal cell carcinoma: a new perspective on an old knowledge
L. Locantore1, M. Cucca1, D. Grigolato1, M. Zuffante1, M. Ferdeghini; Nuclear Medicine Unit, University Hospital of Verona, Verona, ITALY.

EP-0664
PSA cutoff for ordering NaF PET/CT bone scan in patients with newly diagnosed prostate cancer
I. Sarikaya1, A. Elgazzar1, A. Baqer3, P. Sharma2, M. Alfeeli3; 1Kuwait University Faculty of Medicine, Kuwait, KUWAIT, 2Kuwait University Faculty of Medicine, Kuwait, KUWAIT, 3Mubarak Al Kabeer Hospital, Kuwait, KUWAIT.

EP-0665
The value of Ga-68 PSMA-11 PET/CT in the primary staging of biopsy proven prostate cancer
H. Ilhan1, D. Schmidt1, V. Wenter1, A. Todica1, C. Cyran1, A. Rominger1, W. P. Fendler1; 1Department of Nuclear Medicine, University Hospital of Munich, Munich, GERMANY.

EP-0666
Semiquantitative analysis of 18F-choline uptake in prostate gland of patients with untreated cancer: relationships with Risk Assessment Score and patient’s outcome
M. Castellani1, L. Florimonte1, M. Vadrucci1, V. Longari1, E. Orunesu1, R. Benti1; 1Department of Nuclear Medicine, Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, MILAN, ITALY.

EP-0667
PSMA Avid Liver Hemangioma
K. Oksuzoglu1, T. Onen, H. T. Turoglu, S. Inanir, T. Y. Erdil; Marmara University School of Medicine, Nuclear Medicine Department, Istanbul, TURKEY.

EP-0668
The Value of 68Ga-PSMA PET/CT in Biochemical Recurrence of Prostatic Carcinoma (Pca)
E. Abamor1, T. Çakır1, A. Çakır1, A. Bilici1, S. Güven1, T. Atasever1; 1Medipol Mega University Hospital, Department of Nuclear Medicine, ISTANBUL, TURKEY.

EP-0669
Does delayed FDG PET/CT imaging improve diagnostic sensitivity in lymph node staging of muscle invasive bladder cancer?
A. Girard, Jr.1, S. Tria2, J. Wouters2, D. Vilain, M. Rouanne, C. Kettler1, E. Le Stanc, J. Grellier; Hôpital Foch, Suresnes, FRANCE.

EP-0670
The influence of postdiuretic late phase imaging in visual and quantitative evaluation of uroepithelial tumors by F-18 FDG PET/CT
Z. Koç; P. Ozcan Kara, E. Sezer; Mersin University Hospital, Mersin, TURKEY.

EP-0671
Sarcoid-like reaction in prostate cancer patients assessed by 18-F-choline PET-CT
N. Eftychiou1, M. Wong1, J. Hunter1, S. Dizdarevic2; 1Brighton and Sussex University Hospitals, Brighton, UNITED KINGDOM, 2Clinical Imaging Science Centre BSMS, Brighton, UNITED KINGDOM.

EP-0672
Early 68Ga-PSMA PET/CT imaging in assessment of prostate cancer and its impact on patient’s management comparing to standard protocol
M. Beheshti1, Z. Paymani1, H. Geinitz1, G. Broinger1, D. Gehring1, T. Leopoldseder1, B. Gray1, W. Loidl1, W. Langsteger1; 1PET-CT Center Linz, St. Vincent’s Hospital, Linz, AUSTRIA.

EP-0673
18F-Choline PET/CT & functional parameters in treatment evaluation of patients with castration resistant prostate cancer submitted to Abiraterone: preliminary data
D. Pizzuto1, S. Annunziata1, D. Ripani1, C. Altini1, C. Caltaredella1, V. Rufini1; 1Institute of Nuclear Medicine, Università Cattolica del S. Cuore “A. Gemelli” Rome, Roma, ITALY, 2PET-CT Center, Policlinico “A. Gemelli”, Rome, Roma, ITALY.
EP-0674
Appropriateness of prescription of 18F-Choline PET/CT in 218 patients with prostate cancer

S. Chondrogiannis, M. C. Marzola, G. Grassetto, G. Borotto, E. Tommasi, L. Tamisa, A. M. Maffone, L. Pavan, L. Rampin, D. Rubello; Nuclear Medicine - PET/CT centre, Santa Maria della Misericordia Hospital of Rovigo, Rovigo, ITALY.

EP-0675
68Ga-Psma Hbed Pet/Ct in the assessment of biochemical recurrence in radically treated prostate cancer patients

P. Caroli1, M. Celli1, R. Gunelli2, V. Lanzetta2, V. Di Iorio2, A. Romeo2, L. Fantini2, M. Pancisi2, A. Moretti2, R. Galassi2, T. Zencio2, G. Paganelli3, F. Matteucci4; 1Nuclear Medicine Unit IRCCS IRST, Meldola, ITALY, 2Urology Unit AVR, Forlì, ITALY, 3Radiotherapy Unit IRCCS IRST, Meldola, ITALY, 4Radiotherapy Unit IRCCS IRST, Meldola, ITALY.

EP-0676
The Role of 68Ga-PSMA PET/CT in Newly Diagnosed Primary Prostatic Carcinoma (Pca)

E. Abamor1, T. Çakır1, A. Çakır2, A. Bilici3, S. Güven4, T. Atasever1; 1Medipol Mega University Hospital, Department of Nuclear Medicine, ISTANBUL, TURKEY, 2Medipol Mega University Hospital, Department of Pathology, ISTANBUL, TURKEY, 3Medipol Mega University Hospital, Department of Oncology, ISTANBUL, TURKEY, 4Medipol Mega University Hospital, Department of Urology, ISTANBUL, TURKEY.

EP-0677
Extracting more information from 68Ga-PSMA-11 PET/CT performed for primary staging of prostate cancer

O. Sahin1, E. Kaymak Akgun1, E. Demirci1, M. Ocak3, A. Aygün2, H. Pehlivanoglu2, E. Karayel1, A. Kural4, L. Kabasakal1; 1Department of Nuclear Medicine, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, TURKEY, 2Department of Nuclear Medicine Sisli Etfal Training and Research Hospital, Istanbul, Istanbul, TURKEY, 3Department of Pharmaceutical Technology, Pharmacy Faculty, Istanbul University, Istanbul, Istanbul, TURKEY, 4Department of Urology, Acibadem University, Istanbul, TURKEY.

EP-0678
Role of [18F]Choline PET/CT guided stereotactic body radiotherapy in patients with oligometastatic prostate cancer

R. Boni1, A. Marciano1, R. Zanca2, M. Sollini3, E. Notini4, D. Baldaccini5, F. Matteucci5, P. Cocuzza5, P. Ferrazza5, G. Coraggio1, F. Paiar1, G. Pasqualetti5, L. Galli1, L. Mannelli1, F. Pasqualetti1, P. Erba1; 1ASST Papa Giovanni XXIII-Nuclear Medicine, Bergamo, ITALY, 2Nuclear Medicine, Department of Translational Research and New Technologies in Medicine, Pisa, ITALY, 3Humanitas University, Milan, ITALY, 4Radiation Oncology, AOUR, Pisa, ITALY, 5Geriatric Unit, University of Pisa, Pisa, ITALY, 6Medical Oncology, AOUR, Pisa, ITALY, 7Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.

EP-0679
Castration-Resistant Prostate Cancer Patterns of Metastasis Evaluated by 68Ga-PSMA PET/CT

M. Silva1, R. Silva1,2, P. Lapa1,3, G. Costa1,3, J. Pedroso de Lima1,2,3; 1Centro Hospitalar da Universidade de Coimbra, Coimbra, PORTUGAL, 2Istituto delle Scienze Nucleari Applicate a Sante (ICNAS), Coimbra, PORTUGAL, 3Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL.

EP-0680
Can We Predict the Sites of the Recurrence of Tuba-Ovarian Cancer by F18-FDG PET/CT Depending on CA-125 Level?

E. Ciftci1, B. Turgut1, S. Erturk1, Z. Hasbek1, B. Cetin2, H. Aker3; 1Cumhuriyet University, School Of Medicine, Department Of Nuclear Medicine, Sivas, TURKEY, 2Recep Tayyip Erdogan University, School Of Medicine, Department Of Internal Medicine, Division Of Oncology, Rize, TURKEY, 3cumhuriyet University, School Of Medicine, Department Of Pathology, Sivas, TURKEY.

EP-0681
Differential between ovarian tumor with solid portions and Stage I malignant ovarian cancer by FDG PET/CT

R. Nakamoto, Y. Nakamoto, T. Ishimori, A. Kido, K. Togashi; Kyoto University Hospital, Kyoto, JAPAN.
EP-0683
Incidence and clinical Significance of Neck Node metastasis in Patients With cervix malignant lesion
S. Yoon; Women’s Cancer Center, Cheil General Hospital, Dankook University College of Medicine, Seoul, KOREA, REPUBLIC OF.

EP-0684
Comparison of Diagnostic Value of PET/CT and Ca-125 Assay in Detection of Residual and Recurrent Tumor in Follow-up Ovarian Cancer
G. Çekin1, I. Bezircioğlu2, S. Yiğit1; 1İzmir Katip Çelebi University, Atatürk Training and Research Hospital, Nuclear Medicine Department, Izmir, TURKEY, 2İzmir University of Economics, Medical Faculty, Obstetric and Gynecology Department, İzmir, TURKEY, 1İzmir Katip Celebi University, Atatürk Training and Research Hospital, Pathology Department, Izmir, TURKEY.

EP-0685
Effect of XbaI G > T Polymorphism of the Glucose Transporter 1 Gene on F 18 FDG Uptake in Gynecological Cancers
O. Yaylali1, A. Koseler2, D. K. Sakarya1, D. Yuksel1, T. Sengoz1, V. Fenkı1; 1Pamukkale University Dept of Nuclear Medicine, Denizli, TURKEY, 2Pamukkale University Dept of Biophysics, Denizli, TURKEY, 1Pamukkale University Dept of Gynecology, Denizli, TURKEY.

EP-0686
18FDG PET with Low Dose CT versus Contrast Enhanced CT in the Detection of Recurrent or Residual Tumor in Ovarian Cancer
A. Repetto1, N. Ota1, C. Sampoli1, S. Rubi1, M. Oporta1, H. Navaroli1, M. Toscano1, C. Perna1; 1Hospital Universitari Son Espases, Palma, SPAIN, 2Hospital Universitari Son Espases/IdiSPla, Palma, SPAIN.

EP-0687
The role of PET/CT in the detection of residual/recurrent tumor in patients with ovarian cancer whose Ca-125 value is within normal limits
G. Cekin1, I. Bezircioğlu2, S. Yiğit1; 1İzmir Katip Çelebi University, Atatürk Training and Research Hospital, Nuclear Medicine Department, Izmir, TURKEY, 2İzmir University of Economics, Medical Faculty, Obstetric and Gynecology Department, İzmir, TURKEY, 1İzmir Katip Celebi University, Atatürk Training and Research Hospital, Pathology Department, Izmir, TURKEY.

EP-0688
Prognostic value of metabolic criteria with 18F-FDG PET/CT in patients with follicular lymphoma
M. Cozar Santiago1, J. Garcia Garzon2, M. Soler Peter3, C. Igua Saenz1, R. Sanz Llorens1, R. Sanchez Jurado1, J. Aguilar Barrios1, V. Faus Rodrigo1, E. Riera Gil2, J. Ferrer Rebolleda1; 1ERESA-General University Hospital, Valencia, SPAIN, 2CETIR-PET Unit, Esplugues, SPAIN.

EP-0689
Outcome and survival of patients with primary testicular lymphomas delineated by control or restaging FDG PET/CT
E. Alagoz1, K. Okuyucu, S. ince, N. Arslan; Gülhane Training and Research Hospital, Department of Nuclear Medicine, Ankara, Turkey, Ankara, TURKEY.

EP-0690
SUVmax of 10 is a Highly Specific and Moderately Sensitive Cutoff Between Aggressive and Indolent Non-Hodgkin Lymphoma: Analysis of 331 Patients with FDG-PET/CT
G. Alobthani1, K. Isaaehi, T. Watake, K. Matsunaga, H. Kato, M. Tatsumi, E. Shimosegawa, J. Hatazawa; Osaka University, Osaka, JAPAN.

EP-0691
18F-FDG PET/CT in Primary Extranodal Lymphoma: Evaluation of Treatment Response and Prognosis
B. Salvatore1, R. Fonti1, A. De Renzo1, S. Pellegrina2, I. L. Ferrara1, C. Mainolfo1, L. Marano1, C. Selleri1, F. Pane1, S. Del Vecchio1, L. Pace1; 1IBB-CNR, NAPLES, ITALY, 2University “Federico II”, NAPLES, ITALY, 3University of Salerno, Salerno, ITALY.

EP-0692
Diagnostic value of dynamic F-18 FDG PET/CT in patients with malignant lymphoma
K. Terazawa1, T. Shinuya1, Y. Otomi1, M. Kubo1, K. Takechi1, H. Otsuka1, M. Harada1; 1Tokushima University Hospital, Tokushima, JAPAN, 2Okayama University Hospital, Okayama, JAPAN, 3Tokushima Red Cross Hospital, Komatsushima, JAPAN.

EP-0693
Limited Benefit of Additional Contrast-Enhanced CT to End-of-Treatment PET/CT Evaluation in Patients with Follicular Lymphoma
G. Paone1, M. Raditchkova-Sarnelli, L. Giovanella, E. Zucca1, L. Ceriani; Oncology Institute of Southern Switzerland, Bellinzona, SWITZERLAND.
EP-0694
Application of Quantitative Indexes on FDG PET to Treatment Response Evaluation of Indolent Lymphoma
H. Kim, J. Paeng, T. Kim, M. Kim, G. Cheon, D. Lee, J. Chung, K. Kang; Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF.

EP-0695
Does PET reconstruction method affect Deauville scoring in lymphoma patients?
B. Enilorac1, C. Nganoa1, C. Fruchart1, A. Gac1, S. Chantepie1, G. Damaj1, C. Lasnon1,2, N. Aide1,3; 1CHU de Caen, Caen, FRANCE, 2Centre François Baclesse, Caen, FRANCE, 3INSERM U1086 ‘ANTICIPE’, Caen, FRANCE.

EP-0696
Do PET textural features have an additional value over visual assessment for the diagnosis of bone involvement on baseline FDG PET scans in diffuse large B cell lymphomas patients?
N. Aide1,2, M. Talbot1, C. Nganoa1, C. Fruchart1, G. Damaj1, C. Lasnon1,2, N. Aide1,3; 1Nuclear Medicine Department, University Hospital, CAEN, FRANCE, 2INSERM U1086 ‘ANTICIPE’, Caen, FRANCE, 3Normandy University, CAEN, FRANCE, 4Hematology Institute, University Hospital, CAEN, FRANCE, 5Nuclear Medicine Department, Francois Baclesse Centre, CAEN, FRANCE.

EP-0697
MTV and TLG of staging PET/CT as predictors of outcome in Hodgkin Lymphoma patients: preliminary results of a single center study
M. Spallino1, M. Cuzzocrea1, C. Spadavecchia1,2, S. Morzenti1, E. De Ponti1, S. Bolis1, C. Landoni1,2, L. Guerra1; 1University of Milan-Bicocca, Milan, ITALY, 2Post graduate school of Medical Physics, Milan, ITALY, 3Medical Physics Department, San Gerardo Hospital, Monza, ITALY, 4Department of Hematology, San Gerardo Hospital, Monza, ITALY, 5Department of Nuclear Medicine, San Gerardo Hospital, Monza, ITALY.

EP-0698
Prognostic role of final FDG-PET in relationship to absolute monocyte count at diagnosis for Diffuse Large B Cell Lymphoma (DLBCL)
A. Franceschetta1, R. Marcheselli2, R. D’Apollo1, L. Massi1, A. Casolo1, S. Sacchi1, N. Prandini1; 1Nuclear Medicine, Modena, ITALY, 2Clinical Oncology, Modena, ITALY.

EP-0699
Quantitative and qualitative analyses of metabolic response at end of treatment 18F-FDG PET-CT scan can predict outcome in diffuse large B-cell lymphoma
L. Baratto1, F. Wu1, J. Sabile2, T. Liang3, J. Rosenberg4, R. Adavni2, E. Mittra1; 1Stanford University, Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford, CA, UNITED STATES OF AMERICA, 2Stanford University, Department of Medicine, Division of Medical Oncology, Stanford, CA, UNITED STATES OF AMERICA, 3Stanford University School of Medicine, Department of Radiology, Stanford, CA, UNITED STATES OF AMERICA.

EP-0700
Investigation of correlation between PET/CT findings and clinical parameters in patients with multiple myeloma
R. Wang, L. Di, J. Zhang, C. Zhao, Y. Fan, Z. Fu, X. Zhang, Q. Jiang; Peking University First Hospital, Beijing, CHINA.

EP-0701
Application of F-18-FDG PET/CT in staging and metabolic activity assessment of multiple myeloma
R. Wang, L. Di, J. Zhang, C. Zhao, Y. Fan, X. Zhang, G. Zhao, Y. Cui, M. Liu, L. Kang, Y. Wang; Peking University First Hospital, Beijing, CHINA.

EP-0702
18F-FDG-PET/CT In Solitary Plasmacytoma: Metabolic Behavior And Possible Role In Prediction Of Progression To Multiple Myeloma
D. Albano1, F. Bertagna1, M. Bertoli1, G. Bosio1, M. Bonacina1, E. Cerudelli1, R. Durmo1, M. Gazzelli1, R. Giubbini1; Spedali Civili Brescia, Brescia, ITALY.

EP-0703
Association between 18F-fluorodeoxyglucose uptake and CD38, CD138 expression in myeloma cells and clinical parameters in patients with multiple myeloma
A. Cengiz1, H. U. Arda1, F. Doger1, I. Yavuçoğlu1, Y. Yürekli1, A. Z. Bolaman1; 1Adnan Menderes University Medical School Department of Nuclear Medicine, Aydin, TURKEY, 2Adnan Menderes University Medical School Department of Internal Medicine, Aydin, TURKEY, 3Adnan Menderes University Medical School Department of Pathology, Aydin, TURKEY, 4Adnan Menderes University Medical School Department of Hematology, Aydin, TURKEY.
EP-0704
18F-FDG PET/CT In Premalignant Stages Of Multiple Myeloma: Preliminary Analysis
F. J. Pena Pardo, G. A. Jiménez Londoño, A. M. García Vicente, A. Palomar Muñoz, N. D. Disatuar Ruiz, Á. Soriano Castrejón; Nuclear Medicine Service. Hospital General Universitario de Ciudad Real, Ciudad Real, SPAIN.

EP-0705
18F-fluorocholine versus 18F-fluorodeoxyglucose for PET/CT in staging, follow-up or suspected relapse of multiple myeloma
J. Zhang-Yin1, O. Benesty1, A. Cattereau1, M. Gauthé1, M. Calzada1, K. Kerrou1, J. Ohnona1, V. Gaura-Schmidt1, V. Natà1, F. Montravers1, L. Garderet1, J. Talbot1, 1Hôpital Tenon, Paris, FRANCE; 2Hôpital Saint-Antoine, Paris, FRANCE.

EP-0706
Monoclonal gammopathy of undetermined significance (MGUS): Computational analysis of PET/CT images
R. Piva1, A. Nieri1, C. Campi1, F. Fiz2, A. Bellini1, M. Bauckneht1, A. Borra1, S. Morbelli1, A. Buschiazzo1, A. Orengo1, A. Massone1, M. Piano1, G. Sambuceti1, C. Marini1; 1IRCCS AO San Martino IST, Genova, ITALY; 2Department of Mathematics, University of Genoa, Genova, ITALY; 3Nuclear Medicine Unit, Department of Radiology, Uni-Klinikum, Tübingen, GERMANY; 4CNR SPIN (Superconductors, oxides and other innovative materials and devices), Genova, ITALY; 5CNR Institute of Bioimages and Molecular Physiology, Milan, ITALY.

EP-0707
11C-Methionine versus 18F-Fluorodeoxyglucose PET/CT imaging in patients with multiple myeloma and other plasma cell malignancies: initial staging and re-staging
M. I. Morales-Lozano1, B. García-García1, S. Villar1, E. Guillen1, P. Rodríguez Otero1, F. Grisanti1, L. Sancho1, R . Ramos1, V. Moran1, J. San Miguel1, J. Richter1, M. J. García-Vellonso1; Clínica Universidad de Navarra, Pamplona, SPAIN.

EP-0708
Diagnostic Value Of 18F-FDG PET/CT Imaging In Patients With Multiple Myeloma
U. Telci1, S. Ucak Semiring2, M. Sahin1, T. Basoglu1; Ondokuz Mayis University Nuclear Medicine Department, Samsun, TURKEY.

EP-05 during congress opening hours, e-Poster Area
Clinical Oncology: Bone

EP-0709
Osteoarthrosis of the knee evaluated using images of bone uptake of myocardial perfusion agent
R. Tanaka, M. Ebine; Chiba Institute of Science, Choshi, JAPAN.

EP-0710
 extrasosseous Accumulation of Tc-99m-MDP on Bone Scan in a Four-years-old Boy With Acute Lymphoblastic Leukemia: Case Report
F. Banezhad Jannubi1, M. Pourmehdi2, N. Ayati; Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC.

EP-0711
Clinical value of Tc-99m-MIBI scintigraphy for bone lesions with indefinite diagnosis by Tc-99m-MDP bone imaging
Z. J. Ren1, H. H. Yang2, H. X. Wang2, Y. Liu2, Q. Kong2; 1Shandong Jining No.1 People’s Hospital, Shandong province, CHINA, 2Shandong Cancer Hospital affiliated to Shandong University, Shandong province, CHINA.

EP-0712
Interobserver agreement in the evaluation of Sodium Fluoride-PET/CT for the evaluation of bone metastases in prostate cancer
H. D. Zacho1, R. F. Fonager1, J. B. Nielsen1, C. H. Nielsen1, H. W. Hendel1, L. J. Petersen1; 1Dept of Nuclear Medicine, Aalborg University Hospital, Aalborg, DENMARK; 2Dept of Nuclear Medicine, Herlev Hospital, Herlev, DENMARK.

EP-0713
Feasibility Of Nuclear Medicine In Prognosis And Evaluation Of Effectiveness Of Therapy By Bisphosphonates
V. Sukhov1, A. Marin1, P. Kirichenko2, K. Zaplatnikov3; 1Military Medical Academy, ST. PETERSBURG, RUSSIAN FEDERATION, 2MAZ Nuclear Medicine, Nuernberg, GERMANY.

EP-0714
When there is no other option: Utility of Bone Scintigraphy in Oncology in a resource constrained environment
E. N. B. Hammond; Ghana Atomic Energy Commission/ National Centre for Radiotherapy and Nuclear Medicine, Accra, GHANA.
**EP-0715**
Comparison of \(^{99}\)Tc-MDP Bone Scintigraphy and \(^{18}\)F-FDG PET/CT to predict histologic response to neoadjuvant chemotherapy in patients with osteosarcoma
B. Byun, S. Lim, K. Lee, C. Kong, J. Choi; Korea Institute of Radiological and Medical Sciences, Seoul, KOREA, REPUBLIC OF.

**EP-0716**
The usefulness of maximum standardized uptake value of quantitative bone SPECT/CT
M. Ishibashi, Y. Tanabe, T. Ogawa; Faculty of Medicine, Tottori University, Yonago, JAPAN.

**EP-0717**
Tc\(^{99}\)MDP SPECT-CT based modified Mirel’s classification - a new approach to evaluate for impending pathologic fractures
S. Riaz\(^1\), H. Bashir\(^2\), I. K. Nazir\(^2\), S. Butt\(^2\), F. Qamar\(^2\); \(^1\)Nuclear Medicine department, Shaukat Khanum Memorial Cancer Hospital & Research Centre (SKMCH&RC), Lahore, PAKISTAN; \(^2\)Radiology department, SKMCH&RC, Lahore, PAKISTAN.

**EP-0718**
Diagnostic impact of quantitative bone SPECT/CT for patients with bone metastasis caused by castration resistant prostate cancer
Y. Fukushima, S. Kumita, G. Kimura, J. Akatsuka, T. Hamana, Y. Sugihara, T. Ando; Nippon Medical School, TOKYO, JAPAN.

**EP-0719**
Hybrid bone scintigraphy in gastrointestinal malignancies
N. Rashid, H. Bashir, S. Riaz, A. Hassan; Nuclear Medicine department, Shaukat Khanum Memorial Cancer Hospital & Research Centre (SKMCH&RC), Lahore, PAKISTAN.

**EP-0720**
The diagnostic ability of dynamic positron emission tomography with F-18 fluorodeoxyglucose and C-11 methionine in patients with musculoskeletal lesions
T. Shinya\(^1\), Y. Otomi\(^2\), K. Terazawa\(^3\), M. Kubo\(^3\), M. Harada\(^3\), S. Kanazawa\(^3\); \(^1\)Okayama University Hospital, Okayama-city, JAPAN; \(^2\)Tokushima University Hospital, Tokushima-city, JAPAN.

**EP-0721**
Interval from first symptoms to diagnosis in high-grade primary osteosarcoma and Ewing sarcoma of bone in relation to metabolic activity on FDG-PET/CT
A. C. M. Luijtgaarden\(^1\), E. A. Usmanij\(^1\), F. de Geus-Oei\(^2\), J. J. W. de Rooy\(^3\), U. E. Flucke\(^3\), S. E. J. Kaal\(^3\), V. L. M. N. Soomers\(^3\); \(^1\)Radiation Oncology department, SKMCH&RC, Lahore, PAKISTAN; \(^2\)Radiology department, SKMCH&RC, Lahore, PAKISTAN; \(^3\)Leiden University Medical Center, Leiden, NETHERLANDS, 1The Institute of Cancer Research & Royal Marsden Hospital, London, UNITED KINGDOM.

**EP-0722**
Diagnostic performance of 18F-FDG PET/CT in patients with Kaposi sarcoma: a preliminary retrospective study
S. Annunziata\(^1\), A. Borab\(^2\), A. Giambenedetto\(^2\), A. Rizzo\(^2\), M. L. Calcagno\(^2\), E. L. D’Amato\(^2\), V. Rufini\(^2\); \(^1\)Institute of Nuclear Medicine, Università Cattolica del Sacro Cuore, Rome, ITALY; \(^2\)Institute of Infectious Diseases, Università Cattolica del Sacro Cuore, Rome, ITALY.

**EP-0723**
The F-18 FDG PET/CT and CT evaluation of pleural plaques
Z. Koç, P. Özcan Kara, Y. Balcı; Mersin University Hospital, Mersin, TURKEY.

**EP-0724**
Ga68 DOTATATE PET/CT Imaging In Oncogenic Osteomalacia - Experience From A Tertiary Hospital In Southern India
J. Hephzibah, T. V. Paul, D. Mathew, N. Shanthly, R. Oommen; Christian Medical College, Vellore, VELLORE, INDIA.
EP-0726
Quantification of tumor blood flow in sarcomas from dynamic 99mTc-MIBI SPECT: Validation and clinical employment
W. Y. Ussov1, V. M. Gulyaev2, E. V. Barysheva, O. Y. Borodin, I. I. Anisenjad, Y. I. Tyukalov1; 1Institute of Cardiology, Tomsk, RUSSIAN FEDERATION, 2Tomsk Regional Institute of Oncology, Tomsk, RUSSIAN FEDERATION, 3Clinical and Diagnostic Center, Tomsk, RUSSIAN FEDERATION, 4Institute of Oncology, Tomsk, RUSSIAN FEDERATION.

EP-0727
Applying radiomics and machine learning on PET images to predict lung metastases in soft tissue sarcoma patients
I. Shiri1, A. Rahmim1, H. Abdollahi1, P. Geramifar1, A. Bitarafan-Rajabi1,2; 1Department of Medical Physics, School of Medicine, Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 2Department of Radiology, Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA.

EP-0728
Voxel-based analysis of I-123 IMP in patients with uveal malignant melanoma: comparison with ROI analysis
M. Yoshimura1, T. Aida2, D. Hakamata2, K. Uchida2, K. Suzuki1, H. Goto1; 1Tokyo Medical University, Tokyo, JAPAN, 2Tokyo Medical University Hospital, Tokyo, JAPAN.

EP-0729
Lymphoscintigraphy and sentinel node biopsy optimal visualization in thick and high risk melanoma: five years experience
A. Koljevic Markovic, S. Tasic, L. Mijatovic Teodorovic, I. Markovic, M. Buta, R. Djordic, M. Jankovic; 1National Cancer Research Center Serbia, Belgrade, SERBIA, 2Faculty of Medicine, University of Kragujevac, Kragujevac, SERBIA, 3Faculty of Medicine, University of Belgrade, Belgrade, SERBIA, 4School of Engineering, University of Belgrade, Belgrade, SERBIA.

EP-0730
Absolute number of new lesions in 18F-FDG PET/CT is more predictive of clinical outcome than SUV changes in metastatic melanoma patients receiving ipilimumab
H. Anwar1, C. Sachpekis2, J. Winkler2, A. Kopp-Schneider, U. Haberkorn3, J. Hassel4, A. Dimitrakopoulou-Strauss1; 1Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, GERMANY, 2National Center for Tumor Diseases, Heidelberg, GERMANY, 3Department of Biostatistics, German Cancer Research Center, Heidelberg, GERMANY, 4Division of Nuclear Medicine, University of Heidelberg, Heidelberg, GERMANY.

EP-0731
FDG-PET/CT in the Evaluation of Non-Melanoma Skin Cancers
A. Sabaté-Llubera1, P. C. Notta1, E. Linares-Tello1, J. R. Ferreres2, R. Tarragona-Fernández3, T. Soler-Monsó4, L. Rodríguez-Bel5, A. Lucas-Calduch1, J. L. Vercher-Conejero1, M. Cortés-Romera1, C. Gámez-Cenzano1; 1PET Unit, Department of Nuclear Medicine-IDI. Hospital Universitari de Bellvitge-IDIBELL, L’Hospital de Llobregat (Barcelona), SPAIN, 2Department of Dermatology. Hospital Universitari de Bellvitge-IDIBELL, L’Hospital de Llobregat (Barcelona), SPAIN, 3Department of Plastic Surgery. Hospital Universitari de Bellvitge-IDIBELL, L’Hospital de Llobregat (Barcelona), SPAIN, 4Department of Pathology. Hospital Universitari de Bellvitge-IDIBELL, L’Hospital de Llobregat (Barcelona), SPAIN, 5Department of Radiation Oncology-Institut Català d’Oncologia. Hospital Duran i Reynals-IDIBELL, L’Hospital de Llobregat (Barcelona), SPAIN.

EP-0732
Is whole body 18F-FDG PET/CT including the extremities routinely warranted in melanoma patients?
K. Pinker-Domenig1,2, H. Schoeder1, G. Ulamer1, T. Saidon1, K. Juluru1, S. Huang2, W. A. Weber, C. C. Riedl1; 1Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA, 2Medical University of Vienna, Vienna, AUSTRIA.

EP-0733
Clinical Relevance of Imaging the Lower Limbs When Staging or Restaging Malignant Cutaneous Melanoma Using 18F-FDG PET/CT
N. Plouznikoff, F. ArsenaULT; Centre Hospitalier de l’Université de Montréal (CHUM), Montréal, QC, CANADA.
EP-0734
A portable hybrid camera for fused optical and scintigraphic imaging: clinical experience in 90 patients with melanoma
C. A. Tapies, Sr., N. Sanchez, R. Pigem, R. Rull, p. paredes, p. perlaza, S. Vidal-Sicart; hospital clinic de Barcelona, barcelona, SPAIN.

EP-0735
18-F-FDG-PET/CT In Head And Neck Mucosal Melanoma
R. Durmo, F. Bertagna, D. Albano, M. Bertoli, M. Bonacina, M. Gazzilli, E. Cerudelli, R. Giubbini; spedali civili brescia, brescia, ITALY.

EP-0736
Does SPECT/CT Improve Sentinel Node Detection in Melanoma Patients
K. Nikoletic1, S. Tonjer1, S. Hegg1, M. Møll Dalen1, E. Spangen Høset1, M. Knezevic2; 1Drammen hospital, Nuclear Medicine Department, Drammen, NORWAY, 2Bærum hospital, Department of Surgery, Bærum, NORWAY.

EP-0737
Comparison of 123I-IMP SPECT, 18F-FDG PET/CT, and 18F-FDOPA PET/CT in Detection of Choroidal Malignant Melanoma
K. Kato1, T. Odagawa1, T. Tsutsumi1, M. Honda1, K. Kunimoto1, R. Mukumoto1, S. Matsuzawa1, S. Abe1, S. Naganawa1; 1Nagoya University Graduate School of Medicine, Nagoya, JAPAN, 2Nagoya University Hospital, Nagoya, JAPAN.

EP-0738
Functional Radiographic Profiling of Immunotherapy Related Toxicities with 18F-FDG-PET/CT in Patients with Metastasized Malignant Melanoma
Y. Zhuwu, S. Nekolla, J. Kohlmeier, A. Krakhardt, M. Schweiger, M. Mustafa; Klinikum rechts der Isar, Munich, GERMANY.

EP-0739
18FFluorodeoxyglucose Positron Emission Tomography/Computed Tomography Findings In Ocular Melanoma
J. Benouhoud, S. Choukry, Y. Shimi, A. Guensi; CHU Ibn Rochd, Casablanca, MOROCCO.

EP-0740
Necrosis determines FDG-avidity in cerebral metastases of malignant melanoma - correlating 18F-FDG-uptake with histological parameters
M. Mustafa, H. Einhellig, M. Boxberg, T. Pyka, J. Kohlmeier, A. Krakhardt, M. Schweiger; Klinikum rechts der Isar, Munich, GERMANY.
EP-0746
Contribution of FDG PET/CT In Staging and Management of Pediatric Patients with Osteosarcoma
A. K. Fidan, G. Ucmak, I. Kerimel, B. B. Demirel, B. E. Akkas; S.B.U. Ankara Oncology Research and Training Hospital, Nuclear Medicine Department, Ankara, TURKEY.

EP-0747
Correlation of Tumor Necrosis Ratio and Metabolic Parameters of Initial Staging FDG PET/CT In Pediatric Patients with Osteosarcoma
G. Ucmak, A. K. Fidan, I. Kerimel, B. E. Akkas, B. B. Demirel; S.B.U. Ankara Oncology Research and Training Hospital, Nuclear Medicine Department, Ankara, TURKEY.

EP-0748
Sentinel lymph node biopsy (SLNB) before and after neo-adjuvant chemotherapy (NAC) in locally advanced breast cancer, our results
J. M. Espejo Niño, A. Esteban Figueiruelo, E. Rodenño Ortiz De Zárate, P. Cobos Baena, L. Andres Alvarez; Hospital Universitario Cruces, Barakaldo, SPAIN.

EP-0749
Comparison of the diagnostic value of preoperative sentinel lymph node (SLN) imaging using conventional scintigraphy and SPECT/CT in penile cancer patients with non-palpable inguinal lymph nodes
U. Lützen, B. Egeler, M. Jüptner, Y. Zhao, M. Marx, C. M. Naumann, K. Jünnemann, M. Zuhayra; UKSH, Campus Kiel, Kiel, GERMANY.

EP-0750
Diagnostic Accuracy Of Sentinel Lymph Node Biopsy In Patients With Endometrial Cancer

EP-0751
Tc-99m-PSMA-guided intraoperative lymph node localization in recurrent prostate cancer
M. C. Schmidt, D. Pfister, C. Kobe, M. Dietlein, M. Dietlein, A. Heidenreich, A. Drezga; ‘University Hospital of Cologne, Dpt. of Nuclear Medicine, Cologne, GERMANY, ‘University Hospital of Cologne, Dpt. of Urology, Cologne, GERMANY.

EP-0752
Wire-guided localization vs 123I radioactive seed localization in nonpalpable breast lesions

EP-0753
Time to relapse is associated with altered lymphatic drainage and sentinel node location in recurrent breast cancer
P. Borrelli, S. Viêira, S. Vidal-Sicart, M. van Essen, H. van Tinteren, R. A. Valdés Olmos; Sahlgrenska University Hospital, Göteborg, SWEDEN, ‘Netherlands Cancer Institute, Amsterdam, NETHERLANDS, ‘University Hospital Clinic, Barcelona, SPAIN, ‘Leiden University Medical Center, Leiden, NETHERLANDS.

EP-0754
Sentinel Lymph Node Biopsy in Cutaneous Melanoma: Analysis of 362 Patients from a Single Institution
L. Jaukovic, M. Radulovic, M. Rajoivc, L. Kandolf-Sekulovic; Military Medical Academy, Belgrade, SERBIA.

EP-0755
Incidence and implications of atypical lymphatic drainage in patients with Primary Cutaneous Malignant Melanoma
M. Oporto, C. Sampol, A. Repetto, N. Orta, H. Navalon, S. Rubi, M. Villar, C. Peña; Hospital Universitari Son Espases, Palma, SPAIN, ‘IdISPa, Palma, SPAIN.

EP-0756
Our Experience with ROLL and SNOLL techniques in clinically occult breast carcinoma
S. M. Nieves Maldonado, Z. Bravo Ferrer, C. Lancha Hernandez, J. Nuñez Cambre, J. Rodriguez, J. Corredoira, A. Rodriguez París; ‘Nuclear Medicine Department, Hospital HM- Modelo de la Coruña, La Coruña, SPAIN, ‘Surgery Department, Hospital HM- Modelo de la Coruña, La Coruña, SPAIN, ‘Radiology Department, Hospital HM- Modelo de la Coruña, La Coruña, SPAIN.
EP-0757
Prognostic Significance Of The Effect Of Delay Time Between Primary Melanoma Biopsy And Sentinel Lymph Node Biopsy
M. L. Dominguez¹, J. P. Suárez², P. Fernandez³, J. I. Raya³, O. D. Rodriguez³, F. M. Gonzalez¹; ¹Nuclear Medicine Department. Central University Hospital of Asturias, Oviedo, SPAIN, ²Nuclear Medicine Department. San Pedro de Alcántara Hospital, Caceres, SPAIN, ³Clinical investigation and trials unit. Virgen del Rocio University Hospital, Sevilla, SPAIN.

EP-0758
Evaluation Of The Influence Of Preoperative Wire-Guided Localization And Radiopharmaceutical Injection With Or Without Radiological Guidance In Global Detection Of Sentinel Lymph Node Biopsy In Patients With Breast Cancer

EP-0759
Internal Mammary Lymph Node in Breast Cancer as a Predictive Value in a High Risk Asymptomatic Population
A. Mestre-Fusco¹, J. Jimeno², M. Sudrez-Piñera¹, J. Espallargas¹, M. Vernet¹, J. Corominas¹, S. Vidal-Sicart¹; ¹Radiology & Nuclear Medicine Department, IMI. Hospital del Mar, PSMar., Barcelona, SPAIN, ²Surgery Department. Hospital del Mar, PSMar., Barcelona, SPAIN, ³Pathology Department. Hospital del Mar, PSMar., Barcelona, SPAIN, ⁴Gynecology Department. Hospital del Mar, PSMar., Barcelona, SPAIN.

EP-0760
Within-patient comparison of two sentinel lymph node tracers: ⁹⁹mTc-Senti-Scint and (ICG-)⁹⁹mTc-nanocolloid
P. Meershoek¹,², M. L. Donswijk³, G. H. KleinJan¹,², N. S. van den Berg², B. van der Hiel², R. A. Valdéz-Olmos¹, J. A. van der Hage³, W. M. C. Klop², W. B. van Leeuwen¹; ¹Leiden University Medical Center, Leiden, NETHERLANDS, ²Netherlands Cancer Institute (NIO-AvL), Amsterdam, NETHERLANDS.

EP-0761
Importance of in-transit sentinel node in patients with cutaneous melanoma
E. Noriega-Álvarez¹, J. Rodríguez-Rubio Corona¹, M. Bajén Lázaro¹, J. Jaller Vanegas¹, A. Benítez Segura¹, J. Marcoval Caus¹, R. Penin Mosquera¹, J. Bermejo Segu¹, C. Gámez Cenzano¹; ¹Nuclear Medicine-PET Department. IDI. Hospital Universitari de Bellvitge-IDIBELL, L’Hospitalet de Llobregat, Barcelona, SPAIN, ²Dermatology Department. Hospital Universitari de Bellvitge-IDIBELL, L’Hospitalet de Llobregat, Barcelona, SPAIN, ³Pathology Department. Hospital Universitari de Bellvitge-IDIBELL, L’Hospitalet de Llobregat, Barcelona, SPAIN, ⁴Plastic Surgery Department. Hospital Universitari de Bellvitge-IDIBELL, L’Hospitalet de Llobregat, Barcelona, SPAIN.

EP-0762
Implementation of sentinel lymph node for cervical and endometrial cancer: early experience

EP-0763
Comparison between planar and tomographic SPET/CT acquisition on sentinel node identification on patients affected by breast cancer and melanoma
S. Chondrogiannis, M. C. Marzola, G. Grassetto, A. M. Maffione, A. Zompa, L. Tamosi, E. Milan, A. Bassan, L. Rampin, D. Rubello; Nuclear Medicine - PET/CT centre, Santa Maria della Misericordia Hospital of Rovigo, Rovigo, ITALY.

EP-0764
Sentinel Lymph Node Biopsy In Patients With Breast Cancer And Axillary Involvement Treated With Neoadyuvant Chemotherapy
S. Sanz-Viedma, V. Scholz-Gutierrez, F. Fernandez-Garcia, C. Lacalle, R. Gomez, M. Martinez Del Valle, L. Vicioso, J. Jimenez Hoyuela; Hospital Clinico Virgen de la Victoria, Malaga, SPAIN.
EP-0765
Relationship Between Sentinel Lymph Node Metastasis Size In Cutaneous Melanoma Patients And The Number Of Lymphadenectomies With Presence Of Additional Lymph Nodes Metastasis
J. Rodríguez-Rubio Corona1, M. Bajén-Lázaro1, E. Noriega-Álvarez2, A. Rodríguez-Gasén3, J. Suils-Ramón4, E. Linares-Tello1, A. Benítez-Segura5, J. Mora-Salvadó6, J. Ferreres-Riera7, M. Soler-Monsó8, D. Pérez Sidelnikova9, C. Gámez-Cenano10; 1Nuclear Medicine-PET Department. IDI. Hospital Universitari de Bellvitge-Idibell, L’Hospitalet de Llobregat (Barcelona), SPAIN, 2Dermatology Department. Hospital Universitari de Bellvitge-Idibell, L’Hospitalet de Llobregat (Barcelona), SPAIN, 3Pathology Department. Hospital Universitari de Bellvitge-Idibell, L’Hospitalet de Llobregat (Barcelona), SPAIN, 4Plastic Surgery Department. IDI. Hospital Universitari de Bellvitge-Idibell, L’Hospitalet de Llobregat (Barcelona), SPAIN.

EP-0766
Gated Reconstruction in 18F-FDG PET-CT Quantitative Imaging: Impact on SUV Estimation of Tumor Motion Inside the Lung and Respiration Gated Radiotherapy Treatment with Dynamic Thorax Phantom

EP-0767
Investigation of automatic thresholding on PET images for volume delineation of lung lesions in radiation therapy treatment
T. Osman1, B. McBride2, T. Hennessy3, S. Downes4; 1University of Wollongong, Wollongong, AUSTRALIA, 2Prince of Wales Hospital, Randwick, AUSTRALIA.

EP-0768
Volume-based assessment of different image reconstruction algorithms and thresholds for FDG-PET/CT based on dose-painting concept
P. Ghafarian1,2, A. Ketabi3,4, M. A. Mosleh-Shirazi5, M. R. Ay6,7, Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran., Tehran, IRAN, ISLAMIC REPUBLIC OF; 2PET/CT and Cyclotron Center, Masih Daneshvar Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Tehran, IRAN, ISLAMIC REPUBLIC OF; 3Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, Iran., Tehran, IRAN, ISLAMIC REPUBLIC OF; 4Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, Iran., Tehran, IRAN, ISLAMIC REPUBLIC OF; 5Medical Imaging Research Center, and Physics Unit, Department of Radiotherapy and Oncology, Namazi Hospital , Shiraz University of Medical Sciences, Shiraz, Iran., Tehran, IRAN, ISLAMIC REPUBLIC OF; 6Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, Iran., Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0769
The role of 18F-Choline (FCH) PET/CT for the prediction of long-term response to radical radiotherapy (RT) in patients with localized prostate cancer (PCa)
L. Cuppari1, M. Sepulcri2, M. Fusella3, A. Zorz4, M. Pauusso1, L. Corti5, G. Saladini6, L. Evangelista7; 1Nuclear Medicine and Molecular Imaging Unit, Veneto Institute of Oncology IOV - IRCCS, Padova, ITALY. 2Radiation Oncology Unit, Veneto Institute of Oncology IOV - IRCCS, Padova, ITALY. 3Medical Physics Unit, Veneto Institute of Oncology IOV - IRCCS, Padova, ITALY.
EP-0771
Variability in reference levels for Deauville classifications applied to lymphoma patients examined with 18F-FDG-PET/CT
M. Sadik1, E. Lind1, O. Enqvist1, J. Ulén1, E. Polymeri1, E. Trägårdh1, L. Edenbrandt1; 1Department of Clinical Physiology, Goteborg, SWEDEN, 2Department of Signals and Systems, Goteborg, SWEDEN.

EP-0772
The value of PET-CT in the evaluation of response to treatment in patients with prostate cancer treated with Radium223
S. S. Medina Ornelas, F. O. Garcia-Perez; Instituto Nacional De Cancerologia, Mexico City, MEXICO.

EP-0773
Unicentric experience in the treatment of metastatic castration-resistant prostate cancer with Ra223
E. Rodeno Ortiz de Zaraté, P. Minguiez Gabiña, I. Fernández Terceiro, A. Gómez de Iturriaga Piña, R. Llarena Ibarquren, A. Urresola Olabarrieta, A. Esteban Figueruela, J. Espejo Niño, A. Sánchez Salmond; Gurutzeta/Cruces University Hospital, Barakaldo, SPAIN.

EP-0774
Outcomes Of Treatment With Ra223 In Patients With Castration-Resistant Prostate Cancer with symptomatic bone metastases and no known visceral metastatic disease

EP-0775
Is the averaged SUV from several hottest voxels an alternative to SUVpeak for quantification of large heterogeneous or small lesions in oncological PET imaging?
A. Ketabi1,2, P. Ghafarian1, S. Masjoadi1, M. A. Mosleh-Shirazi1, M. R. Ay1,2; 1Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 2Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, 3PET/CT and Cyclotron Center, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0776
Back pain in oncology patients does not equal spinal metastases
L. Louw, M. Vangu; University of the Witwatersrand, Johannesburg, SOUTH AFRICA.

EP-0777
A Systematic Review And Meta-Analysis Of FDG-PET/CT As A Screening Tool For Occult Malignancy In Unprovoked Venous Thromboembolism
S. Hess1,2,3, E. C. Frary1,4, P. F. Høilund-Carlsen1,3, O. Gerke1,5; 1Dept. of Nuclear Medicine, Odense University Hospital, Odense, DENMARK, 2Dept. of Radiology and Nuclear Medicine, Hospital Southwest Jutland, Esbjerg, DENMARK, 3Dept. of Clinical Research, Faculty of Health Sciences, University, Odense, DENMARK, 4Department of Cardiology, Nephrology, and Endocrinology, Nordsjælland Hospital Hillerød, Hillerød, DENMARK, 5Centre of Health Economics Research, University of Southern Denmark, Odense, DENMARK.

EP-0778
Use of 18F-FDG PET/CT in early diagnosis of primary neoplasm site in patients with neurologic paraneoplastic syndromes
A. Sowa-Staszczak, M. Opalinska, M. Trofimuk-Muldner, W. Lenda-Tracz, M. Buziak-Bereza, A. Brzozowska-Czarnek, A. Hubalewska-Oydejczyk; Chair and Department of Endocrinology, Jagiellonian University, Medical College, Kraków, POLAND.
EP-0779 Metabolic characterization of anterior mediastinal mass in adult patients by F-18 FDG PET/CT
Z. Koç, P. Özcan Kara, E. Ayan; Mersin University Hospital, Mersin, TURKEY.

EP-0780 Clinical Usefulness Of 18F-FDG PET/CT For The Evaluation Of The Atypical Adrenal Tumors
A. Rubio Rodríguez; Institut Diagnòstic per la Imatge, Girona, SPAIN.

EP-0781 Retrospective Study of Bone Marrow Disease Detection with 18F FDG PET/CT and Correlation with Positive Bone Marrow Biopsies for Haematological Malignancies
M. Hamidian1, J. Crook2, H. Rizvi2, N. Svalding2, Y. Bouchareb1, S. Hallam2, K. Shahabuddin1, H. Jan1, A. Haroon; 1Kowsar Hospital Nuclear Medicine Department, Shiraz, IRAN, ISLAMIC REPUBLIC OF; 2Barts Health NHS Trust, London, UNITED KINGDOM.

EP-0782 Incidental lesions in FDG-PET/CT scans
G. Sipka1, Z. Besenyi1, Z. Lengyel2, L. Pavics1; 1University of Szeged, Szeged, HUNGARY, 2Pozitron-Diagnosztika Központ, Budapest, HUNGARY.

EP-0783 Synchronous and Metachronous Tumors Detected by PET / CT in the Staging of Primary Tumors
B. Perez Lopez, F. Gomez-Caminero Lopez, P. Garcia-Talavera San Miguel, A. Chury Murcia, L. Díaz Gonzalez, E. Martin Gomez, P. Tamayo Alonso; Complejo Asistencial Universitario de Salamanca, Salamanca, SPAIN.

EP-0784 Diagnostic Performance of 68 Ga-SSR PET-CT in patients with Ga-SSR Metastatic Ga-SSR Membrane Antigen
K. Agrawal, B. M. Patil; 1Kansai Medical University, Osaka, JAPAN, 2Kansai Medical University Medical Center, Osaka, JAPAN, 3Perseus Proteomics Inc., Tokyo, JAPAN, 4Kansai Medical University, Radioisotope Research Center, Osaka, JAPAN.

EP-0785 Association Between Gastric FDG Uptake in PET-CT and 14-C UBT Results in Patients Referred for Non-Gastric Cancer PET-CT Studies
A. Hassanzadeh-Rad, F. Farsiabi, M. Eftekhari, A. Fard-Esfahani, B. Fallahi, A. Emami-Ardekani, D. Beiki; Research Center for Nuclear Medicine, Tehran, IRAN, ISLAMIC REPUBLIC OF.
EP-0790
Improvement of therapeutic efficacy by combing 90Y-ITGA6B4-mediated radioimmunotherapy (RIT) with dual PI3K and mTOR inhibitor NVP-BEZ235
W. Aung1, A. B. Tsuji1, H. Sudo1, A. Sugyo1, Y. Uka1, K. Kouda1, Y. Kurosawa1, T. Furukawa1, T. Saga1, T. Higashi1; 1Department of Molecular Imaging and Theranostics, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, JAPAN, 2Perseus Proteomics Inc., Tokyo, JAPAN, 3Innovation Center for Advanced Medicine, Fujita Health University, Toyoake, JAPAN, 4Department of Radiological and Medical Laboratory Sciences, Nagoya University Graduate School of Medicine, Nagoya, JAPAN, 5Department of Diagnostic Radiology, Kyoto University Hospital, Kyoto, JAPAN.

EP-0791
Preferential Tumor Accumulation in Mice bearing Human Head and Neck Cancer using Radionuclide-carrying Liposomes aiming for Radiotheranostics
I. O. Umeda, S. Hamamichi, H. Fujii; National Cancer Center, Kashiwa, JAPAN.

EP-0792
Combination Therapy of Medullary Thyroid Cancer Using Radiation and Vandetanib
V. Sandblom1, J. Spetz1, E. Shubbar1, J. Swanpalmer1, E. Forsstell-Aronsson1; 1Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Cancer Center, Sahlgrenska Academy, University of Gothenburg, Gothenburg, SWEDEN, 2Department of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Gothenburg, SWEDEN.

EP-0793
Receptor Binding Kinetics of PSMA-Specific Peptides Determined by Surface Plasmon Resonance Measurements
G. Winter1, A. Vogt1, G. Glätting1, P. Kletting1, A. J. Beer1; 1Department of Nuclear Medicine, Ulm University, Ulm, GERMANY, 2Medical Radiation Physics, Department of Nuclear Medicine, Ulm University, Ulm, GERMANY.

EP-0794
Radioiodination Of Small Stapled Peptides For p53 Therapy
S. Lundsten1, D. Spiegelberg1, V. Agmo Hernández2, C. Brown3, K. Edwards4, D. Lane5, M. Nestor1; 1Department of Immunology, Genetics and Pathology, Uppsala University, UPPSALA, SWEDEN, 2Department of Chemistry – BMC, Uppsala University, UPPSALA, SWEDEN, 3p53Lab, A*STAR, SINGAPORE, SINGAPORE, 4Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, SWEDEN.

EP-0795
Radium-223 and metastatic prostate cancer: new insights from cellular studies
I. A. Marques1, A. M. Abrantes1,2,3, A. R. Neves1, A. S. Pires1,2,3, G. Costa1,2,3, T. Rodrigues1, P. Matafonse1,2, E. Tavares-Silva1,4, R. Seiça1, A. Figueredo1, M. F. Botelho1,2,3; 1Biophysics Institute, IBILI-Faculty of Medicine, University of Coimbra, Coimbra, PORTUGAL, 2CIMAGO, Faculty of Medicine, University of Coimbra, Coimbra, PORTUGAL, 3CNC-IBILI, University of Coimbra, Coimbra, PORTUGAL, 4Department of Nuclear Medicine, CHUC, Coimbra, PORTUGAL, 5Laboratory of Biostatistics and Medical Informatics, IBILI-Faculty of Medicine, University of Coimbra, Coimbra, PORTUGAL, 6Laboratory of Physiology, IBILI-Faculty of Medicine, University of Coimbra, Coimbra, PORTUGAL, 7Department of Complementary Sciences, Coimbra Health School (ESTeSC), Polytechnic Institute of Coimbra, Coimbra, PORTUGAL, 8Department of Urology and Renal Transplantation, CHUC, Coimbra, PORTUGAL.

EP-0796
Cell Survival in Colorectal Cancer under Yttrium-90 and Megavoltage X-ray
N. Forwood1,2, Y. Gholami3, R. Harvie1, K. Willowsnon1, R. Bromley1, V. Howell1, H. Ryu1, Z. Kuncic1, D. L. Bailey1,6; 1Department of Nuclear Medicine, Royal North Shore Hospital, St Leonards, AUSTRALIA, 2Faculty of Health Sciences, Sydney University, Sydney University, AUSTRALIA, 3Institute of Medical Physics, Sydney University, Sydney, AUSTRALIA, 4Kolling Institute, St Leonards, AUSTRALIA, 5Department of Radiation Oncology, Royal North Shore Hospital, St Leonards, AUSTRALIA, 6Faculty of Health Sciences, Sydney University, Sydney, AUSTRALIA, 7School of Physics, University of Sydney, Sydney, Australia.

EP-0797
Potential use of PRRT with 177Lu-octreotate beyond NETs : preliminary in vitro data in melanoma and multiple myeloma
W. Delbart1, Z. Wimana, M. Vercruysen, N. Meuleman, G. Ghanem, P. Flamen; Jules Bordet Institute, Brussels, BELGIUM.

EP-0798
Improving Image Quality in Preclinical ¹⁸F-FDG TOF PET through Higher Definition Image Reconstruction
M. I. Menendez1, J. Zhang, R. Moore, M. Friel, K. Binzel, M. V. Knopp; The Ohio State University, Columbus, OH, UNITED STATES OF AMERICA.
EP-0799
Radiotherapeutic Nanoparticles Containing a Ruthenium-Based Radiosensitizer for EGFR-Positive Oesophageal Cancer
M. R. Gill1, J. U. Menon1, R. C. Carlisle1, J. A. Thomas1, P. J. Jarman2, K. A. Vallis3; 1University of Oxford, Oxford, UNITED KINGDOM, 2University of Sheffield, Sheffield, UNITED KINGDOM.

EP-0800
Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30
M. Marinova, M. Mücke, L. Mahlberg, M. Essler, H. Cuhls, L. Radbruch, R. Conrad, H. Ahmadzadehfar; University Hospital Bonn, Bonn, GERMANY.

EP-0801
I-131-mIBG therapy in high-risk neuroblastoma patients at end of induction chemotherapy
M. C. Schmidt1, B. Hero2, B. Decarolis2, A. Eggert1, F. Berthold1, A. Drzega1, T. Simon1; 1University Hospital of Cologne, Dpt. of Nuclear Medicine, Cologne, GERMANY, 2University Hospital of Cologne, Dpt. of Pediatric Hemato-Oncology, Cologne, GERMANY, 3Charité Berlin, Dpt. of Pediatric Hemato-Oncology, Berlin, GERMANY.

EP-0802
Phase 1/2 open-label trial to assess the safety and preliminary efficacy of 177Lu-OPS201 as peptide receptor radionuclide therapy in patients with somatostatin receptor-positive, progressive neuroendocrine tumours
G. Nicolas1,2, R. P. Baum3, K. Hermannn1, M. Lassmann1, R. J. Hicks4, A. R. Haug5, S. Navalkissoor6, H. Oberwittler1, T. Wang1, D. Wild1; 1University of Basel Hospital, Basel, SWITZERLAND, 2Royal Free Hospital, London, UNITED KINGDOM, 3Zentrumsklinik Bad Berka, Bad Berka, GERMANY, 4University Hospital Würzburg, Würzburg, GERMANY, 5UCLA, Los Angeles, CA, UNITED STATES OF AMERICA, 6Cedars Sinai Medical Center, Los Angeles, CA, UNITED STATES OF AMERICA, 7Medical University of Vienna, Vienna, AUSTRIA, 8Ipsen, Les Ulis, FRANCE, 9Ipsen, Cambridge, MA, UNITED STATES OF AMERICA.

EP-0803
Association between uptake on 68Ga-DOTATOC and 18F-FDG PET/CT with uptake and mean absorbed dose on 177Lutetium-SSA gamma imaging during PRRT
D. M. V. Huizing1, E. A. Aalbersberg1, C. Schuchhardt2, B. J. de Wit - van der Veen1, I. Wahraen1, A. Singh1, H. R. Kulkarni4, M. P. M. Stokkel5, R. P. Baum2; 1Department of Nuclear Medicine, ENETS Center of Excellence, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, NETHERLANDS, 2THERANOSTICS Center for Molecular Radiotherapy, ENETS Center of Excellence, Zentrumsklinik Bad Berka, Bad Berka, GERMANY, 3Department of Radiation Oncology, ENETS Center of Excellence, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, NETHERLANDS.

EP-0804
Quality of Life Improvements in Patients with progressive Midgut Neuroendocrine Tumors: the NETTER-1 Phase III Trial
J. Strosberg1, E. Wolin2, B. Chasen3, M. Kulke4, D. Bushnell5, M. Caplin2, R. P. Baum7, P. Kunz8, T. Hobday9, A. Hendisfar10, K. Oberg11, M. Lopera Sierra12, P. Ruszniewski13, E. Krenning14; 1Moffitt Cancer Center, Tampa, FL, UNITED STATES OF AMERICA, 2Montefiore Einstein Center for Cancer Care, Bronx, NY, UNITED STATES OF AMERICA, 3The University of Texas MD Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA, 4Zentrumsklinik Bad Berka, Bad Berka, GERMANY, 5Stanford University Medical Center, Stanford, CA, UNITED STATES OF AMERICA, 6Royal Free Hospital, London, UNITED KINGDOM, 7Zentrumsklinik Bad Berka, Bad Berka, GERMANY, 8Mayo Clinic College of Medicine, Rochester, MN, UNITED STATES OF AMERICA, 9Cedars Sinai Medical Center, Los Angeles, CA, UNITED STATES OF AMERICA, 10Advanced Accelerator Applications, New York, NY, UNITED STATES OF AMERICA, 11Hopital Beaujon, Clichy, FRANCE, 12Ipsen, Cambridge, MA, UNITED STATES OF AMERICA.

EP-0805
Monte Carlo Based SPECT Activity Quantification and Tumor Dosimetry for 177Lu-DOTATATE Treatments
J. Marin1, J. Svensson2, T. Rydén3, E. Wikberg1, A. Elf4, V. Johansson1, P. Bernhardt1; 1Department of Radiation Physics, Gothenburg, SWEDEN, 2Department of Oncology, Gothenburg, SWEDEN, 3Department of Surgery, Gothenburg, SWEDEN.
EP-0806
Haematological toxicity in patients with somatostatin receptor positive tumours showing high bone and bone marrow involvement treated with 177Lu-Dotatate
M. Cremonesi1, M. E. Ferrari1, L. Bodei1, F. Botta1, M. Colandrea1, S. M. Baio1, P. A. Rocca1, G. Prisco1, G. Buonsanti2, D. Militano1, C. Garibaldi1, R. Orecchia1, C. M. Grana1; 1Istituto Europeo di Oncologia, Milano, ITALY, 2Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.

EP-0807
A long term efficacy of PRRT in patients with advanced, non-resectable paraganglioma/pheochromocytoma tumours, related to SDHx gene mutation
A. D. Kolarska-Cwikla1, M. Pęczkowska2, J. Michałow ska2, A. Lewczuk3, L. Bodei4, M. Kidd4, J. M. Modlin1, J. B. Cwikla1; 1MSC Memorial Cancer Centre and Institute Maria Skłodowska-Curie, Warsaw, POLAND, 2Institute of Cardiology, Warsaw, POLAND, 3Medical University of Gdańsk, Gdańsk, POLAND, 4Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA, 5Wren Laboratories, Branford, CT, UNITED STATES OF AMERICA, 6Yale University, New Haven, CT, UNITED STATES OF AMERICA, 7Faculty of Medical Sciences, University of Warmia and Mazury, Olsztyn, POLAND.

EP-0808
Red Bone Marrow Dosimetry and Haematotoxicity in 177Lu-DOTATATE PRRT
S. Tshori1, S. Glasberg2, D. Luder2, Y. Krausz2, D. Gross2, A. Schwartz2, N. Freedman2,3; 1Kaplan Medical Center, Rehovot, ISRAEL, 2Hadassah Hebrew University Medical Center, Jerusalem, ISRAEL, 3Tel Aviv Sourasky Medical Centre, Tel Aviv, ISRAEL.

EP-0809
Safety, Biodistribution, and Efficacy of 67Cu-SARTATE targeted therapy in somatostatin receptor expressing tumours in mice
E. M. van Dam1, C. M. Jeffery1, J. L. Stoner2, A. V. Hedt3, M. J. Harris1; 1Clarity Pharmaceuticals, Sydney, AUSTRALIA, 2Idaho State University, Pocatello, ID, UNITED STATES OF AMERICA.

EP-0810
Treatment of 28 Paragangliomas with 177Lu-octreotate based PRRT
D. Smit Duijzentkunst, T. Brabander, J. Hendriks, A. van Linge, R. Feelders, R. Oldenburg, E. Krenning, D. Kwekkeboom, D. Luder, Erasmus MC, Rotterdam, NETHERLANDS.

EP-0811
Siopen Scoring System to quantifying response to 131-I-MIBG metabolic treatment in HR-NB relapse: review of local experience
C. Olianti1, P. Saletti2, G. Simontacchi1, A. Tondo1; 1Nuclear Medicine Unit - Careggi University Hospital, Florence, ITALY, 2Health Physic Unit, Careggi University Hospital, Florence, ITALY, 3Radiotherapy Unit, Careggi University Hospital, Florence, ITALY, 4OncoHematology Unit, Meyer University Hospital, Florence, ITALY.

EP-0812
Outcome of Lutetium DOTANOC therapy in metastatic neuroendocrine tumor: Preliminary experience
P. K. Pradhan, D. Datta, S. Gambhir, A. Mishra, A. Agarwal; SGPGIMS, Lucknow, INDIA.

EP-0813
SUVmax predicts survival in patients with diffuse large B-cell lymphoma who received radioimmunotherapy using 131I-rituximab as consolidation therapy
J. Choi1, L. Lim1, B. Byun1, B. Kim1, C. Choi2, S. Lim1, D. Shin1, H. Kang1; 1Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, KOREA, REPUBLIC OF, 2Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF.

EP-0814
FDG uptake at baseline may predict absorbed dose in tumor lesions in indolent Non-Hodgkin lymphoma patients treated With the novel antibody-radionuclide-conjugate 177Lu-lilotomab satetaxetan
A. Londalen1, J. Blakkisrud1, J. Dahl1, M. Revheim1,4, H. Holte1, A. Kolstad4, C. Stokke1,5; 1Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, NORWAY, 2Department of Diagnostic Physics, Oslo University Hospital, Oslo, NORWAY, 3Nordic Nanovector ASA, Oslo, NORWAY, 4Faculty of Medicine, University of Oslo, Oslo, NORWAY, 5Department of Oncology, Radiumhospital, Oslo University Hospital, Oslo, NORWAY, 6Oslo and Akershus University College of Applied Science, Oslo, NORWAY.

EP-61 during congress opening hours, e-Poster Area
Radionuclide Therapy & Dosimetry: Radioimmunotherapy (RIT)

EP-0815
SUVmax predicts survival in patients with diffuse large B-cell lymphoma who received radioimmunotherapy using 131I-rituximab as consolidation therapy (continued)
J. Choi1, L. Lim1, B. Byun1, B. Kim1, C. Choi2, S. Lim1, D. Shin1, H. Kang1; 1Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, KOREA, REPUBLIC OF, 2Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF.
**EP-0815**
Effect of selenium supplement for protection of salivary glands from I-131 radiation damage in patients with differentiated thyroid cancer

**J. Lee**1, **H. Son**1, **S. Lee**1; 1Catholic Kwandong University College of Medicine, Incheon, KOREA, REPUBLIC OF; 2Soochunhyang University Hospital, Cheonan, KOREA, REPUBLIC OF.

**EP-0816**
Higher Body Weight and Distant Metastasis are Associated with Higher Radiation Exposure to the Household Environment from Patients with Thyroid Cancer after Radioactive Iodine Therapy

**S. Kuo**1, **J. Lin**2, **M. Liou**2, **B. Huang**1, **K. Chang**1, **R. Cheng**1; 1Chang Gung Memorial Hospital, Keelung, TAIWAN, 2Chang Gung Memorial Hospital, Taoyuan, TAIWAN.

**EP-0817**
Abnormal Uptake Of 131 Iodine On Surgical Clips, A Case Report

**A. Buitrago**1, **M. Galler**1, **H. Lasolle1**, **C. Bournaud2**, **F. Giammarie1,2**, **E. Levigoureux**1,2; 1Hospices civils de Lyon, Groupement Hospitalier Est, Bron, FRANCE, 2Université Lyon 1 Claude Bernard, Lyon, FRANCE.

**EP-0818**
Clinical Significance of Iodine-131 ablation therapy post total thyroidectomy in differentiated thyroid cancer

**K. Utsunomiya**1, **H. Iwai**2, **K. Suzuki**2, **N. Kan1**, **Y. Kono2**, **K. Maruyama2**, **Y. Ueno2**, **N. Tanigawa2**; 1Kansai Medical University Medical Center, Monguchi, JAPAN, 2Kansai Medical University Hospital, Hirakata, JAPAN.

**EP-0819**
Acceptable radiation exposure to contacts of patients treated with low dose radioactive iodine (I-131) post family counseling can pave the way for high dose I-131 therapy on outpatient basis

**K. Salmani**1, **S. Yassin1**, **T. Munshy1**, **M. Almalki2**, **S. Zatari1**, **Z. Khan1**, **S. Elmosry1**, **D. Abdelmoety1**, **M. Al-Ezzi1**, **M. Al-Otaiby1**, **H. Fedah1**, **M. Alhazmi1**, **N. Ali1**, **A. Idris1**; 1King Abdullah Medical City (KAMC), Makka, SAUDI ARABIA, 2Ministry of health, KSA, Riyadh, SAUDI ARABIA.

**EP-0820**
Thyroid Cancer and Galectin-3

**Z. Hasbek**1, **G. Duman**1, **T. Candar**1, **S. A. Erturk**1, **A. Cakmakci**1; 1Cumhuriyet University School of Medicine, Sivas, TURKEY, 2Ufuk University School of Medicine, ANKARA, TURKEY.

**EP-0821**
BRAF\[^{V600E}\] and \[^{99mTc}\text{-MIBI}\] scintigraphy are usefull diagnostic tools in identifying metastatic differentiated thyroid cancer patients refractory to radioiodine therapy

**A. Campenni**1, **M. Siracusa2**, **M. Stipo2**, **S. Pignata1**, **F. Di Mauro1**, **R. Ruggeri2**, **S. Baldani1**; 1Unit of Nuclear Medicine of Messina, Messina, ITALY, 2Unit of Endocrinology of Messina, Messina, ITALY.

**EP-0822**
Investigation Of The Effect Of Vitamin C On Oxidative Stress Parameters Due To Radioiodine Treatment In Hyperthyroidism Patients

**S. Ozdemir**1, **K. Ustun1**, **D. U lécker2**, **Y. Ziya Tan3**, **M. Aşik4**, **F. C elik5**; 1Canakkale Onsekiz Mart University, Faculty of Medicine, Department of Nuclear Medicine, Canakkale, TURKEY, 2Canakkale Onsekiz Mart University, Faculty Of Medicine, Department of Endocrinology and Metabolic Disease, Canakkale, TURKEY, 3Canakkale Onsekiz Mart University, Faculty of Medicine, Department of Biochemistry, Canakkale, TURKEY, 4Canakkale Onsekiz Mart University, Faculty of Medicine, Department of Endocrinology and Metabolic Disease, Canakkale, TURKEY.

**EP-0823**
Influence of coexisting Hashimoto thyroiditis on the postoperative residual thyroid tissue ablation success after the first dose of 3.7 GBq of iodine-131 in patients with differentiated thyroid carcinoma

**M. P. Rajic**1, **M. Vlajkovic**1, **S. Ilic**1, **M. Stevic**1, **M. Kojic**1; 1University of Niš Medical School, Niš, SERBIA.

**EP-0824**
Risk factors for predicting osteoporosis in patients who receive tsh-supressive levothyroxe treatment for differentated thyroid carcinoma

**C. Soydal**1, **E. Ozkan**1, **D. Nak1**, **A. H. Elhan1**, **N. Kucuk1**, **M. K. Kir1**; 1Ankara University Medicel Faculty, Nuclear Medicine, Ankara, TURKEY, 2Ankara University Medicel Faculty, Biostatistics, Ankara, TURKEY.

**EP-0825**
National survey and harmonization of practices of I-131 therapy for thyroid cancer in Finland

**T. E. J. Noponen**1, **M. Tenhunen**1, **J. Heikkinen**1, **V. Tunninen**1, **H. Mäenpää1**; 1Department of Clinical Physiology Nuclear Medicine, Turku University Hospital, Turku, FINLAND, 2Department of Radionuclide Treatments, Cancer Centre, Helsinki University Hospital, Helsinki, FINLAND, 3Department of Medical Physics, Etelä-Savo Hospital District, Mikkeli, FINLAND, 4Department of Nuclear Medicine, Satakunta Central Hospital, Pori, FINLAND.
EP-0826  
Predictive factors of a disease-free status in post-operative differentiated thyroid cancer patients treated with 131I  

EP-0827  
Radioiodine uptake by thyroglossal duct remnant after radioiodine therapy for differentiated thyroid carcinoma  
M. Jinjuji, M. Nakajo, T. Tani, T. Yoshiura; Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, JAPAN.

EP-0828  
Comparison of the Prescribed Dose of Radioiodine Ablation (Low Dose versus High Dose) in patients with Intermediate to High Risk Thyroid Cancer: An Inverse Probability of Treatment Weighting Analysis  
Y. Iizuka, K. Katagiri, K. Ogura, M. Mizowaki; Kyoto University, Kyoto, JAPAN.

EP-0829  
False positive thymus uptake on 131-I post-therapeutic scan of DTC patients  

EP-0830  
The long term effect after 10 years of radioiodine therapy in patient with subclinical hyperthyroidism  
S. S. Abdelrazek, P. Szumowski, M. Sykala, A. Polak, J. Mysliwiec; Department of Nuclear Medicine, Medical University of Białystok, Białystok, POLAND.

EP-0831  
Usefulness of radioiodine therapy in low risk patients with papillary thyroid cancer  
E. Takacsova, M. Bartovic, R. Kralik; St. Elisabeth Cancer Institute, BRATISLAVA, SLOVAKIA.

EP-0832  
Radioiodine Treatment of Thyroid Papillary Carcinoma in Patient on Hemodialysis: Treatment Protocol and Dosimetric Results  
J. Bang, H. Lee; Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul National Univer, Seongnam, KOREA, REPUBLIC OF.

EP-0833  
Comparison Between Preablative Tc-99m Pertechnetate Scintigraphy and Postablative I-131 Whole Body Scan for Evaluation of Remnant Thyroid Tissue in Differentiated Thyroid Cancer  
G. Mutevelizade, Y. Parlik, 45030, E. Sayit, G. Gumuser; Celal Bayar University, Manisa, TURKEY.

EP-0834  
The difference of clinical characteristics and outcome according to FDG avidity in pulmonary metastases of different thyroid cancer  
S. Wu, H. Wang; Affiliated Jiayong Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, CHINA.

EP-0835  
Efficacy And Dosimetry Analysis In Low Risk Thyroid Carcinoma Patients Treated With Low Doses Of 131-I  
M. Guiote Moreno, A. Santos Bueno, L. Mena Bares, F. Maza Muret, E. Carmona Asenjo, M. Albalá González, E. Ortega Moreno, E. Rodriguez Cáceres, J. Vallejo Casas; Hospital Universitario Reina Sofía, IMIBIC, Córdoba, SPAIN.

EP-0836  
Is F-18 Fluorodeoxyglucose PET/CT Useful In The Management Of TENIS?  
A. Bhattacharya, D. Singh, A. Jois, A. Sood, B. R. Mittal; Postgraduate Institute of Medical education and Research, Chandigarh, INDIA.

EP-0837  
Clinical outcome of radioiodine therapy in Graves’ disease related to patient specific thyroid absorbed dose calculations- 3 years of experience in Nuclear Medicine Department of “Theagenio” Anticancer Hospital of Thessaloniki  
M. KOTZASARLIDOU, K. GIANOPOULOU, P. EXADAKTILOU, V. MAMOUGA, T. KALATHAS, V. HATZIPAVLIDOU; “Theagenio” Anticancer Hospital, Thessaloniki, GREECE, 2Aristotelion University of Thessaloniki, Thessaloniki, GREECE.

EP-0838  
Is serum Thyroglobulin level an indication of distant metastasis location?  
EP-0839
Thyroid ablation with 1.1GBq (30mCi) iodine-131 with patients with papillary thyroid carcinoma at intermediate risk for recurrence
I. El Bez, M. Somai, S. Bennour, I. Slim, M. Ben Slimene; institut Salah Azaiez, Tunis, TUNISIA.

EP-0840
Efficacy of Radiiodine Therapy For Graves’ Disease: Standardized Vs Calculated Activity
I. Slim, N. Sahli, T. Ben Ghachem, I. El Bez, I. Meddeb, K. Limam, A. Mhiiri, I. Yeddes, M. F. Ben Slimene; Department of Nuclear Medicine, Salah Azaiez Institut, Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, TUNISIA.

EP-0841
The Relationship Between Disease Perception, Anxiety, Depression And Quality Of Life In Thyroid Cancer Patients
U. Elboga, G. Akyıldız, Y. Celen; Gaziantep University, Gaziantep, TURKEY.

EP-0842
Over-time Titters Evolution of Positive Thyroglobulin Antibodies at Radio Iodine Ablation Treatment
P. Soeiro, R. Silva, G. Costa, P. Gil, J. Pedroso de Lima; Serviço de Medicina Nuclear do Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL, Instituto das Ciências Nucleares Aplicadas à Saúde, Coimbra, PORTUGAL, Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL.

EP-0843
Detecting dedifferentiation in differentiated thyroid carcinoma - our experience
F. N. Brandão, M. Silvestre, M. Rio Carvalho, I. Patrocínio Carvalho, R. Sousa, P. Ratão, T. C. Ferreira, L. Salgado; Instituto Português de Oncologia Lisboa Francisco Gentil E.P.E., Lisboa, PORTUGAL.

EP-0844
The efficacy of radiiodine therapy in patients with non-toxic multinodular goiter with large cold nodules
S. S. Abdelrazek, P. Szumowski, A. Polak, M. Mojsak, P. Lisiewicz, A. Konopka, J. Myśliwiec; Department of Nuclear Medicine Medical University of Bialystok, Bialystok, POLAND.

EP-0845
Effect of radiiodine ablation in Graves’ ophthalmopathy
P. K. Pradhan, N. Yadav, A. Arya, S. Yadav, V. Kanojia; SGPGIMS, Lucknow, INDIA.

EP-0846
Low Iodine Diet In Patients With Differentiated Thyroid Cancer
M. Dobrenic; Clinical Hospital Centre Zagreb, Zagreb, CROATIA.

EP-0847
Role of tALP and ECOG Performance Status in predicting survival in mCRPC patients receiving 223Ra-dichloride
G. A. Follacchio, V. Frantellizzi, S. Sollaku, M. S. De Feo, F. Monteleone, M. Liberatore, A. Farcomeni, M. Pacilia, G. De Vincentis; Sapienza University of Rome, Rome, ITALY, Policlinico Umberto I, Rome, ITALY.

EP-0848
Definition of a Predictive Score to guide therapeutic management in metastatic CRPC patients eligible to 223Ra-dichloride treatment
G. A. Follacchio, V. Frantellizzi, M. Pontico, M. S. De Feo, F. Monteleone, M. Liberatore, A. Farcomeni, M. Pacilia, G. De Vincentis; Sapienza University of Rome, Rome, Italy, Policlinico Umberto I, Rome, Italy.

EP-0849
Prediction of the response to the pain palliation radionuclide therapy for metastatic bone pain: the role of 188Re-HEDP SPECT/CT
C. Liu, Y. Zhang, B. Zhu, Q. Yue; Fudan University Shanghai Cancer Center, Shanghai, CHINA.

EP-0850
18DFG PET is predictive of patient outcome in Xo/fi go therapy
A. Tofani, R. Pirisino, P. Pizzichini, F. Scopinaro; Azienda Ospedaliera Sant’Andrea, Roma, ITALY, Sapienza Università di Roma, Roma, ITALY.
EP-0851
Baseline 18F-FDG PET/CT and bone scintigraphy in the prediction of response and prognosis of patients treated with 223-Ra
A. García Vicente1, F. Pena Pardo1, W. Martinez Bravo1, M. Amo-Salas2, B. González García1, J. García Carbonero1, J. Villa Guzman1, B. Sanchez Gil1, N. Mohedano Mohedano1, J. Gomez-Aldaravi Gutierrez1, L. Martinez Dher2, A. Soriano Castrejon1; 1General Hospital of Ciudad Real, Ciudad Real, SPAIN, 2University of Castilla La Mancha, Ciudad Real, SPAIN.

EP-0852
The Effects of prior Docetaxel administration on the result of Ra223 therapy
Z. Képes1, M. Ilyés2, Á. Deák3, A. Vánczku2, A. Káplár2, O. Szántó1, I. Garai2; 1Department of Medical Imaging, University of Debrecen, Debrecen, HUNGARY, 2ScanoMed Ltd, University of Debrecen, Debrecen, HUNGARY, 3Medical School of University of Debrecen, Debrecen, HUNGARY.

EP-0853
Semiquantitative evaluation of 223Radium-dichloride uptake in bone metastases during radiometabolic therapy in castration-resistant prostate cancer
A. Cimino, A. Niccoli Asabella, C. Ferrari, V. Lavelli, C. Altini, N. Addante, M. Fanelli, G. Rubini; Nuclear Medicine Unit, AOU Policlinic of Bari, University of Bari, Bari, ITALY.

EP-0854
Description of the first 51 patient treated with Radium 223 dichloride in Argentina
M. J. Bastianello1,2; 1Instituto Universitario CEMIC, Ciudad de Buenos Aires, ARGENTINA, 2Instituto Alexander Fleming, Ciudad de Buenos Aires, ARGENTINA.

EP-0855
Dosimetry of Targeted Ra-223 Treatment for Metastatic Castration-Resistant Prostate Cancer
S. Matsuo1, S. Kinuya1, A. Mizokami1, K. Nakajima2, H. Wakabayashi1, T. Kudo2; 1Kanazawa University, Kanazawa, JAPAN, 2Nagasaki University, Nagasaki, JAPAN.

EP-0856
Safety, effectiveness and haematological toxicity of 223Ra-dichloride: a single Centre experience
R. Laudicella, F. Minutoli, A. Sindoni, F. E. M. Quattrociocchi, L. Sturiale, S. A. Pignata, B. Pagano, S. Baldari; Unit of Nuclear Medicine, Department of Biomedical and Dental Sciences and of Morphofunctional Imaging; University of Messina, Messina, ITALY.

EP-0857
Co-existing lymph node and bone metastases may be negative predictive marker of survival in patients with CRPC treated with 223Ra-dichloride
S. Dizdarevic, M. Jessop, P. Begley, A. Robinson; Brighton and Sussex University Hospitals NHS Trust, Brighton, UNITED KINGDOM.

EP-0858
Experiences with Xofigo (223RaCl2) Therapy
R. Német1, Z. Besenyő2, L. Pávics2, A. Mardzás2; 1Department of Nuclear Medicine, University of Szeged, Szeged, HUNGARY, 2Department of Oncotherapy, University of Szeged, Szeged, HUNGARY.

EP-0859
Samarium-153-EDTMP For Bone Pain Relief in Patients With Metastatic Superscan
I. Slim, I. El Bez, J. Meddej, M. Somai, T. Ben Ghachem, A. Mhiri, I. Yeddes, M. F. Ben Slimene; Department of Nuclear Medicine, Salah Azaiez Institut, Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, TUNISIA.

EP-0860
Objective response evaluation to therapy with 223Ra-dichloride by absolute quantification of 99mTc-MDP uptake and dose-response relationship evaluation: preliminary results
C. Tranfaglia1, C. P. L. Fulcheri2, V. Reggiani2, R. Tarducci2, M. E. Dottorini2; 1Nuclear Medicine Department, Hospital Santa Maria della Misericordia, Perugia, ITALY, 2Medical Physics Department, Hospital Santa Maria della Misericordia, Perugia, ITALY.

EP-0861
Optimal selection of patients for Xofigo treatment and case report on our first patient with re-treatment
R. P. Jóba, S. Czibor, I. Szilvási; Medical Center, Hungarian Defence Forces, Budapest, HUNGARY.
EP-0862
Evolutionary assessment with 18F-Fluoride PET / CT in patients with castration-resistant metastatic prostate cancer treated with Ra-223
J. S. Blanco Cano, Sr., A. Garcia Burillo, D. Villasboas Rosciolesi, E. Camilo Villamizar, J. Castell Conesa; Hospital Universitari Vall d’Hebron, Barcelona, SPAIN.

EP-0863
Yttrium-90 resin microspheres radioembolization (SIRT) of primitive and secondary liver tumors: survival and safety study

EP-0864
Clinical Outcome Of “Real Life” HCC Patients Treated With 90Y Microspheres Radioembolization: A Single Center Experience
M. FINESI, F. CHECCHI, R. PASSERA, M. BELLO’, G. BISI, D. DEANDREIS; Nuclear Medicine, AOU Città della Salute e della Scienza, Torino, ITALY.

EP-0865
Is the Technetium-99m Macroaggregated Albumin Scintigraphy a Certain Surrogate of 90Y-loaded Microspheres In the Treatment of Primary and Secondary Liver Cancer?
R. De Teresa Herrera, 1. Plaza De Las Heras, C. Field Galan, S. Seijas Marcos, B. Rodrigue Alfonso, J. Cardona Arbories, S. Mendez Alonso, M. Mitjavila Casanovas; Hospital Universitario Puerta De Hierro, Majadahonda, MA, SPAIN.

EP-0866
Monte Carlo Based Dose Assessment for 90Y Radioemboliation, a Comparison Between 99mTc-MAA SPECT/CT and 90Y-TheraSpheres PET/CT
S. Rijnsdorp1, A. L. Wolf1, D. E. Oprea-Lager1, J. J. de Vries1, A. van Lingen1, 1Catharina Hospital, Eindhoven, NETHERLANDS, 2Netherlands Cancer Institute, Amsterdam, NETHERLANDS, 3VU Medical Center, Amsterdam, NETHERLANDS.

EP-0867
Uncertainties in geometric-mean based lung shunt fraction for 90Y radioembolization
S. C. Kappadath, A. Balagopal, A. Mahvash; UT MD Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA.

EP-0868
Hepatic Radioembolization With 90Y Glass Microspheres: Our Experience
M. L. Dominguez1, C. Vigil1, J. E. Rodriguez2, B. Fernandez1, A. M. Alvarez3, N. Martin1, N. A. Perez1, C. Salvat1, F. M. Gonzalez2; 1Nuclear Medicine Department, Central University Hospital of Asturias, Oviedo, SPAIN, 2Radiology Department. Central University Hospital of Asturias, Oviedo, SPAIN.

EP-0869
Comparison of Therapy Response Between PERCIST and RECIST Criteria After Yttrium-90 Therapy in HCC Patients

EP-0870
Incidence of Kidney Injury Post Y-90 Radioembolization: A Single Centre Experience
W. Peh, Y. Khor; Singapore General Hospital, Singapore, SINGAPORE.

EP-0871
 Autoradiography of a resected hepatocellular carcinoma treated with 90Y radioembolization illustrates uptake differences between viable and infarcted areas
J. Hemmingsson1, J. Mölne2, J. Högberg3, J. Svensson1, M. Rizell1, P. Bernhardt1; 1Clinical Sciences, Gothenburg, SWEDEN, 2Biomedicine, Gothenburg, SWEDEN, 3Medical Physics, Linköping, SWEDEN.

EP-0872
Multi-modal image analysis for optimized treatment safety and effectiveness of radioembolization of liver tumors
E. Jafargholi Rangraz, K. Baete, M. Koole, G. Maleux, C. Deroose, J. Nuyts; KU Leuven, Leuven, BELGIUM.
EP-0873
Effectiveness and safety of transarterial Y-90 radioembolization for unresectable intrahepatic cholangiocarcinoma
G. Boni1, T. Depalo1, I. Bargellini2, C. Vivaldi2, S. Mazzari1, F. Guidaccio1, E. Bozzi2, L. Caponi2, C. Traino1, G. Manca1, G. Masi1, R. Cioni2, D. Volterrani1; 1Regional Center of Nuclear Medicine, University Hospital of Pisa, Pisa, ITALY, 2Department of Radiology, Vascular and Interventional Radiology, University Hospital of Pisa, Pisa, ITALY.

EP-0874
Radioactive Synoviorthesis on Hemophilic Arthropathy: Tunisian First Cases
I. Slim1, I. Meddeb1, I. El Bez2, T. Ben Ghachem2, S. Bennoun2, A. Mhiri1, W. Saied1, I. Yeddes3, M. F. Ben Slimene1; 1Department of Nuclear Medicine, Salah Azaiez Institut, Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, TUNISIA, 2Department of orthopaedic surgery, Children hospital of Tunis, Tunis, TUNISIA.

EP-0875
Experience with 223-Radium in the Czech Republic
A. Chodacki1; Masaryk Hospital, Usti n. L., KZ a.s., Usti nad Labem, CZECH REPUBLIC.

EP-0876
Re-188 Patch Radionuclide Therapy for Keloids: A 3 year follow up study
P. Gupta1, K. K. Verma1, R. Kumar1, P. Kumar1, A. Malhotra1, G. P. Bhandopadhya2, C. S. Bol1; All India Institute of Medical Sciences, New Delhi, INDIA.

EP-0877
Radioactive Synoviorthesis In Chronic Sinovitis. Is It A Good Choice? A Review Of Cases
I. Javato Moreno1, B. Perez Lopez1, M. E. Martin Gomez2, P. Garcia-Talavera San Miguel1, C. Montilla Morales2, E. Martin Gomez1, F. Gomez-Caminero Lopez2, C. A. Achury Murcia3, M. F. Tamayo Alonso3; 1University of Salamanca, Salamanca, SPAIN, 2Nuclear Medicine Department. University Hospital of Salamanca, Salamanca, SPAIN, 3Rheumatology Department. University Hospital of Salamanca, Salamanca, SPAIN.

EP-0878
The Relation Between Tumor Metabolic Parameters on F-18 FDG PET/CT, Hepatic Artery Perfusion Scan and Therapy Response in Cholangiocellular Carcinoma Treated with Y-90 Microspheres
M. Bozkurt1, B. Volkan Salanci2, U. B. Bozkulut1, G. Eldem3, M. F. Bozkurt1, S. Kilickap1, B. Peynircioglu1, B. Cil2, O. Ugur3; Hacettepe University Faculty of Medicine, Ankara, TURKEY.

EP-0879
Quanti/fication of the Fat Fraction in Bone Marrow using Fat-Water Magnetic Resonance Imaging
M. Salas-Ramirez1, J. Tran-Gia1, C. Kesenheimer2, A. M. Weng2, H. Kästler1, M. Lassmann1; 1Department of Nuclear Medicine, University of Würzburg, Würzburg, GERMANY, 2Department of Diagnostic and Interventional Radiology, University of Würzburg, Würzburg, GERMANY.

EP-0880
A method for 177Lu-PRRT tumour dosimetry based on hybrid planar-SPECT/CT images and semi-automatic segmentation
D. Roth1, J. Gustafsson1, A. Sundlov2, K. Sjögren-Gleisner1; 1Medical Radiation Physics, Clinical Sciences Lund, Lund University, Lund, SWEDEN, 2Oncology and Pathology, Clinical Sciences Lund, Lund University, Lund, SWEDEN, 3Department of Oncology, Skåne University Hospital, Lund, SWEDEN.

EP-0881
Radiation self-monitoring data of patients receiving 177Lu-DOTATATE peptide receptor radiotherapy for dosimetry informed radiation protection
L. Livieratos1, T. Brothwood2, D. Aniceto1, R. Fernandez1, C. Sibley-Allen1, K. Adamson1, S. Allen1, V. Lewington1, 2; 1Guy’s and St Thomas Hospitals, London, UNITED KINGDOM, 2King’s College, London, UNITED KINGDOM.
EP-0882
OpenDose: Generating reference data for Nuclear Medicine dosimetry
M. Chauvin1, D. Borys2, F. Bottá1, P. Bzowski1, M. A. Coca Pérez3, M. Cremonesi4, J. Dabin1, A. M. Denis-Baclela1, A. Desbree1, Z. El Bitar1, N. Falzone1, L. Ferrer10, D. Franck9, N. Lanconelli11, A. Maiani12, A. Malaroda13, K. Matsuki14, E. McKay15, M. Pacilio16, J. Pieter17, J. L. Rodríguez18, L. Struevens5, L. A. Torres Arché19, A. Vergara GIl20, J. M. Fernández21, B. Lee22, A. P. Robinson14, D. Sarrau15, M. Bardies1; 1Centre de Recherches en Cancérologie de Toulouse, Toulouse, FRANCE, 2Silesian University of Technology, Gliwice, POLAND, 3Istituto Europeo di Oncologia, Milano, ITALY, 4MEDSCAN Nuclear Medicine and PET/CT Centre, Concepción, CHILE, 5Belgian Nuclear Research Centre, Mol, BELGIUM, 6National Physical Laboratory, Teddington, UNITED KINGDOM, 7Institut de Radioprotection et de Sécurité Nucléaire, Fontenay-aux-Roses, FRANCE, 8Institut Pluridisciplinaire Hubert Curien, Strasbourg, FRANCE, 9Oxford Institute for Radiation Oncology, Oxford, UNITED KINGDOM, 10Institut de Cancérologie de l’Ouest, St Herblain, FRANCE, 11University of Bologna, Bologna, ITALY, 12Centro Nazionale di Adroterapia Oncologica, Pavia, ITALY, 13University of Wollongong, Wollongong, AUSTRALIA, 14Saint George Hospital, Sydney, AUSTRALIA, 15Azienda Ospedaliera Universitaria Policlinico Umberto I Roma, ITALY, 16Clínica Las Condes, Santiago de Chile, CHILE, 17Centro de Isótopos (CENTIS), La Habana, CUBA, 18National Physical Laboratory, Teddington, UNITED KINGDOM, 19Centre de Recherche en Acquisition et Traitement de l’Image pour la Santé, Lyon, FRANCE.

EP-0883
Compartmental model for 223Ra-Dichloride in Patients with metastatic bone disease from castration-resistant prostate cancer
J. Taprogge1, I. Murray2, G. Flux1; 1St George’s University Hospitals NHS Foundation Trust, London, UNITED KINGDOM, 2Joint Department of Physics, Royal Marsden NHS Hospital, Sutton, UK & the Institute of Cancer Research, London, UNITED KINGDOM.

EP-0884
A method to objectively determine the internalization rate of radionuclide labelled ligands using mathematical modelling
A. Vogt1, G. Winter1, N. J. Begum2, C. Solbach1, A. J. Beer1, G. Glattung3, P. Ketting1; 1Department of Nuclear Medicine, Ulm University, Ulm, GERMANY, 2Medical Radiation Physics, Department of Nuclear Medicine, Ulm University, Ulm, GERMANY.

EP-0885
A Full Reference Tissue Model with Non-Vanishing Blood Volume Fractions for Kinetic Analysis of Dynamic FDG-PET Data
M. Scussolini1, S. Garbarino2, G. Sambuceti2, M. Plana3, A. Buschiazzo4, M. Bauckneht5, C. Manni6, G. Caviglia7; 1Department of Mathematics, University of Genova, Genova, ITALY, 2Centre for Medical Image Computing, Department of Computer Science, University College London, London, UNITED KINGDOM, 3Nuclear Medicine Unit, Department of Health Sciences, University of Genova and IRCCS AOUC Martino-Ist, Genova, ITALY, 4CNR Institute of Bioimages and Molecular Physiology, Section of Genova, Genova, ITALY.

EP-0886
Investigation of influence of anti-thyroid drug discontinuation time on 131I biokinetics in patients with benign thyroid disease
V. Topic Vucenovic1, K. Vucicevic1, Z. Rajkovaca2, D. Stanimirovic3, G. Vuleta4, D. Jelić5, B. Miljkovic6; 1Department of Pharmacokinetics and Clinical Pharmacy, University of Banja Luka - Faculty of Medicine, Banja Luka, BOSNIA AND HERZEGOVINA, 2Department of Pharmacokinetics and Clinical Pharmacy, University of Belgrade - Faculty of Pharmacy, Belgrade, SERBIA, 3Institute of Nuclear Medicine and Thyroid Gland Disease, University Clinical Centre of the Republic of Srpska, Banja Luka, BOSNIA AND HERZEGOVINA, 4Department of Physical Chemistry, University of Banja Luka - Faculty of Medicine, Banja Luka, BOSNIA AND HERZEGOVINA.

EP-0887
SPECT/CT calibration using clinical dosimetry workstations for peptide receptor radionuclide therapy (PRRT) in patients treated with 177Lu-DOTATATE
E. Mora Ramirez1,2,3, L. Santoro1, D. Trauchessec4, S. Chouaf5, D. Jouffrey3, J. Pouget1, P. Kotski1,2; 1Centre de Recherche en Cancérologie de Toulouse, France, Toulouse, FRANCE, 2UMR 1037 INSERM/Université Paul Sabatier, Toulouse, FRANCE, 3Universidad de Costa Rica, CICANUM, Escuela de Física, San Pedro, San José, COSTA RICA, 4Department of Nuclear Medicine, Institut du Cancer de Montpellier, Montpellier, FRANCE, 5INSERM UMR 1194, Montpellier Cancer Research Institute, Montpellier, FRANCE.
EP-0888
Dosimetric estimations using commercial workstations for peptide receptor radionuclide therapy (PRRT) patients treated with 177Lu-DOTATATE
E. Mora Ramirez1,2, L. Santoro3, D. Trauchessec4, S. Choua4, E. Deshayes5, J. Pouget5, P. Kotzki6, M. Bardies7,1; 1Centre de Recherches en Cancérologie de Toulouse, Toulouse, FRANCE, 2UMR 1037 INSERM Université Paul Sabatier, Toulouse, FRANCE, 3Universidad de Costa Rica, CICANUM, Escuela de Física, San Pedro, San José, COSTA RICA, 4Department of Nuclear Medicine, Institut du Cancer de Montpellier, Montpellier, FRANCE, 5INSERM UMR 1194, Montpellier Cancer Research Institute, Montpellier, FRANCE.

EP-066 during congress opening hours, e-Poster Area
Radionuclide Therapy & Dosimetry: Preclinical and Clinical Dosimetry & Radiobiology

EP-0889
Eye lens dosimetry of workers during medical interventional procedures and surgery
G. Bera1, G. Gelli2, X. Michel3; 1Groupe Hospitalier Pitié-Salpêtrière, Paris, FRANCE, 2SPRA HIA PERCY, Clamart, FRANCE.

EP-0890
[^Sc] Sc-PSMA-617—an alternative to[^68]Ga-PSMA-617 for pre therapeutic dosimetry in metastatic castration resistant prostate carcinoma (mCRPC)?
A. Khawar1, E. Eppard1, H. Ahmadzadehfar1, S. Kürpig2, M. Meisenheimer3, J. P. Sinnes2, F. C. Gaertner2, F. Roesci1, M. Essler1, R. A. Bundschuh1; 1Department of nuclear medicine, University Hospital, Bonn, GERMANY, 2Institute for nuclear chemistry, Johannes Gutenberg-University, Mainz, GERMANY.

EP-0891
Assessment of Statistical Dose Uncertainty Propagation for Lu177 SPECT Imaging with an Automated Internal Dosimetry Research Tool as a result of fast SPECT Acquisition Protocols
A. Vija1, M. Cachovan2, G. Böning1; 1Siemens Medical Solutions USA, Inc., Molecular Imaging, Hoffman Estates, IL, UNITED STATES OF AMERICA, 2Siemens Healthcare GmbH, Forchheim, GERMANY.

EP-0892
Identification of mediators in media-transferred radiation-induced bystander effect in breast cancer cells
K. L. Madsen1, P. F. Heilund-Carlsen1, B. B. Olsen1; Odense University Hospital, Odense, DENMARK.
EP-0898
Dosimetry study of 99mTc-NTP 15-5 imaging of cartilage in preclinical and clinical trials using the GATE Monte Carlo platform
G. Fois1,2, C. Valli1, E. Jouberton1,3, P. Auzeloux1, N. Sas1, F. Cachin1,4, J. Chezal5, E. Miot-Noirault1, L. Maigne1,2; 1Clermont Auvergne University, Aubiere, FRANCE, 2UMR6533 CNRS/IN2P3, Clermont-Ferrand, FRANCE, 3CLCC Jean Perrin, Clermont-Ferrand, FRANCE, 4UMR1240 INSERM, Clermont-Ferrand, FRANCE.

EP-0899
Relative error in the Survival Fraction and the Biologically Equivalent Dose due to uncertainties on the absorbed dose estimations in Molecular Radiotherapy
A. Malaroda; University of Wollongong, Wollongong, AUSTRALIA.

EP-0900
Impact of image reconstruction parameters on the dose-volume histogram for PET-based dosimetry for Y-90 radioembolization
H. Ma1, X. Hou1, F. Benard1, A. Celler1; 1University of British Columbia, Vancouver, BC, CANADA, 2British Columbia Cancer Research Centre, Vancouver, BC, CANADA.

EP-0901
Is there agreement between predicted 99mTc-MAG3-SPECT and post-treatment 18F-PET absorbed doses in SIRT using 3D voxel dosimetry?
L. Sancho Rodriguez1, M. Rodriguez-Fraile1, J. Bilbao1, M. Ibarra Ibarra1, C. Beorlegui Artesa1, A. Benito1, V. Moran1, J. Marti Climent1, E. Guillon1, B. Sangro1; 1Clinica Universidad de Navarra, Pamplona, SPAIN, 2Universidad de Navarra, Pamplona, SPAIN.

EP-0902
Absorbed kidney doses in patients retreated with Lu-177-octreotide at progression
V. Reijonen1, H. Mäenpää1, J. Heikkonen1, M. Tenhunen1, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, FINLAND.

EP-0903
Gelofusine improves the Clinical Feasibility of Insulinoma Treatment using Radiolabeled Exendin
T. Jansen1, M. Buitinga1, J. van der Kroon1, MW. Woliner-van der Weg1, M. Bos1, M. Jansen1, E. Aarntent1, M. Béhée1, D. Wild1, M. Bron1, E. Visser1, M. Gothhardt1; 1Department of Radiology and Nuclear Medicine, Radboudumc, Nijmegen, NETHERLANDS, 2Center for Radiopharmaceutical Sciences ETH-FIS-USZ, Paul Scherer Institut, Villigen, SWITZERLAND, 3Division of Nuclear Medicine, University Hospital Basel, Basel, SWITZERLAND.

EP-0904
Influence of Breathing Motion on Kidney Volume Determination for Application in Targeted Radionuclide Therapy
C. Sebesta1, J. C. Sanders2,3, C. Schmidkonz1, M. Beck1, T. Kuetter1, P. Ritt1; 1University Hospital Erlangen, Erlangen, GERMANY, 2Pattern Recognition Lab, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, GERMANY.

EP-0905
Dose distribution in human kidneys after treatment with 177Lu-DOTATATE using EUBED
K. Olde1, J. Svensson1, T. Rydén1, R. Hermann1, E. Forssell-Aronsson1, B. Wängberg1, P. Bernhardt1; 1Department of Oncology, The Sahlgrenska Academy, Sahlgrenska University Hospital, Gothenburg, SWEDEN, 2Department of Radiation Physics, Institute of Clinical Sciences, The Sahlgrenska Academy, Sahlgrenska University Hospital, Gothenburg, SWEDEN, 3Department of Surgery, The Sahlgrenska Academy, Sahlgrenska University Hospital, Gothenburg, SWEDEN.

EP-0906
Value of personalised radiation absorbed dose calculations for the radioiodine ablation therapy in patients with low-risk well differentiated thyroid cancer
N. Yeyin1, N. Alan Selcuk2, E. Demirci3, T. Toklu4, R. Akyel4, O. Sahin1, A. Boz4, F. Yapar6, M. Abuqbeitah4, L. Kabasakal1; 1Department of Nuclear Medicine, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, TURKEY, 2Department of Nuclear Medicine, Faculty of Medicine, Yeditepe University, Istanbul, TURKEY, 3Department of Nuclear Medicine Sisli Etfal Training and Research Hospital, Istanbul, Istanbul, TURKEY, 4Department of Nuclear Medicine Umraniye Training and Research Hospital, Istanbul, Istanbul, TURKEY, 5Department of Nuclear Medicine, School of Medicine, Akdeniz University, Antalya, TURKEY, 6Department of Nuclear Medicine, Cukurova University Faculty of Medicine, Adana, TURKEY.

EP-0907
Prediction vs Prognosis of Ki-67 Index Expression After Combined In-111-DTPA-oc / n.c.a. Lu-177-Dotatate Intra-arterial Infusions, in GEP-NETs Treated Patients
G. S. Limouris1, M. Paphiti1, I. Karfis1, E. Z. Dimitriadis2, S. Chondroyiannis3, V. R. McCready4, D. Rubello5; 1Medical Faculty, National and Kapodistrian University of Athens, Athens, GREECE, 2Institute Claudus Regaud, University of Paul Sabatier, Toulouse, FRANCE, 3Nuclear Medicine Department, Santa Maria della Misericordia Hospital, Rovigo, ITALY, 4Institute Cancer Research, Sutton Surrey & Royal Sussex County Hospital, Brighton, UNITED KINGDOM.
EP-0908  
Improved models of hepatic artery vasculature for improved treatment planning of radioembolization of liver cancer  
N. Crookston, E. Frey; Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA.

EP-0909  
Effects of Zinc for Gastrointestinal System as a Radioprotective Agent  
A. Akbulut, M. Sadic, N. Yumusak, F. N. Aydinbelge, G. Koca, M. Korkmaz; 1Department of Nuclear Medicine, University of Health Sciences, Ankara Training and Research Hospital, Ankara, TURKEY, 2Department of Pathology, Harran University Faculty of Veterinary Medicine, Sanliurfa, Sanliurfa, TURKEY.

EP-0910  
Review Of Our Experience In Treatment Of Liver Tumors With Y-90 SIR-Spheres  
T. Pipikos, M. Ginos, F. Vlachou, K. Dalianis, G. Tsoukalos, M. Vogiatzis, E. Tsikas, D. Papoutsanis, V. Prassopoulos; 1Nuclear Medicine & PET/CT Department, Hygeia SA, Marousi, GREECE, 2Interventional Radiology Department, Hygeia SA, Marousi, GREECE, 3Medical Physics Department, Hygeia SA, Marousi, GREECE.

EP-0911  
Uncertainty analysis in the calibration of an emission tomography system for quantitative imaging  
M. D’Arienzo, M. Cox; 1ENEA, National Institute of Ionizing Radiation Metrology, Rome, ITALY, 2NPL, National Physical Laboratories, Teddington, UNITED KINGDOM.

EP-0912  
A tool for treatment planning of 99mTc-microsphere radioembolization  
V. Raposo, D. Martinez, N. Galleria, F. Mañeru, M. Ribelles, F. Caudepon, L. Bragado, N. Fuenteamilla, A. Rubio, S. Miquelez, S. Pellejero; Complejo Hospitalario de Navarra, Pamplona, SPAIN.

EP-0913  
Dose-rate correlation with tumour volume in NET patients occurring Lu-177-DOTATATE therapy  
S. Gnesini, M. Montero, P. Cuñat, J. O. Prior; 1Institute of Physics, University of Lausanne, 2Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, Lausanne, SWITZERLAND.

EP-0914  
99mTc-MIBI Or 11C-Methionine PET/CT In Primary Hyperparathyroidism With Inconclusive Preoperative Work-up?  
D. Maccara, C. Caldarella, A. Giordano, I. Bruno; 1Institute of Nuclear Medicine, Università Cattolica del S. Cuore “A. Gemelli”, Rome, ITALY, 2PET-CT Center, Policlinico “A. Gemelli”, Rome, ITALY, 3Nuclear Medicine Unit, Policlinico “A. Gemelli”, Rome, ITALY.

EP-0915  
Comparison of 99mTc-sestamibi and 18F-Fluorocholine PET/CT in localization of hyper-functioning parathyroid glands  
I. Bossert, S. Chytiris, M. Hodolc, C. Vellani, E. Brugola, D. D’Ambrosio, G. Marian, L. Chiavota, G. Trifrio; 1Nuclear Medicine Unit – Istituti Clinici Sciennifici Maugeri Spa SB IRCCS, Pavia, ITALY, 2Endocrinology Unit – Istituti Clinici Sciennifici Maugeri Spa SB IRCCS, Pavia, ITALY, 3Nuclear Medicine Research Department Jason, Graz, AUSTRIA, 4University Olomouc, Olomouc, CZECH REPUBLIC, 5Medical Physics Unit – Istituti Clinici Sciennifici Maugeri Spa SB IRCCS, Pavia, ITALY, 6Regional Center of Nuclear Medicine, University of Pisa, Pisa, ITALY.

EP-0916  
F18-choline PET/CT as a second line tracer for parathyroid adenoma detection in primary hyperparathyroidism  
E. Quak, D. Blanchard, B. Houdu, Y. Le Roux, R. Ciappuccini, D. De Roucourt, J. Grellard, Y. Reznik, B. Clarisse, N. Aide; 1Francois Baclesse Cancer Centre, Caen, FRANCE, 2University Hospital, Caen, FRANCE.

EP-0917  
An insulinoma in a critically hypoglycemic newborn identified by F18-FDOPA PET-CT  
S. Salamon, K. Kvaternik, C. Gstettner, C. Hosbein, R. M. Aigner; Medical University of Graz, Department of Radiology, Division of Nuclear Medicine, Graz, AUSTRIA.

EP-0918  
Determine the relationship between scintigraphic Sestamibi uptake and biological parameters of parathyroid adenomas in patients underwent surgery at our Center since 2005 to 2015  
EP-0919

Our experience in the diagnosis of parathyroid adenoma with planar scintigraphy 99mTc-Sestamibi-99mT04 during the last 10 years

EP-0920

Serum Osteoprotogerin Levels in Primary Hyperparathyroidism and its Correlation with Hyperparathyroidism Markers: A Randomized Controlled Trial
B. T. Okudan, A. Ç. Karç, M. Klıncıkaya, N. Coşkun, T. Turhan, D. Berker; 1Ankara Numune Hospital Nuclear Medicine Clinic, Ankara, TURKEY; 2Ankara Numune Hospital Endocrinology Clinic, Ankara, TURKEY; 3Ankara Numune Hospital Biochemistry Clinic, Ankara, TURKEY.

EP-0921

SPECT/CT’s Superiority over Ultrasonography for Preoperative Localization of Parathyroid Adenomas in Primary Hyperparathyroidism: A Retrospective Clinical Trial
N. Coşkun, B. T. Okudan; Ankara Numune Hospital, Nuclear Medicine Clinic, Ankara, TURKEY.

EP-0922

Contribution of SPECT/CT Imaging to 131-I NP-S9 Planar Images in Patients with Hypersecretory Adrenal Syndromes and Incidentally Discovered Adrenal Masses
A. Sainz-Esteban, M. Ruiz Gómez, J. Gómez Hidalgo, A. Rodríguez Cobo, M. González Selma, C. Gamazo Laherrán, M. Alonso Rodríguez, R. Ruano Pérez; Hospital Clínico Universitario de Valladolid, VALLADOLID, SPAIN.

EP-0923

Comparison of early SPECT/CT and dual-phase planar imaging with early SPECT/CT Tc-99m Sestamibi Parathyroid Scintigraphy. Can we avoid planar imaging?
J. Gómez Hidalgo, A. Sainz-Esteban, A. Cobo Rodríguez, M. González Selma, M. Ruiz Gómez, C. Gamazo Laherrán, M. Alonso Rodríguez, R. Ruano Pérez; Hospital Clínico Universitario de Valladolid, VALLADOLID, SPAIN.

EP-0924

Added Value of SPECT-CT Scintigraphy in The assessment of Patients With Hyperparathyroidism
I. Slim, I. El Bez, I. Meddeh, T. Ben Ghachem, K. Trabelsi, A. Mniri, I. Yeddès, M. F. Ben Slimene; Department of Nuclear Medicine, Salah Azaiez Institut, Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, TUNISIA.

EP-0925

A Type of Uptake in Dual-Phase of 99m Tc Sestamibi SPECT/CT Parathyroid Scintigraphy in Patients with Inadequately Controlled Secondary Hyperparathyroidism in Relation to Histopathology and Parathormone Level-Experience of One Centre
M. H. Listewnik, H. Piwowarska-Bilska, K. Safranow, M. Ostrowski, J. Iwanowski, M. Chosia, M. Laszczynska, M. Kurnatowicz, B. Birkenfeld; Pomeranian Medical University in Szczecin, Szczecin, POLAND.

EP-0926

Optimization of 99mTc-sestamibi/123I subtraction SPECT/CT protocol for parathyroid scintigraphy
V. Tunninen, T. Kauppinen, H. Esurla, Satakunta Central Hospital, PORI, FINLAND, Helsinki University Hospital/HUS Medical Imaging Center, Helsinki, FINLAND, Faculty of Biomedical Sciences and Engineering, Tampere University of Technology, Tampere, FINLAND, Department of Radiology, Tampere University Hospital, Tampere, FINLAND.

EP-0927

The role of Natural killer T cells in autoimmune thyroid disease during pregnancy and postpartum
T. Bogović Crncić, S. Grbac Ivankovic, N. Girotto, I. Mrakovcic Sutic; 1Dept. of Nuclear medicine, Clinical Hospital Centre Rijeka, Rijeka, CROATIA; 2Dept. of physiology and immunology, Medical faculty, University of Rijeka, Rijeka, CROATIA.

EP-0928

Thyroid vascularisation correlates with skin microcirculation in patients with Graves’ disease
K. Zaletel, N. Bedernjak Bajuk, S. Gapersžek, H. Lenasi; 1Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, SLOVENIA; 2Faculty of Medicine, University of Ljubljana, Ljubljana, SLOVENIA.

EP-0929

Thyroid disorders in children and teenagers with down syndrome: accidental association or cross linking?
I. El Bez, M. Somai, D. Ben Sellem, M. Ben Slimene; institut Salah Azaiez, Tunis, TUNISIA.
EP-0936 Prevalence of Incidental Findings Identified by CTPA in Women of Reproductive Age

N. Champion, J. Flemming; Memorial University of Newfoundland, St. John’s, NL, CANADA.

EP-0937 V/P SPECT to measure lung function deterioration in COPD

M. Bajč, Y. Chen, W. Jun, J. Xu, C. Wang, H. Huang, X. He, A. Lindqvist; 1University Hospital Lund, Lund, SWeden, 2Chang zheng Hospital, Shanghai, CHINA, 3Xin qiao Hospital, Chongqing, CHINA, 4Hua dong Hospital, Shanghai, CHINA, 5Suzhou University Affiliated Tumor Hospital, Suzhou, CHINA, 6Helsinki University Hospital, Helsinki, FINLAND.

EP-0938 Myotonic Dystrophy With Nonalcoholic Fatty Liver Disease: A Possible Relationship With Intestinal Permeability?

D. Maccora1, G. Silvestri2, D. Di Giuda1, D. Ripani1, S. Rossi2, A. Petrucci1, V. Valenza1; 1Institute of Nuclear Medicine, Università Cattolica del S. Cuore “A. Gemelli”, Rome, ITALY, 2Institute of Neurology, Università Cattolica del S. Cuore “A. Gemelli”, Rome, ITALY.

EP-0939 SPECT Defaecography - a Valuable Tool in Evaluation of Patients with Hirschsprung’s Disease

N. H. Hansen1,2, S. Hvidsten1, N. Qvist1,2, R. G. Nielsen1, P. F. Høilund-Carlsen1,2, J. A. Simonsen1; 1Odense University Hospital, Odense C, DENMARK, 2University of Southern Denmark, Odense C, DENMARK.

EP-0940 Abdominal retention index of 75sechcat according to response to treatment with resincolestiramine

P. C. Notta1, J. Suils ramón1, L. Rubio-Alvarez1, A. Rodriguez-Gasén1, S. Maisterra- Santos2, J. Guardiola-Capo2, J. Romero-Zayas1, J. Mora-Salvado1, P. Saldana-Gutierrez2, G. Reynés-llompard1, L. Gracia-Sanchez1, J. Mestre-Martí1, C. Gómez-Cezamo1, J. Nuclear Medicine-PET Department. IDI. Hospital Universitari de Bellvitge-IDIBELL. L’Hospitalet de Llobregat, Barcelona, SPAIN, 2Gastroenterology Department. Hospital Universitari de Bellvitge-IDIBELL. L’Hospitalet de Llobregat, Barcelona, SPAIN, 3Medical Physics Department. ICO. L’Hospitalet de Llobregat, Barcelona, SPAIN.
EP-0941
Intra gastric distribution in gastric emptying - Does it help?
S. Muthu, I. Niematallah, N. Ali, R. Sajjan, M. Prescott; Central Manchester University Hospitals NHS Trust, Manchester, UNITED KINGDOM.

EP-0942
The role of 99mTc-DMSA scan in the investigative algorithm for children with vesicouretal reflux - retrospective study
D. Chroustova1, J. Langer2, I. Urbanova3, J. Tmka4, J. Kubinyi5; 1Department of Nuclear Medicine, General University Hospital and First Faculty of Medicine, Charles University in Prague, PRAGUE 2, CZECH REPUBLIC, 2Clinic of Paediatrics and Adolescent Medicine, General University Hospital, Medical Faculty of Charles University, Prague, PRAGUE 2, CZECH REPUBLIC, 3Department of Paediatrics, University Hospital Bulovka, PRAGUE 9, CZECH REPUBLIC, 4Department of Medical Physics, General University Hospital and First Faculty of Medicine, Charles University in Prague, PRAGUE 2, CZECH REPUBLIC.

EP-0943
Lung Perfusion Scintigraphy in Pediatric Age: Quality and Safety in 10-Year Experience regarding Pediatric Nuclear Medicine Practice
M. Pizzoferro, D. Alabrese, M. F. Villani, E. Villanucci, S. Chiapparelli, M. C. Garganese; IRCCS Bambino Gesù Pediatric Hospital, Rome, ITALY.

EP-0944
The reliability of estimated glomerular filtration rate in South African children
J. L. Holness1, A. Brink2, M. R. Davids1, J. M. Warwick2; 1Stellenbosch University and Tygerberg Hospital, Cape Town, SOUTH AFRICA, 2University of Cape Town and Red Cross Children’s Hospital, Cape Town, SOUTH AFRICA.

EP-0945
Incidental vesicourethral reflux diagnosis on excretory renal nuclear medicine investigations
D. Ben Sellem, L. Zaabar, J. El Bez, B. Dhaouadi, B. Letaief, M. F. Ben Slimene; University of Tunis El Manar, Tunis, TUNISIA.

EP-0946
Evaluation of the EANM Pediatric Dosage Card Regarding DMSA Scintigraphy
J. Weng1, E. Vestergren2, E. Wikberg2; 1Department of Radiation Physics, University of Gothenburg, Gothenburg, SWEDEN, 2Dept of Medical Physics and Biophysics, Sahlgrenska University Hospital, Gothenburg, SWEDEN.

EP-0947
Evaluation of Renal Split Function in Pediatric Patients with 99m-DMSA Scintigraphy, Comparison between Geometric Mean and Voxelbased Analysis on SPECT/IdCT
M. H. Reichkendler, L. Borgwardt; Rigshospitalet Copenhagen University Hospital, Copenhagen, DENMARK.

EP-0948
Radio guided surgery of a renal metastasis from differentiated thyroid carcinoma (DTC): a case report
L. Martino1, R. Falabella1, F. Ponti1, A. Fè1, L. Mussolin1, A. Vita1, G. Vita1, L. Landolfi1, M. Veltin1; 1Dept. of Nuclear Medicine A.O.R. San Carlo, Potenza, ITALY, 2Dept. of Urology A.O.R. San Carlo, Potenza, ITALY, 3SIC Dept. of Pathology A.O.R. San Carlo - IRCCS-CROB, Potenza - Rionero in Vulture, ITALY, 4Dept. of Internal Medicine University Hospital, Salerno, ITALY, 5Dept. of Nuclear Medicine A.O., Cosenza, ITALY.

EP-0949
F+30 versus F-15 Furosemide Tc99m-MAG3 Renogram Drainage Parameters in Hydronephrotic and Normal Pediatric Kidneys
S. Turpin1, P. J. Martineau2, D. Barrieras1, O. Djahangirian1, J. Franc-Guimond1, A. M. Houle1, R. Lambert1; 1CHU Sainte-Justine, Montreal, QC, CANADA, 2The University of Ottawa, Ottawa, ON, CANADA.

EP-0950
Evaluate the effects of age and sex on glomerular filtration rate
H. M. Yassin1, M. H. Khedr2, M. W. Shafaa2, M. Hagar2; 1Cairo University, Cairo, EGYPT, 2Helwan University, Cairo, EGYPT.
EP-0951
Impact of furosemide on image quality of Ga-68 PSMA PET-CT in prostate cancer patients
L. W. M. van Kolmthout, A. J. A. T. Braat, M. G. E. H. Lam, B. de Keizer; University Medical Center Utrecht, Utrecht, NETHERLANDS.

EP-0952
Gravity Assisted Diuresis Renography in patients with Urinary Diversion
G. Tartaglione¹, N. Foschi², C. Gandi², P. F. Bassi²;
¹Nuclear Medicine, Cristo Re Hospital, Rome, ITALY;
²Urology, UCSC, Policlinico A. Gemelli, Rome, ITALY.

EP-0953
Assessment of six different single plasma sample methods measuring glomerular filtration rate in children
S. Ha, J. Lee; Asan Medical Center, University of Ulsan College of Medicine, Seoul, KOREA, REPUBLIC OF.

EP-0954
Comparison of GFR Estimation by CKD-EPI, C&G, MDRD and GFR Measuring by Tc-99m DTPA
Z. Hasbek, S. Ertenk, E. Çifte, A. Cakmakciar, B. Turgut; Cumhuriyet University School of Medicine, Department of Nuclear Medicine, SIVAS, TURKEY.

EP-0956
Testicular Scintigraphy - Our Experience
A. Sá Pinto, V. M. Alves, A. Oliveira, J. Pereira; Centro Hospitalar de Sáo João, Porto, PORTUGAL.

EP-0957
Our Experience With DMSA In Pediadtrics Patients With Suspected APN
A. J. Guzmán Cruz, Y. Ramírez Escalante, M. Coronado Poggio, L. García Zoghby, S. Riskallal Monzón, L. Dominguez Gadea; Hospital Universitario La Paz, Madrid, SPAIN.

EP-0958
Relative Renal Efficiency Calculation by Scintigraphy: Tc⁹⁹m MAG-3 dynamic study Versus Tc⁹⁹m DMSA static study in Different Renal Diseases
D. E. Sharaf, H. M. Gad; Urology & Nephrology Center, Mansoura, EGYPT.

EP-0959
Nephrolithiasis:99mTc-DMSA scintigraphy
D. BEN SELLEM, L. ZAABAR, B. DHAOUADI, I. EL BEZ, B. LETAIEF, M. F. BEN SLIMENE; University of Tunis El Manar, Tunis, TUNISIA.

EP-0960
Is There a Correlation Between MAG3 Tubular Extraction Rate and Estimated Glomerular Filtration Rate in Transplanted Kidney?
A. Hrelja, S. Grbac-Ivanković, J. Simić, S. Racki, B. Vujicic; Clinical Hospital Rijeka, Rijeka, CROATIA.

EP-0961
Prediction of permanent renal damage using dimercaptosuccinic acid renal scintigraphy in children with vesicoureteral reflux and urinary tract infection
M. Radulovic, L. Jaukovic, M. Sisic, B. Ajdinovic; Military medical academy, Institute of Nuclear medicine, Belgrade, SERBIA.

EP-0962
A new quality control parameter for slope-intercept GFR measurement
J. L. Holness¹,², J. M. Warwick¹; ¹Stellenbosch University, Cape Town, SOUTH AFRICA, ²Tygerberg Hospital, Cape Town, SOUTH AFRICA.

EP-0963
Technetium-99m-dimercaptosuccinic acid renal scintigraphy in children with urinary tract infections
I. El Bez, M. Somai, K. Trabelsi, A. Mhiri, D. Ben Selle, M. Ben Slimene; insitut Salah Azaiez, Tunis, TUNISIA.

EP-0964
Scintigraphic Evaluation of Perconditioning Protection on Renal Ischemia/Reperfusion Injury in Rats
Z. Sedaghat¹, H. Fatemikia¹, K. Tanha¹, M. Zahir⁰, B. Seifi², M. Assadi¹; ¹Bushehr University of Medical Sciences, Bushehr, IRAN, ISLAMIC REPUBLIC OF, ²Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0965
Standardisation of F-15 renography with renal output efficiency
N. D. Assaf, A. A. Nawwar², I. Laurence¹, F. Zananiri¹, M. Darby¹; ¹Southmead Hospital, Bristol, UNITED KINGDOM, ²Clinical Oncology and Nuclear Medicine department, Faculty of Medicine, Cairo University, Cairo, EGYPT.
EP-0966
Activity quantification (E%) in late postmobilization images with mean parenchymal transit time MPTT in dilated and obstructed pelvis when diuretic test is contraindicated
C. Olianti1, F. Tutino1, A. Ciaccia1, M. Allocca1, E. Butti2, M. Materassi1, M. Antonello1, L. Masieri1, Nuclear Medicine Unit, Careggi University Hospital, Florence, ITALY, 2University of Florence, Florence, ITALY, 3University of Florence, Florence, ITALY, 4Nephrology and Dialysis Unit, Meyer Pediatric University Hospital, Florence, ITALY, 5Radiodiagnostic Unit, Meyer Pediatric University Hospital, Florence, ITALY, 6Pediatric Urology, Meyer Pediatric University Hospital, Florence, ITALY.

EP-0967
Tc99m DTPA renography owes a characteristic pattern in patients with chronic parenchymal renal disease associated with significant renal function impairment
S. M. W. Yassin1, K. Salman2, A. Bakhsh2, H. Abdallah2, Z. Khan1; 1King Abdulla Medical City (KAMC), Jeddah, SAUDI ARABIA, 2King Abdulla Medical City (KAMC), Makkah, SAUDI ARABIA.

EP-0968
Is normalized residual activity a good marker of renal output efficiency in hydrenephrosis?
I. El Bez, M. Somai, K. Trabelsi, A. Mhiri, I. Slim, M. Ben Slimene; institut Salah Azaiez, Tunis, TUNISIA.

EP-0969
Does Anteroposterior Pelvic Diameter Predict of the Need of Diuretic in Cases of 99mTc-MAG3 Stasis after Basal Renogram?
H. C. Martins1, G. Costa1, A. Moreira1, R. Silva1, J. Pedroso de Lima1,2, 1Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL, 2Instituto de Ciências Nucleares Aplicadas à Saúde, Coimbra, PORTUGAL.

EP-0970
Value of real-time time-activity curves when evaluating need for diuretic on dynamic renograms
P. Holdgaard1, A. Erskv1, N. Bebbington1, Sygehus Lillebaelt, Veje, DENMARK, 2Siemens Healthineers, Aarhus, DENMARK.

EP-0971
Infected Polycystic Kidney Disease: Role Of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
J. Benouhoud, S. CHOUKRY, Y. SHIMI, A. GUENSI; CHU Ibn Rochd, Casablanca, MOROCCO.

EP-0972
Diagnostic performance of 99mTc-HMPAO-labeled leucocyte scan for diabetic foot osteomyelitis in relation to foot part involved and imaging technique
S. Georga1, C. Manes1, T. Didangelos1, G. Arsov1; 13rd Dept of Nuclear Medicine, Aristotle University Medical School, Papageorgiou General Hospital, THESALONIKI, GREECE, 2Diabetes Center, Papageorgiou General Hospital, THESALONIKI, GREECE, 3Diabetes Center, 1st Propedeutic Dept. of Internal Medicine, Aristotle University Medical School, ‘AHEPA’ Hospital, THESALONIKI, GREECE.

EP-0973
Concordance between MRI and 99mTc-HMPAO WBCs scan in suspect osteomyelitis: results from a single centre experience
I. Grassi1, G. Pontone1, F. Albertini2, C. Orzincolo2, E. Del Giudice1; 1Nuclear Medicine Unit, Ospedale degli Infermi, Faenza (Ra), ITALY, 2Radiology Unit, Ospedale degli Infermi, Faenza (Ra), ITALY.

EP-0974
Does Additional Low Dose Heparin Pre-administration Improve Cardiac Glucose Metabolism Suppression in FDG PET/CT?
N. L. van der Sluis-van der Zee, A.M. van den Berk, A.M Schootens; Meander Medical Center, Amersfoort, NETHERLANDS.

EP-0975
An enlarged left adrenal gland is an indirect sign of sepsis in patients referred to FDG PET CT for a suspected or proven infectious disease, even in the absence of any evident infectious focus on PET images
C. Drouet1, F. Goehringer1, C. Besseau1, H. Tissot1, C. Manca1, P. Marie1; 1CHU de Besançon, Besancon, FRANCE, 2CHU de Nancy, Nancy, FRANCE.

EP-0976
The presence of elevated C-reactive protein (CRP) and fever during 18F-FDG-PET/CT increases diagnostic yield in patients with fever of unknown origin
K. Mulders-Manders, I. Kouijzer, M. Janssen, A. Simon, C. Bleeker-Rovers; Radboudumc, Nijmegen, NETHERLANDS.
EP-0977
Usefulness of F-18 FDG PET/CT for Detecting Bone Involvement in Patients with Sarcoidosis
A. Georgakopoulos1, N. Pianou1, E. D. Manalip2, L. Kolilekas1, S. A. Papiris1, S. N. Chatziioannou1; 1Biomedical Research Foundation of the Academy of Athens, Clinical and Translational Research, Nuclear Medicine Division, PET/CT section, Athens, GREECE, 22nd Pulmonary Medicine Department, “Attikon” University Hospital, Athens Medical School, National and Kapodistrian University of Athens, Athens, GREECE, 7th Pulmonary Medicine Department and Asthma Center, Sotini Hospital for Chest Diseases, Athens, GREECE, 22nd Pulmonary Medicine Department and Asthma Center, Sotini Hospital for Chest Diseases, Athens, GREECE.

EP-0978
Comparative Effectiveness Of 18F-FDG PET-CT And CT Angiography For The Evaluation Of Large-Vessel Vasculitis
M. Moragas, M. Andreu, M. Montequdo, A. Carejas, J. Martin, A. Rodríguez, C. Diaz, J. Oliva, L. Bernà; Hospital Parc Taulí, Sabadell (Barcelona), SPAIN.

EP-0979
Effectiveness of long-term chronic suppressive antibiotic therapy in chronic joint infection: follow-up by 99mTc-HMPAO-labeled leukocyte scan
M. Ricci, M. Pontico, G. A. Follaccia, M. De feo, F. Monteleone, G. De Vincenti, G. Cecarelli, M. Liberatore; Università di Roma “Sapienza”, ROMA, ITALY.

EP-0980
Diagnostic value of Tc99m- Ubiquicidine in differentiation between osteomyelitis and bone tumors
K. Aryan1, M. Ayati1, M. Norouzi1; 1Mashhad university of medical sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF, 2Nuclear medicine research center, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-0981
99mTc-sulesomab and 99mTc-nanocolloid bone marrow imaging in prosthetic joint infection
P. Gouveia, A. Sousa, R. Sousa, R. Teixeira, R. Brito, L. Amorim, M. Oliveira, A. Silva, R. Castro; Centro Hospitalar do Porto, Porto, PORTUGAL.

EP-0982
Diagnostic Accuracy of 18F-FDG PET in Evaluating Disease Activity in Patients with Chronic Inflammatory Bowel Disease: a Bivariate Meta-analysis
G. Treglia1, R. Sadeghi2, A. Viccaro1, B. Muoio1, L. Giovanella1; 1Nuclear Medicine and PET/CT Center, Oncology Institute of Southern Switzerland, Bellinzona, SWITZERLAND, 2Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF; 1Radiation Oncology, Oncology Institute of Southern Switzerland, Bellinzona, SWITZERLAND.

EP-0983
Quantitative 123I-SAP scintigraphy in the follow-up of AL Amyloidosis Patients
R. J. van Rheenen, B. P.C. Hazenberg, R. A. J. O. Dierckx, A. W. J. M. Glaudemans; UMCG, Groningen, NETHERLANDS.

EP-0984
Valence of F-18-FDG-PET/CT in diagnostics of inflammatory foci
L. Knappe, F. A. Verburg, M. Luster, D. Librizzi; Philipps-Universität Marburg, Marburg, GERMANY.

EP-0985
Multimodal imaging in cardiovascular infections: the case of the infectious complications after Bentall procedure
R. Boni1, A. Bruno1, E. Lazzeri1, M. Sollini1, R. Zanca2, A. Marciano3, A. De La Fuente4, R. Donia5, F. Menichetti2, C. Tascini6, M. Ferraro5, P. Erba2; 1ASST Papa Giovanni XXIII Nuclear Medicine, Bergamo, ITALY, 2Regional Center of Nuclear Medicine, Department of Translational Research and Advanced Technology in Medicine, University of Pisa, Pisa, ITALY, 3Nuclear Medicine Humanitas University, Rozzano, Milan, ITALY, 4Division of Infectious Diseases, University Hospital of Pisa, Pisa, ITALY, 5vascular Surgery, University Hospital of Pisa, Pisa, ITALY.

EP-0986
Respective Role of 18F-FDG PET/CT and 99mTc-HMPAO-WBC SPECT/CT in Patients With Suspected Prosthetic Material-Associated Cardiovascular Infections
K. Šenica1, D. Šfiligoj Planjšek1, A. Sočan1, M. Logar1, J. Kšela1, L. Ležaj1; 1Department of Nuclear Medicine, Medical Centre Ljubljana, Ljubljana, SLOVENIA, 2Clinic for Infectious Diseases and Febrile Illnesses, University Medical Centre Ljubljana, Ljubljana, SLOVENIA, 3Department of Cardiovascular Surgery, University Medical Centre Ljubljana, Ljubljana, SLOVENIA.
EP-0998 Evaluation of 18-FDG PET/CT in diagnosis of large vessel vasculitis
A. Bakos1, Z. Besenyő1, S. Urbán1, R. Hemelein1, L. Kovács1, L. Pávics1; 1Department of Nuclear Medicine University of Szeged, Szeged, HUNGARY, 2Department of Rheumatology University of Szeged, Szeged, HUNGARY.

EP-0999 Heterotopic ossification in Intensive Care Unit patients imaged with bone scan
C. Sioka, E. Konstanti, K. Papadimitrioupolos, A. Papadopoulos, V. Ragos, X. Xourgia, V. Koulouras, A. Fotopoulos; University Hospital of Ioannina, Ioannina, GREECE.

EP-1000 Paget Disease and Bone Scintigraphy: an 8-Year Single-Center Experience
S. Diodato, A. Matti, R. Bonfiglioli, L. Zanoni, M. Leverato, S. Fantl, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, ITALY.
EP-1001
The value of 99mTc bone scintigraphy in detecting a low grade infection of a total hip or knee arthroplasty
C. Schlenkhoff, Jr.1, P. Mantovani1, T. Randau1,2, F. Gärtner1,2, M. Essler1,2; 1University Bonn, Bonn, GERMANY, 2Orthopaedics and Trauma Surgery, University Bonn, GERMANY.

EP-1002
Assessment of relative uptake of mandibular condyles in a normal population
A. Fernandes1, T. Faria1, P. Coelho2, A. Oliveira1, J. Pereira2; 1Hospital de São João, Porto, PORTUGAL, 2Universidade Fernando Pessoa, Porto, PORTUGAL.

EP-1003
Technetium-99m HDP SPECT/CT evaluation of persistent and recurrent pain post lumbar spine fusion
K. Al Riyami1,2, S. Voo1; 1UCLH, London, UNITED KINGDOM, 2Hospital Universitario de Canarias, Santa Cruz de Tenerife, SPAIN.

EP-1004
Review of bone scan imaging in Bertolotti syndrome

EP-1005
Predictive value of 18F-NaF PET/CT in the assessment of osteoporosis: comparison with Dual-energy X-ray Absorptiometry (DXA)
S. Haim1, R. Zakavi1, L. Imamovic1, M. Beheshiti1, A. Rezaee1, B. Saboury1, A. Alavi1, W. Langsteiger1, M. Beheshiti1; 1PET-CT Center Linz, St. Vincent’s Hospital, Linz, AUSTRIA, 2Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, IRAN, 3Division of Nuclear Medicine, University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA.

EP-1006
Scintigraphic Assessment Of Pedicular Screw Loosening In Patients With Spinal Arthrodesis
J. Sabater-Sancho, A. Amr-Rey, R. Díaz-Expósito, Sr., I. Casáns-Tormo, J. Orozco-Cortés, V. López-Prior; Servicio De Medicina Nuclear, Hospital Clínico Universitario De Valencia, Valencia, SPAIN.

EP-1007
Mandibular Condylar Hyperplasia. Diagnosis And Follow-Up By Bone SPECT And SPECT/CT
A. Amr-Rey1, J. Casáns-Tormo1, M. Puche-Torres2, A. Sada-Malumbres2, R. Díaz-Expósito1, J. Sabater-Sancho1, J. Orozco-Cortés1, V. López-Prior1; 1Nuclear Medicine, University Clinic Hospital, Valencia, SPAIN, 2Maxillofacial Surgery, University Clinic Hospital, Valencia, SPAIN.

EP-1008
Value of the pre-iodine ablation thyroglobulin serum levels in predicting remission in differentiated thyroid cancer
H. Boudriga1, M. Ben Fredj2, M. Ben Rejeb2, A. Ezzine2, S. Mensf2, M. Guezguez2; 1Laboratory of medical imaging, LR12E506 Monastir university, Monastir, TUNISIA, 2University hospital of Sahloud, Nuclear medicine department, Sousse, TUNISIA.

EP-1009
Decrease of the rate of affected margins in non palpable breast lesions with 1125 Radioguided Seed Localization technique

EP-1010
Radiotracer-guided localization for thoracosopic resection of small and subsolid pulmonary nodules
P. K. Rehm1, J. Jahjah2, A. Mitqhal2, L. Flors1; University of Virginia Health System, Charlottesville, VA, UNITED STATES OF AMERICA.

EP-1011
Feasibility of portable gamma camera imaging in intraoperative radioguided parathyroid adenoma identification
Z. Koç, P. Ozcan Kara, A. Dağ, M. Berkeşoğlu; Mersin University Hospital, Mersin, TURKEY.

EP-76 during congress opening hours, e-Poster Area
Conventional & Specialised Nuclear Medicine: Imaging Guided Surgery (Benign)
EP-1007
Mandibular Condylar Hyperplasia. Diagnosis And Follow-Up By Bone SPECT And SPECT/CT
A. Amr-Rey1, J. Casáns-Tormo1, M. Puche-Torres2, A. Sada-Malumbres2, R. Díaz-Expósito1, J. Sabater-Sancho1, J. Orozco-Cortés1, V. López-Prior1; 1Nuclear Medicine, University Clinic Hospital, Valencia, SPAIN, 2Maxillofacial Surgery, University Clinic Hospital, Valencia, SPAIN.

EP-1008
Value of the pre-iodine ablation thyroglobulin serum levels in predicting remission in differentiated thyroid cancer
H. Boudriga1, M. Ben Fredj2, M. Ben Rejeb2, A. Ezzine2, S. Mensf2, M. Guezguez2; 1Laboratory of medical imaging, LR12E506 Monastir university, Monastir, TUNISIA, 2University hospital of Sahloud, Nuclear medicine department, Sousse, TUNISIA.

withdrawn
EP-1012
Radioguided surgery for primary hyperparathyroidism by evolved protocol from SPECT and portable gamma camera to SPECT CT and hybrid portable gamma camera
J. Orozco Cortés, Sr., R. Díaz-Expósito, S. Vidal Sicart, N. Sanchez Izquierdo, D. Foster, N. Cassinello Fernandez, O. Vidal, R. Jover, F. Lomeña, I. Casans Tormo; 1Hospital Clinic Valencia, Valencia, SPAIN, 2Hospital Clinic Barcelona, Barcelona, SPAIN.

EP-1013
Ultrasound gold quantum clusters intrinsically labeled with 64Cu for in vivo PET/NIRF imaging of lymph nodes
H. Zhang, J. Yang, A. Ahad, W. Weber, M. Kircher; Memorial Sloan-Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.

EP-1014
The Role of SPECT/CT for diagnosis of thoracic splenosis
M. Totaro, G. Petracca Ciavarella, M. Guerra, M. Scarale, M. Mangiacotti, V. Frusciante, Sr.; Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, ITALY.

EP-1016
Kinetic analysis using asialoglycoprotein receptor scintigraphy with Tc-99m GSA dynamic SPECT/CT for assessment of hepatic function
Y. Fukuda, T. Sanomura, H. Okuda, Y. Yamamoto, K. Okano, N. Kudomi, Y. Nishiyama; 1Kagawa University, Kita-gun Kagawa, JAPAN, 2Kagawa University Department of Gastrointestinal Surgery, Kita-gun Kagawa, JAPAN.

EP-1017
The Value of Clinical Audit Beyond Measuring Performance: Evidence from the National NHS England PET-CT Clinical Audit Programme

EP-1018
Optimized Lymphoscintigraphy in Grading of Lymphedema of the Lower Extremities: An Attempt to Clinicoscintigraphic Staging
M. A. A. Mostafa; Prince Mohamed Bin Abdelaziz Hospital, Riyadh, SAUDI ARABIA.

EP-1019
Intraperitoneal Scintigraphy in the Diagnosis of Pleural Effusion in Peritoneal Dialysis
I. Latorre Agraz, B. Cueto Cañadas, D. Balaguer Muñoz, P. Abreu Sánchez, M. D. Reyes Ojeda, T. Mut Dólera, M. C. Plancha Mansanet, E. Caballero Calabuig, M. B. Vizzacino Castillo; Hospital Dr. Peset, Valencia, SPAIN.

EP-1020
Possible substitutes for stable iodine tablet in aim of suppression of radioactive iodine uptake
T. Hongyo, Sr., M. Namise, Y. Sawai, K. Yamamoto; Osaka University, Suita, JAPAN.
## Technologist e-Poster Walks

<table>
<thead>
<tr>
<th>E-TPW1</th>
<th>Tuesday, October 24, 2017, 08:00 - 09:30, e-Poster Walk Area, Level 2, between Suite B and Suite C, Screen 6</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Technologist e-Poster Session 1</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Chairs:</strong> A. Santos (Lisbon, PORTUGAL) A. Gedo (Lisbon, PORTUGAL)</td>
<td></td>
</tr>
<tr>
<td><strong>E-TPW01</strong></td>
<td>Effects of ROI definition and reconstruction method on Standardized Uptake Value</td>
</tr>
<tr>
<td>K. Škalčič, D. Bogović, S. Škalčič, N. Kusturić, S. Dražumerič; Institut of Oncology, Ljubljana, SLOVENIA.</td>
<td></td>
</tr>
<tr>
<td><strong>E-TPW02</strong></td>
<td>The Effects of Different Reconstruction Algorithms on 18F-FDG PET/CT Images</td>
</tr>
<tr>
<td>Y. Parlak, D. Goksoy, G. Mutevelizade, G. Gumuser, E. Sayit; Celal Bayar University, Manisa, TURKEY.</td>
<td></td>
</tr>
<tr>
<td><strong>E-TPW03</strong></td>
<td>Role of Post reconstruction Gaussian filter in PET scan</td>
</tr>
<tr>
<td>S. Tayal, A. Gandhi; Kailash Cancer Hospital &amp; Research Centre, Vadodara, India.</td>
<td></td>
</tr>
<tr>
<td><strong>E-TPW04</strong></td>
<td>Discovery IQ 4R- Optimization of parameters of acquisition and reconstruction in clinical 18F-FDG PET-CT studies</td>
</tr>
<tr>
<td>H. Paninho¹, D. Faria², S. Francesco¹, J. Fernandes³, J. Oliveiria²; ESSUA-Health School of University of Aveiro, Aveiro, PORTUGAL; HPP-Medicina Molecular, SA, Porto, PORTUGAL; Lenitudes Medical Center &amp; Research, SGPS, SA, Santa Maria da Feira, PORTUGAL.</td>
<td></td>
</tr>
<tr>
<td><strong>E-TPW05</strong></td>
<td>Studies on Scattered Radiation out of Field of View and Effect of Scatter Correction in 3D brain PET</td>
</tr>
<tr>
<td>M. Honda¹, Y. Sakuragi², S. Abe³, N. Fujita³, K. Kunimoto¹, T. Odagawa³, K. Kato¹; ¹Department of Radiological and Medical Laboratory Sciences, Nagoya University Graduate School of Medicine, Nagoya, JAPAN; ²Department of Radiological Technology, Nagoya University Hospital, Nagoya, Japan; ³Nagoya University, Nagoya, JAPAN.</td>
<td></td>
</tr>
<tr>
<td><strong>E-TPW06</strong></td>
<td>The measurement accuracy of analyzing software for PET/CT</td>
</tr>
<tr>
<td>S. Matsuzawa¹, S. Abe², Y. Sakuragi², N. Fujita³, M. Honda¹, K. Kunimoto¹, R. Mukumoto¹, T. Odagawa³, K. Kato¹; ¹Nagoya University Graduate School of Medicine, Nagoya, JAPAN, ²Nagoya University Hospital, Nagoya, JAPAN.</td>
<td></td>
</tr>
<tr>
<td><strong>E-TPW07</strong></td>
<td>Influence of Reconstruction Parameters on ¹⁸F-FDG PET Activity Quantification of Small Objects: a Phantom Study</td>
</tr>
<tr>
<td>X. Liang¹, S. Han¹, X. Hu¹, X. Xiao¹, P. Xiao¹, Q. Xie¹; Huazhong University of Science and Technology, Wuhan, CHINA.</td>
<td></td>
</tr>
<tr>
<td><strong>E-TPW08</strong></td>
<td>Activity Quantification of ¹⁸F-FDG in the Presence of an Iodinated Contrast Medium</td>
</tr>
<tr>
<td>A. Svensson¹, B. Olsson¹, J. Oddstig², C. Hindorf², L. Jonsson³; ¹Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Lund, SWEDEN; ²Radiation Physics, Skåne University Hospital, Lund, SWEDEN; ³Department of Medical Radiation Physics, Lund University, Lund, SWEDEN.</td>
<td></td>
</tr>
<tr>
<td><strong>E-TPW09</strong></td>
<td>Clinical Trial of PET VCAR and ROVER</td>
</tr>
<tr>
<td>N. G. Wolff¹, S. Parameswaran²; ¹Sydvestjysk Sygehus - Department of Radiology and Nuclear Medicine, Esbjerg, DENMARK; ²Odense Universitetshospital - Department of Nuclear Medicine, Odense, DENMARK.</td>
<td></td>
</tr>
<tr>
<td><strong>E-TPW10</strong></td>
<td>Studies on the crosstalk rate in simultaneous myocardial imaging with dual radionuclides using cardiac focusing collimator</td>
</tr>
<tr>
<td>K. Kunimoto¹, S. Abe², N. Fujita³, M. Honda¹, S. Matsuzawa¹, R. Mukumoto¹, T. Odagawa³, K. Kato¹; ¹Department of Radiological and Medical Laboratory Sciences, Nagoya University Graduate School of Medicine, Nagoya, JAPAN; ²Nagoya University Hospital, Nagoya, JAPAN; ³Department of Radiological Technology, Nagoya University Hospital, Nagoya, JAPAN.</td>
<td></td>
</tr>
</tbody>
</table>

*E-Poster not submitted*
E-TPW11
Nal(Tl) and CZT-camera based detectors: comparison of image parameters
M. J. F. Sousa1, D. Vieira1, C. Alves2, L. Santos2, L. Olo2, P. Oliveira2, A. Nunes3, F. Godinho4, G. Cantinho4, L. F. Metello1,5; 1ESS-IPP, Nuclear Medicine Dept, Porto, PORTUGAL, 2DCC – Dr. Campos Costa, Nuclear Medicine Dept, iCUF Institute, Porto, PORTUGAL, 3Atomedical, Nuclear Medicine Dept., Lisbon, PORTUGAL, 4Univ. Hosp. of Santa Maria, Nuclear Medicine Dept. – University of Lisbon, Lisbon, PORTUGAL, 5IsoPor–Azores, Nuclear Medicine Dept., Angra do Heroismo, Azores, PORTUGAL.

E-TPW12
Impact of segmentation-based enhancement on conjugated gradient reconstruction system in bone SPECT imaging
K. Okuda, S. Fujii, S. Sakimoto, T. Ida, S. Moriyama; Tottori University Hospital, Tottori, JAPAN.

E-TPW13
Scintigraphy of the nasal cavity and maxillar sinuses
M. M. Joergensen; Rigshospitalet, Copenhagen, DENMARK.

E-TPW14
A novel automatic gamma function fitting program of the time activity curve for the input function determination in the 99mTc-ECD non-invasive quantification method
Y. Tanaka1, Y. Uchiyama2, A. Takaki1, S. Ito1; 1Graduate School of Health Sciences, Kumamoto University, Kumamoto, JAPAN, 2Faculty of Life Sciences, Kumamoto University, Kumamoto, JAPAN, 3Teikyo University, Omuta, JAPAN.

E-TPW15
Examination of quantitative bone SPECT images using the anatomical normalization template
A. Kikuchi1, G. Okuyama1, S. Kumazawa1, M. Kitama1, K. Miwa1, K. Kawakami1; 1Hokkaido University Hospital, Sapporo, JAPAN, 2Tochigi, Ootawara, JAPAN, 3Tokyo, Gyuouku, JAPAN.

E-TPW16
An exploitation of the time range selection for SPECT to calculate the GFR
Y. Wang, M. Liu; Department of Nuclear medicine Fudan University, Shanghai, CHINA.

E-TPW17
Evaluation of SPECT/CT Image Applying to Three-Dimensional Printing Phantom
J. Lee1, H. Park2; 1Songho College, Gangwon-do, KOREA, REPUBLIC OF, 2Shingu College, Seongnam, KOREA, REPUBLIC OF.

E-TPW18
Quality control on DIGIRAD Solid state X-ACT camera: the role of the technologist
S. Sustar, S. Rep, B. Trebec, B. Simonic, I. Slodnjak, L. Lezaic; Department of Nuclear Medicine, Ljubljana, SLOVENIA.

E-TPW19
SeHCAT measurements of bile acid retention using a collimated gamma camera
M. Lorentzon, P. Fransson, A. Larsson; Umeå University, Umeå, SWEDEN.

E-TPW20
Comparison of different Attenuation Correction methods in DaTscan examination
F. H. Gomes1, M. F. Soares1, F. Brolund2, A. Danielsson3, L. Vieira1; 1Lisbon School of Health Technology, Lisbon, PORTUGAL, 2Karolinska Institutet, STOCKHOLM, SWEDEN, 3Karolinska Universitetssjukhuset Solna, STOCKHOLM, SWEDEN.

E-TPW21
Accuracy of the F-18 Calibration Factor in a Capintec Calibrator
S. Ta/uni015Ftan1, S. Tanriverdi1, E. Ozdogan1, N. O. Kucuk2; 1eczacibasi Monrol Nuclear Products, Ankara, TURKEY, 2Ankara University, Ankara, TURKEY.

E-TPW22
Resurrection and return to the technological cycle of enriched Molybdenum-98 from liquid waste produced by technetium-99m generators
A. Rogov, E. Stasyuk, E. Nesterov, E. Oz Logan1, N. O. Kucuk; 1eczacibasi Monrol Nuclear Products, Ankara, TURKEY, 2Ankara University, Ankara, TURKEY.
E-TPW23  Determination of radioquimic purity (RCP) of 99mTc-Tektrotyd with an alternative chromatographic method
E. López Martínez, J. L. Gómez Perales, E. Ariza Cabrera, F. Martín Estrada; SAS, Algeciras, SPAIN.

E-TPW24  Comparison between two different methods for radionuclide purity determination in the first eluate of a 99Mo/99mTc generator
A. Bassan, M. C. Marzola, C. Secchiero, A. Patrian, S. Cittadini, T. Tinazzo, A. Ferretti, A. Massara, S. Chondrogiannis, D. Rubello; Nuclear Medicine - PET/CT centre, Santa Maria della Misericordia Hospital of Rovigo, Rovigo, ITALY.

E-TPW26  Action protocol in breaking the cold chain in cold kits thermolabile
E. López Martínez, E. Ariza Cabrera, M. Cardoso Rodríguez; SAS, Algeciras, SPAIN.

E-TPW27  Creation of a labeled technetium-99m colloid drug for the detection of guarding lymph nodes
A. Rogov1, E. Stasyuk1, E. Nesterov1, E. Ilina1, V. Sadkin1, L. Larionova1, V. Chernov1,2; 1National Research Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION, 2Tomsk Cancer Research Institute, Tomsk, RUSSIAN FEDERATION.

E-TPW28  A method of DOTA-SP90 with 111In labeling, has stability and potential for breast cancer imaging
S. Lee, S. Lo, Y. Huang, M. Chen, M. Li, C. Chang; Institute of Nuclear Energy Research, Taoyuan, TAIWAN.

E-TPW29  Dynamic in vivo molecular imaging of 18F-INER1577 in mice
M. Li1, C. Shiue2, C. Feng1, H. Chang1; 1Institute of Nuclear Energy Research, Atomic Energy Council, Taoyuan City, TAIWAN, 2PET Center, National Taiwan University Hospital, Taipei, TAIWAN.

E-TPW30  The Effectiveness of Heat-Denatured Red Blood Cell (RBC) SPECT/CT Study for Patient Management When the Pathology is Unclear: A Pictorial Case Series
M. Carmody, M. A. Vartzokas, S. Yusuf, W. Svensson; Imperial College and Healthcare NHS Trust, London, UNITED KINGDOM.

E-TPW31  Methods of time efficiency improvement following relocation to a new department
W. Heegaard1, B. Hoyer Mathiasen2, P. Holdgaard3; 1Department of Nuclear Medicine, Vejle Hospital, Vejle, DENMARK, 2Department of Procurement & Clinical Engineering, Central Denmark Region, Aarhus, DENMARK.

E-TPW32  Will the new PET radiopharmaceuticals overtake Myocardial Perfusion Imaging in the diagnosis of CAD?
R. F. S. Moreira, A. I. P. Queiraz, C. Paixa, C. Soares; Queen Elizabeth Hospital Birmingham, UK, Birmingham, UNITED KINGDOM.

E-TPW33  Planning of multi-tracer session for clinical and research activity in a PET center
M. Scarlattei, S. Migliari, A. Sammartano, G. Baldari, C. Cidda, G. Serelli, C. Ghetti, O. Ortentzia, L. Ruffini; AOU Pr, Parma, ITALY.

E-TPW34  Impact of different acquisition and reconstruction protocols on image quality in [68Ga]PSMA PET/MRI
S. Milachowski1, A. Kanzog2, F. Büther2, T. Allkemper1, L. Stegger2; 1Institute of Clinical Radiology, University Hospital Muenster, Muenster, GERMANY, 2Department of Nuclear Medicine, University Hospital Muenster, Muenster, GERMANY.

E-TPW35  Assessment Ga-68 PSMA progress in patient with prostate cancer
R. R. Farshbaf Aghaenejad; University Tehran, Tehran, IRAN, ISLAMIC REPUBLIC OF.

E-TPW36  Gallium-67 Delayed Imaging in the Evaluation of Sarcoidosis: Is It Really Necessary?
J. Patrina1, D. B. Faria2, T. S. Vieira2, D. Sousa3, F. A. Silva3; 1PET Center, National Taiwan University Hospital, Taipei, TAIWAN, 2Lenitudes Medical Center & Research, Santa Maria da Feira, PORTUGAL, 3School Of Health Sciences - University of Aveiro, Aveiro, PORTUGAL.
E-TPW37
Copper-64 and its role in Theranostics and Nuclear Medicine
M. J. Correia1, P. Costa1, S. Sequeira2, A. Nunes3, L. Olo4, C. Alves5, L. F. Metello1; 1Nuclear Medicine Department, ESS-P.Porto, Porto, PORTUGAL, 2Nuclear Medicine Department, IPOFG, Porto, PORTUGAL, 3Nuclear Medicine Department, DCC – Dr. Campos Costa – ICUF, Matosinhos, Porto, PORTUGAL, 4Nuclear Medicine Department, IsoPor – Azores, Angra do Heroísmo, PORTUGAL.

E-TPW38
Optimal collimation for 223Ra planar imaging
T. Otani1, Y. Kunikane2, S. Takashi2, R. Bando2, A. Fujita2, M. Amano2, Y. Fukunaga1, H. Otsuka1, H. Miyoshi1; 1Tokushima University, Tokushima, JAPAN, 2Tokushima University Hospital, Tokushima, JAPAN.

E-TPW39
Radium-223 In The Treatment Of Metastatic Castration-Resistant Prostate Cancer
C. Vazzana1, S. Morano1, A. Di Lascio1, C. Granà1, M. Chinola; 1Veneto Oncology Institute - IOV IRCCS, Padova, ITALY, 2Hospital Bianchi Melacrino Morelli, Reggio Calabria, ITALY, 3Hospital A. Cardarelli, Napoli, ITALY, 4European Institute of Oncology, Milano, ITALY.

E-TPW40
Half-Time SPECT/CT Acquisition for Post Therapy [177Lu–DOTA, Tyr3] Octreotide Imaging

E-TPW43
The viability of the attenuation CT for calcium scoring
M. Louwe; Westfriesgasthuis, Hoorn, NETHERLANDS.

E-TPW44
Implication of using cardiac MAR algorithm with regards to the interpretation of infected PM- and ICD wires
J. Ellingsen, E. Andersen, H. Stokmo; Oslo University Hospital, Oslo, NORWAY.

E-TPW45
DDS-A, microDDSA and KARI100, what else
M. Budinsky, S. Kozakova; Masaryk Memorial Cancer Institute, Brno, CZECH REPUBLIC.

E-TPW46
Skin Contamination of Nuclear Medicine Staff in NM Departments: preliminary results

E-TPW47
Development and Validation of Simple Methods to Reduce Radiation Exposure to Public from FDG PET/CT Patients
E. Koester, S. Frye, R. Muzaffer, M. M. Osman; Saint Louis University, St. Louis, MO, UNITED STATES OF AMERICA.

E-TPW48
Quantification of technegas contamination
K. S. Ramer, N. S. Larsen, M. N. Lonsdale, D. L. Dachstern; Bispebjerg Hospital, Copenhagen, DENMARK.

E-TPW49
Evaluation of Radiation Exposure to Nurse on Nuclear Medicine examination by Use Radioisotope
J. Jeong, C. Lee, Y. Seo, H. Choi, Y. Kim, W. Won; National Cancer Center, Goyang-si, KOREA, REPUBLIC OF.
E-TPW50
Dose Rates from the Patient in Conventional Nuclear Medicine: “To Void or Not to Void”, that is the Question!

E-TPW51
Optimization of the exposure to the extremities of the technologists in nuclear medicine based on daily routine workflow
L. Vojo, K. Zeimpekis; University Hospital Zurich, Zurich, SWITZERLAND.

E-TPW52
The predicting value of 18F-FDG PET/CT imaging of radioactive iodine treatment efficacy in patients with bone metastasis from differentiated thyroid cancer
D. Wang, C. Ma; Affiliated Xinhua Hospital of Shanghai Jiaotong University School of Medicine, Shanghai, CHINA.

E-TPW53
Use of 4D-PET/CT in the Radiotherapy Treatment Planning of the Retropertitoneal Lesions Near the Diaphragm

E-TPW54
Developing an Educational Strategy for Hybrid Imaging Practitioners: A Tailored Approach
R. Menezes; Oxford University Hospitals NHS Foundation Trust, Headington, Oxford, UNITED KINGDOM.

E-TPW55
In Search of Minimum Time-Interval Between the Two Continuous FDG-PET Scans of the Same Subjects
S. Han, X. Liang, X. Hu, L. Wan, P. Xiao, Q. Xie; Huazhong University of Science and Technology, Wuhan, CHINA, Raydata Technology Co., Ltd., Ezhou, CHINA.

E-TPW56
Laser Scanning And Computed Tomography 3D: Application In The Skin Surface Modelling Of PIXI Phantom Head
Technologist e-Poster Session 4

**E-TPW61**
Residual Activity Correction Successfully Adjusts Myocardial Blood Flow Measurements in Time-efficient $^{13}$N-ammonia Myocardial Perfusion PET/CT
P. A. Doodeman, S. V. Lazarenko, F. M. van der Zant, M. Wondergem, R. J. J. Knol; Northwest Clinics Alkmaar, Alkmaar, NETHERLANDS.

**E-TPW62**
Left ventricular volumes and EF measured with $^{13}$N-ammonia PET/CT varies substantially with the software package used for analysis
V. S. Barten-Bruin$^{1,2}$, S. V. Lazarenko$^{1,2}$, L. C. J. Zaai$^{1}$, F. M. van der Zant$^{1,2}$, M. Wondergem$^{1,2}$, R. J. J. Knol$^{1,2}$; $^{1}$Department of Nuclear Medicine, Northwest Clinics, Alkmaar, NETHERLANDS, $^{2}$Cardiac Imaging Division Alkmaar, Alkmaar, NETHERLANDS.

**E-TPW63**
Comparison of MPI SPECT/CT scans acquired with LEHR collimator and reduced time IQ•SPECT system
S. Ferreira$^{1}$, P. Begley$^{1}$, M. Jessop$^{2}$, A. Aldous$^{2}$, N. Eftychiou$^{1}$, N. Singh$^{1}$, S. Dizdarevic$^{1}$, E. Sousa$^{1}$; $^{1}$Lisbon School of Health Technology, Polytechnic Institute of Lisbon, Lisbon, PORTUGAL, $^{2}$Brighton and Sussex University Hospitals, Brighton, UNITED KINGDOM.

**E-TPW64**
Motion reduction activities in patients undergoing myocardial perfusion SPECT with the Discovery NM 530c(D530c)
D. Lee, W. Choi, W. Jung; Asan Medical Center, Seoul, KOREA, REPUBLIC OF.

**E-TPW65**
The washout rate and the heart to mediastinum ratio of $^{123}$I-beta-methyl-iodophenyl pentadecanoic acid can reflect the severity of myocardial damage
T. Iimori$^{1}$, H. Miyachi$^{2}$, K. Sawada$^{1}$, T. Umezawa$^{1}$, T. Sada$^{1}$, Y. Masuda$^{1}$, Y. Kuwabara$^{2}$, T. Uno$^{1}$, Y. Kobayashi$^{2}$; $^{1}$Department of Radiology, Chiba University Hospital, Chiba, JAPAN, $^{2}$Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, JAPAN, $^{3}$Department of Diagnostic Radiology and Radiation Oncology, Chiba University Graduate School of Medicine, Chiba, JAPAN.

**E-TPW66**
A cost effective protocol for increasing patient throughput using a combination of half time imaging with $^{99m}$Tc Tetrofosmin and Regadenoson in Stress Myocardial Perfusion Imaging
P. J. Turner, T. Watts, F. Whittingham; The Royal Wolverhampton NHS Trust, Wolverhampton, UNITED KINGDOM.

**E-TPW67**
Role of F18 Choline PET/CT in Brain Tumors
L. Reiser$^{1}$, A. Haroon$^{2}$, Y. Bouchareb$^{2}$, G. Testanara$^{2}$, C. Copland$^{2}$, E. McKintosh$^{2}$, N. Hartman$^{2}$; $^{1}$Purdue University College of Pharmacy, West Lafayette, IN, UNITED STATES OF AMERICA, $^{2}$Barts Health NHS Trust, St Bartholomew’s Hospital, London, UNITED KINGDOM.

**E-TPW68**
Development of reference values for DaTSCAN semi-quantitative analysis
A. Neves$^{1}$, B. Ribeiro$^{1}$, M. Correia$^{1}$, V. Lameiras$^{1}$, E. Pereira$^{1,2}$, L. Oliveira$^{1}$, E. Caroline$^{1}$, L. Vieira$^{1,2}$; $^{1}$Nuclear Medicine Degree, Escola Superior de Tecnologia da Saúde de Lisboa/Instituto Politécnico de Lisboa, Lisbon, PORTUGAL, $^{2}$Scientific Area of Nuclear Medicine, Escola Superior de Tecnologia da Saúde de Lisboa/Instituto Politécnico de Lisboa, Lisbon, PORTUGAL.

---

**E-TPW4**
Tuesday, October 24, 2017, 08:00 - 09:30, e-Poster Walk Area, Level 2, between Foyer A and Foyer C, Screen 9
E-TPW69
Feasibility of an automatic $^{123}$I-IMP non-invasive quantitative measurement method for evaluation of regional cerebrovascular reactivity
T. Tomimatsu¹, D. Koreeda¹, A. Ofuji¹, H. Ohura², A. Takaki³, S. Ito³; ¹Graduate School of Health Sciences, Kumamoto University, Kumamoto, JAPAN, ²National Organization Saga Hospital, Saga, JAPAN, ³Teikyo University, Omuta, JAPAN.

E-TPW70
Fully automatic striatal region of interest setting program using magnetic resonance images for a new $^{123}$I-FP-CIT quantification method
S. Ota¹, Y. Uchiyama², A. Takaki³, S. Ito³; ¹Graduate School of Health Sciences, Kumamoto University, Kumamoto, JAPAN, ²Faculty of Life Sciences, Kumamoto University, Kumamoto, JAPAN, ³Teikyo University, Omuta, JAPAN.

E-TPW71
Clinical Usefulness of $^{[18F]}$FC119S PET as an Auxiliary Diagnostic Methods for Dementia
B. Byun¹, S. Lim¹, K. Lee¹, J. Choi¹, J. Ha¹, S. Park¹, D. Chi²; ¹Korea Institute of Radiological and Medical Sciences, Seoul, KOREA, REPUBLIC OF, ²Research Institute of Labeling, Futurechem Co., Ltd, Seoul, KOREA, REPUBLIC OF.

E-TPW72
A Case Study Detailing the Development of a Protocol for the Detection, Diagnosis and Analysis of a Cerebral Spinal Fluid Leak Study
E. Seal; Queen Elizabeth Hospital Birmingham, Birmingham, UNITED KINGDOM.

E-TPW73
Comparison of Imaging Techniques spect and pect in the pre surgical evaluation of refractory epilepsy
G. Paixao, A. Queiroz, R. Moreira, C. Soares; Queen Elizabeth Hospital, Birmingham, UNITED KINGDOM.

E-TPW74
Spleen Uptake on Bone Scan after Liver Transplantations
Y. Lim; Pusan National University Yangsan Hospital, YANG SAN, KOREA, REPUBLIC OF.

E-TPW75
Static Bone Scintigraphy Images of Hands and Feet - How low can we go?
M. Tayyab, H. Mikkelsen, B. Haddock, U. B. Andersen, C. Suetta, P. Hovind; Rigshospitalet, Glostrup, DENMARK.

E-TPW76
SPECT-MR of Spine for Patients with Back Pain: First UK Experience
N. Musa, R. Victoria, H. Jan, M. Ahmed, J. Bull, G. Testanaro, A. Haroon; Barts Health NHS Trust, St Bartholomew's Hospital, London, UNITED KINGDOM.

E-TPW77
Evaluation of Renal Scarring Using Ultrasound and Renal Scintigraphy
A. B. Ahmed, IV¹, A. Abdullah²; ¹Ministry of Health, Fujairah, UNITED ARAB EMIRATES, ²Sudan University for science and Technology, Khartoum, SUDAN.

E-TPW78
Interest of the estimation of the GFR with technetium 99m-DTPA in the comparasion of the analysis of three methods of creatinine clearance estimation after kidney transplantation
A. Sellam, K. Limam, W. Elajmi; Military Hospital, Tunis, TUNISIA.

E-TPW79
Interest of $^{99mTc}$DTPA dynamic renal scintigraphy with furosemid test in the exploration of ureteropelvic junction syndrome: Report of 37 cases
S. Touil¹,², Y. Shimi¹,², A. Koumba¹,², H. Aschawa¹,², A. Guensi¹,²; ¹Faculty of medicine and pharmacy of Casablanca, Casablanca, MOROCCO, ²Nuclear medicine service, Ibn Rochd University Hospital, Casablanca, MOROCCO.

E-TPW80
Evaluation of factors that may contribute to the hepatobiliary excretion of $^{99mTc}$-MAG3
B. Bento, C. Amorim, D. Costa, P. Santos, S. Chin, M. R. Victor, M. Filipe, A. I. Santos; Serviço de Medicina Nuclear - Hospital Garcia de Orta, Almada, PORTUGAL.
E-TPW81
Influence of the geometry and positioning of the regions of interest in the transplanted renogram
J. F. V. Rodrigues1, J. Rayo1, J. Vicente1, E. Carolina1, S. Figueiredo1, L. Vieira1; 1Escola Superior de Tecnologia da Saúde de Lisboa, Lisboa, PORTUGAL, 2Department of Nuclear Medicine at the Hospital Santa Cristina, Badajoz, SPAIN, 3Scientific Area of Mathematics, Escola Superior de Tecnologia da Saúde de Lisboa/Instituto Politécnico de Lisboa, Lisboa, PORTUGAL, 4Scientific Area of Nuclear Medicine, Escola Superior de Tecnologia da Saúde de Lisboa/Instituto Politécnico de Lisboa, Lisboa, PORTUGAL, 5GMOSM – Instituto Superior de Engenharia de Lisboa/Instituto Politécnico de Lisboa, Lisboa, PORTUGAL.

E-TPW82
Tailoring gastric emptying studies to patients needs: a requirement for best practice
S. Johnson, C. Sibley-Allen, A. Nunes; Guy’s and St. Thomas’ NHS Foundation Trust, London, UNITED KINGDOM.

withdrawn
Annual Congress of the European Association of Nuclear Medicine

List of Exhibitors

EANM'17

World Leading Meeting

October 21 – 25, 2017 | Vienna, Austria
INDUSTRY PROGRAMME

30th

ANNUAL SCIENTIFIC MEETING
### Bayer: Four years of radium Ra 223 dichloride on the market: what have we learned?

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 – 13:20</td>
<td>Learning from trials and experience in mCRPC</td>
</tr>
<tr>
<td></td>
<td>Joe O’Sullivan (UK):</td>
</tr>
<tr>
<td>13:20 – 13:30</td>
<td>Lesson 1: who to treat, when, and why</td>
</tr>
<tr>
<td></td>
<td>Val Lewington (UK)</td>
</tr>
<tr>
<td>13:30 – 13:40</td>
<td>All faculty (Chair: Joe O’Sullivan, UK): Panel discussion</td>
</tr>
<tr>
<td>13:40 – 13:55</td>
<td>Lesson 2: 10 key steps to improve your service</td>
</tr>
<tr>
<td></td>
<td>Yong Du (UK)</td>
</tr>
<tr>
<td>13:55 – 14:05</td>
<td>Lesson 3: our journey to becoming an expert centre</td>
</tr>
<tr>
<td></td>
<td>Wouter Vogel (The Netherlands)</td>
</tr>
<tr>
<td>14:05 – 14:15</td>
<td>All faculty (Chair: Joe O’Sullivan, UK): Panel discussion</td>
</tr>
</tbody>
</table>

### Advanced Accelerator Applications: 
**Lutathera® (¹⁷⁷Lu-Dotatate): A New Era of Treatment in GEPNETs**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 – 13:05</td>
<td>Welcome</td>
</tr>
<tr>
<td></td>
<td>Prof. Dr. Eric Krenning (Erasmus MC, Rotterdam, Netherlands):</td>
</tr>
<tr>
<td>13:05 – 13:35</td>
<td>A New Era of Treatment in GEPNETs</td>
</tr>
<tr>
<td></td>
<td>Dr. Christos Toumpanakis (Royal Free and University College London, UK)</td>
</tr>
<tr>
<td>13:35 – 13:55</td>
<td>PRRT: Real World Experience</td>
</tr>
<tr>
<td></td>
<td>Dr. Gill Vivian (King’s College Hospital, London, UK)</td>
</tr>
<tr>
<td>13:55 – 14:15</td>
<td>The Future for PRRT</td>
</tr>
<tr>
<td></td>
<td>Dr. Lisa Bodei (Memorial Sloan Kettering Cancer Center, New York, US)</td>
</tr>
<tr>
<td>14:15 – 14:30</td>
<td>Questions and Discussion</td>
</tr>
<tr>
<td></td>
<td>Prof. Dr. Eric Krenning</td>
</tr>
</tbody>
</table>
Sunday, October 22, 2017  13:00 – 14:30, Hall G1

BTG

sponsored by: [BTG]

Monday, October 23, 2017  13:00 – 14:30, Hall F2

GE Healthcare: Clinical Impact of GE Healthcare’s latest innovations

Chairs Prof. Arturo Chiti, Humanitas University, Italy

Managing difficult CAD patients utilising latest technology & techniques
Prof. Richard Underwood, Royal Brompton & Harefield Hospitals, UK

Clinical experience with D670 CZT for bone imaging
Prof. Michael Kreissl, University Hospital Magdeburg, Germany

Improving oncology imaging with digital PET/CT
Dr. Martin Hüllner, University Hospital Zurich, Switzerland

Organizing a productive clinical PET/MR service
Prof. Aurélie Kas, Groupe Hospitalier Pitié-Salpêtrière, France

sponsored by: [GE Healthcare]
**Sponsored Symposia**

**Monday, October 23, 2017**

**13:00 – 14:30, Hall K**

**Siemens: NEW Developments in Molecular Imaging**

Join us for lunch as leading experts in molecular imaging share insights into the most recent advances in SPECT/CT including xSPECT Quant® and PET/CT focusing on next-generation SiPM-based systems.

**Moderator:** Prof. Frank M. Bengel, Medizinische Hochschule, Hannover, Germany

xSPECT Quant: SPECT/CT quantification in clinical practice

John Prior, Ph.D., M.D. Professor and Head of Nuclear Medicine and Molecular Imaging Lausanne University Hospital (CHUV), Lausanne, Switzerland

Beyond current SiPM-based PET technology: What is achievable?

Bernard Bendriem, Ph.D., Principal Expert, Research and Development, Siemens Healthineers, Knoxville, Tennessee, USA

Beyond current SiPM-based PET technology: More than a vision, first images.

Carl von Gall, M.D., Product Manager, Siemens Healthineers Hoffman Estates, Illinois, USA

sponsored by: **SIEMENS Healthineers**

1 xSPECT Quant is not commercially available in some countries. Due to regulatory reasons, its future availability cannot be guaranteed.

2 The product mentioned herein is currently under development and does not yet fulfill all the essential requirements according to the European Medical Device Directive (93/42/EEC) and its national implementations. It is not yet commercially available in the European Union and not available for sale in the US or any other country. Future availability cannot be guaranteed.

**Monday, October 23, 2017**

**13:00 – 14:30, Hall G1**

**Sirtex: SIR-Spheres® Y-90 resin microspheres: Establishing the evidence base for SIRTand best practices for everyday use**

**Chair:** Ken Herrmann, Essen, Germany

13:00 – 13:05 Welcome and introduction

Ken Herrmann Essen, Germany

13:05 – 13:25 Latest evidence on Y-90 resin microspheres in mCRC and HCC

Niklaus Schäfer Lausanne, Switzerland

13:25 – 13:35 Latest information on Y-90 resin microspheres and Glucose 5%

Philipp Paprottka Munich, Germany

13:35 – 13:50 Angiographical aspects, interacting with dosimetry calculations for Y90 SIRT

Antonio Martinez de la Cuesta Pamplona, Spain

13:50 – 14:05 What is new with the European Directive 2013/59/EURATOM and the impact on SIRT dosimetry

Cinzia Pettinato Bologna, Italy

14:05 Implications of the new data for clinical practice

All

sponsored by: **SIRTeX**
Tuesday, October 24, 2017

Sanofi Genzyme: The Role of Nuclear Medicine in Thyroid Cancer Management

**Chair: Prof. Frederik Verburg**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 – 13:05</td>
<td>Welcome and introduction</td>
</tr>
<tr>
<td></td>
<td>Prof. Frederik Verburg – Nuclear Medicine department, Marburg University Hospital, Marburg, Hessen, Germany</td>
</tr>
<tr>
<td>13:05 – 13:20</td>
<td>Importance of ablative treatment in Differentiated Thyroid Cancer</td>
</tr>
<tr>
<td></td>
<td>Prof. Martha Hoffmann, Radiology Center, Nuclear Medicine and PET/CT, Vienna, Austria</td>
</tr>
<tr>
<td>13:20 – 13:35</td>
<td>How Nuclear Medicine improves Follow-Up in Differentiated Thyroid Cancer</td>
</tr>
<tr>
<td></td>
<td>(Note: intermediate and high risk patients and pts with TgAb)</td>
</tr>
<tr>
<td>13:35 – 13:50</td>
<td>Imaging in Diagnosis and Follow-Up of Medullary Thyroid Cancer</td>
</tr>
<tr>
<td></td>
<td>Prof. Michael Kreissl, Klinikum Augsburg, Augsburg, Germany</td>
</tr>
<tr>
<td>13:50 – 14:00</td>
<td>Closing remarks</td>
</tr>
<tr>
<td></td>
<td>Prof. Frederik Verburg</td>
</tr>
</tbody>
</table>

**Sponsored by:** SANOFI GENZYME

Tuesday, October 24, 2017

Blue Earth Diagnostics: Axumin™ (fluciclovine (18F)) - A Newly Approved Imaging Option for Recurrent Prostate Cancer A Scientific Update

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 – 13:05</td>
<td>Welcome and introduction</td>
</tr>
<tr>
<td></td>
<td>Dr. Frode Willoch, MD, PhD, Faculty of Medicine, University of Oslo, Oslo, Norway</td>
</tr>
<tr>
<td>13:05 – 13:20</td>
<td>Clinical Experience of fluciclovine (18F) PET/CT imaging in men with suspected recurrent prostate cancer and PSA values &lt;1ng/mL.</td>
</tr>
<tr>
<td></td>
<td>Dr. Frode Willoch, MD, PhD, Faculty of Medicine, University of Oslo, Oslo, Norway</td>
</tr>
<tr>
<td></td>
<td>Dr. Eugene J. Teoh, MRCP, FRCR, Department of Oncology, University of Oxford, UK</td>
</tr>
<tr>
<td>13:35 – 13:50</td>
<td>Practical experience of using fluciclovine (18F) in radiotherapy decisionmaking and field planning; preliminary results from a randomized controlled study</td>
</tr>
<tr>
<td></td>
<td>Prof. Ashesh B. Jani, MD, MSEE, Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA, US</td>
</tr>
<tr>
<td>13:50 – 14:00</td>
<td>Summary and Closing remarks</td>
</tr>
<tr>
<td></td>
<td>Dr. Frode Willoch, MD, PhD, Faculty of Medicine, University of Oslo, Oslo, Norway</td>
</tr>
</tbody>
</table>

**Sponsored by:** BLUE EARTH
Tuesday, October 24, 2017

Eli Lilly and Company: Amyloid and Tau imaging in Alzheimer’s Disease: What we have learned from the use of PET Neuroimaging in clinical trials

13:00 – 13:05  Welcome and introduction
Michael Devous, Sr., PhD, FSNMMI (Pennsylvania, United States of America)

13:05 – 13:25  Quantitation and its role in Amyvid scan interpretation
Michael Devous, Sr., PhD, FSNMMI (Pennsylvania, United States of America)

13:25 – 13:45  Clinical utility of biomarkers in making a diagnosis of patients with cognitive decline
Michael Devous, Sr., PhD, FSNMMI (Pennsylvania, United States of America)

13:45 – 14:05  The incremental diagnostic value of Amyloid PET in memory clinics
Giovanni Frisoni, MD (Geneva, Switzerland)

14:05 – 14:20  Questions and answers
All

14:20  Summary & closing remarks
Giovanni Frisoni, MD (Geneva, Switzerland)
A NEW PERSPECTIVE MAKES ALL THE DIFFERENCE

RESEARCH4LIFE
an EANM initiative to foster research

EARL.EANM.ORG
# List of Exhibitors (A – Z)

<table>
<thead>
<tr>
<th>Company</th>
<th>Booth No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABT Molecular Imaging, Inc.</td>
<td>266</td>
</tr>
<tr>
<td>ABX advanced biochemical compounds</td>
<td>420</td>
</tr>
<tr>
<td>ABX-CRO advanced pharmaceutical services</td>
<td>264</td>
</tr>
<tr>
<td>ACOM SRL</td>
<td>261</td>
</tr>
<tr>
<td>Advanced Accelerator Applications (AAA)</td>
<td>310</td>
</tr>
<tr>
<td>Advanced Cyclotron Systems, Inc</td>
<td>217</td>
</tr>
<tr>
<td>AG Medical</td>
<td>216</td>
</tr>
<tr>
<td>Agfa HealthCare</td>
<td>425</td>
</tr>
<tr>
<td>Ai4R SAS (Isotope4life)</td>
<td>403</td>
</tr>
<tr>
<td>AIMN – Italian Association of Nuclear Medicine</td>
<td>370</td>
</tr>
<tr>
<td>AIPES – Association of Imaging Producers and Equipment Suppliers</td>
<td>249</td>
</tr>
<tr>
<td>Alliance Medical &amp; Life Radiopharma</td>
<td>233/236</td>
</tr>
<tr>
<td>ANMI SA (Wallonia Export &amp; Investment Agency)</td>
<td>318</td>
</tr>
<tr>
<td>ANZSNM/WFNMB – Australian and New Zealand Society of Nuclear Medicine/</td>
<td>361</td>
</tr>
<tr>
<td>World Federation of Nuclear Medicine and Biology</td>
<td></td>
</tr>
<tr>
<td>ARCCNM/AOFNMB – Asian Regional Cooperative Council for Nuclear Medicine/</td>
<td>363</td>
</tr>
<tr>
<td>Asia Oceania Federation of Nuclear Medicine and Biology</td>
<td></td>
</tr>
<tr>
<td>AREVA Med / Macrocyclics</td>
<td>234</td>
</tr>
<tr>
<td>Arronax / Arronax Plus (Isotope4life)</td>
<td>403</td>
</tr>
<tr>
<td>ASNC – American Society of Nuclear Cardiology</td>
<td>367</td>
</tr>
<tr>
<td>Atlanpole Biotherapies (Isotope4life)</td>
<td>403</td>
</tr>
<tr>
<td>Bayer</td>
<td>245</td>
</tr>
<tr>
<td>Berthold Technologies GmbH</td>
<td>205</td>
</tr>
<tr>
<td>Best Cyclotron Systems, Inc.</td>
<td>268</td>
</tr>
<tr>
<td>Biocompatibles UK Ltd (BTG)</td>
<td>417</td>
</tr>
<tr>
<td>Biodex Medical Systems, Inc.</td>
<td>204</td>
</tr>
<tr>
<td>Biowin (Wallonia Export &amp; Investment Agency)</td>
<td>318</td>
</tr>
<tr>
<td>Blue Earth Diagnostics</td>
<td>407</td>
</tr>
<tr>
<td>BNMS – British Nuclear Medicine Society</td>
<td>355</td>
</tr>
<tr>
<td>Bruker BioSpin</td>
<td>309</td>
</tr>
</tbody>
</table>

EANM Corporate Member CM
### List of Exhibitors

<table>
<thead>
<tr>
<th>Exhibitor</th>
<th>Booth</th>
</tr>
</thead>
<tbody>
<tr>
<td>BV Cyclotron VU <em>(The Pavilion)</em></td>
<td>238</td>
</tr>
<tr>
<td>C.Curie bvba/sprl <em>(The Pavilion)</em></td>
<td>238</td>
</tr>
<tr>
<td>Cambridge Isotope Laboratories, Inc.</td>
<td>251</td>
</tr>
<tr>
<td>CANM – Canadian Association of Nuclear Medicine</td>
<td>366</td>
</tr>
<tr>
<td>Capintec, Inc.</td>
<td>314</td>
</tr>
<tr>
<td>Casram SA</td>
<td>246</td>
</tr>
<tr>
<td>CBmed</td>
<td>257</td>
</tr>
<tr>
<td>Center of Molecular Research</td>
<td>206</td>
</tr>
<tr>
<td>Chelatec <em>(Isotope4life)</em></td>
<td>403</td>
</tr>
<tr>
<td>CHEMATECH</td>
<td>259</td>
</tr>
<tr>
<td>Cisbio</td>
<td>260</td>
</tr>
<tr>
<td>CMR Naviscan Corporation</td>
<td>218</td>
</tr>
<tr>
<td>Comecer Group</td>
<td>412</td>
</tr>
<tr>
<td>Crystal Photonics GmbH</td>
<td>242</td>
</tr>
<tr>
<td>CSNM – Chinese Society of Nuclear Medicine</td>
<td>365</td>
</tr>
<tr>
<td>Curium</td>
<td>307</td>
</tr>
<tr>
<td>Cyclomedica Europe Ltd.</td>
<td>413</td>
</tr>
<tr>
<td>Cyclopharma</td>
<td>210</td>
</tr>
<tr>
<td>DDD-Diagnostic A/S</td>
<td>311</td>
</tr>
<tr>
<td>DGN e.V. – German Society of Nuclear Medicine</td>
<td>353</td>
</tr>
<tr>
<td>Diasource SA <em>(Wallonia Export &amp; Investment Agency)</em></td>
<td>318</td>
</tr>
<tr>
<td>diXit s.r.l.</td>
<td>267</td>
</tr>
<tr>
<td>DOSiSoft SA</td>
<td>316</td>
</tr>
<tr>
<td>EARL – EANM Research Ltd.</td>
<td>351</td>
</tr>
<tr>
<td>ec² Software Solutions</td>
<td>219</td>
</tr>
<tr>
<td>Eckert &amp; Ziegler Strahlen- und Medizintechnik AG</td>
<td>302</td>
</tr>
<tr>
<td>Eczacibasi-Monrol Nuclear Products Co.</td>
<td>313</td>
</tr>
<tr>
<td>Edizioni Minerva Medica</td>
<td>369</td>
</tr>
<tr>
<td>EFRS – European Federation of Radiographer Societies</td>
<td>350</td>
</tr>
<tr>
<td>EIBIR – European Institute for Biomedical Imaging Research</td>
<td>362</td>
</tr>
<tr>
<td>EITA – European Isotopes Transport Association</td>
<td>368</td>
</tr>
<tr>
<td>Elimplex-Medizintechnik GesmbH + Ludlum Measurements Inc.</td>
<td>209</td>
</tr>
<tr>
<td>Elysia-raytest</td>
<td>317</td>
</tr>
<tr>
<td>Epsilon Elektronik San. ve Tic. A.S. – ERS</td>
<td>312</td>
</tr>
</tbody>
</table>

*CM* EANM Corporate Member
### List of Exhibitors

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Booth Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESR – European Society of Radiology</td>
<td>204A</td>
</tr>
<tr>
<td>Euromedical Instruments <em>(The Pavilion)</em></td>
<td>238</td>
</tr>
<tr>
<td>GADEE Medizinsysteme GmbH</td>
<td>265</td>
</tr>
<tr>
<td>GE Healthcare</td>
<td>416</td>
</tr>
<tr>
<td>Getinge La Calhène</td>
<td>422</td>
</tr>
<tr>
<td>Greek Society of Nuclear Medicine and Biology</td>
<td>352</td>
</tr>
<tr>
<td>Hake Medical Technology (Beijing) Co., Ltd.</td>
<td>258</td>
</tr>
<tr>
<td>Hermes Medical Solutions</td>
<td>301</td>
</tr>
<tr>
<td>Hidex Oy</td>
<td>406</td>
</tr>
<tr>
<td>HOY Scandinavian ApS</td>
<td>238</td>
</tr>
<tr>
<td>Huayi Isotopes Co.</td>
<td>208</td>
</tr>
<tr>
<td>IAEA – International Atomic Energy Agency</td>
<td>364</td>
</tr>
<tr>
<td>IASON GmbH</td>
<td>253</td>
</tr>
<tr>
<td>IBA</td>
<td>308</td>
</tr>
<tr>
<td>IDB Holland bv</td>
<td>310</td>
</tr>
<tr>
<td>Institute of Isotopes Co., Ltd.</td>
<td>305</td>
</tr>
<tr>
<td>Inter Medical Medizintechnik GmbH</td>
<td>235</td>
</tr>
<tr>
<td>INVIA Medical Imaging Solutions</td>
<td>227</td>
</tr>
<tr>
<td>inviCRO</td>
<td>207</td>
</tr>
<tr>
<td>IQ Medical Services</td>
<td>229</td>
</tr>
<tr>
<td>IRE ELIT SA</td>
<td>318</td>
</tr>
<tr>
<td>Isotop4Life</td>
<td>403</td>
</tr>
<tr>
<td>ITD Isotope Technologies Dresden GmbH</td>
<td>239</td>
</tr>
<tr>
<td>ITEL Telecomunicazioni</td>
<td>256</td>
</tr>
<tr>
<td>ITM Isotopen Technologien München AG</td>
<td>231</td>
</tr>
<tr>
<td>JSC Isotope/Rusatom Healthcare</td>
<td>415</td>
</tr>
<tr>
<td>JSNM – Japanese Society of Nuclear Medicine</td>
<td>358</td>
</tr>
<tr>
<td>Keosys <em>(Isotope4life)</em></td>
<td>403</td>
</tr>
<tr>
<td>Kliniken.de – job board</td>
<td>371</td>
</tr>
<tr>
<td>KSNM – Korean Society of Nuclear Medicine</td>
<td>203</td>
</tr>
<tr>
<td>LabLogic Systems Ltd.</td>
<td>406</td>
</tr>
<tr>
<td>Lemer Pax</td>
<td>403</td>
</tr>
<tr>
<td>Lightpoint Medical Ltd.</td>
<td>228</td>
</tr>
<tr>
<td>Lynax s.r.o.</td>
<td>202</td>
</tr>
</tbody>
</table>

*EANM Corporate Member*
<table>
<thead>
<tr>
<th>Exhibitor</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>MAP Medical Technologies Oy</td>
<td>254</td>
</tr>
<tr>
<td>MED Nuklear-Medizintechnik Dresden GmbH – a Company of NUVIA <em>(The Pavilion)</em></td>
<td>238</td>
</tr>
<tr>
<td>Medi-Radiopharma Co., Ltd.</td>
<td>319</td>
</tr>
<tr>
<td>Mediso</td>
<td>304</td>
</tr>
<tr>
<td>Medisystem <em>(Isotope4life)</em></td>
<td>403</td>
</tr>
<tr>
<td>MIE medical imaging electronics GmbH</td>
<td>408</td>
</tr>
<tr>
<td>MLabs B.V.</td>
<td>226</td>
</tr>
<tr>
<td>MIM Software Inc.</td>
<td>237</td>
</tr>
<tr>
<td>Mirada Medical</td>
<td>215</td>
</tr>
<tr>
<td>MNT Kwint International bv <em>(The Pavilion)</em></td>
<td>238</td>
</tr>
<tr>
<td>MOLECUBES NV</td>
<td>250</td>
</tr>
<tr>
<td>MR SOLUTIONS</td>
<td>201</td>
</tr>
<tr>
<td>NICESOFT <em>(The Pavilion)</em></td>
<td>238</td>
</tr>
<tr>
<td>Norgine Ltd.</td>
<td>223</td>
</tr>
<tr>
<td>NRG</td>
<td>306</td>
</tr>
<tr>
<td>Nuclear Shields BV</td>
<td>424</td>
</tr>
<tr>
<td>Nucleis <em>(Wallonia Export &amp; Investment Agency)</em></td>
<td>318</td>
</tr>
<tr>
<td>NVNG – Dutch Society of Nuclear Medicine</td>
<td>354</td>
</tr>
<tr>
<td>OGNMB – Austrian Society of Nuclear Medicine and Molecular Imaging</td>
<td>359</td>
</tr>
<tr>
<td>Oncidium Foundation</td>
<td>347</td>
</tr>
<tr>
<td>ONCOVISION</td>
<td>421</td>
</tr>
<tr>
<td>ORA-NEPTIS – Optimized Radiochemical Applications</td>
<td>211</td>
</tr>
<tr>
<td>Osimis SA <em>(Wallonia Export &amp; Investment Agency)</em></td>
<td>318</td>
</tr>
<tr>
<td>PARS ISOTOPE</td>
<td>418</td>
</tr>
<tr>
<td>PerkinElmer</td>
<td>269</td>
</tr>
<tr>
<td>Philips</td>
<td>402</td>
</tr>
<tr>
<td>PI Medical Diagnostic Equipment B.V. <em>(The Pavilion)</em></td>
<td>238</td>
</tr>
<tr>
<td>PMB-ALCEN</td>
<td>409</td>
</tr>
<tr>
<td>PMOD Technologies Ltd.</td>
<td>232</td>
</tr>
<tr>
<td>POLATOM, Radioisotope Centre of National Centre for Nuclear Research</td>
<td>410</td>
</tr>
<tr>
<td>Progenics Pharmaceuticals, Inc.</td>
<td>411</td>
</tr>
<tr>
<td>RAD4MED <em>(Wallonia Export &amp; Investment Agency)</em></td>
<td>318</td>
</tr>
<tr>
<td>rapp-iso GmbH</td>
<td>220</td>
</tr>
<tr>
<td>Rotem GmbH</td>
<td>244</td>
</tr>
</tbody>
</table>

*CM* EANM Corporate Member
<table>
<thead>
<tr>
<th>Exhibitor</th>
<th>Booth</th>
</tr>
</thead>
<tbody>
<tr>
<td>ROTOP Pharmaka GmbH</td>
<td>414</td>
</tr>
<tr>
<td>RoWe Med AG – Medical 4 Life</td>
<td>214</td>
</tr>
<tr>
<td>Sanofi Genzyme</td>
<td>247</td>
</tr>
<tr>
<td>Scintomics GmbH</td>
<td>230</td>
</tr>
<tr>
<td>Sedecal Molecular Imaging – SMI</td>
<td>241</td>
</tr>
<tr>
<td>Seibersdorf Labor GmbH</td>
<td>262</td>
</tr>
<tr>
<td>Sichuan Tianle Photonics Co., Ltd.</td>
<td>213</td>
</tr>
<tr>
<td>Siemens Healthineers</td>
<td>401</td>
</tr>
<tr>
<td>Sirtex Medical Europe GmbH</td>
<td>405</td>
</tr>
<tr>
<td>SNMI – Society of Nuclear Medicine, India</td>
<td>243</td>
</tr>
<tr>
<td>SNMMI – Society of Nuclear Medicine and Molecular Imaging</td>
<td>356</td>
</tr>
<tr>
<td>Southern Scientific Ltd.</td>
<td>406</td>
</tr>
<tr>
<td>Spectrum Dynamics Medical</td>
<td>404</td>
</tr>
<tr>
<td>Springer Nature</td>
<td>360</td>
</tr>
<tr>
<td>SurgicEye GmbH (The Pavilion)</td>
<td>238</td>
</tr>
<tr>
<td>SYNTHRA GmbH</td>
<td>263</td>
</tr>
<tr>
<td>Taiyo Nippon Sanso Corporation</td>
<td>255</td>
</tr>
<tr>
<td>Tema Sinergie</td>
<td>303</td>
</tr>
<tr>
<td>TERUMO Europe NV</td>
<td>224</td>
</tr>
<tr>
<td>The Pavilion</td>
<td>238</td>
</tr>
<tr>
<td>THERACTION</td>
<td>423</td>
</tr>
<tr>
<td>TRASIS S.A.</td>
<td>419</td>
</tr>
<tr>
<td>Triskem International (Isotope4life)</td>
<td>403</td>
</tr>
<tr>
<td>TSNM – Turkish Society of Nuclear Medicine</td>
<td>357</td>
</tr>
<tr>
<td>UEMS/EBNM – European Union of Medical Specialists/Section and European Board of Nuclear Medicine</td>
<td>348</td>
</tr>
<tr>
<td>Uniteko</td>
<td>212</td>
</tr>
<tr>
<td>US DOE, Isotopes</td>
<td>240</td>
</tr>
<tr>
<td>VANDERWILT techniques b.v. (The Pavilion)</td>
<td>238</td>
</tr>
<tr>
<td>Von Gahlen Nederland BV</td>
<td>315</td>
</tr>
<tr>
<td>Wallonia Export &amp; Investment Agency</td>
<td>318</td>
</tr>
<tr>
<td>WARMTH</td>
<td>349</td>
</tr>
<tr>
<td>Wisepress Medical Bookshop</td>
<td>400</td>
</tr>
<tr>
<td>WOLFMET (M&amp;I Materials Ltd.) (The Pavilion)</td>
<td>238</td>
</tr>
<tr>
<td>Yantai Dongcheng Pharmaceuticals Group Co., Ltd.</td>
<td>248</td>
</tr>
</tbody>
</table>

EANM Corporate Member CM
Exhibitors (sorted by Booth No.)

<table>
<thead>
<tr>
<th>Company</th>
<th>Booth No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>MR SOLUTIONS</td>
<td>201</td>
</tr>
<tr>
<td>Lynax s.r.o.</td>
<td>202</td>
</tr>
<tr>
<td>KSNM – Korean Society of Nuclear Medicine</td>
<td>203</td>
</tr>
<tr>
<td>Biodex Medical Systems, Inc.</td>
<td>204</td>
</tr>
<tr>
<td>ESR – European Society of Radiology</td>
<td>204A</td>
</tr>
<tr>
<td>Berthold Technologies GmbH</td>
<td>205</td>
</tr>
<tr>
<td>Center of Molecular Research</td>
<td>206</td>
</tr>
<tr>
<td>inviCRO</td>
<td>207</td>
</tr>
<tr>
<td>Huayi Isotopes Co.</td>
<td>208</td>
</tr>
<tr>
<td>Elimplex-Medizintechnik GesmbH + Ludlum Measurements Inc.</td>
<td>209</td>
</tr>
<tr>
<td>Cyclopharma</td>
<td>210</td>
</tr>
<tr>
<td>ORA-NEPTIS – Optimized Radiochemical Applications</td>
<td>211</td>
</tr>
<tr>
<td>Uniteko</td>
<td>212</td>
</tr>
<tr>
<td>Sichuan Tianle Photonics Co., Ltd.</td>
<td>213</td>
</tr>
<tr>
<td>RoWe Med AG – Medical 4 Life</td>
<td>214</td>
</tr>
<tr>
<td>Mirada Medical</td>
<td>215</td>
</tr>
<tr>
<td>AG Medical</td>
<td>216</td>
</tr>
<tr>
<td>Advanced Cyclotron Systems, Inc.</td>
<td>217</td>
</tr>
<tr>
<td>CMR Naviscan Corporation</td>
<td>218</td>
</tr>
<tr>
<td>ec² Software Solutions</td>
<td>219</td>
</tr>
<tr>
<td>rapp-iso GmbH</td>
<td>220</td>
</tr>
<tr>
<td>Norgine Ltd.</td>
<td>223</td>
</tr>
<tr>
<td>TERUMO Europe NV</td>
<td>224</td>
</tr>
<tr>
<td>MLabs B.V.</td>
<td>226</td>
</tr>
<tr>
<td>INVIA Medical Imaging Solutions</td>
<td>227</td>
</tr>
<tr>
<td>Lightpoint Medical Ltd.</td>
<td>228</td>
</tr>
<tr>
<td>IQ Medical Services</td>
<td>229</td>
</tr>
<tr>
<td>Scintomics GmbH</td>
<td>230</td>
</tr>
<tr>
<td>ITM Isotopen Technologien München AG</td>
<td>231</td>
</tr>
<tr>
<td>PMOD Technologies Ltd.</td>
<td>232</td>
</tr>
</tbody>
</table>

*EANM Corporate Member*
<table>
<thead>
<tr>
<th>Exhibitor</th>
<th>Booth No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alliance Medical &amp; Life Radiopharma</td>
<td>233/236</td>
</tr>
<tr>
<td>AREVA Med / Macrocyclins</td>
<td>234</td>
</tr>
<tr>
<td>Inter Medical Medizintechnik GmbH</td>
<td>235</td>
</tr>
<tr>
<td>MIM Software Inc.</td>
<td>237</td>
</tr>
<tr>
<td>BV Cyclotron VU</td>
<td>238</td>
</tr>
<tr>
<td>C.Curie bvba/sprl</td>
<td>238</td>
</tr>
<tr>
<td>Euromedical Instruments</td>
<td>238</td>
</tr>
<tr>
<td>HOY Scandinavian ApS</td>
<td>238</td>
</tr>
<tr>
<td>MED Nuklear-Medizintechnik Dresden GmbH – a Company of NUVIA</td>
<td>238</td>
</tr>
<tr>
<td>MNT Kwint International bv</td>
<td>238</td>
</tr>
<tr>
<td>NICESOFT</td>
<td>238</td>
</tr>
<tr>
<td>PI Medical Diagnostic Equipment B.V.</td>
<td>238</td>
</tr>
<tr>
<td>SurgicEye GmbH</td>
<td>238</td>
</tr>
<tr>
<td>The Pavilion – EANM Corporate Member</td>
<td>238</td>
</tr>
<tr>
<td>VANDERWILT techniques b.v.</td>
<td>238</td>
</tr>
<tr>
<td>WOLFMET (M&amp;I Materials Ltd.)</td>
<td>238</td>
</tr>
<tr>
<td>ITD Isotope Technologies Dresden GmbH</td>
<td>239</td>
</tr>
<tr>
<td>US DOE, Isotopes</td>
<td>240</td>
</tr>
<tr>
<td>Sedecal Molecular Imaging – SMI</td>
<td>241</td>
</tr>
<tr>
<td>Crystal Photonics GmbH</td>
<td>242</td>
</tr>
<tr>
<td>SNMI – Society of Nuclear Medicine, India</td>
<td>243</td>
</tr>
<tr>
<td>Rotem GmbH</td>
<td>244</td>
</tr>
<tr>
<td>Bayer AG</td>
<td>245</td>
</tr>
<tr>
<td>Casram SA</td>
<td>246</td>
</tr>
<tr>
<td>Sanofi Genzyme</td>
<td>247</td>
</tr>
<tr>
<td>Yantai Dongcheng Pharmaceuticals Group Co., Ltd.</td>
<td>248</td>
</tr>
<tr>
<td>AIPES – Association of Imaging Producers and Equipment Suppliers</td>
<td>249</td>
</tr>
<tr>
<td>MOLECUBES NV</td>
<td>250</td>
</tr>
<tr>
<td>Cambridge Isotope Laboratories, Inc.</td>
<td>251</td>
</tr>
<tr>
<td>IASON GmbH</td>
<td>253</td>
</tr>
<tr>
<td>MAP Medical Technologies Oy</td>
<td>254</td>
</tr>
<tr>
<td>Taiyo Nippon Sanso Corporation</td>
<td>255</td>
</tr>
<tr>
<td>ITEL Telecomunicazioni</td>
<td>256</td>
</tr>
<tr>
<td>CBmed</td>
<td>257</td>
</tr>
<tr>
<td>Exhibitor Name</td>
<td>Page</td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>Hake Medical Technology (Beijing) Co., Ltd.</td>
<td>258</td>
</tr>
<tr>
<td>CHEMATECH</td>
<td>259</td>
</tr>
<tr>
<td>Cisbio</td>
<td>260</td>
</tr>
<tr>
<td>ACOM SRL</td>
<td>261</td>
</tr>
<tr>
<td>Seibersdorf Labor GmbH</td>
<td>262</td>
</tr>
<tr>
<td>SYNTHRA GmbH</td>
<td>263</td>
</tr>
<tr>
<td>ABX-CRO advanced pharmaceutical services</td>
<td>264</td>
</tr>
<tr>
<td>GAEDE Medizinsysteme GmbH</td>
<td>265</td>
</tr>
<tr>
<td>ABT Molecular Imaging, Inc.</td>
<td>266</td>
</tr>
<tr>
<td>diXit s.r.l.</td>
<td>267</td>
</tr>
<tr>
<td>Best Cyclotron Systems, Inc.</td>
<td>268</td>
</tr>
<tr>
<td>PerkinElmer</td>
<td>269</td>
</tr>
<tr>
<td>Hermes Medical Solutions</td>
<td>301</td>
</tr>
<tr>
<td>Eckert &amp; Ziegler Strahlen- und Medizintechnik AG</td>
<td>302</td>
</tr>
<tr>
<td>Tema Sinergie</td>
<td>303</td>
</tr>
<tr>
<td>Mediso</td>
<td>304</td>
</tr>
<tr>
<td>Institute of Isotopes Co. Ltd.</td>
<td>305</td>
</tr>
<tr>
<td>NRG</td>
<td>306</td>
</tr>
<tr>
<td>Curium</td>
<td>307</td>
</tr>
<tr>
<td>IBA</td>
<td>308</td>
</tr>
<tr>
<td>Bruker BioSpin</td>
<td>309</td>
</tr>
<tr>
<td>Advanced Accelerator Applications (AAA)</td>
<td>310</td>
</tr>
<tr>
<td>IDB Holland bv</td>
<td>310</td>
</tr>
<tr>
<td>DDD-Diagnostic A/S</td>
<td>311</td>
</tr>
<tr>
<td>Epsilon Elektronik San. ve Tic. A.S. – ERS</td>
<td>312</td>
</tr>
<tr>
<td>Eczacibasi-Monrol Nuclear Products Co.</td>
<td>313</td>
</tr>
<tr>
<td>Capintec, Inc.</td>
<td>314</td>
</tr>
<tr>
<td>Von Gahlen Nederland BV</td>
<td>315</td>
</tr>
<tr>
<td>DOSissoft SA</td>
<td>316</td>
</tr>
<tr>
<td>Elysia-raytest</td>
<td>317</td>
</tr>
<tr>
<td>ANMI SA</td>
<td>318</td>
</tr>
<tr>
<td>Biowin</td>
<td>318</td>
</tr>
<tr>
<td>Diasource SA</td>
<td>318</td>
</tr>
<tr>
<td>Ire Elit SA</td>
<td>318</td>
</tr>
</tbody>
</table>

CM: EANM Corporate Member
<table>
<thead>
<tr>
<th>Exhibitor</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nucleis</td>
<td>318</td>
</tr>
<tr>
<td>Osimis SA</td>
<td>318</td>
</tr>
<tr>
<td>RAD4MED</td>
<td>318</td>
</tr>
<tr>
<td>Wallonia Export &amp; Investment Agency</td>
<td>318</td>
</tr>
<tr>
<td>Medi-Radiopharma Co., Ltd.</td>
<td>319</td>
</tr>
<tr>
<td>Oncidium Foundation</td>
<td>347</td>
</tr>
<tr>
<td>UEMS/EBNM – European Union of Medical Specialists/Section and European Board of Nuclear Medicine</td>
<td>348</td>
</tr>
<tr>
<td>WARMTH</td>
<td>349</td>
</tr>
<tr>
<td>EFRS – European Federation of Radiographer Societies</td>
<td>350</td>
</tr>
<tr>
<td>EARL – EANM Research Ltd.</td>
<td>351</td>
</tr>
<tr>
<td>Greek Society of Nuclear Medicine and Biology</td>
<td>352</td>
</tr>
<tr>
<td>DGN e.V. – German Society of Nuclear Medicine</td>
<td>353</td>
</tr>
<tr>
<td>NVNG – Dutch Society of Nuclear Medicine</td>
<td>354</td>
</tr>
<tr>
<td>BNMS – British Nuclear Medicine Society</td>
<td>355</td>
</tr>
<tr>
<td>SNMMI – Society of Nuclear Medicine and Molecular Imaging</td>
<td>356</td>
</tr>
<tr>
<td>TSNM – Turkish Society of Nuclear Medicine</td>
<td>357</td>
</tr>
<tr>
<td>JSNM – Japanese Society of Nuclear Medicine</td>
<td>358</td>
</tr>
<tr>
<td>OGNMB – Austrian Society of Nuclear Medicine and Molecular Imaging</td>
<td>359</td>
</tr>
<tr>
<td>Springer Nature</td>
<td>360</td>
</tr>
<tr>
<td>ANZSNM/WFNMB – Australian and New Zealand Society of Nuclear Medicine/World Federation of Nuclear Medicine and Biology</td>
<td>361</td>
</tr>
<tr>
<td>EIBIR – European Institute for Biomedical Imaging Research</td>
<td>362</td>
</tr>
<tr>
<td>ARCCNM/AOFNMB – Asian Regional Cooperative Council for Nuclear Medicine/Asia Oceania Federation of Nuclear Medicine and Biology</td>
<td>363</td>
</tr>
<tr>
<td>IAEA – International Atomic Energy Agency</td>
<td>364</td>
</tr>
<tr>
<td>CSNM – Chinese Society of Nuclear Medicine</td>
<td>365</td>
</tr>
<tr>
<td>CANM – Canadian Association of Nuclear Medicine</td>
<td>366</td>
</tr>
<tr>
<td>ASNC – American Society of Nuclear Cardiology</td>
<td>367</td>
</tr>
<tr>
<td>EITA – European Isotopes Transport Association</td>
<td>368</td>
</tr>
<tr>
<td>Edizioni Minerva Medica</td>
<td>369</td>
</tr>
<tr>
<td>AIMN – Italian Association of Nuclear Medicine</td>
<td>370</td>
</tr>
<tr>
<td>Kliniken.de – job board</td>
<td>371</td>
</tr>
<tr>
<td>Wisepress Medical Bookshop</td>
<td>400</td>
</tr>
<tr>
<td>Siemens Healthineers</td>
<td>401</td>
</tr>
</tbody>
</table>
## List of Exhibitors

### 30th Annual Congress of the European Association of Nuclear Medicine (EANM'17)

**World Leading Meeting**

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Philips</td>
<td>402</td>
</tr>
<tr>
<td>A4R SAS</td>
<td>403</td>
</tr>
<tr>
<td>Arronax / Arronax Plus</td>
<td>403</td>
</tr>
<tr>
<td>Atlanpole Biotherapies</td>
<td>403</td>
</tr>
<tr>
<td>Chelatec</td>
<td>403</td>
</tr>
<tr>
<td>Isotop4Life</td>
<td>403</td>
</tr>
<tr>
<td>Keosys</td>
<td>403</td>
</tr>
<tr>
<td>Lemer Pax</td>
<td>403</td>
</tr>
<tr>
<td>Medisystem</td>
<td>403</td>
</tr>
<tr>
<td>Triskem International</td>
<td>403</td>
</tr>
<tr>
<td>Spectrum Dynamics Medical</td>
<td>404</td>
</tr>
<tr>
<td>Sirtex Medical Europe GmbH</td>
<td>405</td>
</tr>
<tr>
<td>Hidex Oy</td>
<td>406</td>
</tr>
<tr>
<td>LabLogic Systems Ltd.</td>
<td>406</td>
</tr>
<tr>
<td>Southern Scientific Ltd.</td>
<td>406</td>
</tr>
<tr>
<td>Blue Earth Diagnostics</td>
<td>407</td>
</tr>
<tr>
<td>MIE medical imaging electronics GmbH</td>
<td>408</td>
</tr>
<tr>
<td>PMB-ALCEN</td>
<td>409</td>
</tr>
<tr>
<td>POLATOM, Radioisotope Centre of National Centre for Nuclear Research</td>
<td>410</td>
</tr>
<tr>
<td>Progenics Pharmaceuticals, Inc.</td>
<td>411</td>
</tr>
<tr>
<td>Comecer Group</td>
<td>412</td>
</tr>
<tr>
<td>Cyclomedica Europe Ltd.</td>
<td>413</td>
</tr>
<tr>
<td>ROTOP Pharmaka GmbH</td>
<td>414</td>
</tr>
<tr>
<td>JSC Isotope/Rusatom Healthcare</td>
<td>415</td>
</tr>
<tr>
<td>GE Healthcare</td>
<td>416</td>
</tr>
<tr>
<td>Biocompatibles UK Ltd (BTG)</td>
<td>417</td>
</tr>
<tr>
<td>PARS ISOTOPE</td>
<td>418</td>
</tr>
<tr>
<td>TRASIS S.A.</td>
<td>419</td>
</tr>
<tr>
<td>ABX advanced biochemical compounds</td>
<td>420</td>
</tr>
<tr>
<td>ONCOVISION</td>
<td>421</td>
</tr>
<tr>
<td>Getinge La Calhène</td>
<td>422</td>
</tr>
<tr>
<td>THERACLION</td>
<td>423</td>
</tr>
<tr>
<td>Nuclear Shields BV</td>
<td>424</td>
</tr>
<tr>
<td>Agfa HealthCare</td>
<td>425</td>
</tr>
</tbody>
</table>

<sup>CM</sup> EANM Corporate Member
Exhibition Plans

201  MR SOLUTIONS
202  Lynx s.r.o.
203  KSNM – Korean Society of Nuclear Medicine
204  Biomed Medical Systems, Inc.
204A  ESR – European Society of Radiology
205  Berthold Technologies GmbH
206  Center of Molecular Research
207  inviCRO
208  Huayi Isotopes Co.
209  ELXImex-Medizintechnik GesmbH + Ludum Measurements, Inc.
210  Cyclotapharma
211  OBANEPFIS – Optimized Radiochemical Applications
212  Uniteko
213  Sichuan Tianle Photonics Co. Ltd.
214  RoWe Med AG – Medical 4 Life
215  Mirada Medical
216  AG Medical
217  Advanced Cyclotron Systems, Inc
218  CMR Naviscan Corporation
219  ecn Software Solutions
220  rapp-iso GmbH
221  Norgine Ltd.
222  TELUMO Europe NV
223  MII Labs B.V.
224  INWA Medical Imaging Solutions
225  Lightpoint Medical Ltd.
226  IQ Medical Services
227  Scintomics GmbH
228  ITM Isopen Technologien München AG
229  PMOEO Technologies Ltd.
230  Alliance Medical & Life Radiopharma
231  AREVA Med / Macrocycles
232  Inter Medical Medizintechnik GmbH
233  MM Software Inc.
234  The Pavilion
  » BV/Cyclotron SYS
  » C.Cure bvba/srl
  » Euromedical Instruments
235  ITD Isotope Technologies Dresden GmbH
236  US DOE, Isotopes
237  Sedecal Molecular Imaging – SMI
238  Crystal Photonics GmbH
239  SNM – Society of Nuclear Medicine India
240  Rotem GmbH
241  Bayer
242  SNM – Society of Nuclear Medicine India
243  Casram SA
244  Sanofi Genzyme
245  Yantai Dongcheng Pharmaceuticals Group Co., Ltd.
246  APIES – Association of Imaging Producers and Equipment Suppliers
247  MOLECUBES NV
248  Cambridge Isotope Laboratories, Inc.
249  IASON GmbH
250  MAP Medical Technologies Oy
251  Taino Nippon Sanso Corporation
252  ITEL Telecomunicazioni
253  CBmed
254  Hake Medical Technology (Beijing) Co., Ltd.
255  CHEMTECH
256  Gisbio
257  ACOM SRL
258  Seibersdorf Labor GmbH
259  SYNTHRA GmbH
260  ABX-CRO advanced pharmaceutical services
261  SANO/FiGenzyme
262  ABT Molecular Imaging, Inc.
263  Yantai Dongcheng Pharmaceuticals Group Co., Ltd.
264  CHEMTECH
265  GAEDE Medizinsysteme GmbH
266  MNT Kwint International bv
267  Hake Medical Technology (Beijing) Co., Ltd.
268  dXit s.r.l.
269  Best Cyclotron Systems, Inc.
270  MED Nuklear-Medizintechnik Dresden GmbH – a Company of NUVIA
271  WNI Kwant International bv
272  NICESOFT
273  BV Medical Diagnostic Equipment B.V.
274  SURGY Eye GmbH
275  WOLFMET (M&I Materials Ltd.)
### Exhibition Plans

<table>
<thead>
<tr>
<th>Booth No.</th>
<th>Company/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>301</td>
<td>Hermes Medical Solutions</td>
</tr>
<tr>
<td>302</td>
<td>Eckert &amp; Ziegler Strahlen- und Medientechnik AG</td>
</tr>
<tr>
<td>303</td>
<td>Tema Siergie</td>
</tr>
<tr>
<td>304</td>
<td>Medics AG</td>
</tr>
<tr>
<td>305</td>
<td>Institute of Isotopes Co. Ltd</td>
</tr>
<tr>
<td>306</td>
<td>NRG</td>
</tr>
<tr>
<td>307</td>
<td>Curium AG</td>
</tr>
<tr>
<td>308</td>
<td>IBA Source AG</td>
</tr>
<tr>
<td>309</td>
<td>Bruker BioSpin</td>
</tr>
<tr>
<td>310</td>
<td>Advanced Accelerator Applications (AAA)</td>
</tr>
<tr>
<td>311</td>
<td>IDB Holland bv</td>
</tr>
<tr>
<td>312</td>
<td>DDD-Diagnostic A/S</td>
</tr>
<tr>
<td>313</td>
<td>Epsilon Elektronik San. ve Tic. A.S. – ERS</td>
</tr>
<tr>
<td>314</td>
<td>Capintec, Inc.</td>
</tr>
<tr>
<td>315</td>
<td>Von Gahlen Nederland BV</td>
</tr>
<tr>
<td>316</td>
<td>DOSIsoft SA</td>
</tr>
<tr>
<td>317</td>
<td>Elysia-raytest</td>
</tr>
<tr>
<td>318</td>
<td>Wallonia Export &amp; Investment Agency</td>
</tr>
<tr>
<td>319</td>
<td>Medi-Radiopharma Co., Ltd.</td>
</tr>
<tr>
<td>347</td>
<td>Oncidium Foundation</td>
</tr>
<tr>
<td>348</td>
<td>UEMS/EANM – European Union of Medical Specialists/Section and European Board of Nuclear Medicine</td>
</tr>
<tr>
<td>349</td>
<td>WARMTH</td>
</tr>
<tr>
<td>350</td>
<td>EFRS – European Federation of Radiographer Societies</td>
</tr>
<tr>
<td>351</td>
<td>EARL – EANM Research Ltd.</td>
</tr>
<tr>
<td>352</td>
<td>Greek Society of Nuclear Medicine and Biology</td>
</tr>
<tr>
<td>353</td>
<td>DGN e.V. – German Society of Nuclear Medicine</td>
</tr>
<tr>
<td>354</td>
<td>NVNG – Dutch Society of Nuclear Medicine</td>
</tr>
<tr>
<td>355</td>
<td>BNMS – British Nuclear Medicine Society</td>
</tr>
<tr>
<td>356</td>
<td>SNMMI – Society of Nuclear Medicine and Molecular Imaging</td>
</tr>
<tr>
<td>357</td>
<td>TSNM – Turkish Society of Nuclear Medicine</td>
</tr>
<tr>
<td>358</td>
<td>JSNM – Japanese Society of Nuclear Medicine</td>
</tr>
<tr>
<td>359</td>
<td>OGNMB – Austrian Society of Nuclear Medicine and Molecular Imaging</td>
</tr>
<tr>
<td>360</td>
<td>Springer Nature</td>
</tr>
<tr>
<td>361</td>
<td>ANZSNM/WFNMB – Australian and New Zealand Society of Nuclear Medicine/World Federation of Nuclear Medicine and Biology</td>
</tr>
<tr>
<td>362</td>
<td>EIBIR – European Institute for Biomedical Imaging Research</td>
</tr>
<tr>
<td>363</td>
<td>ARCCNM/AOFNMB – Asian Regional Cooperative Council for Nuclear Medicine/Asia Oceania Federation of Nuclear Medicine and Biology</td>
</tr>
<tr>
<td>364</td>
<td>IAEA – International Atomic Energy Agency</td>
</tr>
<tr>
<td>365</td>
<td>CSNM – Chinese Society of Nuclear Medicine</td>
</tr>
<tr>
<td>366</td>
<td>CANM – Canadian Association of Nuclear Medicine</td>
</tr>
<tr>
<td>367</td>
<td>ASCC – American Society of Nuclear Cardiology</td>
</tr>
<tr>
<td>368</td>
<td>EITA – European Isotopes Transport Association</td>
</tr>
<tr>
<td>369</td>
<td>Edizioni Minerva Medica</td>
</tr>
<tr>
<td>370</td>
<td>AIWN – Italian Association of Nuclear Medicine</td>
</tr>
<tr>
<td>371</td>
<td>Kliniken.de – job board</td>
</tr>
</tbody>
</table>
Annual Congress of the European Association of Nuclear Medicine

Exhibition Plans

EANM'17 World Leading Meeting

October 21–25, 2017 | Vienna, Austria

30th Annual Congress of the European Association of Nuclear Medicine

World Leading Meeting

Exhibition Plans

400 Wisepress Medical Bookshop
401 Siemens Healthcare
dm
402 Philips
dm
403 Isotop4Life
dm
  > Actir SAS
  > Armanox / Armanox Plus
  > Adapta Biothrapies
  > CHElutec
  > Kesays
  > Lerner Pax
dm
  > Medisystem
  > Triskem International
dm
404 Spectrum Dynamics Medical
dm
405 Sirtex Medical Europe GmbH
406 Hidex Oy
406 LabLogic Systems Ltd.
406 Southern Scientific Ltd.
407 Blue Earth Diagnostics
408 MIE medical imaging electronics GmbH
409 PMB-ALCEN
410 POLATOM, Radioisotope Centre of National Centre for Nuclear Research
411 Progenics Pharmaceuticals, Inc.
412 Comecer Group
dm
413 Cyclomedica Europe Ltd.
414 ROTOP Pharmaka GmbH
415 JSC Isotope/Rusatom Healthcare
dm
416 GE Healthcare
dm
417 Biocompatibles UK Ltd (BTG)
dm
418 PARIS ISOTOPE
dm
419 TRASSIS A
420 ABX advanced biochemical compounds
421 ONCOVISION
422 Getinge La Calhène
423 THERACLION
424 Nuclear Shields BV
425 Agfa HealthCare
ABT Molecular Imaging

3024 Topside Business Park Drive
37777 Louisville
United States
Phone: +1 865 982 0098
E-Mail: info@abt-mi.com
Web: http://www.abt-mi.com

„Simplifying global access to FDG & advanced PET biomarkers“
ABT Molecular Imaging offers the BG-75 “Dose on Demand” Biomarker Generator, providing in-house access to PET biomarkers. The BG-75 System has three principle components that make it unique; a compact accelerator, integrated micro-chemistry, and automated quality control. The system provides simple and efficient single or batch production of F-18 FDG, and other advanced PET radioisotopes. The complete system, including dose synthesis and quality control, can be housed in a 5.6 x 5.6 meter room adjacent to the PET/CT System. The small size and integrated components take the place of a large, conventional systems requiring a 300 square meter facility, with fully equipped hot labs, quality control equipment, and significant staffing for operation. The size and complexity difference provides a much lower barrier to entry to have access to radioisotopes on demand, and enables the expansion of advanced radiochemistry research in clinical and pre-clinical Molecular Imaging. ABT was started in 2006 by Dr. Ron Nutt, and is located in Knoxville, Tennessee. It is very close to where clinical PET was developed over the past 25 years at CTI Molecular Imaging, which Dr. Nutt co-founded.

ABX advanced biochemical compounds - Biomedizinische Forschungsreagenzien GmbH

Heinrich-Glaeser-Str. 10 - 14
1454 Radeberg
Germany
Phone: +49 35 28-40 41 60
Fax: +49-35 28-40 41 65
E-Mail: info@abx.de
Web: http://www.abx.de/

ABX is the leading manufacturer of PET precursors and peptides as well as reagent kits and cassettes. We offer:
- FDG reagent kits and cassettes for nearly all FDG modules
  - * Mannose Triflate (OMF US and Europe)
  - * Cryptand222 (kryptofix)
- F-PSMA-1007 precursor, reagents and cassettes for GE MX, GE FX, ORA Neptis, IBA Synthera and Trasis AIO modules
- nucleophilic and electrophilic F-DOPA precursors as well as reagents and cassettes
- FLT, F-Choline, F-MISO, PET and NAF precursors, reagents and cassettes
- comprehensive range of “scientific” precursors for oncology such as Fluoroestradiol, FAZA… and neurology like Raclopride, Fallypride, PK11195, Flumazenil, beta-CIT, PIB…
- SPECT precursors, e. g. CuMIBI (DMF US and Europe), MIBG, ECD
- PEPTIDES, e. g. PSMA-11, DOTA-TOC, DOTA-TATE and DOTA-NOC for Gallium68 labelling
- novel theranostic PSMA-ligand PSMA-617 for Lutetium-177 labelling
- Gallium-68 reagents kits and cassettes
- Lutetium-177 reagents kits and cassettes
- O-18 WATER
- Performance of stability studies
- Development of radiotracers and labelling as well as purification strategies

We are well experienced in GMP production and also do offer custom synthesis according to Q7 chapter 19 for clinical PET studies (APIs). Our laboratories and clean rooms are GMP certified and meet pharmaceutical standards. We are GMP and ISO13485 certified.
ABX-CRO advanced pharmaceutical services Forschungsgesellschaft m.b.H. Booth No. 264

Blasewitzer Str. 78-80
1307 Dresden
Germany
Phone: +49 351214440
Fax: +49 3512144415
E-Mail: info@abx-cro.com
Web: http://www.abx-cro.com

ABX-CRO is a globally operating clinical research organization with a strong focus on pre-clinical and clinical molecular imaging and molecular radiotherapy.

Based on over 15 years’ experience in diagnostic and therapeutic oncology, neurology and other disease areas, ABX-CRO provides you with unique opportunities to test your drug candidates in complex pre-clinical disease models, assessed quantitatively using molecular and functional imaging (PET, SPECT, CT, MRI). We translate pre-clinical results into First in Man studies and support you with design and execution of efficient late stage clinical trials, minimizing your costs and time to marketing authorization. ABX-CRO makes translational medicine a visible reality.

ABX-CRO is very proud to present QDOSE, the only comprehensive dosimetry solution, featuring seamless integration of the new ICRP-endorsed IDAC-Dose 2.1 dose calculator enabling anatomically realistic phantom-based dose calculation using the official:
– ICRP Adult Reference Computational Phantoms (ICRP 110)
– ICRP Specific Absorbed Fractions (ICRP 133)

QDOSE is a comprehensive internal dosimetry software suite for both, systemic and selective internal radiation therapy (IRT). QDOSE is platform-independent, clinically validated, and user-friendly. It enables state-of-the-art evaluation of safety and efficacy (e.g. tumour) dosimetry.

Acom Booth No. 261

LOC. CAVALLINO 39/a-b
62010 MONTECOSARO
Italy
Phone: +39733229739
Fax: +39 733560352
E-Mail: amministrazione@acompet.it
Web: http://www.acompet.it

ACOM SrL, established in 1999, is one of the most interesting Company in Europe in Nuclear Medicine. ACOM’s aim is to improve the quality of life in oncological, cardiovascular and neurological patients. In 2002 ACOM was officially recognized by the Italian competent Authority for pharmaceutical products (AIFA) as a Pharmaceutical Development Center. In 2007, ACOM was certified by AIFA and in October 2007 by EMEA.

Since its start ACOM has carried out intensive research for developing new radiopharmaceuticals to be used with PET scan devices such as Copper-64 and Iodine-124 produced on a cyclotron using an innovative compact solid target irradiation system (CRIS). In fact, thanks to a long term cooperation with the Washington University of Saint Louis, ACOM has successfully achieved the required know-how to manufacture the copper 64 on industrial scale basis according to GMP standards. Moreover, ACOM is the only existing Company bearing a trade registration which allows the use of Copper 64 in the human body.

The professional skills of the team, the capacity to operate in critical contexts and an innovative approach demonstrated by constant investment in research and development, are just some of the distinctive features developed over more than ten years in business.

For any further information please visit our stand and our WEB page (www.acompet.it) where you can find our news and events continuously updated.
ADVANCED ACCELERATOR APPLICATIONS

4 rue de la tour de l’île
1204 Geneva
Switzerland
Phone: +41 225190700
E-Mail: annalisa.zanuso@adacap.com
Web: http://www.adacap.com/

Advanced Accelerator Applications (NASDAQ:AAAP) is an innovative radiopharmaceutical company that develops, produces and commercializes innovative diagnostic and therapeutic molecular nuclear medicine products. AAA currently has 21 production and research & development facilities, and over 500 employees in 13 countries.

AAA is an established leader in molecular nuclear diagnostic radiopharmaceuticals for PET and SPECT. AAA currently markets 9 radiopharmaceuticals (8 in Europe and 1 in the US) mainly used in clinical oncology, cardiology and neurology.

AAA is also developing a pipeline of theragnostic pairings for oncology indications. The company’s theragnostic platform involves radiolabeling a targeting molecule with either Ga 68 for diagnostic use, or Lu 177 for therapy.

AAA’s first theragnostic pairing addresses neuroendocrine tumors, an orphan indication. The diagnostic drug, marketed as NETSPOT® in the US or SomaKit TOC™ in Europe, is approved for use; while the therapeutic drug, lutetium Lu 177 dotatate (Lutathera®) is under review for registration with the EMA and FDA. Additional pairings target GIST, prostate and breast cancer.

Acquired by AAA in 2016, IDB Holland is a leading manufacturer and worldwide distributor of Lutetium 177 (LuMark® Lu-177 chloride), radiopharmaceuticals and sources for nuclear medicine. IDB supplies customers in over 40 countries in Europe, Africa, Asia, Australia, South America, the United States and Canada.

Advanced Cyclotron Systems Inc (ACSI)

#150 - 7280 River Road
V6X 1X5 Richmond, BC
Canada
Phone: +16042761493
E-Mail: info@advancedcyclotron.com
Web: http://www.advancedcyclotron.com

Advanced Cyclotron Systems, Inc. (ACSI) is a world leader in the design and manufacturing of cyclotron systems. With over 25 years of experience and more than 50 cyclotron systems installed, ACSI can provide a wide range of equipment and services worldwide. ACSI cyclotrons are used for the commercial production and distribution of PET and SPECT nuclides by internationally recognized companies and leading universities and research facilities. ACSI cyclotrons are designed, manufactured, and assembled in Richmond, Canada.

ACSI offers a full spectrum of cyclotron systems ranging from PET cyclotrons to medium and high energy accelerators. All ACSI manufactured cyclotrons have variable energy and employ external ion source technology, offering the highest beam current output available on the market.

The versatility, high beam current and exceptional quality of ACSI cyclotrons are the reasons why many of the world’s most prestigious universities and research centres, as well as some of the most successful commercial radioisotope producers have chosen ACSI cyclotrons to meet their radioisotope production needs.

For more information, please visit www.advancedcyclotron.com
As a market leader in the fast-growing sector of enterprise-wide IT, Agfa HealthCare's IT solutions work across departments and disciplines. Integrating medical, nursing, administrative and business information, and streamlining workflows and operations, they allow care providers to increase their efficiency and effectiveness, resulting in improved quality of care, speed and cost-effectiveness.

Imaging systems
Agfa HealthCare's imaging systems are designed to bring vital information to medical professionals, wherever they are, within and beyond the healthcare enterprise. They capture, process and print diagnostic images from multiple sources and across a multitude of image-intensive specialties and departments, including radiology, cardiology, women's care and intensive care units.

Nuclear Medicine
Agfa HealthCare's Integrated Solutions for Nuclear Medicine offer clinicians a unique solution to fully integrate the Nuclear Medicine department's workflow and optimize the inter-departmental communications. Running on one workstation the solution supports the patient's entire exam flow, from arrival at the hospital, to the final distribution of nuclear medicine results, and includes specialized functionality to process, read and report all Nuclear Medicine, SPECT, PET, and multi-modality images.
AIMN, Italian Association of Nuclear Medicine and Molecular Imaging

Via Carlo Farini 81
20159 Milano
Italy
Phone: +39 266802323
E-Mail: segreteria@aimn.it
Web: https://www.aimn.it/

AIMN was founded in 1990 unifying two previous Societies, both born in 1956: the Italian Society of Medical Radiology (SIRM), which in 1956 assumed in its acronym a N to become the Italian Society of Medical Radiology and Nuclear Medicine (SIRMN) and the Italian Society of Nuclear Medicine and Biology (SIBMN), founded by leading Internists with a primary interest in Physiology and already working in Nuclear Medicine since late 40’s. Pivotal and pioneering events were in 1957 the publication of the first issue of Minerva Nucleare and in 60’s the creation of the first Schools of Specialization and of the first autonomous departments of Nuclear Medicine. Actually, AIMN is constituted by almost 800 members, regrouping the large majority of Italian Nuclear Physicians, in strict connection with all the Professionals involved in our field. AIMN is also a founding Member of the Italian Federation of the Medical Radiological Area (FiDESMAR). The scientific quality and the prestige of AIMN may be derived by the leading international role of many associated and by the qualified participation of many Italian members to the most important international scientific events in Nuclear Medicine and Molecular Imaging. Actually the President of AIMN is O. Schillaci, leading an Executive Committee constituted by L. Mansi, vice President, O. Bagni, M. Boero, M. C. Marzola, L. Evangelista and A. Garufo, with A. Cuocolo and T. Varetto as technical members.

AIPES - Association of Imaging Producers and Equipment Suppliers

Alliance Medical GmbH

Westring 168
44579 Castrop-Rauxel
Germany
E-Mail: info@alliancemedical.eu
Web: http://www.alliancemedical.de

Alliance Medical and Life Radiopharma provides medical imaging services across Europe in the UK, Germany, Ireland, Italy, the Netherlands, and Spain.

By uniting technical excellence and exceptional service in a business model that delivers outstanding value for money, we have enjoyed consistent growth for more than 25 years. We work collaboratively with clinicians, health care organisations and academic institutions to provide high quality and cost effective imaging for our customers and better services for our patients.

Alliance Medical has a proven track record of service delivery across both the publically and privately funded healthcare markets in Europe with an emphasis on quality and sustainability.
American Society of Nuclear Cardiology

4340 East-West Highway
Suite 1120
20814 Bethesda, Maryland
United States
Phone:  +1 301 215 7575
Fax: +1 301-215-7113
E-Mail: info@asnc.org
Web: http://www.asnc.org

The American Society of Nuclear Cardiology (ASNC) is the recognized world leader in quality, education, advocacy and standards in cardiovascular nuclear imaging, with over 4,000 members worldwide. ASNC is dedicated to continuous quality improvement, education and patient-centered imaging, illustrating the ongoing commitment as a leader in the field of nuclear imaging and improving patient outcomes. ASNC establishes standards for excellence in cardiovascular imaging through the development of clinical guidelines, professional education, advocacy and research development. ASNC’s members are comprised of cardiologists, radiologists, physicians, scientists, technologists, imaging specialists and other professionals committed to the science and practice of nuclear cardiology. Two upcoming ASNC meetings: ASNC’s 23rd Annual Scientific Session will be held in San Francisco, California, September 6-9, 2018 and NC Today will be held in Chicago, Illinois, April 20-22, 2018.

The Society will be celebrating its 25th Anniversary in 2018!

ANMI SA

Allée du Six Août 8
4000 Liège Liège
Belgium
Phone:  +32 4 366 3099
E-Mail: info@anmi.be
Web: http://anmi.be

ANMI SA is a precursor supplier for radiometal labeled radiopharmaceuticals and a global service provider in the nuclear medicine field, located in Liège, Belgium. ANMI has developed innovative solutions to facilitate the synthesis of these theranostic radiopharmaceuticals and to ease their daily production in hospitals.
ANMI SA has a strong expertise in peptide synthesis, and modification of peptides or antibodies focused at adding any linker and chelating agent.
The company’s expertise is based on a strong market and regulatory knowledge of the nuclear medicine area and can provide premium quality products and services.
ANMI’s R&D team is working on several new tracers for different applications such as neuro endocrine tumors or prostate cancer for imaging and therapeautic applications.

ARCCNM/AOFNMB - Asian Regional Cooperative Council for Nuclear Medicine/Asia Oceania Federation of Nuclear Medicine and Biology

Booth No. 367

Booth No. 318

Booth No. 363
AREVA Med / Macrocyclics

1 Place Jean Millier
92400 Courbevoie
France
Web:  http://www.arevamed.com

AREVA Med is a biotech company developing innovative therapies in oncology. AREVA Med has developed new processes for producing lead-212 (212Pb), a rare radioactive isotope used in Targeted Alpha Therapy. AREVA Med sponsored and completed the 1st phase 1 trial with 212Pb. Today, we are working with our partners and are looking for new partnerships to develop new 212Pb-based targeted therapies to address unmet medical needs. With two world class facilities in France and in the US, we are able to produce and supply 212Pb for preclinical and clinical development needs.

Macrocyclics, global leader in medical chelation chemistry applications acquired by AREVA Med in 2011, is dedicated to leading-edge innovation of new chelating agent platforms critical for the advancement of diagnostic & therapeutic medicine. The company maintains an extensive library of catalog products for basic and applied research clients as well as custom cGMP products to accelerate early stage and advanced clinical development programs. Macrocyclics also offers strategic services including consultation, site-specific bioconjugation, peptide synthesis or proteomic analysis. Macrocyclics has an established reputation for research & development specifically geared toward meeting the emerging needs of the medical community. Macrocyclics platform technologies are adaptable to a broad range of radionuclides such as 64Cu, 68Ga, and 89Zr for PET as well as therapeutic isotopes (177Lu, 166Ho, and 225Ac).

Arronax and ArronaxPlus

1 rue Aronnax
BP 10112
44817 SAINT HERBLAIN CEDEX
France
Phone:  +33 2 28 21 21 29
E-Mail:  arronax@cyclotron-nantes.fr
Web:  http://www.cyclotron-nantes.fr

Arronax is a cyclotron installed in Nantes/Saint-Herblain in 2009, as a result of a 10-years long scientific partnership between medicine and nuclear physics and is considered as unique by the international scientific community (high energy, high intensity, proton, deuteron, and alpha beams, pulsed alpha beam). Arronax is managed by a public interest group (GIP ARRONAX) whose members are CNRS, Inserm, Nantes University, Institute Mines Telecom, Nantes University Hospital, ICO cancer center, Ministry of Research (MESR) and Pays de la Loire Regional Council. Its mission is to run the high energy (70 MeV), high intensity (750 µA) cyclotron Arronax for research in nuclear medicine and related fields, industrial productions and training.

ArronaxPlus equipment (4 technological and scientific platforms) is driven by GIP Arronax involving five other partners: Subatech, CRCNA, Department of Nuclear Medicine, University Hospital of Nantes and ICO, CEISAM, CEMA-Oniris. It was held in the Equipment Financing Program of Excellence (Equipex) of Investments for the Future. With a budget of € 8 million for the period from 2012 to 2019, ArronaxPlus will make additional investments in existing facilities for the development of multidisciplinary research in nuclear medicine and radiolysis and make Nantes a global hub for R & D and promotion in these areas.

Atlanpole Biotherapies

Booth No. 234

Booth No. 403

Booth No. 403
Australian and New Zealand Society of Nuclear Medicine

PO Box 6178
Vermont South
Victoria 3133 Melbourne
Australia
Phone: +61 1300 330 402
Fax: +61 3 8677 2970
E-Mail: secretariat@anzsnm.org.au
Web: https://www.anzsnm.org.au/

The Australian and New Zealand Society of Nuclear Medicine (ANZSNM.org.au) was founded in 1969 and is the major professional society representing all those practising Nuclear Medicine in Australia and New Zealand. The Society includes physicians, physicists, radiopharmaceutical scientists, technologists, nurses, educators, industry representatives and others interested in the practice of Nuclear Medicine. The Society is distinguished by its inclusion of all different disciplines operating at all levels of office-bearer from President to state branch and Special Interest Group (SIG) membership.

ANZSNM has close ties with other professional groups in Nuclear Medicine including the Australasian Association of Nuclear Medicine Specialists (AANMS), which represents all practising nuclear medicine physicians and nuclear radiologists, and the Australasian College of Physical Scientists & Engineers in Medicine (ACPSEM), which represents medical physicists and radiopharmaceutical scientists. The Society welcomes others such as radiologists, cardiologists and medical and radiation oncologists to participate in the Society and be involved in this expanding area of healthcare.

In 2018 the ANZSNM annual conference will be part of the WFNMB 2018 Congress, to be held at the Melbourne Convention and Exhibition Centre, Victoria, Australia from 20-24 April 2018. More details at wfnmb2018.com.

Bayer AG

Müllerstr. 178
13353 Berlin
Germany
Web: http://www.bayer.com

Bayer: Science For A Better Life

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015.
Berthold Technologies GmbH & Co. KG
Calmbacher Str. 22
75323 Bad Wildbad
Germany
Phone: +49 7081 177-0
Fax: +49 7081 177-100
E-Mail: info@Berthold.com
Web: https://www.berthold.com/en/rp/home

BERTHOLD TECHNOLOGIES is located in Bad Wildbad, Germany. Since more than 65 years, we are developing and manufacturing high quality instruments for radiation protection. Berthold is worldwide established as a premium supplier of radiation protection instrumentation including customised solutions. High reliability and advanced technology are our key features. The portfolio comprises of:
- Radioactive contamination measurement
- Dose and dose rate for Gammas and Neutrons in continuous and pulsed fields
- Low Level counting
- Airborne radioactivity as aerosols, Iodine, noble gas and Tritium

In addition, we provide engineering, installation and commissioning of turnkey solutions in order to meet and exceed the specific requirements of nuclear facilities and PET centres.

We invite you to visit our exhibition booth 205 in Hall X2.

Best Cyclotron Systems
413 March Road
K2K 0E4 Kanata
Canada
E-Mail: marketing@theratronics.ca
Web: http://www.bestcyclotron.com/index.html

Best Cyclotron Systems manufacture a range of variable energy cyclotrons including 15MeV, 25MeV, 28MeV, 35MeV, and 70MeV. These cost-effective machines are customizable for users based on their needs, and have research, diagnosis, and treatment applications. It is currently the only company in North America that produces these cyclotrons. Included in the package with the cyclotron, we also provide targets, automated radiochemistry, infrastructure, operations and maintenance support. We recently finished installing and testing a collaborative project with the Italian National Laboratory for a 70MeV proton cyclotron.
Biodex Medical Systems, Inc.

20 Ramsey Road
11967 Shirley, NY
United States
Phone: +1 631-924-9000
Fax: +1 631-924-9241
E-Mail: info@biodex.com
Web: http://www.biodex.com/nuclearmedicine

Biodex Medical Systems, Inc. announces their next generation of Nuclear Medicine products: Atomlab 500 Dose Calibrator, Wipe Test Counter and combination unit, the Atomlab 500 Plus. Now featuring Windows 10 Operating System and Microsoft SQL database in addition to Atomlab software, the all-in-one smart-display takes these quiet, reliable workhorses to the next level.

The Atomlab™ 960 Thyroid Uptake System features unique positioning LED for accurate thyroid centering – a first in Thyroid Uptake System design. A complete, mobile, self-contained Medical Spectrometer System, the Atomlab 960 is an advanced multi-purpose spectrum analysis instrument designed for diverse nuclear medicine applications. The NEW optional DICOM Interface program integrates the Atomlab 960 with your hospital management system, streamlining workflow and improving communication.

Clear-Lead™ Mobile X-Ray Barriers are designed for use around any imaging procedure using ionizing radiation. The unique hour-glass contour of the Clear-Lead™ Personal Mobile Barrier provides “hands-on” patient access while providing radiation protection (0.5 mm LE) where it’s needed. Ideal for CT and PET/CT Suites, Clear-Lead™ Windows are the shatter resistant choice when a large undistorted radiation protection window is necessary.

The Biodex commitment to innovative excellence spans over 60 years. Their customer-driven support is why leading medical facilities around the globe call Biodex first. Visit

Biowin

Booth No. 318

Blue Earth Diagnostics Limited

Oxford Science Park
Magdalen Centre
Robert Robinson Avenue
OX4 4GA Oxford
United Kingdom
Phone: +44 (0)1865 784186
E-Mail: contact@blueearthDx.com
Web: http://www.blueearthdiagnostics.com

Blue Earth Diagnostics is a molecular imaging diagnostics company focused on the development and commercialization of novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. Formed in 2014, Blue Earth Diagnostics is led by recognized experts in the clinical development and commercialization of innovative nuclear medicine products. The Company’s first approved and commercially available product is Axumin™ (fluciclovine F 18), a novel molecular imaging agent approved in the United States and the European Union for use in PET imaging to detect and localize prostate cancer in men experiencing suspected biochemical recurrence. The Company is funded by Syncona Limited, an investment company listed on the London Stock Exchange (LON: SYNC). For more information, visit: www.blueearthdiagnostics.com.
British Nuclear Medicine Society

The Sir Colin Campbell Building
Triumph Road
NG7 2TU Nottingham
United Kingdom
Phone: +44 115 7484 504
E-Mail: info@bnms.org.uk
Web: https://www.bnms.org.uk

The British Nuclear Medicine Society (BNMS) established in 1966 is the only independent UK forum devoted to all aspects of Nuclear Medicine. The BNMS is concerned with promoting the clinical benefits of nuclear medicine and supporting the clinical practice, education, research and development of nuclear medicine within the UK. Membership is open to those who have a substantial interest and involvement in the provision of nuclear medicine services in the UK and overseas.

The official journal of the Society is Nuclear Medicine Communications.

Officers of the Society: Prof Sobhan Vinjamuri, President, Mrs Jilly Croasdale, Honorary Treasurer, Prof John Buscombe, President-Elect, Dr Richard Graham, Honorary Secretary.

At the BNMS booth, delegates can find:
- Information on BNMS membership – discount to new members signing up at the meeting.
- Information about future meetings in the UK
- BNMS Brochures and Publications
- Answers to any other questions regarding the BNMS

Pass by our stand for a chance to win Free attendance at our Spring Meeting 2018 which will be held at The ICC, Birmingham, UK on 14th – 16th April.

Bruker

Rudolf-Plank-Str. 23
76275 Ettlingen
Germany
E-Mail: raphaelle.diss@bruker.com
Web: http://www.bruker.com

Offering the largest range of Preclinical Imaging systems, Bruker is committed to supporting the scientific community with high-end instruments dedicated to disease research, translational science and Molecular Imaging. Our non-invasive in-vivo imaging modalities are designed to deliver greater scientific insight based on animal-centric solutions.

Bruker offers advanced preclinical imaging solutions for a broad spectrum of application areas, such as oncology, neurology, cardiology, inflammation, infectious diseases, functional and anatomical neuroimaging, orthopedics, cardiac imaging and stroke models. Our range of imaging modalities includes PET/SPECT/CT Imaging, MRI imaging, PET/MRI Imaging, and microCT imaging.
At BTG we are focused on bringing to market innovative products in specialist areas of medicine to better serve doctors and patients. Our growing portfolio of Interventional Medicine products is designed to advance the treatment of cancer, severe emphysema, severe blood clots and varicose veins, while our Specialty Pharmaceuticals portfolio offers antidotes that alleviate toxicity and treat rare conditions.

Healthcare is constantly evolving – so BTG never stands still. Inspired by a deep understanding of our customers’ needs, we’re working to meaningfully improve the lives of patients and their healthcare experience.

Our competitive advantage is our dedication to finding smart, often unconventional solutions to complex medical problems. Many of our products combine medicines, device technology and new techniques in order to deliver more targeted treatments. We also invest in the clinical evidence to help demonstrate the value of our products to doctors, patients, and healthcare systems.

Doing what’s right for patients is what gets us to work in the morning. It’s part of our DNA. By staying true to this principle and our values, we’ve earned a strong reputation for the quality of our products and our commitment to innovation.

Whether developed in our own labs or in partnership with clinicians, academics and other companies, we believe passionately that medical innovation has the power to improve human health.

Imagine where we can go.

BV Cyclotron VU

De Boelelaan 1081
1081 HV Amsterdam
Netherlands
Phone: +31 20 44 491 23
E-Mail: web@cyclotron.nl
Web: http://www.cyclotron.nl

BV Cyclotron VU (BVC) is founded in 1987 and located on the campus of the VU University Amsterdam, The Netherlands. We are a market-leading provider of radiopharmaceuticals and radionuclides used in imaging techniques such as SPECT and PET for medical diagnostics and research. We currently run three modern cyclotrons and several GMP-compliant production units for the production of our radiopharmaceuticals and GMP-grade radionuclides. Driven by our passion to create products that helps to improve patients’ lives, our company is strongly committed to R&D. We count on our cooperation partners for the safe and reliable distribution of our products.

Our product portfolio consists of: [18F]-FDG, Zirconium-89 [89Zr], Iodine-124 [124I], other 18F-tracers like Fluoromethylcholine, Florbetaben, and [81Rb/81mKr]-generators.

For more information, please visit www.cyclotron.nl
### C.CURIE bvba/sprl

**Booth No. 238**

Jan Dekinderstraat 29/3  
1731 Zellik  
Belgium  
Phone: +32 (0) 2 466 63 42  
E-Mail: sales@ccurie.be  
Web: [http://www.ccurie.be](http://www.ccurie.be)

C.CURIE offers now a wide range of products in the nuclear medicine field and is a business partner for introducing new technologies. The new technologies are dosimetry solutions for Lu, Y and others, Cherenkov detection and more important we sell and deliver service for the new CZT technology from Spectrum Dynamics for SPECT/CT gamma cameras.

### Cambridge Isotope Laboratories, Inc.

**Booth No. 251**

3 Highwood Drive  
1876 Tewksbury  
United States  
Phone: +1 9787498000  
Fax: +1 9787492768  
E-Mail: cilsales@isotope.com  
Web: [https://isotope.com](https://isotope.com)

Cambridge Isotope Laboratories, Inc. (CIL) is one of the world’s leading suppliers of 18O water and the preferred supplier to premier FDG providers. In response to the increasing needs of the PET community, CIL has undertaken multiple expansions of its 18O separation facility over the past few years. The combined synthetic expertise, cGMP experience and reputation for high-quality cGMP and non-cGMP nuclear medicine compounds and precursors allows CIL and its subsidiary, ABX Advanced Biochemicals, to offer complete PET chemistry solutions for the molecular imaging community. ABX is the leading supplier of PET precursors worldwide and also offers cGMP custom synthesis and development of labeling strategies for new tracers.

### Canadian Association of Nuclear Medicine (CANM)

**Booth No. 366**

P.O. Box 4383, Station E  
K1S 2L0 Ottawa  
Canada  
Phone: +1 613-882-5097  
E-Mail: canm@canm-acmn.ca  
Web: [http://www.canm-acmn.ca](http://www.canm-acmn.ca)

Please stop by the Canadian Association of Nuclear Medicine (CANM) booth (#366) for the latest information about the work of the Association and to learn more about the PANGEA Project and the publication of e-Le Patient.

Come to booth # 366 and register to receive this free e-publication aimed at giving information about nuclear medicine to referring physicians, patients and the general public. Printed copies of this publication will also be available at our booth. Please come and meet dynamic members of our Association! Bienvenue!
Capintec INC

7 Vreeland road
7932 Florham Park
United States
Phone: +1 2018259500
Fax: +1 2018251336
E-Mail: getinfo@capintec.com
Web: http://www.capintec.com

Capintec is a leading worldwide supplier of energy measurement products and services. Capintec is dedicated to continuous quality improvement that leads to uncompromising quality in the development of the most advanced technology and services in the industry.

For over 50 years, Capintec has been recognized as a world leader in the development, manufacturing and marketing of state-of-the-art radiation measuring and monitoring instrumentation. With thousands of instruments in use world-wide, the company continually provides new and innovative solutions to radiation measuring applications. By offering products with applications in Nuclear Medicine, Nuclear Cardiology, Oncology, Endocrinology, Diagnostic Radiology, and Radiation Therapy, the company continues to grow.

CASRAM SA

Via Cantonale 31
6805 Mezzovico
Switzerland
Phone: +41 91 611 21 10
E-Mail: info@casram.com
Web: http://www.casram.com

CASRAM is a Swiss producer of sintered Tungsten alloys.

From the powder metallurgy workshop down to the final inspection after machining according to your drawings, CASRAM provides the complete manufacturing process of any kind of radiation shielding devices.

Most common applications are vial containers, syringe shieldings, collimators, MLC's and other various shielding components.

CASRAM is certified by EN 9100, ISO 9001, ISO 14001, OHSAS 18001.
CBmed GmbH - Center for Biomarker Research in Medicine  
Stiftungtalstrasse 5  
8010 Graz  
Austria  
E-Mail: office@cbmed.at  
Web: http://www.cbmed.org

CBmed, a limited company owned by Austrian (medical) universities and research centers, is a federal funded competence center for excellence that was founded in 2014. CBmed links excellent research infrastructure (e.g. CoreLabs for metabolomics, NGS, proteomics, immunology, MALDI-MS and in-vivo imaging), scientific expertise and medical knowledge with national and international industry partners for systematic medical biomarker research.

CBmed brings together scientific experts with leading pharmaceutical, diagnostic, medical-technology and IT industry partners. In addition, CBmed has a strong network in the area of Biobanking including the largest Biobank in Europe, Biobank Graz, and became the first certified Expert Centre for the European Biobanking Research Initiative, BBMRI-ERIC.

Currently, the 25 running CBmed research projects are identifying new biomarkers, validating potential biomarkers and conducting translational biomarker research for products to be used in clinical practice. CBmed’s goal is to develop easily applicable, targeted, minimally invasive biomarkers for better diagnosis, better therapy monitoring and a more personalized treatment of patients. Therefore, combining multi-omics technologies with in-vivo molecular imaging is the ultimate aim.

CBmed COMBINES!
Visit our booth to find out more and explore cooperation opportunities!

Center of Molecular Research  
Booth No. 206

CHELATEC  
Booth No. 403

Chelatec is a private company founded in 2000, providing Research and Development services in Radiolabelling and Preclinical Studies. Areas of expertise include: Radiopharmaceuticals, Customized radiolabeling, Small animal studies, Binding assay, Immunoreactivity...Our three-years perspective: Business Units dedicated to the centralized manufacturing of Radiopharmaceuticals for clinical applications.
CHEMATECH
Booth No. 259
2 rue Pauline Kergomard
Parc Mazen-Sully
21000 Dijon
France
Phone: +33380441900
Fax: 33380441901
E-Mail: info@chematech-mdt.com
Web: http://www.chematech-mdt.com

CheMatech is a unique company in Europe specializing in the design and synthesis of bifunctional chelating agents such as DOTA, NOTA and NODAGA derivatives. These molecules are widely used for peptides or antibodies labelling especially with 67/68Ga, 111In, 64/67Cu. CheMatech offers a wide range of functionalized and protected chelating agents from milligrams to kilograms scale. CheMatech also realizes custom syntheses of new chelators.

Cisbio
Booth No. 260
Parc Marcel Boiteux
30200 Codolet
France
Phone: +33 466796811
E-Mail: fservent@cisbio.com

Cisbio Bioassays is a privately held life sciences company committed to improving human healthcare. With more than 30 years of experience in vitro diagnostics and drug discovery, we provide creative technological solutions and partnerships to the global scientific community. With more than 30 years of development in immunoassays (RIA and ELISA) in Oncology and Endocrinology, Cisbio Bioassays is a partner of choice for medical device in ELISA for specialized testing, like Chromogranin A, Hyaluronic Acid, N-terminal Procollagen III Peptide and S100A12.

Cisbio Bioassays has facilities in France, the United States, China and Japan, and a network of distributors across the globe.

The Exhibiting COMPANY’s main areas of activity are:
• Endocrinology
• Fertility
• Autoimmunity
• Tumors markers
CMR Naviscan Corporation

Booth No. 218

2720 Loker Avenue West Suite O
92010 Carlsbad, CA
United States
Phone: +1 877 260 1360
E-Mail: info@cmr-naviscan.com
Web: http://www.cmr-naviscan.com

CMR Naviscan Corporation develops and markets compact, high resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The CMR Naviscan Solo II High Resolution PET scanner is currently installed and available in breast imaging centers throughout the world. Through a unique combination of gentle immobilization, advanced photonics and image processing, the scanner provides tomographic images with a resolution as small as 1.6 mm, with Sensitivity and Specificity greater than 90 % for index lesions. PET-Guided Biopsy Accessory is available with the scanner. CMR Naviscan offers its products and services globally through a team of local representatives.

COMECKER GROUP

Booth No. 412

VIA MAESTRI DEL LAVORO 90
48014 CASTELBOLOGNE
Italy
E-Mail: marketing@comecker.com
Web: http://www.comecker.com

Comecker, founded in Castel Bolognese (Italy) in the mid 1970’s, is a world leader in protection technologies in the field of nuclear medicine, pharmaceutical isolation technology and nuclear power plant equipment. Comecker produces shielding systems and equipment for special applications, designed for large industrial groups and research organizations. We work for hospitals, universities and pharmaceutical companies on tailored projects for the production of isolators for the treatment of toxic substances to be kept in safety. For nuclear plant management, we produce equipment for the processing, deactivation and disposal of radioactive substances deriving from nuclear plants.

From 2012 Comecker is become a Part of Comecker Group after the takeover of the companies Veenstra and Vitrae Czech.

At present, the Group employs 280 people and has achieved a turnover of 55 million Euro in 2016. With two production sites in Castel Bolognese (Italy) and Joure (Holland), locations at Hradec Kralove (Czech Republic), Philadelphia (Usa), Dubai (Uae), Mumbai (India) and Taipei (Taiwan), Comecker markets its products in over 100 countries worldwide through a direct sales network and through partnerships with some of the largest producers of nuclear medicine equipment.
Crystal Photonics GmbH  
Albert-Einstein-Straße 16  
12489 Berlin  
Germany  
Phone: +49 30 34669300  
Fax: +49 30 34669299  
E-Mail: info@crystal-photonics.com  
Web: http://www.crystal-photonics.com

Crystal Photonics is engaged in Nuclear Medicine for highly qualified products of Molecular Imaging and for intraoperative and transcutaneous sentinel lymph node localization (SLNE) since 20 years. With our probes starts the also new PSMA-technology for Prostate Cancer. We present our very new Hand-Held-Gamma-Camera “CrystalCam” and the surgical Gamma Probe System “Crystal Probe - automatic” with our excellent “Wireless Probe”; various cable probes and a set of outstanding Laparoscopic Probes for minimal invasive surgeries (MIC). A wide range of miniaturized nuclear radiation detectors for synthesis modules and GRP-conform analysis of tracers completed our program. Latest development is the “CrystalAnalyzer” - a coincidence measuring system of positron-emitting tracers for application in the HPLC and small animal investigations, which don't need any shielding. For more information, please visit www.crystal-photonics.com

CSNM - Chinese Society of Nuclear Medicine  
West China Hospital, Sichuan University  
Add: No. 37 Guo Xue Xiang  
610041 Chengdu, Sichuan  
China

Chinese Society of Nuclear Medicine (CSNM) is a branch of Chinese Medical Association. In May 1980, the first National Conference of Nuclear Medicine was held in Shijiazhuang, Hebei province, and CSNM was found. CSNM devotes its great attention to nuclear medicine extend and application in China through academic promotion, professional training, government’s adviser, international exchange and related collaboration with other domestic and international associations.

CSNM consists of about 9000 members who come from 31 provinces across China and play very important roles in their local areas from establishing a new unit to developing a novel technology of nuclear medicine. Base on standing committee decisions, suggestions and CSNM’s guidelines, all of subcommittees and task groups carry out specialized works and projects dealing with clinical diagnosis, management and basic research for heart, lung, brain, bone, thyroid, kidney, liver, and many other organs and systems. CSNM makes great contributions in many fields to keep up a steady increase of nuclear medicine in China.
Curium

20 rue Quentin Bauchard
75008 Paris
France
Phone: +33 1 69 85 70 70
E-Mail: contactus@curiumpharma.com
Web: http://www.curiumpharma.com

Curium is a world-class nuclear medicine solutions provider with more than a century of industry experience. Formed by the merger of IBA Molecular and Mallinckrodt Nuclear Medicine LLC, Curium is the largest vertically integrated radiopharmaceutical product manufacturer in the industry.

With manufacturing facilities across Europe and the United States, Curium supports over 14 million patients around the world with SPECT, PET and therapeutic radiopharmaceuticals to provide potentially life-saving diagnostic solutions. The Curium brand name is inspired by the work of radiation researchers Marie and Pierre Curie and emphasizes a focus on nuclear medicine. To learn more, visit curiumpharma.com.

Cyclomedica Europe Ltd.

Unit A5 Calmount Business Park, Ballymount
12 Dublin
Ireland
Phone: +32 473 56 05 56
E-Mail: rvanloon@cyclomedica.com
Web: http://www.cyclopharm.com.au

Cyclomedica is a radiopharmaceutical company servicing the global medical community. The company's mission is to provide nuclear medicine- and referring physicians with the ability to improve patient care outcomes.

Cyclomedica is well-known for its Technegas Generator. For more than 30 years Technegas is the leading technology for the diagnosis of pulmonary-embolism with a valuable diagnostic contribution to the clinical management of patients suffering from other respiratory diseases like COPD and Asthma.

The Technegas technology produces radioactive labeled carbon nanoparticles, after adding Technetium-99m to a carbon crucible and heating it for a few seconds at around 2,700 °C. In as little as 2 to 3 breaths, a combination of nanoparticles in argon gas is inhaled by the patient via a breathing apparatus, which then allows multiple views and tomography imaging under a SPECT camera to diagnose various types of pulmonary and ventilation disorders.

Recent advances in camera hardware and software technology have created a new landscape for Technegas. The co-registration of SPECT and CT, have now given clinicians the ability to generate a ventilation and perfusion study that is quantifiable to the lobular level. The result is a diagnostic tool that provides quantifiable functional and structural imaging of the lungs.

NEW

During this EANM 2017, Cyclomedica will launch the Radioisotope Concentrator (ULTRALUTE). This device permits high specific activity elution, thereby exter...
CYCLOPHARMA
Booth No. 210

3 rue Marie Curie
Biopôle Clermont Limagne
63360 Saint Beauzire
France
Phone: +33 4 73 63 27 00
Fax: +33 4 73 63 27 05
E-Mail: contact@cyclopharma.fr
Web: http://cyclopharma.fr/fr/

Created in 2000, Cyclopharma is specialized in the development and the commercialization of molecular imaging solutions resolutely innovation-oriented, capable of characterizing diseases and adapted to patients’ specificities.

With more than 100 collaborators and a turnover of 20 millions euros, Cyclopharma is investing intensely in R&D and collaborative development. Thanks to a dense territorial grid, Cyclopharma has been starting its international development since 2015, with the objective of becoming the European leader of personalized medicine.

DDD-Diagnostic A/S
Booth No. 311

Dr. Neergaards Vej 5E
2970 Hørsholm
Denmark
E-Mail: info@ddd-diagnostic.dk
Web: http://www.ddd-diagnostic.dk

DDD Diagnostic A/S, based in Denmark, manufactures a range of gamma cameras from organ specific cameras to general purpose cameras. Until 2012, DDD Diagnostic A/S was an OEM manufacturer involved in the design and development of some of the most successful gamma camera systems used in the world. DDD has been in the market since 1987, and presently there are more than 2500 DDD-manufactured gamma cameras installed worldwide.

Today, DDD Diagnostic A/S develops and markets the gamma camera systems described below under its own brand name. DDD cameras are durable and reliable with small footprint and superb image quality.

• QuantumCam, a dual-head general purpose SPECT camera that can be used for routine nuclear medicine procedures and useful in hospitals with limited space
• CorCam, a dedicated cardiac camera with 90-degree fixed detector design that allows performance of prone- and supine cardiac imaging
• Solo, a small Field of View system for planar imaging that can be used for low and high energy isotopes
• Solo Mobile, a mobile small Field of View gamma camera that runs on battery and easily can be moved around the various hospital departments
• NephroCam, a large Field of View, single-detector camera for Radioisotope Renography

DDD-Diagnostic A/S is represented worldwide by independent local companies with exclusive rights for marketing, selling and servicing the products developed and manufactured under DDD Diagnostic’s ow
DIAsource ImmunoAssays SA

rue du Bosquet 2
1348 Louvain-la-Neuve
Belgium
Phone: +32 10849911
E-Mail: info@diasource.be
Web: http://www.diasource-diagnostics.com

30 years of experience in IVD (kits and instrumentation)

DIAsource ImmunoAssays®, an international diagnostic company based in Belgium, develops, manufactures and markets clinical diagnostic products in the field of endocrinology and infectious diseases.

We are committed to Vitamin D, including IVD and RUO Products. Our panel of assays allows the performant detection and measurement of various forms of Vitamin D metabolites: 25(OH) Vitamin D, 1,25(OH)2 Vitamin D.

Constantly looking for new technologies and applications, we put our expertise in the development of new antibodies and assays to measure relevant biomarkers. We are strengthening our position in the diagnostic market by validating our ELISA assays on our open automate. These innovation mark a turning point for our company, and makes of DIAsource, already renowned in the RIA market, a complete diagnostic provider.

We also provide selected instrumentation: we offer Elisa reader, washer and shaker, along with open and closed fully automated Elisa platforms helping our customers to automate their tests.

Present in more than 75 countries through his professional network of 80 distributors, DIAsource ImmunoAssays® also sells directly his own products and products from other selected manufacturers to IVD laboratories in some European countries.

In January of 2016 DIAsource ImmunoAssays® has been acquired by Anteo (www.anteodx.com).

DIXIT s.r.l.

Via Giacosa 38
10125 Torino
Italy
Web: http://www.widen.it

Dixit, a spin-off of the University of Turin and the Italian National Institute of Nuclear Physics (INFN), is a company specialised in imaging management within clinical trials.

It developed WIDEN (www.widen.it), a Web Service designed to make the management and review of imaging studies in clinical trials simpler, more effective and more reliable. In such a way trials can scale in size and statistical significance can be achieved in a short time.

Dixit works with leading international imaging and oncological societies and cooperative groups that use qualitative and quantitative imaging, especially PET, in their cancer treatment protocols.

Since 2012, WIDEN has been used in more than 20 multi-centre clinical trials, whose coordinating bodies reside in Austria, France, Italy and Switzerland. WIDEN users are located in 25 different countries and more than 200 clinical centres.

WIDEN is also suitable for retrospective imaging-based clinical trials, that could be simply configured and operated. Their data can be easily analysed, so as to quickly evaluate the results and design more ambitious, prospective trials to validate them.
DOSISOFT

45-47 Avenue Carnot
94230 CACHAN
France

Phone: +33 141242626
E-Mail: info@dosisoft.com
Web: http://www.dosisoft.com

Founded in 2002, DOSISOFT is a leading software editor specialized in RT Planning, Patient QA and Molecular Imaging. Over 160 centers in 18 countries use its comprehensive and innovative vendor-neutral solutions to treat patients suffering from cancer.

PLANET® Onco: solution to help Physicians in the implementation of Oncology techniques like Diagnosis, RT, Chemotherapy, Adaptive therapy with complete structure segmentations: GTV, BTV, CTV, PTV, OAR and quantified therapy monitoring from multimodal imaging (CT, MRI, PET, SPECT).

PLANET® Onco also provides advanced feature extraction and texture analysis for patient therapy response assessment and machine learning / radiomics studies.

PLANET® Dose: complete, versatile and high-performance software for personalized 3D dosimetry applied to Targeted Radionuclide Therapies in particular based on 90-Yttrium microspheres and 177-Lutetium. It provides pre & post-implementation dosimetry, estimation of time-integrated activity and allows comparison possibilities between treatment planning and validation control dose maps. Consolidation of multi-treatment stages is also available.

PLANET® Neuro: solution designed to increase accuracy and confidence in the diagnosis of neurodegenerative diseases especially Alzheimer, dementia with Lewy bodies, Parkinson and Epilepsy. It allows you to create your own database of normality with your SPECT/PET data.

Dutch Society of Nuclear Medicine

Emmastraat 2 A
4811 AG Breda
Netherlands

Phone: +31 850200625
E-Mail: info@nvng.nl
Web: http://www.nvng.nl

The Dutch Association of Nuclear Medicine (NVNG) was founded in 1968 and has a multidisciplinary character. Its members are predominantly from the disciplines of chemistry, pharmacy, physics, medicine and radiochemistry. The association currently has 420 members.

Aim:

Dutch Association of Nuclear Medicine aims the promotion of nuclear medicine, with particular attention to quality, such as the correct application of radioactive substances in the medical field, as well as scientific research and organizational and social aspects.

In co-operation with Kloosterhof Neer BV the Dutch Association of Nuclear Medicine publish:

• The Procedure Guidelines in Nuclear Medicine

With our first loose leaf edition appearing in 1988, our profession was already aware that the practice of Nuclear Medicine is not an arbitrary matter but that patients deserve that we perform diagnostics and treatment in an unambiguous and accountable manner.

There are three reasons that make this edition a rather special one.

o Firstly, this is not only a work of revision but also, with many new chapters, of complete renewal.

o Secondly, this will be the last edition to appear in print. With advancing digitization, revision will be done on a continuous, online and modular basis from now on.

o Thirdly, owing to surging interest in and from neighbouring nations, this revision has been published in English.
EARL - EANM Research Ltd

Schmalzhofgasse 26
1060 Vienna
Austria
Phone: +43 (0)1 890 44 27
Fax: +43 (0)1 890 44 27 9
E-Mail: earl@eanm.org
Web: http://www.earl.eanm.org

EARL is a 100% subsidiary of the EANM, founded in 2006 in order to promote research in the field of Nuclear Medicine and Molecular Imaging. Its focus is on enhancing quality of Nuclear Medicine Practice for the benefit of public health. In this regard EARLs main activity is the EARL FDG PET/CT Accreditation for providing a standard of PET/CT Scanner performance to harmonize the acquisition and interpretation of PET/CT Scans, which is essential in multi-centre trials as well as clinical practice.

To learn more about EARL please visit us at the booth!

ec² Software Solutions

3035 E. Patrick Lane
Suite 1
89120 Las Vegas
United States
Phone: +1 9738850904
E-Mail: dcarr@ec2software.com
Web: http://www.ec2software.com

ec² Software Solutions LLC., the leading software provider to the Molecular Imaging Community, recently acquired Numa LLC., a software company focused on developing and commercializing workflow and compatibility solutions for molecular imaging. Together, ec² and Numa provide innovative management solutions for cyclotrons, radiopharmacies, hot lab operations, image processing, archiving and reporting.

Nuclear Medicine Information System (NMIS) and BioDose:

These programs are used in the largest medical centers and outpatient imaging clinics to manage their Nuclear Medicine, Nuclear Cardiology and PET departments.

BioTrax QMS: This 21CFR Part 11 validated quality management system is used in PET and Pharma manufacturing facilities.

Radiopharmacy Management Information System (RMIS) and BioRx: These programs are used in radiopharmacies worldwide to manage the production and distribution of radioactive isotopes.

NumaStatus: NumaStatus is a web based application that is optimized to accurately and easily report the patient's radiation dose for nuclear medicine and PET procedures in a DICOM format.

NumaLink: NumaLink is a valuable tool for exchanging patient studies between nuclear medicine computer systems or nuclear medicine and PACS.

NumaStore: NumaStore provides a robust, reliable, and user-friendly image
Eckert & Ziegler Radiopharma Segment

Robert-Rössle-Straße 10
13125 Berlin
Germany
E-Mail: info.radiopharma@ezag.de
Web: http://radiopharma.com/

Eckert & Ziegler Radiopharma is a business division of the Eckert & Ziegler group, with headquarters in Berlin, Germany. We are specialized in the field of nuclear medicine and molecular imaging. Our core competence is the provision of pharmaceutical services as well as versatile, innovative and high-quality technical solutions. Our product portfolio consists of radiochemicals, radiopharmaceuticals (Yttriga and GalliaPharm – the world’s first pharmaceutical grade GMP Ge-68/Ga-68 Generator), a wide range of radiosynthesis technology (Modular-Lab), radiochromatography equipment and accessories.

Our expertise in trivalent metals for Theranostics purposes empowers us to support ambitious startups and institutions with knowhow, technical and radiochemical support as well as financial assistance.

Our well established network of production sites produces different radiopharmaceutical products for compound labeling. Furthermore, we offer contract manufacturing of medicinal products or components for clinical trial supply as well as commercial purposes.

Eckert & Ziegler Isotope Products

www.ezag.com
isotope@ezag.com

Eckert & Ziegler Isotope Products offers the world’s largest range of sealed radiation sources for quality control in nuclear imaging, therapeutic radiology and biomedical applications. Products include Co-57 flood sources, OEM-quality replacement Ge-68 and Gd-153 sources for PET and SPECT applications, a complete range of multi-modal markers and other reference or calibration products necessary for today’s nuclear medicine departments.

Eczacibasi Monrol Nuclear Products

Barbaros Mh. Sutcuyolu Cad. No:72/A Atasehir
34746 Istanbul
Turkey
Phone: +90 216 544 0 544
Fax: +90 216 472 4148
E-Mail: info@monrol.com
Web: http://www.monrol.com

Eczacibasi Monrol Nuclear Products has been leading the development of the Turkish Nuclear Medicine market with the production of high-quality radiopharmaceuticals as a market leader and is the first company carrying out radioisotope R&D activities in Turkey.

Eczacibasi Monrol has 10 world-class production facilities, 6 in Turkey and 4 international (Bulgaria, Poland, Romania, Egypt) employing modern and environment-friendly technologies. The company also has been operating cyclotrons in Kuwait, United Arab Emirates and Ankara. Both local and international facilities are utilized by a range of PET and SPECT products complying fully with all national and international regulations related to its manufacturing and service activities, including current GMP, to ensure that its products are of the highest quality.

Along with its production capabilities Eczacibasi Monrol also offers global brands to Turkish Nuclear Medicine Market via its strong distribution channels. For the international market, Eczacibasi Monrol does not only export over 35 countries but also is the solution partner supplying start-up, operational and hand-over services.
Edizioni Minerva Medica

Corso Bramante, 83
10126 Torino
Italy
Web: http://www.minervamedica.it

Edizioni Minerva Medica S.p.A. publishes some forty scientific journals which are indexed by the most important international bibliographic databases. Many of them are the official organs of important Italian and foreign medical societies.

The Minerva Medica catalogue lists over 1,500 scientific titles which target medical students, physicians and nurses and they represent a benchmark in scientific literature for all medical and surgical specialties.

Today the third and fourth generations are perpetuating the tradition of the founder faithful to his belief that it is best if a publisher of medical books and journals always remains in touch with clinical reality. On these sound foundations, Minerva Medica plans a future packed with new ideas and new projects fully abreast of the times.

EITA

Maastraat 17/19
2800 Mechelen
Belgium
E-Mail: info@eita.org
Web: http://www.eita.org

EITA is a non-profit association, which was founded in 1998 by European logistics companies, trained, licensed and specialized in handling and transport (by Road, Air and Sea) of radioactive isotopes, which are mainly used for medical purpose and / or research.

The key objectives of EITA:

• To perform all activities related to the handling, packing and transport of radioactive isotopes in full compliance with the highest levels of safety and security taken into account the requests and the demands of the industry including public health care. In order to guarantee this commitment all our members obtained the EITA Quality label.

• To represent our members and the industry at national, international and European meetings aiming for harmonized and clear regulations, taking into account the developments in the industry.

• To provide a forum for our members by means of meetings, symposia, conferences to exchange information and to get updated with the latest changes and developments in the world of radioactive isotopes.

• To increase the awareness of the public in relation to the handling, transport and use of radioactive isotopes.

• To keep permanent contact with the industry and competent authorities to be able to react immediately to any upcoming change in the market as well as to any change in the legal environment.

Contact persons during the conference: Mr. Serge Goossens
Elimpex-Medizintechnik GesmbH

Spechtgasse 32
2340 Mödling
Austria
Phone: +43 2236 410450
Fax: +43 2236 410459
E-Mail: info@elimpex.com
Web: http://www.elimpex.com

Elimpex-Medizintechnik offers a full range of innovative solutions for Nuclear Medicine, Diagnostic Radiology, Radiation Therapy and Radiation Safety.
We offer:
• Software solutions
• Measurement systems for Diagnosis, Radiation Safety, Monitoring
• Hot lab and iodine therapy equipment

Elysia S.A.

Cyclotron, Allée du Six Août 8 (B30)
4000 Liège
Belgium
Phone: +3242427850
E-Mail: info@elysia-raytest.com
Web: http://www.elysia-raytest.com

Elysia-raytest is a solution provider for radio-pharmaceutical producers and nuclear medicine departments. We provide radio synthesis units, LIMS solutions, services, chromatography and quality control systems to nuclear medicine departments and to radio-pharmaceutical industries.
We design, manufacture, sell and service instruments used for the measurement of radioactivity and quality control, in close collaboration with radiopharmaceutical providers to develop new products and improve existing solutions.
Our mission is to make the measurement of radioactivity, the peptide labelling and quality control of radiopharmaceuticals easier, faster and safer.
To find out how Elysia can help you, please visit us at booth 317 or check our website.
EPSILON ELEKTRONIK SAN. VE TIC. A.S

19 MAYIS MH DR SEVKET BEY SK NO:3/A SISLI
34360 ISTANBUL
Turkey
Phone: +90 212 219 56 57
Fax: +90 212 219 82 22
E-Mail: info@epsilonsources.com
Web: http://www.epsilonsources.com

Epsilon Elektronik was established in 1993 to provide sales, marketing, and technical service activities in the healthcare sector. The company has initiated its product research and development activities in 2008 and started to produce high-quality Ge-68 quality assurance sources for PET and PET-CT systems.

In 2013, ERS (Epsilon Radioactive Sources) brand name was established and started to produce nuclear medicine quality assurance sources under this brand name. The company has enriched its product range by adding PET and PET-CT quality assurance sources for other major OEM manufacturers, Co-57 flood sources, dose calibrator reference sources, spot markers, rod sources in 2014 respectively. ERS serves high-quality radioactive source products including PET and PET-CT sources, dose calibrator sources, flood sources, spot markers and rod sources for the nuclear medicine market in Europe, Middle East, South Africa and Far East countries through its specialized distributor network. ERS continues to invest in research and development activities of ERS in order to develop new and customized sources and sustain international growth.

EUROMEDICAL INSTRUMENTS

3 rue de l’Arrivée
CIT - BP 241
75749 Paris Cedex 15
France
Phone: +33 (0) 983 62 63 17
Fax: +33 (0) 972 38 81 35
E-Mail: sales@em-instruments.com
Web: http://www.em-instruments.com

EUROMEDICAL Instruments sarl is the exclusive worldwide sales and marketing company of the Europrobe, a state-of-the-art surgical gamma probe manufactured by EUROAD SA, Strasbourg, France, one of the main manufacturers in the world for this type of equipment.

EURORAD SA, founded in 1982 (based in France) is a high technology company specialised in R&D, Service and Production of mono and polycrystalline semiconductors for radiation detectors.

The Europrobe has specifically been designed to meet the needs of surgeons and nuclear medicine physicians. It enables to accurately detect areas of increased radionucleotide uptake. Europrobe is unsurpassed in its ability to detect a wide range of isotopes, and is ideal in a wide range of applications including, radioguided surgery, sentinel node detection, direct detection of labeled cells…

With a single Readout Module and a whole range of gamma probe options, Europrobe fulfils all the needs of per-operative and percutaneous detection within 7 major clinical fields: Breast, Gynaecology, Dermatology, Head & Neck, Endocrinology, Urology and Nuclear medicine.

Furthermore, a Fluorescent detection modality was recently added via an add-on module, which in combination to the core gamma detection, enables to reach close to 100% detection of sentinel nodes, and thus fulfils standard of care’s dual detection obligation.

Europrobe systems are commercialised in 67 countries worldwide, including the USA, and since
European Federation of Radiographer Societies (EFRS)  
Booth No. 350

Catharijnesingel 73  
3511GM Utrecht  
Netherlands  
Phone: +31 118640703  
E-Mail: info@efrs.eu  
Web: http://www.efrs.eu

The EFRS is a non-profit organisation, set up by professional societies that represent radiographers in the geographic continent Europe. The role of the EFRS is to represent, promote and develop the profession of radiographers in Europe, within the whole range of medical imaging, nuclear medicine and radiotherapy.

European Institute for Biomedical Imaging Research (EIBIR)  
Booth No. 362

Neutorgasse 9  
1010 Vienna  
Austria  
Phone: +43-1-533-4064-13  
E-Mail: office@eibir.org  
Web: http://www.eibir.org/

The European Institute for Biomedical Imaging Research (EIBIR) supports researchers and industry partners in the coordination of biomedical imaging research throughout Europe and beyond. EIBIR offers expert advice, professional project management and coordination, dissemination and exploitation services for dedicated international collaborative research projects and clinical studies. Since its foundation in 2006, EIBIR has helped biomedical imaging researchers gain almost €80 million in funding. As a non-profit organisation, EIBIR provides its proposal preparation and project management services to researchers on an institutional membership basis. For a moderate annual fee, researchers within an institution can avail of EIBIR’s experienced and expert support. EIBIR currently has more than 80 institutional members from 20 countries across Europe.

European Society of Radiology (ESR)  
Booth No. 204A

Neutorgasse 9  
1010 Vienna  
Austria  
Phone: +43-1-533-4064  
E-Mail: office@myesr.org  
Web: http://www.myesr.org/
GAEDE Medizinsysteme GmbH

Im Moos 6
D-79112 Freiburg
Germany
Phone: +49 (0)7665-93457-0
Fax: +49-(0)7665-93457-20
E-Mail: info@gaede.de
Web: http://www.gaede.com

For more than 25 years GAEDE has been known as the company in Germany that develops, produces and distributes its own nuclear medical systems and software. The production center is located in Freiburg, in the south west of Germany. Having regional marketing and service centers as well as distributing companies abroad, GAEDE provides service for many installed systems in Germany, Austria, France and Switzerland as well as in other countries. With the development of new completely digital detector electronics and a dual detector SPECT system with variable detector positioning the production focus has now shifted to these systems, with interest from customers all over the world. For certain camera systems of other manufacturers GADE offers the refurbishment of detectors and modernization of the nuclear medical processing system.

Range of Products

- **GKS-2000** Dual Head SPECT Camera 54 cm x 40 cm
- **GKS-2000** Cardiac Dual Head Cardiac Camera 37 cm x 21.5 cm
- **GKS-1** Thyroid Camera 18 cm x 18 cm
- **GKS-1000** SPECT Camera 54 cm x 40 cm
- **GKS-400** Planar Camera 40 cm x 40 cm
- **GKS-300** Medium Field Camera 30 cm x 30 cm
- **GKS-200** Small Field Camera 22 cm x 22 cm

For more details please visit our website: www.gaede.com

GE HEALTHCARE

Chalfont St.Giles
HP8 Buckinghamshire
United Kingdom
Web: http://www.gehealthcare.com

GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter – great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients. For more information about GE Healthcare, visit our website at www.gehealthcare.com.
The German Society of Nuclear Medicine (DGN e.V.) is a scientific society with headquarters in Göttingen. Its goal is to promote nuclear medicine in basic and applied research in the fields of diagnostics, therapy, and radiation protection. This is done at national and increasingly at international level too. The DGN e.V. has about 1,500 members, including not only specialists in nuclear medicine and physicians from other disciplines but also engineers and scientists. Its president is Prof. Dr. Bernd Joachim Krause from the Department of Nuclear Medicine, University Hospital Rostock.

For more information, please visit www.nuklearmedizin.de

Getinge La Calhène is part of the Getinge group and has developed innovative solutions complying with safety, security, reliability and performance constraints. The equipment designed, manufactured and serviced by the company contributes to the safe transport of fissile materials / pharmaceutical materials and protection of operators in the nuclear and pharmaceutical industries.

DPTE® patented transfer solutions are installed in hot cells, on isolators and pharmaceutical production lines throughout the world. Our DPTE® equipment ensures secure, ultra-clean transfer of sterile and/or toxic materials, into and out of clean zones. It is the industry standard for transfer of aseptic or toxic products in nuclear and biomedical research institutions and the pharmaceutical industry globally.

Leak-tight bi-directional transfer is assured with our wide range of Beta parts including re-usable containers (PE, stainless steel), tubing and DPTE-BetaBag® in a variety of diameters, volumes and materials to suit a variety of applications.

La Calhène supplies the nuclear industry and nuclear medicine laboratories with a complete range of remote manipulators for all standard and specific applications, from the small capacity MA 30 to the large capacity MT 200 (telescopic type), including the MT 200 TAO computer-assisted remote manipulator with robotic function. Isolators, shielded casks (PADIRAC and AGNES) and glove box equipment complete the company’s range.
Hake Medical Technology (Beijing) Co. Ltd.  

Building 6 No. 9, Tianfu Road  
Biomedical Industrial Park  
Daxing District  
102600 Beijing  
China  
Web: http://www.hake.net.cn

Hake Medical Technology (Beijing) Co., Ltd. is a publicly listed (Stock Code: 837371) professional company in providing one-stop solution for medical radiation. For its innovative products and services, Hake Medical was awarded as National High-tech Enterprise and Zhongguancun High-tech Enterprise, the only company awarded the honor in the industry. Hake Medical focused on providing radiation protection and shielding to nuclear medicine, radiology, radiotherapy and MRI department, as well as detection and monitoring of radiopharmaceuticals.

Hake Medical was founded in 2005, with headquarter in Biomedical Industrial base in Beijing and branch covering main cities of China.

Hellenic Society of Nuclear Medicine and Molecular Imaging (HSNM&MI)  

Ippokratous 44-46  
106 80 Athens  
Greece  
Phone: +30 210 5238777  
Fax: +30 210 5203 710  
E-Mail: info@nuclear-medicine.gr  
Web: http://www.nuclear-medicine.gr/

Hellenic Society of Nuclear Medicine and Molecular Imaging (HSNM&MI) was founded in 1968, as Greek Society of Nuclear Medicine and Biology, by the renowned Honoured Member of the Academy of Athens for Sciences and Philosophy, Professor of Medicine V. Malamos. It is one of the oldest European societies in nuclear medicine and its membership now numbers approximately 400.

Society Mission:
• Expert Consulting for the Greek State that guides and constructs Regulations and Institutions in Nuclear Medicine, like Education, Retraining, Radiation Protection and Dosimetry.
• Actions to ensure the education to Nuclear Doctors, training in the highest possible level and creating the right conditions for continuous education of its members. Simultaneously provide continuous training to trainees and all health professionals working in the field of nuclear medicine.
• Creates committees which are referring and recommending to the Board of Directors issues and solutions affecting the Nuclear Medicine.
• Protecting and establishing the spiritual property of its members.

Nuclear Medicine Departments in Greece:
• 25 departments in the public hospitals and even more departments in private hospitals
• 12 PET-CT cameras (in both public and private practice departments).

International Congresses hosted by HSNM&MI:
• European Nuclear Medicine Congress (Athens, 1970’s)
• 19th EANM Congress (Athens, 2006)
• 5th BCNM Congress (Thessaloniki, 2016)
• Candidate for 14th WFNMB (Athens, 2026)
Hermes Medical Solutions AB
Booth No. 301

Skeppsbron 44
111 30 Stockholm
Sweden
Phone: +46 (0) 8 19 03 25
Fax: +46 (0) 8 18 43 54
E-Mail: info@hermesmedical.com
Web: http://www.hermesmedical.com

Recognised for over 40 years for Clinical Excellence and Innovation in Molecular Imaging, HERMES Medical Solutions delivers end to end Clinical Workflow for the integration, visualization, processing, reporting and archiving of imaging data from multiple modalities within Molecular Imaging and Radiology. Our solutions enable physicians to provide faster and more accurate diagnosis and more effective treatment of patients, thereby improving patient outcome and increasing efficiency.

HERMES Medical Solutions’ leadership within Molecular Imaging has been built upon technological innovation, financial stability and, historical success. We are committed to the continuous development of cutting-edge software solutions for clinical environments, academic institutions and industry partners. HERMES Medical Solutions offers the most comprehensive Enterprise Molecular Imaging solutions available for diagnosis and treatment planning, making Precision Personalised Medicine a reality.

We look forward to welcoming you to booth 301

Hidex Oy
Booth No. 406

Lemminkäisenkatu 62
20520 Turku
Finland
Phone: +358 107435570
E-Mail: marja.lindell@hidex.com
Web: http://hidex.com/

Hidex is a high technology company which develops and manufactures high performance analysis equipment for life science research, radiation measurement and nuclear medicine. Our products utilize modern technology and excellent tradition of workmanship. With strong links to the scientific community we continue to innovate and develop to improve scientific research and safety of everyday life.

For Nuclear Medicine applications Hidex offers Oxygen-15 labelled water generator systems. Oxygen-15 water is the gold standard in blood flow studies. Cardiac imaging and PET/MRI applications are convenient, safe and easy with the automated Hidex Radiowater Generator.

During the EANM’17 Hidex is proud to present our Automatic Gamma Counter. The touch screen operated compact and powerful counter is specifically designed for PET and Nuclear medicine applications as well as small animal imaging applications. The system can even be equipped with an on board balance for automatic reporting of activity per mass or volume.
Hoy Scandinavian

Jacob Møllersgade 4
9560 Hadsund
Denmark
Phone: +145 702 710 97
E-Mail: info@hoyscandinavian.dk
Web: http://www.hoyscandinavian.dk

Our focus is to supply Nuclear, PET and Radiochemistry departments with high quality products and equipment.

The Export marked.
With our own product line "HOY Exclusive", we offer shielding products for radiation protection in general. Our products all have a timeless Scandinavian design and offers ergonomic comfort, and are aligned with European standards.

"HOY Exclusive", are offered worldwide through our highly qualified dealers.

Our Home marked
In Scandinavia, we supply both "HOY Exclusive" and we proudly represent some of the major brands within Nuclear Medicine and Radiochemistry.

We manage the development of customized assignments such as desk, wall, waste covering and customer-made lead glass. Hot cell alteration and moving of radiochemistry departments.

As a part of representing major brands, we also offer routine equipment service.

Our history.
In 1993, the company HOY Scandinavian was founded in Denmark. The company has grown over the years and is today an established expert within its field.

Probably the best shielding in the world.

Contacts: Erik Troue Jensen E*MBA, CEO, Sales and Project Management; Ole Høj, Senior Adviser, Sales and Product Management; Annie Borgersen, Sales assistant

Huayi Isotopes Company

4438 Sheppard Ave East, unit 377
M1S 5V9 Toronto
Canada
Phone: +1 6472982102
E-Mail: antony@huayi-isotopes.com
Web: http://www.hic.cc

Jiangsu Huayi Technology Co., Ltd. (Huayi Technology), was established in 2001 as a high-tech and innovative enterprise in Jiangsu, China. Huayi Technology is engaged primarily in research, development and production for emerging industries. Our products and services are focused in these categories: Active Pharmaceutical Ingredients (APIs), medical isotopes, reagent kits, sterile vials, radiopharmaceuticals and radioactive tracers. Our API production process follows cGMP standards and is approved by United States Food and Drug Administration (FDA). Our radiopharmaceutical cGMP facility is certified by the Chinese FDA.

Huayi Technology has established a Radioisotope-Labelling Research Center and Molecular Imaging Research Institute equipped with IBA cyclotron, Micro-PET/CT and SPECT/CT, dedicated to the development of new types of tracers as well as the screening and evaluation of new drugs. This facility has significantly shortened the development cycle of new drugs and reduced research and development costs.

We have completed the national 863 Program (or State High-Tech Development Plan), the “Torch Plan” (Torch Program: Promoting Innovation and High-Tech Industrialization), and the provincial Achievement Transformation program. We are recognized by the Chinese Natural Science Foundation and other technology projects.
IASON GmbH
Feldkirchner Strasse 4
8054 Graz-Seiersberg
Austria
Phone: +43 316284300
Fax: +43 3162843004
E-Mail: office@iason.eu
Web: http://www.iason.eu

IASON is a leading specialist supplier for nuclear medicine application and in the production of PET tracers. By means of constant further development and practice-oriented cooperation with medical institutions, we deliver top quality products and make available our know-how to numerous satisfied customers all over Europe.

The core competencies of IASON include concepts for the distribution of pharmaceuticals with a very short shelf-life and for the increase in efficiency of the process sequences. Furthermore, we implement safety tools in the case of radioactivity and to guarantee modern hygienic standards for the handling of pharmaceuticals. Further areas of competence of IASON include the oncology (early detection and treatment of cancer etc.), the neurology (diagnosis and surgical planning) and the cardiology (detection and treatment of heart diseases). Each area has an investment volume of 4 to 10 billion USD.

In addition, IASON supplies highly sensitive immunoassays to medical institutions, which are used in the diagnosis and treatment of many diseases.

IBA
Chemin du cyclotron,3
1348 Louvain-la-Neuve
Belgium
E-Mail: info-cyclo@iba-group.com
Web: http://www.iba-radiopharmasolutions.com/

Based on longstanding expertise, IBA RadioPharma Solutions supports hospitals and radiopharmaceutical distribution centers with their in-house radioisotopes production by providing them global solutions, from project design to the operation of their facility. In addition to high-quality technology production equipment, IBA has developed in-depth experience in setting up GMP radiopharmaceuticals production centers.

Our main products:
Cyclone® KUBE is a fixed-energy cyclotron that accelerates negative ions up to 18 MeV and that host up to two proton sources.

Synthera®+ is a multi-purpose automated synthesizer for the production of 18FDG, other compounds (18FCH, 18FLT, Na18F, 68Ga peptides ...). This smallest available module on the market is designed to accommodate a wide range of radiochemistry processes.

IntegraLab® is a fully integrated solution combining equipment and services for the development of Radiopharmaceutical Production Centers.
IDB HOLLAND BV, an Advanced Accelerator Applications company

Weverstraat 17
5111 PV Baarle-Nassau
Netherlands
Phone: +31 135079558
E-Mail: sales@idb-holland.com
Web: http://www.idb-holland.com

Founded in 1982, IDB Holland is a leading manufacturer and worldwide distributor of Lutetium 177 (LuMark® Lu-177 chloride). IDB Holland also provides radiopharmaceuticals, radioactive sources for PET/SPECT calibrations, and custom made products for Industry, Research Laboratories and Nuclear Medicine Departments. IDB supplies customers in over 40 countries in Europe, Africa, Asia, Australia, South America, the United States and Canada.

IDB was acquired by Advanced Accelerator Applications (NASDAQ:AAAP), an innovative radiopharmaceutical company that develops, produces and commercializes innovative diagnostic and therapeutic molecular nuclear medicine products in 2016. AAA currently has 21 production and research & development facilities, and over 500 employees in 13 countries.

AAA is an established leader in molecular nuclear diagnostic radiopharmaceuticals for PET and SPECT. AAA currently markets 9 radiopharmaceuticals (8 in Europe and 1 in the US) mainly used in clinical oncology, cardiology and neurology.

AAA is also developing a pipeline of theragnostic pairings for oncology indications. The company’s theragnostic platform involves radiolabeling a targeting molecule with either Ga-68 for diagnostic use, or Lu-177 for therapy. AAA’s first theragnostic pairing addresses neuroendocrine tumors, an orphan indication. The diagnostic drug, marketed as NETSPOT® in the US or SomaKit TOC™ in Europe, is approved for use; while*
IZOTOP is the major Hungarian centre for the research, development and production of radioisotopes and other products for a broad range of application areas, especially healthcare, research and industry. Hundreds of products manufactured in our facilities and distributed worldwide.

Company operates in accordance with ISO 9001 and ISO 14001 QA system. We have GMP Certificate for pharmaceutical preparation and ISO 13485 standard for design, production and distribution of radioactive immunoassay kits.

Products / Services:
- Sm-153 -labelling MULTIBONE kit for pharmaceutical preparation
- Ready to take part in R&D and manufacturing of active pharmaceutical ingredients, cold kits as well as investigational products for clinical trials.
- Immunoassay kits for diagnostic (thyroid, tumour markers, protein hormones etc.) and research purposes (RIA/IRMA and ELISA)
- Organic compounds labelled with C-14 or H-3 radioisotopes / Custom radiosynthesis / Service for GMP syntheses of C-14 labelled APIs or Drug Substances / Radiochemical repuriﬁcation service
- Ir-192 and Co-60 industrial sources / Laboratory and industrial gamma irradiators / Hot cells/ Containers for transportation of radioactive material

Inter Medical Medizintechnik GmbH

Daimlerstraße 34-36
32312 Luebbecke
Germany
Phone: +49 (0) 5741 2359-0
Fax: +49 (0) 5741 2359-10
E-Mail: contact@IntMed.de
Web: http://www.intmed.eu/

The Inter Medical Medizintechnik GmbH Company is specialized in medicine software and hardware with the focal point in Nuclear Medicine technique.

Long time experience in product innovations, development and production of Nuclear systems make Inter Medical to a competent partner for all technical requirements in the Nuclear Medicine and other medical departments. Quality on each step of our business is our main goal, also expressed through the certifications for the European ISO standard given to Inter Medical.

Visit our booth to see how we can enhance your institute with our product portfolio of 1-2-3-n Head Gamma Cameras.
### International Atomic Energy Agency (IAEA)

**Booth No. 364**

Wagramerstrasse, 5  
Vienna International Center  
A-1400 Vienna  
Austria  
Phone: +43 1 2600 00000  
Web: [http://www-naweb.iaea.org/nahu/NM/about.html](http://www-naweb.iaea.org/nahu/NM/about.html)

The IAEA is the world’s center of cooperation in the nuclear field. It was set up as the world’s “Atoms for Peace” organization in 1957 within the United Nations family. The Agency works with its Member States and multiple partners worldwide to promote safe, secure and peaceful nuclear technologies. The IAEA Secretariat is headquartered at the Vienna International Centre in Vienna, Austria. The mission of the Section of Nuclear Medicine and Diagnostic Imaging (NMDI) of the Division of Human Health: “The Agency shall seek to accelerate and enlarge the contribution of atomic energy to peace, health and prosperity throughout the world.” It has the specific mission of fostering the application of nuclear medicine techniques as part of the clinical management of certain types of diseases. Different activities are run under this subprogram: Coordinated Research Projects (CRPs); Expert Meetings to advise the Agency on specific topics; Publications and Manuals, including educational material, and creation of educational website and databases. Also, the section manages projects related to quality improvement in the clinical practice of nuclear medicine.

### INVIA Medical Imaging Solutions

**Booth No. 227**

3025 Boardwalk Street  
Suite 200  
48108 Ann Arbor, Michigan  
United States  
Phone: +1 734-205-1231  
E-Mail: info@inviasolutions.com  
Web: [http://www.inviasolutions.com](http://www.inviasolutions.com)

With a foundation of clinically validated algorithms, 4DM provides advanced cardiovascular quantification and image displays in a single, configurable application which has been commercially available for more than 15 years. 4DM is integrated with all major scanner and PACS environments. 4DM is also available as stand-alone software that can be installed on Windows laptops and PCs.

Based in Ann Arbor, Michigan, INVIA is dedicated to advancing patient care by developing state-of-the-art, non-invasive cardiology imaging software solutions. Physicians use our software, 4DM, to accurately quantify, review, and report cardiac perfusion, function, and anatomy. 4DM originated at The University of Michigan, an institution devoted to excellence and leadership. Today, INVIA preserves close-ties to the University and remains dedicated to quality; committed to accuracy; and devoted to 4DM customers.

Visit us at booth #227 in Hall X2 to explore 4DM’s latest features, including all-new reporting and enhancements for PET – the new Inflammatory protocol as well as enhanced CFR review for PET and SPECT.

For more information, visit [www.inviasolutions.com](http://www.inviasolutions.com)
Invicro Booth No. 207

27 Drydock Avenue  
7th Floor West  
2210 Boston  
United States  
Phone: +1 6179042100  
E-Mail: info@invicro.com  
Web: http://www.invicro.com

We are the quantitative imaging experts working across the entire drug development spectrum to better diagnose, characterize, treat and cure disease. Invicro is leading innovation to elucidate biological processes for our pharmaceutical and biotechnology partners around the world. Based in Boston, MA, Invicro was founded in 2008 with the mission of improving the role and function of quantitative imaging in translational drug discovery and development across all therapeutic areas. Our 300+ team provides a full range of imaging informatics, imaging engineering and imaging science services including contract imaging, research and clinical trial management services, custom data analysis, and biomarker development and utilization. Our integrated software offerings include VivoQuant™ and iPACS® for image data management, visualization and high-throughput processing for data management.

IQ Medical Services Booth No. 229

4390 SW 73 Avenue  
33155 Miami  
United States  
Phone: +1-305-290-4176  
E-Mail: customerservice@iqmedicalservices.com  
Web: http://www.iqmedicalservices.com/

iQ Medical Services was founded in 2007 as a consulting service provider and supply chain management company oriented to the Healthcare Industry. iQ Medical Services is mainly focused and highly specialized in PET/SPECT Radiopharmacy Solutions, with orientation and expertise in the integration of products and services that would support customers on how to design, build, start-up, and operate a complete PET/SPECT facility. Our core expertise in this area include:

• PET/SPECT Product Expertise and Applications Consulting  
• QA/RA/GMP Consulting  
• Project Management  
• Supply Chain and Order Management  
• Equipment Procurement and Installation Services, Start-Up and Qualification with Integrated multivendor Warranty and Service Solution  
• Customized Lab Equipment Configurations a for Tracer of Choice  
• Facility Start-up and QMS Integration  
• Site Management and Operation

iQ Medical Services is an ISO 9001 certified company that operates at a global level. Our Services have been executed in over 70 sites and more than 20 countries for the past 10 years.
IRE ELIT

Avenue de l’Espérance, 1
6220 FLEURUS
Belgium
Phone:  +32 71 82 9493
E-Mail:  radiopharmaceutical@ire-elit.eu
Web:  http://www.ire.eu

We offer SIMPLE, INNOVATIVE and SUSTAINABLE solutions for development, production, end-use of RADIOPHARMACEUTICALS.

Our portfolio is supported by R&D team committed in research programs with several universities and academic centers across the world. This cooperation is a key factor to develop new radiopharmaceuticals like our new Ga-68 generator Galli Eo®.

Producing 25% of 99Mo world demand, we have industrial culture, knowhow and GMP certified facilities to produce and deliver high quality products. Our daily challenge: provide promising and easy to use radiopharmaceuticals for your preparations. YOUR SUCCESS IS OUR PASSION.

Let’s start to talk on booth 318!

Isotope Technologies Dresden GmbH

Rossendorfer Ring 42
1328 Dresden
Germany
Phone:  +49 351 266 34-0
Fax:  +49 351 266 34-10
E-Mail:  info@isotope-td.de
Web:  http://www.isotope-td.de

Isotope Technologies Dresden (ITD) GmbH is a globally active company that manufactures turnkey solutions in the area of Nuclear Medicine (NUC), Radionuclide-Production (RN-P), Material Testing (MAT), Positron-Emission-Tomography (PET) and Ionisation-Detector-Recycling (ISD).

Services include
- Advisory and Project Management
- Development and Design
- Sourcing and Production
- Qualification and Validation
- Installation and After-Sales-Service

for producers, manufacturers and users of radioactive substances.

The high quality of the products is ensured by the collaboration of an experienced team that consists of designers, assembly technicians, radiochemists and project managers.

The product scope includes the following necessary systems and components, among others:
- Hot cells, mini cells, dispensing and distribution cells
- Laminar flow work benches for aseptic work
- Radionuclide fume hoods
- Shielding and specific radiation protection solutions for α-, β- and γ-radiation
- Laboratory equipment - containers, cabinets, tables, lead castles
- Manipulators
- Equipment for the production of radiochemicals and radiopharmaceuticals

Isotope Technologies Dresden GmbH was founded in 2008 in Dresden-Rossendorf and since 1 June 2017, ITD is part of the Eckert & Ziegler Strahlen- und Medizintechnik AG.
Isotope4life

Chateau de la Chantrerie
95 route de Gachet
44300 Nantes
France
Phone: +33 2 40251399
E-Mail: hallouin@atlanpole.fr
Web: http://www.atlanpolebiotherapies.com

The first consortium dedicated to Radioisotopes applications, aiming at mutualisation and coordination of skills and actors concerned by the use of radioisotopes for health in order to overcome hurdles to innovation in the radiopharmaceutical domain. The main goal of ISOTOP4LIFE is to facilitate the use of Radiopharmaceuticals for diagnostic and therapeutic applications.

ISOTOP4LIFE is a one-stop offer providing R&D, technology transfer and industrialization capacities, with academic, clinical, industrial partners as well as a high-energy, high-intensity cyclotron ARRONAX. It is also a commercial coordination offer with an identified gate for Pharmaceutical industry.

ISOTOP4LIFE is leading the project of "LA FABRIQUE", a building dedicated to GMP production in order to welcome companies and academics for radiopharmaceuticals production and distribution at a National and European level.

ITEL Telecomunicazioni Srl

Via Labriola 39
70037 Ruvo di Puglia
Italy
Phone: +39 0803611033
Fax: +39 0803611114
E-Mail: itel@itelte.it
Web: http://www.itelte.it

Established 30 years ago in the telecommunications sector, thanks to the expertise acquired in electromagnetic waves, fields and radiations, ITEL Telecomunicazioni® today works in the medical, pharmaceutical and electromagnetic compatibility fields, offering high-tech products and services that have in common the application of ionizing and non-ionizing radiations: electromagnetic and magnetic field shielding for diagnostic and intraoperative imaging and industrial environments, medical site auditing, integrated project planning and design of complex healthcare facilities, radiopharmaceuticals and services for nuclear medicine (division ITELPHARMA), research and development of medical mechatronics technologies, electromagnetic compatibility tests & measurements (division EMC TEST LAB).

As part of these activities, ITEL has developed a range of services for Radiopharmacies, both those already operational and those of new construction. From Sterility Tests, to Bioburden Analysis, to advice and training on GMP, ITEL is configured as a global partner for each Radiopharmacy and Nuclear Medicine Department.

Of course ITEL can be configured as a „full service provider“ able to follow the planned construction of a radiopharmacy from design, to commissioning, qualification and validation activities and preparation of the quality system, with full knowledge and competence in relation to GMP requirements.
ITM Isotopen Technologien München AG

Lichtenbergstrasse 1
85748 Garching
Germany
Phone: +49 89 329 8986 60
E-Mail: info@itm.ag
Web: http://www.itm.ag

ITM Isotopen Technologien München AG is a privately held group of companies dedicated to the development, production and global supply of innovative diagnostic and therapeutic radionuclides and radiopharmaceuticals. Since its foundation in 2004, ITM and its subsidiaries have established the GMP manufacturing and a robust global supply network of a novel, first-in-class medical radionuclides and -generator platform for a new generation of targeted cancer diagnostics and therapies. Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development addressing a range of cancers such as neuroendocrine cancers or bone metastases. ITM’s main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve outcomes and quality of life for cancer patients while at the same time reducing side-effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology.

For more information about ITM, please visit: www.itm.ag

Japanese Society of Nuclear Medicine

2-28-45 Hon-Komagome, Bunkyo-ku
113-0021 Tokyo
Japan
Phone: +81-3-3947-0976
Fax: +81-3-3947-2535
E-Mail: anm@xvg.biglobe.ne.jp
Web: http://www.jsnm.org

The JSNM was established in 1964 which currently has over 3,600 members. The JSNM has been working hard to promote the development of nuclear medicine through the collaboration with the SNMMI, EANM, AOFNMB (Asia and Oceania Federation of Nuclear Medicine and Biology), ARCCNM (Asian Regional Cooperative Council for Nuclear Medicine), World Federation of Nuclear Medicine and Biology (WFNMB) and individual societies of many countries.

The JSNM is proud to announce that the 2022 Congress of the WFNMB will be held in Kyoto, Japan. The JSNM’s campaign for three years for this bid had been keenly supported by many countries and societies. The JSNM sincerely appreciate this.

The Annals of Nuclear Medicine (ANM) is the official journal indexed in the most of major sites such as Journal Citation Reports/Science Edition, PubMed/Medline. The ANM is now one of the most popular journal in the field. The Best papers are selected every year and the winners are awarded with grant. Please come to the web site at http://www.springer.com/medicine/nuclear+medicine/journal/12149.

We are waiting for you to treat you with a variety of Japanese traditions at our booth with the utmost hospitality, OMOTENASHI. Join us!
JSC Isotope / Rusatom Healthcare

Pogodinskaya str. 22
119435 Moscow
Russia
Phone: +7 4959819617
Fax: +7 4992452492
E-Mail: isotop@isotop.ru
Web: http://www.isotop.ru/en/

JSC Isotope is a subsidiary 100% owned by Rosatom State Atomic Energy Corporation, responsible for distribution and marketing of isotope products manufactured by Rosatom enterprises. On the strength of Rosatom unique production capacities, we guarantee reliable supplies of high quality isotope products to the international market.

JSC Isotope has a deep expertise in organizing prompt supplies of products and solutions for nuclear medicine, in particular: isotopes (especially Mo-99) and radiopharmaceuticals (Mo-99/Tc-99m, W-188/Re-188, I-131, Sm-153).

Among JSC „Isotope“ partners there are more than 100 foreign customers in over 30 countries and more than 600 organizations in Russia.

JSC Rusatom Healthcare is the integrator within Rosatom State Atomic Energy Corporation, established for purposes of development and production of equipment and radionuclide products for nuclear medicine and medical radiology, as well as industrial equipment based on radiation technologies.

The main mission of Rusatom Healthcare is the organization and integration of production facilities to create a full-/f_l  edged domestic market for modern high-tech equipment and innovative radionuclide products and radiopharmaceuticals for nuclear medicine and medical radiology, as well as modern industrial equipment based on radiation technologies, with subsequent promotion of competitive products abroad.

KEOSYS

13 impasse Serge Reggiani
BP 10222
44815 SAINT HERBLAIN CEDEX
France
Phone: +33 2 53 59 12 90
E-Mail: sales@keosys.com
Web: http://www.keosys.com

Founded in 2001, Keosys has established itself as a leading full-service Imaging CRO focused on bringing high quality images and services to its customers. With over 15 years’ experience in medical imaging, Keosys helps pharmaceutical and biotechnology companies bring new drugs to market by leveraging imaging data in clinical trials. In addition to its leading proprietary cloud-based platform to centralize and analyze imaging data, Keosys offers project management services and scientific expertise that allow sponsors to focus on their core business rather than operational bottlenecks and difficulties managing large complex data sets.

Keosys has worked on more than 90 clinical trials and has centralized over 68 million DICOM images for 35,000 patients over the past 10 years. Keosys has a long track record working on Phase II and III trials in the oncology, neurology, and cardiology space and has long history managing trials in the fields of Molecular Imaging and Nuclear Medicine.

The company is headquartered in France and has subsidiary in the United States (New York City) and Asia (Singapore).
Kliniken.de

Betenstr. 13-15
44137 Dortmund
Germany
Phone: +49 231 91448877
E-Mail: anzeigen@kliniken.de
Web: http://www.kliniken.de

Kliniken.de the recruiting specialist works exclusively for hospitals, clinics, private practices and retirement homes. We have in-depth knowledge concerning all the special aspects of staffing in medical professions. With over 17 years of experience our company supports our clients to succeed in a proven quality.

KSNM – The Korean Society of Nuclear Medicine

Gumho palace B/D #1705, 29th Jibong-ro, Jongno-Gu
3121 Seoul
Korea
Phone: +82-2-745-2040
Fax: +82-2-745-3833
E-Mail: ksnm@ksnm.or.kr
Web: http://ksnm.or.kr/

The Korean Society of Nuclear Medicine (KSNM) is a scientific and professional organization founded in 1961. The business of KSNM includes holding academic meetings, publication of journals and books, planning and research of promoting science and health, training and qualification of NM specialists. There are 360 NM specialists, 140 PET/CT and 290 SPECT cameras in Korea.

The aims of KSNM are the promotion of nuclear medicine and cooperation of each member from nuclear Medicine’s various related scientific fields of radiochemistry, radiopharmacy, dosimetry and pharmacokinetics/pharmacodynamics of radiopharmaceuticals, nuclear and molecular imaging analysis, nuclear and molecular imaging instrumentation, radiation biology and radionuclide therapy. KSNM hosted Asia Oceania Congress of Nuclear Medicine and (1984, 2015) and World Congress of Nuclear Medicine and Biology (2006).

The official journal of KSNM is ‘Nuclear Medicine and Molecular Imaging (NMMI)’, published from 1967 and is being published six times a year by Springer.

For the future, the Korean Society of Nuclear Medicine provides effective training and cultivates future talent to prepare for upcoming changes in an ever-diversifying environment. Clinical practice and research applying molecular imaging and PET/CT and treatment procedures using radiopharmaceuticals will continue to flourish, and the KSNM will lead the advancement of the field of nuclear medicine in Korea.
LabLogic Systems Limited
Paradigm House
3 Melbourne Avenue
Broomhill
S10 2QJ Sheffield
United Kingdom
Phone: +44 114 266 7267
Fax: +44 114 266 3944
E-Mail: solutions@lablogic.com
Web: http://www.lablogic.com

LabLogic is a manufacturer of instruments and software to the Life Science, PET/Nuclear Medicine and Radiation Safety sectors. We have over 35 years’ experience and expertise in providing solutions within highly regulated environments.

Within PET and Nuclear Medicine, LabLogic have a range of market leading products which can be found in some of the world’s most prestigious laboratories. Our products include a range of QC equipment including innovative r-TLC, r-HPLC instruments and a single point of control radiochromatography software package – Laura for PET. The complete QC package is also available from LabLogic, just ask about the QC solution.

Furthermore Lablogic offer PETra, a purpose built PET LIMS system designed to improve efficiency and compliance. What’s unique about PETra is that it directly captures data from all the equipment used. It acts as a central repository all information within PET production including batch record management, QMS, trending, inventory, instrument maintenance etc.

LabLogic will be showcasing its Tracer QC system at EANM’17. Utilising an instrument smaller than a desktop PC to perform the essential PET QC tests with just single touch operation, this system is already creating a great deal of interest across the nuclear medicine community. For further information please contact our office or visit booth #406 at the show to see it demonstrated.

Lemer Pax / Medisystem
72 rue de Lorraine 44240 LA CHAPELLE SUR ERDRE
Z.A. Erdre Active - Malabry
44240 LA CHAPELLE SUR ERDRE
France
Phone: +33 6 86 65 21 21
E-Mail: charlotte.bebin@lemerpax.com
Web: http://www.lemerpax.com

Live a unique Virtual Reality experience and discover a complete offer of effective radiation protection solutions from preparation to injection of any radioisotopes - come visit us on booth n° 403 / hall X4.

Indeed, the two French historic leaders in the radiation protection industry join forces to serve you better and to offer you a full array of innovative solutions, incorporating the most advanced technologies to protect yourself efficiently against ionizing radiations.

To discover the breadth of our product range, we invite you to dive in a virtual nuclear medicine department to manipulate virtually ergonomic hotcells, automatic injectors, or mobile shields for preparation, injection and storage of radiopharmaceuticals.

Among many innovative products, you will discover the latest version of Posijet®, an independent fractionation and injection unit for high energy radiopharmaceuticals which has been co-developed by the Lemer Pax design office in partnership with nuclear medicine operators and which offers a unique and very user-friendly interface. You will also discover the Medi 9000 Research 2R, a brand new research hotcell with 2 glove ports designed by Medisystem engineers to offer an ergonomic and compact solution for the Ga68 synthesis, fractionation and measurement as well as for the fractionation of fluorinated pharmaceuticals (Medi 9000 is compatible with all synthesis modules on the market).

Feel free to visit our experts on booth n° 403 / hall X4 to...
Lightpoint Medical Ltd
Booth No. 228

Misbourne Works, Waterside
Bucks
HP5 1PE Chesham
United Kingdom
Phone: +44(0)1494917697
E-Mail: info@lightpointmedical.com
Web: http://www.lightpointmedical.com

Lightpoint Medical is an innovative medical device company dedicated to improving health outcomes for cancer patients through image-guided surgery. The company's products address the pressing medical need for better tools to detect cancer during surgery in order to improve clinical outcomes and reduce healthcare costs.

The company has three products: The LightPath™ Imaging System (CE marked) for imaging surgical specimens, the EnLight™ laparoscopic probe for minimally-invasive prostate surgery (under development), and HARLI™ for open surgery and life sciences (2017 launch).

Lynax s.r.o.
Booth No. 202

MAP Medical Technologies Oy
Booth No. 254

MAP Medical Technologies Oy, founded in 1991, is an independent Finnish company. The mission of our company is to develop and manufacture radiopharmaceuticals to serve nuclear medicine professionals. Our highly devoted team and modern production facilities offer a unique setting for production of best quality pharmaceuticals.

We can provide to our customers and partners several products and services in the field of nuclear medicine.

• Our products: FDG, Fluorocholine, Sodium Fluoride, Fluorothymidine (FLT), Fluoroestradiol (FES), Ga-68 DOTA-NOC, Ga-68 PSMA, Lu-177-PSMA, P-32 solution for injection, I-123 CLINDE, I-123 beta-CIT, I-123 Epidepride and others.

• Investigational products: New diagnostic radiopharmaceuticals in close collaboration with our partners in prominent research institutions for such degenerative brain disorders like Parkinson's disease, Alzheimer's disease and others, which are related to activity and amount of neurotransmitters like dopamine, serotonin and others.

• Contract manufacturing of radiopharmaceuticals: We can offer our GMP facility and know how to other medical communities to test label and produce their own radiopharmaceutical compounds. We have possibility a small scale manufacturing set up for the customer needs. With this unique set up we can save both money and time of the customer for example in production for clinical trial batch.

We are committed for collaboration with nuclear medicine professionals.
MED Nuklear-Medizintechnik Dresden GmbH

Dornblüthstraße 14 A
1277 Dresden
Germany
Phone: +49 (0)351 433 00 50
Fax: +49 (0)351 433 00 518
E-Mail: export@nuklear-medizintechnik.de
Web: http://www.nuklear-medizintechnik.de

MED Nuklear-Medizintechnik Dresden GmbH designs and manufactures laboratory counters and radiation monitoring systems for nuclear medicine, PET-centres and therapy stations:
- dose calibrators
- uptake-counters, incorporation counters, well-counters, waste water counters
- patient dose monitoring systems
- contamination monitors (portable and hand-foot-clothing monitors)
- waste and release monitors
All laboratory counters and dose calibrators are PC-based.

The product line of MED Nuklear-Medizintechnik Dresden GmbH also contains instruments for dose and/or dose rate measurement and radiation protection accessories, e.g. syringe shieldings.

MED Nuklear-Medizintechnik Dresden GmbH is a company of NUVIA since 2014.

Medi-Radiopharma Ltd.

10-12, Szamos utca
2030 Érd
Hungary
Phone: +36 23521261
Fax: +36-23-521-260
E-Mail: order@mediradiopharma.hu
Web: http://www.mediradiopharma.com

Our company is for research, development and manufacturing of generic in vivo kits for Tc-99m labelling as MIBI, HM-PAO (stabilized and non-stabilized), MAA, HSA nanocolloids, MDP, DMSA, Br-IDA, DTPA and PYP. Three Technetium-99m labelled kits (Senti-Scint, Nano-Scan and Nano-Albumon kit) are available with different particle sizes to support various sentinel studies. All products are registered in several countries all over the world and manufactured under cGMP conditions.

We offer CE-marked MediCheck Q.C. kit (and its refill-packs) for rapid quality control of registered and extemporaneously prepared radiopharmaceuticals. CE-marked Medi-Media Fill kits are for controlling aseptic manufacturing process, the environment and personnel. Next to these, sterile and sterile, evacuated vials of different sizes and types are available in our assortment.

Chemical precursors for radiopharmaceutical preparation are synthetized in our recently opened GMP API laboratory. Contractual research, quality control evaluations from radio HPLC, animal distribution, subvisible particals determination, etc., manufacturing of investigational medicinal products as well as development and manufacturing validated analitical methods are part of our cGMP licence. Sterile and vacuum vials, compilation of sterile centrifuge-tubes and solutions for preparation of radio-labelled blood-cells are also available.
Mediso

MiE medical imaging electronics GmbH

MiLabs

### Mediso

Booth No. 304

**Hauptstrasse 112**  
23845 Seth  
Germany

**Phone:** +49 4194 9977-0  
**Fax:** +49 4194 9977-55  
**E-Mail:** mie@miegermany.de  
**Web:** http://www.miegermany.de/

MiE has produced nuclear medicine systems (SPECT & PET) and accessories for the complete customer needs since 1981. During this time MiE have gained extensive experience in user specific requirements and have adapted it to the market and specific user needs. All our products are CE certified and FDA cleared, thus new with full warranty and min. 10 years guaranteed spare part support.

Our workstation name SCINTRON is developed to close the gap between shortened development cycles and more durable mechanics and electronics. This computer is design to acquire data as well as process and view studies from our new or already installed Gamma Camera and PET systems.

The in-house research, development, electronic and mechanic department ensure that we provide always the latest technologies. This allows us to meet the specific needs of our customers.

The MiE company is certified in accordance with EN ISO 9001:2008, EN ISO 13485:2012 + AC: 2012 and all our systems are with Annex II of Directive 93/42/EWG approved. Also, we are registered at the FDA – our systems are 510(k) approved since 1995. This extensive certification is the basis for the manufacture and distribution of medical products on the world market.

### MiLabs

Booth No. 226

**Heidelberglaan 100 STR 4.105**  
3584 Utrecht  
Netherlands

**Phone:** +31 88 756 5343  
**Fax:** +31 88 756 0094  
**E-Mail:** info@milabs.com  
**Web:** https://www.milabs.com

MiLabs provides molecular imaging solutions for biomedical and pharmaceutical research. MiLabs' imaging platforms let's you do more by imaging less.

These imaging systems contribute worldwide to the development of new diagnostic solutions and therapies for diseases such as diabetes, cancer, cardiac, neurodegenerative diseases and more.

U-SPECT is the fastest, most sensitive and highest resolution small-animal SPECT system currently available. MiLabs fused state-of-the-art adaptive PET with its SPECT technology, by introducing the VECTorCT. This versatile nuclear imaging system is extremely user friendly, fully integrated and enables simultaneous ultra-high resolution PET/SPECT imaging in combination with a choice of in-line low-dose high-resolution CT systems. MiLabs’ concurrent PET/SPECT and Hybrid Optical Imaging (OI) system empowers you to study different physiological and molecular functions at the same time.
MIM Software Inc.  
Booth No. 237  

25800 Science Park Drive  
Suite 180  
44122 Cleveland, OH  
United States  
Phone: +1 216 455 0600  
Fax: +1 216-455-0601  
Web: https://www.mimsoftware.com/

MIM Software Inc. provides a single platform solution for all of your PET and Nuclear Medicine viewing and quantitation needs. MIM Encore, the backbone of MIM’s solution, provides tools for customized workflow management, automated serial exam review, advanced PET/CT and SPECT/CT visualization, automatic PET tumor segmentation, and nuclear medicine processing. MIMnuro includes quantitative PET/SPECT analysis tools to aid in the detection of neurological disorders for the following tracers: FDG, Amyvid™, NeuraCeq™, Vizamyl™, HMPAO and DaTscan™. MIM provides an integrated cardiac PET and SPECT quantitative analysis solution, MIMcardiac, which offers advanced left-ventricle segmentation for calculating ejection fractions, polar plots, and difference imaging. MIM’s SurePlan Liver Y90 package provides time saving tools for liver VOI definition, multi-modality fusion, and Y90 PET and SPECT dose calculation.* MIM Assistant, a data management and archiving solution, is easily integrated for fast data transfer and automated study routing, retrieval, and workflow processing. Professionals can collaborate securely and reliably by sharing images from anywhere with MIMcloud. All these solutions provide unmatched efficiency and save time while enhancing patient care.

* This functionality is pending 510(k) clearance, and is not yet commercially available in the United States or in some other countries. Please contact your MIM rep for details.

Mirada Medical Ltd 
Booth No. 215

Oxford Centre for Innovation,  
New Road  
Oxford  
OX1 1BY Oxford  
United Kingdom  
E-Mail: annamaria.albano@mirada-medical.com

Mirada develops software applications that provide simple and accessible solutions to complex image analysis problems in the diagnosis and treatment of cancer and other diseases. Through automation, our products improve consistency and productivity while enabling clinicians to deliver more personalized care. By combining deep learning technology with our thorough understanding of the challenges faced, Mirada is leading the development of next generation imaging software and decision support products. Our staff are passionate about using their expertise to help our customers provide better healthcare for more patients.

Mirada offers vendor-neutral applications for reading Nuclear Medicine, SPECT/CT, PET/CT, and PET/MR, with flexible display protocols and workflows. Deformable registration is performed for image comparison and quantitative response to therapy is assessed with comprehensive tools for PERCIST, WHO and RECIST analysis. Results are saved for editing and review, allowing convenient time-saving access.

Mirada’s portfolio also includes knowledge sharing solutions providing referring physicians access to rich images and reports, plus software designed exclusively for efficient preparation and elegant presentation of images at tumor board. Mirada software is available in an array of deployments including stand-alone, thin client, floating license and PACS integrations.

Products: XD, XD Nuclear Medicine, Casemeeting, Caseaccess, RTx, Workflow Box, Simplicit90Y
MNT Kwint International BV  
Industrieweg 4a  
4104 AR Culemborg  
Netherlands  
Phone:  +31 (0)345535127  
E-Mail:  geert@mnt-int.com  
Web:  http://www.mnt-int.com

In general our company is specialized in the field of Health Physics, Radiochemistry, Nuclear Medicine, Radiotherapy and -diagnostics & Waste-management. For more than 30 years our program is based on:

- handling and storing radioactive pharmaceuticals; radioactive solid- & liquid waste
- furnishing radioactive laboratories, rooms for production radioactive chemicals/materials, clean rooms, treatment- and accelerator rooms, waste-rooms, etc.;
- Personal protection;
- Waste water vacuum plants for iodine 131 treatments
- Shielded and unshielded hospital furniture

MOLECUBES NV  
Ottergemsesteenweg Zuid 808 BUS 325  
9000 Ghent  
Belgium  
E-Mail:  info@molecubes.com  
Web:  http://www.molecubes.com/

MOLECUBES stand for modular benchtop preclinical imaging. Three high-end imaging cubes allow you to combine SPECT (Gamma-Cube), PET (Beta-Cube) and CT (X-Cube) imaging in a time and space efficient way. The combination of patented pinhole design, additive manufacturing techniques and high-resolution detector technology ensures competitive performance for full body mice and rat imaging. Intuitive user-interfacing and fast post-processing also allow for high-throughput scanning.
MR Solutions Ltd  
Ashbourne House  
The Guildway, Old Portsmouth Road  
GU3 1LR Guildford  
United Kingdom  
Phone: +44 (0) 1483 532146  
Fax: +44 (0) 1483 594086  
E-Mail: info@mrsolutions.com  
Web: http://www.mrsolutions.com

MR SOLUTIONS is the worldwide leader in superconducting cryogen-free, preclinical MRI systems with multiple proven installations of its 7T, 4.7T, 3T and PET/MRI. Recently, MR SOLUTIONS has pushed its technology even higher and introduced a new 9.4T cryogen-free MR imaging system. Two product lines are available: Powerscan and Flexiscan. Flexiscan requires no specialist knowledge and can be operated by running predefined settings. Powerscan is focused on high end MR applications and is available with adjustable magnetic field strengths ranging from 0.1T to 9.4T. The system allows physicists to alter the hardware, software and pulse sequences. For multi-modality imaging, MR SOLUTIONS has developed PET and SPECT modules that are very light, compact and detachable. This unique and innovative design allows the users to interchange these modules either on the MRI or on the CT for your research applications: PET/MR, PET/CT, SPECT/MR, SPECT/CT, or simply to operate them as a stand-alone device. MR Solutions holds the prestigious Queen’s awards for enterprise, Innovation 2016 and is the winner in the global R&D 100 awards. MR SOLUTIONS has over 30 years of imaging technology development and manufactures all its product in house.

NICEOFT  
79 avenue Denfert Rochereau  
75014 Paris  
France  
Phone: +33 153 622 400  
Fax: +33 153 620 010  
E-Mail: sales@nicesoft.com  
Web: http://nicesoft.com

Since 1998, NICESOFT seeks to exceed customer expectations by developing innovative Web solutions for Medical Imaging departments. We combine zero-footprint Web technology with a high specialization in Nuclear Medicine & Radiology to design applications that can run on any device or platform (PC, Mac, tablets, smartphones) without any installation. Our VENUS product line provides a complete range of solutions for Nuclear Medicine and Radiology departments, from online appointment booking to a full-Web Viewing & Processing Application Server that allows to access your images from anywhere. We are the leading RIS provider for Nuclear Medicine departments in France and have also equipped sites across Europe (Germany, Belgium, Italy, Finland, Ireland, Luxembourg, etc), the US, China and the Middle East. Come and see why!
Norgine Limited

Norgine House, Widewater Place
Moorhall Road
Harefield
UB9 6NS Uxbridge
United Kingdom
Web: http://www.norgine.com

Norgine is a leading European specialist pharmaceutical company with a direct commercial presence in all major European markets. In 2016, Norgine’s total revenue was EUR 368 million. Norgine employs over 1,000 people across its commercial, development and manufacturing operations and manages all aspects of product development, production, marketing, sale and supply.
Norgine specialises in gastroenterology, hepatology, cancer and supportive care.
Norgine is headquartered in the Netherlands. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites in Hengoed, Wales and Dreux, France.
For more information, please visit www.norgine.com
In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com.
NORGINE and the sail logo are trademarks of the Norgine group of companies.

Nuclear Shields B.V.

Akkervoortweg 5
5827 AP Vortum-Mullem
Netherlands

Nuclear Shields has a Holland based production facility and has over 40 years of experience in producing lead products for nuclear medical purposes. Nuclear Shields is the go-to place for transparent, quick & reliable purchasing of high-quality radiation related products. Nuclear shields offers a wide range of products, including shielded hotlab cabinets, radiation monitoring products, personal radiation protection products, waste and storage solutions and custom made solutions. Next to this, Nuclear Shields also offers a wide range of collimators.
Visit booth #424 in exhibitor’s hall X4, or visit our webshop at www.Nuclear-Shields.com
Nucleis

Allée du Six-Août, 8
4000 Liège
Belgium
E-Mail: info@nucleis.eu
Web: http://www.nucleis.eu

Nucleis is a pharmaceutical company developing, manufacturing and commercialising radiopharmaceuticals drugs dedicated to PET Imaging, for diagnostic and therapy monitoring. We are focused on helping our customer to provide the best care thanks to the highest reliability, flexibility and also by offering an innovative portfolio of radiopharmaceuticals drugs. Nucleis holds a FDG Marketing Authorisation (Glucotrace) in Belgium, The Netherlands, Germany, France and Luxembourg. Our company is a spin-out from the University of Liège, created in 2017, which can rely on a highly skilled team. This expertise is illustrated by more than 4000 manufactured batches and more than 150,000 distributed doses from the manufacturing site of Liège in Belgium. Nucleis is also the partner of choice for Contract Manufacturing Officer activities and is an authorised manufacturer of GE Healthcare radiopharmaceuticals and of Blue Earth Diagnostics.

NUVIA

85 Avenue Archimède
13857 Aix-en-Provence
France
E-Mail: healthcare@nuviatech.com
Web: http://www.nuvia-group.com

Nuvia offers a unique array of technologies and services for application of ionizing radiation in a catalogue of highly reliable products which can be tailored on-request, such as dose calibrators, different types of counters, contamination monitors, and radiation protection equipment. Our components are manufactured in our workshops and are the result of our R&D processes. From modelling to implementation, we use exclusive know-how and state-of-the art technologies in its systems. Being a strong partner in system deliveries, Nuvia provides tailor-made solutions fitted to needs and requirements of the customer.

OGNMB - Austrian Society of Nuclear Medicine and Molecular Imaging

Schmalzhofgasse 26
1060 Vienna
Austria
E-Mail: office@ogn.at
Web: http://www.ogn.at

The Austrian Society of Nuclear Medicine and Molecular Imaging (OGNMB) represents the activities of the nuclear medical community in Austria to all official bodies (such as ministries, federal and regional medical societies or health authorities) and comprises all scientific fields closely related to NM and MI, e.g. medicinal radiochemistry, radiopharmacy, medical physics and radiation protection. Founded in 1968 in Vienna, the OGNMB currently welcomes around 250 members in good standing (ca. 180 NM specialists and ca. 40 NM physicians in training). Bi-annually the OGNMB organizes the prestigious Austrian Winter Symposium, “Radioactive Isotopes in Molecular Imaging” (formerly also known as Bad Gastein meeting) – in upcoming January for its 33rd time! For more informations come to our booth and collect flyers for next year’s meetings and further info-material.
Oncidium Foundation

Chemin de l’Infante, 84
1420 Braine-l’Alleud
Belgium
E-Mail: richard.zimmermann@oncidium-life.org
Web: http://www.oncidium-life.org

The Oncidium Foundation based in Belgium (creation 2011) aims at increasing awareness about radiotherapy in NM and promoting at a worldwide level the development of radiotherapeutics (RTs). Very recently Oncidium was confirmed for larger funding and is presently in a process to completely refurbish its website and reorganize itself. Oncidium will become a platform to create cohesion between RT stakeholders, building a community strong enough to lobby for RTs.

For the first time Oncidium will be present with a booth during a NM congress thanks to the EANM team. This will help to make the foundation more visible and better explain the different foundation’s programs. In particular the foundation is looking for volunteers who can help to gather but also to spread information about marketed or under clinical development RTs, represent Oncidium locally, help to translate information in any language. In particular, on top of providing the latest data on progresses in RTs through weekly news, the web site aims at connecting directly patients with physicians and will display information about nearest treatment centers through interactive maps. This information must be as complete as possible and provided in the language of the patient.

Eventually, depending upon funding from new sponsors, Oncidium intends to support financially the clinical development of efficient RTs disregarded by industry and to support access to RTs for patients that cannot afford such therapies.

ONCOVISION

C/JERONIMO DE MONSORIU Nº 92 BAJO IZDA
46022 VALENCIA
Spain
E-Mail: info@oncovision.com
Web: http://www.oncovision.com

Oncovision is a leading provider of innovative medical imaging devices for the diagnosis and treatment of cancer. Has grown into a dynamic brand in a technologically competitive, high-growth industry.

We boast a clinical product line that includes market-leading Sentinella, a unique intra-operative Gamma Camera and the revolutionary Mammi PET, a breast cancer diagnostic device capable of visualizing lesions of less than 1.6mm and quantifying tumor activity. Completes its portfolio with Wprobe, the gold standard in radio guided surgery.

Oncovision has distinguished itself through for developing and bring to the market innovative products to generate significant benefits on patients. Also, the company plans to bring forth technical and clinical solutions for an accurate diagnosis and treatment of cancer, providing the highest-quality, best-performing products.

You can also visit us on the web at www.oncovision.com
Optimized Radiochemical Applications (ORA-NEPTIS)  Booth No. 211
50B Rue de la Gendarmerie
5600 Philippeville
Belgium
Phone:  +32 71 61 38 23
Fax:  +32 71 61 40 53
E-Mail:  info@oradiochem.eu
Web:  http://www.neptis-vsa.com

ORA, a certified ISO13485 medical devices manufacturer, is a leading supplier of innovative radiochemistry solutions for the radiopharmaceutical industry. ORA provides the NEPTIS® synthesizers, a range of open and flexible platforms. These platforms offer the most freedom and the best efficiency for the competitive deployment of new PET tracers and innovative radiopharmaceuticals to support the nuclear medicine community.

NEPTIS® platforms are combinations of multi-purpose synthesizers coupled with advanced software system meeting the latest GMP requirements. NEPTIS® platforms are offering the capability of creating an unlimited number of individualized radio-tracer synthesis applications. Therefore NEPTIS® concept contributes in restoring freedom for researchers with an open platform, in providing developers with a robust tool from clinical trials to commercial production, and in offering producers a guarantee for reliable and repetitive performance.

The proven expertise of ORA coupled with the NEPTIS® platform and its extensive regulatory documentation support, makes it possible to meet new challenges of maximizing current PET tracers production and speeding up the development of new drugs to market.

Osimis  Booth No. 318
rue des chasseurs ardennais 3
4031 Angleur
Belgium
Phone:  +32 478132163
E-Mail:  fl@osimis.io
Web:  http://www.osimis.io

It is our mission to re-wire the medical imaging space through the use of open source, interoperable and standards compliant software.

Osimis offers products and solutions that enable simple and lightweight transmission, visualisation, collaboration and artificial intelligence for medical imaging.
**Company Profiles**

**PARS Isotope**

Booth No. 418

88, East 23 St, Azadegan Blvd.
South Sheykh Bahaei St.
Tehran
Iran
Phone: +98 2188630303
Fax: +98 2188337024
E-Mail: info@parsisotope.com
Web: http://www.parsisotope.com

Pars Isotope is a leading producer and supplier of medical radioisotopes in the Middle East. With more than 50 products in the world of nuclear medicine, we are the one who can supply different radiopharmaceuticals used in treatment and diagnosis. Based on our deep-seated knowledge and experience in radiopharmaceuticals production.

To enhance the quality and quantity of medical products according to cGMP regulations Pars Isotope is involved in a project to implement new modern facilities for RRP, CKP and PET in Iran. Additionally, we are focused on the following activities according to our profession and capabilities:

- Production of 12 different types of Tc-99m cold kits like MIBI, EC, ECD, Sulfurcolloid, BrIDA, MDP, DTPA, DMSA, MAA, PYP, RBC, Antimony and …
- Production of 5 different types of Tc-99m peptide kits like Trodat, Octreotide, UBI and …
- Production of 5 types of radionuclide generators used in PET & SPECT like Ga-68 Generator, Re-188 Generator, Tc99m-Generator and …
- Production of 22 various ready-to-use radiopharmaceuticals in diagnostics and therapeutics like I-131, Sm-153 EDTMP, I-131 MIBG, Lu-177 PSMA and …
- Production of 7 different types of radiochemical used in production of radiopharmaceuticals like P-32, Y-90, Sm-153 and …
- Development and optimization of advanced methodologies in production of radiopharmaceuticals.

**PerkinElmer**

Booth No. 269

68 Elm Street
MA 01748 Hopkinton
United States
Phone: 00508-435-9500
E-Mail: info@perkinelmer.com
Web: http://www.perkinelmer.com/invivo

PerkinElmer is uniquely positioned to bring instruments, reagents and services to enable comprehensive translational imaging & detection solutions for your research. Our offering includes multiple imaging modalities: PET, SPECT, Fluorescence, Cerenkov, Bioluminescence and x-ray imaging. Learn more about our PET/CT imaging system with a compact, easy-to-use footprint that fits on your bench-top. PerkinElmer’s PET system and radionuclides such as 89Zr and 124I offers excellent sensitivity and quantification of lead compounds for applications such as oncology, cardiology, and PK/biodistribution studies.
Philips

Royal Philips
Amstelplein 2
1096 BC Amsterdam
Netherlands
Phone: +31 20 59 77777
Web: http://www.philips.com

Philips is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. This commitment to continuous health can be seen in Philips focus on precision medicine and portfolio of molecular imaging and nuclear medicine solutions, which combine people, processes and technology to enhance imaging and improve patient care. At EANM, Philips will showcase its suite of advanced molecular imaging solutions and applications, including Vereos Digital PET/CT and IntelliSpace Portal 9, for a comprehensive experience in transformative patient care. https://www.usa.philips.com/healthcare/about/events-calendar/eanm-2017

PI Medical Diagnostic Equipment B.V.

Bliek 14
NL-4941 SG RAAMSDONKSVEER
Netherlands
Phone: +31 162 729102
E-Mail: info@pi-medical.nl
Web: http://www.pi-medical.nl

PI Medical Diagnostic Equipment B.V. works closely together with a group of well established international producers of high-quality equipment and represents these companies in the Netherlands. PI Medical offers a wide range of instruments and accessories for the nuclear medicine market. The product range includes FDG dispensing systems, dose calibrators, contamination and radiation monitors, PET and SPECT phantoms and other QA devices, radiation shielding materials, laser systems for PET/CT, patient positioning devices, etc.

PI Medical is furthermore specialized in gamma probes and ICG probes for the sentinel node procedure, the company has been deeply involved in the development of these products.

Next to equipment PI Medical also supplies I-125 seeds for tumor localization and calibration sources for PET and SPECT applications in the Benelux countries.
PMB-ALCEN

Route des Michels CD56
Chemin de la Corneirelle
13790 PEYNIER
France
Phone: +33 442531313
Fax: +33 42533083
E-Mail: contact@pmb-alcen.com
Web: http://www.pmb-alcen.com/en

PMB-ALCEN designs, manufactures and commercializes high-technology products used in the medical, nuclear power, research, defense & security and industry fields. Our expertise lies in the complex assembly of materials which are dissimilar, such as metals and ceramics, as well as in the development and manufacture of linear accelerators and cyclotrons.

We have been designing and developing a cutting-edge automated system for the production of radiotracers. These are essential in clinical medicine, especially in PET imaging. It combines a superconducting cyclotron with an innovative radiochemistry room, complete with an automated QC system. We are more than just another radiopharmaceutical dispenser. We have envisioned a unique system designed to improve and optimize patient care, while providing new grounds for further research in the nuclear medicine and medical imaging fields.

We offer an alternative to traditional radiotracer production centers, by providing an unprecedented proximity to both patients and imaging departments, allowing a same-day diagnosis with multiple radiotracers and decreasing the need in staff. IMiGiNE is a game-changing solution that grants imaging centers access to a variety of radiopharmaceuticals, at a low cost.

PMOD Technologies LLC

Sumatrastrasse 25
8006 Zurich
Switzerland
Phone: +41 44 350 46 00
Fax: +41 44 350 46 01
E-Mail: info@pmod.com
Web: http://www.pmod.com

PMOD Technologies aims to equip researchers with best-in-class software tools for biomedical imaging in humans and animals. Founded in 2003 as a spin-off from the Zurich PET center, PMOD has a strong background in PET image quantification.

The PMOD suite of software tools is a comprehensive platform for quantitative biomedical imaging. It arguably represents the leading solution for PET kinetic modeling, and supports all required image pre-processing steps such as image matching, brain image normalization, and automated volume-of-interest definition. Furthermore, it encompasses solutions for the pattern analysis of brain images and for attractive 3D image visualization.

PMOD boasts an expanding customer base comprising more than 500 sites with over 1500 active users worldwide. As of 2016, the use of PMOD has been reported in more than 1300 publications. Vibrant collaborations with a number of flagship institutions ensure that the methodology and scope of the PMOD software remain leading-edge and come to the end user at unprecedented speed.

Brands: PBAS, PKIN, PXMOD, PCARD, PGEM, PFUS, P3D, PNEURO, PALZ, PSEG, PSAMPLE.
Radioisotope Centre POLATOM is manufacturer and distributor of the radioisotopic products applied in medicine, research and development, industry and environment protection.

In the nuclear medicine field, POLATOM offers the radiopharmaceuticals for diagnosis and therapy: 131I-Sodium iodide capsules, 131I-solution for injection, 131I-hippurate, 131I-MIBG, 123I-MIBG, 89Sr-Strontium chloride, 32P-Ortho-phosphate, kits for technetium labelling (Tektrotyd, PoltechMIBI, PoltechColloid, PoltechDMSA, PoltechDTPA, PoltechMBiDA, PoltechMDP, PoltechRBC – Pyrophosphate), 99Mo / 99mTc– generators, ItraPol 90Y and LutaPol 177Lu for peptide labelling and accessories for nuclear medicine. The medical production is certified for compliance with cGMP. Quality Assurance System established at the Radioisotope Centre POLATOM in the area of manufacturing, sales, dispatching and transport of radioactive materials is certified according to PN-EN ISO 9001:2009.

POLATOM is a world famous supplier of high quality radiopharmaceuticals and diagnostic kits for nuclear medicine and important manufacturer of radiochemical products for customers all over the world.

Progenics develops innovative medicines and other technologies to target and treat cancer. Progenics’ pipeline includes: 1) therapeutic agents designed to precisely target cancer (AZEDRA® and 1095), 2) PSMA-targeted imaging agents for prostate cancer (1404 and PyL™), and 3) imaging analysis tools. Progenics’ first commercial product, RELISTOR® (methylnaltrexone bromide) for OIC, is partnered with Valeant Pharmaceuticals International, Inc.
rapp-iso GmbH

Mehlbydiek 50
24376 Kappeln
Germany
Phone: +49 (0) 46 42 / 96429-0
Fax: +49 (0) 46 42 / 96429-29
E-Mail: info@rapp-iso.de
Web: http://www.rapp-iso.de

Our customers protect, save and preserve life. We support them.
Since 1981, we have been advising and supporting companies, institutions and institutes in the fields of medicine and environmental protection in technology issues. We take responsibility in all phases of planning, purchasing, installation and maintenance of your technical equipment.
With our work we contribute to achieving the highest quality standards in the areas of medicine and environmental protection.

We rely on:
• continuous knowledge updating and training
• comprehensive industry monitoring and vendor independence
• individual advice and around-the-clock service

Our knowledge ensures your treatment success
Our customers never just buy products. They always acquire the long-term benefits that the products have for them.
For more than 30 years, our company tradition has been providing expert advice and reliable support to our customers.
Precise measuring instruments support the diagnosis and thus the healing. Our offer covers the entire product range of all manufacturers. In this way, we are always able to offer the latest technical innovations to your needs.
Regular inspection of the instruments and calibration of the measuring instruments is a responsibility for us.
Short distances, direct communication and fast, efficient solutions are our basis.

Rotem GmbH

Rathenaustraße 4
4179 Leipzig
Germany
Phone: +49 341 2444925
Fax: +49 341 2444922
E-Mail: rotemeur@hyox18.de
Web: http://www.rotem-medical.com

Rotem, a longtime world leader in consumables for PET imaging, supplies cyclotrons around the world with complete packages for radiotracer production. Our product line is centered on Oxygen-18 enriched water, plastic cassettes, precursors and full reagent kits for various synthesis modules. All products are produced in accordance with cGMP requirements according to the EU & PIC/S and are manufactured at our US FDA-inspected facility. Rotem’s cGMP certified Mannose Triflate holds a certificate of suitability from the EDQM. Production is supported by Rotem’s in-house certified analytical lab with a wide array of equipment and QC method development capabilities. Users enjoy full technical and regulatory support from our highly qualified staff along with excellent customer service.
Rotem is particularly active in the design and production of consumables for radiotracers under development. These projects benefit from our interdisciplinary expertise, the result of a longstanding and close cooperation with radiopharmacies worldwide.
Rotem GmbH in Leipzig serves customers in Europe, with local representatives in the U.K. and Eire.
ROTOP Pharmaka GmbH

Bautzner Landstrasse 400
1328 Dresden
Germany
Phone: +49 351 26310100
Fax: +49 351 26310313
E-Mail: service@rotop-pharmaka.de
Web: http://www.rotop-pharmaka.de

ROTOP Pharmaka is a leading German pharmaceutical company that produces cGMP compliant radiopharmaceuticals for diagnostics and therapy in Nuclear Medicine and Molecular Imaging and distributes them in more than 30 countries worldwide. With almost 20 years of experience in the development, production, authorization and distribution of sterile kits for radionuclide radiopharmaceuticals ROTOP continuously expands its product portfolio by developing new products and entering new strategic partnerships.

Our portfolio includes:
- A comprehensive range of Tc-99m kits
- GMP-compliant production of agents for Tc-99m kits
- Quality control sets for Tc-99m radiopharmaceuticals
- Distribution of pharmaceuticals that are produced by subcontractors for ROTOP
- Pharmaceutical Development

We will be happy to welcome you at our booth #414.

RoweMed AG

Juri-Gagarin-Ring 4
19370 Parchim
Germany
Phone: +49 (0) 3871 - 451280
Fax: +49 (0) 3871 - 451282
E-Mail: info@rowemed.de
Web: http://www.rowemed.de

RoweMed AG is an innovative plastic-manufacturing MedTech company. Our focus is on complex customized systems, especially for the handling of sensitive pharmaceuticals.

We realize „turnkey“ projects for our customers, from the initial sketch to CAD design and rapid prototyping right through to an approved serial product. For our projects we offer the complete documentation.

In our certified clean rooms, we offer injection molding, assembly and packaging from a single source. This is how we realize high-efficiency individual processing, small series and automated large series.
Sanofi Genzyme

Gooimeer 10
1411 DD Naarden
Netherlands
Web: http://www.sanogenzyme.com/

Sanofi Genzyme, the specialty care global business unit of Sanofi, focuses on rare diseases, multiple sclerosis, oncology, and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. Our approach is shaped by our experience developing highly specialized treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Learn more at www.sanogenzyme.com.

Scintomics GmbH

Lindach 4
82256 Fürstenfeldbruck
Germany
Phone: +49 8141 150550
Fax: +49 8141 1505515
E-Mail: info@scintomics.com
Web: http://www.scintomics.com

SCINTOMICS is a worldwide active private company, developing and providing synthesizers for GMP production of innovative and routine radiopharmaceuticals, quality control equipment and corresponding services.

AT THIS YEAR’S EANM MEETING, SCINTOMICS LAUNCHES >RADIOHYBRID TRACERS<, A GROUNDBREAKING NEW TRACER CONCEPT. FIRST POWERFUL EXAMPLES OF RADIOHYBRID TRACERS ARE [F-18]rhPSMA-7 AND [Ga-68]rhPSMA-7 WHICH OFFER HIGH AFFINITY AND EXCELLENT BIODISTRIBUTION IN MAN AND ARE PRODUCED IN LESS THAN 1000 SECONDS WITH OUTSTANDING YIELDS.

The Radiohybrid Tracer platform is an extremely valuable and groundbreaking addition to SCINTOMICS tracer portfolio, comprising of the unique CXCR4 PET-ligand Ga-68-Pentixafor, the therapeutic CXCR4-ligand Pentixather, the newest generation of CXCR4 ligands with high affinity to murine CXCR4 and the high affinity avß3-ligand Ga-68-Avebetrin.

SEDECAL MOLECULAR IMAGING

PELAYA 13, POL. IND. RIO DE JANEIRO
28110 MADRID
Spain
Phone: +34 916280544
E-Mail: info@sedecal.com
Web: http://www.sedecal.com

SEDECAL MOLECULAR IMAGING (SMI) with headquarters in Spain, is one of the oldest provider of Preclinical Molecular Imaging Devices with equipment all over the world in the most prestigious organizations. The company is part of SEDECAL GROUP, founded in 1994 with the investment in R&D as philosophy. The wide range of portfolio covers PET, CT, SPECT, PET/CT, SPECT/CT, PET/SPECT/CT and PET/MR systems. Our State of the art technology, PET in REAL TIME make us unique in the market. The PET in real Time will revolutionize the way of how the PET systems perform, being more accurate and faster.

We continue investing in I+D to design new systems introducing new technology and the way we are flexible to include changes into our systems depending of the client´s need.

SEDECAL is at the cutting edge of Molecular Imaging systems development due to the R&D investment and the flexibility with their clients, creating specified equipment to satisfy the professional needs in any country. This season SEDECAL will launch a new edge of compact systems more suitable for Molecular Imaging professionals.
Seibersdorf Labor GmbH

Forschungszentrum
2444 Seibersdorf
Austria
Phone: +43 50 550 2500
Fax: +43 50 550 2502
E-Mail: office@seibersdorf-laboratories.at
Web: http://www.seibersdorf-laboratories.at

ALL-IN-ONE SERVICE FOR NUCLEAR MEDICINE
Our team offers a comprehensive service covering everything linked to work with radiation, from ionizing radiation to laser radiation. We focus specifically on the needs of our customers in the field of nuclear medicine.

EXPERT OPINIONS | PLANNING | ADMINISTRATIVE PROCEDURES
• Radiation protection expert opinions
• Safety and incident analyses, emergency planning, waste disposal concepts
• Expert opinions on laser and optical radiation safety
• Classification of measurement devices
• Consultation on approval procedures
• Documents and reports required for approval

DOSIMETERS
• Whole body dosimeters
• Ring and forehead dosimeters
• Area dosimeters
• Approved dosimetry service

TRAINING | EXERCISES
• Radiation protection officers in medicine
• Authorized doctors
• Advanced training courses

RADIOPHARMACEUTICALS
• Production and development of radiopharmaceuticals
• Production to order for in-house pharmacies, pharmacokinetics and microPET

CALIBRATION
• Therapy and radiation protection dosimeters
• Diagnostic dosimeters and dosimeters for constancy testing

OUR QUALITY STANDARDS
• Accredited testing center for ionizing radiation and radiation protection
• Accredited calibration laboratory for radiation protection
• Authorized verification body for r
Sichuan Tianle Photonics Co., Ltd.

#70 Li xing zhi jia, Keji Road
Economic Development Zone
Chongzhou
611230 Chengdu
China
Phone: +86 (0)28 8222 8986
Fax: +86 (0)28 8222 6797
E-Mail: info@sctlxd.com
Web: http://www.tianlephotonics.com

Sichuan Tianle Photonics Co., Ltd. (hereinafter referred to as “Tianle Photonics” or “Company”) was founded in March 2014, by a team from rare earth industry and artificially synthesized crystal/ceramic industry experts. Tianle Photonics dedicates its whole effort and intelligence to the producing and manufacturing of scintillation materials, laser materials and related appliances. The products of Tianle Photonics are mainly used in medical imaging systems such as PET/CT scan system, neutron sensor and oil detection equipment.

The industry of artificially synthesized crystal/ceramic materials have been developed for decades. Different methodologies have been implemented for different products. As for the scintillation crystals and ceramic materials, the variety of physical properties of materials have limited their applications in certain areas. The main products Tianle Photonics is producing are rare earth silicates such as Lutetium Silicate (Ce:LSO), Yttrium Lutetium Silicate (Ce:LYSO) and Yttrium Silicate (Ce:YSO) and rare earth aluminates such as rare earths doped Yttrium Orthoaluminate (Lu:YAP) and rare earths doped Yttrium Aluminum Garnet (Nd:YAG and Ce:YAG), with the major applications in the high energy physical, high energy detection facilities, and nuclear applications.

We’re a company that dedicate to scintillator crystal growth and crystal array assembly.

Siemens Healthcare GmbH

Henkestraße 127
91052 Erlangen
Germany
Web: https://www.healthcare.siemens.com/molecular-imaging

Siemens Healthineers is committed to becoming the trusted partner of healthcare providers worldwide, enabling you to improve patient outcomes while reducing costs. Siemens Healthineers is dedicated to helping our partners be successful – clinically, operationally and financially – from prevention through diagnosis and treatment.

In June 2017, Symbia Intevo Bold™ was introduced at SNMMI. This system combines proven SPECT technologies with the latest CT innovations to make high-performance CT even better. In addition to highlighting the advantages of Symbia Intevo Bold, xSPECT Bone™ and xSPECT Quant™ will be featured at EANM. These technologies provide an opportunity to expand into advanced nuclear medicine applications, such as orthopedics and therapy monitoring.

Visit the Siemens booth to also see the future of PET/CT imaging and to learn more about the value of FlowMotion™ continuous bed motion technology. For more information, please visit https://www.healthcare.siemens.com/molecular-imaging

1 Symbia Intevo Bold, xSPECT Quant for 123I, 111In and 177Lu are not yet commercially available in some countries. Due to regulatory reasons, their future availability cannot be guaranteed. Please contact your local Siemens organization for further details.
Sirtex Medical Europe GmbH

Joseph Schumpeter Allee 33
53227 Bonn
Germany
Phone: +49 (0) 228 18407 30
Fax: +49 (0) 228 18407 35
E-Mail: info@sirtex-europe.com
Web: http://www.sirtex.com

Sirtex is a global life-sciences company and actively engaged in the field of liver-directed therapies for cancer patients. The current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres® Y-90 resin microspheres (microscopic Yttrium-90 resin beads). To date, more than 73,000 doses have been supplied worldwide to treat patients with liver cancer at more than 1,000 medical centres in over 40 countries.

The innovative technology of Sirtex, SIR-Spheres® Y-90 resin microspheres are a medical device used in an interventional radiology procedure known as selective internal radiation therapy (SIRT), or radioembolisation, which targets high doses of short-range beta radiation directly to liver tumours.

SIR-Spheres® microspheres were approved in 2002 for use in the treatment of a variety of unresectable liver tumours as well as in hepatocellular carcinoma within the European Union under a CE Mark.

Society of Nuclear Medicine and Molecular Imaging (SNMMI)

1850 Samuel Morse Drive
20190 Reston
United States
Phone: +1-703-708-9000
Fax: +1-703-708-9020
E-Mail: nwenzel-lamb@snmmi.org
Web: https://www.snmmi.org

The Society of Nuclear Medicine and Molecular Imaging (SNMMI), headquartered in Reston, Va., is a nonprofit scientific and professional organization, founded in 1954, that promotes the science, technology and practical application of nuclear medicine and molecular imaging. SNMMI strives to be a leader in unifying, advancing and optimizing molecular imaging, with an ultimate goal of improving human health. With 17,000 members worldwide, SNMMI represents nuclear and molecular imaging professionals, all of whom are committed to the advancement of the field.

In addition to publishing journals, newsletters and books, the Society also sponsors international meetings and workshops designed to increase the competencies of nuclear medicine and molecular imaging practitioners and to promote new advances in the science of nuclear medicine, molecular imaging and therapy. The Society maintains an active advocacy program to promote and encourage research and the advancement of nuclear medicine science and produces a number of programs to help physicians and technologists remain current with the latest advances. The Society also sponsors education programs for consumers to help them understand nuclear medicine, molecular imaging and therapy and the constructive role it can play in both diagnostic and therapeutic therapies.
Spectrum Dynamics Medical

Rue de Lausanne 31
1110 Morges
Switzerland
Phone: +41-21-544-4710
Fax: +41-21-544-4711
E-Mail: info@spectrum-dynamics.com
Web: http://www.spectrum-dynamics.com

Spectrum Dynamics Medical revolutionized the practice of nuclear cardiology with the 1st clinical & commercially available CZT imaging scanner. The D-SPECT® and D-SPECT-L™ nuclear cardiology imaging systems dramatically enhances image quality, improves workflow, allows the ability to reduce radiation exposure by implementing unique low dose protocols and provides the platform for advanced imaging protocols, i.e. Dynamic SPECT and Simultaneous Multi Isotope.

For more information, visit www.spectrum-dynamics.com or call +1-941-256-3660 or +41-21-544-4710. Please visit us at Booth 404 in Hall X4.

Springer Nature

Tiergartenstr. 17
69121 Heidelberg
Germany
Phone: +49 6221 487-0
Fax: +49 6221 487 8366
Web: http://www.springernature.com

Springer Nature is one of the world’s leading global research, educational and professional publishers, home to an array of respected and trusted brands providing quality content through a range of innovative products and services. Springer Nature is the world’s largest academic book publisher, publisher of the world’s most influential journals and a pioneer in the field of open research. The company numbers almost 13,000 staff in over 50 countries and has a turnover of approximately EUR 1.5 billion. Springer Nature was formed in 2015 through the merger of Nature Publishing Group, Palgrave Macmillan, Macmillan Education and Springer Science+Business Media. Find out more: www.springernature.com

SurgicEye GmbH

Friedenstr. 18A
81671 Munich
Germany
Phone: +49 89 54 99 89 001
E-Mail: info@surgiceye.com
Web: http://www.surgiceye.com

SurgicEye is a solution provider for mobile nuclear medicine imaging for image guided interventions. With declineSPECT SurgicEye has products for 3D radio-guided surgery supporting the operations with images on the spot. Besides the declineSPECT product line, SurgicEye provides OEM solution for image processing, image reconstruction, image fusion and software based dose planning and dosimetry solutions.
Synthra GmbH

Albert-Einstein-Ring 21
22761 Hamburg
Germany
Phone:  +49 (0) 40 881674370
E-Mail:  info@synthra.com
Web:  http://www.synthra.com

Synthra is a worldwide leading and specialized manufacturer of branded radio synthesizer and concentrates over 35 years of real experiences in the field of targetry radiopharmaceutical production, quality control and lab automation.
We undertake automated production of molecular imaging tracers and continuously provide innovative solutions to facilitate and improve the production of tracers for PET and MI. Our portfolio comprises 11C, 18F, 13N and 68Ga. It includes targets, radio synthesizer (incl. customized modules), quality control equipment, spare parts and service. Our radio synthesizer combine high performance and efficiency with high flexibility that enable the production of research 11C-, 18F-, 13N- and 68Ga-radiotracers.
Besides the attractive design, our software and synthesizer are user-friendly. Most common our modules offer an easy possibility to create own sequences for the synthesis of new radiopharmaceuticals. It also offers an integrated self-cleaning system which is a far more ecofriendly and a time-efficient feature.
Product line and brands:
18F Fluorine synthesizer: RNplus, RNplus Research, Multitracer, FDGtwo, F-Dopa (electrophile), NaF
11C Carbon synthesizer: C-Choline, GPextent, MeI, MeIplus (CO2, CH4 or Research)
Radiometal synthesizer: 68Ga Peptide
RadChrom+ Quality Control Equipment, Metabolite Analysis

TAIYO NIPPON SANSO Corporation

1-3-26 Koyama
Shinagawa-ku
142-8558 Tokyo
Japan
Phone:  +81 3 57888550
Fax:  +81 3 57888710
E-Mail:  Isotope.TNS@tn-sanso.co.jp
Web:  https://stableisotope.tn-sanso.co.jp/english/

TAIYO NIPPON SANSO, established in 1910, is a leading global industrial gas manufacturer. We developed the most energy efficient Oxygen-18O separation process utilizing our cryogenic air separation and ultra-clean technology. Since 2004, we have been supplying Water-18O to the world PET market. To meet the growing demand we completed our three plants with capacity of 600kg/year in 2015 by using state of the art separation technology.
The largest capacity of 600kg/year with these three independent plants and GMP capability enable us to secure the stable supply of the highest and consistent quality of Water-18O, continuing to contribute to the advancement of the PET industry.
**Tema Sinergie, S.p.A**

**Booth No. 303**

Via Malpighi, 120  
48018 Faenza RA  
Italy  
Phone: +39 0546 622 663  
Fax: +39 0546 621 640  
E-Mail: tema@temasinergie.com  
Web: http://www.temasinergie.com

Tema Sinergie is a dynamic and innovative company that designs, produces and installs solutions and systems suitable for PET Cyclotron, Nuclear Medicine, Radiotherapy, Radiodiagnostics, Industrial and Metrology applications; and works with Hospitals, Research Laboratories & Institutes, Universities and Industrial Companies that work in fields requiring the control of ionizing radiation. For thirty years, Tema Sinergie has improved the design and production of complete systems for the handling of Radiopharmaceuticals, to meet the highest standards for GMP and radioprotection safety levels, while improving the work quality of all who are involved in Radiochemistry & Radiopharmaceuticals R & D and Nuclear Medicine.

Tema Sinergie will be showing several kinds of equipments among which you will find some of its flagship products such as Karl100, the smallest and safest dose administration system; AGLTS, the most advanced GMP compliant glove integrity testing system for isolators and RABs; and ENVIRO, a complete real time monitoring system for the detection and measurement of environmental radiation, air contamination, temperature, humidity and pressure. You will also be introduced to our brand new concept of Radioprotection, the groundbreaking NEXT combo of a non-shielded isolator and a shielded automatic dispenser.

**TERUMO**

**Booth No. 224**

7 rue Eugéne et Armand Peugeot  
92500 Rueil Malmaison  
France  
Web: http://www.terumo-europe.com/en-emea

Founded in Tokyo in 1921, Terumo is a multinational company with more than 90 years’ experience in developing best in class medical devices. At Terumo Interventional Systems, we constantly work to refine and perfect our products so that interventionists and healthcare patients can do more to support their patients.

Terumo offers intervention in all dimensions: from access to closure with specialized resources dedicated to Interventional Oncology particularly focusing on Selective Internal Radiation Therapy (SIRT) and nuclear medicine support.

Within Interventional Oncology, Terumo is working in partnership with Interventional Radiologists and Nuclear Medics to ensure they have access to the high quality tools for their patients. This partnership is based on Terumo’s comprehensive range of technology and services to support HealthCare Professionals with their patient needs. Terumo offers a large range of devices ranging from access devices Progreat® microcatheter, GT Wire® and Occlusafe® balloon occlusion catheter as well as embolics including Azur®, HydroPearl to a complete range of loco-regional therapies including LifePearl® drug-eluting microspheres and QuiremSpheres®.

QuiremSpheres® the next generation SIRT technology was launched at CIRSE 2017 with further updates planned for EANM 2017.
The Nuclear Health Accelerator

Westerduinweg 3
1755 LE PETTEN
Netherlands
Phone:  +31 224 564 950
Fax:  +31 224 568 912
E-Mail:  info@nrg.eu
Web:  http://www.theNuclearHealthAccelerator.com

The Nuclear Health Accelerator
NRG | PALLAS
For a Long Healthy Life
Our quest for saving lives began back in the 1960s with research & production of medical isotopes. On our site in Petten, north of Amsterdam, the right infrastructure and expertise came together to make this happen. Breakthroughs in scanning technology increasingly allowed for precise diagnosis of cancer and cardiovascular diseases. This led to phenomenal growth and worldwide acceptance of radiopharmaceuticals. Now, NRG has become a world leader in the production of key ingredients for these medicines.
We expect amazing, future breakthroughs in the treatment of life-threatening diseases by using personalized and targeted radiopharmaceuticals. To support this, the NRG site is being overhauled with a major investment program. Next to a new reactor (PALLAS) and processing plant, a state-of-art R&D environment and supporting facilities will be created to cater for the needs of all pioneers in this exciting field of medicine.
Pioneering Medical Solutions
The Nuclear Health Accelerator is set up by NRG | PALLAS to explore, innovate and create amazing new medical solutions together with our academic partners. We know that such advances can only be realised when curiosity, knowledge, funds and facilities marry. The setup of this gateway is such that expertise and academic know-how from all around the world and across all disciplines can start working together in proximity of and in safety to the source.

Theraclion

102 rue Etienne Dolet
92240 Malakoff
France
Phone:  +33 155489070
Fax:  +33 155489078
E-Mail:  contact@theraclion.com
Web:  http://www.theraclion.com

Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound. Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules.
Trasis

Rue Gilles Magnée, 90
5530 Ans
Belgium
E-Mail: info@trasis.com
Web: http://www.trasis.com

At Trasis our primary focus is allowing the medical community to access new radiolabelled therapeutic and diagnostic substances easier and faster. To this end, we design, manufacture, sell and support high performance synthesizers, dose preparation equipment, their shielding and accessories. We also develop customized synthetic methods and instruments. We can provide GMP Active Pharmaceutical Ingredients (API) and assist our customers with their regulatory affairs.

Our proven radiopharmaceutical expertise, coupled with our high end instruments allows us to provide fully integrated solutions for an effective tracer production and faster transition from drug development to marketing authorization. Our equipment is used worldwide in nuclear medicine departments, research centers, radiopharmaceutical production facilities and pharmaceutical companies.

Triskem International

3 rue des Champs Géons ZAC de l’Eperon 35170 BRUZ
ZAC de l’Eperon
35170 BRUZ
France
Phone: +33 2 99 05 42 14
E-Mail: mlanger@triskem.fr
Web: http://www.triskem.com/

Triskem International is a leading provider of extraction chromatographic resins and solutions for the separation of radioactive elements.

Triskem’s main product line consists of a wide selection of different extraction chromatographic resins which allow the separation of radionuclides from various samples and matrices (irradiated targets, environmental, medical and bioassay as well as waste and decommissioning samples). Our products are standard technology in radiochemistry and they are used by international accredited laboratories and monitoring agencies such as the IAEA, AREVA, IRSN, CEA, BfS…).

Our resins are increasingly finding application in the production and quality control of radionuclides (such as Cu-64/7, Sc-44/7, Zr-89, Ge-68, Ga-67, Ti-44, alpha emitters…) for medical use, and are employed by leading radionuclide manufacturers worldwide.

Triskem International places a strong focus on the development of new resins and separation methods to meet your separation needs. If you’d like to receive more detailed information, or if you’d like to discuss a specific separation problem please contact us under: contact@triskem.fr.
Turkish Society of Nuclear Medicine (TSNM)  
Booth No. 357

Cinnah Caddesi Pilot Sokak No:10/12  
6650 Ankara  
Turkey

Phone: +90 312441 00 45  
Fax: +90 312 441 12 97  
E-Mail: dernekmerkezi@tsnm.org  
Web: http://www.tsnm.org

Turkish Society of Nuclear Medicine (TSNM) was founded in 1975 soon after the approval of Nuclear Medicine as an independent medical specialty by the Ministry of Health. TSNM aims to promote clinical practice, research and education in nuclear medicine for the benefit of public health. TSNM also holds a unique position to provide collaboration between national health authorities, departments of nuclear medicine in universities and training and research hospitals, industrial suppliers and other medical societies. The society organizes several scientific activities each year, national congresses in spring and a symposium dedicated on a different topic of interest in winter season and regular educational events called “School of Nuclear Medicine” designed for residents and young physicians by the experts of the scientific task groups involved within TSNM. Currently TSNM has 777 members including physicians, physicists, pharmacists and technologists. The official journal of TSNM is “Molecular Imaging and Radionuclide Therapy, MIRT” (http://mirt.tsnmjournals.org). MIRT is published in English and indexed in PubMed, PubMed Central, EBSCO and some other scientific indexes and provides open access to its content. The society also publishes an electronic journal, “Nuclear Medicine Seminars” which is in Turkish dedicated to educational articles on specific topics by the invited editors in each issue.

UEMS / EBNM - European Board of Nuclear Medicine  
Booth No. 348

Schmalzhofgasse 26  
1060 Vienna  
Austria

Phone: +43 (0) 1 890 44 27  
Fax: +43 (0) 1 890 44 27 9  
E-Mail: office@uems.eanm.org  
Web: http://www.uems.eanm.org

The European Union of Medical Specialists (UEMS) is the oldest medical organisation in Europe as it celebrated its 50th anniversary in 2008.

With a current membership from 37 countries, it is the representative organisation of the National Associations of Medical Specialists in the European Union and its associated countries.

Medical Specialties

The UEMS represents more than 50 medical disciplines through various bodies and structures. The most important ones are the 43 Specialist Sections, which represent independently recognised specialties. They have created a European Board as a subgroup, in conjunction with the relevant European Society, with a view to defining European standards of medical education and training. They also contribute to the work of Multidisciplinary Joint Committees (MJC) which address fields of a multidisciplinary nature.

Section and European Board of Nuclear Medicine

Nuclear Medicine has been an independent medical specialty since 1988. The Section of Nuclear Medicine was constituted in 1990 and the European Board of Nuclear Medicine (EBNM) was created in 1993 with the main objective to guarantee the highest standards in the field of nuclear medicine. In 2003, the UEMS Section and European Board of Nuclear Medicine (UEMS/EBNM) merged in order to unify and facilitate activities.
Uniteko Co., Ltd

77, Seondong-gil, Chowol-eup
12732 Gyeonggi-do
South Korea

Incorporated 2010, Uniteko Co., Ltd has accelerated its rate of growth as a leader of radiation measurement system developer. We have many customers including general hospitals, a variety of R&D institutes, nuclear power plants, military-related institutes, and fire-defense related institutes.

Our product areas include import and developing of radiation measurement equipments and systems and radiation shielding equipments.

In addition, we are a supplier of many types of isotopes for biological and chemical research purpose, a consultant for radiation safety and a service provider for radiation-related businesses.

We are growing with our reliable supplying and customer satisfactory service, and are trying to be a leading company with sustainable investment for new facility and system development.

US DOE ISOTOPE PROGRAM

1 Bethel Valley Road
37831-6158 Oak Ridge
United States
Phone: +1 865 574 6984
E-Mail: isotopes@ornl.gov
Web: https://isotopes.gov/

The United States Department of Energy Isotope Program is an Isotope subprogram that supports the production, and the development of production techniques of radioactive and stable isotopes that are in short supply for research and applications. Isotopes are high-priority commodities of strategic importance for the Nation and are essential for energy, medical and national security applications and for basic research; a goal of the program is to make critical isotopes more readily available to meet domestic U.S. needs.
VANDERWILT techniques bv

Parallelweg-zuid 33-02
5281 LB Boxtel
Netherlands
Phone: +31 0411 686019
E-Mail: G.vanderwilt@wxs.nl
Web: http://www.FOR-MED.nl

VANDERWILT techniques is a design, engineering and manufacturing company for medical devices in nuclear medicine and custom made accessories:
- Custom-moulded polymer FOR-MED patient positioning supports
- Foot support for SPECT/CT
- Breast support prone position
  - Dedicated pinhole collimators
  - Tungsten syringe shields
  - Manual dispensing and dose calibrator unit PET
  - Lead and tungsten vial containers
  - High Resolution Micro phantoms for small animal systems
  - Thyroid phantom
- Dynamic Heart phantom (AGATE)
- SeHCAT panels, Place resolution phantoms and NEMA calibration panels
- Sharp Needle Waste containers
- Waste containers
- OP containers
- Shielded heating device

VANDERWILT techniques design and manufacture customized products for daily laboratory and clinical nuclear medicine practice as well as research purposes, using state-of-the-art and innovative production methods. Typically, our customers are universities, hospitals and nuclear medicine departments, as well as radiopharmaceutical and imaging equipment companies.

Von Gahlen Nederland B.V.

Kelvinstraat 9
6902 PW Zevenaar
Netherlands
Phone: +31 (0)316 528 275
Fax: +31 (0)316 333 649
E-Mail: info@vongahlen.nl
Web: http://www.vongahlen.com

Von Gahlen designs and manufactures lead shielding products for the radio pharmacy and nuclear medicine industry. Our products range from transportation solutions to complete manufacturing lines, including semi or fully automated dispensing systems. Since its founding over 4 decades ago, Von Gahlen has become a world leader and global player in these industries. With our strong customer focus, we have managed to provide high quality products that meet or exceed industry standards and safety requirements. Von Gahlen hot cell installations may be found all over the world, including many of the largest turnkey installations in the field.

Due to its extensive experience, Von Gahlen is involved from the earliest planning and design stages up to and including the completed installation and validation, working closely with the customer at all stages to ensure that every requirement is met and to produce the best equipment available for the application.

Our team of professionals includes highly qualified technical designers as well as experienced manufacturing and installation personnel. Our modern factory is equipped with the latest computerized equipment. Von Gahlen is an ISO 9001 Certified Company. Our quality assurance program has been audited and approved by numerous customers.

Von Gahlen is proud to be at the forefront of advancing technology.
Wallonia Export & Investment (AWEX) Booth No. 318

Place Saintelette no 2
1080 Brussels
Belgium
Phone: +32 2 421 87 09
Fax: +32 2 421 85 37
E-Mail: g.marien@awex.be
Web: http://www.awex-export.be

The Wallonia Export & Investment Agency (AWEX) is the Wallonia Region of Belgium’s government agency in charge of foreign trade promotion and foreign investment attraction. The agency has a worldwide network of more than 100 Economic Commercial Advisors.

WARMTH - World Association of Radiopharmaceutical and Molecular Therapy Booth No. 349

Nuclear Medicine Rajiv Gandhi Cancer Institute & Research Centre
Sector 5 Rohini
110085 Delhi
India
Phone: +1-650-219-1030
E-Mail: info@warmth.org
Web: http://warmth.org

The „World Association of Radiopharmaceutical and Molecular Therapy“ (WARMTH) extends its activities throughout the world. WARMTH is the only worldwide organisation founded to promote the use of radionuclide molecular therapy, and of the relatively novel paradigm of ‘Theragnostics.’

WARMTH is a voluntary non-profit organization of individuals specifically associated for the purposes, and for using the means, to achieve the following research and educational objectives:

· Advance science and education of therapeutic nuclear medicine and radiopharmaceutical therapy including dosimetry, treatment evaluation, radiation physics, radiation biology and radiation protection for the benefit of public health and humanity.
· Work towards worldwide access to radionuclide therapy by harmonizing good practice.
· Educating nuclear medicine professionals in the use of radionuclide therapies and to facilitate research in this area. WARMTH’s major initiatives for sharing and disseminating information are:

1. annual International Conferences on Radionuclide Therapy (ICRT)
2. Timely workshops and symposia on focused clinical areas
3. Provide a suitable platform for the dissemination and discussion of the latest results in the field of Nuclear Medicine Therapy, and related subjects through the quarterly academic publication of World Journal of Nuclear Medicine, and
4. Establishment of the World Theragnostics Academy, for training and promoting educational activities.
Wisepress Medical Bookshop

15 Lyon Road
Merton
SW19 2RL London
United Kingdom
Phone:  +44 2087151812
E-Mail:  marketing@wisepress.com
Web:  http://www.wisepress.com

Wisepress.com, Europe’s leading conference bookseller, attend around 200 conferences every year. We have an extensive range of books and journals relevant to the themes of this conference available at our booth. We also have a comprehensive range of STM titles available on our online bookshop. Follow us on Twitter @WisepressBooks.

Wolfmet

M&I Materials ltd
Hibernia Way
Trafford Park
M320ZD Manchester
United Kingdom
Phone:  +44 1618645506
Fax: +44 1618645444
E-Mail:  stevejeffery@mimaterials.com
Web:  http://www.wolfmet.com/

NEW – Wolfmet 3D printed tungsten collimators

Wolfmet tungsten alloy has been the automatic choice for radiation shielding and collimators in nuclear medicine for many years.

Now Wolfmet is opening up a world of new possibilities with the introduction of Wolfmet 3D printed tungsten. This revolutionary new process makes complex high-precision tungsten collimators a reality.

The benefits of this new technology include:

• High density components which reduce septal penetration and therefore improve imaging
• Collimator compatibility with the new generation of SPECT/MRI scanners
• Reduced development costs – no tooling charges
• Rapid production of prototypes
• Easy modifications of designs
• Reduced time from development to actual production

Wolfmet is part of the Pavilion consortium. Come and visit us to learn more about this exciting new development.

In addition, we will have examples of our standard shields for nuclear medicine – FDG pots, vial shields and customised shields.
World Federation of Nuclear Medicine & Biology / Australian and New Zealand Society of Nuclear Medicine  
Booth No. 361

ANZSNM: Postal Address  PO Box 6178 Vermont South Victoria 3133 Australia
WFNMB: Congress venue: MCEC (Melbourne Convention and Exhibition Centre)
Victoria
3133 Melbourne
Australia
Phone:  +61 1300 330 402
E-Mail:  secretariat@anzsnm.org.au
Web:  http://www.wfnmb2018.com/

About the WFNMB: One of our principal activities is to support education efforts for nuclear physicians, physicists, radiopharmacists, radiochemists, technologists and other nuclear medicine scientists, especially from the developing world. In achieving its programmatic goals, the WFNMB will work with its member societies, and with international health and scientific bodies like the International Atomic Energy Agency (IAEA) and the World Health Organisation (WHO). This will enable us to enhance nuclear medicine education and improve access to the highest quality nuclear medicine care.

YanTai DongCheng Pharmaceutical Group Co.,Ltd  
Booth No. 248
ESMIT eLearning
No Limits, Full Education

87 Recorded CME Sessions
This section features selected CME and Plenary sessions recorded at EANM congresses since 2012 onwards.

Webinars on
Basic Nuclear Medicine, Paediatric Nuclear Medicine, PET and MoRe, PET/CT, PET/CT for Technologists
Many more to come soon...

elearning.eanm.org
EANM wishes to thank the following companies for their support as Corporate Members (alphabetical order):

<table>
<thead>
<tr>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advanced Accelerator Applications</td>
</tr>
<tr>
<td>Biocompatibles UK Ltd</td>
</tr>
<tr>
<td>Bruker BioSpin Preclinical Imaging Division</td>
</tr>
<tr>
<td>Comecer</td>
</tr>
<tr>
<td>Curium</td>
</tr>
<tr>
<td>Eckert &amp; Ziegler</td>
</tr>
<tr>
<td>Eli Lilly</td>
</tr>
<tr>
<td>GE Healthcare</td>
</tr>
<tr>
<td>Hermes</td>
</tr>
<tr>
<td>IBA</td>
</tr>
<tr>
<td>IBA Molecular</td>
</tr>
<tr>
<td>Company Profile</td>
</tr>
<tr>
<td>---------------------------------------</td>
</tr>
<tr>
<td>Isotope4life</td>
</tr>
<tr>
<td>JSC Isotope</td>
</tr>
<tr>
<td>Mediso Medical Imaging Systems</td>
</tr>
<tr>
<td>Monrol (Eczacibasi)</td>
</tr>
<tr>
<td>NRG</td>
</tr>
<tr>
<td>PARS Isotope</td>
</tr>
<tr>
<td>Philips</td>
</tr>
<tr>
<td>Siemens Healthineers</td>
</tr>
<tr>
<td>Spectrum Dynamics Medical</td>
</tr>
<tr>
<td>Tema Sinergie</td>
</tr>
<tr>
<td>The Pavilion</td>
</tr>
</tbody>
</table>
Imprint

Publisher
European Association of Nuclear Medicine
Schmalzhofgasse 26, 1060 Vienna, Austria
Phone: +43-(0)1-890 44 27
Fax: +43-(0)1-890 44 27-9
Email: office@eanm.org
URL: www.eanm.org

Editors
Francesco Giammarile, EANM Congress Chair 2017-2019
Andreas Felser, EANM Executive Director
Susanne Koebe, EANM Project Manager, Congress

Content
No responsibility is taken for the correctness of this information.
Information as per date of printing September 2017.

Layout & Design
Robert Punz, EANM Executive Office
Annual Congress of the European Association of Nuclear Medicine

October 13 – 17, 2018
Düsseldorf, Germany

eanm18.eanm.org